gene	entrez_id	variant	disease	doid	phenotypes	drugs	drug_interaction_type	evidence_type	evidence_direction	evidence_level	clinical_significance	evidence_statement	citation_id	source_type	asco_abstract_id	citation	nct_ids	rating	evidence_status	evidence_id	variant_id	gene_id	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	chromosome2	start2	stop2	representative_transcript2	ensembl_version	reference_build	variant_summary	variant_origin	last_review_date	evidence_civic_url	variant_civic_url	gene_civic_url
JAK2	3717	V617F	Lymphoid Leukemia	1037				Diagnostic	Supports	B	Negative	JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL).	16081687	PubMed		Levine et al., 2005, Blood		4	accepted	1	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253				Diagnostic	Supports	B	Negative	GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	15146165	PubMed		Lasota et al., 2004, Lab. Invest.		3	accepted	2	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).	22081665	PubMed		LaRochelle et al., 2011, Oncotarget		2	accepted	3	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/3	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A.	22490330	PubMed		Ribeiro et al., 2012, Blood		3	accepted	4	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/4	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
JAK2	3717	V617F	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	B	Positive	JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).	16081687	PubMed		Levine et al., 2005, Blood		4	accepted	5	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/5	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	V617F	Bone Marrow Cancer	4960				Diagnostic	Supports	B	Positive	The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.	19287384	PubMed		Kilpivaara et al., 2009, Nat. Genet.		4	accepted	7	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28
KRAS	3845	G12	Acute Leukemia	12603				Diagnostic	Supports	B	Positive	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	24571676	PubMed		Andrade et al., 2014, BMC Cancer		3	accepted	8	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/8	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	Q61	Melanoma	1909				Diagnostic	Supports	B	Positive	Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.	23861977	PubMed		Tschandl et al., 2013, PLoS ONE		3	accepted	10	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/10	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Does Not Support	B	Resistance	Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	PubMed		LaRochelle et al., 2011, Oncotarget		4	accepted	11	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/11	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
MAP2K1	5604	P124S	Melanoma	1909		Selumetinib		Predictive	Supports	D	Resistance	A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.	19915144	PubMed		Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	12	82	31	15	66729162	66729162	C	T	ENST00000307102.5					75	GRCh37	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/12	https://civic.genome.wustl.edu/links/variants/82	https://civic.genome.wustl.edu/links/genes/31
MAP2K1	5604	Q56P	Melanoma	1909		Selumetinib		Predictive	Supports	D	Resistance	A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.	19915144	PubMed		Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	13	83	31	15	66727451	66727451	A	C	ENST00000307102.5					75	GRCh37	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/13	https://civic.genome.wustl.edu/links/variants/83	https://civic.genome.wustl.edu/links/genes/31
NRAS	4893	Q61	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Resistance	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	23569304	PubMed		Trunzer et al., 2013, J. Clin. Oncol.		4	accepted	14	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/14	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	GIST cancer with D842V mutation is resistant to imatinib.	15928335	PubMed		Corless et al., 2005, J. Clin. Oncol.		4	accepted	15	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/15	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		4	accepted	16	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/16	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
ARAF	369	S214C	Lung Non-small Cell Carcinoma	3908		Sorafenib		Predictive	Supports	C	Sensitivity/Response	In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.	24569458	PubMed		Imielinski et al., 2014, J. Clin. Invest.		2	accepted	17	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/17	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119		Idarubicin		Predictive	Supports	B	Sensitivity/Response	Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	PubMed		LaRochelle et al., 2011, Oncotarget		4	accepted	18	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/18	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
JAK2	3717	V617F	Polycythemia Vera	8997				Predictive	Supports	B	Sensitivity/Response	In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.	16709929	PubMed		Kiladjian et al., 2006, Blood	NCT00241241	4	accepted	19	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/19	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	V617F	Polycythemia Vera	8997		Fedratinib		Predictive	Supports	D	Sensitivity/Response	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.	18394554	PubMed		Wernig et al., 2008, Cancer Cell		3	accepted	20	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/20	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28
NRAS	4893	G13D	Melanoma	1909		Tanespimycin		Predictive	Supports	C	Sensitivity/Response	Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.	18375819	PubMed		Banerji et al., 2008, Mol. Cancer Ther.		2	accepted	21	93	36	1	115258744	115258744	C	T	ENST00000369535.4					75	GRCh37	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/21	https://civic.genome.wustl.edu/links/variants/93	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61L	Melanoma	1909		Temozolomide		Predictive	Supports	C	Sensitivity/Response	In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.	21576590	PubMed		Soon et al., 2011, Arch Dermatol		2	accepted	22	95	36	1	115256529	115256529	T	A	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/22	https://civic.genome.wustl.edu/links/variants/95	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61R	Melanoma	1909		Temozolomide		Predictive	Supports	C	Sensitivity/Response	In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.	21576590	PubMed		Soon et al., 2011, Arch Dermatol		2	accepted	23	96	36	1	115256529	115256529	T	C	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/23	https://civic.genome.wustl.edu/links/variants/96	https://civic.genome.wustl.edu/links/genes/36
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	22081665	PubMed		LaRochelle et al., 2011, Oncotarget		4	accepted	24	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/24	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		4	accepted	25	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/25	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
KIT	3815	D816V	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT.	16384925	PubMed		Cairoli et al., 2006, Blood		4	accepted	26	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/26	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29
NRAS	4893	MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	24666267	PubMed		Therkildsen et al., 2014, Acta Oncol		3	accepted	27	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/27	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	V600	Melanoma	1909				Diagnostic	Supports	B	Positive	BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.	21166657	PubMed		Lee et al., 2011, Br. J. Dermatol.		4	accepted	30	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/30	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients.	24512939	PubMed		El Ghannam et al., Blood Cells Mol. Dis.		3	accepted	31	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/31	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
ALK	238	F1174L	Inflammatory Myofibroblastic Tumor	0050905		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	21030459	PubMed		Sasaki et al., 2010, Cancer Res.		3	accepted	32	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/32	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1174L	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	21030459	PubMed		Sasaki et al., 2010, Cancer Res.		3	accepted	33	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/33	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
KIT	3815	L576P	Melanoma	1909		Sorafenib,Nilotinib,Imatinib	Substitutes	Predictive	Supports	D	Resistance	The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.	19671763	PubMed		Woodman et al., 2009, Mol. Cancer Ther.		3	accepted	34	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/34	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12/G13	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201).	15696205	PubMed		Pao et al., 2005, PLoS Med.		3	accepted	35	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/35	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	Q61	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype for NRAS (7.1% [1/14] vs 38.1% [110/289]).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	36	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/36	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
ALK	238	F1174L	Neuroblastoma	769		Alectinib		Predictive	Supports	D	Sensitivity/Response	CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	21575866	PubMed		Sakamoto et al., 2011, Cancer Cell		3	accepted	37	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/37	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1174L	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Sensitivity/Response	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	21948233	PubMed		Heuckmann et al., 2011, Clin. Cancer Res.		3	accepted	38	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/38	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	R1275Q	Neuroblastoma	769		TAE684		Predictive	Supports	D	Sensitivity/Response	TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.	18923525	PubMed		George et al., 2008, Nature		3	accepted	39	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/39	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
ARAF	369	S214C	Lung Non-small Cell Carcinoma	3908		Sorafenib		Predictive	Supports	D	Sensitivity/Response	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	PubMed		Imielinski et al., 2014, J. Clin. Invest.		3	accepted	40	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/40	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3
ARAF	369	S214C	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Supports	D	Sensitivity/Response	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	PubMed		Imielinski et al., 2014, J. Clin. Invest.		3	accepted	41	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/41	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3
KIT	3815	L576P	Melanoma	1909		Dasatinib		Predictive	Supports	D	Sensitivity/Response	The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.	19671763	PubMed		Woodman et al., 2009, Mol. Cancer Ther.		3	accepted	42	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/42	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	D842I	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	PubMed		Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	43	98	38	4	55152092	55152093	GA	AT	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/43	https://civic.genome.wustl.edu/links/variants/98	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	PubMed		Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	44	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/44	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842Y	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	PubMed		Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	45	100	38	4	55152092	55152092	G	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/45	https://civic.genome.wustl.edu/links/variants/100	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	I843DEL	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.	22745105	PubMed		Heinrich et al., 2012, Clin. Cancer Res.		3	accepted	46	101	38	4	55152095	55152097	ATC		ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/46	https://civic.genome.wustl.edu/links/variants/101	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842_I843delinsVM	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	PubMed		Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	47	102	38	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/47	https://civic.genome.wustl.edu/links/variants/102	https://civic.genome.wustl.edu/links/genes/38
ALK	238	R1275Q	Neuroblastoma	769		TAE684		Predictive	Supports	D	Resistance	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	18923525	PubMed		George et al., 2008, Nature		3	accepted	48	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/48	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	49	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/49	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Poor Outcome	In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	50	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/50	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.	22490330	PubMed		Ribeiro et al., 2012, Blood		4	accepted	51	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/51	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.	22490330	PubMed		Ribeiro et al., 2012, Blood		4	accepted	52	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/52	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253				Prognostic	Does Not Support	B	N/A	There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	16551858	PubMed		Wardelmann et al., 2006, Clin. Cancer Res.		3	accepted	53	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/53	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
NRAS	4893	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).	15951308	PubMed		Bowen et al., 2005, Blood		3	accepted	56	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/56	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	G12	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML.	16434492	PubMed		Bacher et al., 2006, Blood		3	accepted	57	92	36	1	115258747	115258748			ENST00000369535.4					75	GRCh37	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/57	https://civic.genome.wustl.edu/links/variants/92	https://civic.genome.wustl.edu/links/genes/36
KIT	3815	EXON 11 MUTATION	Melanoma	1909		Imatinib		Predictive	Supports	B	Sensitivity/Response	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	23775962	PubMed		Hodi et al., 2013, J. Clin. Oncol.	NCT00424515	3	accepted	58	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/58	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	A	Poor Outcome	In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	61	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/61	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		5	accepted	62	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/62	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	63	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/63	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		5	accepted	64	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/64	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.	24512939	PubMed		El Ghannam et al., Blood Cells Mol. Dis.		5	accepted	65	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/65	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	22291079	PubMed		Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	66	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/66	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.	22490330	PubMed		Ribeiro et al., 2012, Blood		4	accepted	67	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/67	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	22291079	PubMed		Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	68	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/68	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		5	accepted	69	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/69	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
KIT	3815	EXON 14 MUTATION	Gastrointestinal Stromal Tumor	9253				Prognostic	Supports	B	Poor Outcome	GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.	16551858	PubMed		Wardelmann et al., 2006, Clin. Cancer Res.		3	accepted	70	69	29	4	55595501	55595651			ENST00000288135.5					75	GRCh37	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.	Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/70	https://civic.genome.wustl.edu/links/variants/69	https://civic.genome.wustl.edu/links/genes/29
NRAS	4893	MUTATION	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.	22180178	PubMed		Jakob et al., 2012, Cancer		3	accepted	71	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/71	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	V600E and V600M	Melanoma	1909		Dabrafenib		Predictive	Supports	C	Sensitivity/Response	A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.	23031422	PubMed		Ponti et al., 2012, J Hematol Oncol		3	accepted	73	13	5	7	140453135	140453137			ENST00000288602.6					75	GRCh37	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/73	https://civic.genome.wustl.edu/links/variants/13	https://civic.genome.wustl.edu/links/genes/5
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973				Diagnostic	Supports	B	Positive	In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.	18073307	PubMed		Elisei et al., 2008, J. Clin. Endocrinol. Metab.		5	accepted	74	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/74	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
RET	5979	C634W	Thyroid Gland Medullary Carcinoma	3973		Motesanib		Predictive	Supports	D	Resistance	Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.	21422803	PubMed		Coxon et al., 2012, J. Endocrinol. Invest.		3	accepted	75	112	42	10	43609950	43609950	C	G	ENST00000355710.3					75	GRCh37	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/75	https://civic.genome.wustl.edu/links/variants/112	https://civic.genome.wustl.edu/links/genes/42
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973		Motesanib		Predictive	Supports	D	Resistance	Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.	21422803	PubMed		Coxon et al., 2012, J. Endocrinol. Invest.		3	accepted	76	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/76	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973		JAK2 Inhibitor AZD1480		Predictive	Supports	D	Sensitivity/Response	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	23056499	PubMed		Couto et al., 2012, PLoS ONE		3	accepted	77	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/77	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973				Prognostic	Supports	B	Poor Outcome	Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.	9839497	PubMed		Egawa et al., 1998, Jpn. J. Clin. Oncol.		4	accepted	78	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/78	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
BRAF	673	V600E	Thyroid Cancer	1781				Diagnostic	Supports	B	Positive	BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.	21594703	PubMed		Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	79	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/79	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Diagnostic	Supports	B	Positive	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	24570209	PubMed		Crescenzi et al., 2014, Horm. Metab. Res.		5	accepted	80	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/80	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909				Prognostic	Does Not Support	B	Poor Outcome	BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.	24586605	PubMed		Meckbach et al., 2014, PLoS ONE		2	accepted	82	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/82	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	E542K	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	B	N/A	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	24559322	PubMed		Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther		4	accepted	83	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/83	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	V600E	Melanoma	1909		Trametinib,MEK Inhibitor PD0325901	Substitutes	Predictive	Does Not Support	D	Resistance	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.	24576830	PubMed		Nissan et al., 2014, Cancer Res.		3	accepted	86	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/86	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	B	Sensitivity/Response	KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	24559322	PubMed		Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther		4	accepted	87	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/87	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Resistance	In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone).	23325582	PubMed		Peeters et al., 2013, Clin. Cancer Res.		3	accepted	88	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/88	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Sorafenib,Panitumumab	Combination	Predictive	Supports	D	Sensitivity/Response	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	19001320	PubMed		Di Nicolantonio et al., 2008, J. Clin. Oncol.		3	accepted	89	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/89	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.	24576830	PubMed		Nissan et al., 2014, Cancer Res.		3	accepted	90	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/90	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Lung Non-small Cell Carcinoma	3908		Dabrafenib		Predictive	Supports	C	Resistance	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.	23524406	PubMed		Rudin et al., 2013, J Thorac Oncol		2	accepted	91	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/91	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E and AMPLIFICATION	Colorectal Cancer	9256		Selumetinib		Predictive	Supports	E	Resistance	COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF V600E gene. BRAF V600E amplification was observed in 1/11 colorectal cancer patient samples evaluated, indicating this subclone (28% of cells) would be MEK inhibitor resistant.	21098728	PubMed		Corcoran et al., 2010, Sci Signal		4	accepted	92	14	5	7	140434279	140624564			ENST00000288602.6					75	GRCh37	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/92	https://civic.genome.wustl.edu/links/variants/14	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma.    Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination therapy in contrast to 19% in those receiving monotherapy (P = 0.09).  Of 162 patients with V600E or V600K mutation, 108 were given combination therapy and 54 monotherapy.  After 1 year, 41% of patients in the combination group were alive and progression free whereas this was 9% in the monotherapy group (P<0.001).   Median progression-free survival was 9.4 months with combination and 5.8 months with monotherapy. Hazard ratio for progression or death was 0.39 (95% CI, 0.25 to 0.62; P<0.001).	23020132	PubMed		Flaherty et al., 2012, N. Engl. J. Med.	NCT01072175	3	accepted	93	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/93	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600D	Melanoma	1909		Dabrafenib		Predictive	Supports	B	Sensitivity/Response	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	23463675	PubMed		Ponti et al., 2013, J. Clin. Pathol.		5	accepted	94	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/94	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.	24583796	PubMed		Menzies et al., 2014, Clin. Cancer Res.		5	accepted	95	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/95	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		PLX4720,Pictilisib Bismesylate	Combination	Predictive	Supports	D	Sensitivity/Response	Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.	23845441	PubMed		Rad et al., 2013, Cancer Cell		3	accepted	96	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/96	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Nutlin-3,PLX4720	Combination	Predictive	Supports	D	Sensitivity/Response	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.	23812671	PubMed		Ji et al., 2013, Clin. Cancer Res.		2	accepted	97	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/97	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Capecitabine,Bevacizumab,Vemurafenib	Combination	Predictive	Supports	D	Sensitivity/Response	This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Capecitabine, bevacizumab and vemurafenib combination therapy resulted in 100% tumor growth inhibition (TGI) and 190% increased lifespan (ILS) compared to vehicle treated controls. Seven mice experienced partial response and two experienced complete response. Triplet therapy resulted in better TGI and ILS compared to any agent in isolation or capecitabine + vemurafenib doublet therapy (p <0.05, p <0.0001, for all comparisons).	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	98	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/98	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and three harbored BRAF WT (but mutant KRAS). Of the six BRAF V600E expressing cell lines, four were sensitive to vemurafenib (IC50 ranging between 0.025 and 0.35 uM; HT29, Colo205, Colo741, LS411N). Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation (none of the three BRAF wt cell lines had IC50s less than 10uM). Authors note that one of the vemurafenib-resistant cell lines harboring BRAF V600E (RKO) harbored a concurrent activating PIK3CA H1047R mutation. Nude, athymic mice with HT29 xenografts treated with vemurafenib experienced substantial tumor inhibition and increased lifespan at every dose tested, though authors found 75 mg/kg twice daily to be optimal (95% tumor growth inhibition, 90% increased lifespan compared to vehicle treated controls).	22180495	PubMed		Yang et al., 2012, Cancer Res.		2	accepted	99	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/99	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Does Not Support	B	Poor Outcome	Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.	24354346	PubMed		Walczyk et al., 2014, Clin. Endocrinol. (Oxf)		5	accepted	102	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/102	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	24594804	PubMed		Chen et al., 2014, PLoS ONE		5	accepted	103	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/103	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	24388723	PubMed		Nagore et al., 2014, J. Am. Acad. Dermatol.		3	accepted	104	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/104	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	21594703	PubMed		Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	105	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/105	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	24396464	PubMed		He et al., 2014, Oncol Lett		3	accepted	106	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/106	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	21594703	PubMed		Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	107	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/107	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	16455956	PubMed		Thiede et al., 2006, Blood		3	accepted	108	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/108	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		4	accepted	109	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/109	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Negative	Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	110	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/110	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Negative	NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	16076867	PubMed		Schnittger et al., 2005, Blood		4	accepted	111	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/111	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes.	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		5	accepted	112	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/112	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		4	accepted	113	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/113	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	114	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/114	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	115	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/115	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	A	Positive	AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	19357394	PubMed		Vardiman et al., 2009, Blood		5	accepted	116	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/116	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.	17957027	PubMed		Gale et al., 2008, Blood		2	accepted	117	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/117	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.	16076867	PubMed		Schnittger et al., 2005, Blood		4	accepted	118	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/118	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.	16455956	PubMed		Thiede et al., 2006, Blood		3	accepted	119	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/119	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with normal karyotype in older (>60) patients.	19059939	PubMed		Schlenk et al., 2009, Haematologica	NCT00151242	3	accepted	120	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/120	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	PubMed		Ley et al., 2010, N. Engl. J. Med.		4	accepted	121	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/121	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Does Not Support	B	Sensitivity/Response	In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).	19965647	PubMed		Burnett et al., 2010, Blood		3	accepted	122	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/122	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
PIK3CA	5290	EXON 10 MUTATION	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Does Not Support	B	Resistance	In chemotherapy-refractory patients with metastatic colorectal cancer and KRAS wt tumors, Exon 10 PIK3CA mutations (listed as Exon 9 in the source) had no significant impact on response rate (6/21 [28.6%] vs 115/317 [36.3%]; OR: 0.70; p = 0.47), disease control rate, median progression free survival or median overall survival (46 vs 51 weeks, HR: 1.30, p=0.28) following cetuximab + chemotherapy than wildtype PIK3CA. In multivariate analysis of KRAS wildtype patients, PIK3CA was not significantly associated with patient outcome. Authors conclude that PIK3CA exon 10 mutation status does not appear relevant to treatment response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	123	106	37	3	178935998	178936122			ENST00000263967.3					75	GRCh37	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/123	https://civic.genome.wustl.edu/links/variants/106	https://civic.genome.wustl.edu/links/genes/37
NRAS	4893	Q61	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	B	Resistance	In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy (N=480).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	124	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/124	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
ALK	238	F1174L	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Resistance	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.	22072639	PubMed		Bresler et al., 2011, Sci Transl Med		3	accepted	125	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/125	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
BRAF	673	V600E	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	126	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/126	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Supports	B	Resistance	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.	19965647	PubMed		Burnett et al., 2010, Blood		3	accepted	127	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/127	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).	17957027	PubMed		Gale et al., 2008, Blood		4	accepted	128	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/128	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.	17957027	PubMed		Gale et al., 2008, Blood		3	accepted	129	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/129	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	15626738	PubMed		Bagrintseva et al., 2005, Blood		3	accepted	130	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/130	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		SU5614		Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	15626738	PubMed		Bagrintseva et al., 2005, Blood		3	accepted	131	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/131	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with metastatic colorectal cancer harboring KRAS mutations (primarily G12/G13; n=230 out of 253 total KRAS mutant patients) had lower response rates (17/253; 6.7% vs KRAS wt 126/352; 35.8%; P < .0001), disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS. Authors note that these patients were treated with cetuximab prior to widespead adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	134	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/134	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.	18202412	PubMed		Livre et al., 2008, J. Clin. Oncol.		3	accepted	135	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/135	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	PubMed		De Roock et al., 2010, JAMA		4	accepted	136	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/136	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Supports	B	Resistance	ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.	19965647	PubMed		Burnett et al., 2010, Blood		3	accepted	137	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/137	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
PIK3CA	5290	EXON 21 MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	138	105	37	3	178951882	178952495			ENST00000263967.3					75	GRCh37	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/138	https://civic.genome.wustl.edu/links/variants/105	https://civic.genome.wustl.edu/links/genes/37
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119		Cytarabine,Daunorubicin	Combination	Predictive	Supports	B	Resistance	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.	18591546	PubMed		Virappane et al., 2008, J. Clin. Oncol.		3	accepted	139	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/139	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
ALK	238	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	D	Sensitivity/Response	CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.	21575866	PubMed		Sakamoto et al., 2011, Cancer Cell		3	accepted	141	7	1	2	29443631	29443631	G	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Somatic	2021-03-31 18:23:11 UTC	https://civic.genome.wustl.edu/links/evidence_items/141	https://civic.genome.wustl.edu/links/variants/7	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1174L	Neuroblastoma	769		TAE684		Predictive	Supports	D	Sensitivity/Response	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.	18923525	PubMed		George et al., 2008, Nature		4	accepted	142	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/142	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	R1275Q	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Sensitivity/Response	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	22072639	PubMed		Bresler et al., 2011, Sci Transl Med		3	accepted	143	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/143	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
FGFR3	2261	FGFR3-BAIAP2L1	Bladder Carcinoma	4007		PD173074		Predictive	Supports	D	Sensitivity/Response	Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074.	23558953	PubMed		Wu et al., 2013, Cancer Discov		3	accepted	144	53	23	4	1795039	1810599			ENST00000340107.4	7	97991744	97920963	ENST00000005260.8	75	GRCh37	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/144	https://civic.genome.wustl.edu/links/variants/53	https://civic.genome.wustl.edu/links/genes/23
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	PubMed		De Roock et al., 2010, JAMA		4	accepted	145	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/145	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Supports	B	Sensitivity/Response	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.	19059939	PubMed		Schlenk et al., 2009, Haematologica	NCT00151242	2	accepted	146	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/146	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Supports	B	Sensitivity/Response	Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.	22417203	PubMed		Patel et al., 2012, N. Engl. J. Med.		2	accepted	147	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/147	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Valproic Acid		Predictive	Supports	B	Sensitivity/Response	For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.	24797300	PubMed		Tassara et al., 2014, Blood	NCT00151255	2	accepted	148	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/148	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		NSC348884,Tretinoin	Combination	Predictive	Supports	D	Sensitivity/Response	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.	21719597	PubMed		Balusu et al., 2011, Blood		3	accepted	149	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/149	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Anti-CD123,Anti-CD33	Combination	Predictive	Supports	E	Sensitivity/Response	CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy.	24927407	PubMed		Ehninger et al., 2014, Blood Cancer J		2	accepted	150	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/150	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Anti-CD33		Predictive	Supports	E	Sensitivity/Response	CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy.	24927407	PubMed		Ehninger et al., 2014, Blood Cancer J		2	accepted	151	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/151	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119		NSC348884		Predictive	Supports	D	Sensitivity/Response	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	21719597	PubMed		Balusu et al., 2011, Blood		3	accepted	152	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/152	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119		Induction Therapy		Predictive	Supports	E	Sensitivity/Response	NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.	15659725	PubMed		Falini et al., 2005, N. Engl. J. Med.		3	accepted	153	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/153	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35
TSC1	7248	FRAMESHIFT TRUNCATION	Lung Non-small Cell Carcinoma	3908		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.	19966866	PubMed		Liang et al., 2010, Oncogene		3	accepted	154	124	46	9	135766735	135820008			ENST00000298552.3					75	GRCh37	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/154	https://civic.genome.wustl.edu/links/variants/124	https://civic.genome.wustl.edu/links/genes/46
TSC1	7248	LOSS-OF-FUNCTION	Bladder Carcinoma	4007		Everolimus		Predictive	Supports	B	Sensitivity/Response	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	22923433	PubMed		Iyer et al., 2012, Science	NCT00805129	3	accepted	155	125	46	9	135766735	135820008			ENST00000298552.3					75	GRCh37	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/155	https://civic.genome.wustl.edu/links/variants/125	https://civic.genome.wustl.edu/links/genes/46
FLT3	2322	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835).	14726504	PubMed		Frhling et al., 2004, J. Clin. Oncol.		2	accepted	156	519	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/156	https://civic.genome.wustl.edu/links/variants/519	https://civic.genome.wustl.edu/links/genes/24
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.	22291079	PubMed		Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	157	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/157	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.	21537333	PubMed		Schnittger et al., 2011, Leukemia		4	accepted	158	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/158	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.	17957027	PubMed		Gale et al., 2008, Blood		2	accepted	159	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/159	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
IDH1	3417	R132	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.	20805365	PubMed		Schnittger et al., 2010, Blood		3	accepted	160	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/160	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML.	19221039	PubMed		Gaidzik et al., 2009, Blood		3	accepted	162	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/162	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.	19221039	PubMed		Gaidzik et al., 2009, Blood		4	accepted	163	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/163	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 9 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.	19221039	PubMed		Gaidzik et al., 2009, Blood		4	accepted	165	130	49	11	32413518	32413610			ENST00000332351.3					75	GRCh37	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/165	https://civic.genome.wustl.edu/links/variants/130	https://civic.genome.wustl.edu/links/genes/49
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA.	19965647	PubMed		Burnett et al., 2010, Blood		3	accepted	166	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/166	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation.	18450602	PubMed		Schlenk et al., 2008, N. Engl. J. Med.		4	accepted	167	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/167	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients).	14726504	PubMed		Frhling et al., 2004, J. Clin. Oncol.		3	accepted	168	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/168	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.	23632886	PubMed		Gaidzik et al., 2013, Blood		3	accepted	170	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/170	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed.	17965322	PubMed		Bacher et al., 2008, Blood		3	accepted	171	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/171	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
MGMT	4255	PROMOTER METHYLATION	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Better Outcome	MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.	11070098	PubMed		Esteller et al., 2000, N. Engl. J. Med.		4	accepted	172	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/172	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).	17957027	PubMed		Gale et al., 2008, Blood		4	accepted	173	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/173	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved.	19059939	PubMed		Schlenk et al., 2009, Haematologica	NCT00151242	3	accepted	174	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/174	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old.	16455956	PubMed		Thiede et al., 2006, Blood		3	accepted	175	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/175	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189).	16076867	PubMed		Schnittger et al., 2005, Blood		5	accepted	176	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/176	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	15659725	PubMed		Falini et al., 2005, N. Engl. J. Med.		3	accepted	177	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/177	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.	22417203	PubMed		Patel et al., 2012, N. Engl. J. Med.		2	accepted	179	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/179	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants.	19047294	PubMed		Bchner et al., 2009, J. Clin. Oncol.		3	accepted	180	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/180	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years).	24855211	PubMed		Linch et al., 2014, Blood		4	accepted	181	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/181	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients.	22430270	PubMed		Gaidzik et al., 2012, J. Clin. Oncol.		3	accepted	182	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/182	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated).	18450602	PubMed		Schlenk et al., 2008, N. Engl. J. Med.		3	accepted	183	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/183	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old.	20026798	PubMed		Becker et al., 2010, J. Clin. Oncol.		4	accepted	184	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/184	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004).	16051734	PubMed		Dhner et al., 2005, Blood		3	accepted	185	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/185	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).	22490330	PubMed		Ribeiro et al., 2012, Blood		3	accepted	186	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/186	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	22291079	PubMed		Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	187	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/187	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.	22490330	PubMed		Ribeiro et al., 2012, Blood		3	accepted	188	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/188	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.	22490330	PubMed		Ribeiro et al., 2012, Blood		3	accepted	189	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/189	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	A	Poor Outcome	Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.	24801015	PubMed		Port et al., 2014, Ann. Hematol.		3	accepted	190	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/190	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.	21537333	PubMed		Schnittger et al., 2011, Leukemia		4	accepted	191	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/191	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.	21537333	PubMed		Schnittger et al., 2011, Leukemia		4	accepted	192	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/192	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation.	21537333	PubMed		Schnittger et al., 2011, Leukemia		4	accepted	193	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/193	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
KRAS	3845	G12/G13	Colorectal Cancer	9256				Prognostic	Supports	D	Poor Outcome	KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.	18202412	PubMed		Livre et al., 2008, J. Clin. Oncol.		3	accepted	194	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/194	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone.	16455956	PubMed		Thiede et al., 2006, Blood		4	accepted	195	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/195	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).	19587375	PubMed		Schnittger et al., 2009, Blood		2	accepted	196	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/196	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients.	24855211	PubMed		Linch et al., 2014, Blood		3	accepted	198	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/198	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.	24859829	PubMed		Tian et al., 2014, Int. J. Hematol.		3	accepted	199	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/199	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.	19536888	PubMed		Renneville et al., 2009, Cancer		2	accepted	201	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/201	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence.	19536888	PubMed		Renneville et al., 2009, Cancer		2	accepted	202	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/202	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML.	19221039	PubMed		Gaidzik et al., 2009, Blood		3	accepted	203	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/203	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.	18559874	PubMed		Paschka et al., 2008, J. Clin. Oncol.		3	accepted	204	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/204	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML.	18591546	PubMed		Virappane et al., 2008, J. Clin. Oncol.		3	accepted	205	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/205	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML.	18591546	PubMed		Virappane et al., 2008, J. Clin. Oncol.		3	accepted	206	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/206	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49
WT1	7490	EXON 9 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.	18559874	PubMed		Paschka et al., 2008, J. Clin. Oncol.		3	accepted	210	130	49	11	32413518	32413610			ENST00000332351.3					75	GRCh37	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/210	https://civic.genome.wustl.edu/links/variants/130	https://civic.genome.wustl.edu/links/genes/49
BRCA1	672	LOSS-OF-FUNCTION	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.	23346317	PubMed		Goff, 2013, J Gynecol Oncol		4	accepted	211	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/211	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.	23346317	PubMed		Goff, 2013, J Gynecol Oncol		4	accepted	212	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/212	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552				Diagnostic	Does Not Support	C	Positive	Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.	25212276	PubMed		Schmidt et al., 2014, Leukemia		2	accepted	213	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/213	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.	11290608	PubMed		Yamamoto et al., 2001, Blood		3	accepted	214	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/214	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
KRAS	3845	G12	Lung Non-small Cell Carcinoma	3908				Diagnostic	Does Not Support	B	Positive	KRAS mutations in lung cancer patients are not associated with smoking history, age or gender.	18794081	PubMed		Riely et al., 2008, Clin. Cancer Res.		3	accepted	215	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/215	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
U2AF1	7307	Q157P/R	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.	23029227	PubMed		Qian et al., 2012, PLoS ONE		3	accepted	217	127	48	21	44514777	44514777	T	G	ENST00000291552.4					75	GRCh37	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/217	https://civic.genome.wustl.edu/links/variants/127	https://civic.genome.wustl.edu/links/genes/48
U2AF1	7307	S34Y/F	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.	23029227	PubMed		Qian et al., 2012, PLoS ONE		3	accepted	218	128	48	21	44524456	44524456	G	A	ENST00000291552.4					75	GRCh37	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/218	https://civic.genome.wustl.edu/links/variants/128	https://civic.genome.wustl.edu/links/genes/48
CCND2	894	PROMOTER DEMETHYLATION	Stomach Cancer	10534				Diagnostic	Supports	D	Negative	CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.	14612939	PubMed		Oshimo et al., 2003, Int. J. Oncol.		3	accepted	219	22	9	12	4381437	4382937			ENST00000261254.3					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/219	https://civic.genome.wustl.edu/links/variants/22	https://civic.genome.wustl.edu/links/genes/9
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	A	Positive	The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.	20537386	PubMed		An et al., 2010, Leuk. Res.		4	accepted	220	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/220	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
CCND1	595	OVEREXPRESSION	Breast Cancer	1612				Diagnostic	Supports	B	Positive	Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.	15961768	PubMed		Arnold et al., 2005, J. Clin. Oncol.		4	accepted	221	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/221	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.	11290608	PubMed		Yamamoto et al., 2001, Blood		3	accepted	222	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/222	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
IDH1	3417	R132	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype.	20376086	PubMed		Ho et al., 2010, Leukemia		2	accepted	223	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/223	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132C	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation.	20538800	PubMed		Abbas et al., 2010, Blood		3	accepted	224	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/224	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253				Diagnostic	Supports	B	Positive	KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT.	10485475	PubMed		Taniguchi et al., 1999, Cancer Res.		2	accepted	225	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/225	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12C	Lung Cancer	1324				Diagnostic	Supports	B	Positive	KRAS G12C occur more frequently in women than men.	23014527	PubMed		Dogan et al., 2012, Clin. Cancer Res.		2	accepted	227	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/227	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Lung Cancer	1324				Diagnostic	Supports	B	Positive	KRAS G12D mutation occurs in never smokers significantly more often than in smokers.	23014527	PubMed		Dogan et al., 2012, Clin. Cancer Res.		3	accepted	228	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/228	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).	24736073	PubMed		Lim et al., 2014, J Thorac Oncol		3	accepted	229	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/229	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
AKT1	207	E17K	Breast Cancer	1612		Akt Inhibitor MK2206		Predictive	Does Not Support	D	Sensitivity/Response	Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.	23888070	PubMed		Beaver et al., 2013, Clin. Cancer Res.		3	accepted	231	4	2	14	105246551	105246551	C	T	ENST00000407796.2					75	GRCh37	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/231	https://civic.genome.wustl.edu/links/variants/4	https://civic.genome.wustl.edu/links/genes/2
ABL1	25	BCR-ABL	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	D	Resistance	BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	12476305	PubMed		Nimmanapalli et al., 2002, Oncogene		3	accepted	232	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/232	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	COS7 cell lines transfected with BCR-ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	15194504	PubMed		Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.		4	accepted	233	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/233	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	B	Resistance	In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.	20537386	PubMed		An et al., 2010, Leuk. Res.		4	accepted	234	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/234	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	COS7 cell lines transfected with BCR-ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	15194504	PubMed		Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.		4	accepted	235	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/235	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ALK	238	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	A 28 year-old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy. The patient achieved a partial response, but progressed after 5 months of treatment. Molecular analysis at relapse identified C1156Y in the ALK kinase domain of the fusion at an allele frequency of 41.8%. This variant was undetected by Sanger sequencing in the tumor collected before crizotinib treatment. Cytotoxicity assays revealed Ba/F3 cells expressing EML4-ALK C1156Y were more resistant to crizontinib than those expressing EML4-ALK wildtype. Immunoblot demonstrated crizontinib reduced tyrosine phosphorylation of the wildtype fusion, but not the EML4-ALK C1156Y fusion.	20979473	PubMed		Choi et al., 2010, N. Engl. J. Med.		4	accepted	236	6	1	2	29445258	29445258	C	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/236	https://civic.genome.wustl.edu/links/variants/6	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	A 28 year-old patient with non-small cell lung cancer was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months, followed by rapid disease progression. Analysis of pleural effusion samples obtained after relapse found L1196M at an allele frequency of 14%. This variant was undetected by Sanger sequencing in the tumor collected before crizotinib treatment. Cytotoxicity assays revealed Ba/F3 cells expressing EML4-ALK L1196M were more resistant to crizontinib than those expressing EML4-ALK wildtype. Immunoblot demonstrated crizontinib reduced tyrosine phosphorylation of the wildtype fusion, but not the EML4-ALK L1196M fusion.	20979473	PubMed		Choi et al., 2010, N. Engl. J. Med.		4	accepted	237	7	1	2	29443631	29443631	G	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/237	https://civic.genome.wustl.edu/links/variants/7	https://civic.genome.wustl.edu/links/genes/1
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Resistance	The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.	25668228	PubMed		Denis et al., 2015, Clin. Chim. Acta		5	accepted	238	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/238	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Resistance	In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.	15728811	PubMed		Kobayashi et al., 2005, N. Engl. J. Med.		3	accepted	239	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/239	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Resistance	In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.	21430269	PubMed		Sequist et al., 2011, Sci Transl Med		4	accepted	240	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/240	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
ERBB2	2064	L755S	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	241	39	20	17	37880220	37880220	T	C	ENST00000269571.5					75	GRCh37	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/241	https://civic.genome.wustl.edu/links/variants/39	https://civic.genome.wustl.edu/links/genes/20
ESR1	2099	L536Q	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		3	accepted	242	46	21	6	152419920	152419921	TC	AG	ENST00000440973.1					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/242	https://civic.genome.wustl.edu/links/variants/46	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	D538G	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		3	accepted	243	47	21	6	152419926	152419926	A	G	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/243	https://civic.genome.wustl.edu/links/variants/47	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537C	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		3	accepted	244	48	21	6	152419923	152419923	A	G	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/244	https://civic.genome.wustl.edu/links/variants/48	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537N	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		3	accepted	245	49	21	6	152419922	152419922	T	A	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/245	https://civic.genome.wustl.edu/links/variants/49	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537S	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		3	accepted	246	50	21	6	152419923	152419923	A	C	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/246	https://civic.genome.wustl.edu/links/variants/50	https://civic.genome.wustl.edu/links/genes/21
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.	22368270	PubMed		Man et al., 2012, Blood		4	accepted	247	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/247	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation.	18230792	PubMed		Zhang et al., 2008, J. Natl. Cancer Inst.		4	accepted	248	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/248	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
KIT	3815	V654A	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	249	73	29	4	55594258	55594258	T	C	ENST00000288135.5					75	GRCh37	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/249	https://civic.genome.wustl.edu/links/variants/73	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.	16618717	PubMed		Livre et al., 2006, Cancer Res.		3	accepted	250	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/250	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Lung Adenocarcinoma	3910		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients.	19794967	PubMed		Marchetti et al., 2009, Neoplasia		3	accepted	251	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/251	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	E542K	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	256	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/256	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Does Not Support	B	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumor (located in rectum) of one patient who experienced partial response (patient 38; Supplemental Table 1), following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	258	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/258	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	A	Sensitivity/Response	Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	12476305	PubMed		Nimmanapalli et al., 2002, Oncogene		5	accepted	259	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/259	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	20537386	PubMed		An et al., 2010, Leuk. Res.		5	accepted	260	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/260	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552		Dasatinib,Nilotinib	Substitutes	Predictive	Supports	A	Sensitivity/Response	The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.	20537386	PubMed		An et al., 2010, Leuk. Res.		4	accepted	261	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/261	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.	20979473	PubMed		Choi et al., 2010, N. Engl. J. Med.		4	accepted	262	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/262	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
CCND3	896	LOSS	T-cell Lymphoblastic Leukemia/lymphoma	715		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.	23079656	PubMed		Sawai et al., 2012, Cancer Cell		3	accepted	263	23	10	6	41902671	41909586			ENST00000372991.4					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/263	https://civic.genome.wustl.edu/links/variants/23	https://civic.genome.wustl.edu/links/genes/10
CDK4	1019	EXPRESSION	Estrogen-receptor Positive Breast Cancer	0060075		Alpelisib		Predictive	Supports	D	Sensitivity/Response	In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.	25002028	PubMed		Vora et al., 2014, Cancer Cell	NCT01219699	4	accepted	264	25	13	12	58141510	58146304			ENST00000257904.6					75	GRCh37	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/264	https://civic.genome.wustl.edu/links/variants/25	https://civic.genome.wustl.edu/links/genes/13
DDR2	4921	G253C	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	266	141	51	1	162729671	162729671	G	T	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/266	https://civic.genome.wustl.edu/links/variants/141	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	G505S	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	267	142	51	1	162741822	162741822	G	A	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/267	https://civic.genome.wustl.edu/links/variants/142	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	G774V	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	268	144	51	1	162748407	162748407	G	T	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/268	https://civic.genome.wustl.edu/links/variants/144	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	I638F	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	269	143	51	1	162745497	162745497	A	T	ENST00000367922.3					75	GRCh37	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/269	https://civic.genome.wustl.edu/links/variants/143	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	L239R	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	270	140	51	1	162729630	162729630	T	G	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/270	https://civic.genome.wustl.edu/links/variants/140	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	L63V	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		4	accepted	271	139	51	1	162724415	162724415	C	G	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/271	https://civic.genome.wustl.edu/links/variants/139	https://civic.genome.wustl.edu/links/genes/51
DDR2	4921	S768R	Lung Non-small Cell Carcinoma	3908		Erlotinib,Dasatinib	Combination	Predictive	Supports	C	Sensitivity/Response	In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.	22328973	PubMed		Hammerman et al., 2011, Cancer Discov		3	accepted	272	145	51	1	162748390	162748390	T	A	ENST00000367922.3					75	GRCh37	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/272	https://civic.genome.wustl.edu/links/variants/145	https://civic.genome.wustl.edu/links/genes/51
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Exon 19 deletion has been shown to be correlated with gefitinib response.	16730237	PubMed		Ji et al., 2006, Cancer Cell		4	accepted	273	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/273	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G719S	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.	15118125	PubMed		Paez et al., 2004, Science		4	accepted	274	134	19	7	55241707	55241707	G	A	ENST00000275493.2					75	GRCh37	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/274	https://civic.genome.wustl.edu/links/variants/134	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.	24457318	PubMed		Fukihara et al., 2014, Oncology		4	accepted	275	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/275	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.	15118125	PubMed		Paez et al., 2004, Science		4	accepted	276	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/276	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Pemetrexed,Erlotinib	Combination	Predictive	Supports	C	Sensitivity/Response	In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.	24636847	PubMed		Li et al., 2014, Lung Cancer		3	accepted	277	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/277	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Staurosporine		Predictive	Supports	E	Sensitivity/Response	In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.	24658966	PubMed		Ai et al., 2014, Amino Acids		1	accepted	278	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/278	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
ERBB2	2064	D769H	Breast Cancer	1612		Neratinib,Lapatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		4	accepted	279	35	20	17	37880261	37880261	G	C	ENST00000269571.5					75	GRCh37	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/279	https://civic.genome.wustl.edu/links/variants/35	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	D769Y	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		4	accepted	280	36	20	17	37880261	37880261	G	T	ENST00000269571.5					75	GRCh37	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/280	https://civic.genome.wustl.edu/links/variants/36	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	L755_T759del	Breast Cancer	1612		Neratinib,Lapatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	281	37	20	17	37880219	37880233	TTGAGGGAAAACACA		ENST00000269571.5					75	GRCh37	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/281	https://civic.genome.wustl.edu/links/variants/37	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	G309A	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	282	38	20	17	37868205	37868205	G	C	ENST00000269571.5					75	GRCh37	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/282	https://civic.genome.wustl.edu/links/variants/38	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	L755S	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	283	39	20	17	37880220	37880220	T	C	ENST00000269571.5					75	GRCh37	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/283	https://civic.genome.wustl.edu/links/variants/39	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	L755W	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	284	40	20	17	37880220	37880220	T	G	ENST00000269571.5					75	GRCh37	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/284	https://civic.genome.wustl.edu/links/variants/40	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	P780INS	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	285	41	20	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5					75	GRCh37	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/285	https://civic.genome.wustl.edu/links/variants/41	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	R678Q	Breast Cancer	1612		Neratinib,Lapatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	286	42	20	17	37879658	37879658	G	A	ENST00000269571.5					75	GRCh37	ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/286	https://civic.genome.wustl.edu/links/variants/42	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	R896C	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	287	43	20	17	37881616	37881616	C	T	ENST00000269571.5					75	GRCh37	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/287	https://civic.genome.wustl.edu/links/variants/43	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	V777L	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	288	44	20	17	37881000	37881000	G	T	ENST00000269571.5					75	GRCh37	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/288	https://civic.genome.wustl.edu/links/variants/44	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	V842I	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.	23220880	PubMed		Bose et al., 2013, Cancer Discov		5	accepted	289	45	20	17	37881332	37881332	G	A	ENST00000269571.5					75	GRCh37	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/289	https://civic.genome.wustl.edu/links/variants/45	https://civic.genome.wustl.edu/links/genes/20
ESR1	2099	L536Q	Breast Cancer	1612		Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.	24185510	PubMed		Robinson et al., 2013, Nat. Genet.		5	accepted	290	46	21	6	152419920	152419921	TC	AG	ENST00000440973.1					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/290	https://civic.genome.wustl.edu/links/variants/46	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	D538G	Breast Cancer	1612		Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.	24185510	PubMed		Robinson et al., 2013, Nat. Genet.		5	accepted	291	47	21	6	152419926	152419926	A	G	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/291	https://civic.genome.wustl.edu/links/variants/47	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537C	Breast Cancer	1612		Tamoxifen,Fulvestrant	Substitutes	Predictive	Supports	D	Sensitivity/Response	Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.	24185510	PubMed		Robinson et al., 2013, Nat. Genet.		5	accepted	292	48	21	6	152419923	152419923	A	G	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/292	https://civic.genome.wustl.edu/links/variants/48	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537N	Breast Cancer	1612		Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.	24185510	PubMed		Robinson et al., 2013, Nat. Genet.		5	accepted	293	49	21	6	152419922	152419922	T	A	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/293	https://civic.genome.wustl.edu/links/variants/49	https://civic.genome.wustl.edu/links/genes/21
ESR1	2099	Y537S	Breast Cancer	1612		Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.	24185510	PubMed		Robinson et al., 2013, Nat. Genet.		5	accepted	294	50	21	6	152419923	152419923	A	C	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/294	https://civic.genome.wustl.edu/links/variants/50	https://civic.genome.wustl.edu/links/genes/21
FGFR2	2263	FGFR2-MGEA5	Cholangiocarcinoma	4947		Ponatinib		Predictive	Supports	C	Sensitivity/Response	In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response.	24550739	PubMed		Borad et al., 2014, PLoS Genet.		2	accepted	295	52	22	10	123243212	123357917			ENST00000457416.2	10	103544209	103552700	ENST00000361464.3	75	GRCh37	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/295	https://civic.genome.wustl.edu/links/variants/52	https://civic.genome.wustl.edu/links/genes/22
FGFR2	2263	FGFR2-TACC3	Cholangiocarcinoma	4947		Pazopanib,Ponatinib	Sequential	Predictive	Supports	C	Sensitivity/Response	In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	24550739	PubMed		Borad et al., 2014, PLoS Genet.		3	accepted	296	54	22	4	123243212	123357598			ENST00000358487.5	4	1723266	1741505	ENST00000313288.4	75	GRCh37	In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/296	https://civic.genome.wustl.edu/links/variants/54	https://civic.genome.wustl.edu/links/genes/22
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Lestaurtinib		Predictive	Supports	B	Sensitivity/Response	CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.	14726387	PubMed		Smith et al., 2004, Blood		4	accepted	297	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/297	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Sensitivity/Response	Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation.	18230792	PubMed		Zhang et al., 2008, J. Natl. Cancer Inst.		4	accepted	298	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/298	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Tyrphostin AG 1296		Predictive	Supports	D	Sensitivity/Response	AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.	12357354	PubMed		Tse et al., 2002, Leukemia		4	accepted	299	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/299	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
GATA2	2624	EXPRESSION	Lung Adenocarcinoma	3910		Bortezomib,Fasudil	Combination	Predictive	Supports	D	Sensitivity/Response	Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.	22541434	PubMed		Kumar et al., 2012, Cell		4	accepted	301	57	25	3	128198270	128212028			ENST00000341105.2					75	GRCh37	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/301	https://civic.genome.wustl.edu/links/variants/57	https://civic.genome.wustl.edu/links/genes/25
KIT	3815	INTERNAL DUPLICATION	Malignant Anus Melanoma	14145		Imatinib		Predictive	Supports	C	Sensitivity/Response	In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment.	18421059	PubMed		Hodi et al., 2008, J. Clin. Oncol.		3	accepted	302	67	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/302	https://civic.genome.wustl.edu/links/variants/67	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	L576P	Lung Non-small Cell Carcinoma	3908		Nilotinib,Dasatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib.	17372901	PubMed		Antonescu et al., 2007, Int. J. Cancer		3	accepted	303	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/303	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V654A	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.	16638875	PubMed		Prenen et al., 2006, Clin. Cancer Res.		3	accepted	304	73	29	4	55594258	55594258	T	C	ENST00000288135.5					75	GRCh37	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/304	https://civic.genome.wustl.edu/links/variants/73	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12D	Lung Non-small Cell Carcinoma	3908		Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression.	19029981	PubMed		Engelman et al., 2008, Nat. Med.		4	accepted	305	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/305	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.	20978259	PubMed		De Roock et al., 2010, JAMA		4	accepted	306	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/306	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
MGMT	4255	PROMOTER METHYLATION	Glioblastoma Multiforme	3068		Temozolomide		Predictive	Supports	A	Sensitivity/Response	In a randomized clinical trial, patients with MGMT promoter methylation benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.	15758010	PubMed		Hegi et al., 2005, N. Engl. J. Med.		5	accepted	307	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/307	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	PROMOTER METHYLATION	Glioblastoma Multiforme	3068		Carmustine		Predictive	Supports	B	Sensitivity/Response	MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.	11070098	PubMed		Esteller et al., 2000, N. Engl. J. Med.		4	accepted	308	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/308	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	PROMOTER METHYLATION	Glioblastoma Multiforme	3068		O6-Benzylguanine		Predictive	Supports	E	Sensitivity/Response	In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.	11070098	PubMed		Esteller et al., 2000, N. Engl. J. Med.		4	accepted	309	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/309	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
PIK3CA	5290	E542K	Breast Cancer	1612		PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	21558396	PubMed		Tanaka et al., 2011, Clin. Cancer Res.		4	accepted	310	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/310	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E542K	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Rapamycin inhibits transformation induced by mutation in PIK3CA.	15647370	PubMed		Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	311	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/311	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Breast Cancer	1612		PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	21558396	PubMed		Tanaka et al., 2011, Clin. Cancer Res.		4	accepted	314	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/314	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PML	5371	PML-RARA	Acute Promyelocytic Leukemia	0060318		Tretinoin		Predictive	Supports	B	Sensitivity/Response	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	8674046	PubMed		Yoshida et al., 1996, Cancer Res.		5	accepted	316	108	39	15	74287058	74325755			ENST00000268058.3	17	38504568	38513048	ENST00000254066.5	75	GRCh37	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/316	https://civic.genome.wustl.edu/links/variants/108	https://civic.genome.wustl.edu/links/genes/39
PTEN	5728	R233*	Breast Cancer	1612		MTOR Inhibitor		Predictive	Supports	D	Sensitivity/Response	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.	20085938	PubMed		Courtney et al., 2010, J. Clin. Oncol.		4	accepted	317	110	41	10	89717672	89717672	C	T	ENST00000371953.3					75	GRCh37	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/317	https://civic.genome.wustl.edu/links/variants/110	https://civic.genome.wustl.edu/links/genes/41
TP53	7157	R175H	Breast Cancer	1612		Doxorubicin		Predictive	Supports	D	Sensitivity/Response	Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.	22698404	PubMed		Jackson et al., 2012, Cancer Cell		3	accepted	319	116	45	17	7578406	7578406	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/319	https://civic.genome.wustl.edu/links/variants/116	https://civic.genome.wustl.edu/links/genes/45
TSC1	7248	FRAMESHIFT TRUNCATION	Invasive Bladder Transitional Cell Carcinoma	6477		Everolimus		Predictive	Supports	B	Sensitivity/Response	A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus.	22923433	PubMed		Iyer et al., 2012, Science	NCT00805129	3	accepted	320	124	46	9	135766735	135820008			ENST00000298552.3					75	GRCh37	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/320	https://civic.genome.wustl.edu/links/variants/124	https://civic.genome.wustl.edu/links/genes/46
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.	11290608	PubMed		Yamamoto et al., 2001, Blood		3	accepted	322	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/322	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
IDH1	3417	R132	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.	20368538	PubMed		Wagner et al., 2010, J. Clin. Oncol.		2	accepted	323	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/323	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132C	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	20538800	PubMed		Abbas et al., 2010, Blood		2	accepted	324	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/324	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	R140	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2.	22616558	PubMed		Zhou et al., 2012, Leuk. Lymphoma		2	accepted	327	62	27	15	90631934	90631934			ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/327	https://civic.genome.wustl.edu/links/variants/62	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival.	20421455	PubMed		Thol et al., 2010, Blood	NCT00209833	3	accepted	328	570	27	15	90626277	90645736			ENST00000330062.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/328	https://civic.genome.wustl.edu/links/variants/570	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R140	Myelodysplastic Syndrome	0050908				Prognostic	Does Not Support	B	N/A	In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794).	21997850	PubMed		Lin et al., 2012, Ann. Hematol.		2	accepted	329	62	27	15	90631934	90631934			ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/329	https://civic.genome.wustl.edu/links/variants/62	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R140	Myelodysplastic Syndrome	0050908				Prognostic	Does Not Support	B	N/A	R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	22033490	PubMed		Patnaik et al., 2012, Leukemia		3	accepted	330	62	27	15	90631934	90631934			ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/330	https://civic.genome.wustl.edu/links/variants/62	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R172K	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	22616558	PubMed		Zhou et al., 2012, Leuk. Lymphoma		2	accepted	331	63	27	15	90631838	90631838	C	T	ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/331	https://civic.genome.wustl.edu/links/variants/63	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R172K	Myelodysplastic Syndrome	0050908				Prognostic	Does Not Support	B	N/A	In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival).	21997850	PubMed		Lin et al., 2012, Ann. Hematol.		2	accepted	332	63	27	15	90631838	90631838	C	T	ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/332	https://civic.genome.wustl.edu/links/variants/63	https://civic.genome.wustl.edu/links/genes/27
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253				Prognostic	Does Not Support	B	N/A	KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST.	12000708	PubMed		Corless et al., 2002, Am. J. Pathol.		3	accepted	333	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/333	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 11 MUTATION	Lung Cancer	1324				Prognostic	Does Not Support	B	N/A	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.	15217946	PubMed		Boldrini et al., 2004, Clin. Cancer Res.		2	accepted	334	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/334	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12	Colorectal Cancer	9256				Prognostic	Does Not Support	B	N/A	In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival.	19934290	PubMed		Ogino et al., 2009, Clin. Cancer Res.		4	accepted	336	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/336	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	N/A	There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.	11208838	PubMed		Schiller et al., 2001, J. Clin. Oncol.		3	accepted	337	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/337	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
U2AF1	7307	Q157P/R	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1.	23029227	PubMed		Qian et al., 2012, PLoS ONE		2	accepted	338	127	48	21	44514777	44514777	T	G	ENST00000291552.4					75	GRCh37	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/338	https://civic.genome.wustl.edu/links/variants/127	https://civic.genome.wustl.edu/links/genes/48
U2AF1	7307	Q157P/R	Myelodysplastic Syndrome	0050908				Prognostic	Does Not Support	B	N/A	In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.	23029227	PubMed		Qian et al., 2012, PLoS ONE		2	accepted	339	127	48	21	44514777	44514777	T	G	ENST00000291552.4					75	GRCh37	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/339	https://civic.genome.wustl.edu/links/variants/127	https://civic.genome.wustl.edu/links/genes/48
U2AF1	7307	S34Y/F	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.	23029227	PubMed		Qian et al., 2012, PLoS ONE		2	accepted	340	128	48	21	44524456	44524456	G	A	ENST00000291552.4					75	GRCh37	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/340	https://civic.genome.wustl.edu/links/variants/128	https://civic.genome.wustl.edu/links/genes/48
CCND1	595	EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	Three studies have found no significant survival impact for CCND1 in lung cancer.	17070615	PubMed		Gautschi et al., 2007, Lung Cancer		3	accepted	342	19	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/342	https://civic.genome.wustl.edu/links/variants/19	https://civic.genome.wustl.edu/links/genes/8
PTEN	5728	R233*	Glioblastoma Multiforme	3068				Prognostic	Does Not Support	B	Poor Outcome	PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients.	22479427	PubMed		Carico et al., 2012, PLoS ONE		3	accepted	343	110	41	10	89717672	89717672	C	T	ENST00000371953.3					75	GRCh37	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/343	https://civic.genome.wustl.edu/links/variants/110	https://civic.genome.wustl.edu/links/genes/41
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.	20537386	PubMed		An et al., 2010, Leuk. Res.		5	accepted	344	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/344	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.	24662454	PubMed		Douillard et al., 2014, J Thorac Oncol		3	accepted	347	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/347	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
IDH1	3417	R132	Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation.	19933982	PubMed		Dubbink et al., 2009, Neurology		3	accepted	348	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/348	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Better Outcome	In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation.	20127344	PubMed		Bleeker et al., 2010, Acta Neuropathol.		3	accepted	349	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/349	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	R140	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2.	21596855	PubMed		Green et al., 2011, Blood		3	accepted	350	62	27	15	90631934	90631934			ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/350	https://civic.genome.wustl.edu/links/variants/62	https://civic.genome.wustl.edu/links/genes/27
SF3B1	23451	MUTATION	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Better Outcome	Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex.	21995386	PubMed		Papaemmanuil et al., 2011, N. Engl. J. Med.		3	accepted	352	215	44	2	198254508	198299815			ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/352	https://civic.genome.wustl.edu/links/variants/215	https://civic.genome.wustl.edu/links/genes/44
CCND1	595	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Inceased copy number of CCND1 is associated with poorer overall survival.	17070615	PubMed		Gautschi et al., 2007, Lung Cancer		3	accepted	354	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/354	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
CCND1	595	EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Three studies have associated CCND1 expression with poorer survival.	17070615	PubMed		Gautschi et al., 2007, Lung Cancer		3	accepted	355	19	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/355	https://civic.genome.wustl.edu/links/variants/19	https://civic.genome.wustl.edu/links/genes/8
CCND1	595	OVEREXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.	15961768	PubMed		Arnold et al., 2005, J. Clin. Oncol.		4	accepted	356	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/356	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
CCND1	595	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.	16309541	PubMed		Thomas et al., 2005, Int J Exp Pathol		4	accepted	357	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/357	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
CCND1	595	OVEREXPRESSION	Mantle Cell Lymphoma	0050746				Prognostic	Supports	B	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.	17891190	PubMed		Jares et al., 2007, Nat. Rev. Cancer		4	accepted	358	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/358	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
CCND2	894	OVEREXPRESSION	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.	10547574	PubMed		Takano et al., 1999, J. Pathol.		4	accepted	359	21	9	12	4382938	4414516			ENST00000261254.3					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/359	https://civic.genome.wustl.edu/links/variants/21	https://civic.genome.wustl.edu/links/genes/9
CCND2	894	OVEREXPRESSION	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	10547574	PubMed		Takano et al., 1999, J. Pathol.		4	accepted	360	21	9	12	4382938	4414516			ENST00000261254.3					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/360	https://civic.genome.wustl.edu/links/variants/21	https://civic.genome.wustl.edu/links/genes/9
CCND2	894	OVEREXPRESSION	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.	10547574	PubMed		Takano et al., 1999, J. Pathol.		4	accepted	361	21	9	12	4382938	4414516			ENST00000261254.3					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/361	https://civic.genome.wustl.edu/links/variants/21	https://civic.genome.wustl.edu/links/genes/9
CCND2	894	OVEREXPRESSION	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.	10547574	PubMed		Takano et al., 1999, J. Pathol.		4	accepted	362	21	9	12	4382938	4414516			ENST00000261254.3					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/362	https://civic.genome.wustl.edu/links/variants/21	https://civic.genome.wustl.edu/links/genes/9
CCNE1	898	OVEREXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels.	12432043	PubMed		Keyomarsi et al., 2002, N. Engl. J. Med.		4	accepted	363	24	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.	N/A	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/363	https://civic.genome.wustl.edu/links/variants/24	https://civic.genome.wustl.edu/links/genes/11
CCNE1	898	OVEREXPRESSION	Gastric Adenosquamous Carcinoma	5635				Prognostic	Supports	B	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.	10224221	PubMed		Donnellan et al., 1999, FASEB J.		4	accepted	364	24	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.	N/A	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/364	https://civic.genome.wustl.edu/links/variants/24	https://civic.genome.wustl.edu/links/genes/11
CCNE1	898	OVEREXPRESSION	Gastric Adenosquamous Carcinoma	5635				Prognostic	Supports	B	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	10224221	PubMed		Donnellan et al., 1999, FASEB J.		4	accepted	365	24	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.	N/A	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/365	https://civic.genome.wustl.edu/links/variants/24	https://civic.genome.wustl.edu/links/genes/11
CDKN2A	1029	PROMOTER HYPERMETHYLATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival.	23111194	PubMed		Bradly et al., 2012, Diagn. Mol. Pathol.		3	accepted	367	27	14	9	21974827	21994591			ENST00000498124.1					75	GRCh37	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/367	https://civic.genome.wustl.edu/links/variants/27	https://civic.genome.wustl.edu/links/genes/14
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.	24623981	PubMed		Ding et al., 2014, Onco Targets Ther		4	accepted	369	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/369	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.	24729716	PubMed		Li et al., 2014, Onco Targets Ther		4	accepted	370	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/370	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.	11290608	PubMed		Yamamoto et al., 2001, Blood		3	accepted	371	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/371	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	11585760	PubMed		Whitman et al., 2001, Cancer Res.		4	accepted	372	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/372	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.	17940205	PubMed		Whitman et al., 2008, Blood		4	accepted	373	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/373	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
IDH1	3417	R132	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.	20494930	PubMed		Thol et al., 2010, Haematologica		4	accepted	374	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/374	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	R172K	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2.	21596855	PubMed		Green et al., 2011, Blood		3	accepted	375	63	27	15	90631838	90631838	C	T	ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/375	https://civic.genome.wustl.edu/links/variants/63	https://civic.genome.wustl.edu/links/genes/27
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253				Prognostic	Supports	B	Poor Outcome	KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.	10485475	PubMed		Taniguchi et al., 1999, Cancer Res.		3	accepted	376	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/376	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.	18528420	PubMed		Chng et al., 2008, Leukemia		3	accepted	377	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/377	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.	15597105	PubMed		Mascaux et al., 2005, Br. J. Cancer		3	accepted	378	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/378	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
NOTCH1	4851	D1642H	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context.	20007775	PubMed		Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	380	135	50	9	139399219	139399219	C	G	ENST00000277541.6					75	GRCh37	Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/380	https://civic.genome.wustl.edu/links/variants/135	https://civic.genome.wustl.edu/links/genes/50
NOTCH1	4851	R2327W	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	20007775	PubMed		Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	381	136	50	9	139391212	139391212	G	A	ENST00000277541.6					75	GRCh37	Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/381	https://civic.genome.wustl.edu/links/variants/136	https://civic.genome.wustl.edu/links/genes/50
NOTCH1	4851	S2275FS	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	20007775	PubMed		Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	382	138	50	9	139391369	139391370		A	ENST00000277541.6					75	GRCh37	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.	Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/382	https://civic.genome.wustl.edu/links/variants/138	https://civic.genome.wustl.edu/links/genes/50
NOTCH1	4851	V2444FS	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	20007775	PubMed		Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	383	137	50	9	139390861	139390861	G	TGT	ENST00000277541.6					75	GRCh37	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/383	https://civic.genome.wustl.edu/links/variants/137	https://civic.genome.wustl.edu/links/genes/50
PIK3CA	5290	EXON 10 MUTATION	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutated tumors, 58% (109/189) had mutations in exon 10 (listed as exon 9 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 10 mutation was not significantly associated with differences in colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.15 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted.	22357840	PubMed		Liao et al., 2012, Clin. Cancer Res.		2	accepted	384	106	37	3	178935998	178936122			ENST00000263967.3					75	GRCh37	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/384	https://civic.genome.wustl.edu/links/variants/106	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E542K	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035).	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	385	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/385	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	387	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/387	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumors of four patients (Patient Ids: 7, 42, 52, 64; Table S1) and the metastatic tumor of one patient (11; Table S1), who experienced disease progression following treatment. It was also noted in the primary tumors of 3 patients (25, 48, 88; Table S1) who experienced stable disease following treatment.This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, one patient (38, Table S1) had PIK3CA H1047R as the only noted variant, but experienced partial response.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	388	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/388	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
TP53	7157	R175H	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	16489069	PubMed		Olivier et al., 2006, Clin. Cancer Res.		3	accepted	389	116	45	17	7578406	7578406	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/389	https://civic.genome.wustl.edu/links/variants/116	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R248Q	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8).	16489069	PubMed		Olivier et al., 2006, Clin. Cancer Res.		3	accepted	390	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/390	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R248Q	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	9569050	PubMed		Berns et al., 1998, Br. J. Cancer		3	accepted	391	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/391	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R248W	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.	16489069	PubMed		Olivier et al., 2006, Clin. Cancer Res.		3	accepted	392	118	45	17	7577539	7577539	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/392	https://civic.genome.wustl.edu/links/variants/118	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R249	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53.	9569050	PubMed		Berns et al., 1998, Br. J. Cancer		3	accepted	393	119	45	17	7577535	7577535	C	G	ENST00000269305.4					75	GRCh37	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/393	https://civic.genome.wustl.edu/links/variants/119	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273C	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	16489069	PubMed		Olivier et al., 2006, Clin. Cancer Res.		3	accepted	395	121	45	17	7577121	7577121	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/395	https://civic.genome.wustl.edu/links/variants/121	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273C	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	9569050	PubMed		Berns et al., 1998, Br. J. Cancer		3	accepted	396	121	45	17	7577121	7577121	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/396	https://civic.genome.wustl.edu/links/variants/121	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273H	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	16489069	PubMed		Olivier et al., 2006, Clin. Cancer Res.		3	accepted	397	122	45	17	7577120	7577120	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/397	https://civic.genome.wustl.edu/links/variants/122	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273H	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	9569050	PubMed		Berns et al., 1998, Br. J. Cancer		3	accepted	398	122	45	17	7577120	7577120	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/398	https://civic.genome.wustl.edu/links/variants/122	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R249	Breast Cancer	1612		Doxorubicin		Predictive	Supports	B	Sensitivity/Response	Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.	9569050	PubMed		Berns et al., 1998, Br. J. Cancer		3	accepted	399	119	45	17	7577535	7577535	C	G	ENST00000269305.4					75	GRCh37	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/399	https://civic.genome.wustl.edu/links/variants/119	https://civic.genome.wustl.edu/links/genes/45
U2AF1	7307	Q157P/R	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.	23861105	PubMed		Wu et al., 2013, Am. J. Hematol.		3	accepted	400	127	48	21	44514777	44514777	T	G	ENST00000291552.4					75	GRCh37	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/400	https://civic.genome.wustl.edu/links/variants/127	https://civic.genome.wustl.edu/links/genes/48
U2AF1	7307	S34Y/F	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.	23861105	PubMed		Wu et al., 2013, Am. J. Hematol.		3	accepted	401	128	48	21	44524456	44524456	G	A	ENST00000291552.4					75	GRCh37	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/401	https://civic.genome.wustl.edu/links/variants/128	https://civic.genome.wustl.edu/links/genes/48
CSF1R	1436	MEF2D-CSF1R	Acute Lymphoblastic Leukemia	9952		Imatinib,GW-2580	Substitutes	Predictive	Supports	D	Sensitivity/Response	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	24186003	PubMed		Lilljebjrn et al., 2014, Leukemia		3	accepted	403	30	33	1	156446804	156470620			ENST00000348159.4	5	149433787	149441412	ENST00000286301.3	75	GRCh37	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/403	https://civic.genome.wustl.edu/links/variants/30	https://civic.genome.wustl.edu/links/genes/33
PRKACA	5566	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.	24578576	PubMed		Honeyman et al., 2014, Science		4	accepted	405	31	17	19	14628951	14629232			ENST00000254322.2	19	14202500	14218221	ENST00000308677.4	75	GRCh37	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/405	https://civic.genome.wustl.edu/links/variants/31	https://civic.genome.wustl.edu/links/genes/17
BCL2	596	IGH-BCL2	Diffuse Large B-cell Lymphoma	0050745				Diagnostic	Supports	B	Positive	The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	12075054	PubMed		Rosenwald et al., 2002, N. Engl. J. Med.		4	accepted	407	151	59	14	106032614	107288051				18	60794268	60987019	ENST00000333681.4	75	GRCh37	The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/407	https://civic.genome.wustl.edu/links/variants/151	https://civic.genome.wustl.edu/links/genes/59
FOXP1	27086	AMPLIFICATION	Diffuse Large B-cell Lymphoma	0050745				Diagnostic	Supports	B	Positive	Amplification of FOXP1 is shown to be associated with ABC DLBCL.	18765795	PubMed		Lenz et al., 2008, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	408	153	56	3	71003844	71633140			ENST00000318789.4					75	GRCh37	Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/408	https://civic.genome.wustl.edu/links/variants/153	https://civic.genome.wustl.edu/links/genes/56
REL	5966	AMPLIFICATION	Diffuse Large B-cell Lymphoma	0050745				Diagnostic	Supports	B	Positive	Amplification of REL is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	12075054	PubMed		Rosenwald et al., 2002, N. Engl. J. Med.		4	accepted	409	154	57	2	61108709	61149800			ENST00000295025.8					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/409	https://civic.genome.wustl.edu/links/variants/154	https://civic.genome.wustl.edu/links/genes/57
RUNX1	861	MUTATION	Acute Myeloid Leukemia	9119		Cytarabine		Predictive	Supports	B	Resistance	In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).	21343560	PubMed		Gaidzik et al., 2011, J. Clin. Oncol.	NCT00146120,NCT00151242	4	accepted	411	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/411	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
IGF2	3481	OVEREXPRESSION	Prostate Cancer	10283		Linsitinib		Predictive	Supports	D	N/A	OSI-906, an IGF1R/INSR inhibitor, does not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines.	25670080	PubMed		Vidal et al., 2015, Cancer Cell		3	accepted	412	156	60	11	2150348	2170833			ENST00000300632.5					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/412	https://civic.genome.wustl.edu/links/variants/156	https://civic.genome.wustl.edu/links/genes/60
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).	16818686	PubMed		Jackman et al., 2006, Clin. Cancer Res.		4	accepted	413	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/413	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
IGF2	3481	OVEREXPRESSION	Prostate Cancer	10283		Cabazitaxel,Docetaxel,Linsitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate cancer cell lines.	25670080	PubMed		Vidal et al., 2015, Cancer Cell		3	accepted	414	156	60	11	2150348	2170833			ENST00000300632.5					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/414	https://civic.genome.wustl.edu/links/variants/156	https://civic.genome.wustl.edu/links/genes/60
TET2	54790	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death.	22430270	PubMed		Gaidzik et al., 2012, J. Clin. Oncol.		4	accepted	415	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/415	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
AURKA	6790	EXPRESSION	Ovarian Carcinoma	4001				Prognostic	Supports	B	Better Outcome	In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression.	19157502	PubMed		Mendiola et al., 2009, Hum. Pathol.		3	accepted	416	158	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/416	https://civic.genome.wustl.edu/links/variants/158	https://civic.genome.wustl.edu/links/genes/61
TET2	54790	MUTATION	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Better Outcome	In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.	19666869	PubMed		Kosmider et al., 2009, Blood		4	accepted	417	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/417	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
VHL	7428	MUTATION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Better Outcome	In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival.	18464292	PubMed		Patard et al., 2008, Int. J. Cancer		4	accepted	418	160	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/418	https://civic.genome.wustl.edu/links/variants/160	https://civic.genome.wustl.edu/links/genes/58
TET2	54790	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.	22430270	PubMed		Gaidzik et al., 2012, J. Clin. Oncol.		4	accepted	419	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/419	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
PBRM1	55193	MUTATION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	N/A	In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival.	23620406	PubMed		Hakimi et al., 2013, Clin. Cancer Res.		3	accepted	420	161	62	3	52581857	52719852			ENST00000394830.3					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/420	https://civic.genome.wustl.edu/links/variants/161	https://civic.genome.wustl.edu/links/genes/62
TET2	54790	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	N/A	In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival.	21343549	PubMed		Metzeler et al., 2011, J. Clin. Oncol.		4	accepted	421	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/421	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
VHL	7428	MUTATION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	N/A	In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival.	23620406	PubMed		Hakimi et al., 2013, Clin. Cancer Res.		3	accepted	422	160	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/422	https://civic.genome.wustl.edu/links/variants/160	https://civic.genome.wustl.edu/links/genes/58
BCL2	596	EXPRESSION	Diffuse Large B-cell Lymphoma	0050745				Prognostic	Supports	B	Poor Outcome	In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival.	9207459	PubMed		Gascoyne et al., 1997, Blood		4	accepted	423	152	59	18	60790579	60987361			ENST00000398117.1					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/423	https://civic.genome.wustl.edu/links/variants/152	https://civic.genome.wustl.edu/links/genes/59
BCL2	596	EXPRESSION	Diffuse Large B-cell Lymphoma	0050745				Prognostic	Supports	B	Poor Outcome	In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS.	9207459	PubMed		Gascoyne et al., 1997, Blood		4	accepted	424	152	59	18	60790579	60987361			ENST00000398117.1					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/424	https://civic.genome.wustl.edu/links/variants/152	https://civic.genome.wustl.edu/links/genes/59
EZH2	2146	MUTATION	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts.	20601954	PubMed		Nikoloski et al., 2010, Nat. Genet.		3	accepted	425	163	63	7	148504477	148581370			ENST00000320356.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/425	https://civic.genome.wustl.edu/links/variants/163	https://civic.genome.wustl.edu/links/genes/63
TET2	54790	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.	21828143	PubMed		Chou et al., 2011, Blood		4	accepted	426	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/426	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
TET2	54790	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival.	21343549	PubMed		Metzeler et al., 2011, J. Clin. Oncol.		4	accepted	427	157	55	4	106067450	106200973			ENST00000513237.1					75	GRCh37	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/427	https://civic.genome.wustl.edu/links/variants/157	https://civic.genome.wustl.edu/links/genes/55
VHL	7428	LOSS-OF-FUNCTION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival.	11793370	PubMed		Schraml et al., 2002, J. Pathol.		3	accepted	428	159	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/428	https://civic.genome.wustl.edu/links/variants/159	https://civic.genome.wustl.edu/links/genes/58
RUNX1	861	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047).	21343560	PubMed		Gaidzik et al., 2011, J. Clin. Oncol.	NCT00146120,NCT00151242	4	accepted	429	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/429	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
RUNX1	861	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup.	21343560	PubMed		Gaidzik et al., 2011, J. Clin. Oncol.	NCT00146120,NCT00151242	4	accepted	430	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/430	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
FLI1	2313	EWSR1-FLI1 Type 1	Ewing Sarcoma	3369				Prognostic	Supports	B	Better Outcome	In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions.	9552022	PubMed		de Alava et al., 1998, J. Clin. Oncol.		4	accepted	431	164	53	22	29664007	29683123			ENST00000397938.2	11	128675261	128683162	ENST00000527786.2	75	GRCh37	Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/431	https://civic.genome.wustl.edu/links/variants/164	https://civic.genome.wustl.edu/links/genes/53
EZH2	2146	Y646	Diffuse Large B-cell Lymphoma	0050745				Diagnostic	Supports	B	Positive	Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls.	20081860	PubMed		Morin et al., 2010, Nat. Genet.		4	accepted	432	165	63	7	148508726	148508728			ENST00000320356.2					75	GRCh37	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).	Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/432	https://civic.genome.wustl.edu/links/variants/165	https://civic.genome.wustl.edu/links/genes/63
EZH2	2146	Y646	Follicular Lymphoma	0050873				Diagnostic	Supports	B	Positive	Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls.	20081860	PubMed		Morin et al., 2010, Nat. Genet.		4	accepted	433	165	63	7	148508726	148508728			ENST00000320356.2					75	GRCh37	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).	Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/433	https://civic.genome.wustl.edu/links/variants/165	https://civic.genome.wustl.edu/links/genes/63
KMT2D	8085	LOSS-OF-FUNCTION	Follicular Lymphoma	0050873				Diagnostic	Supports	B	Positive	MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples. Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma. Mutations were predicted to be loss-of-function.	21796119	PubMed		Morin et al., 2011, Nature		3	accepted	435	167	64	12	49412758	49449107			ENST00000301067.7					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/435	https://civic.genome.wustl.edu/links/variants/167	https://civic.genome.wustl.edu/links/genes/64
BTK	695	C481S	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	B	Resistance	Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.	24869598	PubMed		Woyach et al., 2014, N. Engl. J. Med.		4	accepted	436	168	65	X	100611165	100611165	A	T	ENST00000308731.7					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/436	https://civic.genome.wustl.edu/links/variants/168	https://civic.genome.wustl.edu/links/genes/65
AKT1	207	Q79K	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.	24265152	PubMed		Shi et al., 2014, Cancer Discov		4	accepted	439	169	2	14	105243048	105243048	G	T	ENST00000407796.2					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/439	https://civic.genome.wustl.edu/links/variants/169	https://civic.genome.wustl.edu/links/genes/2
ALK	238	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Amplification of wild-type EML4-ALK in the non-small cell lung carcinoma cell line, H3122, caused resistance to crizotinib.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		3	accepted	440	170	1	2	42396490	42528380			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/440	https://civic.genome.wustl.edu/links/variants/170	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		4	accepted	441	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/441	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The L1196M mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		4	accepted	442	7	1	2	29443631	29443631	G	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Somatic	2021-03-31 18:23:11 UTC	https://civic.genome.wustl.edu/links/evidence_items/442	https://civic.genome.wustl.edu/links/variants/7	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK S1206Y	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		4	accepted	443	172	1	2	29443600	29443600	G	T	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/443	https://civic.genome.wustl.edu/links/variants/172	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	A lung adenocarcinoma patient responded to crizotinib treatment for 12 months, after which the cancer relapsed and sequencing of the ALK tyrosine kinase domain revealed a 1151insT mutation. This mutation was not found in the pre-crizotinib biopsy. EML4-ALK T1151insT was expressed In Ba/F3 cells and an IC50 of 431.8 nM was obtained, which was 16 times higher than for EML4-ALK wild-type, indicating strong crizotinib resistance. EML4-ALK containing H3122 NSCLC cells were incubated in increasing levels of crizotinib inducing resistance. The resulting cell line H3122 CR2 had IC50 10x greater to crizotinib than parental H3122, and was found to contain 1151 insT mutation. In western blots, pALK levels in H3122 CR2 cells remained apparent under 1000 nM crizotinib, whereas pALK signal was ablated under these conditions in parental H3122 cells.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		4	accepted	444	173	1	2	29445271	29445272		CGT	ENST00000389048.3					75	GRCh37	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/444	https://civic.genome.wustl.edu/links/variants/173	https://civic.genome.wustl.edu/links/genes/1
APC	324	MUTATION	Colon Carcinoma	1520		JW55		Predictive	Supports	D	Sensitivity/Response	Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.	22440753	PubMed		Waaler et al., 2012, Cancer Res.		3	accepted	445	174	66	5	112043218	112181936			ENST00000457016.1					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/445	https://civic.genome.wustl.edu/links/variants/174	https://civic.genome.wustl.edu/links/genes/66
APC	324	MUTATION	Colorectal Cancer	9256		G007-LK		Predictive	Supports	D	Sensitivity/Response	G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.	23539443	PubMed		Lau et al., 2013, Cancer Res.		4	accepted	446	174	66	5	112043218	112181936			ENST00000457016.1					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/446	https://civic.genome.wustl.edu/links/variants/174	https://civic.genome.wustl.edu/links/genes/66
AR	367	F877L	Prostate Cancer	10283		Apalutamide,Enzalutamide	Substitutes	Predictive	Supports	D	Resistance	Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines.	23779130	PubMed		Joseph et al., 2013, Cancer Discov		4	accepted	447	175	67	X	66943549	66943549	T	C	ENST00000374690.3					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/447	https://civic.genome.wustl.edu/links/variants/175	https://civic.genome.wustl.edu/links/genes/67
AR	367	W742	Prostate Carcinoma	10286		Bicalutamide		Predictive	Supports	D	Resistance	LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.	12517791	PubMed		Hara et al., 2003, Cancer Res.		4	accepted	448	176	67	X	66937370	66937372			ENST00000374690.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/448	https://civic.genome.wustl.edu/links/variants/176	https://civic.genome.wustl.edu/links/genes/67
ASXL1	171023	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type.	25412851	PubMed		Ohgami et al., 2015, Mod. Pathol.		2	accepted	449	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/449	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
ASXL1	171023	MUTATION	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype.	25412851	PubMed		Ohgami et al., 2015, Mod. Pathol.		3	accepted	450	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/450	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
ASXL1	171023	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33).	25308295	PubMed		Shivarov et al., 2015, Leuk. Lymphoma		4	accepted	451	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/451	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
ATM	472	MUTATION	Glioblastoma Multiforme	3068		Temozolomide		Predictive	Supports	D	Sensitivity/Response	Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	23960094	PubMed		Eich et al., 2013, Mol. Cancer Ther.		3	accepted	452	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/452	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
ATM	472	MUTATION	Melanoma	1909		Temozolomide		Predictive	Supports	D	Sensitivity/Response	Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	23960094	PubMed		Eich et al., 2013, Mol. Cancer Ther.		3	accepted	453	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/453	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
ATM	472	UNDEREXPRESSION	Cancer	162		NU7441,KU-0060648	Substitutes	Predictive	Supports	D	Sensitivity/Response	ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control.	23761041	PubMed		Riabinska et al., 2013, Sci Transl Med		5	accepted	454	179	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/454	https://civic.genome.wustl.edu/links/variants/179	https://civic.genome.wustl.edu/links/genes/69
ATM	472	MUTATION	Hematologic Cancer	2531		Olaparib		Predictive	Supports	D	Sensitivity/Response	Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma.	20739657	PubMed		Weston et al., 2010, Blood		5	accepted	455	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/455	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
AURKA	6790	AMPLIFICATION	Esophagus Adenocarcinoma	4914		Cisplatin,Alisertib	Combination	Predictive	Supports	E	Sensitivity/Response	Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.	22302096	PubMed		Sehdev et al., 2012, Mol. Cancer Ther.		3	accepted	456	180	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/456	https://civic.genome.wustl.edu/links/variants/180	https://civic.genome.wustl.edu/links/genes/61
AURKA	6790	OVEREXPRESSION	Cervical Adenocarcinoma	3702		Paclitaxel		Predictive	Supports	D	Resistance	In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol.	12559175	PubMed		Anand et al., 2003, Cancer Cell		3	accepted	457	181	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/457	https://civic.genome.wustl.edu/links/variants/181	https://civic.genome.wustl.edu/links/genes/61
BAP1	8314	EXPRESSION	Uveal Melanoma	6039				Prognostic	Supports	B	Better Outcome	In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival.	25147369	PubMed		van Essen et al., 2014, Br J Ophthalmol		3	accepted	458	182	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/458	https://civic.genome.wustl.edu/links/variants/182	https://civic.genome.wustl.edu/links/genes/70
BAP1	8314	MUTATION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.	23797736	PubMed		Sato et al., 2013, Nat. Genet.		5	accepted	459	183	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/459	https://civic.genome.wustl.edu/links/variants/183	https://civic.genome.wustl.edu/links/genes/70
BAP1	8314	MUTATION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type.	23792563	PubMed		2013, Nature		5	accepted	461	183	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/461	https://civic.genome.wustl.edu/links/variants/183	https://civic.genome.wustl.edu/links/genes/70
BRAF	673	AKAP9-BRAF	Thyroid Gland Papillary Carcinoma	3969				Diagnostic	Supports	B	Positive	The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant.	15630448	PubMed		Ciampi et al., 2005, J. Clin. Invest.		4	accepted	462	184	5	7	91570181	91625114			ENST00000356239.3	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/462	https://civic.genome.wustl.edu/links/variants/184	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.	23612012	PubMed		Andrulis et al., 2013, Cancer Discov		3	accepted	463	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/463	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRCA1	672	MUTATION	Epithelial Ovarian Cancer	2152				Prognostic	Supports	B	Better Outcome	In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.	22274685	PubMed		Bolton et al., 2012, JAMA		3	accepted	464	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/464	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Epithelial Ovarian Cancer	2152				Prognostic	Supports	B	Better Outcome	In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.	22274685	PubMed		Bolton et al., 2012, JAMA		3	accepted	465	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/465	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
CCNE1	898	AMPLIFICATION	Ovarian Carcinoma	4001				Prognostic	Supports	B	Poor Outcome	In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.	20336784	PubMed		Nakayama et al., 2010, Cancer		4	accepted	466	187	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/466	https://civic.genome.wustl.edu/links/variants/187	https://civic.genome.wustl.edu/links/genes/11
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse.	19304957	PubMed		Ho et al., 2009, Blood	NCT00002798,NCT00070174	4	accepted	467	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/467	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients.	25014773	PubMed		Matsuo et al., 2014, Blood Cancer J		4	accepted	468	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/468	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15
DNMT3A	1788	MUTATION	T-cell Acute Lymphoblastic Leukemia	5603				Prognostic	Supports	B	Poor Outcome	In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005).	23341344	PubMed		Grossmann et al., 2013, Genes Chromosomes Cancer		4	accepted	469	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/469	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
EGFR	1956	AMPLIFICATION	Barrett's Adenocarcinoma	7941				Prognostic	Supports	B	Poor Outcome	In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.	20840671	PubMed		Marx et al., 2010, Histopathology		3	accepted	470	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/470	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	AMPLIFICATION	Cervical Squamous Cell Carcinoma	3744				Prognostic	Supports	B	Poor Outcome	In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.	21730982	PubMed		Iida et al., 2011, Br. J. Cancer		3	accepted	471	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/471	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	COPY NUMBER VARIATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival.	17538160	PubMed		Temam et al., 2007, J. Clin. Oncol.		4	accepted	472	191	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/472	https://civic.genome.wustl.edu/links/variants/191	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.	16943533	PubMed		Chung et al., 2006, J. Clin. Oncol.		4	accepted	473	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/473	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Brain Glioblastoma Multiforme	3073				Prognostic	Supports	B	Poor Outcome	In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival.	14583498	PubMed		Shinojima et al., 2003, Cancer Res.		3	accepted	474	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/474	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
ERG	2078	EWSR1-ERG	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	23706910	PubMed		Warren et al., 2013, Hum. Pathol.		5	accepted	475	194	71	22	29664007	29683123			ENST00000397938.2	21	39751949	39755845	ENST00000398907.1	75	GRCh37	EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/475	https://civic.genome.wustl.edu/links/variants/194	https://civic.genome.wustl.edu/links/genes/71
ERG	2078	TMPRSS2-ERG	Prostate Carcinoma	10286				Diagnostic	Supports	B	Positive	TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples.	16254181	PubMed		Tomlins et al., 2005, Science		3	accepted	476	195	71	21	42879877	42879992			ENST00000398585.3	21	39751949	39817544	ENST00000398910.1	75	GRCh37	TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/476	https://civic.genome.wustl.edu/links/variants/195	https://civic.genome.wustl.edu/links/genes/71
FGFR3	2261	Y375C	Bladder Carcinoma	4007				Diagnostic	Supports	B	Positive	Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.	20542753	PubMed		Bodoor et al., 2010, Cancer Epidemiol		3	accepted	477	196	23	4	1806099	1806099	A	G	ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/477	https://civic.genome.wustl.edu/links/variants/196	https://civic.genome.wustl.edu/links/genes/23
FLI1	2313	EWSR1-FLI1	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples.	23706910	PubMed		Warren et al., 2013, Hum. Pathol.		5	accepted	478	197	53	22	29664007	29683123			ENST00000397938.2	11	128651853	128683162	ENST00000527786.2	75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/478	https://civic.genome.wustl.edu/links/variants/197	https://civic.genome.wustl.edu/links/genes/53
FOXL2	668	C134W	Ovarian Granulosa Cell Tumor	2999				Diagnostic	Supports	B	Positive	FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors.	20693978	PubMed		Jamieson et al., 2010, Mod. Pathol.		4	accepted	479	198	72	3	138665163	138665163	G	C	ENST00000330315.3					75	GRCh37	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/479	https://civic.genome.wustl.edu/links/variants/198	https://civic.genome.wustl.edu/links/genes/72
IDH1	3417	R132	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Better Outcome	In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.	19228619	PubMed		Yan et al., 2009, N. Engl. J. Med.		5	accepted	480	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/480	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132	Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.	19228619	PubMed		Yan et al., 2009, N. Engl. J. Med.		5	accepted	481	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/481	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	R172	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Better Outcome	In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.	19228619	PubMed		Yan et al., 2009, N. Engl. J. Med.		5	accepted	482	199	27	15	90631837	90631839			ENST00000330062.3					75	GRCh37	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/482	https://civic.genome.wustl.edu/links/variants/199	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R172	Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.	19228619	PubMed		Yan et al., 2009, N. Engl. J. Med.		5	accepted	483	199	27	15	90631837	90631839			ENST00000330062.3					75	GRCh37	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/483	https://civic.genome.wustl.edu/links/variants/199	https://civic.genome.wustl.edu/links/genes/27
IKZF1	10320	DELETION	B-lymphoblastic Leukemia/lymphoma	0080630				Prognostic	Supports	B	Poor Outcome	In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions.	22699455	PubMed		Krentz et al., 2013, Leukemia		4	accepted	484	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/484	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
KIT	3815	M541L	Chronic Myeloid Leukemia	8552				Diagnostic	Does Not Support	B	Positive	M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease.	16307017	PubMed		Krger et al., 2006, Leukemia		4	accepted	485	201	29	4	55593464	55593464	A	C	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/485	https://civic.genome.wustl.edu/links/variants/201	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560DEL	Thymic Carcinoma	3284		Imatinib		Predictive	Supports	C	Sensitivity/Response	In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.	15201427	PubMed		Strbel et al., 2004, N. Engl. J. Med.		5	accepted	486	202	29	4	55593612	55593614	GTT		ENST00000288135.5					75	GRCh37	V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.	Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/486	https://civic.genome.wustl.edu/links/variants/202	https://civic.genome.wustl.edu/links/genes/29
KRAS	3845	G12	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations.	18528420	PubMed		Chng et al., 2008, Leukemia		4	accepted	487	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/487	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations.	18528420	PubMed		Chng et al., 2008, Leukemia		4	accepted	488	80	30	12	25398281	25398282			ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/488	https://civic.genome.wustl.edu/links/variants/80	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations.	18528420	PubMed		Chng et al., 2008, Leukemia		4	accepted	489	203	30	12	25380275	25380277			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/489	https://civic.genome.wustl.edu/links/variants/203	https://civic.genome.wustl.edu/links/genes/30
MGMT	4255	PROMOTER METHYLATION	Oligodendroglioma	3181				Prognostic	Supports	B	Better Outcome	In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival.	19901104	PubMed		van den Bent et al., 2009, J. Clin. Oncol.		4	accepted	490	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/490	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	PROMOTER METHYLATION	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Better Outcome	In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.	15758010	PubMed		Hegi et al., 2005, N. Engl. J. Med.		5	accepted	491	85	34	10	131264495	131265656			ENST00000306010.7					75	GRCh37	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/491	https://civic.genome.wustl.edu/links/variants/85	https://civic.genome.wustl.edu/links/genes/34
NCOA3	8202	AMPLIFICATION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival.	23322234	PubMed		Burandt et al., 2013, Breast Cancer Res. Treat.		3	accepted	492	204	74	20	46130646	46285621			ENST00000372004.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/492	https://civic.genome.wustl.edu/links/variants/204	https://civic.genome.wustl.edu/links/genes/74
NCOA3	8202	OVEREXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival.	23322234	PubMed		Burandt et al., 2013, Breast Cancer Res. Treat.		3	accepted	493	205	74	20	46130646	46285621			ENST00000372004.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/493	https://civic.genome.wustl.edu/links/variants/205	https://civic.genome.wustl.edu/links/genes/74
NOTCH1	4851	MUTATION	Mantle Cell Lymphoma	0050746				Prognostic	Supports	B	Poor Outcome	14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years).	22210878	PubMed		Kridel et al., 2012, Blood		3	accepted	494	206	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/494	https://civic.genome.wustl.edu/links/variants/206	https://civic.genome.wustl.edu/links/genes/50
NOTCH1	4851	P2514FS	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival. NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status.	21670202	PubMed		Fabbri et al., 2011, J. Exp. Med.		3	accepted	495	207	50	9	139390649	139390650			ENST00000277541.6					75	GRCh37	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.	Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/495	https://civic.genome.wustl.edu/links/variants/207	https://civic.genome.wustl.edu/links/genes/50
NRAS	4893	MUTATION	Multiple Myeloma	9538				Prognostic	Supports	B	N/A	In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival.	18528420	PubMed		Chng et al., 2008, Leukemia		4	accepted	496	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/496	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61	Follicular Thyroid Carcinoma	3962				Prognostic	Supports	B	N/A	In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36).	22650231	PubMed		Fukahori et al., 2012, Thyroid		3	accepted	497	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/497	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
PAX8	7849	PAX8-PPARG	Follicular Thyroid Carcinoma	3962				Diagnostic	Supports	B	Positive	PAX8PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hrthle cell tumors.	12727991	PubMed		Nikiforova et al., 2003, J. Clin. Endocrinol. Metab.		3	accepted	498	209	75	2	113992971	114036521			ENST00000429538.3	3	12329400	12475810	ENST00000397015.2	75	GRCh37	PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/498	https://civic.genome.wustl.edu/links/variants/209	https://civic.genome.wustl.edu/links/genes/75
PBRM1	55193	MUTATION	Renal Cell Carcinoma	4450				Prognostic	Supports	B	Better Outcome	In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations.	23333114	PubMed		Kapur et al., 2013, Lancet Oncol.		3	accepted	499	161	62	3	52581857	52719852			ENST00000394830.3					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/499	https://civic.genome.wustl.edu/links/variants/161	https://civic.genome.wustl.edu/links/genes/62
PGR	5241	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression.	16497822	PubMed		Dowsett et al., 2006, Ann. Oncol.		3	accepted	500	210	76	11	100900355	101001255			ENST00000325455.5					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/500	https://civic.genome.wustl.edu/links/variants/210	https://civic.genome.wustl.edu/links/genes/76
PGR	5241	EXPRESSION	Breast Cancer	1612		Tamoxifen		Predictive	Does Not Support	B	N/A	In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen.	23280579	PubMed		Patani et al., 2013, Int. J. Cancer		3	accepted	501	210	76	11	100900355	101001255			ENST00000325455.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/501	https://civic.genome.wustl.edu/links/variants/210	https://civic.genome.wustl.edu/links/genes/76
PGR	5241	EXPRESSION	Breast Cancer	1612		Tamoxifen,Exemestane	Substitutes	Predictive	Does Not Support	B	N/A	In patients with breast cancer, those with low expression of PgR treated with tamoxifen had the same disease-free survial as those with high expression of PgR.	21422407	PubMed		Bartlett et al., 2011, J. Clin. Oncol.		4	accepted	502	210	76	11	100900355	101001255			ENST00000325455.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/502	https://civic.genome.wustl.edu/links/variants/210	https://civic.genome.wustl.edu/links/genes/76
PGR	5241	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression.	21422407	PubMed		Bartlett et al., 2011, J. Clin. Oncol.		4	accepted	503	210	76	11	100900355	101001255			ENST00000325455.5					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/503	https://civic.genome.wustl.edu/links/variants/210	https://civic.genome.wustl.edu/links/genes/76
PIK3CA	5290	AMPLIFICATION	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.	22292935	PubMed		Shi et al., 2012, BMC Cancer		3	accepted	504	212	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/504	https://civic.genome.wustl.edu/links/variants/212	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	DELETION	Prostate Adenocarcinoma	2526				Prognostic	Supports	B	Poor Outcome	In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions.	17700571	PubMed		Yoshimoto et al., 2007, Br. J. Cancer		4	accepted	505	213	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/505	https://civic.genome.wustl.edu/links/variants/213	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.	21163703	PubMed		De Roock et al., 2011, Lancet Oncol.		3	accepted	506	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/506	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Prostate Cancer	10283		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).	11504908	PubMed		Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	507	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/507	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
RUNX1	861	MUTATION	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age.	23341344	PubMed		Grossmann et al., 2013, Genes Chromosomes Cancer		3	accepted	508	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/508	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
RUNX1	861	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006).	22753902	PubMed		Mendler et al., 2012, J. Clin. Oncol.		4	accepted	509	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/509	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
SF3B1	23451	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival. A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases).	23568491	PubMed		Wan et al., 2013, Blood		4	accepted	510	215	44	2	198254508	198299815			ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/510	https://civic.genome.wustl.edu/links/variants/215	https://civic.genome.wustl.edu/links/genes/44
SMAD4	4089	MUTATION	Pancreatic Adenocarcinoma	4074				Prognostic	Supports	B	Poor Outcome	In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.	19584151	PubMed		Blackford et al., 2009, Clin. Cancer Res.		3	accepted	511	216	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/511	https://civic.genome.wustl.edu/links/variants/216	https://civic.genome.wustl.edu/links/genes/77
SMARCA4	6597	MUTATION	Small Cell Carcinoma Of The Ovary Hypercalcemic Type	7651				Diagnostic	Supports	B	Positive	Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA.	24658004	PubMed		Jelinic et al., 2014, Nat. Genet.		5	accepted	512	217	78	19	11071598	11172958			ENST00000358026.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/512	https://civic.genome.wustl.edu/links/variants/217	https://civic.genome.wustl.edu/links/genes/78
SMARCA4	6597	INACTIVATING MUTATION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations.	24658004	PubMed		Jelinic et al., 2014, Nat. Genet.		4	accepted	513	218	78	19	11071598	11172958			ENST00000358026.2					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/513	https://civic.genome.wustl.edu/links/variants/218	https://civic.genome.wustl.edu/links/genes/78
TERT	7015	AMPLIFICATION	Acral Lentiginous Melanoma	6367				Prognostic	Supports	B	Poor Outcome	In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival.	25219713	PubMed		Diaz et al., 2014, J. Am. Acad. Dermatol.		3	accepted	514	219	79	5	1253282	1295162			ENST00000310581.5					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/514	https://civic.genome.wustl.edu/links/variants/219	https://civic.genome.wustl.edu/links/genes/79
TERT	7015	PROMOTER MUTATION	Skin Melanoma	8923				Prognostic	Supports	B	Poor Outcome	In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients.	25217772	PubMed		Griewank et al., 2014, J. Natl. Cancer Inst.		3	accepted	515	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/515	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
TERT	7015	PROMOTER MUTATION	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Poor Outcome	In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants). However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations.	23955565	PubMed		Nonoguchi et al., 2013, Acta Neuropathol.		4	accepted	516	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/516	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
TP53	7157	DELETERIOUS MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations.	22090360	PubMed		Skinner et al., 2012, Clin. Cancer Res.		3	accepted	517	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/517	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations.	8901856	PubMed		Koch et al., 1996, J. Natl. Cancer Inst.		3	accepted	518	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/518	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.	19941080	PubMed		Yamasaki et al., 2010, Ann. Surg. Oncol.		4	accepted	519	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/519	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	B-lymphoblastic Leukemia/lymphoma	0080630				Prognostic	Supports	B	Poor Outcome	In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations.	22699455	PubMed		Krentz et al., 2013, Leukemia		4	accepted	520	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/520	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients.	24836762	PubMed		Bally et al., 2014, Leuk. Res.		4	accepted	521	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/521	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Myeloma	0070004				Prognostic	Supports	B	Poor Outcome	In patients with myeloma, those with mutations in TP53 had worse overall survival than those without.	17215851	PubMed		Chng et al., 2007, Leukemia		4	accepted	522	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/522	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53.	11325447	PubMed		Alsner et al., 2001, Radiother Oncol		4	accepted	523	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/523	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival.	11325447	PubMed		Alsner et al., 2001, Radiother Oncol		4	accepted	524	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/524	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	TRUNCATING MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients.	21467160	PubMed		Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res.		4	accepted	525	223	45	17	7573998	7579714			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/525	https://civic.genome.wustl.edu/links/variants/223	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	TRUNCATING MUTATION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis.	21467160	PubMed		Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res.		4	accepted	526	223	45	17	7573998	7579714			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/526	https://civic.genome.wustl.edu/links/variants/223	https://civic.genome.wustl.edu/links/genes/45
TTF1	7270	AMPLIFICATION	Lung Adenocarcinoma	3910				Prognostic	Does Not Support	B	N/A	6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.	19040416	PubMed		Barletta et al., 2009, J. Cell. Mol. Med.		3	accepted	527	224	80	9	135251008	135282209			ENST00000334270.2					75	GRCh37		Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/527	https://civic.genome.wustl.edu/links/variants/224	https://civic.genome.wustl.edu/links/genes/80
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.	11248153	PubMed		Slamon et al., 2001, N. Engl. J. Med.		5	accepted	528	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/528	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.	15911866	PubMed		Marty et al., 2005, J. Clin. Oncol.		5	accepted	529	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/529	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
CHEK2	11200	LOSS-OF-FUNCTION	Cancer	162				Predisposing	Supports	B	Uncertain Significance	Heterozygous germline truncating (frameshift) and missense mutations confer highly penetrant predisposition to multiple cancer types including sarcoma, breast cancer, and brain tumors. Screening of individuals with Li-Fraumeni syndrome but lacking TP53 mutations identified 1/4 classical and 2/18 LFS variant presentation. This included 1 large family pedigree with strong co-segregation of the mutation with cancer development.	10617473	PubMed		Bell et al., 1999, Science		5	accepted	531	230	8950	22	29083732	29137832			ENST00000328354.6					75	GRCh37		Rare Germline	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/531	https://civic.genome.wustl.edu/links/variants/230	https://civic.genome.wustl.edu/links/genes/8950
PRKACA	5566	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma.	25698061	PubMed		Graham et al., 2015, Mod. Pathol.		5	accepted	532	31	17	19	14628951	14629232			ENST00000254322.2	19	14202500	14218221	ENST00000308677.4	75	GRCh37	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/532	https://civic.genome.wustl.edu/links/variants/31	https://civic.genome.wustl.edu/links/genes/17
KRAS	3845	G12/G13	Pancreatic Adenocarcinoma	4074		Gemcitabine,Trametinib	Combination	Predictive	Supports	B	Resistance	Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas.	24915778	PubMed		Infante et al., 2014, Eur. J. Cancer	NCT01231581	4	accepted	622	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/622	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
CDK12	51755	LOSS-OF-FUNCTION	Ovarian Serous Carcinoma	0050933		Olaparib		Predictive	Supports	D	Sensitivity/Response	In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.	24240700	PubMed		Bajrami et al., 2014, Cancer Res.		4	accepted	623	236	12112	17	37618292	37691399			ENST00000447079.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/623	https://civic.genome.wustl.edu/links/variants/236	https://civic.genome.wustl.edu/links/genes/12112
IKZF1	10320	DELETION	B-lymphoblastic Leukemia/lymphoma	0080630				Prognostic	Supports	B	Poor Outcome	IKZF1 deletions are associated with poor outcome in patients with childhood BCR-ABLpositive B-cell precursor acute lymphoblastic leukemia even when treated with imatinib. This phenomenon was observed in patients treated in the pre-TKI era as well as those treated with imatinib when compared to wild-type patients undergoing similar treatment.	24366361	PubMed		van der Veer et al., 2014, Blood		3	accepted	624	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/624	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
IKZF1	10320	DELETION	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	IKZF1 deletions in patients with BCR-ABLpositive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients.	19770381	PubMed		Martinelli et al., 2009, J. Clin. Oncol.		3	accepted	625	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/625	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
IKZF1	10320	DELETION	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	A targeted copy number screen of 131 precursor B-ALL cases revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Furthermore non-high-risk patients with IKZF1 deletions exhibited a ~12-fold higher relative relapse rate than those without IKZF1 deletions.	20445578	PubMed		Kuiper et al., 2010, Leukemia		3	accepted	626	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/626	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
IDH2	3418	R172	Peripheral T-cell Lymphoma	0050749				Prognostic	Does Not Support	B	Better Outcome	In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24).	26268241	PubMed		Wang et al., 2015, Blood		3	accepted	627	199	27	15	90631837	90631839			ENST00000330062.3					75	GRCh37	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/627	https://civic.genome.wustl.edu/links/variants/199	https://civic.genome.wustl.edu/links/genes/27
IDH2	3418	R172	Peripheral T-cell Lymphoma	0050749				Diagnostic	Supports	B	Positive	IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.	22215888	PubMed		Cairns et al., 2012, Blood		4	accepted	628	199	27	15	90631837	90631839			ENST00000330062.3					75	GRCh37	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/628	https://civic.genome.wustl.edu/links/variants/199	https://civic.genome.wustl.edu/links/genes/27
IKZF1	10320	DELETION	B-lymphoblastic Leukemia/lymphoma	0080630				Prognostic	Supports	B	Poor Outcome	In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse (CIR) than wildtype IKZF1.	24740809	PubMed		Beldjord et al., 2014, Blood	NCT00222027,NCT00327678	4	accepted	629	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/629	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
NT5C2	22978	R367Q	T-cell Acute Lymphoblastic Leukemia	5603		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	630	238	9189	10	104852955	104852955	C	T	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/630	https://civic.genome.wustl.edu/links/variants/238	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	K359Q	T-cell Acute Lymphoblastic Leukemia	5603		Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	631	239	9189	10	104852980	104852980	T	G	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/631	https://civic.genome.wustl.edu/links/variants/239	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	D407A	T-cell Acute Lymphoblastic Leukemia	5603		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	632	240	9189	10	104850745	104850745	T	G	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/632	https://civic.genome.wustl.edu/links/variants/240	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	R367Q	T-cell Acute Lymphoblastic Leukemia	5603		Nelarabine,Arabinosylguanine	Substitutes	Predictive	Does Not Support	D	Resistance	CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	633	238	9189	10	104852955	104852955	C	T	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/633	https://civic.genome.wustl.edu/links/variants/238	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	D407A	T-cell Acute Lymphoblastic Leukemia	5603		Nelarabine,Arabinosylguanine	Substitutes	Predictive	Does Not Support	D	Resistance	CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	635	240	9189	10	104850745	104850745	T	G	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/635	https://civic.genome.wustl.edu/links/variants/240	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	K359Q	T-cell Acute Lymphoblastic Leukemia	5603		Arabinosylguanine,Nelarabine	Substitutes	Predictive	Does Not Support	D	Resistance	CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	636	239	9189	10	104852980	104852980	T	G	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/636	https://civic.genome.wustl.edu/links/variants/239	https://civic.genome.wustl.edu/links/genes/9189
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	B	Resistance	BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML.	18818391	PubMed		Jabbour et al., 2008, Blood		5	accepted	637	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/637	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Ponatinib		Predictive	Supports	D	Sensitivity/Response	Molecular dynamics simulations and calculated solvated interaction energies indicate BCR-ABL F317L mutations are Ponatinib sensitive.	24236021	PubMed		Tanneeru et al., 2013, PLoS ONE		3	accepted	638	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/638	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Ponatinib		Predictive	Supports	B	Sensitivity/Response	Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations like F317L.	25349473	PubMed		Miller et al., 2014, Biologics		5	accepted	639	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/639	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
TP53	7157	MUTATION	B-lymphoblastic Leukemia/lymphoma	0080630				Prognostic	Supports	B	Poor Outcome	In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients.	21747090	PubMed		Hof et al., 2011, J. Clin. Oncol.		4	accepted	640	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/640	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DNA BINDING DOMAIN MUTATION	Oral Squamous Cell Carcinoma	0050866				Prognostic	Supports	B	Poor Outcome	Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain. These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding.	12509970	PubMed		Yamazaki et al., 2003, Oral Oncol.		4	accepted	641	242	45	17	7577149	7578443			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/641	https://civic.genome.wustl.edu/links/variants/242	https://civic.genome.wustl.edu/links/genes/45
EGFR	1956	T790M	Lung Cancer	1324		Gefitinib,Multikinase Inhibitor AEE788	Sequential	Predictive	Supports	D	Resistance	Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.	18227510	PubMed		Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.		5	accepted	642	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/642	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
PTEN	5728	LOSS	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.	17700571	PubMed		Yoshimoto et al., 2007, Br. J. Cancer		4	accepted	643	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/643	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Bladder Carcinoma	4007		Everolimus		Predictive	Supports	B	Resistance	PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.	23989949	PubMed		Seront et al., 2013, Br. J. Cancer		4	accepted	644	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/644	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.	24387334	PubMed		Dillon et al., 2014, Curr Drug Targets		1	accepted	645	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/645	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Rociletinib		Predictive	Supports	B	Sensitivity/Response	In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.	25923550	PubMed		Sequist et al., 2015, N. Engl. J. Med.	NCT01526928	4	accepted	646	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/646	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
ATM	472	S2289*	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	3	accepted	647	243	69	11	108196840	108196841	TC		ENST00000278616.4					75	GRCh37	A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/647	https://civic.genome.wustl.edu/links/variants/243	https://civic.genome.wustl.edu/links/genes/69
ATM	472	N2875H	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	3	accepted	648	244	69	11	108218044	108218044	A	C	ENST00000278616.4					75	GRCh37	A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain	Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/648	https://civic.genome.wustl.edu/links/variants/244	https://civic.genome.wustl.edu/links/genes/69
NF2	4771	Y177FS	Peritoneal Mesothelioma	1788		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	C	Resistance	A frameshift mutation in NF2 at position Y177 was found in a patient who did not respond to the standard platinum doublet chemotherapy regimen.	25798586	PubMed		Sheffield et al., 2015, PLoS ONE		3	accepted	649	245	3870	22	30051593	30051594		T	ENST00000338641.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/649	https://civic.genome.wustl.edu/links/variants/245	https://civic.genome.wustl.edu/links/genes/3870
BRCA2	675	LOSS-OF-FUNCTION	Prostate Cancer	10283		Olaparib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	4	accepted	650	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/650	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.	12949711	PubMed		Hirota et al., 2003, Gastroenterology		3	accepted	651	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/651	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	V561A	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Sensitivity/Response	293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor.	12949711	PubMed		Hirota et al., 2003, Gastroenterology		3	accepted	652	247	38	4	55141036	55141036	T	C	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/652	https://civic.genome.wustl.edu/links/variants/247	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	This prospective study of 127 pretreatment patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 85 patients harbored KIT exon 11 mutated GISTs: 71 had an in-frame deletion and 15 had unspecified point mutations (3 codon 557 cases, 3 codon 559 cases, 6 codon 560 cases and 2 codon 576 cases). Of patients harboring KIT exon 11 mutated GISTs, 71 (83.5%) had a partial response, 7 had stable disease, 4 had progressive disease and 3 were nonassessable.  Patients with KIT exon 11 mutations were significantly more likely to have a partial response than those with KIT exon 9 mutations (P=.0006)  or double WT kinases (WT KIT and WT PDGFRA; P < .0001). The presence of a KIT exon 11 mutation was the strongest predictor of response (Hazard ratio= 7.85). Patients harboring KIT exon 11 mutant GISTs experienced longer event free survival (median: 687 days) than those with  KIT exon 9 mutant or double WT kinase GISTs (200 days and 82 days, respectively). Furthermore, patients whose tumors expressed an exon 11 mutant KIT had improved overall survival compared to patients whose tumor expressed an exon 9 mutant KIT (P = .0034)  or double WT kinases (P <.0001).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		4	accepted	654	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/654	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
TERT	7015	C228T	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene.	25024077	PubMed		Xing et al., 2014, J. Clin. Oncol.		5	accepted	655	248	79	5	1295228	1295228	G	A	ENST00000310581.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/655	https://civic.genome.wustl.edu/links/variants/248	https://civic.genome.wustl.edu/links/genes/79
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=159 BRAF, N=26 TERT promoter mutated) or no mutations in either gene (N=287)(P<0.001).	25024077	PubMed		Xing et al., 2014, J. Clin. Oncol.		5	accepted	656	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/656	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
TERT	7015	PROMOTER MUTATION	Thyroid Cancer	1781				Diagnostic	Supports	B	Positive	TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers. This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples.	23766237	PubMed		Liu et al., 2013, Endocr. Relat. Cancer		3	accepted	657	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/657	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
TERT	7015	PROMOTER MUTATION	Thyroid Cancer	1781				Prognostic	Supports	B	Poor Outcome	TERT promoter mutation C228T is significantly associated with BRAF V600E mutation, a marker of more aggressive tumors, in papillary thyroid cancer (PTC). Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild-type allele of TERT. TERT promoter mutations were also enriched in the more aggressive tall cell PTC compared to follicular or conventional PTC (30.8% vs 10.3%, P=0.046) and in the worse outcome anaplastic thyroid cancer than differentiated thyroid cancers (46.3% vs 12.2%, P=3108).	23766237	PubMed		Liu et al., 2013, Endocr. Relat. Cancer		3	accepted	658	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/658	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
XRCC1	7515	R194W	Lung Non-small Cell Carcinoma	3908		Vinorelbine,Gemcitabine,Docetaxel	Substitutes	Predictive	Supports	B	Sensitivity/Response	The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.	19157633	PubMed		Sun et al., 2009, Lung Cancer		4	accepted	659	249	6144	19	44057574	44057574	G	A	ENST00000262887.5					75	GRCh37		Rare Germline	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/659	https://civic.genome.wustl.edu/links/variants/249	https://civic.genome.wustl.edu/links/genes/6144
GSTP1	2950	DELETION	Ovarian Carcinoma	4001		Paclitaxel,Carboplatin,Cisplatin	Substitutes	Predictive	Supports	D	Sensitivity/Response	Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay. There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin.	25010864	PubMed		Sawers et al., 2014, Br. J. Cancer		4	accepted	660	250	2473	11	67351066	67354131			ENST00000398606.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/660	https://civic.genome.wustl.edu/links/variants/250	https://civic.genome.wustl.edu/links/genes/2473
BIRC7	79444	AMPLIFICATION	Colon Cancer	219		Cisplatin		Predictive	Supports	D	Resistance	Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner. This study highlighted Livin as a potential player in colon cancer therapy.	23188704	PubMed		Ding et al., 2013, Tumour Biol.		4	accepted	661	251	14842	20	61867235	61871859			ENST00000217169.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/661	https://civic.genome.wustl.edu/links/variants/251	https://civic.genome.wustl.edu/links/genes/14842
EGFR	1956	EXON 4 DELETION	Epithelial Ovarian Cancer	2152		Cisplatin		Predictive	Supports	D	Resistance	A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type EGFR. The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays.	23764753	PubMed		Zhang et al., 2013, Carcinogenesis		4	accepted	662	252	19	7	55214299	55214433			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/662	https://civic.genome.wustl.edu/links/variants/252	https://civic.genome.wustl.edu/links/genes/19
KRAS	3845	RS61764370	Epithelial Ovarian Cancer	2152		Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	B	Resistance	The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3).	22139083	PubMed		Ratner et al., 2012, Oncogene		3	accepted	664	254	30	12	25360224	25360224	A	C	ENST00000311936.3					75	GRCh37	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.	Common Germline	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/664	https://civic.genome.wustl.edu/links/variants/254	https://civic.genome.wustl.edu/links/genes/30
ERCC5	2073	RS751402	Parietal Lobe Ependymoma	0050903				Prognostic	Supports	B	Poor Outcome	The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies. 55 post-operative frozen samples were used in this study. The results were also confirmed in vitro by treating neuroblastoma and B-cell lines expressing the wild-type or rs751402 polymorphism and finding that the rs751402 polymorphism was correlated with higher survival.	26338418	PubMed		Somers et al., 2015, Genes Dev.		3	accepted	665	255	1741	13	103498198	103498198	A	G	ENST00000355739.4					75	GRCh37		Common Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/665	https://civic.genome.wustl.edu/links/variants/255	https://civic.genome.wustl.edu/links/genes/1741
KIT	3815	3' UTR MUTATION	Acral Lentiginous Melanoma	6367				Diagnostic	Supports	B	Positive	The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most strongly correlated with acral lentigious melanoma.	21119596	PubMed		Godshalk et al., 2011, Oncogene		3	accepted	666	256	29	4	55604724	55606881			ENST00000288135.5					75	GRCh37		Common Germline	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/666	https://civic.genome.wustl.edu/links/variants/256	https://civic.genome.wustl.edu/links/genes/29
NT5C2	22978	K359Q	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Mnster Clinical Trials.	23377281	PubMed		Tzoneva et al., 2013, Nat. Med.		4	accepted	667	239	9189	10	104852980	104852980	T	G	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/667	https://civic.genome.wustl.edu/links/variants/239	https://civic.genome.wustl.edu/links/genes/9189
EZH2	2146	INTRON 6 MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (mCRC). Blood samples from 106 patients with mCRC before and after treatment were used for this study.	21926398	PubMed		Crea et al., 2012, Ann. Oncol.		4	accepted	668	257	63	7	148524359	148525831			ENST00000320356.2					75	GRCh37		Common Germline	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/668	https://civic.genome.wustl.edu/links/variants/257	https://civic.genome.wustl.edu/links/genes/63
MTHFR	4524	A222V	Stomach Cancer	10534		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.	18704422	PubMed		Huang et al., 2009, Cancer Chemother. Pharmacol.		3	accepted	669	258	3672	1	11856378	11856378	G	A	ENST00000376592.1					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/669	https://civic.genome.wustl.edu/links/variants/258	https://civic.genome.wustl.edu/links/genes/3672
GSTP1	2950	I105V	Colorectal Cancer	9256		FOLFOX Regimen		Predictive	Supports	B	Sensitivity/Response	Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study.	19922504	PubMed		Chen et al., 2010, Cancer Sci.		4	accepted	670	259	2473	11	67352689	67352689	A	G	ENST00000398606.3					75	GRCh37		Common Germline	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/670	https://civic.genome.wustl.edu/links/variants/259	https://civic.genome.wustl.edu/links/genes/2473
ABCG2	9429	Q141K	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.	22112610	PubMed		Tian et al., 2012, Gynecol. Oncol.		3	accepted	671	260	7451	4	89052323	89052323	G	T	ENST00000237612.3					75	GRCh37		Common Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/671	https://civic.genome.wustl.edu/links/variants/260	https://civic.genome.wustl.edu/links/genes/7451
XRCC1	7515	Q399R	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.	22551904	PubMed		Liao et al., 2012, J Thorac Oncol		4	accepted	672	261	6144	19	44055726	44055726	T	C	ENST00000262887.5					75	GRCh37	XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/672	https://civic.genome.wustl.edu/links/variants/261	https://civic.genome.wustl.edu/links/genes/6144
XRCC1	7515	Q399R	Cervical Cancer	4362		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.	16875718	PubMed		Chung et al., 2006, Gynecol. Oncol.		4	accepted	673	261	6144	19	44055726	44055726	T	C	ENST00000262887.5					75	GRCh37	XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/673	https://civic.genome.wustl.edu/links/variants/261	https://civic.genome.wustl.edu/links/genes/6144
ABCB1	5243	S893T	Ovarian Cancer	2394		Paclitaxel		Predictive	Supports	B	Sensitivity/Response	The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.	16467099	PubMed		Gren et al., 2006, Clin. Cancer Res.		3	accepted	674	262	4244	7	87160618	87160618	A	T	ENST00000265724.3					75	GRCh37		Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/674	https://civic.genome.wustl.edu/links/variants/262	https://civic.genome.wustl.edu/links/genes/4244
ABCB1	5243	I1145I	Lung Non-small Cell Carcinoma	3908		Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.	22296372	PubMed		Yan et al., 2011, Asian Pac. J. Cancer Prev.		2	accepted	675	263	4244	7	87138645	87138645	A	G	ENST00000265724.3					75	GRCh37	ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.	Common Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/675	https://civic.genome.wustl.edu/links/variants/263	https://civic.genome.wustl.edu/links/genes/4244
ERCC2	2068	K751Q	Osteosarcoma	3347		Cisplatin		Predictive	Supports	B	Resistance	The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.	19434073	PubMed		Caronia et al., 2009, Pharmacogenomics J.		4	accepted	676	264	1736	19	45854919	45854919	T	G	ENST00000391945.4					75	GRCh37		Rare Germline	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/676	https://civic.genome.wustl.edu/links/variants/264	https://civic.genome.wustl.edu/links/genes/1736
ERCC2	2068	K751Q	Lung Non-small Cell Carcinoma	3908		Paclitaxel,Carboplatin	Combination	Predictive	Supports	B	Sensitivity/Response	The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.	19470925	PubMed		Gandara et al., 2009, J. Clin. Oncol.		3	accepted	677	264	1736	19	45854919	45854919	T	G	ENST00000391945.4					75	GRCh37		Rare Germline	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/677	https://civic.genome.wustl.edu/links/variants/264	https://civic.genome.wustl.edu/links/genes/1736
TYMS	7298	5' TANDEM REPEAT	Colorectal Cancer	9256		Fluorouracil,Irinotecan	Combination	Predictive	Supports	B	Resistance	The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy were followed in this study.	20628391	PubMed		Martinez-Balibrea et al., 2010, Br. J. Cancer		3	accepted	678	265	5971	18	657604	657742			ENST00000323274.10					75	GRCh37		Rare Germline	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/678	https://civic.genome.wustl.edu/links/variants/265	https://civic.genome.wustl.edu/links/genes/5971
LRP1B	53353	EXON 12-22 DELETION	Ovarian Cancer	2394		Doxorubicin		Predictive	Supports	D	Resistance	A minimum common region of deletion of 0.19Mb, encompassing exons 1222 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin. siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin.	22896685	PubMed		Cowin et al., 2012, Cancer Res.		3	accepted	679	266	12146	2	141665446	141777671			ENST00000389484.3					75	GRCh37		Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/679	https://civic.genome.wustl.edu/links/variants/266	https://civic.genome.wustl.edu/links/genes/12146
FGFR1	2260	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907		PD173074		Predictive	Supports	D	Sensitivity/Response	Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing.	21160078	PubMed		Weiss et al., 2010, Sci Transl Med		5	accepted	680	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/680	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	EXPRESSION	Lung Cancer	1324		Ponatinib		Predictive	Supports	D	Sensitivity/Response	Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression.	24771645	PubMed		Wynes et al., 2014, Clin. Cancer Res.		4	accepted	681	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/681	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Poor Outcome	In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking.	23182986	PubMed		Kim et al., 2013, J. Clin. Oncol.		4	accepted	682	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/682	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Poor Outcome	This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.	25086725	PubMed		Seo et al., 2014, Virchows Arch.		3	accepted	683	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/683	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.	23806793	PubMed		Tran et al., 2013, Lung Cancer		2	accepted	684	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/684	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Cancer	162				Prognostic	Supports	B	Poor Outcome	Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studies are warranted for confirmation.	25171497	PubMed		Chang et al., 2014, PLoS ONE		4	accepted	685	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/685	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		PD173074		Predictive	Supports	D	Sensitivity/Response	Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.	21666749	PubMed		Dutt et al., 2011, PLoS ONE		4	accepted	686	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/686	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907				Prognostic	Does Not Support	B	Poor Outcome	Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis.	25433983	PubMed		Jiang et al., 2015, Lung Cancer		4	accepted	687	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/687	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
ROS1	6098	REARRANGEMENT	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib.  Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner.	25264305	PubMed		Shaw et al., 2014, N. Engl. J. Med.	NCT00585195	4	accepted	688	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/688	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
MET	4233	AMPLIFICATION	Gastric Adenocarcinoma	3717		Onartuzumab		Predictive	Supports	C	Sensitivity/Response	A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases.	22389872	PubMed		Catenacci et al., 2011, Cancer Discov		3	accepted	689	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/689	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
ATR	545	I774FS	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability. These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions).	19470935	PubMed		Zighelboim et al., 2009, J. Clin. Oncol.		4	accepted	690	271	524	3	142274740	142274740			ENST00000350721.4					75	GRCh37	Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.	Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/690	https://civic.genome.wustl.edu/links/variants/271	https://civic.genome.wustl.edu/links/genes/524
EGFR	1956	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	5520		Fluorouracil,Cetuximab,Platinum Compound	Combination	Predictive	Does Not Support	B	Sensitivity/Response	EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.	21048039	PubMed		Licitra et al., 2011, Ann. Oncol.		4	accepted	691	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/691	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Does Not Support	B	Sensitivity/Response	EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.	23265711	PubMed		Licitra et al., 2013, Eur. J. Cancer	NCT00122460,NCT00154102	4	accepted	692	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/692	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.	22056021	PubMed		Pirker et al., 2012, Lancet Oncol.	NCT00148798	4	accepted	693	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/693	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Does Not Support	B	Resistance	In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).	24577117	PubMed		Vermorken et al., 2014, Ann. Oncol.		3	accepted	694	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/694	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.	24799460	PubMed		Argiris et al., 2014, Ann. Oncol.	NCT01487733	4	accepted	695	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/695	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Panitumumab		Predictive	Supports	B	Resistance	In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.	23746666	PubMed		Vermorken et al., 2013, Lancet Oncol.	NCT00460265	3	accepted	696	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/696	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Does Not Support	B	Resistance	In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC.	24577089	PubMed		Pogorzelski et al., 2014, Cell Death Dis		4	accepted	697	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/697	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
RET	5979	KIF5B-RET	Lung Adenocarcinoma	3910		Vandetanib		Predictive	Supports	C	Sensitivity/Response	A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient.	23584301	PubMed		Gautschi et al., 2013, J Thorac Oncol		2	accepted	698	273	42	10	32306071	32345359			ENST00000302418.4	10	43609928	43625799	ENST00000355710.3	75	GRCh37	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)	Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/698	https://civic.genome.wustl.edu/links/variants/273	https://civic.genome.wustl.edu/links/genes/42
HRAS	3265	G13D	Colorectal Cancer	9256		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	C	Resistance	Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.	26561417	PubMed		Boidot et al., 2016, Int J Colorectal Dis		3	accepted	699	274	2747	11	534285	534285	C	T	ENST00000451590.1					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/699	https://civic.genome.wustl.edu/links/variants/274	https://civic.genome.wustl.edu/links/genes/2747
HRAS	3265	MUTATION	Cancer	162		Binimetinib,MEK Inhibitor PD0325901,Selumetinib,Everolimus,MTOR Kinase Inhibitor AZD8055	Substitutes	Predictive	Supports	D	Sensitivity/Response	A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055).	26544513	PubMed		Kiessling et al., 2015, Oncotarget		3	accepted	700	275	2747	11	533873	534289			ENST00000451590.1					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/700	https://civic.genome.wustl.edu/links/variants/275	https://civic.genome.wustl.edu/links/genes/2747
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.	26664143	PubMed		Zhong et al., 2015, Onco Targets Ther		4	accepted	701	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/701	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Better Outcome	In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).	26313362	PubMed		Schmidt et al., 2015, PLoS ONE		3	accepted	702	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/702	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Ovarian Serous Carcinoma	0050933				Prognostic	Supports	B	Better Outcome	High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).	26625204	PubMed		Darb-Esfahani et al., 2016, Oncotarget		3	accepted	703	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/703	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Melanoma	1909		Nivolumab,Pembrolizumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.	26086854	PubMed		Carbognin et al., 2015, PLoS ONE		4	accepted	704	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/704	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
MTOR	2475	MUTATION	Bladder Carcinoma	4007		Everolimus,Pazopanib	Combination	Predictive	Supports	C	Sensitivity/Response	A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro.	24625776	PubMed		Wagle et al., 2014, Cancer Discov		3	accepted	705	277	2073	1	11166592	11322564			ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/705	https://civic.genome.wustl.edu/links/variants/277	https://civic.genome.wustl.edu/links/genes/2073
AKT2	208	EXPRESSION	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.	22842582	PubMed		Grell et al., 2012, Int. J. Oncol.		3	accepted	706	278	254	19	40736224	40791302			ENST00000392038.2					75	GRCh37		Somatic	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/706	https://civic.genome.wustl.edu/links/variants/278	https://civic.genome.wustl.edu/links/genes/254
AKT1	207	E17K	Melanoma	1909		Uprosertib		Predictive	Supports	D	Sensitivity/Response	A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.	24735930	PubMed		Lassen et al., 2014, Mol. Cancer		2	accepted	707	4	2	14	105246551	105246551	C	T	ENST00000407796.2					75	GRCh37	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/707	https://civic.genome.wustl.edu/links/variants/4	https://civic.genome.wustl.edu/links/genes/2
PTEN	5728	LOSS	Melanoma	1909		Uprosertib		Predictive	Supports	D	Sensitivity/Response	Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B.	24735930	PubMed		Lassen et al., 2014, Mol. Cancer		2	accepted	708	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/708	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
AKT1	207	E17K	Breast Cancer	1612		Capivasertib		Predictive	Supports	C	Sensitivity/Response	In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.	26351323	PubMed		Davies et al., 2015, Mol. Cancer Ther.	NCT01353781	3	accepted	709	4	2	14	105246551	105246551	C	T	ENST00000407796.2					75	GRCh37	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/709	https://civic.genome.wustl.edu/links/variants/4	https://civic.genome.wustl.edu/links/genes/2
PIK3CA	5290	E545K	Breast Cancer	1612		Akt Inhibitor MK2206,Pictilisib	Substitutes	Predictive	Supports	D	Sensitivity/Response	PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.	23888070	PubMed		Beaver et al., 2013, Clin. Cancer Res.		3	accepted	710	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/710	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Breast Cancer	1612		PI3Kbeta Inhibitor AZD8186		Predictive	Supports	D	Sensitivity/Response	Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.	25398829	PubMed		Hancox et al., 2015, Mol. Cancer Ther.		2	accepted	711	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/711	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
MTOR	2475	MUTATION	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.	26490311	PubMed		Kong et al., 2016, Clin. Cancer Res.		3	accepted	712	277	2073	1	11166592	11322564			ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/712	https://civic.genome.wustl.edu/links/variants/277	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	H1968Y	Melanoma	1909		PI3K/BET Inhibitor LY294002,Capivasertib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.	26490311	PubMed		Kong et al., 2016, Clin. Cancer Res.		3	accepted	713	283	2073	1	11188519	11188519	G	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/713	https://civic.genome.wustl.edu/links/variants/283	https://civic.genome.wustl.edu/links/genes/2073
PTEN	5728	LOSS	Cancer	162		Paclitaxel,Buparlisib,Carboplatin	Combination	Predictive	Supports	B	Sensitivity/Response	All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.	25672916	PubMed		Hyman et al., 2015, Cancer Chemother. Pharmacol.	NCT01297452	3	accepted	714	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/714	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
NF2	4771	K159FS*16	Breast Cancer	1612		Temsirolimus		Predictive	Supports	C	Sensitivity/Response	23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.	25878190	PubMed		Moulder et al., 2015, Ann. Oncol.		3	accepted	715	279	3870	22	30050673	30050675			ENST00000338641.4					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/715	https://civic.genome.wustl.edu/links/variants/279	https://civic.genome.wustl.edu/links/genes/3870
PTEN	5728	LOSS	Breast Cancer	1612		Alpelisib		Predictive	Supports	D	Resistance	A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.	25409150	PubMed		Juric et al., 2015, Nature		4	accepted	716	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/716	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
EGFR	1956	S492R	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.	22270724	PubMed		Montagut et al., 2012, Nat. Med.		4	accepted	717	453	19	7	55228009	55228009	C	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/717	https://civic.genome.wustl.edu/links/variants/453	https://civic.genome.wustl.edu/links/genes/19
FBXW7	55294	MUTATION	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).	26508446	PubMed		Lupini et al., 2015, BMC Cancer		2	accepted	718	281	12903	4	153245446	153332714			ENST00000281708.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/718	https://civic.genome.wustl.edu/links/variants/281	https://civic.genome.wustl.edu/links/genes/12903
SMAD4	4089	MUTATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient).	26508446	PubMed		Lupini et al., 2015, BMC Cancer		2	accepted	719	216	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/719	https://civic.genome.wustl.edu/links/variants/216	https://civic.genome.wustl.edu/links/genes/77
SMAD4	4089	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Supports	D	Resistance	In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab.	26046389	PubMed		Cheng et al., 2015, Cancer Biol. Ther.		3	accepted	720	282	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/720	https://civic.genome.wustl.edu/links/variants/282	https://civic.genome.wustl.edu/links/genes/77
MTOR	2475	P2213S	Melanoma	1909		Capivasertib,PI3K/BET Inhibitor LY294002	Combination	Predictive	Supports	D	Sensitivity/Response	In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.	26490311	PubMed		Kong et al., 2016, Clin. Cancer Res.		3	accepted	722	284	2073	1	11184580	11184580	G	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/722	https://civic.genome.wustl.edu/links/variants/284	https://civic.genome.wustl.edu/links/genes/2073
BRAF	673	AGK-BRAF	Melanoma	1909		Sorafenib		Predictive	Supports	C	Sensitivity/Response	BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	23890088	PubMed		Botton et al., 2013, Pigment Cell Melanoma Res		2	accepted	723	285	5	7	141250989	141255367			ENST00000355413.4	7	140434279	140494267	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/723	https://civic.genome.wustl.edu/links/variants/285	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	AGK-BRAF	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	23890088	PubMed		Botton et al., 2013, Pigment Cell Melanoma Res		2	accepted	724	285	5	7	141250989	141255367			ENST00000355413.4	7	140434279	140494267	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/724	https://civic.genome.wustl.edu/links/variants/285	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	PAPSS1-BRAF	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib.	24345920	PubMed		Hutchinson et al., 2013, Clin. Cancer Res.		3	accepted	725	286	5	4	108603171	108641608			ENST00000265174.4	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/725	https://civic.genome.wustl.edu/links/variants/286	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	PAPSS1-BRAF	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling.	24345920	PubMed		Hutchinson et al., 2013, Clin. Cancer Res.		3	accepted	726	286	5	4	108603171	108641608			ENST00000265174.4	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/726	https://civic.genome.wustl.edu/links/variants/286	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	TRIM24-BRAF	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was "pan-negative" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib.	24345920	PubMed		Hutchinson et al., 2013, Clin. Cancer Res.		3	accepted	727	287	5	7	138145079	138239711			ENST00000343526.4	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/727	https://civic.genome.wustl.edu/links/variants/287	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597R	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.	23715574	PubMed		Bahadoran et al., 2013, J. Clin. Oncol.		4	accepted	728	288	5	7	140453145	140453145	A	C	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/728	https://civic.genome.wustl.edu/links/variants/288	https://civic.genome.wustl.edu/links/genes/5
ERBB3	2065	OVEREXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.	25520391	PubMed		Cushman et al., 2015, Clin. Cancer Res.		4	accepted	729	289	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/729	https://civic.genome.wustl.edu/links/variants/289	https://civic.genome.wustl.edu/links/genes/1733
NT5E	4907	OVEREXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.	25520391	PubMed		Cushman et al., 2015, Clin. Cancer Res.		3	accepted	730	290	3976	6	86159809	86205496			ENST00000257770.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/730	https://civic.genome.wustl.edu/links/variants/290	https://civic.genome.wustl.edu/links/genes/3976
EZH2	2146	OVEREXPRESSION	Cancer	162				Prognostic	Supports	B	Poor Outcome	High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.	26683709	PubMed		Jiang et al., 2016, Oncotarget		4	accepted	731	291	63	7	148504477	148581370			ENST00000320356.2					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/731	https://civic.genome.wustl.edu/links/variants/291	https://civic.genome.wustl.edu/links/genes/63
IDH1	3417	R132C	Acute Myeloid Leukemia	9119		GSK321		Predictive	Supports	D	Sensitivity/Response	Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.	26436839	PubMed		Okoye-Okafor et al., 2015, Nat. Chem. Biol.		3	accepted	732	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/732	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
MET	4233	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K.	17463250	PubMed		Engelman et al., 2007, Science		4	accepted	733	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/733	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
MYD88	4615	OVEREXPRESSION	Breast Cancer	1612		Paclitaxel		Predictive	Supports	D	Resistance	In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression.	26596839	PubMed		Xiang et al., 2016, Tumour Biol.		2	accepted	734	292	3742	3	38179969	38184510			ENST00000417037.2					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/734	https://civic.genome.wustl.edu/links/variants/292	https://civic.genome.wustl.edu/links/genes/3742
MET	4233	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.	21623265	PubMed		Ou et al., 2011, J Thorac Oncol	NCT00585195	3	accepted	735	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/735	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Cancer	162		Crizotinib		Predictive	Supports	D	Sensitivity/Response	The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletion results in an in-frame deletion in the MET protein. Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers.	26547802	PubMed		Togashi et al., 2015, Lung Cancer		3	accepted	736	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/736	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
EGFR	1956	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS.	26439803	PubMed		Park et al., 2015, Oncotarget		3	accepted	737	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/737	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).	26130666	PubMed		Yoo et al., 2016, Cancer Res Treat		4	accepted	738	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/738	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
PIK3CA	5290	P471L	Merkel Cell Carcinoma	3965		Idelalisib		Predictive	Supports	C	Sensitivity/Response	A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.	26466009	PubMed		Shiver et al., 2015, N. Engl. J. Med.		3	accepted	739	294	37	3	178928226	178928226	C	T	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/739	https://civic.genome.wustl.edu/links/variants/294	https://civic.genome.wustl.edu/links/genes/37
RET	5979	EXPRESSION	Breast Cancer	1612		Vandetanib		Predictive	Supports	D	Sensitivity/Response	Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth.	26686064	PubMed		Hatem et al., 2016, Int. J. Cancer		2	accepted	740	295	42	10	43572475	43625799			ENST00000355710.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/740	https://civic.genome.wustl.edu/links/variants/295	https://civic.genome.wustl.edu/links/genes/42
RIT1	6016	OVEREXPRESSION	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion.	26617739	PubMed		Xu et al., 2015, Int J Clin Exp Pathol		3	accepted	741	296	4875	1	155870065	155880706			ENST00000368322.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/741	https://civic.genome.wustl.edu/links/variants/296	https://civic.genome.wustl.edu/links/genes/4875
RIT1	6016	MUTATION	Lung Adenocarcinoma	3910		Selumetinib,Pictilisib	Substitutes	Predictive	Supports	D	Sensitivity/Response	RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the "oncogene negative" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice. GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro. Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro.	24469055	PubMed		Berger et al., 2014, Oncogene		3	accepted	742	297	4875	1	155870065	155880706			ENST00000368322.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/742	https://civic.genome.wustl.edu/links/variants/297	https://civic.genome.wustl.edu/links/genes/4875
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pembrolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.	26086854	PubMed		Carbognin et al., 2015, PLoS ONE		4	accepted	743	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/743	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
MYCN	4613	AMPLIFICATION	Neuroblastoma	769		FACT Complex-targeting Curaxin CBL0137		Predictive	Supports	D	Sensitivity/Response	The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc.) by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells. High MYCN expression was found to sensitize neuroblastoma cells to CBL0137.	26537256	PubMed		Carter et al., 2015, Sci Transl Med		3	accepted	744	298	3741	2	16080686	16087129			ENST00000281043.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/744	https://civic.genome.wustl.edu/links/variants/298	https://civic.genome.wustl.edu/links/genes/3741
SMO	6608	D473H	Medulloblastoma	0050902		Vismodegib		Predictive	Supports	C	Resistance	In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).	19726788	PubMed		Yauch et al., 2009, Science		3	accepted	745	299	5365	7	128849189	128849189	G	C	ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/745	https://civic.genome.wustl.edu/links/variants/299	https://civic.genome.wustl.edu/links/genes/5365
SMO	6608	MUTATION	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	B	Resistance	In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients.	25759020	PubMed		Atwood et al., 2015, Cancer Cell		4	accepted	746	300	5365	7	128828713	128853386			ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/746	https://civic.genome.wustl.edu/links/variants/300	https://civic.genome.wustl.edu/links/genes/5365
SMO	6608	MUTATION	Basal Cell Carcinoma	2513		PSI,Arsenic Trioxide	Substitutes	Predictive	Supports	D	Sensitivity/Response	Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-//GLI inhibitor) or arsenic trioxide.	25759020	PubMed		Atwood et al., 2015, Cancer Cell		4	accepted	747	300	5365	7	128828713	128853386			ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/747	https://civic.genome.wustl.edu/links/variants/300	https://civic.genome.wustl.edu/links/genes/5365
PTCH1	5727	MUTATION	Medulloblastoma	0050902		Sonidegib		Predictive	Supports	B	Sensitivity/Response	133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with sonidegib.	24651015	PubMed		Kool et al., 2014, Cancer Cell		4	accepted	748	301	4645	9	98205262	98270943			ENST00000331920.6					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/748	https://civic.genome.wustl.edu/links/variants/301	https://civic.genome.wustl.edu/links/genes/4645
PTCH1	5727	LOH	Medulloblastoma	0050902		Vismodegib		Predictive	Supports	B	Sensitivity/Response	Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study.	26169613	PubMed		Robinson et al., 2015, J. Clin. Oncol.	NCT00939484,NCT01239316	2	accepted	749	302	4645	9	98205262	98270943			ENST00000331920.6					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/749	https://civic.genome.wustl.edu/links/variants/302	https://civic.genome.wustl.edu/links/genes/4645
STK11	6794	EXON 1-2 MUTATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets.	26625312	PubMed		Pcuchet et al., 2015, Oncotarget		4	accepted	750	303	5534	19	1205740	1218499			ENST00000326873.7					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/750	https://civic.genome.wustl.edu/links/variants/303	https://civic.genome.wustl.edu/links/genes/5534
STK11	6794	UNDEREXPRESSION	Prostate Cancer	10283		SB202190		Predictive	Supports	D	Sensitivity/Response	STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.	26391455	PubMed		Grossi et al., 2015, Autophagy		2	accepted	751	304	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/751	https://civic.genome.wustl.edu/links/variants/304	https://civic.genome.wustl.edu/links/genes/5534
SYK	6850	OVEREXPRESSION	Ovarian Cancer	2394		Paclitaxel		Predictive	Supports	D	Resistance	Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.	26096845	PubMed		Yu et al., 2015, Cancer Cell		3	accepted	752	305	5572	9	93564069	93660831			ENST00000375754.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/752	https://civic.genome.wustl.edu/links/variants/305	https://civic.genome.wustl.edu/links/genes/5572
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Panitumumab		Predictive	Supports	B	Sensitivity/Response	p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.	23746666	PubMed		Vermorken et al., 2013, Lancet Oncol.	NCT00460265	3	accepted	753	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/753	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
PRKACA	5566	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	25557953	PubMed		Cornella et al., 2015, Gastroenterology		4	accepted	754	31	17	19	14628951	14629232			ENST00000254322.2	19	14202500	14218221	ENST00000308677.4	75	GRCh37	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/754	https://civic.genome.wustl.edu/links/variants/31	https://civic.genome.wustl.edu/links/genes/17
SMO	6608	D473H	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	D	Resistance	D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.	25759020	PubMed		Atwood et al., 2015, Cancer Cell		3	accepted	755	299	5365	7	128849189	128849189	G	C	ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/755	https://civic.genome.wustl.edu/links/variants/299	https://civic.genome.wustl.edu/links/genes/5365
PIK3CA	5290	AMPLIFICATION	Epithelial Ovarian Cancer	2152		Pictilisib		Predictive	Supports	C	Sensitivity/Response	One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A total of 60 patients with advanced solid tumors were enrolled in this study.	25370471	PubMed		Sarker et al., 2015, Clin. Cancer Res.		2	accepted	756	212	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/756	https://civic.genome.wustl.edu/links/variants/212	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	V600E	Melanoma	1909		Pictilisib		Predictive	Supports	C	Sensitivity/Response	One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.	25370471	PubMed		Sarker et al., 2015, Clin. Cancer Res.		2	accepted	757	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/757	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
CDKN2A	1029	p16 EXPRESSION	Oropharynx Cancer	8557				Prognostic	Supports	A	Better Outcome	720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.	20530316	PubMed		Ang et al., 2010, N. Engl. J. Med.	NCT00047008	4	accepted	758	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/758	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	p16 EXPRESSION	Oropharynx Cancer	8557		Cetuximab		Predictive	Does Not Support	B	Resistance	This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.	26712222	PubMed		Rosenthal et al., 2016, J. Clin. Oncol.		4	accepted	759	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/759	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
ERBB2	2064	AMPLIFICATION	Breast Cancer	1612		AKTi-1/2		Predictive	Supports	D	Sensitivity/Response	Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).	18725974	PubMed		She et al., 2008, PLoS ONE		3	accepted	760	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/760	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Breast Cancer	1612		Neratinib		Predictive	Supports	B	Sensitivity/Response	Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.	20142587	PubMed		Burstein et al., 2010, J. Clin. Oncol.		3	accepted	761	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/761	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Rociletinib		Predictive	Supports	D	Sensitivity/Response	CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.	24065731	PubMed		Walter et al., 2013, Cancer Discov		3	accepted	762	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/762	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
ALK	238	EML4-ALK L1152R	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	Case-report of a patient with an acquired ALK L1152R mutation and resistance to crizotinib treatment. A cell line model also showed resistance against ALK inhibition.	21791641	PubMed		Sasaki et al., 2011, Cancer Res.		4	accepted	763	307	1	2	29445270	29445270	A	C	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/763	https://civic.genome.wustl.edu/links/variants/307	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	11 patients with crizotinib-resistant NSCLC were analyzed for this study. Two harbored the G1269A mutation that also led to crizotinib-resistance in-vitro.	22235099	PubMed		Doebele et al., 2012, Clin. Cancer Res.		4	accepted	764	308	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37	The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.	Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/764	https://civic.genome.wustl.edu/links/variants/308	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	2 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation. One of these patients also harbored a L1196M mutation. In vitro follow-up showed reduced crizotinib-induced ALK dephosphorylation (293T) and apoptosis (Ba/F3) when EML4-ALK G1269A overexpression was compared to EML4-ALK overexpression in these cell lines.	23344087	PubMed		Kim et al., 2013, J Thorac Oncol		3	accepted	765	308	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37	The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.	Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/765	https://civic.genome.wustl.edu/links/variants/308	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Two out of 11 patients with an acquired crizotinib resistance showed new ALK copy-number gain (defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen), both with >4 fold increase. One of them also harbored a resistance mutation (G1269A).	22235099	PubMed		Doebele et al., 2012, Clin. Cancer Res.		3	accepted	766	170	1	2	42396490	42528380			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/766	https://civic.genome.wustl.edu/links/variants/170	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by FISH) and harbored an EGFR L858R mutation.	23344087	PubMed		Kim et al., 2013, J Thorac Oncol		2	accepted	767	170	1	2	42396490	42528380			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/767	https://civic.genome.wustl.edu/links/variants/170	https://civic.genome.wustl.edu/links/genes/1
ERBB4	2066	MUTATION	Melanoma	1909		Lapatinib		Predictive	Supports	D	Sensitivity/Response	ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients). Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro. ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth.	19718025	PubMed		Prickett et al., 2009, Nat. Genet.		4	accepted	770	310	1734	2	212295697	212578308			ENST00000342788.4					75	GRCh37	ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.	Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/770	https://civic.genome.wustl.edu/links/variants/310	https://civic.genome.wustl.edu/links/genes/1734
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Cabozantinib		Predictive	Supports	D	Sensitivity/Response	20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to control20%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib.	25242168	PubMed		Song et al., 2015, Int. J. Cancer		3	accepted	771	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/771	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
EGFR	1956	VIII	Glioblastoma Multiforme	3068		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	16282176	PubMed		Mellinghoff et al., 2005, N. Engl. J. Med.		4	accepted	772	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/772	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	VIII	Glioblastoma Multiforme	3068		Afatinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence. Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations.	26423602	PubMed		Alshami et al., 2015, Oncotarget		2	accepted	773	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/773	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
PTEN	5728	EXPRESSION	Glioblastoma Multiforme	3068		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	16282176	PubMed		Mellinghoff et al., 2005, N. Engl. J. Med.		4	accepted	774	313	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/774	https://civic.genome.wustl.edu/links/variants/313	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	EXPRESSION	Glioblastoma Multiforme	3068		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation). It was less effective in one cell-line with PTEN deletion.	25939761	PubMed		Zahonero et al., 2015, Mol. Cancer Ther.		2	accepted	775	313	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/775	https://civic.genome.wustl.edu/links/variants/313	https://civic.genome.wustl.edu/links/genes/41
NRG1	3084	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Lapatinib		Predictive	Supports	D	Sensitivity/Response	In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines.	21840482	PubMed		Wilson et al., 2011, Cancer Cell		4	accepted	776	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/776	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
NRG1	3084	EXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.	21900593	PubMed		Yonesaka et al., 2011, Sci Transl Med		4	accepted	777	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/777	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
NRG1	3084	EXPRESSION	Ovarian Cancer	2394		Seribantumab		Predictive	Supports	D	Sensitivity/Response	An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo. An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo.	20227043	PubMed		Sheng et al., 2010, Cancer Cell		3	accepted	778	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/778	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
NRG1	3084	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Gemcitabine,Paclitaxel,Cisplatin,Carboplatin	Substitutes	Predictive	Supports	D	Sensitivity/Response	In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy.	23390248	PubMed		Hegde et al., 2013, Sci Transl Med		3	accepted	779	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/779	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
AREG	374	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth. Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable). The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.	21791641	PubMed		Sasaki et al., 2011, Cancer Res.		3	accepted	780	315	389	4	75310851	75320726			ENST00000395748.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/780	https://civic.genome.wustl.edu/links/variants/315	https://civic.genome.wustl.edu/links/genes/389
AREG	374	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Resistance	Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.	23344087	PubMed		Kim et al., 2013, J Thorac Oncol		2	accepted	781	315	389	4	75310851	75320726			ENST00000395748.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/781	https://civic.genome.wustl.edu/links/variants/315	https://civic.genome.wustl.edu/links/genes/389
EGFR	1956	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	9625170	PubMed		Rubin Grandis et al., 1998, J. Natl. Cancer Inst.		3	accepted	782	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/782	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Esophagus Squamous Cell Carcinoma	3748		Nimotuzumab		Predictive	Does Not Support	B	Sensitivity/Response	55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).	26459251	PubMed		Jia et al., 2016, Clin Transl Oncol		3	accepted	783	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/783	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8  0.5 vs. 11.0  2.8 months, P = 0.007; OS: 9.7  0.5 vs. 21.5  1.5 months, P = 0.03.	26459251	PubMed		Jia et al., 2016, Clin Transl Oncol		3	accepted	784	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/784	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
TGFA	7039	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	9625170	PubMed		Rubin Grandis et al., 1998, J. Natl. Cancer Inst.		3	accepted	785	316	5742	2	70674412	70781147			ENST00000295400.6					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/785	https://civic.genome.wustl.edu/links/variants/316	https://civic.genome.wustl.edu/links/genes/5742
EGFR	1956	G724S	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules.	24894453	PubMed		Cho et al., 2014, Mol. Cancer		4	accepted	786	317	19	7	55241722	55241722	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/786	https://civic.genome.wustl.edu/links/variants/317	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G719S	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation.	24894453	PubMed		Cho et al., 2014, Mol. Cancer		4	accepted	787	134	19	7	55241707	55241707	G	A	ENST00000275493.2					75	GRCh37	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/787	https://civic.genome.wustl.edu/links/variants/134	https://civic.genome.wustl.edu/links/genes/19
AREG	374	EXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15months, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC.	23374602	PubMed		Pentheroudakis et al., 2013, BMC Cancer		3	accepted	788	315	389	4	75310851	75320726			ENST00000395748.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/788	https://civic.genome.wustl.edu/links/variants/315	https://civic.genome.wustl.edu/links/genes/389
EREG	2069	EXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.	23374602	PubMed		Pentheroudakis et al., 2013, BMC Cancer		3	accepted	789	318	1737	4	75230860	75254468			ENST00000244869.2					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/789	https://civic.genome.wustl.edu/links/variants/318	https://civic.genome.wustl.edu/links/genes/1737
MAPK1	5594	E322K	Head And Neck Squamous Cell Carcinoma	5520		Erlotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.	26181029	PubMed		Van Allen et al., 2015, JAMA Oncol	NCT00779389	4	accepted	791	320	4532	22	22127164	22127164	C	T	ENST00000215832.6					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/791	https://civic.genome.wustl.edu/links/variants/320	https://civic.genome.wustl.edu/links/genes/4532
MAPK1	5594	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		WZ4002		Predictive	Supports	D	Resistance	Resistance to WZ4002 was induced in cell lines. Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002. Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro. Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients. MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification.	22961667	PubMed		Ercan et al., 2012, Cancer Discov		4	accepted	792	321	4532	22	22108789	22221919			ENST00000215832.6					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/792	https://civic.genome.wustl.edu/links/variants/321	https://civic.genome.wustl.edu/links/genes/4532
FGFR1	2260	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008). In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010).	26673008	PubMed		Shi et al., 2016, Oncotarget		2	accepted	793	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/793	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
KRAS	3845	A146V	Lung Non-small Cell Carcinoma	3908		Abemaciclib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.	24836576	PubMed		Van Allen et al., 2014, Nat. Med.		2	accepted	794	322	30	12	25378561	25378561	G	A	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/794	https://civic.genome.wustl.edu/links/variants/322	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Lung Non-small Cell Carcinoma	3908		Palbociclib		Predictive	Supports	D	Sensitivity/Response	In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment.	20609353	PubMed		Puyol et al., 2010, Cancer Cell		1	accepted	795	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/795	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
MET	4233	MUTATION	Papillary Renal Cell Carcinoma	4465		Foretinib		Predictive	Supports	B	Sensitivity/Response	In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate.  A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively.	23213094	PubMed		Choueiri et al., 2013, J. Clin. Oncol.	NCT00726323	3	accepted	796	323	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Rare Germline	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/796	https://civic.genome.wustl.edu/links/variants/323	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.	25971939	PubMed		Paik et al., 2015, Cancer Discov		3	accepted	797	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/797	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
FGFR1	2260	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting. Significant risk of bias was reported for the included studies.	26115874	PubMed		Ipenburg et al., 2016, Target Oncol		2	accepted	798	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/798	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Infigratinib		Predictive	Supports	D	Sensitivity/Response	FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts.	26015511	PubMed		Gke et al., 2015, Clin. Cancer Res.		3	accepted	799	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/799	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	EXPRESSION	Gastric Adenocarcinoma	3717		Infigratinib		Predictive	Supports	D	Sensitivity/Response	FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.	26637881	PubMed		Schmidt et al., 2015, Anticancer Res.		2	accepted	800	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/800	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	EXPRESSION	Bladder Carcinoma	4007		PD173074,Dovitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074). IC50 values for PD173074 and TKI-258 (Dovitinib) were in nanomolar range compared with micromolar concentration for SU5402.	21119661	PubMed		Lamont et al., 2011, Br. J. Cancer		2	accepted	801	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/801	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
FGFR3	2261	EXPRESSION	Bladder Carcinoma	4007		Tyrosine Kinase Inhibitor SU5402,PD173074,Dovitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression.	21119661	PubMed		Lamont et al., 2011, Br. J. Cancer		3	accepted	803	325	23	4	1795039	1810599			ENST00000440486.2					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/803	https://civic.genome.wustl.edu/links/variants/325	https://civic.genome.wustl.edu/links/genes/23
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC.	25267748	PubMed		Chung et al., 2014, J. Clin. Oncol.		3	accepted	804	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/804	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
CBLC	23624	EXPRESSION	Cancer	162		Olaparib		Predictive	Supports	D	Resistance	The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib.	25883215	PubMed		Frankum et al., 2015, Oncotarget		2	accepted	805	326	9705	19	45281126	45303891			ENST00000270279.3					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/805	https://civic.genome.wustl.edu/links/variants/326	https://civic.genome.wustl.edu/links/genes/9705
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	B	Resistance	This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).	26623049	PubMed		Osumi et al., 2015, Mol Clin Oncol		2	accepted	806	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/806	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
PTPRD	5789	MUTATION	Head And Neck Carcinoma	1542		JSI-124		Predictive	Supports	D	Sensitivity/Response	In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild-type cells. The authors generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F).	26267899	PubMed		Peyser et al., 2015, PLoS ONE		3	accepted	807	327	4692	9	8314246	10033790			ENST00000381196.4					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/807	https://civic.genome.wustl.edu/links/variants/327	https://civic.genome.wustl.edu/links/genes/4692
DEFA1	1667	EXPRESSION	Prostate Cancer	10283		Docetaxel		Predictive	Supports	B	Sensitivity/Response	Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients.	26261420	PubMed		Kohli et al., 2015, Onco Targets Ther		2	accepted	808	328	1428	8	6835172	6837602			ENST00000382692.2					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/808	https://civic.genome.wustl.edu/links/variants/328	https://civic.genome.wustl.edu/links/genes/1428
ERCC1	2067	EXPRESSION	Bladder Carcinoma	4007		Cisplatin		Predictive	Does Not Support	B	Sensitivity/Response	Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.	26162296	PubMed		Klatte et al., 2015, J. Urol.		4	accepted	809	329	1735	19	45916692	45926824			ENST00000013807.5					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/809	https://civic.genome.wustl.edu/links/variants/329	https://civic.genome.wustl.edu/links/genes/1735
ERCC1	2067	EXPRESSION	Bladder Carcinoma	4007				Prognostic	Supports	B	Better Outcome	ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis.	26162296	PubMed		Klatte et al., 2015, J. Urol.		2	accepted	810	329	1735	19	45916692	45926824			ENST00000013807.5					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/810	https://civic.genome.wustl.edu/links/variants/329	https://civic.genome.wustl.edu/links/genes/1735
NOTCH1	4851	AMPLIFICATION	Colorectal Cancer	9256		NOTCH1 Antibody (PF-06293622)		Predictive	Supports	D	Sensitivity/Response	NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622).	26152787	PubMed		Arcaroli et al., 2016, Int. J. Cancer		2	accepted	811	330	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/811	https://civic.genome.wustl.edu/links/variants/330	https://civic.genome.wustl.edu/links/genes/50
NOTCH1	4851	AMPLIFICATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p=0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.	26152787	PubMed		Arcaroli et al., 2016, Int. J. Cancer		2	accepted	812	330	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/812	https://civic.genome.wustl.edu/links/variants/330	https://civic.genome.wustl.edu/links/genes/50
NRG1	3084	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Patritumab		Predictive	Supports	B	Sensitivity/Response	In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.	26137564	PubMed		Mendell et al., 2015, EBioMedicine		4	accepted	813	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/813	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
WEE1	7465	RS3910384	Lung Non-small Cell Carcinoma	3908		Platinum Compound,Gemcitabine	Combination	Predictive	Supports	B	Sensitivity/Response	The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868.	26057002	PubMed		Liu et al., 2015, Sci Rep		3	accepted	814	331	6104	11	9599943	9599943	A	G	ENST00000450114.2					75	GRCh37		Common Germline	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/814	https://civic.genome.wustl.edu/links/variants/331	https://civic.genome.wustl.edu/links/genes/6104
FNTB	2342	RS11623866	Ovarian Cancer	2394		Lonafarnib		Predictive	Supports	B	Resistance	57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609G>C) GG genotype (HRPFS 6.2, 95%CI=2.01, 19.41, P=0.002; HROS 9.6, 95%CI=1.89, 48.54, P=0.006).	26033044	PubMed		Bachmann et al., 2015, Br J Clin Pharmacol		2	accepted	815	332	1950	14	65453063	65453063	G	C	ENST00000246166.2					75	GRCh37		Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/815	https://civic.genome.wustl.edu/links/variants/332	https://civic.genome.wustl.edu/links/genes/1950
BRAF	673	V600E	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Does Not Support	B	Resistance	This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation.	25989278	PubMed		Rowland et al., 2015, Br. J. Cancer		4	accepted	816	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/816	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
PTPRT	11122	PROMOTER HYPERMETHYLATION	Head And Neck Squamous Cell Carcinoma	5520		JSI-124,Stattic	Substitutes	Predictive	Supports	D	Sensitivity/Response	PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC. The authors found that PTPRT promoter methylation and sensitivity to Stattic (a STAT3 SH2 domain inhibitor) or JSI-124 (a JAK/STAT3 pathway inhibitor) are significantly correlated (P<0.05).	25982282	PubMed		Peyser et al., 2016, Oncogene		2	accepted	817	333	8878														Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/817	https://civic.genome.wustl.edu/links/variants/333	https://civic.genome.wustl.edu/links/genes/8878
VEGFA	7422	UNDEREXPRESSION	Colorectal Cancer	9256		Bevacizumab,Irinotecan,Levoleucovorin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.	25973082	PubMed		Tsai et al., 2015, Int J Clin Exp Pathol		2	accepted	818	334	6071	6	43738444	43752346			ENST00000372055.4					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/818	https://civic.genome.wustl.edu/links/variants/334	https://civic.genome.wustl.edu/links/genes/6071
DNMT1	1786	EXPRESSION	Ovarian Cancer	2394		Decitabine		Predictive	Supports	D	Sensitivity/Response	DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (, 0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment.	25968887	PubMed		Stewart et al., 2015, Cancer Res.		3	accepted	819	335	1510	19	10244022	10305811			ENST00000340748.4					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/819	https://civic.genome.wustl.edu/links/variants/335	https://civic.genome.wustl.edu/links/genes/1510
KRAS	3845	MUTATION	Ovarian Cancer	2394		Decitabine		Predictive	Supports	D	Sensitivity/Response	KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine.	25968887	PubMed		Stewart et al., 2015, Cancer Res.		3	accepted	820	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/820	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
PDCD4	27250	EXPRESSION	Lung Cancer	1324		Paclitaxel		Predictive	Supports	B	Sensitivity/Response	PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.	25928036	PubMed		Xu et al., 2015, J. Proteome Res.		4	accepted	821	337	10573	10	112631596	112659763			ENST00000393104.2					75	GRCh37	A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.	N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/821	https://civic.genome.wustl.edu/links/variants/337	https://civic.genome.wustl.edu/links/genes/10573
MGMT	4255	RS16906252	Glioblastoma Multiforme	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013). Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status.	25910840	PubMed		Rapkins et al., 2015, Neuro-oncology		3	accepted	822	338	34	10	131265545	131265545	C	T	ENST00000306010.7					75	GRCh37		Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/822	https://civic.genome.wustl.edu/links/variants/338	https://civic.genome.wustl.edu/links/genes/34
TFF3	7033	EXPRESSION	Breast Cancer	1612		Aminoglutethimide,Tamoxifen	Substitutes	Predictive	Supports	B	Sensitivity/Response	TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers.	25900183	PubMed		May et al., 2015, Endocr. Relat. Cancer		3	accepted	823	339	5737	21	43731777	43735761			ENST00000518498.1					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/823	https://civic.genome.wustl.edu/links/variants/339	https://civic.genome.wustl.edu/links/genes/5737
DKK1	22943	NUCLEAR EXPRESSION	Colorectal Cancer	9256		Levoleucovorin,Oxaliplatin,Irinotecan,Fluorouracil	Combination	Predictive	Supports	B	Resistance	Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)].	25788273	PubMed		Aguilera et al., 2015, Oncotarget		3	accepted	824	340	9171	10	54074056	54077417			ENST00000373970.3					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/824	https://civic.genome.wustl.edu/links/variants/340	https://civic.genome.wustl.edu/links/genes/9171
CD44	960	ISOFORM EXPRESSION	Cancer	162		RG7356		Predictive	Supports	D	Sensitivity/Response	CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform. 2/3 patients with CD44s had SD as best response. Overall, 5 patients had an OR.	25762343	PubMed		Birzele et al., 2015, Clin. Cancer Res.		3	accepted	825	341	855	11	35160728	35251574			ENST00000428726.2					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/825	https://civic.genome.wustl.edu/links/variants/341	https://civic.genome.wustl.edu/links/genes/855
EGF	1950	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Supports	D	Resistance	3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive.	25677871	PubMed		Ansell et al., 2016, J. Oral Pathol. Med.		3	accepted	826	342	1634	4	110834047	110933422			ENST00000265171.5					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/826	https://civic.genome.wustl.edu/links/variants/342	https://civic.genome.wustl.edu/links/genes/1634
MDM2	4193	EXPRESSION	Malignant Pleural Mesothelioma	7474		Pemetrexed,Cisplatin	Combination	Predictive	Supports	B	Resistance	72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy).	25668009	PubMed		Walter et al., 2015, Br. J. Cancer		1	accepted	827	343	3465	12	69201956	69239214			ENST00000462284.1					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/827	https://civic.genome.wustl.edu/links/variants/343	https://civic.genome.wustl.edu/links/genes/3465
MDM2	4193	EXPRESSION	Malignant Pleural Mesothelioma	7474				Prognostic	Supports	B	Poor Outcome	72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed).	25668009	PubMed		Walter et al., 2015, Br. J. Cancer		3	accepted	828	343	3465	12	69201956	69239214			ENST00000462284.1					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/828	https://civic.genome.wustl.edu/links/variants/343	https://civic.genome.wustl.edu/links/genes/3465
HMOX1	3162	EXPRESSION	Renal Cell Carcinoma	4450		Sorafenib,Sunitinib	Substitutes	Predictive	Supports	B	Resistance	In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival ( (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib.	26309414	PubMed		Zheng et al., 2015, Onco Targets Ther		3	accepted	829	344	2657	22	35776828	35790207			ENST00000216117.8					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/829	https://civic.genome.wustl.edu/links/variants/344	https://civic.genome.wustl.edu/links/genes/2657
SPHK1	8877	OVEREXPRESSION	Cervical Cancer	4362				Prognostic	Supports	B	Poor Outcome	SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS. SPHK1 expression did not directly predict OS. High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009).	26311741	PubMed		Kim et al., 2015, Oncotarget		2	accepted	830	345	7041	17	74380731	74383936			ENST00000323374.4					75	GRCh37		Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/830	https://civic.genome.wustl.edu/links/variants/345	https://civic.genome.wustl.edu/links/genes/7041
CASP8	841	EXPRESSION	Ewing Sarcoma Of Bone	3368		Conatumumab		Predictive	Supports	D	Sensitivity/Response	In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.	26291055	PubMed		Kang et al., 2015, Br. J. Cancer		3	accepted	831	346	761	2	202122759	202152434			ENST00000358485.4					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/831	https://civic.genome.wustl.edu/links/variants/346	https://civic.genome.wustl.edu/links/genes/761
TYMS	7298	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Resistance	mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).	26502926	PubMed		Chamizo et al., 2015, BMC Pulm Med		3	accepted	832	347	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/832	https://civic.genome.wustl.edu/links/variants/347	https://civic.genome.wustl.edu/links/genes/5971
PBK	55872	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.	26745678	PubMed		Li et al., 2016, Oncotarget		3	accepted	835	348	13276	8	27667137	27695612			ENST00000301905.4					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/835	https://civic.genome.wustl.edu/links/variants/348	https://civic.genome.wustl.edu/links/genes/13276
MET	4233	AMPLIFICATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib.	26724472	PubMed		Zhang et al., 2016, J Thorac Oncol		2	accepted	836	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/836	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
SMARCA4	6597	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Cisplatin,Vinorelbine	Combination	Predictive	Supports	B	Sensitivity/Response	SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).	26671993	PubMed		Bell et al., 2016, Clin. Cancer Res.		3	accepted	837	349	78	19	11071598	11172958			ENST00000358026.2					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/837	https://civic.genome.wustl.edu/links/variants/349	https://civic.genome.wustl.edu/links/genes/78
SMARCA4	6597	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or high expression (P=0.009). In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002).	26671993	PubMed		Bell et al., 2016, Clin. Cancer Res.		3	accepted	838	349	78	19	11071598	11172958			ENST00000358026.2					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/838	https://civic.genome.wustl.edu/links/variants/349	https://civic.genome.wustl.edu/links/genes/78
SETBP1	26040	EXON 4 MUTATION	Chronic Myeloid Leukemia	8552				Prognostic	Supports	B	Poor Outcome	Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients. Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01).	23222956	PubMed		Piazza et al., 2013, Nat. Genet.		3	accepted	839	350	10024	18	42531877	42531918			ENST00000282030.5					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/839	https://civic.genome.wustl.edu/links/variants/350	https://civic.genome.wustl.edu/links/genes/10024
SETBP1	26040	G870S	Chronic Myeloid Leukemia	8552				Prognostic	Supports	D	Poor Outcome	Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins. This may be linked to the mutation abrogating a ubiquitination site.	23222956	PubMed		Piazza et al., 2013, Nat. Genet.		3	accepted	840	351	10024	18	42531913	42531913	G	A	ENST00000282030.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/840	https://civic.genome.wustl.edu/links/variants/351	https://civic.genome.wustl.edu/links/genes/10024
ALK	238	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	3908		Ceritinib,Crizotinib,Luminespib	Sequential	Predictive	Supports	C	Resistance	In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922. Subsequent chemotherapy (carboplatinpemetrexed) was administered and the patient had a response for 6 months before progression. Exome sequencing revealed the C1156Y mutation was present in <7% of the pretreatment tumor and in ~50% of the crizotinib tumor prior to ceritinib therapy.	26698910	PubMed		Shaw et al., 2016, N. Engl. J. Med.	NCT01970865	3	accepted	841	6	1	2	29445258	29445258	C	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/841	https://civic.genome.wustl.edu/links/variants/6	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with metastatic ALK-rearranged NSCLC after progression under sequential crizotinib, ceritinib, HSP90 inhibitor AUY922 and chemotherapy followed by crizotinib again. Third generation ALK inhibitor lorlatinib led to a partial response that lasted for 8 months. The C1156Y mutation was confirmed in a sample prior to initial crizotinib (<7% of cells), following crizotinib treatment (~50% of cells) and following lorlatinib resistance (100% of cells). However, a second ALK mutation (C1156Y & L1198F) was detected in the lorlatinib resistant tumor.	26698910	PubMed		Shaw et al., 2016, N. Engl. J. Med.	NCT01970865	3	accepted	842	6	1	2	29445258	29445258	C	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/842	https://civic.genome.wustl.edu/links/variants/6	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK C1156Y-L1198F	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	C	Resistance	Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156YL1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months.	26698910	PubMed		Shaw et al., 2016, N. Engl. J. Med.	NCT01970865	4	accepted	843	352	1	2	29443625	29445258			ENST00000389048.3					75	GRCh37	EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/843	https://civic.genome.wustl.edu/links/variants/352	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK C1156Y-L1198F	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156YL1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months.	26698910	PubMed		Shaw et al., 2016, N. Engl. J. Med.	NCT01970865	4	accepted	844	352	1	2	29443625	29445258			ENST00000389048.3					75	GRCh37	EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/844	https://civic.genome.wustl.edu/links/variants/352	https://civic.genome.wustl.edu/links/genes/1
BRCA1	672	LOSS-OF-FUNCTION	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	2	accepted	845	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/845	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
AREG	374	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Docetaxel,Cetuximab	Combination	Predictive	Supports	B	Resistance	47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel.	21653686	PubMed		Tinhofer et al., 2011, Clin. Cancer Res.		2	accepted	846	315	389	4	75310851	75320726			ENST00000395748.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/846	https://civic.genome.wustl.edu/links/variants/315	https://civic.genome.wustl.edu/links/genes/389
EGFR	1956	VIII	Head And Neck Squamous Cell Carcinoma	5520		Docetaxel,Cetuximab	Combination	Predictive	Supports	B	Resistance	47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS.	21653686	PubMed		Tinhofer et al., 2011, Clin. Cancer Res.		2	accepted	848	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/848	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab,Docetaxel	Combination	Predictive	Does Not Support	B	Sensitivity/Response	47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no impact on PFS (P=0.73) or OS (P=0.75).	21653686	PubMed		Tinhofer et al., 2011, Clin. Cancer Res.		3	accepted	849	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/849	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
TP53	7157	MUTATION	Gastric Adenocarcinoma	3717		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).	24740294	PubMed		Xu et al., 2014, PLoS ONE		3	accepted	850	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/850	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Breast Cancer	1612		Doxorubicin		Predictive	Supports	D	Sensitivity/Response	In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy.	22698404	PubMed		Jackson et al., 2012, Cancer Cell		4	accepted	851	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/851	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
CDKN1A	1026	EXPRESSION	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p=0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p=0.002). Multivariate analysis was also significant (p=0.001, HR 6.14; 95% CI 2.03, 18.55).	24708484	PubMed		Sim et al., 2014, BMC Cancer		3	accepted	852	355	913	6	36646487	36655108			ENST00000405375.1					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/852	https://civic.genome.wustl.edu/links/variants/355	https://civic.genome.wustl.edu/links/genes/913
ALCAM	214	EXPRESSION	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p=0.003; HR 5.61; 95% CI 1.81, 17.35).	24708484	PubMed		Sim et al., 2014, BMC Cancer		3	accepted	853	356	259	3	105085753	105295744			ENST00000306107.5					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/853	https://civic.genome.wustl.edu/links/variants/356	https://civic.genome.wustl.edu/links/genes/259
EGFR	1956	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).	24653627	PubMed		Shen et al., 2014, Chin. J. Cancer Res.		3	accepted	854	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/854	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
STMN1	3925	EXPRESSION	Endometrial Carcinoma	2871		Paclitaxel		Predictive	Supports	B	Resistance	33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.	24587245	PubMed		Werner et al., 2014, PLoS ONE		3	accepted	855	357	3255	1	26211931	26232957			ENST00000426559.2					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/855	https://civic.genome.wustl.edu/links/variants/357	https://civic.genome.wustl.edu/links/genes/3255
CCND1	595	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	0060075		Tamoxifen		Predictive	Supports	B	Resistance	The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.	15138475	PubMed		Stendahl et al., 2004, Br. J. Cancer		3	accepted	856	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/856	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
RSF1	51773	AMPLIFICATION	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo).	24367492	PubMed		Keilty et al., 2013, PLoS ONE		2	accepted	857	358	12121	11	77371041	77532063			ENST00000308488.6					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/857	https://civic.genome.wustl.edu/links/variants/358	https://civic.genome.wustl.edu/links/genes/12121
CCND1	595	AMPLIFICATION	Breast Cancer	1612		Tamoxifen		Predictive	Does Not Support	B	Resistance	In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed.	24367492	PubMed		Keilty et al., 2013, PLoS ONE		3	accepted	858	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/858	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
AR	367	OVEREXPRESSION	Breast Cancer	1612		Dactolisib		Predictive	Supports	D	Sensitivity/Response	In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).	24356815	PubMed		Wang et al., 2014, Mol. Cancer Ther.		3	accepted	859	359	67	X	66764465	66950461			ENST00000374690.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/859	https://civic.genome.wustl.edu/links/variants/359	https://civic.genome.wustl.edu/links/genes/67
CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib.	25587029	PubMed		Zhao et al., 2014, Oncotarget		3	accepted	860	360	914	12	12870058	12875305			ENST00000228872.4					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/860	https://civic.genome.wustl.edu/links/variants/360	https://civic.genome.wustl.edu/links/genes/914
NRG1	3084	EXPRESSION	Cancer	162		Anti-ErbB3 Monoclonal Antibody AV-203		Predictive	Supports	D	Sensitivity/Response	This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response.	25542901	PubMed		Meetze et al., 2015, Clin. Cancer Res.		3	accepted	861	314	2593	8	31497942	32622294			ENST00000523534.1					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/861	https://civic.genome.wustl.edu/links/variants/314	https://civic.genome.wustl.edu/links/genes/2593
ERBB3	2065	EXPRESSION	Cancer	162		Anti-ErbB3 Monoclonal Antibody AV-203		Predictive	Does Not Support	D	Sensitivity/Response	The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models. ERBB3 expression was not predictive of response.	25542901	PubMed		Meetze et al., 2015, Clin. Cancer Res.		3	accepted	862	361	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/862	https://civic.genome.wustl.edu/links/variants/361	https://civic.genome.wustl.edu/links/genes/1733
AR	367	V7 EXPRESSION	Prostate Cancer	10283		Abiraterone,Enzalutamide	Substitutes	Predictive	Supports	B	Resistance	Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone.	25184630	PubMed		Antonarakis et al., 2014, N. Engl. J. Med.		3	accepted	863	362	67	X	66764662	66915917			ENST00000504326.1					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/863	https://civic.genome.wustl.edu/links/variants/362	https://civic.genome.wustl.edu/links/genes/67
PTEN	5728	LOSS	Gastric Adenocarcinoma	3717		Lapatinib,Trastuzumab	Substitutes	Predictive	Supports	B	Resistance	In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups.	25300346	PubMed		Zhang et al., 2015, Oncology		2	accepted	864	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/864	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
ERBB3	2065	EXPRESSION	Pancreatic Ductal Adenocarcinoma	3498		Pertuzumab,9F7-F11	Combination	Predictive	Supports	D	Sensitivity/Response	In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression.	25216528	PubMed		Thomas et al., 2014, Oncotarget		3	accepted	865	361	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/865	https://civic.genome.wustl.edu/links/variants/361	https://civic.genome.wustl.edu/links/genes/1733
UGT1A	7361	EXPRESSION	Colorectal Cancer	9256		Ganetespib		Predictive	Supports	D	Resistance	Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.  Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression. High UGT1A expression was correlated with ganetespib resistance. Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition. HCT116 and SW480 cell lines became resistant through UGT1A overexpression.	25210794	PubMed		Landmann et al., 2014, Cell Death Dis		3	accepted	866	363	6023	2	234526291	234681956			ENST00000373450.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/866	https://civic.genome.wustl.edu/links/variants/363	https://civic.genome.wustl.edu/links/genes/6023
ERBB4	2066	NUCLEAR TRANSLOCATION	Breast Cancer	1612		Trastuzumab		Predictive	Supports	D	Resistance	HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.	25153719	PubMed		Mohd Nafi et al., 2014, Oncotarget		2	accepted	867	364	1734	2	212240446	213403565			ENST00000342788.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/867	https://civic.genome.wustl.edu/links/variants/364	https://civic.genome.wustl.edu/links/genes/1734
ERBB4	2066	EXPRESSION	Breast Cancer	1612		Trastuzumab		Predictive	Supports	D	Resistance	siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.	25153719	PubMed		Mohd Nafi et al., 2014, Oncotarget		2	accepted	868	365	1734	2	212240446	213403565			ENST00000342788.4					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/868	https://civic.genome.wustl.edu/links/variants/365	https://civic.genome.wustl.edu/links/genes/1734
ERBB4	2066	EXPRESSION	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway.	25590338	PubMed		Canfield et al., 2015, Cell Cycle		3	accepted	869	365	1734	2	212240446	213403565			ENST00000342788.4					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/869	https://civic.genome.wustl.edu/links/variants/365	https://civic.genome.wustl.edu/links/genes/1734
SLFN11	91607	EXPRESSION	Colorectal Cancer	9256		7-Ethyl-10-Hydroxycamptothecin		Predictive	Supports	D	Sensitivity/Response	In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan).	25089570	PubMed		Tian et al., 2014, Anticancer Drugs		2	accepted	870	366	16872	17	33677324	33700639			ENST00000394566.1					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/870	https://civic.genome.wustl.edu/links/variants/366	https://civic.genome.wustl.edu/links/genes/16872
AURKA	6790	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Cisplatin		Predictive	Supports	B	Resistance	High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.	25082261	PubMed		Xu et al., 2014, J Transl Med		4	accepted	871	181	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/871	https://civic.genome.wustl.edu/links/variants/181	https://civic.genome.wustl.edu/links/genes/61
KRAS	3845	RS61764370	Head And Neck Squamous Cell Carcinoma	5520		Cisplatin		Predictive	Supports	B	Resistance	In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04).	25081901	PubMed		Chung et al., 2014, Ann. Oncol.	NCT00003809,NCT00425750,NCT00503997	3	accepted	872	254	30	12	25360224	25360224	A	C	ENST00000311936.3					75	GRCh37	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.	Common Germline	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/872	https://civic.genome.wustl.edu/links/variants/254	https://civic.genome.wustl.edu/links/genes/30
RAC1	5879	P29S	Melanoma	1909		Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	D	Resistance	Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.	25056119	PubMed		Watson et al., 2014, Cancer Res.		4	accepted	873	367	4753	7	6426892	6426892	C	T	ENST00000356142.4					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/873	https://civic.genome.wustl.edu/links/variants/367	https://civic.genome.wustl.edu/links/genes/4753
BIRC5	332	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma	3908		Taxane Compound,Platinum Compound	Combination	Predictive	Supports	B	Sensitivity/Response	Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.	24961465	PubMed		Wu et al., 2014, Med. Oncol.		3	accepted	874	368	355	17	76210267	76221717			ENST00000301633.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/874	https://civic.genome.wustl.edu/links/variants/368	https://civic.genome.wustl.edu/links/genes/355
TP53	7157	WILD TYPE	Colorectal Cancer	9256		Oxaliplatin,Capecitabine,Cetuximab	Combination	Predictive	Supports	B	Sensitivity/Response	In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.	24957073	PubMed		Sclafani et al., 2014, J. Natl. Cancer Inst.		3	accepted	875	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/875	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
MRE11	4361	LOSS	Endometrial Cancer	1380		Talazoparib		Predictive	Supports	D	Sensitivity/Response	One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).	24927325	PubMed		Koppensteiner et al., 2014, PLoS ONE		2	accepted	876	370	3586	11	94152895	94227074			ENST00000323929.3					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/876	https://civic.genome.wustl.edu/links/variants/370	https://civic.genome.wustl.edu/links/genes/3586
ATM	472	UNDEREXPRESSION	Gastric Adenocarcinoma	3717		Olaparib		Predictive	Supports	D	Sensitivity/Response	Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).	24841718	PubMed		Kubota et al., 2014, Cell Cycle		4	accepted	878	179	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		N/A	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/878	https://civic.genome.wustl.edu/links/variants/179	https://civic.genome.wustl.edu/links/genes/69
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).	23816960	PubMed		Sequist et al., 2013, J. Clin. Oncol.	NCT00949650	4	accepted	879	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/879	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations.	23816960	PubMed		Sequist et al., 2013, J. Clin. Oncol.	NCT00949650	4	accepted	880	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/880	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.	25862853	PubMed		Banno et al., 2015, Anticancer Res.		2	accepted	881	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/881	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.	22452895	PubMed		Yang et al., 2012, Lancet Oncol.	NCT00525148	3	accepted	882	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/882	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.	22452895	PubMed		Yang et al., 2012, Lancet Oncol.	NCT00525148	3	accepted	883	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/883	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.	22285168	PubMed		Rosell et al., 2012, Lancet Oncol.	NCT00446225	3	accepted	884	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/884	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.	22285168	PubMed		Rosell et al., 2012, Lancet Oncol.	NCT00446225	3	accepted	885	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/885	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
ERBB2	2064	AMPLIFICATION	Uterine Corpus Endometrial Carcinoma	0050939		Afatinib		Predictive	Supports	D	Sensitivity/Response	Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.	25268372	PubMed		Schwab et al., 2014, Br. J. Cancer		2	accepted	886	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/886	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Lapatinib,Trastuzumab,Afatinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.	25537159	PubMed		Rimawi et al., 2015, Clin. Breast Cancer		2	accepted	887	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/887	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
TOP1	7150	AMPLIFICATION	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Sensitivity/Response	FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07.	24256029	PubMed		Nygrd et al., 2014, Scand. J. Gastroenterol.		1	accepted	888	371	5845	20	39657458	39753127			ENST00000361337.2					75	GRCh37		Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/888	https://civic.genome.wustl.edu/links/variants/371	https://civic.genome.wustl.edu/links/genes/5845
CDKN1B	1027	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Cisplatin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients).	24239278	PubMed		Moreno-Galindo et al., 2014, Oral Oncol.		2	accepted	889	372	914	12	12870058	12875305			ENST00000228872.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/889	https://civic.genome.wustl.edu/links/variants/372	https://civic.genome.wustl.edu/links/genes/914
MET	4233	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response.	24192513	PubMed		Schwab et al., 2014, Lung Cancer		2	accepted	890	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/890	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
AGR2	10551	EXPRESSION	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome.	24167368	PubMed		Hrstka et al., 2013, Dis. Markers		1	accepted	891	373	8407	7	16831435	16844704			ENST00000419304.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/891	https://civic.genome.wustl.edu/links/variants/373	https://civic.genome.wustl.edu/links/genes/8407
PIK3CA	5290	MUTATION	Endometrial Cancer	1380		Temsirolimus,Ridaforolimus	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.	24166148	PubMed		Mackay et al., 2014, Cancer		3	accepted	892	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/892	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Endometrial Cancer	1380		Ridaforolimus,Temsirolimus	Substitutes	Predictive	Does Not Support	B	Resistance	94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.	24166148	PubMed		Mackay et al., 2014, Cancer		3	accepted	893	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/893	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
KRAS	3845	MUTATION	Endometrial Cancer	1380		Ridaforolimus,Temsirolimus	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.	24166148	PubMed		Mackay et al., 2014, Cancer		2	accepted	894	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/894	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Oxaliplatin,Capecitabine,Cetuximab	Combination	Predictive	Does Not Support	B	Resistance	141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.	24146218	PubMed		Sclafani et al., 2013, Ann. Oncol.		1	accepted	895	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/895	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
FGFR1	2260	EXPRESSION	Colorectal Cancer	9256		Infigratinib		Predictive	Supports	D	Sensitivity/Response	In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples.	24135816	PubMed		Gke et al., 2013, Digestion		2	accepted	896	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/896	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
NAPRT	93100	PROMOTER HYPERMETHYLATION	Cancer	162		GNE-617		Predictive	Supports	D	Sensitivity/Response	Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid.	24097869	PubMed		Shames et al., 2013, Clin. Cancer Res.		3	accepted	897	374	17016														Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/897	https://civic.genome.wustl.edu/links/variants/374	https://civic.genome.wustl.edu/links/genes/17016
EGFR	1956	EXON 18 OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Bevacizumab	Combination	Predictive	Supports	B	Sensitivity/Response	Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study.	24039832	PubMed		Baty et al., 2013, PLoS ONE		2	accepted	898	375	19	7	55237999	55238735			ENST00000344576.2					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/898	https://civic.genome.wustl.edu/links/variants/375	https://civic.genome.wustl.edu/links/genes/19
ZEB1	6935	EXPRESSION	Mantle Cell Lymphoma	0050746		Gemcitabine,Doxorubicin,Cytarabine	Substitutes	Predictive	Supports	D	Resistance	Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine.	24013721	PubMed		Snchez-Till et al., 2014, Cell Death Differ.		2	accepted	899	376	5649	10	31608101	31818741			ENST00000361642.5					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/899	https://civic.genome.wustl.edu/links/variants/376	https://civic.genome.wustl.edu/links/genes/5649
ZEB1	6935	EXPRESSION	Mantle Cell Lymphoma	0050746		Doxorubicin,Salinomycin	Combination	Predictive	Supports	D	Sensitivity/Response	Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic.	24013721	PubMed		Snchez-Till et al., 2014, Cell Death Differ.		3	accepted	900	376	5649	10	31608101	31818741			ENST00000361642.5					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/900	https://civic.genome.wustl.edu/links/variants/376	https://civic.genome.wustl.edu/links/genes/5649
TIMP1	7076	OVEREXPRESSION	Breast Cancer	1612		Fulvestrant		Predictive	Supports	D	Resistance	TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.	23881388	PubMed		Bjerre et al., 2013, Tumour Biol.		2	accepted	901	377	5777	X	47441712	47446188			ENST00000218388.4					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/901	https://civic.genome.wustl.edu/links/variants/377	https://civic.genome.wustl.edu/links/genes/5777
PTP4A3	11156	OVEREXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR). Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3.	23867504	PubMed		Al-Aidaroos et al., 2013, J. Clin. Invest.		3	accepted	902	378	8908	8	142402093	142441394			ENST00000521578.1					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/902	https://civic.genome.wustl.edu/links/variants/378	https://civic.genome.wustl.edu/links/genes/8908
TYMS	7298	AMPLIFICATION	Lung Adenocarcinoma	3910		Pemetrexed		Predictive	Supports	B	Resistance	TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.	23645741	PubMed		Kasai et al., 2013, Anticancer Res.		3	accepted	903	379	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/903	https://civic.genome.wustl.edu/links/variants/379	https://civic.genome.wustl.edu/links/genes/5971
IGF1R	3480	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98).	23619944	PubMed		Peled et al., 2013, Cell Oncol (Dordr)		2	accepted	904	380	2899	15	99192200	99507759			ENST00000268035.6					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/904	https://civic.genome.wustl.edu/links/variants/380	https://civic.genome.wustl.edu/links/genes/2899
EPHB4	2050	EXPRESSION	Colorectal Cancer	9256		Bevacizumab		Predictive	Supports	B	Resistance	EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC.	23579861	PubMed		Guijarro-Muoz et al., 2013, Med. Oncol.		2	accepted	905	381	1721	7	100400187	100425121			ENST00000358173.3					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/905	https://civic.genome.wustl.edu/links/variants/381	https://civic.genome.wustl.edu/links/genes/1721
TP53	7157	WILD TYPE	Esophageal Carcinoma	1107		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases).	23515910	PubMed		Zhang et al., 2013, Ann. Surg. Oncol.		3	accepted	906	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/906	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
TYMS	7298	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Sensitivity/Response	49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01).	21367480	PubMed		Chen et al., 2011, Lung Cancer		3	accepted	907	382	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/907	https://civic.genome.wustl.edu/links/variants/382	https://civic.genome.wustl.edu/links/genes/5971
TYMS	7298	UNDEREXPRESSION	Prostate Cancer	10283		Pemetrexed		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.	24782778	PubMed		Russell et al., 2014, Front Pharmacol		2	accepted	908	382	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/908	https://civic.genome.wustl.edu/links/variants/382	https://civic.genome.wustl.edu/links/genes/5971
TOP2A	7153	EXPRESSION	Breast Cancer	1612		Doxorubicin		Predictive	Supports	B	Sensitivity/Response	In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients.	15486187	PubMed		Durbecq et al., 2004, Mol. Cancer Ther.		2	accepted	909	383	5848	17	38544768	38574202			ENST00000423485.1					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/909	https://civic.genome.wustl.edu/links/variants/383	https://civic.genome.wustl.edu/links/genes/5848
TOP1	7150	EXPRESSION	Ovarian Cancer	2394		Carboplatin,Topotecan,Cyclophosphamide	Combination	Predictive	Supports	B	Sensitivity/Response	Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant.	19648970	PubMed		Litzow et al., 2010, Bone Marrow Transplant.	NCT00652691	2	accepted	910	384	5845	20	39657458	39753127			ENST00000361337.2					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/910	https://civic.genome.wustl.edu/links/variants/384	https://civic.genome.wustl.edu/links/genes/5845
EGFR	1956	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.	18794099	PubMed		Personeni et al., 2008, Clin. Cancer Res.		3	accepted	911	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/911	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
TOP1	7150	EXPRESSION	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Sensitivity/Response	498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).	19775480	PubMed		Kostopoulos et al., 2009, BMC Cancer		3	accepted	912	384	5845	20	39657458	39753127			ENST00000361337.2					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/912	https://civic.genome.wustl.edu/links/variants/384	https://civic.genome.wustl.edu/links/genes/5845
PRKAA2	5563	T172 PHOSPHORYLATION	Cancer	162		ACLY SiRNA		Predictive	Supports	E	Sensitivity/Response	Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies.	23506848	PubMed		Migita et al., 2013, Am. J. Pathol.		2	accepted	913	385	4503	1	57159476	57159478			ENST00000371244.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/913	https://civic.genome.wustl.edu/links/variants/385	https://civic.genome.wustl.edu/links/genes/4503
HSPA5	3309	EXPRESSION	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU.	23456958	PubMed		Thornton et al., 2013, Int. J. Cancer		4	accepted	914	386	2778	9	127997132	128003609			ENST00000324460.6					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/914	https://civic.genome.wustl.edu/links/variants/386	https://civic.genome.wustl.edu/links/genes/2778
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Anti-EGFR Monoclonal Antibody		Predictive	Supports	B	Resistance	A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).	23435830	PubMed		Wu et al., 2013, J. Cancer Res. Clin. Oncol.		4	accepted	915	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/915	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	EXON 2 MUTATION	Pancreatic Carcinoma	4905		Erlotinib		Predictive	Does Not Support	B	Resistance	KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.	23435671	PubMed		Boeck et al., 2013, J. Gastroenterol.		3	accepted	916	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/916	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	EXON 2 MUTATION	Pancreatic Carcinoma	4905				Prognostic	Supports	B	Poor Outcome	KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005).	23435671	PubMed		Boeck et al., 2013, J. Gastroenterol.		3	accepted	917	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/917	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
EIF4EBP1	1978	PHOSPHORYLATION	Gastric Adenocarcinoma	3717		Everolimus		Predictive	Supports	D	Sensitivity/Response	8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus.	23340172	PubMed		Nishi et al., 2013, Cancer Lett.		2	accepted	918	387	1655	8	37888200	37914663			ENST00000338825.4					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/918	https://civic.genome.wustl.edu/links/variants/387	https://civic.genome.wustl.edu/links/genes/1655
KIT	3815	MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib,Pictilisib	Combination	Predictive	Supports	D	Sensitivity/Response	Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal.	23231951	PubMed		Floris et al., 2013, Clin. Cancer Res.		2	accepted	919	388	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/919	https://civic.genome.wustl.edu/links/variants/388	https://civic.genome.wustl.edu/links/genes/29
TUBB3	10381	EXPRESSION	Cancer	162		Paclitaxel		Predictive	Supports	D	Resistance	High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines.	21576762	PubMed		Ganguly et al., 2011, Oncotarget		2	accepted	920	389	8262	16	89989687	90002505			ENST00000315491.7					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/920	https://civic.genome.wustl.edu/links/variants/389	https://civic.genome.wustl.edu/links/genes/8262
TUBB3	10381	EXPRESSION	Breast Cancer	1612		Taxane Compound		Predictive	Supports	B	Sensitivity/Response	High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.	23218766	PubMed		Wang et al., 2013, Clin. Breast Cancer		2	accepted	921	389	8262	16	89989687	90002505			ENST00000315491.7					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/921	https://civic.genome.wustl.edu/links/variants/389	https://civic.genome.wustl.edu/links/genes/8262
TYMS	7298	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Resistance	mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671  0.844 versus 5.978  1.895, p=0.0142).	23060591	PubMed		Shimizu et al., 2012, Anticancer Res.		3	accepted	922	347	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/922	https://civic.genome.wustl.edu/links/variants/347	https://civic.genome.wustl.edu/links/genes/5971
EGFR	1956	Y1092 PHOSPHORYLATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond.  The authors investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild-type EGFR. Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, P<0.001). In this group, 92 (44.9%) were EGFR mutant. In a subgroup of patients with wild-type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2months vs.1.2months P<0.001) compared with those without phospho-Y1068 expression.	22901364	PubMed		Wang et al., 2012, J. Exp. Clin. Cancer Res.		3	accepted	923	390	19	7	55272951	55272953			ENST00000275493.2					75	GRCh37	Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).	N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/923	https://civic.genome.wustl.edu/links/variants/390	https://civic.genome.wustl.edu/links/genes/19
IGF1R	3480	NUCLEAR EXPRESSION	Sarcoma	1115		IGF1R Monoclonal Antibody		Predictive	Supports	B	Sensitivity/Response	IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871).	22682017	PubMed		Asmane et al., 2012, Eur. J. Cancer	NCT00474760,NCT00617890,NCT00642941,NCT00668148	2	accepted	924	391	2899	15	99192200	99507759			ENST00000268035.6					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/924	https://civic.genome.wustl.edu/links/variants/391	https://civic.genome.wustl.edu/links/genes/2899
CFLAR	8837	EXPRESSION	Prostate Cancer	10283		Bicalutamide		Predictive	Supports	D	Resistance	Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide.	22623731	PubMed		McCourt et al., 2012, Clin. Cancer Res.		3	accepted	925	392	7009	2	201980827	202041410			ENST00000309955.3					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/925	https://civic.genome.wustl.edu/links/variants/392	https://civic.genome.wustl.edu/links/genes/7009
PROM1	8842	EXPRESSION	Hepatocellular Carcinoma	684		Sorafenib		Predictive	Supports	B	Resistance	CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts.	22596232	PubMed		Hagiwara et al., 2012, Br. J. Cancer		2	accepted	926	393	7014	4	15969857	16085324			ENST00000510224.1					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/926	https://civic.genome.wustl.edu/links/variants/393	https://civic.genome.wustl.edu/links/genes/7014
TIMP1	7076	OVEREXPRESSION	Breast Cancer	1612		Paclitaxel		Predictive	Supports	B	Resistance	High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).	22544540	PubMed		Zhu et al., 2012, Med. Oncol.		2	accepted	927	377	5777	X	47441712	47446188			ENST00000218388.4					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/927	https://civic.genome.wustl.edu/links/variants/377	https://civic.genome.wustl.edu/links/genes/5777
FOXP3	50943	EXPRESSION	Breast Cancer	1612		Epirubicin		Predictive	Supports	B	Sensitivity/Response	1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.	22431701	PubMed		Ladoire et al., 2012, Ann. Oncol.		4	accepted	928	394	11587	X	49106897	49121288			ENST00000376207.4					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/928	https://civic.genome.wustl.edu/links/variants/394	https://civic.genome.wustl.edu/links/genes/11587
TYMS	7298	EXPRESSION	Gastric Adenocarcinoma	3717		Raltitrexed		Predictive	Supports	B	Resistance	In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).	22422354	PubMed		Shen et al., 2012, Int. J. Cancer		2	accepted	929	347	5971	18	657604	673578			ENST00000323274.10					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/929	https://civic.genome.wustl.edu/links/variants/347	https://civic.genome.wustl.edu/links/genes/5971
RPS6	6194	PHOSPHORYLATION	Gastric Adenocarcinoma	3717		Everolimus		Predictive	Supports	D	Sensitivity/Response	54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28).	22343617	PubMed		Yoon et al., 2012, Br. J. Cancer		2	accepted	930	395	5013	9	19376309	19376323			ENST00000380394.4					75	GRCh37		N/A	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/930	https://civic.genome.wustl.edu/links/variants/395	https://civic.genome.wustl.edu/links/genes/5013
JAK1	3716	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Enzastaurin		Predictive	Supports	D	Sensitivity/Response	Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.  Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin.	22333600	PubMed		Shimokawa et al., 2012, Br. J. Cancer		4	accepted	931	396	3090	1	65298912	65432187			ENST00000342505.4					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/931	https://civic.genome.wustl.edu/links/variants/396	https://civic.genome.wustl.edu/links/genes/3090
EIF4EBP1	1978	PHOSPHORYLATION	Colorectal Cancer	9256		MTOR Kinase Inhibitor PP242,Dactolisib,WYE354	Substitutes	Predictive	Supports	D	Resistance	12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620).	22262166	PubMed		Zhang et al., 2012, Cell Cycle		2	accepted	932	387	1655	8	37888200	37914663			ENST00000338825.4					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/932	https://civic.genome.wustl.edu/links/variants/387	https://civic.genome.wustl.edu/links/genes/1655
BRCA1	672	EXPRESSION	Malignant Mesothelioma	1790		Vinorelbine		Predictive	Supports	D	Sensitivity/Response	Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.	22190288	PubMed		Busacca et al., 2012, J. Pathol.		2	accepted	933	397	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/933	https://civic.genome.wustl.edu/links/variants/397	https://civic.genome.wustl.edu/links/genes/6
DUSP6	1848	EXPRESSION	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.	22169769	PubMed		Jing et al., 2012, Mol. Cancer Ther.		3	accepted	934	398	1567	12	89741009	89747048			ENST00000279488.7					75	GRCh37		N/A	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/934	https://civic.genome.wustl.edu/links/variants/398	https://civic.genome.wustl.edu/links/genes/1567
KRAS	3845	MUTATION	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines).	22169769	PubMed		Jing et al., 2012, Mol. Cancer Ther.		4	accepted	935	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/935	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	MUTATION	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response.	22169769	PubMed		Jing et al., 2012, Mol. Cancer Ther.		4	accepted	936	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/936	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	G12D	Pancreatic Carcinoma	4905		Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.	22025163	PubMed		Yap et al., 2011, J. Clin. Oncol.		2	accepted	937	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/937	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
PTEN	5728	LOSS	Pancreatic Carcinoma	4905		Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.	22025163	PubMed		Yap et al., 2011, J. Clin. Oncol.		2	accepted	938	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/938	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
HSPB1	3315	EXPRESSION	Pancreatic Ductal Adenocarcinoma	3498		Gemcitabine		Predictive	Supports	D	Sensitivity/Response	HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.	22004109	PubMed		Schfer et al., 2012, J. Cell. Mol. Med.		2	accepted	939	400	2784	7	75931861	75933612			ENST00000248553.6					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/939	https://civic.genome.wustl.edu/links/variants/400	https://civic.genome.wustl.edu/links/genes/2784
NQO1	1728	EXPRESSION	Lung Cancer	1324		Amrubicin		Predictive	Supports	D	Resistance	Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.	21964527	PubMed		Takakuwa et al., 2011, J Thorac Oncol		2	accepted	940	401	1463	16	69743304	69760854			ENST00000320623.5					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/940	https://civic.genome.wustl.edu/links/variants/401	https://civic.genome.wustl.edu/links/genes/1463
NQO1	1728	P187S	Lung Cancer	1324		Amrubicin		Predictive	Supports	D	Sensitivity/Response	The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol.	21964527	PubMed		Takakuwa et al., 2011, J Thorac Oncol		2	accepted	941	402	1463	16	69745145	69745145	G	A	ENST00000320623.5					75	GRCh37		Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/941	https://civic.genome.wustl.edu/links/variants/402	https://civic.genome.wustl.edu/links/genes/1463
BRCA1	672	UNDEREXPRESSION	Ovarian Cancer	2394		Taxane Compound,Platinum Compound	Combination	Predictive	Supports	B	Sensitivity/Response	Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).	21920589	PubMed		Carser et al., 2011, Gynecol. Oncol.		3	accepted	942	403	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/942	https://civic.genome.wustl.edu/links/variants/403	https://civic.genome.wustl.edu/links/genes/6
KRAS	3845	MUTATION	Colorectal Cancer	9256		Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.	21890455	PubMed		Rosa et al., 2011, Clin. Cancer Res.		2	accepted	943	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/943	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
ABCB1	5243	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Paclitaxel		Predictive	Supports	D	Resistance	mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279).	21883677	PubMed		Meng et al., 2011, Respirology		2	accepted	944	404	4244	7	87133175	87342564			ENST00000265724.3					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/944	https://civic.genome.wustl.edu/links/variants/404	https://civic.genome.wustl.edu/links/genes/4244
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Sensitivity/Response	Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells.	21642865	PubMed		Lee et al., 2011, J Thorac Oncol		3	accepted	945	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/945	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
DNMT1	1786	EXPRESSION	Gastric Adenocarcinoma	3717		Cisplatin		Predictive	Supports	B	Resistance	High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect.	21458988	PubMed		Mutze et al., 2011, Eur. J. Cancer		3	accepted	946	335	1510	19	10244022	10305811			ENST00000340748.4					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/946	https://civic.genome.wustl.edu/links/variants/335	https://civic.genome.wustl.edu/links/genes/1510
KRAS	3845	MUTATION	Colorectal Cancer	9256		Dasatinib,Cetuximab	Combination	Predictive	Supports	D	Sensitivity/Response	Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2).	20956938	PubMed		Dunn et al., 2011, Oncogene		3	accepted	947	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/947	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
EGFR	1956	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.	20826716	PubMed		Dahabreh et al., 2011, Ann. Oncol.		4	accepted	948	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/948	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
CXCR4	7852	EXPRESSION	Gastric Adenocarcinoma	3717		Docetaxel		Predictive	Supports	B	Resistance	CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples.	20651371	PubMed		Xie et al., 2010, Anticancer Res.		2	accepted	949	405	6329	2	136871919	136873813			ENST00000409817.1					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/949	https://civic.genome.wustl.edu/links/variants/405	https://civic.genome.wustl.edu/links/genes/6329
MAGEH1	28986	EXPRESSION	Bile Duct Adenocarcinoma	4896		Gemcitabine		Predictive	Supports	D	Resistance	10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH protein expression was found in 4/4 "non-effective" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment.	20088962	PubMed		Ojima et al., 2010, Cancer Sci.		2	accepted	950	406	11261	X	55478538	55479998			ENST00000342972.1					75	GRCh37		N/A	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/950	https://civic.genome.wustl.edu/links/variants/406	https://civic.genome.wustl.edu/links/genes/11261
ABCC3	8714	AMPLIFICATION	Breast Cancer	1612		Monomethyl Auristatin E,Paclitaxel	Substitutes	Predictive	Supports	D	Resistance	44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.	18593940	PubMed		O'Brien et al., 2008, Cancer Res.		3	accepted	951	407	6906	17	48712218	48769613			ENST00000285238.8					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/951	https://civic.genome.wustl.edu/links/variants/407	https://civic.genome.wustl.edu/links/genes/6906
ABCC10	89845	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Paclitaxel		Predictive	Supports	D	Resistance	Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).	18445659	PubMed		Oguri et al., 2008, Mol. Cancer Ther.		3	accepted	952	408	16656	6	43395292	43418168			ENST00000372530.4					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/952	https://civic.genome.wustl.edu/links/variants/408	https://civic.genome.wustl.edu/links/genes/16656
ASNS	440	AMPLIFICATION	Ovarian Cancer	2394		Asparaginase		Predictive	Supports	D	Resistance	ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.	17088436	PubMed		Lorenzi et al., 2006, Mol. Cancer Ther.		2	accepted	953	409	446	7	97481430	97501854			ENST00000175506.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/953	https://civic.genome.wustl.edu/links/variants/409	https://civic.genome.wustl.edu/links/genes/446
EGFR	1956	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression.	16707605	PubMed		Dziadziuszko et al., 2006, Clin. Cancer Res.		3	accepted	954	193	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/954	https://civic.genome.wustl.edu/links/variants/193	https://civic.genome.wustl.edu/links/genes/19
PTEN	5728	EXPRESSION	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).	16404430	PubMed		Fujita et al., 2006, Br. J. Cancer		3	accepted	955	313	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/955	https://civic.genome.wustl.edu/links/variants/313	https://civic.genome.wustl.edu/links/genes/41
CDX2	1045	EXPRESSION	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003).	26789870	PubMed		Dalerba et al., 2016, N. Engl. J. Med.		4	accepted	956	410	927	13	28536274	28545276			ENST00000381020.7					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/956	https://civic.genome.wustl.edu/links/variants/410	https://civic.genome.wustl.edu/links/genes/927
STAT3	6774	SH2 DOMAIN MUTATION	T-cell Large Granular Lymphocyte Leukemia	0050751				Diagnostic	Supports	B	Positive	Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I. Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without.	22591296	PubMed		Koskela et al., 2012, N. Engl. J. Med.		4	accepted	957	411	5516	17	40465342	40475372			ENST00000264657.5					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/957	https://civic.genome.wustl.edu/links/variants/411	https://civic.genome.wustl.edu/links/genes/5516
POU5F1	5460	EXPRESSION	Colon Cancer	219		Oxaliplatin		Predictive	Supports	D	Resistance	OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.	26398480	PubMed		Wen et al., 2015, Oncol. Rep.		2	accepted	958	412	4419	6	31132120	31138470			ENST00000259915.8					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/958	https://civic.genome.wustl.edu/links/variants/412	https://civic.genome.wustl.edu/links/genes/4419
ERBB2	2064	KINASE DOMAIN MUTATION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.	22325357	PubMed		De Grve et al., 2012, Lung Cancer	NCT00730925	3	accepted	959	413	20	17	37879863	37882870			ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/959	https://civic.genome.wustl.edu/links/variants/413	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	Y772_A775DUP	Lung Non-small Cell Carcinoma	3908		Sirolimus,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance. Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion.	19122144	PubMed		Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	960	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/960	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Afatinib		Predictive	Supports	B	Sensitivity/Response	A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks.	22418700	PubMed		Lin et al., 2012, Breast Cancer Res. Treat.		3	accepted	961	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/961	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Pancreatic Adenocarcinoma	4074		Afatinib		Predictive	Supports	D	Sensitivity/Response	Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.	26668065	PubMed		Huguet et al., 2016, Target Oncol		2	accepted	962	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/962	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	D	Sensitivity/Response	Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.	24893891	PubMed		Cross et al., 2014, Cancer Discov		3	accepted	963	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/963	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	C797S	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Resistance	An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.	25939061	PubMed		Thress et al., 2015, Nat. Med.		3	accepted	964	415	19	7	55249091	55249091	T	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/964	https://civic.genome.wustl.edu/links/variants/415	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Sensitivity/Response	This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.	25923549	PubMed		Jnne et al., 2015, N. Engl. J. Med.	NCT01802632	4	accepted	965	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/965	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Sensitivity/Response	This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.	26720284	PubMed		Sequist et al., 2016, JAMA Oncol		3	accepted	966	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/966	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib,Rociletinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	26515464	PubMed		Hirano et al., 2015, Oncotarget		2	accepted	967	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/967	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	26515464	PubMed		Hirano et al., 2015, Oncotarget		2	accepted	968	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/968	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	26515464	PubMed		Hirano et al., 2015, Oncotarget		2	accepted	969	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/969	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
FGFR1	2260	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival.	16454808	PubMed		Hase et al., 2006, J. Oral Pathol. Med.		2	accepted	970	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	N/A	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/970	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
EGFR	1956	VIII	Glioblastoma Multiforme	3068		Rindopepimut		Predictive	Supports	B	Sensitivity/Response	In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.  Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.  A pivotal, randomized Phase III trial is currently underway.	25586468	PubMed		Schuster et al., 2015, Neuro-oncology		3	accepted	971	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/971	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
ERBB2	2064	SERUM LEVELS	Breast Cancer	1612		Lapatinib		Predictive	Supports	B	Sensitivity/Response	Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit.	26811533	PubMed		Lee et al., 2016, J. Clin. Oncol.		4	accepted	972	416	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/972	https://civic.genome.wustl.edu/links/variants/416	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	SERUM LEVELS	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001).	26811533	PubMed		Lee et al., 2016, J. Clin. Oncol.		3	accepted	973	416	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/973	https://civic.genome.wustl.edu/links/variants/416	https://civic.genome.wustl.edu/links/genes/20
THBS2	7058	UNDEREXPRESSION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452). Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade. In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002).	26807188	PubMed		Lin et al., 2015, Am J Transl Res		3	accepted	974	417	5761	6	169615875	169654139			ENST00000366787.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/974	https://civic.genome.wustl.edu/links/variants/417	https://civic.genome.wustl.edu/links/genes/5761
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11).	26771872	PubMed		Tokito et al., 2016, Eur. J. Cancer		2	accepted	975	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/975	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
TERT	7015	PROMOTER MUTATION	Brain Glioma	0060108				Diagnostic	Supports	B	Positive	In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%).	26765760	PubMed		Yuan et al., 2016, J Clin Neurosci		3	accepted	976	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/976	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
EGFR	1956	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).	26722081	PubMed		Fiala et al., 2016, Anticancer Res.		2	accepted	977	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/977	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
NTRK1	4914	NTRK1 FUSIONS	Colorectal Cancer	9256		Larotrectinib		Predictive	Supports	D	Sensitivity/Response	NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion. These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470  (Larotrectinib) (one cell line with fusion (KM12), one control cell line).	26716414	PubMed		Park et al., 2016, Oncotarget		2	accepted	978	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/978	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
IDH1	3417	R132H	Oligodendroglioma	3181		AGI-5198		Predictive	Supports	D	Sensitivity/Response	In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway.	23558169	PubMed		Rohle et al., 2013, Science		4	accepted	979	420	26	2	209113112	209113112	C	T	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/979	https://civic.genome.wustl.edu/links/variants/420	https://civic.genome.wustl.edu/links/genes/26
TERT	7015	RS2736100	Brain Glioma	0060108				Predisposing	Supports	B	Positive	Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33).	26765760	PubMed		Yuan et al., 2016, J Clin Neurosci		2	accepted	980	421	79	5	1286516	1286516	C	A	ENST00000310581.5					75	GRCh37		Common Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/980	https://civic.genome.wustl.edu/links/variants/421	https://civic.genome.wustl.edu/links/genes/79
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	24439929	PubMed		Wu et al., 2014, Lancet Oncol.	NCT01121393	4	accepted	981	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/981	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	24439929	PubMed		Wu et al., 2014, Lancet Oncol.	NCT01121393	4	accepted	982	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/982	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.	25589191	PubMed		Yang et al., 2015, Lancet Oncol.	NCT00949650,NCT01121393	4	accepted	983	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/983	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
STAG2	10735	UNDEREXPRESSION	Bladder Carcinoma	4007				Prognostic	Supports	B	Better Outcome	Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (p=0.009). Complete loss of STAG2 expression was associated with a lower risk of recurrence (P=0.023) and diminished risk of death (P=0.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis.	26838030	PubMed		Qiao et al., 2016, Tumour Biol.		2	accepted	984	422	8553	X	123095568	123236506			ENST00000371157.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/984	https://civic.genome.wustl.edu/links/variants/422	https://civic.genome.wustl.edu/links/genes/8553
HLA-DRA	3122	EXPRESSION	Skin Melanoma	8923		Nivolumab,Atezolizumab,Pembrolizumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fishers exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR() responding (Fishers exact test P=0.025). Preclinical models confirmed the result.	26822383	PubMed		Johnson et al., 2016, Nat Commun		3	accepted	985	423	2622	6	32407619	32412823			ENST00000395388.2					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/985	https://civic.genome.wustl.edu/links/variants/423	https://civic.genome.wustl.edu/links/genes/2622
MYD88	4615	L265P	Waldenstrm's Macroglobulinemia	0060901		Ibrutinib		Predictive	Supports	B	Sensitivity/Response	A prospective study of ibrutinib in 63 symptomatic patients with Waldenstrm's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (89%).	25853747	PubMed		Treon et al., 2015, N. Engl. J. Med.	NCT01614821	4	accepted	986	424	3742	3	38182641	38182641	T	C	ENST00000396334.3					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/986	https://civic.genome.wustl.edu/links/variants/424	https://civic.genome.wustl.edu/links/genes/3742
KRAS	3845	G12V	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.  Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort. These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.280.65), P<0.0001 for OS. Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.0010.08), P<0.0001).	26372703	PubMed		Renaud et al., 2015, Br. J. Cancer		3	accepted	987	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/987	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen.	25199829	PubMed		Lamba et al., 2014, Cell Rep		4	accepted	988	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/988	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen.	25199829	PubMed		Lamba et al., 2014, Cell Rep		2	accepted	989	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/989	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Pancreatic Adenocarcinoma	4074		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo. KRAS mutations were identified in 103 patients using cfDNA. There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients. Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA).	24915778	PubMed		Infante et al., 2014, Eur. J. Cancer	NCT01231581	3	accepted	990	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/990	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		Trametinib,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	24685132	PubMed		Sun et al., 2014, Cell Rep		4	accepted	991	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/991	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Trametinib,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	24685132	PubMed		Sun et al., 2014, Cell Rep		2	accepted	992	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/992	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	A	Resistance	KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.   42% of the tumors evaluated had at least one mutation in exon 2. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival. The related clinical trial ID is NCT00079066.	18946061	PubMed		Karapetis et al., 2008, N. Engl. J. Med.	NCT00079066	5	accepted	993	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/993	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600E	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma.	24947927	PubMed		Zimmer et al., 2014, Clin. Cancer Res.		2	accepted	994	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/994	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	WILD TYPE	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response (n=3) or stable disease (n=4). Authors conclude that RO4987655 has clinical activity in BRAF V600-wt (and BRAF V600E) melanoma. They suggest that other drugs such as immune check point inhibitors are preferred in BRAF wt melanoma, so the role of RO4987655 as a single agent is limited for BRAF WT patients with the possible exception of a small window of opportunity for combinations with MEK inhibitors after immunotherapy progression.	24947927	PubMed		Zimmer et al., 2014, Clin. Cancer Res.		2	accepted	995	426	5	7	140434279	140624564			ENST00000288602.6					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/995	https://civic.genome.wustl.edu/links/variants/426	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	MUTATION	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	C	Resistance	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 3 experienced clinical benefit: 2 stable disease and 1 partial response (1 Patient received study treatment for 323 days). Of 10 NRAS wt patients, 4 experienced clinical benefit. Authors note that RO4987655 demonstrates clinical efficacy in BRAF wildtype melanomas with NRAS mutations.	24947927	PubMed		Zimmer et al., 2014, Clin. Cancer Res.		2	accepted	996	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/996	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 18 patients with KRAS mutant non-small cell lung cancer (NSCLC), 10 experienced clinical benefit: 2 partial responses and 8 patients experiencing stable disease for longer than 8 weeks. The median days on treatment was 58.5 (13-394) with one patient ongoing treatment at the end of the study period (56 weeks). The response rate of patients with KRAS mutant NSCLC was 11%, and 71% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). All responders showed decreases in FDG-uptake. There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. Authors conclude that RO4987655 has some clinical activity in KRAS mutated NSCLC, though patients with KRAS wild-type NSCLC were excluded from this expansion study, so it is not possible to determine whether activity of RO4987655 in NSCLC is related to KRAS mutation status.	24947927	PubMed		Zimmer et al., 2014, Clin. Cancer Res.		3	accepted	997	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/997	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Sensitivity/Response	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD. Median days on treatment was 57 (5-269). Among the patients with KRAS mutant cancer, 52% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. The authors concluded that RO4987655 does not have clinical activity in patients with KRAS mutant advanced colorectal cancer.	24947927	PubMed		Zimmer et al., 2014, Clin. Cancer Res.		2	accepted	998	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/998	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Docetaxel,Selumetinib	Combination	Predictive	Supports	B	Sensitivity/Response	87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 94 months (68-136) in selumetinib group and 52 months (95% CI 38-non-calculable) in placebo group (hazard ratio [HR] for death 080, 80% CI 056-114; one-sided p=021). Median PFS was 53 months (46-64) in selumetinib group and 21 months (95% CI 14-37) in placebo group (HR for progression 058, 80% CI 042-079; one-sided p=0014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<00001).	23200175	PubMed		Jnne et al., 2013, Lancet Oncol.	NCT00890825	4	accepted	999	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/999	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600	Melanoma	1909		Refametinib		Predictive	Supports	C	Resistance	Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).	23434733	PubMed		Weekes et al., 2013, Clin. Cancer Res.		2	accepted	1000	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1000	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	MUTATION	Colorectal Cancer	9256		Refametinib		Predictive	Does Not Support	C	Sensitivity/Response	Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD.	23434733	PubMed		Weekes et al., 2013, Clin. Cancer Res.		2	accepted	1001	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1001	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	Q61K	Neuroblastoma	769		Binimetinib,Everolimus	Combination	Predictive	Supports	D	Sensitivity/Response	In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects.	26821351	PubMed		Kiessling et al., 2016, PLoS ONE		3	accepted	1002	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1002	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	MUTATION	Pancreatic Adenocarcinoma	4074		SCH772984,PI3Kbeta Inhibitor AZD8186	Combination	Predictive	Supports	D	Sensitivity/Response	Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition.	26725216	PubMed		Hayes et al., 2016, Cancer Cell		4	accepted	1003	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1003	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		Teprotumumab,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts.	21985784	PubMed		Ebi et al., 2011, J. Clin. Invest.		3	accepted	1004	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1004	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600E	Melanoma	1909		Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (AZD6244 [selumetinib]) and PI3K/mTOR (BEZ235 [dactolisib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720 (progenitor of vemurafenib)-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).	26678033	PubMed		Penna et al., 2016, Oncotarget		2	accepted	1005	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1005	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
ERBB2	2064	AMPLIFICATION	Breast Cancer	1612		Trastuzumab,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.	16091755	PubMed		Xia et al., 2005, Oncogene		3	accepted	1006	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1006	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Lapatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.	22493419	PubMed		Guarneri et al., 2012, J. Clin. Oncol.		4	accepted	1007	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1007	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Lapatinib,Trastuzumab	Combination	Predictive	Does Not Support	B	Sensitivity/Response	This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139).	26255196	PubMed		Zardavas et al., 2015, Breast		4	accepted	1008	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1008	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.	20124187	PubMed		Blackwell et al., 2010, J. Clin. Oncol.		4	accepted	1009	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1009	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Afatinib		Predictive	Supports	B	Sensitivity/Response	With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.	22418700	PubMed		Lin et al., 2012, Breast Cancer Res. Treat.		3	accepted	1010	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1010	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Afatinib		Predictive	Supports	B	Sensitivity/Response	This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.	26596672	PubMed		Corts et al., 2015, Lancet Oncol.	NCT01441596	3	accepted	1011	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1011	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Afatinib		Predictive	Does Not Support	B	Sensitivity/Response	LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.	26822398	PubMed		Harbeck et al., 2016, Lancet Oncol.	NCT01125566	4	accepted	1012	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1012	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Afatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.	25370464	PubMed		Ring et al., 2015, Clin. Cancer Res.		3	accepted	1013	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1013	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
NOTCH1	4851	P2514FS	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients. NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions.	22077063	PubMed		Rossi et al., 2012, Blood		4	accepted	1014	207	50	9	139390649	139390650			ENST00000277541.6					75	GRCh37	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.	Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1014	https://civic.genome.wustl.edu/links/variants/207	https://civic.genome.wustl.edu/links/genes/50
EZH2	2146	MUTATION	Follicular Lymphoma	0050873				Prognostic	Supports	B	Better Outcome	In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores.	26256760	PubMed		Pastore et al., 2015, Lancet Oncol.		4	accepted	1015	163	63	7	148504477	148581370			ENST00000320356.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1015	https://civic.genome.wustl.edu/links/variants/163	https://civic.genome.wustl.edu/links/genes/63
MRE11	4361	FRAMESHIFT MUTATION	Prostate Cancer	10283		Olaparib		Predictive	Supports	B	Sensitivity/Response	One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment).	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	2	accepted	1016	428	3586	11	94152895	94227074			ENST00000323929.3					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1016	https://civic.genome.wustl.edu/links/variants/428	https://civic.genome.wustl.edu/links/genes/3586
EGFR	1956	VIII	Brain Glioma	0060108		Nimotuzumab		Predictive	Supports	D	Sensitivity/Response	Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy.	26778701	PubMed		Nitta et al., 2016, Cancer Med		1	accepted	1017	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/1017	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
TP53	7157	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53.	26771088	PubMed		Middeke et al., 2016, Br. J. Haematol.		4	accepted	1018	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1018	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
NTRK1	4914	NTRK1 FUSIONS	Lung Adenocarcinoma	3910		Larotrectinib,Lestaurtinib,Crizotinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.  Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth.	24162815	PubMed		Vaishnavi et al., 2013, Nat. Med.		3	accepted	1019	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1019	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
AREG	374	EXPRESSION	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as "high expressor" (either EREG or AREG mRNA level) or "low expressor" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P<.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P=.73; interaction test results were significant [P=.01]). Results were less clear for response rate (interaction P=.17) and OS (interaction P=.11).	26867820	PubMed		Seligmann et al., 2016, JAMA Oncol		4	accepted	1020	315	389	4	75310851	75320726			ENST00000395748.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1020	https://civic.genome.wustl.edu/links/variants/315	https://civic.genome.wustl.edu/links/genes/389
EREG	2069	EXPRESSION	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as "high expressor" (either EREG or AREG mRNA level) or "low expressor" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P<.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P=.73; interaction test results were significant [P=.01]). Results were less clear for response rate (interaction P=.17) and OS (interaction P=.11).	26867820	PubMed		Seligmann et al., 2016, JAMA Oncol		4	accepted	1021	318	1737	4	75230860	75254468			ENST00000244869.2					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1021	https://civic.genome.wustl.edu/links/variants/318	https://civic.genome.wustl.edu/links/genes/1737
ERBB2	2064	AMPLIFICATION	Gastric Adenocarcinoma	3717		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.	20728210	PubMed		Bang et al., 2010, Lancet	NCT01041404	4	accepted	1022	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1022	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Gastric Adenocarcinoma	3717		Lapatinib		Predictive	Supports	B	Sensitivity/Response	TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.	24868024	PubMed		Satoh et al., 2014, J. Clin. Oncol.		3	accepted	1023	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1023	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
KIT	3815	EXPRESSION	Endometrial Cancer	1380		Imatinib		Predictive	Supports	C	Sensitivity/Response	Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).	18607592	PubMed		Kalender et al., 2009, Cancer Chemother. Pharmacol.		2	accepted	1024	429	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1024	https://civic.genome.wustl.edu/links/variants/429	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXPRESSION	Endometrial Cancer	1380		Imatinib		Predictive	Supports	C	Sensitivity/Response	Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment with imatinib led to an objective Response. Surgery was performed and the patient was free of disease two years later.	16487996	PubMed		Salvatierra et al., 2006, Gynecol. Oncol.		2	accepted	1025	429	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1025	https://civic.genome.wustl.edu/links/variants/429	https://civic.genome.wustl.edu/links/genes/29
CBFB	865	CBFB-MYH11	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	22180162	PubMed		Estey, 2012, Am. J. Hematol.		4	accepted	1027	431	776	16	67063148	67116211			ENST00000412916.2	16	15797029	15820911	ENST00000396324.3	75	GRCh37	CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.	Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1027	https://civic.genome.wustl.edu/links/variants/431	https://civic.genome.wustl.edu/links/genes/776
TP53	7157	MUTATION	Adrenocortical Carcinoma	3948				Prognostic	Supports	B	Poor Outcome	TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection.	15922892	PubMed		Sidhu et al., 2005, Eur J Surg Oncol		2	accepted	1028	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1028	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
KMT2A	4297	MLL-MLLT3	Acute Myeloid Leukemia	9119				Diagnostic	Supports	A	Positive	The MLL-MLLT3 translocation, along with other MLL translocations, are so common in acute myeloid leukemia that the World Health Organization has developed a sub-type of "AML with t(9;11)(p22;q23); MLLT3-MLL" under the AML with recurrent genetic abnormalities diagnosis.	19357394	PubMed		Vardiman et al., 2009, Blood		4	accepted	1029	432	3537														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1029	https://civic.genome.wustl.edu/links/variants/432	https://civic.genome.wustl.edu/links/genes/3537
ROS1	6098	REARRANGEMENT	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy.	25667280	PubMed		Mazires et al., 2015, J. Clin. Oncol.		3	accepted	1030	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1030	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
HIF1A	3091	3' UTR Polymorphism	Pancreatic Adenocarcinoma	4074				Prognostic	Supports	B	Poor Outcome	The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.286) and shorter overall survival (OS, P<0.0001), compared with the CT/TT alleles Group. After multivariate Analysis, CC-HIF1A and HIF-1 expression were still significantly associated with OS (P<0.0001).  This SNP is expected to reduce MiR-199a induced repression of HIF-1 Expression.	26872370	PubMed		Wang et al., 2016, Oncotarget		2	accepted	1031	433	2596	14	62213848	62213848	T	C	ENST00000394997.1					75	GRCh37		Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1031	https://civic.genome.wustl.edu/links/variants/433	https://civic.genome.wustl.edu/links/genes/2596
HIF1A	3091	OVEREXPRESSION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation).	20363910	PubMed		Baba et al., 2010, Am. J. Pathol.		3	accepted	1032	434	2596	14	62162258	62214976			ENST00000394997.1					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1032	https://civic.genome.wustl.edu/links/variants/434	https://civic.genome.wustl.edu/links/genes/2596
EPAS1	2034	OVEREXPRESSION	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.	20363910	PubMed		Baba et al., 2010, Am. J. Pathol.		3	accepted	1033	435	1705	2	46524541	46613836			ENST00000263734.3					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1033	https://civic.genome.wustl.edu/links/variants/435	https://civic.genome.wustl.edu/links/genes/1705
HIF1A	3091	OVEREXPRESSION	Sarcoma	1115				Prognostic	Supports	B	Poor Outcome	Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors). High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018).	17103226	PubMed		Shintani et al., 2006, Virchows Arch.		2	accepted	1034	434	2596	14	62162258	62214976			ENST00000394997.1					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1034	https://civic.genome.wustl.edu/links/variants/434	https://civic.genome.wustl.edu/links/genes/2596
VHL	7428	LOSS	Renal Carcinoma	4451		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer. VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors. Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA. Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth.	16341243	PubMed		Thomas et al., 2006, Nat. Med.		3	accepted	1035	436	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1035	https://civic.genome.wustl.edu/links/variants/436	https://civic.genome.wustl.edu/links/genes/58
FLT3	2322	D835	Acute Myeloid Leukemia	9119		Ponatinib,Quizartinib	Substitutes	Predictive	Supports	D	Resistance	An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.  This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220.	23430109	PubMed		Smith et al., 2013, Blood		3	accepted	1036	437	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1036	https://civic.genome.wustl.edu/links/variants/437	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835	Acute Myeloid Leukemia	9119		SU5614		Predictive	Supports	D	Resistance	An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3.	19318574	PubMed		von Bubnoff et al., 2009, Cancer Res.		3	accepted	1037	437	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1037	https://civic.genome.wustl.edu/links/variants/437	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835	Acute Myeloid Leukemia	9119		Sorafenib,Quizartinib	Substitutes	Predictive	Supports	B	Resistance	In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842).  Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro.	22504184	PubMed		Smith et al., 2012, Nature		4	accepted	1038	437	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1038	https://civic.genome.wustl.edu/links/variants/437	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo.	22368270	PubMed		Man et al., 2012, Blood		4	accepted	1039	437	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1039	https://civic.genome.wustl.edu/links/variants/437	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Sensitivity/Response	13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.	22368270	PubMed		Man et al., 2012, Blood		2	accepted	1040	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1040	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
ERBB2	2064	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.	14679114	PubMed		Gatzemeier et al., 2004, Ann. Oncol.		2	accepted	1041	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1041	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.	14967075	PubMed		Lara et al., 2004, Clin Lung Cancer		3	accepted	1042	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1042	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	KINASE DOMAIN MUTATION	Lung Adenocarcinoma	3910		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.  All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.  In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.  No standard of care currently exists for HER2-mutant NSCLC.  While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type.	26598547	PubMed		Mazires et al., 2016, Ann. Oncol.		4	accepted	1043	413	20	17	37879863	37882870			ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1043	https://civic.genome.wustl.edu/links/variants/413	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Lung Small Cell Carcinoma	5409		Trastuzumab,Irinotecan	Combination	Predictive	Supports	C	Sensitivity/Response	This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.	25601188	PubMed		Kinehara et al., 2015, Lung Cancer		4	accepted	1044	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1044	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	Y772_A775DUP	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.  Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.  The patient was subsequently given trastuzumab with no response.  The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by the authors as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations.	26559459	PubMed		Li et al., 2015, Lung Cancer		4	accepted	1045	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1045	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	Y772_A775DUP	Lung Carcinoma	3905		Afatinib		Predictive	Supports	D	Sensitivity/Response	Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.  Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.  Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.  Authors state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab.	19122144	PubMed		Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	1047	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1047	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	P780INS	Lung Adenocarcinoma	3910		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that "HER2-positive lung cancers" is not an adequate term to describe this group of distinguishable illnesses.	25899785	PubMed		Kris et al., 2015, Ann. Oncol.	NCT00818441	3	accepted	1048	41	20	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5					75	GRCh37	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1048	https://civic.genome.wustl.edu/links/variants/41	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Trastuzumab Emtansine		Predictive	Supports	D	Sensitivity/Response	Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.	24898067	PubMed		Cretella et al., 2014, Mol. Cancer		4	accepted	1050	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1050	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PSMB8	5696	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively. Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).	26894977	PubMed		Kwon et al., 2016, Oncotarget		2	accepted	1051	438	4616	6	32808494	32812480			ENST00000374881.2					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1051	https://civic.genome.wustl.edu/links/variants/438	https://civic.genome.wustl.edu/links/genes/4616
PBK	55872	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3  1.2; +, 66.2  3.4; ++, 53.1  9.2; P = 0.002). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).	26894977	PubMed		Kwon et al., 2016, Oncotarget		2	accepted	1052	439	13276	8	27667137	27695612			ENST00000301905.4					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1052	https://civic.genome.wustl.edu/links/variants/439	https://civic.genome.wustl.edu/links/genes/13276
PTTG1	9232	OVEREXPRESSION	Meningioma	3565				Prognostic	Supports	B	Poor Outcome	144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results at the protein level.	26894859	PubMed		Schmidt et al., 2016, Oncotarget		2	accepted	1053	440	7297	5	159848829	159855748			ENST00000352433.5					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1053	https://civic.genome.wustl.edu/links/variants/440	https://civic.genome.wustl.edu/links/genes/7297
LEPR	3953	UNDEREXPRESSION	Meningioma	3565				Prognostic	Supports	B	Poor Outcome	144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results on protein level.	26894859	PubMed		Schmidt et al., 2016, Oncotarget		2	accepted	1054	441	3274	1	65886335	66107242			ENST00000349533.6					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1054	https://civic.genome.wustl.edu/links/variants/441	https://civic.genome.wustl.edu/links/genes/3274
EREG	2069	EXPRESSION	Lung Adenocarcinoma	3910				Prognostic	Supports	E	Poor Outcome	Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice.	26894620	PubMed		Bauer et al., 2016, Mol. Carcinog.		2	accepted	1055	318	1737	4	75230860	75254468			ENST00000244869.2					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1055	https://civic.genome.wustl.edu/links/variants/318	https://civic.genome.wustl.edu/links/genes/1737
EGFR	1956	G465R	Colorectal Cancer	9256		Futuximab/Modotuximab Mixture		Predictive	Supports	C	Sensitivity/Response	An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		4	accepted	1057	443	19	7	55227926	55227926	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1057	https://civic.genome.wustl.edu/links/variants/443	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G465R	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		4	accepted	1058	443	19	7	55227926	55227926	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1058	https://civic.genome.wustl.edu/links/variants/443	https://civic.genome.wustl.edu/links/genes/19
NEDD9	4739	EXPRESSION	Hepatocellular Carcinoma	684				Prognostic	Supports	B	Poor Outcome	IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model). In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05).	26893853	PubMed		Li et al., 2016, Mol Clin Oncol		3	accepted	1059	444	3852	6	11185051	11382581			ENST00000504387.1					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1059	https://civic.genome.wustl.edu/links/variants/444	https://civic.genome.wustl.edu/links/genes/3852
ETS2	2114	RS461155	Lung Non-small Cell Carcinoma	3908		Cisplatin,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.001.81, P = 0.05; aHR = 0.80, 95% CI = 0.690.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4  10-7, and 3  10-4, respectively).	26893365	PubMed		Hong et al., 2016, Oncotarget		2	accepted	1060	445	1763	21	40191638	40191638	A	G	ENST00000360214.3					75	GRCh37		Common Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1060	https://civic.genome.wustl.edu/links/variants/445	https://civic.genome.wustl.edu/links/genes/1763
KRT18	3875	UNDEREXPRESSION	Prostate Cancer	10283				Prognostic	Supports	D	Poor Outcome	Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels). An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells. Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade.	26892177	PubMed		Yin et al., 2016, Int. J. Oncol.		2	accepted	1061	446	3215	12	53342655	53346684			ENST00000388837.2					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1061	https://civic.genome.wustl.edu/links/variants/446	https://civic.genome.wustl.edu/links/genes/3215
FGF13	2258	CYTOPLASMIC EXPRESSION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR. Results were recapitulated in cell lines and public databases.	26891277	PubMed		Yu et al., 2016, Int. J. Cancer		3	accepted	1062	447	1883	X	137715011	138286269			ENST00000370603.3					75	GRCh37		N/A	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1062	https://civic.genome.wustl.edu/links/variants/447	https://civic.genome.wustl.edu/links/genes/1883
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Diagnostic	Supports	A	Positive	A t(X;18) translocation resulting in the fusion SYT-SSX (SS18-SSX1 or SS18-SSX2) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. The prevalence of this fusion in synovial sarcoma approaches 100% when there is adequate tumor RNA for RT-PCR. Its specificity for synovial sarcoma, has been confirmed by molecular screening of other morphologically similar sarcomas.	11607825	PubMed		Ladanyi, 2001, Oncogene		4	accepted	1063	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1063	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX2	6757	SS18-SSX2	Synovial Sarcoma	5485				Diagnostic	Supports	A	Positive	A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. This translocation results primarily in two fusions. SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (aka SS18-SSX2). The ratio of SYT-SSX1 to SYT-SSX2 cases is close to 2:1.	11607825	PubMed		Ladanyi, 2001, Oncogene		4	accepted	1064	449	5501														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1064	https://civic.genome.wustl.edu/links/variants/449	https://civic.genome.wustl.edu/links/genes/5501
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Diagnostic	Supports	B	Positive	A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 29 (64%) had a SYTSSX1 (SS18-SSX1) fusion transcript.	9428816	PubMed		Kawai et al., 1998, N. Engl. J. Med.		3	accepted	1065	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1065	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX2	6757	SS18-SSX2	Synovial Sarcoma	5485				Diagnostic	Supports	B	Positive	A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 16 (36%) contained a SYTSSX2 (SS18-SSX2) fusion transcript.	9428816	PubMed		Kawai et al., 1998, N. Engl. J. Med.		3	accepted	1066	449	5501														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1066	https://civic.genome.wustl.edu/links/variants/449	https://civic.genome.wustl.edu/links/genes/5501
SSX2	6757	SS18-SSX2	Synovial Sarcoma	5485				Prognostic	Supports	B	Better Outcome	In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0).	9428816	PubMed		Kawai et al., 1998, N. Engl. J. Med.		3	accepted	1067	449	5501														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1067	https://civic.genome.wustl.edu/links/variants/449	https://civic.genome.wustl.edu/links/genes/5501
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Prognostic	Supports	B	Poor Outcome	In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0).	9428816	PubMed		Kawai et al., 1998, N. Engl. J. Med.		3	accepted	1068	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1068	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Diagnostic	Supports	B	Positive	In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas. Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90% of both monophasic and biphasic synovial sarcomas. The fusion has clear diagnostic value, though the authors caution that it is not perfectly specific to synovial sarcomas, and suggest that demonstration of t(X;18) in a spindle cell neoplasm should be integrated with the morphology, immunoprofile, and clinical setting of the tumour.	11122430	PubMed		Pfeifer et al., 2000, Histopathology		4	accepted	1069	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1069	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Diagnostic	Supports	B	Positive	In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 85% of the synovial sarcomas were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1).	11144931	PubMed		O'Sullivan et al., 2000, Mod. Pathol.		4	accepted	1070	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1070	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX1	6756	SS18-SSX1	Malignant Peripheral Nerve Sheath Tumor	5940				Diagnostic	Supports	B	Positive	In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 75% of the malignant peripheral nerve sheath tumors (MPNSTs) were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1).	11144931	PubMed		O'Sullivan et al., 2000, Mod. Pathol.		3	accepted	1071	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1071	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX1	6756	SS18-SSX1	Synovial Sarcoma	5485				Prognostic	Supports	B	Poor Outcome	This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively.	11782370	PubMed		Ladanyi et al., 2002, Cancer Res.		4	accepted	1072	448	5500														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1072	https://civic.genome.wustl.edu/links/variants/448	https://civic.genome.wustl.edu/links/genes/5500
SSX2	6757	SS18-SSX2	Synovial Sarcoma	5485				Prognostic	Supports	B	Better Outcome	This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively.	11782370	PubMed		Ladanyi et al., 2002, Cancer Res.		3	accepted	1073	449	5501														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1073	https://civic.genome.wustl.edu/links/variants/449	https://civic.genome.wustl.edu/links/genes/5501
SSX4	6759	SS18-SSX4	Synovial Sarcoma	5485				Diagnostic	Supports	C	Positive	Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions.	10359553	PubMed		Skytting et al., 1999, J. Natl. Cancer Inst.		2	accepted	1074	450	5503	18	23612363	23670589			ENST00000415083.2	X	48261524	48265521	ENST00000376884.2	75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1074	https://civic.genome.wustl.edu/links/variants/450	https://civic.genome.wustl.edu/links/genes/5503
ABCB1	5243	S893A/T	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along with a tendency toward a longer overall survival (p = 0.057).	22906996	PubMed		Kim et al., 2012, Oncology		3	accepted	1075	451	4244	7	87160618	87160618	A	C	ENST00000265724.3					75	GRCh37	Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information.	Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1075	https://civic.genome.wustl.edu/links/variants/451	https://civic.genome.wustl.edu/links/genes/4244
ABCB1	5243	I1145I	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093).	22906996	PubMed		Kim et al., 2012, Oncology		3	accepted	1076	263	4244	7	87138645	87138645	A	G	ENST00000265724.3					75	GRCh37	ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.	Common Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/1076	https://civic.genome.wustl.edu/links/variants/263	https://civic.genome.wustl.edu/links/genes/4244
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Docetaxel,Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.	25693012	PubMed		Swain et al., 2015, N. Engl. J. Med.	NCT00567190	5	accepted	1077	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1077	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
EGFR	1956	S492R	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Sensitivity/Response	Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.	22270724	PubMed		Montagut et al., 2012, Nat. Med.		2	accepted	1078	453	19	7	55228009	55228009	C	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1078	https://civic.genome.wustl.edu/links/variants/453	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	S492R	Colorectal Cancer	9256		Panitumumab,Futuximab/Modotuximab Mixture	Substitutes	Predictive	Supports	D	Sensitivity/Response	In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		4	accepted	1079	453	19	7	55228009	55228009	C	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1079	https://civic.genome.wustl.edu/links/variants/453	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	S492R	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		4	accepted	1080	453	19	7	55228009	55228009	C	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1080	https://civic.genome.wustl.edu/links/variants/453	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	R451C	Colorectal Cancer	9256		Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Substitutes	Predictive	Supports	D	Sensitivity/Response	In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		2	accepted	1081	454	19	7	55227884	55227884	C	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1081	https://civic.genome.wustl.edu/links/variants/454	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	K467T	Colorectal Cancer	9256		Futuximab/Modotuximab Mixture,Panitumumab	Substitutes	Predictive	Supports	D	Sensitivity/Response	In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		3	accepted	1082	455	19	7	55227933	55227933	A	C	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/1082	https://civic.genome.wustl.edu/links/variants/455	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	K467T	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.	26888827	PubMed		Snchez-Martn et al., 2016, Clin. Cancer Res.		3	accepted	1083	455	19	7	55227933	55227933	A	C	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/1083	https://civic.genome.wustl.edu/links/variants/455	https://civic.genome.wustl.edu/links/genes/19
FCGR2A	2212	H167R	Breast Cancer	1612				Prognostic	Does Not Support	B	N/A	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival.	22906996	PubMed		Kim et al., 2012, Oncology		3	accepted	1084	456	1842	1	161479745	161479745	A	G	ENST00000271450.6					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1084	https://civic.genome.wustl.edu/links/variants/456	https://civic.genome.wustl.edu/links/genes/1842
FCGR3A	2214	F212V	Breast Cancer	1612				Prognostic	Does Not Support	B	N/A	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival.	22906996	PubMed		Kim et al., 2012, Oncology		3	accepted	1085	457	1844	1	161514542	161514542	A	C	ENST00000367969.3					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1085	https://civic.genome.wustl.edu/links/variants/457	https://civic.genome.wustl.edu/links/genes/1844
FCGR2B	2213	I232T	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81). The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03).	24989892	PubMed		Norton et al., 2014, Cancer Immunol Res		4	accepted	1086	458	1843	1	161643798	161643798	T	C	ENST00000358671.5					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1086	https://civic.genome.wustl.edu/links/variants/458	https://civic.genome.wustl.edu/links/genes/1843
FCGR3A	2214	F212V	Breast Cancer	1612		Trastuzumab		Predictive	Does Not Support	B	N/A	1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F).	24989892	PubMed		Norton et al., 2014, Cancer Immunol Res		4	accepted	1087	457	1844	1	161514542	161514542	A	C	ENST00000367969.3					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1087	https://civic.genome.wustl.edu/links/variants/457	https://civic.genome.wustl.edu/links/genes/1844
FCGR2A	2212	H167R	Breast Cancer	1612				Prognostic	Does Not Support	B	N/A	1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.	24989892	PubMed		Norton et al., 2014, Cancer Immunol Res		4	accepted	1088	456	1842	1	161479745	161479745	A	G	ENST00000271450.6					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1088	https://civic.genome.wustl.edu/links/variants/456	https://civic.genome.wustl.edu/links/genes/1842
EGFR	1956	P753S	Skin Squamous Cell Carcinoma	3151		Sirolimus,Cetuximab	Combination	Predictive	Supports	C	Sensitivity/Response	72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.	24934779	PubMed		Ganesan et al., 2016, J. Clin. Oncol.		3	accepted	1089	460	19	7	55242487	55242487	C	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/1089	https://civic.genome.wustl.edu/links/variants/460	https://civic.genome.wustl.edu/links/genes/19
PML	5371	PML-RARA	Acute Promyelocytic Leukemia	0060318				Diagnostic	Supports	A	Positive	The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML.	7628753	PubMed		Diverio et al., Haematologica		5	accepted	1090	108	39	15	74287058	74325755			ENST00000268058.3	17	38504568	38513048	ENST00000254066.5	75	GRCh37	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1090	https://civic.genome.wustl.edu/links/variants/108	https://civic.genome.wustl.edu/links/genes/39
PML	5371	PML-RARA	Acute Promyelocytic Leukemia	0060318		Tretinoin,Arsenic Trioxide	Combination	Predictive	Supports	A	Sensitivity/Response	ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	11704842	PubMed		Degos et al., 2001, Oncogene		5	accepted	1091	108	39	15	74287058	74325755			ENST00000268058.3	17	38504568	38513048	ENST00000254066.5	75	GRCh37	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1091	https://civic.genome.wustl.edu/links/variants/108	https://civic.genome.wustl.edu/links/genes/39
PML	5371	B2 DOMAIN MUTATION	Acute Promyelocytic Leukemia	0060318		Tretinoin		Predictive	Supports	B	Resistance	Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.	23670176	PubMed		Tomita et al., 2013, Int. J. Hematol.		4	accepted	1092	461	39	15	74315213	74315219			ENST00000268058.3					75	GRCh37	The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1092	https://civic.genome.wustl.edu/links/variants/461	https://civic.genome.wustl.edu/links/genes/39
PML	5371	PML-RARA A216V	Acute Promyelocytic Leukemia	0060318		Tretinoin		Predictive	Supports	C	Resistance	The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.	21613260	PubMed		Goto et al., 2011, Blood		4	accepted	1093	462	39	15	74315213	74315213	C	T	ENST00000268058.3					75	GRCh37	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1093	https://civic.genome.wustl.edu/links/variants/462	https://civic.genome.wustl.edu/links/genes/39
PML	5371	PML-RARA L218P	Acute Promyelocytic Leukemia	0060318		Tretinoin		Predictive	Supports	C	Resistance	The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide.	21613260	PubMed		Goto et al., 2011, Blood		3	accepted	1094	463	39	15	74315219	74315219	T	C	ENST00000268058.3					75	GRCh37	L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1094	https://civic.genome.wustl.edu/links/variants/463	https://civic.genome.wustl.edu/links/genes/39
MET	4233	EXON 14 MUTATION and AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	64-year old female (non-smoker) was diagnosed with NSCLC. A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping. Further, amplification of the MET gene was observed. The patient was given crizotinib and CT scans showed a positive response after 8 weeks of treatment.	26729443	PubMed		Awad et al., 2016, J. Clin. Oncol.		3	accepted	1095	464	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1095	https://civic.genome.wustl.edu/links/variants/464	https://civic.genome.wustl.edu/links/genes/52
ERBB2	2064	AMPLIFICATION	Endometrial Serous Adenocarcinoma	5750				Prognostic	Supports	B	Poor Outcome	In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.	15746676	PubMed		Santin et al., 2005, Am. J. Obstet. Gynecol.		4	accepted	1096	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1096	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Endometrial Serous Adenocarcinoma	5750		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.	18555254	PubMed		Santin et al., 2008, Int J Gynaecol Obstet		4	accepted	1097	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1097	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Endometrial Cancer	1380		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.	19840887	PubMed		Fleming et al., 2010, Gynecol. Oncol.		2	accepted	1098	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1098	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
SMO	6608	D473H	Medulloblastoma	0050902		Patidegib		Predictive	Supports	D	Sensitivity/Response	Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation.	22550175	PubMed		Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1099	299	5365	7	128849189	128849189	G	C	ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1099	https://civic.genome.wustl.edu/links/variants/299	https://civic.genome.wustl.edu/links/genes/5365
ROS1	6098	CD74-ROS1 G2032R	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Resistance	Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding.	23724914	PubMed		Awad et al., 2013, N. Engl. J. Med.	NCT00585195	4	accepted	1100	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1100	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		Cabozantinib		Predictive	Supports	D	Sensitivity/Response	Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations.	25351743	PubMed		Katayama et al., 2015, Clin. Cancer Res.		3	accepted	1101	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1101	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts.	26789727	PubMed		Ivey et al., 2016, N. Engl. J. Med.		4	accepted	1102	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1102	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
CEBPA	1050	N-TERMINAL FRAME SHIFT	Acute Myeloid Leukemia	9119		OICR-9429		Predictive	Supports	D	Sensitivity/Response	This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells. OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation. Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations. Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations.	26167872	PubMed		Grebien et al., 2015, Nat. Chem. Biol.		3	accepted	1103	28	15	19	33792961	33793470			ENST00000498907.2					75	GRCh37	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1103	https://civic.genome.wustl.edu/links/variants/28	https://civic.genome.wustl.edu/links/genes/15
FGFR1	2260	ZNF198-FGFR1	Chronic Myeloproliferative Disease	2226		Midostaurin		Predictive	Supports	C	Sensitivity/Response	A t(8;13)(p11;q12) patient with ZNF198-FGFR1-induced progressive myeloproliferative disorder was treated with PKC412. Radiographic studies performed 3 months after initiation of therapy revealed marked improvement of her cervical, mediastinal, and retroperitoneal lymphadenopathy, and marked regression of splenomegaly to normal size.	15448205	PubMed		Chen et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	1104	466	1885														Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1104	https://civic.genome.wustl.edu/links/variants/466	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Breast Cancer	1612		Afimoxifene		Predictive	Supports	D	Resistance	FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.	20179196	PubMed		Turner et al., 2010, Cancer Res.		3	accepted	1105	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1105	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
KDR	3791	A1065T	Angiosarcoma	0001816		Sorafenib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.	19723655	PubMed		Antonescu et al., 2009, Cancer Res.		3	accepted	1106	467	3153	4	55955969	55955969	C	T	ENST00000263923.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1106	https://civic.genome.wustl.edu/links/variants/467	https://civic.genome.wustl.edu/links/genes/3153
KDR	3791	D717V	Angiosarcoma	0001816		Sunitinib,Sorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.	19723655	PubMed		Antonescu et al., 2009, Cancer Res.		3	accepted	1107	468	3153	4	55968180	55968180	T	A	ENST00000263923.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1107	https://civic.genome.wustl.edu/links/variants/468	https://civic.genome.wustl.edu/links/genes/3153
TSC2	7249	Q1178*	Thyroid Gland Carcinoma	3963		Everolimus		Predictive	Supports	C	Sensitivity/Response	The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months.	25295501	PubMed		Wagle et al., 2014, N. Engl. J. Med.		5	accepted	1108	469	47	16	2130300	2130300	C	T	ENST00000219476.3					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1108	https://civic.genome.wustl.edu/links/variants/469	https://civic.genome.wustl.edu/links/genes/47
FLT3	2322	ITD	Acute Promyelocytic Leukemia	0060318				Prognostic	Supports	B	Poor Outcome	In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%).	21461300	PubMed		Hong et al., 2011, Korean J Hematol		3	accepted	1109	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1109	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
MTOR	2475	F2108L	Thyroid Gland Carcinoma	3963		Everolimus		Predictive	Supports	C	Resistance	The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.	25295501	PubMed		Wagle et al., 2014, N. Engl. J. Med.		5	accepted	1110	470	2073	1	11187094	11187094	G	T	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1110	https://civic.genome.wustl.edu/links/variants/470	https://civic.genome.wustl.edu/links/genes/2073
RAD51D	5892	R186*	Breast Cancer	1612				Predisposing	N/A	C	N/A	A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma. Her family history was notable for multiple relatives on her maternal side with breast cancer, including a distant male relative with breast cancer. Multigene panel testing with an 18-gene panel revealed a germline truncating pathogenic mutation in RAD51D (p.R186X; c. 556C>T).	25445424	PubMed		Baker et al., 2015, Clin. Breast Cancer		2	accepted	1111	471	4765	17	33433425	33433425	G	A	ENST00000345365.6					75	GRCh37		Rare Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1111	https://civic.genome.wustl.edu/links/variants/471	https://civic.genome.wustl.edu/links/genes/4765
FLT3	2322	ITD	Acute Promyelocytic Leukemia	0060318		Tretinoin,Anthracycline Antineoplastic Antibiotic	Combination	Predictive	Supports	B	Resistance	In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death.	24981688	PubMed		Lucena-Araujo et al., 2014, Ann. Hematol.		4	accepted	1112	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1112	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Neratinib,Trastuzumab	Sequential	Predictive	Supports	A	Sensitivity/Response	In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint. HER2 positivity was assessed via FISH. At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively. Distant disease-free survival and time to distant recurrence were similar in both groups. These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.	26874901	PubMed		Chan et al., 2016, Lancet Oncol.	NCT00878709	4	accepted	1113	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1113	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ALDH1A2	8854	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.140.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.200.77, p-value 0.007).	26634247	PubMed		Seidensaal et al., 2015, Mol. Cancer		3	accepted	1114	472	7024	15	58245622	58358616			ENST00000249750.4					75	GRCh37		N/A	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1114	https://civic.genome.wustl.edu/links/variants/472	https://civic.genome.wustl.edu/links/genes/7024
ALDH1A2	8854	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Tretinoin		Predictive	Supports	D	Sensitivity/Response	FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50  1 M) as compared to FaDu cells (ED  44 M). Treatment with 3 M ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells.	26634247	PubMed		Seidensaal et al., 2015, Mol. Cancer		2	accepted	1115	473	7024	15	58245622	58358616			ENST00000249750.4					75	GRCh37		N/A	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1115	https://civic.genome.wustl.edu/links/variants/473	https://civic.genome.wustl.edu/links/genes/7024
ALDH1A2	8854	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 nonHPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors. Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors. Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test. Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression.	23635773	PubMed		Kostareli et al., 2013, J. Clin. Invest.		3	accepted	1116	472	7024	15	58245622	58358616			ENST00000249750.4					75	GRCh37		N/A	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1116	https://civic.genome.wustl.edu/links/variants/472	https://civic.genome.wustl.edu/links/genes/7024
CIP2A	57650	EXPRESSION	Pancreatic Ductal Adenocarcinoma	3498				Prognostic	Supports	B	Poor Outcome	Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples. Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression.	26894380	PubMed		Xu et al., 2016, Oncotarget		3	accepted	1117	474	13948	3	108268716	108308299			ENST00000295746.8					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1117	https://civic.genome.wustl.edu/links/variants/474	https://civic.genome.wustl.edu/links/genes/13948
CIP2A	57650	UNDEREXPRESSION	Pancreatic Ductal Adenocarcinoma	3498		Gemcitabine		Predictive	Supports	D	Sensitivity/Response	Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine.	26894380	PubMed		Xu et al., 2016, Oncotarget		3	accepted	1118	475	13948	3	108268716	108308299			ENST00000295746.8					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1118	https://civic.genome.wustl.edu/links/variants/475	https://civic.genome.wustl.edu/links/genes/13948
MIR218-1	407000	EXPRESSION	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment. CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria. miR-218 expression levels were found to be significantly higher in the complete/partial response group.  Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater.	26442524	PubMed		Li et al., 2015, Carcinogenesis		3	accepted	1119	476	24938	4	20529898	20530007			ENST00000384999.1					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1119	https://civic.genome.wustl.edu/links/variants/476	https://civic.genome.wustl.edu/links/genes/24938
ALK	238	EML4-ALK	Lung Acinar Adenocarcinoma	6482		Erlotinib		Predictive	Supports	C	Resistance	A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance.	23181703	PubMed		Tanaka et al., 2012, BMC Cancer		2	accepted	1121	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1121	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	A	Sensitivity/Response	HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care.	16236737	PubMed		Piccart-Gebhart et al., 2005, N. Engl. J. Med.	NCT00045032	4	accepted	1122	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1122	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
BRCA1	672	P968FS	Breast Cancer	1612				Predisposing	Supports	C	Likely Pathogenic	A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1.	24137399	PubMed		Salgado et al., 2013, Oncol Lett		4	accepted	1123	477	6	17	41244645	41244646		GA	ENST00000471181.2					75	GRCh37		Rare Germline	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1123	https://civic.genome.wustl.edu/links/variants/477	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	P968FS	Ovarian Cancer	2394				Predisposing	Supports	C	Pathogenic	A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1.	24137399	PubMed		Salgado et al., 2013, Oncol Lett		4	accepted	1124	477	6	17	41244645	41244646		GA	ENST00000471181.2					75	GRCh37		Rare Germline	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1124	https://civic.genome.wustl.edu/links/variants/477	https://civic.genome.wustl.edu/links/genes/6
ERBB2	2064	Y772_A775DUP	Lung Adenocarcinoma	3910		Trastuzumab Emtansine		Predictive	Supports	C	Sensitivity/Response	A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (trastuzumab emtansine). Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015.	25789838	PubMed		Weiler et al., 2015, J Thorac Oncol		3	accepted	1125	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1125	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
BRAF	673	V600E	Hairy Cell Leukemia	285				Diagnostic	Supports	B	Positive	In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.	21663470	PubMed		Tiacci et al., 2011, N. Engl. J. Med.		4	accepted	1127	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1127	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	VIII	Glioblastoma Multiforme	3068		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	16282176	PubMed		Mellinghoff et al., 2005, N. Engl. J. Med.		3	accepted	1128	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/1128	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
PTEN	5728	EXPRESSION	Glioblastoma Multiforme	3068		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	16282176	PubMed		Mellinghoff et al., 2005, N. Engl. J. Med.		3	accepted	1129	313	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1129	https://civic.genome.wustl.edu/links/variants/313	https://civic.genome.wustl.edu/links/genes/41
KRAS	3845	Q22*	Colon Mucinous Adenocarcinoma	3029		Panitumumab		Predictive	Supports	C	Resistance	A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).	19661358	PubMed		Palmirotta et al., 2009, Anticancer Res.		2	accepted	1131	479	30	12	25398255	25398255	G	A	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1131	https://civic.genome.wustl.edu/links/variants/479	https://civic.genome.wustl.edu/links/genes/30
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Capecitabine,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.	17192538	PubMed		Geyer et al., 2006, N. Engl. J. Med.	NCT00078572	4	accepted	1132	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1132	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab,Capecitabine	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.	19289619	PubMed		von Minckwitz et al., 2009, J. Clin. Oncol.		4	accepted	1133	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1133	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
DDX43	55510	OVEREXPRESSION	Uveal Melanoma	6039		MEK Inhibitor PD0325901,Selumetinib,Trametinib	Substitutes	Predictive	Supports	D	Resistance	MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels. These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib. 6 patients with partial response or stable disease for 16 weeks, were defined as responders (R), 8 patients who had disease progression before 16 weeks were defined as nonresponders (NR). DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045). Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results.	24899684	PubMed		Ambrosini et al., 2014, Mol. Cancer Ther.		4	accepted	1135	481	13005	6	74104471	74127292			ENST00000370336.4					75	GRCh37		Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/1135	https://civic.genome.wustl.edu/links/variants/481	https://civic.genome.wustl.edu/links/genes/13005
KIT	3815	RS3733542	Acute Myeloid Leukemia	9119		Selumetinib		Predictive	Supports	B	Sensitivity/Response	Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation analysis (N=41) revealed the presence of a synonymous SNP rs3733542 (known population frequency of 20%) in exon 18 of the KIT gene in six of ten (60%) patients assessed as having a response or disease stabilization to selumetinib. In contrast, this SNP was detected in only seven of 31 (23%) patients without a response or disease stabilization (P = 0.027, Chi-squared test).	24178622	PubMed		Jain et al., 2014, Clin. Cancer Res.		1	accepted	1136	482	29	4	55602765	55602765	G	C	ENST00000288135.5					75	GRCh37		Common Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1136	https://civic.genome.wustl.edu/links/variants/482	https://civic.genome.wustl.edu/links/genes/29
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Selumetinib		Predictive	Supports	B	Resistance	Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33273 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled.	24178622	PubMed		Jain et al., 2014, Clin. Cancer Res.		2	accepted	1137	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1137	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
TBK1	29110	OVEREXPRESSION	Melanoma	1909		AZ909,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture.	24962318	PubMed		Vu et al., 2014, Mol. Cancer Res.		2	accepted	1138	483	11322	12	64845660	64895888			ENST00000331710.5					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1138	https://civic.genome.wustl.edu/links/variants/483	https://civic.genome.wustl.edu/links/genes/11322
KRAS	3845	MUTATION	Colorectal Cancer	9256		Chemotherapy,Bevacizumab	Combination	Predictive	Supports	B	Resistance	Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01).	23828442	PubMed		Petrelli et al., 2013, Med. Oncol.		4	accepted	1139	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1139	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Cancer	162		G-573,MEK Inhibitor GDC-0623	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations.	23934108	PubMed		Hatzivassiliou et al., 2013, Nature		3	accepted	1140	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1140	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600E	Cancer	162		Cobimetinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).	23934108	PubMed		Hatzivassiliou et al., 2013, Nature		3	accepted	1141	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1141	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	G12C	Lung Non-small Cell Carcinoma	3908		Selumetinib,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.	26125448	PubMed		Jnne et al., 2015, Br. J. Cancer	NCT00890825	3	accepted	1142	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1142	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Lung Non-small Cell Carcinoma	3908		Docetaxel,Selumetinib	Combination	Predictive	Supports	B	Sensitivity/Response	83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.	26125448	PubMed		Jnne et al., 2015, Br. J. Cancer	NCT00890825	1	accepted	1143	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1143	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
STK11	6794	LOSS	Lung Non-small Cell Carcinoma	3908		Selumetinib,Docetaxel	Combination	Predictive	Supports	D	Resistance	A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	22425996	PubMed		Chen et al., 2012, Nature		3	accepted	1144	485	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1144	https://civic.genome.wustl.edu/links/variants/485	https://civic.genome.wustl.edu/links/genes/5534
TP53	7157	MUTATION	Lung Non-small Cell Carcinoma	3908		Docetaxel,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	22425996	PubMed		Chen et al., 2012, Nature		3	accepted	1145	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1145	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Lung Non-small Cell Carcinoma	3908		Docetaxel		Predictive	Supports	D	Resistance	A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	22425996	PubMed		Chen et al., 2012, Nature		3	accepted	1146	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1146	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DELETERIOUS MUTATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11).	26899019	PubMed		Ma et al., 2016, J Thorac Oncol		4	accepted	1147	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/1147	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DELETERIOUS MUTATION	Lung Non-small Cell Carcinoma	3908		Adjuvant Chemotherapy		Predictive	Does Not Support	B	Sensitivity/Response	Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63).	26899019	PubMed		Ma et al., 2016, J Thorac Oncol		2	accepted	1148	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/1148	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	WILD TYPE	Lung Non-small Cell Carcinoma	3908		Adjuvant Chemotherapy		Predictive	Supports	B	Sensitivity/Response	Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005).	26899019	PubMed		Ma et al., 2016, J Thorac Oncol		3	accepted	1149	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1149	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
HAVCR2	84868	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		PD1 Inhibitor		Predictive	Supports	C	Resistance	In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.	26883990	PubMed		Koyama et al., 2016, Nat Commun		3	accepted	1150	486	16394	5	156512843	156536725			ENST00000307851.4					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1150	https://civic.genome.wustl.edu/links/variants/486	https://civic.genome.wustl.edu/links/genes/16394
HAVCR2	84868	OVEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Anti-TIM-3 Monoclonal Antibody,PD1 Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody.	26883990	PubMed		Koyama et al., 2016, Nat Commun		3	accepted	1151	486	16394	5	156512843	156536725			ENST00000307851.4					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1151	https://civic.genome.wustl.edu/links/variants/486	https://civic.genome.wustl.edu/links/genes/16394
ERBB3	2065	OVEREXPRESSION	Cancer	162		Selumetinib,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib. The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines. Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment. I.e. the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression. Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy.	24685132	PubMed		Sun et al., 2014, Cell Rep		3	accepted	1152	289	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1152	https://civic.genome.wustl.edu/links/variants/289	https://civic.genome.wustl.edu/links/genes/1733
ERBB3	2065	OVEREXPRESSION	Cancer	162		Selumetinib,Gefitinib,HER2 Inhibitor CP-724,714	Substitutes	Predictive	Supports	D	Resistance	Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines. MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy. Results were validated in-vivo. Basal ERBB3 expression was associated with higher synergy scores.	24685132	PubMed		Sun et al., 2014, Cell Rep		4	accepted	1153	289	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1153	https://civic.genome.wustl.edu/links/variants/289	https://civic.genome.wustl.edu/links/genes/1733
CDKN2A	1029	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Afatinib		Predictive	Supports	B	Resistance	Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 069 [95% CI 050096], p=0.022) than in p16-positive disease (HR 095 [CI 051175], p=0.67, interaction test p=032).	25892145	PubMed		Machiels et al., 2015, Lancet Oncol.	NCT01345682	2	accepted	1155	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1155	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
MMP2	4313	SERUM LEVELS	Inflammatory Breast Carcinoma	6263		Bevacizumab		Predictive	Supports	B	Sensitivity/Response	MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients.	26921265	PubMed		Tabouret et al., 2016, Oncotarget		3	accepted	1156	487	3549	16	55512883	55540603			ENST00000219070.4					75	GRCh37		N/A	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1156	https://civic.genome.wustl.edu/links/variants/487	https://civic.genome.wustl.edu/links/genes/3549
MMP9	4318	SERUM LEVELS	Inflammatory Breast Carcinoma	6263		Bevacizumab		Predictive	Supports	B	Resistance	MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.	26921265	PubMed		Tabouret et al., 2016, Oncotarget		3	accepted	1157	488	3553	20	44637547	44645200			ENST00000372330.3					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1157	https://civic.genome.wustl.edu/links/variants/488	https://civic.genome.wustl.edu/links/genes/3553
MMP2	4313	SERUM LEVELS	Brain Glioma	0060108		Bevacizumab		Predictive	Supports	B	Sensitivity/Response	Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab.	24327581	PubMed		Tabouret et al., 2014, Neuro-oncology		2	accepted	1158	487	3549	16	55512883	55540603			ENST00000219070.4					75	GRCh37		N/A	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1158	https://civic.genome.wustl.edu/links/variants/487	https://civic.genome.wustl.edu/links/genes/3549
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.	24793816	PubMed		Krop et al., 2014, Lancet Oncol.	NCT01419197	4	accepted	1159	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1159	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.	23020162	PubMed		Verma et al., 2012, N. Engl. J. Med.	NCT00829166	4	accepted	1160	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1160	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ACTA1	58	EXPRESSION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis. Patients were stratified as having high or low ActA levels using the median expression level. LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively).	26950277	PubMed		Hoda et al., 2016, Oncotarget		2	accepted	1161	546	128	1	229566992	229569841			ENST00000366684.3					75	GRCh37		N/A	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1161	https://civic.genome.wustl.edu/links/variants/546	https://civic.genome.wustl.edu/links/genes/128
HSPH1	10808	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169). Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068). This was not found for cytoplasmic expression.	26943774	PubMed		Kimura et al., 2016, Oncotarget		2	accepted	1162	490	8614	13	31710765	31736064			ENST00000320027.5					75	GRCh37		N/A	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1162	https://civic.genome.wustl.edu/links/variants/490	https://civic.genome.wustl.edu/links/genes/8614
HSPH1	10808	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	3717		Fluorouracil,Cisplatin	Substitutes	Predictive	Supports	D	Sensitivity/Response	49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364). In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05).	26943774	PubMed		Kimura et al., 2016, Oncotarget		1	accepted	1163	490	8614	13	31710765	31736064			ENST00000320027.5					75	GRCh37		N/A	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1163	https://civic.genome.wustl.edu/links/variants/490	https://civic.genome.wustl.edu/links/genes/8614
HSPH1	10808	T17 DELETION	Colorectal Cancer	9256		Oxaliplatin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	329 consecutive patients with stage IIIII colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.0120.8; P = .03). A significant interaction between chemotherapy and T17 deletion was found (P =.009).	24512910	PubMed		Collura et al., 2014, Gastroenterology		2	accepted	1164	491	8614	13	31722621	31722637			ENST00000320027.5					75	GRCh37		Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1164	https://civic.genome.wustl.edu/links/variants/491	https://civic.genome.wustl.edu/links/genes/8614
ECSCR	641700	EXPRESSION	Cancer	162		Angiogenesis Inhibitor		Predictive	Does Not Support	B	Sensitivity/Response	Biomarkers for response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08).	26956051	PubMed		Pircher et al., 2016, Oncotarget		1	accepted	1165	492	26599														N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1165	https://civic.genome.wustl.edu/links/variants/492	https://civic.genome.wustl.edu/links/genes/26599
ROBO4	54538	EXPRESSION	Cancer	162		Angiogenesis Inhibitor		Predictive	Does Not Support	B	Sensitivity/Response	Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08).	26956051	PubMed		Pircher et al., 2016, Oncotarget		1	accepted	1166	493	12367	11	124753587	124768177			ENST00000306534.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1166	https://civic.genome.wustl.edu/links/variants/493	https://civic.genome.wustl.edu/links/genes/12367
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pembrolizumab,Atezolizumab,Avelumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining 1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).	26918451	PubMed		Passiglia et al., 2016, Oncotarget		4	accepted	1167	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1167	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
PIM1	5292	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034).	26918046	PubMed		Jiang et al., 2016, J Cancer		2	accepted	1168	494	4286	6	37137979	37143202			ENST00000373509.5					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1168	https://civic.genome.wustl.edu/links/variants/494	https://civic.genome.wustl.edu/links/genes/4286
MDM2	4193	SNP309	Head And Neck Cancer	11934				Prognostic	Supports	B	Poor Outcome	66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002).	26916894	PubMed		Vivenza et al., 2016, Int. J. Biol. Markers		2	accepted	1169	495	3465	12	69202580	69202580	T	G	ENST00000462284.1					75	GRCh37		Common Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1169	https://civic.genome.wustl.edu/links/variants/495	https://civic.genome.wustl.edu/links/genes/3465
TP53	7157	DELETERIOUS MUTATION	Sarcoma	1115		Pazopanib		Predictive	Supports	B	Sensitivity/Response	19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)].	26646755	PubMed		Koehler et al., 2016, Ann. Oncol.		2	accepted	1170	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/1170	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
PIK3CA	5290	E545K	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	D	Resistance	HCC827 cell lines harboring activated PI3K (HCC827 p110 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 M) compared with those harboring GFP alone (IC50, 0.01 M). The presence of p110 E545K also protected HCC827 cells from gefitinib-mediated apoptosis.	16906227	PubMed		Engelman et al., 2006, J. Clin. Invest.		2	accepted	1171	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1171	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Atezolizumab		Predictive	Supports	B	Sensitivity/Response	Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC350%, TC25% and <50%, TC11% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC310%, IC25% and <10%, IC11% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 049 [022-107; p=0068], TC2/3 or IC2/3 HR 054 [033-089; p=0014], TC1/2/3 or IC1/2/3 HR 059 [040-085; p=0005], TC0 and IC0 HR 104 [062-175; p=0871]) but not progression free survival or overall response rate.	26970723	PubMed		Fehrenbacher et al., 2016, Lancet	NCT01903993	4	accepted	1172	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1172	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
KRAS	3845	G12C	Cancer	162		ARS-853,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a hyperexcitable rather than a statically active state. ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays. This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.  Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF.	26739882	PubMed		Patricelli et al., 2016, Cancer Discov		3	accepted	1173	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1173	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
ERBB2	2064	V842I	Colon Cancer	219		Trastuzumab,Neratinib,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		Kavuri et al., 2015, Cancer Discov		4	accepted	1174	45	20	17	37881332	37881332	G	A	ENST00000269571.5					75	GRCh37	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1174	https://civic.genome.wustl.edu/links/variants/45	https://civic.genome.wustl.edu/links/genes/20
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	B	Sensitivity/Response	Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 170 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients.	26973324	PubMed		Kim et al., 2016, Lancet Oncol.	NCT01283516	4	accepted	1175	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1175	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ERBB2	2064	L755S	Colon Cancer	219		Lapatinib,Trastuzumab,Neratinib	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		Kavuri et al., 2015, Cancer Discov		4	accepted	1176	39	20	17	37880220	37880220	T	C	ENST00000269571.5					75	GRCh37	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/1176	https://civic.genome.wustl.edu/links/variants/39	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	V777L	Colon Cancer	219		Lapatinib,Trastuzumab,Neratinib	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		Kavuri et al., 2015, Cancer Discov		4	accepted	1177	44	20	17	37881000	37881000	G	T	ENST00000269571.5					75	GRCh37	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1177	https://civic.genome.wustl.edu/links/variants/44	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	L866M	Colon Cancer	219		Neratinib,Trastuzumab,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		Kavuri et al., 2015, Cancer Discov		4	accepted	1178	496	20	17	37881404	37881404	C	A	ENST00000269571.5					75	GRCh37	This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1178	https://civic.genome.wustl.edu/links/variants/496	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	S310F/Y	Colon Cancer	219		Trastuzumab,Lapatinib,Neratinib	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		Kavuri et al., 2015, Cancer Discov		4	accepted	1179	497	20	17	37868208	37868208			ENST00000269571.5					75	GRCh37	ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/1179	https://civic.genome.wustl.edu/links/variants/497	https://civic.genome.wustl.edu/links/genes/20
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.73.8) and 7.2 months (95% CI 5.79.7).	26371285	PubMed		Schirripa et al., 2015, Ann. Oncol.		3	accepted	1180	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1180	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.	26812186	PubMed		Rowland et al., 2016, Eur. J. Cancer		4	accepted	1181	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1181	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		Ixazomib		Predictive	Supports	D	Resistance	Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib	26709701	PubMed		Chattopadhyay et al., 2015, PLoS ONE		1	accepted	1182	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1182	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Cancer	162		AZD5438		Predictive	Supports	D	Sensitivity/Response	CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice.	26881434	PubMed		Costa-Cabral et al., 2016, PLoS ONE		3	accepted	1183	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1183	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
MIR218-1	407000	UNDEREXPRESSION	Pancreatic Cancer	1793				Prognostic	Supports	D	Poor Outcome	The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007).	26662432	PubMed		Li et al., 2015, Genet. Mol. Res.		3	accepted	1184	498	24938	4	20529898	20530007			ENST00000384999.1					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1184	https://civic.genome.wustl.edu/links/variants/498	https://civic.genome.wustl.edu/links/genes/24938
MET	4233	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy).	26729443	PubMed		Awad et al., 2016, J. Clin. Oncol.		3	accepted	1185	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/1185	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	3910		Capmatinib		Predictive	Supports	C	Sensitivity/Response	A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+.	25971938	PubMed		Frampton et al., 2015, Cancer Discov		3	accepted	1186	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/1186	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment. Overall response rate was 57%, with 46 partial responses and one complete response. Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition. 31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen. 9 were unidentified, suggesting other fusion partners in these instances.	20979469	PubMed		Kwak et al., 2010, N. Engl. J. Med.	NCT00585195	5	accepted	1187	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1187	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		WHI-P154		Predictive	Supports	D	Sensitivity/Response	A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment.	17625570	PubMed		Soda et al., 2007, Nature		5	accepted	1188	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1188	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%.	20979469	PubMed		Kwak et al., 2010, N. Engl. J. Med.	NCT00585195	2	accepted	1189	500	1	2	42396490	42552694			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1189	https://civic.genome.wustl.edu/links/variants/500	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E2;A20	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	E	Sensitivity/Response	Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib.	18927303	PubMed		Takeuchi et al., 2008, Clin. Cancer Res.		4	accepted	1190	501	1	2	42396490	42472827			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1190	https://civic.genome.wustl.edu/links/variants/501	https://civic.genome.wustl.edu/links/genes/1
KDR	3791	R961W	Colorectal Adenocarcinoma	0050861		Regorafenib		Predictive	Supports	C	Sensitivity/Response	Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks.	27004155	PubMed		Loaiza-Bonilla et al., 2016, Cureus		1	accepted	1191	502	3153	4	55961059	55961059	G	A	ENST00000263923.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1191	https://civic.genome.wustl.edu/links/variants/502	https://civic.genome.wustl.edu/links/genes/3153
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		2,4-pyrimidinediamine		Predictive	Supports	D	Sensitivity/Response	In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants.	18593892	PubMed		Choi et al., 2008, Cancer Res.		4	accepted	1192	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1192	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines.	20979469	PubMed		Kwak et al., 2010, N. Engl. J. Med.	NCT00585195	4	accepted	1193	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1193	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response.	18451166	PubMed		McDermott et al., 2008, Cancer Res.		2	accepted	1194	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1194	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Does Not Support	D	Sensitivity/Response	Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations.	18594010	PubMed		Koivunen et al., 2008, Clin. Cancer Res.		2	accepted	1195	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1195	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Sensitivity/Response	EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion.	22912387	PubMed		Heuckmann et al., 2012, Clin. Cancer Res.		2	accepted	1196	500	1	2	42396490	42552694			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1196	https://civic.genome.wustl.edu/links/variants/500	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Does Not Support	D	Sensitivity/Response	Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy.	22912387	PubMed		Heuckmann et al., 2012, Clin. Cancer Res.		2	accepted	1197	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1197	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported.	23724913	PubMed		Shaw et al., 2013, N. Engl. J. Med.	NCT00932893	5	accepted	1198	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1198	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported.	25470694	PubMed		Solomon et al., 2014, N. Engl. J. Med.	NCT01154140	5	accepted	1199	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1199	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.170.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.190.46; P < 0.0001).	24478318	PubMed		Ou et al., 2014, Ann. Oncol.		4	accepted	1200	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1200	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908	Brain neoplasm	Crizotinib		Predictive	Supports	B	Sensitivity/Response	This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level.	27022118	PubMed		Solomon et al., 2016, J. Clin. Oncol.	NCT01154140	4	accepted	1201	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1201	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Retaspimycin Hydrochloride		Predictive	Supports	C	Sensitivity/Response	In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner.	20940188	PubMed		Sequist et al., 2010, J. Clin. Oncol.		2	accepted	1202	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1202	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		Retaspimycin Hydrochloride,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression.	21258415	PubMed		Normant et al., 2011, Oncogene		4	accepted	1203	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1203	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	3908		Alvespimycin,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells.	22912387	PubMed		Heuckmann et al., 2012, Clin. Cancer Res.		2	accepted	1204	500	1	2	42396490	42552694			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1204	https://civic.genome.wustl.edu/links/variants/500	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		Alvespimycin		Predictive	Does Not Support	D	Sensitivity/Response	Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants.	22912387	PubMed		Heuckmann et al., 2012, Clin. Cancer Res.		2	accepted	1205	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1205	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		Crizotinib,Alvespimycin	Combination	Predictive	Supports	D	Sensitivity/Response	Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1.	22912387	PubMed		Heuckmann et al., 2012, Clin. Cancer Res.		2	accepted	1206	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1206	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate.	20979469	PubMed		Kwak et al., 2010, N. Engl. J. Med.	NCT00585195	4	accepted	1207	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1207	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated to PFS and OS. Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.677.02; P=0.002) and 2.72 for OS (95% CI, 1.524.88; P=0.002) compared to wild-type patients or patients with less than 1% mutant allele fraction. Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.259.07; P<0.001) and 2.5 for OS (95% CI, 1.574.02; P<0.001). ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value.	27037411	PubMed		Azuara et al., 2016, Mol. Cancer Ther.		3	accepted	1208	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1208	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
TP53	7157	P47S	Cancer	162		Cisplatin		Predictive	Supports	E	Resistance	The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other tumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability).	27034505	PubMed		Jennis et al., 2016, Genes Dev.		2	accepted	1209	504	45	17	7579548	7579548	G	A	ENST00000269305.4					75	GRCh37		Common Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1209	https://civic.genome.wustl.edu/links/variants/504	https://civic.genome.wustl.edu/links/genes/45
GNAQ	2776	MUTATION	Uveal Melanoma	6039		JQ1		Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line. JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group).	26397223	PubMed		Ambrosini et al., 2015, Oncotarget		2	accepted	1210	505	2317	9	80331003	80646374			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1210	https://civic.genome.wustl.edu/links/variants/505	https://civic.genome.wustl.edu/links/genes/2317
GNA11	2767	MUTATION	Uveal Melanoma	6039		JQ1		Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line.	26397223	PubMed		Ambrosini et al., 2015, Oncotarget		1	accepted	1211	506	2308	19	3094408	3124002			ENST00000078429.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1211	https://civic.genome.wustl.edu/links/variants/506	https://civic.genome.wustl.edu/links/genes/2308
GNA11	2767	Q209	Uveal Melanoma	6039		Selumetinib		Predictive	Does Not Support	B	Sensitivity/Response	101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P<0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P=0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response.	24938562	PubMed		Carvajal et al., 2014, JAMA	NCT01143402	3	accepted	1212	558	2308	19	3118942	3118942			ENST00000078429.4					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1212	https://civic.genome.wustl.edu/links/variants/558	https://civic.genome.wustl.edu/links/genes/2308
GNAQ	2776	Q209	Uveal Melanoma	6039		Selumetinib		Predictive	Does Not Support	B	Sensitivity/Response	101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P<0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P=0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response.	24938562	PubMed		Carvajal et al., 2014, JAMA	NCT01143402	3	accepted	1213	507	2317	9	80409487	80409489			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1213	https://civic.genome.wustl.edu/links/variants/507	https://civic.genome.wustl.edu/links/genes/2317
PMS2	5395	K706FS*19	Glioblastoma Multiforme	3068		Nivolumab		Predictive	Supports	C	Sensitivity/Response	Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers. Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD). Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome. Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers). Treatment with nivolumab was begun and both patients had radiologic response. After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities.	27001570	PubMed		Bouffet et al., 2016, J. Clin. Oncol.		4	accepted	1214	508	4371	7	6022512	6022512			ENST00000265849.7					75	GRCh37		Rare Germline	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1214	https://civic.genome.wustl.edu/links/variants/508	https://civic.genome.wustl.edu/links/genes/4371
KRAS	3845	G12D	Colorectal Cancer	9256				Prognostic	Supports	B	Positive	In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R).	22948721	PubMed		Modest et al., 2012, Oncology		3	accepted	1215	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1215	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Colorectal Cancer	9256		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups.	23313110	PubMed		Fiala et al., Cancer Genet		3	accepted	1216	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1216	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months).	22247021	PubMed		Ihle et al., 2012, J. Natl. Cancer Inst.		3	accepted	1217	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1217	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Adenocarcinoma	3910		Salirasib		Predictive	Does Not Support	B	Sensitivity/Response	In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients.	21847063	PubMed		Riely et al., 2011, J Thorac Oncol		3	accepted	1218	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/1218	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	EXON 2 MUTATION	Pancreatic Cancer	1793		Erlotinib,Gemcitabine	Combination	Predictive	Supports	B	Resistance	In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients.	21862683	PubMed		Kim et al., 2011, Mol. Cancer Ther.		4	accepted	1219	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1219	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Supports	B	Sensitivity/Response	In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses.	22805291	PubMed		Infante et al., 2012, Lancet Oncol.	NCT00687622	2	accepted	1220	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1220	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.2180.706). The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.5851.151) or with wild-type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.9383.543).	16624552	PubMed		Debiec-Rychter et al., 2006, Eur. J. Cancer		4	accepted	1221	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1221	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	MUTATION	Melanoma	1909		Imatinib		Predictive	Supports	B	Sensitivity/Response	In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%. 9/10 partial responses were in patients with exon 11 or 13 KIT mutations.	21690468	PubMed		Guo et al., 2011, J. Clin. Oncol.		3	accepted	1222	388	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1222	https://civic.genome.wustl.edu/links/variants/388	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild-type KIT compared those with KIT exon 11 or PDGFRA mutations. 1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants.	22439647	PubMed		Rutkowski et al., 2012, BMC Cancer		3	accepted	1223	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1223	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 11 MUTATION	Melanoma	1909		Sunitinib		Predictive	Supports	C	Sensitivity/Response	10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response.	22261812	PubMed		Minor et al., 2012, Clin. Cancer Res.		3	accepted	1224	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/1224	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
NRAS	4893	MUTATION	Skin Melanoma	8923		Trametinib,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations.	25542057	PubMed		Coupe et al., 2015, Eur. J. Cancer		2	accepted	1225	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1225	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate).	23414587	PubMed		Ascierto et al., 2013, Lancet Oncol.	NCT01320085	2	accepted	1226	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1226	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	MUTATION	Melanoma	1909		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).	22805292	PubMed		Falchook et al., 2012, Lancet Oncol.	NCT00687622	2	accepted	1227	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1227	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
GNA11	2767	MUTATION	Uveal Melanoma	6039		Trametinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.	22805292	PubMed		Falchook et al., 2012, Lancet Oncol.	NCT00687622	2	accepted	1228	506	2308	19	3094408	3124002			ENST00000078429.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1228	https://civic.genome.wustl.edu/links/variants/506	https://civic.genome.wustl.edu/links/genes/2308
GNAQ	2776	MUTATION	Uveal Melanoma	6039		Trametinib		Predictive	Supports	B	Sensitivity/Response	Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.	22805292	PubMed		Falchook et al., 2012, Lancet Oncol.	NCT00687622	2	accepted	1229	505	2317	9	80331003	80646374			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1229	https://civic.genome.wustl.edu/links/variants/505	https://civic.genome.wustl.edu/links/genes/2317
NRAS	4893	MUTATION	Cancer	162		Trametinib,Metformin	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism.	25504439	PubMed		Vujic et al., 2015, Oncotarget		3	accepted	1230	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1230	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
PTEN	5728	DELETION	Prostate Cancer	10283		Everolimus		Predictive	Supports	B	Sensitivity/Response	In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor.	23582881	PubMed		Templeton et al., 2013, Eur. Urol.	NCT00976755	3	accepted	1231	213	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1231	https://civic.genome.wustl.edu/links/variants/213	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	MUTATION	Endometrial Carcinoma	2871		Everolimus		Predictive	Does Not Support	B	Sensitivity/Response	Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations. No mutations found in PTEN were effective in predicting tumor response to everolimus treatment. The clinical trial associated with this study is NCT00870337.	23238879	PubMed		Trdan et al., 2013, Target Oncol	NCT00870337	3	accepted	1232	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1232	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
GNAQ	2776	Q209	Uveal Melanoma	6039		Refametinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy.	23434733	PubMed		Weekes et al., 2013, Clin. Cancer Res.		2	accepted	1233	507	2317	9	80409487	80409489			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1233	https://civic.genome.wustl.edu/links/variants/507	https://civic.genome.wustl.edu/links/genes/2317
BAP1	8314	MUTATION	Uveal Melanoma	6039		Panobinostat,Vorinostat,Trichostatin A,Valproic Acid	Substitutes	Predictive	Supports	D	Sensitivity/Response	Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas. HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA). RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA).	22038994	PubMed		Landreville et al., 2012, Clin. Cancer Res.		3	accepted	1234	183	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1234	https://civic.genome.wustl.edu/links/variants/183	https://civic.genome.wustl.edu/links/genes/70
BAP1	8314	MUTATION	Malignant Mesothelioma	1790		MC1568,Mocetinostat,Vorinostat	Substitutes	Predictive	Supports	E	Sensitivity/Response	A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression. HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat. The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation.	25970771	PubMed		Sacco et al., 2015, Oncotarget		2	accepted	1235	183	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1235	https://civic.genome.wustl.edu/links/variants/183	https://civic.genome.wustl.edu/links/genes/70
FGFR2	2263	MUTATION	Endometrial Cancer	1380		Ponatinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines.	26574622	PubMed		Kim et al., 2016, Cancer Biol. Ther.		3	accepted	1236	511	22	10	123239371	123357917			ENST00000457416.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1236	https://civic.genome.wustl.edu/links/variants/511	https://civic.genome.wustl.edu/links/genes/22
ALK	238	MUTATION	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	B	Sensitivity/Response	In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.  Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early. Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment. Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months. For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months.	24670165	PubMed		Shaw et al., 2014, N. Engl. J. Med.	NCT01283516	4	accepted	1237	512	1	2	29415640	30144432			ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1237	https://civic.genome.wustl.edu/links/variants/512	https://civic.genome.wustl.edu/links/genes/1
DNMT3A	1788	MUTATION	Myelodysplastic Syndrome	0050908				Prognostic	Supports	B	Poor Outcome	12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results.	21415852	PubMed		Walter et al., 2011, Leukemia		3	accepted	1238	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1238	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
ALK	238	NPM-ALK	Anaplastic Large Cell Lymphoma	0050744		Crizotinib		Predictive	Supports	D	Sensitivity/Response	NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL.	18089725	PubMed		Christensen et al., 2007, Mol. Cancer Ther.		5	accepted	1239	513	1	5	170814120	170818803			ENST00000517671.1	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1239	https://civic.genome.wustl.edu/links/variants/513	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Anaplastic Large Cell Lymphoma	0050744		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL.	21345110	PubMed		Gambacorti-Passerini et al., 2011, N. Engl. J. Med.		4	accepted	1240	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1240	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	NPM-ALK	Anaplastic Large Cell Lymphoma	0050744		Crizotinib		Predictive	Supports	B	Sensitivity/Response	In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	4	accepted	1241	513	1	5	170814120	170818803			ENST00000517671.1	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1241	https://civic.genome.wustl.edu/links/variants/513	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Inflammatory Myofibroblastic Tumor	0050905		Crizotinib		Predictive	Supports	B	Sensitivity/Response	As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	3	accepted	1243	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1243	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	RANBP2-ALK	Inflammatory Myofibroblastic Tumor	0050905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond.	20979472	PubMed		Butrynski et al., 2010, N. Engl. J. Med.	NCT00585195	4	accepted	1244	514	1	2	109335937	109375004			ENST00000283195.6	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1244	https://civic.genome.wustl.edu/links/variants/514	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E20;A20	Cancer	162		Crizotinib		Predictive	Supports	C	Sensitivity/Response	This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination.	25408655	PubMed		Chung et al., 2014, Case Rep Oncol		3	accepted	1245	500	1	2	42396490	42552694			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1245	https://civic.genome.wustl.edu/links/variants/500	https://civic.genome.wustl.edu/links/genes/1
FGFR1	2260	N546K	Ewing Sarcoma Of Bone	3368		Ponatinib		Predictive	Supports	E	Sensitivity/Response	116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.	26179511	PubMed		Agelopoulos et al., 2015, Clin. Cancer Res.		2	accepted	1246	515	1885	8	38274849	38274849	G	T	ENST00000341462.5					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1246	https://civic.genome.wustl.edu/links/variants/515	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Ewing Sarcoma Of Bone	3368		Ponatinib		Predictive	Supports	D	Sensitivity/Response	116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.	26179511	PubMed		Agelopoulos et al., 2015, Clin. Cancer Res.		3	accepted	1247	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	N/A	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1247	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
ROS1	6098	REARRANGEMENT	Lung Adenocarcinoma	3910		Ceritinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing after progression on chemotherapy. Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease. The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe. Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases). The patient next received ceritinib on a Signature Trial" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821). Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1. MRI showed that his brain metastases decreased as well.	26917690	PubMed		Subbiah et al., 2016, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	1248	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1248	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		Foretinib,Cabozantinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.	26372962	PubMed		Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1249	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1249	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		AZD3463,Ceritinib,Brigatinib,Crizotinib	Substitutes	Predictive	Supports	D	Resistance	Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.	26372962	PubMed		Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1250	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1250	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1.	25733882	PubMed		Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1251	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1251	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation. Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype. In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays.	25733882	PubMed		Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	1252	516	4941	6	117638365	117638365	G	T	ENST00000368508.3					75	GRCh37	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1252	https://civic.genome.wustl.edu/links/variants/516	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.  Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays.	25733882	PubMed		Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1253	516	4941	6	117638365	117638365	G	T	ENST00000368508.3					75	GRCh37	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1253	https://civic.genome.wustl.edu/links/variants/516	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74ROS1 fusion. Expression of CD74ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		3	accepted	1254	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1254	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing CD74ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT).	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		2	accepted	1255	465	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1255	https://civic.genome.wustl.edu/links/variants/465	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 L2155S	Lung Non-small Cell Carcinoma	3908		TAE684,Foretinib,Crizotinib	Substitutes	Predictive	Supports	D	Resistance	The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74ROS1 rearrangment. Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification. HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells. In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		3	accepted	1256	517	4941	6	117630062	117630062	A	G	ENST00000368508.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1256	https://civic.genome.wustl.edu/links/variants/517	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing CD74ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74ROS1; however, showed similar sensitivity to foretinib.	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		2	accepted	1257	516	4941	6	117638365	117638365	G	T	ENST00000368508.3					75	GRCh37	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1257	https://civic.genome.wustl.edu/links/variants/516	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing CD74ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		2	accepted	1258	516	4941	6	117638365	117638365	G	T	ENST00000368508.3					75	GRCh37	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1258	https://civic.genome.wustl.edu/links/variants/516	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib.	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		2	accepted	1259	518	4941	6	117631376	117631376	C	G	ENST00000368508.3					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1259	https://civic.genome.wustl.edu/links/variants/518	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib.	25688157	PubMed		Song et al., 2015, Clin. Cancer Res.		2	accepted	1260	518	4941	6	117631376	117631376	C	G	ENST00000368508.3					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1260	https://civic.genome.wustl.edu/links/variants/518	https://civic.genome.wustl.edu/links/genes/4941
ALK	238	CLTC-ALK	Diffuse Large B-cell Lymphoma	0050745		TAE684		Predictive	Supports	D	Sensitivity/Response	A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated.	21494621	PubMed		Cerchietti et al., 2011, PLoS ONE		4	accepted	1261	520	1	17	57697219	57768072			ENST00000269122.3	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1261	https://civic.genome.wustl.edu/links/variants/520	https://civic.genome.wustl.edu/links/genes/1
U2AF1	7307	MUTATION	Myelofibrosis	4971				Prognostic	Supports	B	Poor Outcome	In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001). U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24).	27058230	PubMed		Barraco et al., 2016, Blood Cancer J		4	accepted	1262	521	48	21	44513066	44527697			ENST00000291552.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1262	https://civic.genome.wustl.edu/links/variants/521	https://civic.genome.wustl.edu/links/genes/48
ALK	238	CLTC-ALK	Diffuse Large B-cell Lymphoma	0050745				Prognostic	Supports	C	Poor Outcome	CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort.	19636007	PubMed		Laurent et al., 2009, J. Clin. Oncol.		3	accepted	1263	520	1	17	57697219	57768072			ENST00000269122.3	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1263	https://civic.genome.wustl.edu/links/variants/520	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Diffuse Large B-cell Lymphoma	0050745		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL.	24330038	PubMed		Wass et al., 2014, Eur. J. Haematol.		2	accepted	1264	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1264	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	CLTC-ALK	Diffuse Large B-cell Lymphoma	0050745		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course.	26221234	PubMed		Li et al., 2015, Int J Clin Exp Med		3	accepted	1265	520	1	17	57697219	57768072			ENST00000269122.3	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1265	https://civic.genome.wustl.edu/links/variants/520	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E2;A20	Renal Cell Carcinoma	4450				Predictive	Supports	E	Sensitivity/Response	Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC.	22252991	PubMed		Sugawara et al., 2012, Cancer		3	accepted	1266	501	1	2	42396490	42472827			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1266	https://civic.genome.wustl.edu/links/variants/501	https://civic.genome.wustl.edu/links/genes/1
BRAF	673	DEL 485-490	Cancer	162		Pan-RAF Inhibitor LY3009120		Predictive	Supports	D	Sensitivity/Response	Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib. These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers. In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletionmediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 mol/L in these three cell lines. LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice.	26732095	PubMed		Chen et al., 2016, Cancer Discov		3	accepted	1267	522	5	7	140477838	140477855	AGGTGCTGTCACATTCAA		ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1267	https://civic.genome.wustl.edu/links/variants/522	https://civic.genome.wustl.edu/links/genes/5
ALK	238	R1275Q	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Sensitivity/Response	This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	2	accepted	1269	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1269	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
ALK	238	R1275Q	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	2	accepted	1270	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1270	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1174L	Neuroblastoma	769		Crizotinib		Predictive	Does Not Support	C	Sensitivity/Response	In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	3	accepted	1271	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1271	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC.	23639470	PubMed		Seto et al., 2013, Lancet Oncol.		3	accepted	1272	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1272	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Sensitivity/Response	In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient.	26938871	PubMed		Yoshida et al., 2016, Anticancer Drugs		3	accepted	1273	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1273	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
CD274	29126	EXPRESSION	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively).	27086918	PubMed		Chowdhury et al., 2016, Oncotarget		3	accepted	1274	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1274	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Stomach Carcinoma	5517				Prognostic	Supports	B	Better Outcome	465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each).	27009855	PubMed		Bger et al., 2016, Oncotarget		3	accepted	1275	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1275	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
DUX4	100288687	DUX4 FUSIONS	Acute Lymphoblastic Leukemia	9952				Diagnostic	Supports	D	Positive	A screen for fusion genes in Ph- AYA-ALL (Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults) was performed using RNA-seq from multiple cohorts of ALL patients. DUX4, ZNF384 and MEF2D fusions were the most frequent found.  DUX4 fusions were found only in AYA cases (age 15-39) and this was significant, p=0.016. DUX4 fusions clustered into groups distinct from the other fusions, and these fusions as a whole clustered with Ph- ALL cases. The authors performed extensive in vitro and in vivo experiments to demonstrate that DUX4 fusions are likely early initiating/events and that DUX4 fusion and not DUX4 wild type are tumorigenic. The authors conclude that DUX4 fusions may be a target driver resulting in AYA-ALL, and that AYA-ALL may be a distinct clinical entity.	27019113	PubMed		Yasuda et al., 2016, Nat. Genet.		4	accepted	1276	524	34321														Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1276	https://civic.genome.wustl.edu/links/variants/524	https://civic.genome.wustl.edu/links/genes/34321
DUX4	100288687	DUX4 FUSIONS	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	C	Better Outcome	Ph- ALL (Philadelphia chromosome negative acute lymphoblastic leukemia) gene expression profiles cluster into two main groups, Ph like and non-Ph like ALL.  Non-Ph like ALL have favorable outcomes when compared with Ph like ALL.  DUX4 fusions were discovered in a subset of Ph- ALL tumors through RNA-seq, and their mutation profile was found to cluster with non-Ph like ALL. It was found that patients with DUX4 fusions (N=9) had improved disease free survival over Ph like ALL patients (N=6) in the study. Eight years after complete remission, DUX4 fusion positive patients had over 0.8 disease free survival probability.	27019113	PubMed		Yasuda et al., 2016, Nat. Genet.		3	accepted	1277	524	34321														Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1277	https://civic.genome.wustl.edu/links/variants/524	https://civic.genome.wustl.edu/links/genes/34321
B4GALT1	2683	EXPRESSION	Renal Cell Carcinoma	4450				Prognostic	Supports	B	Poor Outcome	438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002).	27092876	PubMed		Xie et al., 2016, Oncotarget		3	accepted	1278	525	2239	9	33110635	33167354			ENST00000379731.4					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1278	https://civic.genome.wustl.edu/links/variants/525	https://civic.genome.wustl.edu/links/genes/2239
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier.	25153538	PubMed		Gadgeel et al., 2014, Lancet Oncol.	NCT01588028	4	accepted	1279	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1279	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
BCL2L11	10018	DELETION POLYMORPHISM	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	B	Resistance	DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples. 2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population. In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism. Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism. Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.177.43). Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.084.35).	22426421	PubMed		Ng et al., 2012, Nat. Med.		4	accepted	1280	526	7953	2	111883195	111886097			ENST00000393256.3					75	GRCh37		Common Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1280	https://civic.genome.wustl.edu/links/variants/526	https://civic.genome.wustl.edu/links/genes/7953
BCL2L11	10018	DELETION POLYMORPHISM	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5).	22426421	PubMed		Ng et al., 2012, Nat. Med.		4	accepted	1281	526	7953	2	111883195	111886097			ENST00000393256.3					75	GRCh37		Common Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1281	https://civic.genome.wustl.edu/links/variants/526	https://civic.genome.wustl.edu/links/genes/7953
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment.	26708155	PubMed		Shaw et al., 2016, Lancet Oncol.	NCT01871805	5	accepted	1282	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1282	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Resistance	The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib. The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib. Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK. In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild-type expressing cells. Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		4	accepted	1283	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1283	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	C	Sensitivity/Response	The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib. the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation. Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild-type EML4-ALK. In contrast, ceritinib caused loss of viability in EML4-ALK wild-type and I1171T BaF3 cells at comparable concentrations. Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells. Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		4	accepted	1284	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1284	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).  Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib. In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild-type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		3	accepted	1285	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1285	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	D	Resistance	The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasing levels of alectinib culminating in 1 micro-molar, over a course of 7 months. The ALK kinase domain mutation V1180L was found in these cells, and Ba/F3 cells expressing EML4 ALK  V1180L were highly resistant to alectinib. Simulations indicated that the V1180L mutation interfered with alectinib binding. The V1180L mutation was found to be more resistant to alectinib than the I1171T mutation found in an ALK-positive NSCLC patient who developed alectinib resistance on lower dose alectinib  (300mg twice daily).	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		3	accepted	1286	528	1	2	29443679	29443679	C	G	ENST00000389048.3					75	GRCh37	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1286	https://civic.genome.wustl.edu/links/variants/528	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		3	accepted	1287	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1287	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The alectinib resistant cell line H3122 CHR-A1 was generated by culturing of the EML4-ALK (variant 1) containing cell line H3122 with increasing levels of alectinib. Molecular characterization of H3122 CHR-A1 revealed a V1180L ALK kinase domain mutation. The H3122 CHR-A1 cell line required approximately 10 fold increase in crizotinib concentration to induce similar levels of cell death to H3122. Ectopic expression of EML4-ALK V1180L rendered Ba/F3 cells moderately less susceptible to crizotinib than ectopic EML4-ALK.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		2	accepted	1288	528	1	2	29443679	29443679	C	G	ENST00000389048.3					75	GRCh37	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1288	https://civic.genome.wustl.edu/links/variants/528	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	Passaging of the alectinib sensitive EML4-ALK containing H3122 NSCLC cell line with increasing levels of alectinib resulted in an alectinib resistant derivative of this cell line named H3122 CHR-A1. A V1180L missense mutation was found in the kinase domain of ALK in H3122 CHR-A1 cells. Both H3122 and H3122 CHR-A1 cells were highly and equally sensitive to ceritinib induced death. In Ba/F3 cells, ectopic expression of EML4-ALK V1180L rendered cells significantly more sensitive to ceritinib than Ba/F3 containing EML4-ALK I1171T mutant (alectinib and crizotinib resistant) or EML4-ALK wt.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		3	accepted	1289	528	1	2	29443679	29443679	C	G	ENST00000389048.3					75	GRCh37	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1289	https://civic.genome.wustl.edu/links/variants/528	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containing NSCLC cell line H3122 by passaging into higher concentrations of alectinib. This cell line is a model for gain of alectinib resistance, and also shows resistance to crizotinib. On the other hand, the often used tool ALK inhibitor TAE684 was highly effective in killing H3122 CHR-A1, where H3122 cells were only slightly more sensitized to TAE684-induced cell death. Ectopic expression of EML4-ALK V1180L in Ba/F3 cells caused IL3 independent growth as well as marked sensitization to TAE684, to a level greater than that seen in EML4-ALK I1171T (alectinib resistance mutation) or EML4-ALK wt, and over 1000x greater sensitivity than unaltered Ba/F3 + IL3.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		3	accepted	1290	528	1	2	29443679	29443679	C	G	ENST00000389048.3					75	GRCh37	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1290	https://civic.genome.wustl.edu/links/variants/528	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	3908		Brigatinib		Predictive	Supports	D	Sensitivity/Response	ALK mutation V1180L was found in an H3122 derivative cell line that had become alectinib resistant after being passaged in increasing levels of alectinib. EML4-ALK V1180L and EML4-ALK wild-type were ectopically expressed in Ba/F3 cells, and brigatinib showed strong activity against both variants. The IC50 for brigatinib against EML4-ALK wild-type was 0.95, which is about 3x higher than the IC50 that was observed for alectinib, but about 6x lower than that for crizotinib. In contrast, the IC50 for brigatinib against the alectinib resistance variant EML4-ALK V1180L was 0.49, indicating increased sensitivity to brigatinib over non mutant EML4-ALK.	25228534	PubMed		Katayama et al., 2014, Clin. Cancer Res.		2	accepted	1291	528	1	2	29443679	29443679	C	G	ENST00000389048.3					75	GRCh37	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1291	https://civic.genome.wustl.edu/links/variants/528	https://civic.genome.wustl.edu/links/genes/1
ATM	472	UNDEREXPRESSION	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001). Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001).	25423555	PubMed		Kamphues et al., 2015, Pancreas		2	accepted	1292	179	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		N/A	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/1292	https://civic.genome.wustl.edu/links/variants/179	https://civic.genome.wustl.edu/links/genes/69
SIRT1	23411	OVEREXPRESSION	Pancreatic Ductal Carcinoma	3587				Prognostic	Supports	B	Poor Outcome	Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (p=0.002) and multivariate (HR 1.65, p=0.045) analyses. Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability.	24088390	PubMed		Stenzinger et al., 2013, BMC Cancer		3	accepted	1293	529	9538	10	69644427	69678147			ENST00000212015.6					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1293	https://civic.genome.wustl.edu/links/variants/529	https://civic.genome.wustl.edu/links/genes/9538
SIRT1	23411	OVEREXPRESSION	Pancreatic Cancer	1793		Niacinamide		Predictive	Supports	D	Resistance	In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concentrations of 50 M showed similar effects as observed for the application of 25 mM nicotinamide. Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability. In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls.	24088390	PubMed		Stenzinger et al., 2013, BMC Cancer		1	accepted	1294	529	9538	10	69644427	69678147			ENST00000212015.6					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1294	https://civic.genome.wustl.edu/links/variants/529	https://civic.genome.wustl.edu/links/genes/9538
FLT3	2322	TKD MUTATION	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	B	Sensitivity/Response	In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin.	20733134	PubMed		Fischer et al., 2010, J. Clin. Oncol.		3	accepted	1295	56	24	13	28592642	28592642	C	A	ENST00000241453.7					75	GRCh37	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1295	https://civic.genome.wustl.edu/links/variants/56	https://civic.genome.wustl.edu/links/genes/24
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Everolimus		Predictive	Supports	B	Sensitivity/Response	Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.	27091708	PubMed		Andr et al., 2016, J. Clin. Oncol.		4	accepted	1296	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1296	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Everolimus		Predictive	Supports	B	Sensitivity/Response	Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.	27091708	PubMed		Andr et al., 2016, J. Clin. Oncol.		4	accepted	1297	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1297	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
KRAS	3845	G12R	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28).	22983505	PubMed		Ogura et al., 2013, J. Gastroenterol.		4	accepted	1298	530	30	12	25398285	25398285	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1298	https://civic.genome.wustl.edu/links/variants/530	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219). HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively.	27010960	PubMed		Bournet et al., 2016, Clin Transl Gastroenterol		4	accepted	1300	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1300	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
ROS1	6098	REARRANGEMENT	Colorectal Adenocarcinoma	0050861		Crizotinib		Predictive	Supports	E	Sensitivity/Response	A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.  The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors.	24296758	PubMed		Aisner et al., 2014, Mol. Cancer Res.		2	accepted	1301	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1301	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
TP53	7157	P72R	Breast Cancer	1612				Predisposing	Does Not Support	B	Positive	Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.911.05) for heterozygotes and 0.97 (95% CI, 0.861.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.911.04). Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50).	17909070	PubMed		Schmidt et al., 2007, Cancer Res.		4	accepted	1302	531	45	17	7579472	7579472	G	C	ENST00000269305.4					75	GRCh37	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.	Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1302	https://civic.genome.wustl.edu/links/variants/531	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	P72R	Lung Carcinoma	3905				Prognostic	Does Not Support	B	Poor Outcome	Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41. Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20). Authors conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best.	12840112	PubMed		Matakidou et al., 2003, Mutagenesis		3	accepted	1303	531	45	17	7579472	7579472	G	C	ENST00000269305.4					75	GRCh37	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.	Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1303	https://civic.genome.wustl.edu/links/variants/531	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	P72R	Cervical Cancer	4362				Prognostic	Does Not Support	B	Poor Outcome	In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection. However, both confidence intervals had minimums below one (0.9 and 0.6, respectively). So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer.	11535556	PubMed		Klug et al., 2001, Cancer Epidemiol. Biomarkers Prev.		2	accepted	1304	531	45	17	7579472	7579472	G	C	ENST00000269305.4					75	GRCh37	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.	Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1304	https://civic.genome.wustl.edu/links/variants/531	https://civic.genome.wustl.edu/links/genes/45
PALB2	79728	BIALLELIC INACTIVATION	Pancreatic Cancer	1793		Mitomycin		Predictive	Supports	C	Sensitivity/Response	In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up.	21135251	PubMed		Villarroel et al., 2011, Mol. Cancer Ther.	NCT00276744	4	accepted	1305	532	15013	16	23614491	23652631			ENST00000261584.4					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1305	https://civic.genome.wustl.edu/links/variants/532	https://civic.genome.wustl.edu/links/genes/15013
SMAD4	4089	EXPRESSION	Pancreatic Ductal Adenocarcinoma	3498				Prognostic	Supports	B	Better Outcome	In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was assessed by IHC in 56 of 249 (22%).  Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04).	11751510	PubMed		Tascilar et al., 2001, Clin. Cancer Res.		3	accepted	1306	533	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1306	https://civic.genome.wustl.edu/links/variants/533	https://civic.genome.wustl.edu/links/genes/77
FANCC	2176	LOSS-OF-FUNCTION	Pancreatic Cancer	1793		Melphalan,Gemcitabine,Mitomycin,Cisplatin,Chlorambucil	Substitutes	Predictive	Supports	D	Sensitivity/Response	In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC. Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC.	16243825	PubMed		van der Heijden et al., 2005, Clin. Cancer Res.		3	accepted	1307	534	1811	9	97861336	98079984			ENST00000289081.3					75	GRCh37		Unknown	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1307	https://civic.genome.wustl.edu/links/variants/534	https://civic.genome.wustl.edu/links/genes/1811
BRCA2	675	LOSS-OF-FUNCTION	Pancreatic Cancer	1793		Mitomycin		Predictive	Supports	D	Sensitivity/Response	In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.	16243825	PubMed		van der Heijden et al., 2005, Clin. Cancer Res.		2	accepted	1308	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1308	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
PDGFRA	5156	I843DEL	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Sensitivity/Response	15/127 patients with KIT-WT metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 6 GISTs harbored PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro achieved partial response on imatinib treatment. It is not noted whether the patient whose GISTs harbored I843del had partial response or progressive disease.	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	1309	101	38	4	55152095	55152097	ATC		ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1309	https://civic.genome.wustl.edu/links/variants/101	https://civic.genome.wustl.edu/links/genes/38
PDGFRB	5159	EBF1-PDGFRB	Acute Lymphoblastic Leukemia	9952		Imatinib		Predictive	Supports	C	Sensitivity/Response	A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib.	23835704	PubMed		Weston et al., 2013, J. Clin. Oncol.		3	accepted	1310	535	4176	5	158134987	158526769			ENST00000517373.1	5	149493400	149505140	ENST00000261799.4	75	GRCh37	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1310	https://civic.genome.wustl.edu/links/variants/535	https://civic.genome.wustl.edu/links/genes/4176
KRAS	3845	G12D	Tumor Of Exocrine Pancreas	1795				Prognostic	Supports	B	Poor Outcome	In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild-type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67). Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild-type for both (N=17; HR: 95%CI 1.33-7.10).	23565280	PubMed		Rachakonda et al., 2013, PLoS ONE		3	accepted	1311	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1311	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
RB1	5925	EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors.	22619677	PubMed		Zhao et al., 2012, J Oncol		2	accepted	1313	537	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1313	https://civic.genome.wustl.edu/links/variants/537	https://civic.genome.wustl.edu/links/genes/4795
CDKN2A	1029	p16 EXPRESSION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).	22619677	PubMed		Zhao et al., 2012, J Oncol		2	accepted	1314	272	14	9	21968055	21974865			ENST00000498124.1					75	GRCh37	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1314	https://civic.genome.wustl.edu/links/variants/272	https://civic.genome.wustl.edu/links/genes/14
MLH1	4292	METHYLATION	Stomach Carcinoma	5517		Oxaliplatin		Predictive	Supports	B	Resistance	The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples. No association was found between methylation status and clinical factors. The study showed that MLH1 methylation was associated with resistance to treatment with oxaliplatin.	24748501	PubMed		Li et al., 2015, Gastric Cancer		2	accepted	1315	538	3532														Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1315	https://civic.genome.wustl.edu/links/variants/538	https://civic.genome.wustl.edu/links/genes/3532
PTPN11	5781	EXPRESSION	Laryngeal Carcinoma	2600				Prognostic	Supports	B	Poor Outcome	Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth.	24297342	PubMed		Gu et al., 2014, Int. J. Oncol.		2	accepted	1316	539	4685	12	112856718	112947717			ENST00000351677.2					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1316	https://civic.genome.wustl.edu/links/variants/539	https://civic.genome.wustl.edu/links/genes/4685
FLT3	2322	T227M	Renal Cell Carcinoma	4450		Sunitinib		Predictive	Supports	B	Adverse Response	In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77.	19667267	PubMed		van Erp et al., 2009, J. Clin. Oncol.		3	accepted	1317	540	24	13	28624294	28624294	G	A	ENST00000241453.7					75	GRCh37	FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.	Common Germline	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1317	https://civic.genome.wustl.edu/links/variants/540	https://civic.genome.wustl.edu/links/genes/24
PALB2	79728	L531FS*30	Breast Cancer	1612				Diagnostic	Supports	B	Positive	Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer. The study found that among an augmented cohort of breast cancer patients with the variant, there was a hazard ratio of 6.1 (p=.01).  Further there is weak evidence to conclude that breast cancer risk for this variant decreases with age (p=.06).	18628482	PubMed		Erkko et al., 2008, Clin. Cancer Res.		3	accepted	1318	541	15013	16	23646276	23646276			ENST00000261584.4					75	GRCh37		Common Germline	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1318	https://civic.genome.wustl.edu/links/variants/541	https://civic.genome.wustl.edu/links/genes/15013
MTOR	2475	S2215Y	Endometrial Adenocarcinoma	2870		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).	24631838	PubMed		Grabiner et al., 2014, Cancer Discov		2	accepted	1319	542	2073	1	11184573	11184573	G	T	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1319	https://civic.genome.wustl.edu/links/variants/542	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	C1483Y	T-cell Acute Lymphoblastic Leukemia	5603		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L).	24631838	PubMed		Grabiner et al., 2014, Cancer Discov		2	accepted	1320	543	2073	1	11217230	11217230	C	T	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1320	https://civic.genome.wustl.edu/links/variants/543	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	E1799K	Clear Cell Renal Cell Carcinoma	4467		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L).	24631838	PubMed		Grabiner et al., 2014, Cancer Discov		2	accepted	1321	544	2073	1	11190804	11190804	C	T	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1321	https://civic.genome.wustl.edu/links/variants/544	https://civic.genome.wustl.edu/links/genes/2073
FGFR2	2263	N550K	Endometrial Cancer	1380		PD173074		Predictive	Supports	D	Sensitivity/Response	The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.).	18757403	PubMed		Byron et al., 2008, Cancer Res.		3	accepted	1322	545	22	10	123258034	123258034	A	T	ENST00000457416.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1322	https://civic.genome.wustl.edu/links/variants/545	https://civic.genome.wustl.edu/links/genes/22
RB1	5925	OVEREXPRESSION	Pancreatic Adenocarcinoma	4074		Doxorubicin,Gemcitabine,Mitomycin,Fluorouracil	Substitutes	Predictive	Supports	D	Resistance	In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed.	11792751	PubMed		Plath et al., 2002, J. Natl. Cancer Inst.		2	accepted	1324	547	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/1324	https://civic.genome.wustl.edu/links/variants/547	https://civic.genome.wustl.edu/links/genes/4795
PPP1R15A	23645	RS557806	Colorectal Cancer	9256		FOLFIRI Regimen,Bevacizumab	Combination	Predictive	Supports	B	Sensitivity/Response	Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032).	27177629	PubMed		Roh et al., 2016, J. Cancer Res. Clin. Oncol.		1	accepted	1325	548	9722	19	49377242	49377242	G	C	ENST00000200453.5					75	GRCh37		Common Germline	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1325	https://civic.genome.wustl.edu/links/variants/548	https://civic.genome.wustl.edu/links/genes/9722
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Irinotecan,Selumetinib	Combination	Predictive	Supports	B	Sensitivity/Response	31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations. Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days.	25322874	PubMed		Hochster et al., 2015, Cancer Chemother. Pharmacol.		1	accepted	1326	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/1326	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
ALK	238	F1174L	Neuroblastoma	769		AZD3463		Predictive	Supports	D	Sensitivity/Response	The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression.	26786851	PubMed		Wang et al., 2016, Sci Rep		3	accepted	1327	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1327	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
MYCN	4613	AMPLIFICATION	Neuroblastoma	769				Prognostic	Supports	A	Poor Outcome	In a cohort of 1596 neuroblastoma patients.   Five year event free survival was 74 months in non-MYCN amplified cases and 39 months in amplified cases. Differences were significant with p < 0.0001. Five year overall survival was 83 months and non-MYCN amplified cases and 46  months in amplified cases, with p < 0.0001, indicating poorer prognosis for MYCN-amplified cases.	25517749	PubMed		Bresler et al., 2014, Cancer Cell		4	accepted	1328	298	3741	2	16080686	16087129			ENST00000281043.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1328	https://civic.genome.wustl.edu/links/variants/298	https://civic.genome.wustl.edu/links/genes/3741
ALK	238	F1174L	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models.	26554404	PubMed		Infarinato et al., 2016, Cancer Discov		4	accepted	1329	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1329	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1245C	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models.	26554404	PubMed		Infarinato et al., 2016, Cancer Discov		3	accepted	1330	549	1	2	29436859	29436859	A	C	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1330	https://civic.genome.wustl.edu/links/variants/549	https://civic.genome.wustl.edu/links/genes/1
ALK	238	R1275Q	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression.	26554404	PubMed		Infarinato et al., 2016, Cancer Discov		4	accepted	1331	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1331	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells.	26554404	PubMed		Infarinato et al., 2016, Cancer Discov		2	accepted	1332	5	1	2	42396490	42522656			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1332	https://civic.genome.wustl.edu/links/variants/5	https://civic.genome.wustl.edu/links/genes/1
ALK	238	F1245C	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Resistance	A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.	23598171	PubMed		Moss et al., 2013, Lancet Oncol.	NCT00939770	3	accepted	1333	549	1	2	29436859	29436859	A	C	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1333	https://civic.genome.wustl.edu/links/variants/549	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Colorectal Adenocarcinoma	0050861		Crizotinib		Predictive	Supports	E	Sensitivity/Response	26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations.	19737969	PubMed		Lin et al., 2009, Mol. Cancer Res.		1	accepted	1334	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1334	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Breast Cancer	1612		Crizotinib		Predictive	Supports	E	Sensitivity/Response	84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC.	19737969	PubMed		Lin et al., 2009, Mol. Cancer Res.		1	accepted	1335	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1335	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	DEL4-11	Neuroblastoma	769		Brigatinib		Predictive	Supports	D	Sensitivity/Response	The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib. Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM). CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls. Release of brigatinib administration at day 15 resulted in tumor growth (N=2).	27049722	PubMed		Siaw et al., 2016, Oncotarget		3	accepted	1336	550	1	2	29497965	29754982			ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1336	https://civic.genome.wustl.edu/links/variants/550	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION F1245C	Cancer	162		Crizotinib		Predictive	Supports	D	Resistance	A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizotinib (250, 500, 720, 1000, 1440 and 2000 nM). Cell growth occurred in all wells at 250 nM, and was absent at 2000 nM. From 500 through 1440 nM there were progressively fewer resistant clones present. 422 mutations representing 16 different sites were identified. EML4-ALK F1245C was found at 500 nM crizotinib, and was among the 10 most frequently observed mutations. Ba/F3 cells with unaltered EML4-ALK had crizotinib IC50 values for viability of 132 +/- 45 nM. EML4-ALK F1245C clones from the selection assay had IC50 viability value of 425 +/- 100 nM, while Ba/F3 cells expressing reintroduced EML4-ALK F1245C had IC50 value of 269 +/- 194 nM.	22034911	PubMed		Zhang et al., 2011, Chem Biol Drug Des		2	accepted	1337	551	1	2	29436859	29436859	A	C	ENST00000389048.3					75	GRCh37	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1337	https://civic.genome.wustl.edu/links/variants/551	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	C	Sensitivity/Response	A 52 year old male never smoker was diagnosed with stage IV NSCLC adenocarcinoma and was treated with chemotherapy with eventual disease progression. He tested positive for ALK rearrangement via break apart FISH assay, and started crizotinib with near complete response for 27 months. Progression then occurred and biopsy of a pleural nodule was performed with hybrid-capture NGS. EML4-ALK variant 3 with F1245C mutation was found with allele frequency of 2% and tumor purity 13%. Due to slow progression and low tumor burden crizotinib was maintained for additional 8 months, and then he was transitioned onto ceritinib at 750 mg daily. After 3 months ceritinib, complete radiographic response was seen and the patient was without evidence of disease at 6 months. Dose was reduced to 600 mg ceritinib daily due to gastrointestinal side effects.	26775591	PubMed		Kodityal et al., 2016, Lung Cancer		3	accepted	1338	551	1	2	29436859	29436859	A	C	ENST00000389048.3					75	GRCh37	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1338	https://civic.genome.wustl.edu/links/variants/551	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	A 52 year old with a non-smoking history was diagnosed with stage IV NSCLC-adenocarcinoma and treated with chemotherapy.  Upon disease progression, the initial diagnostic biopsy tested positive for ALK-rearrangement using break apart FISH, but the ALK fusion was not sequenced for mutations. Break-apart signal was positive in 66% of tumor cells. Crizotinib was initiated and a sustained near complete response for 27 months was observed, after which an FDG-avid cervical lymph node appeared along with pleural effusions and pleural nodules. A pleural nodule was biopsied and profiled using hybrid-capture next generation sequencing, and revealed EML4-ALK variant 3 with F1245C mutation at mutant allele frequency of 2% and tumor purity of 13%. Crizotinib was maintained for 8 additional months due to low tumor burden and slow progression.	26775591	PubMed		Kodityal et al., 2016, Lung Cancer		2	accepted	1339	551	1	2	29436859	29436859	A	C	ENST00000389048.3					75	GRCh37	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1339	https://civic.genome.wustl.edu/links/variants/551	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		3	accepted	1340	503	1	2	42396490	42491871			ENST00000318522.5	2	29415640	29446394	ENST00000389048.3	75	GRCh37	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1340	https://civic.genome.wustl.edu/links/variants/503	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib. In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably from vehicle, while ceritinib controlled tumor growth. Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild-type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		4	accepted	1341	7	1	2	29443631	29443631	G	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1341	https://civic.genome.wustl.edu/links/variants/7	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1269A	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho-ALK and phospho-AKT (detected by Western blot) at concentrations 10 fold lower than crizotinib. GI50 values were similar in Ba/F3 cells expressing either EML4-ALK wild-type or EML4-ALK G1269A (1.6nM and 2.2nM, respectively). In contrast, crizotinib treatment of Ba/F3 with EML4-ALK G1269A had survival GI50 of 130nM.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		3	accepted	1342	552	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1342	https://civic.genome.wustl.edu/links/variants/552	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK S1206Y	Cancer	162		Ceritinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensitive EML4-ALK wild-type variant obtained in parallel experiments, as well as the GI50 value of 16 nM obtained for crizotinib treatment of EML4-ALK wild-type.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		2	accepted	1343	172	1	2	29443600	29443600	G	T	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1343	https://civic.genome.wustl.edu/links/variants/172	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild-type variant 1 survival IC50 of 1.7 nM reported from parallel experiments. Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations. I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors. Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		4	accepted	1344	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1344	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing EML4-ALK variant 1 with ALK G1202R mutation were assessed for ceritinib sensitivity. Crizotinib was shown to confer significantly more potency than ceritinib (43-fold decrease in IC50). EML4-ALK variant 3 NSCLC cell line H2228 was used in SCID mouse xenografts which were exposed to increasing crizotinib up to 100 mg/kg. Within 40 days tumors progressed, and progressed tumors were assayed for ALK mutation. Of 80 tumors, 6 had ALK mutation and 3 of these were G1202R. Treatment of crizotinib progressed tumors with ceritinib resulted in tumor growth which did not differ appreciably from crizotinib or vehicle treatment of these tumors.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		4	accepted	1345	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1345	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	EML4-ALK variant 3 containing NSCLC cell line H2228 xenografts in SCID beige mice were treated with increasing doses of crizotinib up to 100 mg/kg per day by oral gavage. At approximately 40 days tumors progressed. 80 progressed tumors were tested for ALK mutations, and 6 mutant ALK variants were found. Two of the mutations were at ALK C1156Y. In Ba/F3 cells, EML4-ALK variant 3 with C1156Y was introduced and tested for crizotinib sensitivity. Survival IC50 value of 177 nM was reported, which is 9.3 times the IC50 reported for crizotinib in EML4-ALK wild-type Ba/F3 cells.	24675041	PubMed		Friboulet et al., 2014, Cancer Discov		4	accepted	1346	6	1	2	29445258	29445258	C	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1346	https://civic.genome.wustl.edu/links/variants/6	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC cell line was cultured in increasing levels of crizotinib to produce crizotinib resistant cell lines CR1, CR2 and CR3. H3122 CR2 was found to contain an 1151 insT ALK mutation and increased EML4-ALK levels. The H3122 CR2 cell line survival IC50 value for alectinib treatment was approximately 20x higher than that for H3122 cells.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		3	accepted	1347	173	1	2	29445271	29445272		CGT	ENST00000389048.3					75	GRCh37	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1347	https://civic.genome.wustl.edu/links/variants/173	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Resistance	Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produced from parental H3122 cells (CR1, CR2, CR3). H3122 CR2 was found to contain the 1151 Tins variant as well as elevated EML4-ALK expression. H3122 CR2 cells treated with TAE684 produced IC50 values 20-30 times that of the parental H3122 cells. These results suggest possible variant resistance to the TAE684-derived compound ceritinib.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		3	accepted	1348	173	1	2	29445271	29445272		CGT	ENST00000389048.3					75	GRCh37	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1348	https://civic.genome.wustl.edu/links/variants/173	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	3908		Tanespimycin		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells transduced with EML4-ALK 1151 insT were treated with 17-AAG producing an IC50 value of 44.5 nM, which was 0.4 times that reported for EML4-ALK wildtype in Ba/F3, indicating possible increased dependence of EML4-ALK 1151 insT on HSP90. 17-AAG also reduced survival of the parental IL3-dependent Ba/F3 cells (183.7 nM), indicating increased nonspecific effects of 17_AAG treatment. Crizotinib resistant clones were produced from the parental EML4-ALK variant 1 containing cell line H3122 (CR1, CR2, CR3). H3122 CR2 was found to contain the EML4-ALK InsT variant. H3122 CR2 and H3122 cells were similarly sensitized to 17-AAG death with an IC50 value of approximately 5 nM, while control cells without EML4-ALK had IC50 values approximately 10x higher.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		2	accepted	1349	173	1	2	29445271	29445272		CGT	ENST00000389048.3					75	GRCh37	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1349	https://civic.genome.wustl.edu/links/variants/173	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Cancer	162		Alectinib		Predictive	Supports	D	Resistance	Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reported for alectinib on Ba/F3 with EML4-ALK wild-type. Similar experiments using NPM-ALK instead of EML4-ALK yielded survival IC50 of 549 nM of NPM-ALK G1202R to alectinib, which was 27.9 times higher than IC50 for NPM-ALK wild-type. Western blots of Ba/F3 with NPM-ALK wild-type showed ablation of pALK levels above 100 nM alectinib, while pALK levels were essentially unchanged up to 1000 nM in NPM-ALK G1202R Ba/F3 cells.	25727400	PubMed		Fontana et al., 2015, Cancer Med		3	accepted	1350	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1350	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Cancer	162		Brigatinib		Predictive	Supports	D	Resistance	This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation were more resistant to brigatinib treatment (IC50 325 nM) than cells expressing wildtype EML4-ALK variant 3 (IC50 6 nM). These same experiments performed with the NPM-ALK fusion resulted in IC50 of 149 nM for G1202R and 11nM for wild type, consistent with resistance. In Western blots, ablation of pALK with brigatinib treatment above 100 nM was seen in Ba/F3 cells expressing NPM-ALK wildtype, but remained apparent at 1000 nM brigatinib in NPM-ALK G1202R cells, despite dose-dependent reduction.	25727400	PubMed		Fontana et al., 2015, Cancer Med		3	accepted	1351	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1351	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	3908		Tanespimycin		Predictive	Supports	D	Sensitivity/Response	The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expressed in Ba/F3 and subject to 17-AAG. IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild-type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		2	accepted	1352	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1352	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1269A	Cancer	162		Brigatinib		Predictive	Supports	D	Sensitivity/Response	EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory concentration of 9 nM was seen, which was 1.5 times the IC50 of EML4-ALK wild-type to brigatinib. NPM-ALK G1269A was also tested for brigatinib sensitivity, and IC50 values of 11 nM were reported for both NPM-ALK G1269A and NPM-ALK wild-type. In western blotting, brigatinib at and above 100 nM ablated pALK signal (Y 1604), indicating sensitivity of this variant to brigatinib together with the other results.	25727400	PubMed		Fontana et al., 2015, Cancer Med		2	accepted	1353	552	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1353	https://civic.genome.wustl.edu/links/variants/552	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1269A	Cancer	162		Alectinib		Predictive	Supports	D	Resistance	EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was a 6 fold increase over IC50 for EML4-ALK wild-type. The authors considered a fold difference of 4 to 10 between the alectinib-sensitized wild-type and mutant variant to indicate a resistant mutant variant. In the background of the NPM-ALK fusion, IC50 for G1269A mutation was 104 nM, which was 5.3 fold that reported for NPM-ALK wild-type. Western blots of alectinib treated NPM-ALK G1269A were performed and reduced pALK Y1604 was seen at 300 nM alectinib, and no pALK at 1000 nM. In contrast pALK signal was ablated at and above 100 nM in NPM-ALK wild-type.	25727400	PubMed		Fontana et al., 2015, Cancer Med		3	accepted	1354	552	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1354	https://civic.genome.wustl.edu/links/variants/552	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1269A	Cancer	162		Ceritinib		Predictive	Supports	D	Sensitivity/Response	EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration. IC50 of 33 nM was seen, which was 1.5 times the IC50 for EML4-ALK wild-type, indicating sensitivity of the G1269A mutation to ceritinib in the context of EML4-ALK. The mutation was also tested for ceritinib sensitivity in the context of NPM-ALK, where IC50 values were reported of 19 nM and 20 nM for mutant and wild-type versions, respectively, also indicating sensitivity. In western blots,  Y1604 pALK levels for wild-type NPM-ALK were ablated at 100 nM, while at 100 nM residual pALK levels were seen in G1269A blotting, with ablation of signal at and above 300 nM, which differed somewhat from the equivalent IC50 values reported for mutant and wild-type in the NPM-ALK background, but still agrees with sensitivity to ceritinib for this mutation.	25727400	PubMed		Fontana et al., 2015, Cancer Med		2	accepted	1355	552	1	2	29432682	29432682	C	G	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1355	https://civic.genome.wustl.edu/links/variants/552	https://civic.genome.wustl.edu/links/genes/1
ALK	238	NPM-ALK	Cancer	162		Crizotinib		Predictive	Supports	D	Sensitivity/Response	In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells.	25727400	PubMed		Fontana et al., 2015, Cancer Med		2	accepted	1356	513	1	5	170814120	170818803			ENST00000517671.1	2	29415640	29446394	ENST00000389048.3	75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1356	https://civic.genome.wustl.edu/links/variants/513	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION G1202R	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Resistance	A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28, which correspond to the tyrosine kinase domain of ALK, were sequenced, and ALK G1202A was found. CKIT focal amplification by FISH was also observed. Tumor sample before crizotinib treatment was not available in this case.	22277784	PubMed		Katayama et al., 2012, Sci Transl Med		3	accepted	1357	171	1	2	29443613	29443613	C	T	ENST00000389048.3					75	GRCh37	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1357	https://civic.genome.wustl.edu/links/variants/171	https://civic.genome.wustl.edu/links/genes/1
PIK3CA	5290	MUTATION	Cancer	162		Tanespimycin,Pictilisib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.	25855885	PubMed		Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg		2	accepted	1358	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1358	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	MUTATION	Head And Neck Cancer	11934		Tanespimycin,Pictilisib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening.	25855885	PubMed		Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg		2	accepted	1359	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1359	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	MUTATION	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235.	23619167	PubMed		Lui et al., 2013, Cancer Discov		3	accepted	1360	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1360	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).	25855885	PubMed		Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg		1	accepted	1361	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1361	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were "CAL-33" and "Detroit 562". Wild type cell lines used here were "SCC-9" and "PE/CA-PJ34(clone C12)".	23619167	PubMed		Lui et al., 2013, Cancer Discov		2	accepted	1362	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1362	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Head And Neck Cancer	11934		Dactolisib,Cetuximab	Combination	Predictive	Supports	D	Sensitivity/Response	Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo.	23619167	PubMed		Lui et al., 2013, Cancer Discov		2	accepted	1363	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1363	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Head And Neck Cancer	11934		Trametinib,Pictilisib,Tanespimycin	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.	25855885	PubMed		Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg		2	accepted	1364	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1364	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973		Sorafenib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.	20368568	PubMed		Lam et al., 2010, J. Clin. Oncol.		3	accepted	1365	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1365	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
CDK4	1019	AMPLIFICATION	Liposarcoma	3382		Palbociclib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy.	23569312	PubMed		Dickson et al., 2013, J. Clin. Oncol.	NCT01209598	3	accepted	1366	553	13	12	58141510	58146304			ENST00000257904.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1366	https://civic.genome.wustl.edu/links/variants/553	https://civic.genome.wustl.edu/links/genes/13
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Resistance	A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response. She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months. Liver tumor biopsy was performed and was estimated to be 15% tumor tissue. Next-generation sequencing discovered an ALK I1171N mutation. The tumor was not sequenced prior to alectinib resistance.	25736571	PubMed		Ou et al., 2015, Lung Cancer		2	accepted	1367	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1367	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSION I1171	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	C	Sensitivity/Response	A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases. Liver tumor biopsy was taken and estimated to be 15% tumor. Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells. Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea. CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months.	25736571	PubMed		Ou et al., 2015, Lung Cancer		3	accepted	1368	527	1	2	29445213	29445213	A	G	ENST00000389048.3					75	GRCh37	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1368	https://civic.genome.wustl.edu/links/variants/527	https://civic.genome.wustl.edu/links/genes/1
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Better Outcome	In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56).	16046528	PubMed		Boissel et al., 2005, Blood		3	accepted	1369	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1369	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35
BRCA1	672	MUTATION	Cancer	162		Olaparib		Predictive	Supports	A	Sensitivity/Response	In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.	19553641	PubMed		Fong et al., 2009, N. Engl. J. Med.	NCT00516373	4	accepted	1370	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1370	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Cancer	162		Olaparib		Predictive	Supports	A	Sensitivity/Response	In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.	19553641	PubMed		Fong et al., 2009, N. Engl. J. Med.	NCT00516373	4	accepted	1371	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1371	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
CDKN2A	1029	LOSS	Skin Melanoma	8923		Alvocidib		Predictive	Supports	D	Sensitivity/Response	Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM).	12777976	PubMed		Robinson et al., 2003, Melanoma Res.		2	accepted	1372	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1372	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	LOSS	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.	23898052	PubMed		Logan et al., 2013, Anticancer Res.		3	accepted	1373	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1373	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
CDKN2B	1030	LOSS	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.	23898052	PubMed		Logan et al., 2013, Anticancer Res.		3	accepted	1374	555	916	9	22002902	22009362			ENST00000276925.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1374	https://civic.genome.wustl.edu/links/variants/555	https://civic.genome.wustl.edu/links/genes/916
CDKN2A	1029	LOSS	Skin Melanoma	8923		Palbociclib		Predictive	Supports	D	Sensitivity/Response	In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02).	24495407	PubMed		Young et al., 2014, Pigment Cell Melanoma Res		3	accepted	1375	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1375	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
CDK4	1019	R24C	Skin Melanoma	8923		Palbociclib		Predictive	Supports	D	Sensitivity/Response	In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib).	24495407	PubMed		Young et al., 2014, Pigment Cell Melanoma Res		1	accepted	1376	556	13	12	58145431	58145431	G	A	ENST00000257904.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1376	https://civic.genome.wustl.edu/links/variants/556	https://civic.genome.wustl.edu/links/genes/13
CDKN2A	1029	LOSS	Ovarian Cancer	2394		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses.	21278246	PubMed		Konecny et al., 2011, Clin. Cancer Res.		3	accepted	1377	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1377	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
ASXL1	171023	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001). This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients).	22031865	PubMed		Metzeler et al., 2011, Blood		3	accepted	1378	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1378	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
ASXL1	171023	EXON 12 MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild-type (N=430). Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70).	23018865	PubMed		Schnittger et al., 2013, Leukemia		4	accepted	1379	557	68	20	31021087	31021720			ENST00000375687.4					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1379	https://civic.genome.wustl.edu/links/variants/557	https://civic.genome.wustl.edu/links/genes/68
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.	22802530	PubMed		Utermark et al., 2012, Genes Dev.		3	accepted	1380	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1380	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		A66		Predictive	Supports	D	Sensitivity/Response	Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.	22802530	PubMed		Utermark et al., 2012, Genes Dev.		2	accepted	1381	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1381	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Tgx 221		Predictive	Does Not Support	D	Sensitivity/Response	Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.	22802530	PubMed		Utermark et al., 2012, Genes Dev.		3	accepted	1382	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1382	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	D	Resistance	A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.	17936563	PubMed		Berns et al., 2007, Cancer Cell		2	accepted	1383	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1383	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Resistance	The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).	17936563	PubMed		Berns et al., 2007, Cancer Cell		2	accepted	1384	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1384	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Resistance	A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).	20813970	PubMed		Esteva et al., 2010, Am. J. Pathol.		3	accepted	1385	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1385	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Does Not Support	B	Resistance	While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).	20813970	PubMed		Esteva et al., 2010, Am. J. Pathol.		3	accepted	1386	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1386	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
CALR	811	EXON 9 FRAMESHIFT	Myelofibrosis	4971				Prognostic	Supports	A	Better Outcome	Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)	25037629	PubMed		Tefferi et al., 2014, Blood		4	accepted	1387	559	732	19	13054527	13054727			ENST00000316448.5					75	GRCh37	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1387	https://civic.genome.wustl.edu/links/variants/559	https://civic.genome.wustl.edu/links/genes/732
CSF3R	1441	MUTATION	Chronic Neutrophilic Leukemia	0080187				Diagnostic	Supports	B	Positive	Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)	23656643	PubMed		Maxson et al., 2013, N. Engl. J. Med.		3	accepted	1388	560	1239	1	36932096	36933444			ENST00000373106.1					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1388	https://civic.genome.wustl.edu/links/variants/560	https://civic.genome.wustl.edu/links/genes/1239
CSF3R	1441	MUTATION	Atypical Chronic Myeloid Leukemia	0060597				Diagnostic	Supports	B	Positive	Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)	23656643	PubMed		Maxson et al., 2013, N. Engl. J. Med.		3	accepted	1389	560	1239	1	36932096	36933444			ENST00000373106.1					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1389	https://civic.genome.wustl.edu/links/variants/560	https://civic.genome.wustl.edu/links/genes/1239
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Ponatinib		Predictive	Supports	B	Sensitivity/Response	Study describes a phase 1 clinical trial of ponatinib in treatment of 81 refractory Philadelphia chromosome-positive leukemias. 43 of these patients were considered to have chronic-phase CML. All 12 chronic-phase CML patients with a T315I mutation showed a complete hematologic response. Furthermore, 91% of these patients were estimated to  remain in response at 1 year (95% CI, Kaplan-Meier analysis).	23190221	PubMed		Cortes et al., 2012, N. Engl. J. Med.	NCT00660920	4	accepted	1390	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1390	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
EGFR	1956	T790M	Lung Adenocarcinoma	3910		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.	23470965	PubMed		Yu et al., 2013, Clin. Cancer Res.		3	accepted	1391	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1391	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
MET	4233	AMPLIFICATION	Lung Adenocarcinoma	3910		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	C	Resistance	155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification.	23470965	PubMed		Yu et al., 2013, Clin. Cancer Res.		2	accepted	1392	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1392	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
ERBB2	2064	AMPLIFICATION	Lung Adenocarcinoma	3910		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	C	Resistance	155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.	23470965	PubMed		Yu et al., 2013, Clin. Cancer Res.		1	accepted	1393	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1393	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
EGFR	1956	S768I	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.	25521405	PubMed		Hellmann et al., 2014, J Thorac Oncol		3	accepted	1394	562	19	7	55249005	55249005	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1394	https://civic.genome.wustl.edu/links/variants/562	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	S768I	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.	20522446	PubMed		Masago et al., 2010, Jpn. J. Clin. Oncol.		2	accepted	1395	562	19	7	55249005	55249005	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1395	https://civic.genome.wustl.edu/links/variants/562	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	C797S	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Resistance	Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only	26181354	PubMed		Yu et al., 2015, JAMA Oncol	NCT01802632	1	accepted	1396	415	19	7	55249091	55249091	T	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1396	https://civic.genome.wustl.edu/links/variants/415	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.	26181354	PubMed		Yu et al., 2015, JAMA Oncol	NCT01802632	1	accepted	1397	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1397	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)	24508103	PubMed		McArthur et al., 2014, Lancet Oncol.	NCT01006980	5	accepted	1398	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1398	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine).	24508103	PubMed		McArthur et al., 2014, Lancet Oncol.	NCT01006980	4	accepted	1399	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1399	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma.	26989536	PubMed		Sahadudheen et al., 2016, Case Rep Oncol Med		3	accepted	1400	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1400	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	H1047R	Head And Neck Cancer	11934		Alpelisib		Predictive	Supports	D	Sensitivity/Response	In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 M; SNU-1041, 20.65 M; FaDu, 19.67 M; SCC25, 49.30 M). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels.	25550549	PubMed		Keam et al., 2015, Anticancer Res.		1	accepted	1401	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1401	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Cancer	162		Alpelisib		Predictive	Supports	D	Sensitivity/Response	A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition.	24608574	PubMed		Fritsch et al., 2014, Mol. Cancer Ther.		4	accepted	1402	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1402	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	AMPLIFICATION	Stomach Carcinoma	5517		Alpelisib		Predictive	Supports	D	Sensitivity/Response	474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.	24608574	PubMed		Fritsch et al., 2014, Mol. Cancer Ther.		3	accepted	1403	212	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1403	https://civic.genome.wustl.edu/links/variants/212	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	MUTATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting.	25673558	PubMed		Pietrantonio et al., 2015, Eur. J. Cancer		3	accepted	1404	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1404	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	B	Sensitivity/Response	In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.	26460303	PubMed		Kopetz et al., 2015, J. Clin. Oncol.	NCT00405587	4	accepted	1405	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1405	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Dabrafenib		Predictive	Does Not Support	B	Sensitivity/Response	In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.	22608338	PubMed		Falchook et al., 2012, Lancet	NCT00880321	3	accepted	1406	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1406	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909	Brain neoplasm	Dabrafenib		Predictive	Supports	B	Sensitivity/Response	In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months.	22608338	PubMed		Falchook et al., 2012, Lancet	NCT00880321	4	accepted	1407	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1407	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Cetuximab,Gefitinib,Vemurafenib	Combination	Predictive	Supports	D	Sensitivity/Response	5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.	22281684	PubMed		Prahallad et al., 2012, Nature		3	accepted	1408	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1408	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	A	Sensitivity/Response	Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).	21639808	PubMed		Chapman et al., 2011, N. Engl. J. Med.	NCT01006980	5	accepted	1409	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1409	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation.  Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).	22356324	PubMed		Sosman et al., 2012, N. Engl. J. Med.	NCT00949702	3	accepted	1410	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1410	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Skin Melanoma	8923		Dabrafenib,Trametinib	Combination	Predictive	Supports	A	Sensitivity/Response	The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred at 1% with combination-therapy and 18% in the vemurafenib group.	25399551	PubMed		Robert et al., 2015, N. Engl. J. Med.	NCT01597908	5	accepted	1411	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1411	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
SMAD4	4089	LOSS	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure "metastatic and locally destructive", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007).	19273710	PubMed		Iacobuzio-Donahue et al., 2009, J. Clin. Oncol.		3	accepted	1412	564	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1412	https://civic.genome.wustl.edu/links/variants/564	https://civic.genome.wustl.edu/links/genes/77
BRAF	673	V600E	Colorectal Cancer	9256		Panitumumab,Vemurafenib	Combination	Predictive	Does Not Support	B	Sensitivity/Response	Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.	25589621	PubMed		Yaeger et al., 2015, Clin. Cancer Res.		3	accepted	1413	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1413	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.	24987354	PubMed		Ali et al., 2014, Case Rep Oncol		4	accepted	1414	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1414	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Colorectal Cancer	9256		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway.	26392102	PubMed		Corcoran et al., 2015, J. Clin. Oncol.	NCT01072175	2	accepted	1415	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1415	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	TRIM24-BRAF	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.	24345920	PubMed		Hutchinson et al., 2013, Clin. Cancer Res.		3	accepted	1416	287	5	7	138145079	138239711			ENST00000343526.4	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1416	https://civic.genome.wustl.edu/links/variants/287	https://civic.genome.wustl.edu/links/genes/5
SF3B1	23451	K700E	Breast Cancer	1612		Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor).	25424858	PubMed		Maguire et al., 2015, J. Pathol.		2	accepted	1417	565	44	2	198266834	198266834	T	C	ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1417	https://civic.genome.wustl.edu/links/variants/565	https://civic.genome.wustl.edu/links/genes/44
SF3B1	23451	K666N	Breast Cancer	1612		Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor).	25424858	PubMed		Maguire et al., 2015, J. Pathol.		2	accepted	1418	114	44	2	198267359	198267359	C	A	ENST00000335508.6					75	GRCh37	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1418	https://civic.genome.wustl.edu/links/variants/114	https://civic.genome.wustl.edu/links/genes/44
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients).	21933749	PubMed		Shaw et al., 2011, Lancet Oncol.	NCT00585195	3	accepted	1419	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1419	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
MAP2K7	5609	E116K	Lung Cancer	1324				Prognostic	Supports	B	Poor Outcome	Study examined rare SNPs on MAP2K7 among a discovery and two validation cohorts. It was discovered that the E116K genotype was associated with a reduced median survival time of 4 and 7 months for E/K or K/K genotypes (P=2.61E-7) and an increased cancer death risk for heterozygous (HR=1.49) and homozygous (HR=1.94) genotypes for a pooled cohort. Further nude mice harboring this variant showed increased xenograft growth and metastasis.	27028764	PubMed		Qiu et al., 2016, PLoS Genet.		5	accepted	1420	566	4546	19	7975157	7975157	G	A	ENST00000397979.3					75	GRCh37		Common Germline	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1420	https://civic.genome.wustl.edu/links/variants/566	https://civic.genome.wustl.edu/links/genes/4546
BRAF	673	V600E	Melanoma	1909		Vemurafenib,Cobimetinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mutation. 174 patients were treated with vemurafenib and placebo, and 170 were treated with vemurafenib and cobimetinib and tested for progression free survival. 88 of 174 monotherapy group patients had an event with median progression free survival of 6.5 months. In the combination group 58 of 174 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.57 (0.41-0.80).	25265494	PubMed		Larkin et al., 2014, N. Engl. J. Med.	NCT01689519	4	accepted	1421	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1421	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909		Cobimetinib,Vemurafenib	Combination	Predictive	Supports	B	Sensitivity/Response	In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.	25265494	PubMed		Larkin et al., 2014, N. Engl. J. Med.	NCT01689519	4	accepted	1422	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1422	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
KIT	3815	M541L	Chronic Leukemia	1036		Imatinib		Predictive	Supports	C	Sensitivity/Response	In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months.	25015329	PubMed		Iurlo et al., 2014, Oncotarget		2	accepted	1423	201	29	4	55593464	55593464	A	C	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1423	https://civic.genome.wustl.edu/links/variants/201	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		3	accepted	1424	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1424	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	PDGFRA FUSIONS	Chronic Myelomonocytic Leukemia	0080188				Diagnostic	Supports	A	Negative	The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1425	567	38														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1425	https://civic.genome.wustl.edu/links/variants/567	https://civic.genome.wustl.edu/links/genes/38
PDGFRB	5159	PDGFRB FUSIONS	Chronic Myelomonocytic Leukemia	0080188				Diagnostic	Supports	A	Negative	The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1426	568	4176														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1426	https://civic.genome.wustl.edu/links/variants/568	https://civic.genome.wustl.edu/links/genes/4176
FGFR1	2260	FGFR1 FUSIONS	Chronic Myelomonocytic Leukemia	0080188				Diagnostic	Supports	A	Negative	The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1427	569	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37		Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/1427	https://civic.genome.wustl.edu/links/variants/569	https://civic.genome.wustl.edu/links/genes/1885
BRAF	673	V600E	Colorectal Cancer	9256		Dactolisib,GDC-0879	Combination	Predictive	Supports	D	Sensitivity/Response	In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.	23549875	PubMed		Coffee et al., 2013, Clin. Cancer Res.		3	accepted	1428	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1428	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	MUTATION	Melanoma	1909		Omipalisib,Trametinib	Combination	Predictive	Supports	D	Sensitivity/Response	In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse.	23431193	PubMed		Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	1429	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1429	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	V600E	Gastrointestinal Neuroendocrine Tumor	0050626		Dabrafenib,Trametinib,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).	27048246	PubMed		Klempner et al., 2016, Cancer Discov		3	accepted	1430	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1430	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).	23382472	PubMed		Hurvitz et al., 2013, J. Clin. Oncol.	NCT00679341	3	accepted	1432	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1432	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PDGFRA	5156	PDGFRA FUSIONS	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164				Diagnostic	Supports	A	Positive	The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1433	567	38														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1433	https://civic.genome.wustl.edu/links/variants/567	https://civic.genome.wustl.edu/links/genes/38
PDGFRB	5159	PDGFRB FUSIONS	Hematologic Cancer	2531				Diagnostic	Supports	A	Positive	The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1434	568	4176														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1434	https://civic.genome.wustl.edu/links/variants/568	https://civic.genome.wustl.edu/links/genes/4176
FGFR1	2260	FGFR1 FUSIONS	Hematologic Cancer	2531				Diagnostic	Supports	A	Positive	The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1435	569	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37		Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/1435	https://civic.genome.wustl.edu/links/variants/569	https://civic.genome.wustl.edu/links/genes/1885
JAK2	3717	PCM1-JAK2	Hematologic Cancer	2531				Diagnostic	Supports	A	Positive	The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	1436	571	28												GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1436	https://civic.genome.wustl.edu/links/variants/571	https://civic.genome.wustl.edu/links/genes/28
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Docetaxel,Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.	22149875	PubMed		Baselga et al., 2012, N. Engl. J. Med.	NCT00567190	4	accepted	1437	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1437	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
MTOR	2475	E2014K and E2419K	Transitional Cell Carcinoma	2671		Everolimus,Pazopanib	Combination	Predictive	Supports	C	Sensitivity/Response	A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatment. This patient was exome sequenced and two mutations co-occurring in MTOR were identified. Expression of these mutations in HEK293T cells demonstrated these were activating mutations. The authors propose that these two activating mutations are the reason for the dramatic response to mTOR inhibition and considered them as "biologically plausible" to confer sensitivity to everolimus.	24625776	PubMed		Wagle et al., 2014, Cancer Discov		2	accepted	1438	572	2073	1	11174420	11187857			ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1438	https://civic.genome.wustl.edu/links/variants/572	https://civic.genome.wustl.edu/links/genes/2073
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Lapatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).	22257673	PubMed		Baselga et al., 2012, Lancet	NCT00553358	4	accepted	1439	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1439	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
RICTOR	253260	AMPLIFICATION	Lung Adenocarcinoma	3910		Sapanisertib,Onatasertib	Substitutes	Predictive	Supports	C	Sensitivity/Response	Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months.	26370156	PubMed		Cheng et al., 2015, Cancer Discov		2	accepted	1440	573	20480	5	38938021	39074510			ENST00000357387.3					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1440	https://civic.genome.wustl.edu/links/variants/573	https://civic.genome.wustl.edu/links/genes/20480
PDGFRA	5156	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	B	Sensitivity/Response	A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.	14504092	PubMed		Klion et al., 2004, Blood		4	accepted	1441	574	38	4	54243812	54294350			ENST00000337488.6	4	55141008	55164414	ENST00000257290.5	75	GRCh37	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).	Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/1441	https://civic.genome.wustl.edu/links/variants/574	https://civic.genome.wustl.edu/links/genes/38
ROS1	6098	REARRANGEMENT	Bronchiolo-alveolar Adenocarcinoma	4926		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines.	22215748	PubMed		Bergethon et al., 2012, J. Clin. Oncol.		3	accepted	1443	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1443	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
ROS1	6098	TFG-ROS1	Inflammatory Myofibroblastic Tumor	0050905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.	24875859	PubMed		Lovly et al., 2014, Cancer Discov		3	accepted	1444	576	4941	3	100428269	100447702			ENST00000240851.4	6	117609463	117642557	ENST00000368508.3	75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1444	https://civic.genome.wustl.edu/links/variants/576	https://civic.genome.wustl.edu/links/genes/4941
PDGFRA	5156	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	A	Sensitivity/Response	Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion.	12660384	PubMed		Cools et al., 2003, N. Engl. J. Med.		3	accepted	1445	574	38	4	54243812	54294350			ENST00000337488.6	4	55141008	55164414	ENST00000257290.5	75	GRCh37	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).	Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/1445	https://civic.genome.wustl.edu/links/variants/574	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	C	Resistance	A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment. A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL.	12660384	PubMed		Cools et al., 2003, N. Engl. J. Med.		2	accepted	1446	577	38	4	55144547	55144547	C	T	ENST00000257290.5					75	GRCh37	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/1446	https://civic.genome.wustl.edu/links/variants/577	https://civic.genome.wustl.edu/links/genes/38
PIK3CA	5290	H1047R	Lung Adenocarcinoma	3910		Dactolisib		Predictive	Supports	D	Sensitivity/Response	Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume.	19029981	PubMed		Engelman et al., 2008, Nat. Med.		3	accepted	1447	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1447	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab,Pilaralisib	Combination	Predictive	Supports	D	Sensitivity/Response	In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 (pilaralisib) and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.	23204226	PubMed		Chakrabarty et al., 2013, Cancer Res.		4	accepted	1448	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1448	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
BIRC5	332	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Resistance	13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis.	23204226	PubMed		Chakrabarty et al., 2013, Cancer Res.		4	accepted	1449	578	355	17	76210267	76221717			ENST00000301633.4					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1449	https://civic.genome.wustl.edu/links/variants/578	https://civic.genome.wustl.edu/links/genes/355
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.	8241511	PubMed		el Rouby et al., 1993, Blood		3	accepted	1450	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1450	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions.	18689542	PubMed		Zenz et al., 2008, Blood		4	accepted	1451	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1451	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001).	20697090	PubMed		Zenz et al., 2010, J. Clin. Oncol.		5	accepted	1452	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1452	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
PIK3CA	5290	E545K	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	D	Resistance	PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.	18829560	PubMed		Serra et al., 2008, Cancer Res.		2	accepted	1453	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1453	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	D594A	Skin Melanoma	8923		Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Substitutes	Predictive	Supports	E	Sensitivity/Response	Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.	20141835	PubMed		Heidorn et al., 2010, Cell		3	accepted	1454	579	5	7	140453154	140453154	T	G	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1454	https://civic.genome.wustl.edu/links/variants/579	https://civic.genome.wustl.edu/links/genes/5
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab,PI3K/BET Inhibitor LY294002	Combination	Predictive	Supports	D	Sensitivity/Response	Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.	15324695	PubMed		Nagata et al., 2004, Cancer Cell		3	accepted	1455	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1455	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
BRAF	673	D594V	Skin Melanoma	8923		Sorafenib,Trametinib	Substitutes	Predictive	Supports	E	Sensitivity/Response	Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers.	20141835	PubMed		Heidorn et al., 2010, Cell		3	accepted	1456	580	5	7	140453154	140453154	T	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1456	https://civic.genome.wustl.edu/links/variants/580	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	K483M	Skin Melanoma	8923		Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Substitutes	Predictive	Supports	E	Sensitivity/Response	Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.	20141835	PubMed		Heidorn et al., 2010, Cell		3	accepted	1457	581	5	7	140477859	140477860	TT	CA	ENST00000288602.6					75	GRCh37	The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.	Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1457	https://civic.genome.wustl.edu/links/variants/581	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597R	Skin Melanoma	8923		Trametinib,Vemurafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.	22798288	PubMed		Dahlman et al., 2012, Cancer Discov		2	accepted	1458	288	5	7	140453145	140453145	A	C	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1458	https://civic.genome.wustl.edu/links/variants/288	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597S	Skin Melanoma	8923		Vemurafenib,Trametinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.	22798288	PubMed		Dahlman et al., 2012, Cancer Discov		2	accepted	1459	582	5	7	140453145	140453146	AG	GA	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1459	https://civic.genome.wustl.edu/links/variants/582	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597S	Skin Melanoma	8923		MEK Inhibitor TAK-733		Predictive	Supports	C	Sensitivity/Response	Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.	22798288	PubMed		Dahlman et al., 2012, Cancer Discov		3	accepted	1460	582	5	7	140453145	140453146	AG	GA	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1460	https://civic.genome.wustl.edu/links/variants/582	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597Q	Skin Melanoma	8923		Trametinib,Vemurafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.	22798288	PubMed		Dahlman et al., 2012, Cancer Discov		2	accepted	1461	583	5	7	140453145	140453145	A	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1461	https://civic.genome.wustl.edu/links/variants/583	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	K601E	Skin Melanoma	8923		Trametinib,Vemurafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.	22798288	PubMed		Dahlman et al., 2012, Cancer Discov		3	accepted	1462	584	5	7	140453134	140453134	T	C	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1462	https://civic.genome.wustl.edu/links/variants/584	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597V	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.	22805292	PubMed		Falchook et al., 2012, Lancet Oncol.	NCT00687622	3	accepted	1463	585	5	7	140453146	140453146	G	C	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1463	https://civic.genome.wustl.edu/links/variants/585	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Sensitivity/Response	The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines	26589432	PubMed		Zumsteg et al., 2016, Clin. Cancer Res.		1	accepted	1464	212	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1464	https://civic.genome.wustl.edu/links/variants/212	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Sensitivity/Response	The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines.	26589432	PubMed		Zumsteg et al., 2016, Clin. Cancer Res.		2	accepted	1465	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1465	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
KIT	3815	AMPLIFICATION	Mucosal Melanoma	0050929		Imatinib		Predictive	Supports	B	Resistance	Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months. Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only.	23775962	PubMed		Hodi et al., 2013, J. Clin. Oncol.	NCT00424515	3	accepted	1466	586	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		N/A	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1466	https://civic.genome.wustl.edu/links/variants/586	https://civic.genome.wustl.edu/links/genes/29
PTEN	5728	MUTATION	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Resistance	In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation.	26589432	PubMed		Zumsteg et al., 2016, Clin. Cancer Res.		3	accepted	1467	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1467	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
NF1	4763	MUTATION	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901.	23171796	PubMed		Maertens et al., 2013, Cancer Discov		2	accepted	1468	587	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1468	https://civic.genome.wustl.edu/links/variants/587	https://civic.genome.wustl.edu/links/genes/3867
NF1	4763	MUTATION	Skin Melanoma	8923		MEK Inhibitor PD0325901,Sirolimus	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression.	23171796	PubMed		Maertens et al., 2013, Cancer Discov		3	accepted	1469	587	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1469	https://civic.genome.wustl.edu/links/variants/587	https://civic.genome.wustl.edu/links/genes/3867
NF1	4763	MUTATION	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	C	Resistance	NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.  4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib. Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies. The patient had a progression-free survival (PFS) of about 10 weeks. The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs. Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies. Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance.	23288408	PubMed		Whittaker et al., 2013, Cancer Discov		4	accepted	1470	587	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1470	https://civic.genome.wustl.edu/links/variants/587	https://civic.genome.wustl.edu/links/genes/3867
NF1	4763	MUTATION	Skin Melanoma	8923		AZ628,VTX-11e	Substitutes	Predictive	Supports	D	Sensitivity/Response	NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628. Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro.	23288408	PubMed		Whittaker et al., 2013, Cancer Discov		2	accepted	1471	587	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1471	https://civic.genome.wustl.edu/links/variants/587	https://civic.genome.wustl.edu/links/genes/3867
NRAS	4893	MUTATION	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).	23414587	PubMed		Ascierto et al., 2013, Lancet Oncol.	NCT01320085	2	accepted	1472	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1472	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61	Skin Melanoma	8923		Selumetinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.	18390968	PubMed		Adjei et al., 2008, J. Clin. Oncol.		2	accepted	1473	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1473	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61K	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.	22194965	PubMed		Atefi et al., 2011, PLoS ONE		2	accepted	1474	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1474	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61K	Skin Melanoma	8923		Selumetinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.	22194965	PubMed		Atefi et al., 2011, PLoS ONE		2	accepted	1475	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1475	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	MUTATION	Skin Melanoma	8923		Amuvatinib		Predictive	Supports	D	Sensitivity/Response	Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.	24950457	PubMed		Fedorenko et al., 2014, Melanoma Res.		1	accepted	1476	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1476	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
SMO	6608	MUTATION	Basal Cell Carcinoma	2513		Vismodegib,Sonidegib	Sequential	Predictive	Supports	B	Resistance	Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449). Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H). Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria.	26546616	PubMed		Danial et al., 2016, Clin. Cancer Res.		2	accepted	1477	300	5365	7	128828713	128853386			ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1477	https://civic.genome.wustl.edu/links/variants/300	https://civic.genome.wustl.edu/links/genes/5365
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations.	21483000	PubMed		Gonzalez et al., 2011, J. Clin. Oncol.		3	accepted	1478	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1478	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
NOTCH1	4851	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild-type NOTCH1. Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis.	23086750	PubMed		Oscier et al., 2013, Blood		2	accepted	1479	206	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Unknown	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1479	https://civic.genome.wustl.edu/links/variants/206	https://civic.genome.wustl.edu/links/genes/50
SF3B1	23451	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment. Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002).	23086750	PubMed		Oscier et al., 2013, Blood		4	accepted	1480	215	44	2	198254508	198299815			ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1480	https://civic.genome.wustl.edu/links/variants/215	https://civic.genome.wustl.edu/links/genes/44
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040		Alemtuzumab		Predictive	Supports	B	Sensitivity/Response	Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.	14726385	PubMed		Lozanski et al., 2004, Blood		2	accepted	1481	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1481	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
CALR	811	EXON 9 FRAMESHIFT	Chronic Myeloproliferative Disease	2226		Peginterferon Alfa-2a		Predictive	Supports	B	Sensitivity/Response	Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin.	26486786	PubMed		Verger et al., 2015, Blood		4	accepted	1482	559	732	19	13054527	13054727			ENST00000316448.5					75	GRCh37	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1482	https://civic.genome.wustl.edu/links/variants/559	https://civic.genome.wustl.edu/links/genes/732
ALK	238	HIP1-ALK I1171N	Lung Non-small Cell Carcinoma	3908		Crizotinib,Alectinib	Sequential	Predictive	Supports	C	Resistance	Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (complete response). Liver metastasis was noted after 12 months with sequencing revealing a HIP1-ALK fusion with a I1171N variant.	25393796	PubMed		Ou et al., 2014, J Thorac Oncol		2	accepted	1483	588	1	2	29445213	29445213	A	T	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/1483	https://civic.genome.wustl.edu/links/variants/588	https://civic.genome.wustl.edu/links/genes/1
ALK	238	EML4-ALK I1171S	Lung Non-small Cell Carcinoma	3908		Alectinib,Crizotinib	Sequential	Predictive	Supports	C	Resistance	Case study describes a caucasian male (age 38) never smoker presenting with stage IV non-small cell lung cancer with an ALK rearrangement. Patient was given crizotinib and exhibited a partial response after 5 months with brain metastasis occurring at 21 months. Patient then received alectinib and exhibited partial response however liver metastasis presented after 12 months on alectinib. Sequencing of this liver metastasis revealed an EML4-ALK fusion with an I1171S variant at a variant frequency of 36% (tumor purity estimated as 70%).	25393796	PubMed		Ou et al., 2014, J Thorac Oncol		2	accepted	1484	589	1	2	29445213	29445213	A	C	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1484	https://civic.genome.wustl.edu/links/variants/589	https://civic.genome.wustl.edu/links/genes/1
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status.	24943832	PubMed		Baliakas et al., 2015, Leukemia		5	accepted	1485	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1485	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
NOTCH1	4851	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Does Not Support	B	N/A	In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847).	24943832	PubMed		Baliakas et al., 2015, Leukemia		5	accepted	1486	206	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1486	https://civic.genome.wustl.edu/links/variants/206	https://civic.genome.wustl.edu/links/genes/50
SF3B1	23451	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status.	24943832	PubMed		Baliakas et al., 2015, Leukemia		5	accepted	1487	215	44	2	198254508	198299815			ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1487	https://civic.genome.wustl.edu/links/variants/215	https://civic.genome.wustl.edu/links/genes/44
BIRC3	330	TRUNCATING MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome.	24943832	PubMed		Baliakas et al., 2015, Leukemia		2	accepted	1488	590	353	11	102201730	102207833			ENST00000263464.3					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1488	https://civic.genome.wustl.edu/links/variants/590	https://civic.genome.wustl.edu/links/genes/353
MYD88	4615	L265P	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Better Outcome	MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL.	24943832	PubMed		Baliakas et al., 2015, Leukemia		2	accepted	1489	424	3742	3	38182641	38182641	T	C	ENST00000396334.3					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/1489	https://civic.genome.wustl.edu/links/variants/424	https://civic.genome.wustl.edu/links/genes/3742
PIK3CA	5290	MUTATION	Head And Neck Squamous Cell Carcinoma	5520		Taselisib,Radiation Therapy	Combination	Predictive	Supports	D	Sensitivity/Response	A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions.	26589432	PubMed		Zumsteg et al., 2016, Clin. Cancer Res.		3	accepted	1490	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1490	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	MUTATION	Cancer	162		Ipatasertib		Predictive	Supports	D	Sensitivity/Response	IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively.	23287563	PubMed		Lin et al., 2013, Clin. Cancer Res.		3	accepted	1491	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1491	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Ovarian Cancer	2394		Cisplatin		Predictive	Supports	D	Resistance	A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.	15790433	PubMed		Lee et al., 2005, Gynecol. Oncol.		2	accepted	1492	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1492	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	LOSS	Stomach Carcinoma	5517		Chemotherapy		Predictive	Supports	B	Resistance	Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.	15900596	PubMed		Oki et al., 2005, Int. J. Cancer		2	accepted	1493	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1493	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
EZH2	2146	Y646	Skin Melanoma	8923		GSK126		Predictive	Supports	D	Sensitivity/Response	Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts). EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild-type and untransformed.	26304929	PubMed		Tiffen et al., 2015, Oncotarget		2	accepted	1494	165	63	7	148508726	148508728			ENST00000320356.2					75	GRCh37	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).	Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1494	https://civic.genome.wustl.edu/links/variants/165	https://civic.genome.wustl.edu/links/genes/63
CCND1	595	AMPLIFICATION	Skin Melanoma	8923		Carboplatin,Sorafenib,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).	26307133	PubMed		Wilson et al., 2016, Clin. Cancer Res.		2	accepted	1495	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/1495	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
RAF1	5894	AMPLIFICATION	Skin Melanoma	8923		Carboplatin,Sorafenib,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025).	26307133	PubMed		Wilson et al., 2016, Clin. Cancer Res.		2	accepted	1496	591	4767	3	12625100	12705725			ENST00000251849.4					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1496	https://civic.genome.wustl.edu/links/variants/591	https://civic.genome.wustl.edu/links/genes/4767
KRAS	3845	AMPLIFICATION	Skin Melanoma	8923		Sorafenib,Docetaxel,Carboplatin	Combination	Predictive	Supports	B	Sensitivity/Response	Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035).	26307133	PubMed		Wilson et al., 2016, Clin. Cancer Res.		2	accepted	1497	592	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1497	https://civic.genome.wustl.edu/links/variants/592	https://civic.genome.wustl.edu/links/genes/30
PDGFRB	5159	PDGFRB FUSIONS	Chronic Myeloproliferative Disease	2226		Imatinib		Predictive	Supports	A	Sensitivity/Response	Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6.	16960151	PubMed		David et al., 2007, Blood		4	accepted	1498	568	4176														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1498	https://civic.genome.wustl.edu/links/variants/568	https://civic.genome.wustl.edu/links/genes/4176
ERBB2	2064	AMPLIFICATION	Gastric Adenocarcinoma	3717		Trastuzumab		Predictive	Supports	A	Sensitivity/Response	ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.	20728210	PubMed		Bang et al., 2010, Lancet	NCT01041404	4	accepted	1499	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1499	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PTEN	5728	LOSS	Stomach Cancer	10534		Capivasertib,Docetaxel	Combination	Predictive	Supports	D	Sensitivity/Response	A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.	24088382	PubMed		Li et al., 2013, J Transl Med		1	accepted	1500	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1500	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	MUTATION	Stomach Cancer	10534		Capivasertib		Predictive	Supports	D	Sensitivity/Response	In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control.	24088382	PubMed		Li et al., 2013, J Transl Med		3	accepted	1501	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1501	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Cancer	162		Capivasertib		Predictive	Supports	D	Sensitivity/Response	In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased.	22294718	PubMed		Davies et al., 2012, Mol. Cancer Ther.		3	accepted	1502	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1502	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	MUTATION	Cancer	162		Capivasertib		Predictive	Supports	D	Sensitivity/Response	Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression.	22294718	PubMed		Davies et al., 2012, Mol. Cancer Ther.		3	accepted	1503	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1503	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Capivasertib		Predictive	Supports	D	Sensitivity/Response	HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive.	22294718	PubMed		Davies et al., 2012, Mol. Cancer Ther.		2	accepted	1504	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1504	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Her2-receptor Positive Breast Cancer	0060079		Capivasertib,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment.	22294718	PubMed		Davies et al., 2012, Mol. Cancer Ther.		3	accepted	1505	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1505	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Her2-receptor Positive Breast Cancer	0060079		Lapatinib,Capivasertib	Combination	Predictive	Supports	D	Sensitivity/Response	The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy.	22294718	PubMed		Davies et al., 2012, Mol. Cancer Ther.		3	accepted	1506	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1506	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
TP53	7157	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001).	26837699	PubMed		Nadeu et al., 2016, Blood		5	accepted	1507	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1507	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
ASXL1	171023	MUTATION	Myelofibrosis	4971				Prognostic	Supports	B	Poor Outcome	An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis.	26124496	PubMed		Patel et al., 2015, Blood		3	accepted	1508	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1508	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
NRAS	4893	MUTATION	Melanoma	1909		Binimetinib		Predictive	Supports	D	Sensitivity/Response	In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.	24588908	PubMed		Thumar et al., 2014, Mol. Cancer		3	accepted	1509	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1509	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
IDH2	3418	R172	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).  IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).  In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53aneuploidy.  Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	4	accepted	1511	199	27	15	90631837	90631839			ENST00000330062.3					75	GRCh37	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).	Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/1511	https://civic.genome.wustl.edu/links/variants/199	https://civic.genome.wustl.edu/links/genes/27
CEBPA	1050	BIALLELIC INACTIVATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.  In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53aneuploidy.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	5	accepted	1512	594	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1512	https://civic.genome.wustl.edu/links/variants/594	https://civic.genome.wustl.edu/links/genes/15
ASXL1	171023	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	5	accepted	1513	177	68	20	30946155	31027122			ENST00000375687.4					75	GRCh37	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1513	https://civic.genome.wustl.edu/links/variants/177	https://civic.genome.wustl.edu/links/genes/68
SRSF2	6427	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	5	accepted	1514	595	5210	17	74732402	74733113			ENST00000392485.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1514	https://civic.genome.wustl.edu/links/variants/595	https://civic.genome.wustl.edu/links/genes/5210
FLT3	2322	ITD	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	5	accepted	1515	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1515	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
NRAS	4893	G12/G13	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.  Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRAS (G12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	4	accepted	1516	596	36	1	115258744	115258748			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1516	https://civic.genome.wustl.edu/links/variants/596	https://civic.genome.wustl.edu/links/genes/36
CD274	29126	EXPRESSION	Cancer	162		Nivolumab		Predictive	Supports	B	Sensitivity/Response	Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.	22658127	PubMed		Topalian et al., 2012, N. Engl. J. Med.	NCT00730639	2	accepted	1517	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1517	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
RET	5979	OVEREXPRESSION	Papillary Adenocarcinoma	3112		Sunitinib		Predictive	Supports	C	Sensitivity/Response	A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment.	20696054	PubMed		Jones et al., 2010, Genome Biol.		3	accepted	1518	597	42	10	43572475	43625799			ENST00000355710.3					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1518	https://civic.genome.wustl.edu/links/variants/597	https://civic.genome.wustl.edu/links/genes/42
PML	5371	PML-RARA	Acute Promyelocytic Leukemia	0060318		Tretinoin		Predictive	Supports	C	Sensitivity/Response	A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).	21505136	PubMed		Welch et al., 2011, JAMA		3	accepted	1519	108	39	15	74287058	74325755			ENST00000268058.3	17	38504568	38513048	ENST00000254066.5	75	GRCh37	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1519	https://civic.genome.wustl.edu/links/variants/108	https://civic.genome.wustl.edu/links/genes/39
CTLA4	1493	CTLA4-CD28	Sezary's Disease	8541		Ipilimumab		Predictive	Supports	C	Sensitivity/Response	A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later.	25802883	PubMed		Sekulic et al., 2015, Mol Genet Genomic Med		2	accepted	1520	599	1285	2	204732509	204736210			ENST00000302823.3	2	204599507	204603635	ENST00000324106.8	75	GRCh37	A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1520	https://civic.genome.wustl.edu/links/variants/599	https://civic.genome.wustl.edu/links/genes/1285
AR	367	MUTATION	Prostate Cancer	10283		Cyproterone Acetate,Nilutamide,Bicalutamide,Flutamide	Substitutes	Predictive	Supports	B	Resistance	In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.   Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.  All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer.	26000489	PubMed		Robinson et al., 2015, Cell		4	accepted	1521	600	67	X	66764465	66950461			ENST00000374690.3					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1521	https://civic.genome.wustl.edu/links/variants/600	https://civic.genome.wustl.edu/links/genes/67
PTEN	5728	MUTATION	Prostate Cancer	10283		Alpelisib,Enzalutamide,PI3Kbeta Inhibitor AZD8186	Combination	Predictive	Supports	D	Sensitivity/Response	Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).  Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).  However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice).	25544636	PubMed		Schwartz et al., 2015, Cancer Cell		3	accepted	1522	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1522	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
BRCA1	672	LOSS-OF-FUNCTION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).	23569316	PubMed		Castro et al., 2013, J. Clin. Oncol.		3	accepted	1523	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1523	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).	23569316	PubMed		Castro et al., 2013, J. Clin. Oncol.		3	accepted	1524	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1524	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
NOTCH1	4851	LOSS-OF-FUNCTION	Head And Neck Squamous Cell Carcinoma	5520		Porcupine Inhibitor WNT974		Predictive	Supports	D	Sensitivity/Response	In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor).	24277854	PubMed		Liu et al., 2013, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	1525	601	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1525	https://civic.genome.wustl.edu/links/variants/601	https://civic.genome.wustl.edu/links/genes/50
CDK6	1021	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	0060075		Fulvestrant		Predictive	Supports	B	Resistance	In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.	27252418	PubMed		Alves et al., 2016, Clin. Cancer Res.		4	accepted	1526	602	12	7	92234235	92463231			ENST00000265734.4					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1526	https://civic.genome.wustl.edu/links/variants/602	https://civic.genome.wustl.edu/links/genes/12
CDK6	1021	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	0060075		Palbociclib,Fulvestrant	Combination	Predictive	Supports	D	Sensitivity/Response	Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together.	27252418	PubMed		Alves et al., 2016, Clin. Cancer Res.		2	accepted	1527	602	12	7	92234235	92463231			ENST00000265734.4					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1527	https://civic.genome.wustl.edu/links/variants/602	https://civic.genome.wustl.edu/links/genes/12
FLT3	2322	OVEREXPRESSION	B-cell Adult Acute Lymphocytic Leukemia	0060592		Sunitinib		Predictive	Supports	C	Sensitivity/Response	A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant. A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft.	27181063	PubMed		Griffith et al., 2016, Exp. Hematol.		3	accepted	1528	603	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1528	https://civic.genome.wustl.edu/links/variants/603	https://civic.genome.wustl.edu/links/genes/24
BRCA1	672	MUTATION	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.	24240112	PubMed		Pennington et al., 2014, Clin. Cancer Res.		3	accepted	1529	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1529	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.	24240112	PubMed		Pennington et al., 2014, Clin. Cancer Res.		3	accepted	1530	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1530	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	MUTATION	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.	24240112	PubMed		Pennington et al., 2014, Clin. Cancer Res.		3	accepted	1531	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1531	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.	24240112	PubMed		Pennington et al., 2014, Clin. Cancer Res.		3	accepted	1532	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1532	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
GNAQ	2776	Q209P	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	C	Resistance	A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.	24504448	PubMed		Turajlic et al., 2014, Ann. Oncol.		2	accepted	1533	604	2317	9	80409488	80409488	T	G	ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1533	https://civic.genome.wustl.edu/links/variants/604	https://civic.genome.wustl.edu/links/genes/2317
PTEN	5728	V317FS	Skin Melanoma	8923		Akt Inhibitor MK2206,MEK Inhibitor CI-1040	Combination	Predictive	Supports	D	Sensitivity/Response	A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy. The other copy of PTEN was lost with a chromosome-wide loss of chr 10. Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD184352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line. ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient. This cell line showed overexpression of AKT and no expression of PTEN.	24504448	PubMed		Turajlic et al., 2014, Ann. Oncol.		3	accepted	1534	605	41	10	89720799	89720802	TACT		ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1534	https://civic.genome.wustl.edu/links/variants/605	https://civic.genome.wustl.edu/links/genes/41
RB1	5925	LOSS-OF-FUNCTION	Breast Cancer	1612		Palbociclib		Predictive	Supports	D	Resistance	In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991). In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib. Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments.  In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild-type Rb cells maintained sensitivity.	20473330	PubMed		Dean et al., 2010, Oncogene		3	accepted	1535	606	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1535	https://civic.genome.wustl.edu/links/variants/606	https://civic.genome.wustl.edu/links/genes/4795
CCND1	595	OVEREXPRESSION	Mantle Cell Lymphoma	0050746		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated.	22383795	PubMed		Leonard et al., 2012, Blood	NCT00420056	2	accepted	1536	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1536	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
GNAQ	2776	Q209P	Skin Melanoma	8923		PLX4720		Predictive	Supports	D	Resistance	Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.	24504448	PubMed		Turajlic et al., 2014, Ann. Oncol.		3	accepted	1537	604	2317	9	80409488	80409488	T	G	ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1537	https://civic.genome.wustl.edu/links/variants/604	https://civic.genome.wustl.edu/links/genes/2317
NOTCH1	4851	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049). Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis).	26837699	PubMed		Nadeu et al., 2016, Blood		5	accepted	1538	206	50	9	139388896	139440314			ENST00000277541.6					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1538	https://civic.genome.wustl.edu/links/variants/206	https://civic.genome.wustl.edu/links/genes/50
ATM	472	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021). These mutations were not significantly associated with overall survival.	26837699	PubMed		Nadeu et al., 2016, Blood		5	accepted	1539	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1539	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
SF3B1	23451	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031). While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22).	26837699	PubMed		Nadeu et al., 2016, Blood		5	accepted	1540	215	44	2	198254508	198299815			ENST00000335508.6					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1540	https://civic.genome.wustl.edu/links/variants/215	https://civic.genome.wustl.edu/links/genes/44
ESR1	2099	OVEREXPRESSION	Breast Cancer	1612		Letrozole,Palbociclib	Combination	Predictive	Supports	B	Sensitivity/Response	A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone. The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004). A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months.  Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%).	25524798	PubMed		Finn et al., 2015, Lancet Oncol.	NCT00721409	4	accepted	1541	607	21	6	152128686	152424406			ENST00000206249.3					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1541	https://civic.genome.wustl.edu/links/variants/607	https://civic.genome.wustl.edu/links/genes/21
IDH2	3418	R140	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	In patients with acute myeloid leukemia, the presence of IDH2 R140Q (n=7), IDH2 R172K (n=3) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients overall (N=102; P=0.177). IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004). IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484).	21997850	PubMed		Lin et al., 2012, Ann. Hematol.		2	accepted	1542	62	27	15	90631934	90631934			ENST00000330062.3					75	GRCh37	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/1542	https://civic.genome.wustl.edu/links/variants/62	https://civic.genome.wustl.edu/links/genes/27
MTOR	2475	F2108L	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.	27279227	PubMed		Rodrik-Outmezguine et al., 2016, Nature		4	accepted	1543	470	2073	1	11187094	11187094	G	T	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1543	https://civic.genome.wustl.edu/links/variants/470	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	M2327I	Breast Cancer	1612		MTOR Kinase Inhibitor AZD8055		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.	27279227	PubMed		Rodrik-Outmezguine et al., 2016, Nature		4	accepted	1544	609	2073	1	11177096	11177096	C	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1544	https://civic.genome.wustl.edu/links/variants/609	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	M2327I	Breast Cancer	1612		RapaLink-1,Sirolimus	Substitutes	Predictive	Does Not Support	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.	27279227	PubMed		Rodrik-Outmezguine et al., 2016, Nature		3	accepted	1545	609	2073	1	11177096	11177096	C	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1545	https://civic.genome.wustl.edu/links/variants/609	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	A2034V	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.	27279227	PubMed		Rodrik-Outmezguine et al., 2016, Nature		4	accepted	1547	610	2073	1	11187796	11187796	G	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1547	https://civic.genome.wustl.edu/links/variants/610	https://civic.genome.wustl.edu/links/genes/2073
MTOR	2475	A2034V	Breast Cancer	1612		RapaLink-1,MTOR Kinase Inhibitor AZD8055	Substitutes	Predictive	Does Not Support	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.	27279227	PubMed		Rodrik-Outmezguine et al., 2016, Nature		4	accepted	1548	610	2073	1	11187796	11187796	G	A	ENST00000361445.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1548	https://civic.genome.wustl.edu/links/variants/610	https://civic.genome.wustl.edu/links/genes/2073
PIK3CA	5290	E542K	Head And Neck Squamous Cell Carcinoma	5520		Apitolisib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation.	26787751	PubMed		Dolly et al., 2016, Clin. Cancer Res.		2	accepted	1549	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1549	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Cancer	162		Apitolisib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses.	26787751	PubMed		Dolly et al., 2016, Clin. Cancer Res.		1	accepted	1550	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1550	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	D594G	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors. The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild-type and BRAF V600E survival, p = 0.015 comparing BRAF wild-type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.  There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed.	27404270	PubMed		Amaki-Takao et al., 2016, Oncology		1	accepted	1551	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1551	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001).	27404270	PubMed		Amaki-Takao et al., 2016, Oncology		3	accepted	1552	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1552	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594G	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152).	27404270	PubMed		Amaki-Takao et al., 2016, Oncology		2	accepted	1553	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1553	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594G	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Does Not Support	C	Resistance	Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.	27404270	PubMed		Amaki-Takao et al., 2016, Oncology		1	accepted	1554	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1554	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	C	Sensitivity/Response	Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment.	23969938	PubMed		Baker et al., 2013, Clin. Cancer Res.		1	accepted	1555	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1555	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835H	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	C	Resistance	Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability	23969938	PubMed		Baker et al., 2013, Clin. Cancer Res.		3	accepted	1556	612	24	13	28592642	28592642	C	G	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1556	https://civic.genome.wustl.edu/links/variants/612	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835H/Y	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	D	Resistance	Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.  Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).  Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM).	23969938	PubMed		Baker et al., 2013, Clin. Cancer Res.		1	accepted	1557	613	24	13	28592642	28592642	C	G/A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1557	https://civic.genome.wustl.edu/links/variants/613	https://civic.genome.wustl.edu/links/genes/24
RUNX1	861	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001).	27137476	PubMed		Gaidzik et al., 2016, Leukemia		3	accepted	1558	155	43	21	36160098	36421641			ENST00000300305.3					75	GRCh37	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.	Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1558	https://civic.genome.wustl.edu/links/variants/155	https://civic.genome.wustl.edu/links/genes/43
CCND1	595	AMPLIFICATION	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Does Not Support	D	Sensitivity/Response	28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348).	23898052	PubMed		Logan et al., 2013, Anticancer Res.		2	accepted	1560	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/1560	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab,Palbociclib	Combination	Predictive	Supports	D	Sensitivity/Response	In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.	19874578	PubMed		Finn et al., 2009, Breast Cancer Res.		2	accepted	1561	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1561	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
CCND1	595	AMPLIFICATION	Breast Cancer	1612		Palbociclib		Predictive	Supports	D	Sensitivity/Response	A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines.	19874578	PubMed		Finn et al., 2009, Breast Cancer Res.		2	accepted	1562	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/1562	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
CCND1	595	OVEREXPRESSION	Mantle Cell Lymphoma	0050746		Palbociclib		Predictive	Supports	D	Sensitivity/Response	In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL.	16690963	PubMed		Marzec et al., 2006, Blood		1	accepted	1563	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1563	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
ATM	472	UNDEREXPRESSION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels.	9788599	PubMed		Starostik et al., 1998, Cancer Res.		3	accepted	1564	179	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		N/A	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/1564	https://civic.genome.wustl.edu/links/variants/179	https://civic.genome.wustl.edu/links/genes/69
MET	4233	AMPLIFICATION	Glioblastoma Multiforme	3068		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM.	22162573	PubMed		Chi et al., 2012, J. Clin. Oncol.		3	accepted	1565	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1565	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
MET	4233	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Sensitivity/Response	2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect.	21716144	PubMed		Tanizaki et al., 2011, J Thorac Oncol		4	accepted	1566	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1566	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
JAK1	3716	Q503*	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1). A JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.	27433843	PubMed		Zaretsky et al., 2016, N. Engl. J. Med.		4	accepted	1567	614	3090	1	65321333	65321333	G	A	ENST00000342505.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1567	https://civic.genome.wustl.edu/links/variants/614	https://civic.genome.wustl.edu/links/genes/3090
JAK2	3717	c.1641+1dup	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2. RNA sequencing revealed an in-frame stop codon after exon 12. The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2. Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein. This loss of response was also modeled in another cell line.	27433843	PubMed		Zaretsky et al., 2016, N. Engl. J. Med.		4	accepted	1568	615	28	9	5070053	5070054		G	ENST00000381652.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/1568	https://civic.genome.wustl.edu/links/variants/615	https://civic.genome.wustl.edu/links/genes/28
B2M	567	S14FS	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization.	27433843	PubMed		Zaretsky et al., 2016, N. Engl. J. Med.		3	accepted	1569	616	537	15	45003786	45003789	TCTT		ENST00000558401.1					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1569	https://civic.genome.wustl.edu/links/variants/616	https://civic.genome.wustl.edu/links/genes/537
BRAF	673	PPFIBP2-BRAF	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect.	26072686	PubMed		Menzies et al., 2015, Pigment Cell Melanoma Res		2	accepted	1570	617	5	11	7535001	7586998			ENST00000299492.4	7	140434279	140481493	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1570	https://civic.genome.wustl.edu/links/variants/617	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	KIAA1549-BRAF	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted.	26072686	PubMed		Menzies et al., 2015, Pigment Cell Melanoma Res		1	accepted	1571	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1571	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	EXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001).	18003960	PubMed		Jonker et al., 2007, N. Engl. J. Med.	NCT00079066	4	accepted	1572	354	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1572	https://civic.genome.wustl.edu/links/variants/354	https://civic.genome.wustl.edu/links/genes/19
PTGS2	5743	OVEREXPRESSION	Colorectal Cancer	9256		Aspirin		Predictive	Supports	B	Sensitivity/Response	Mail-in surveys conducted every two years since 1980 evaluated 82,911 woman and 47,363 men for regular aspirin use.  In this cohort, aspirin use was associated with a lower relative risk of colorectal cancer (RR=0.73; 95% CI 0.69-0.87; p<0.001).  Immunohistochemical analysis was employed on a subset of 636 cases to evaluate COX2 overexpression.  Of these tumors, 67% had moderate or strong COX2 expression and 33% had weak or absent COX-2 expression.  In tumors with COX-2 overexpression, regular aspirin use conferred significant risk reduction of colorectal cancer (RR=0.64; 95%CI 0.52-0.78) however, in tumors with reduced COX2 expression, aspirin use had no influence on colorectal cancer incidence (RR=0.96, 95%CI 0.73-1.26).	17522398	PubMed		Chan et al., 2007, N. Engl. J. Med.		3	accepted	1573	619	4659	1	186640923	186649559			ENST00000367468.5					75	GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/1573	https://civic.genome.wustl.edu/links/variants/619	https://civic.genome.wustl.edu/links/genes/4659
BRAF	673	V600	Lung Non-small Cell Carcinoma	3908		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%.	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	3	accepted	1574	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1574	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Langerhans-Cell Histiocytosis	2571		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 14 patients with Langerhans-cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%. Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation.	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	3	accepted	1575	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1575	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	B	Resistance	Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months.	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	3	accepted	1576	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1576	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001).	26466010	PubMed		2015, N. Engl. J. Med.		3	accepted	1577	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1577	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
CD274	29126	EXPRESSION	Merkel Cell Carcinoma	3965		Pembrolizumab		Predictive	Does Not Support	B	Sensitivity/Response	Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).	27093365	PubMed		Nghiem et al., 2016, N. Engl. J. Med.	NCT02267603	2	accepted	1578	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1578	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
BRAF	673	V600E	Hairy Cell Leukemia	285		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.	26352686	PubMed		Tiacci et al., 2015, N. Engl. J. Med.	NCT01711632	2	accepted	1579	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1579	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	G12D	Hairy Cell Leukemia	285		Vemurafenib		Predictive	Supports	C	Resistance	One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patients genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).	26352686	PubMed		Tiacci et al., 2015, N. Engl. J. Med.	NCT01711632	2	accepted	1580	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1580	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
MET	4233	OVEREXPRESSION	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	B	Resistance	Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed. 39% of resistant melanomas were not accounted for by any validated mutational mechanism. c-MET was overexpressed in 21 of 48 (44%) resistant samples. Methylome analysis revealed three CpG clusters (C13) with differential methylation to be negatively correlated with differential c-MET mRNA expression. In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation (  10% and FDR adjusted p  0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor. In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients. In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors.	26359985	PubMed		Hugo et al., 2015, Cell		4	accepted	1581	621	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1581	https://civic.genome.wustl.edu/links/variants/621	https://civic.genome.wustl.edu/links/genes/52
MET	4233	OVEREXPRESSION	Uveal Melanoma	6039		Crizotinib		Predictive	Supports	D	Sensitivity/Response	c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03).	24140933	PubMed		Surriga et al., 2013, Mol. Cancer Ther.		1	accepted	1583	621	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1583	https://civic.genome.wustl.edu/links/variants/621	https://civic.genome.wustl.edu/links/genes/52
MET	4233	OVEREXPRESSION	Skin Melanoma	8923		Vemurafenib		Predictive	Does Not Support	B	Resistance	FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET expression was frequent at the 1 + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the 2 + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival.	23802768	PubMed		Jubb et al., 2013, Histopathology		3	accepted	1584	621	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1584	https://civic.genome.wustl.edu/links/variants/621	https://civic.genome.wustl.edu/links/genes/52
DNMT3A	1788	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age.	27288520	PubMed		Metzeler et al., 2016, Blood		4	accepted	1585	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1585	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations.	27276561	PubMed		Papaemmanuil et al., 2016, N. Engl. J. Med.	NCT00146120	4	accepted	1586	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1586	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
DNMT3A	1788	MUTATION	Acute Myeloid Leukemia	9119		Decitabine		Predictive	Supports	B	Sensitivity/Response	Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)	22124213	PubMed		Metzeler et al., 2012, Leukemia		3	accepted	1587	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1587	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
MET	4233	AMPLIFICATION	Colorectal Cancer	9256		Vemurafenib,Crizotinib	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues. Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro. The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity.	27325282	PubMed		Pietrantonio et al., 2016, Cancer Discov		4	accepted	1588	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1588	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib,Panitumumab	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.	27325282	PubMed		Pietrantonio et al., 2016, Cancer Discov		2	accepted	1589	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1589	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
POT1	25913	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin.	27226433	PubMed		Herling et al., 2016, Blood		3	accepted	1590	623	9935	7	124462440	124570035			ENST00000357628.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1590	https://civic.genome.wustl.edu/links/variants/623	https://civic.genome.wustl.edu/links/genes/9935
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors. 51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months. In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.	27460442	PubMed		Brose et al., 2016, Lancet Oncol.	NCT01286753	3	accepted	1591	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1591	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	A	Sensitivity/Response	Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.	26729184	PubMed		Greig, 2016, Drugs		5	accepted	1592	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1592	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
MKI67	4288	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%.	26341751	PubMed		Petrelli et al., 2015, Breast Cancer Res. Treat.		4	accepted	1593	624	3529	10	129894923	129924649			ENST00000368654.3					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1593	https://civic.genome.wustl.edu/links/variants/624	https://civic.genome.wustl.edu/links/genes/3529
MKI67	4288	EXPRESSION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%. Primary endpoint was death due to prostate cancer. A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78.	23329234	PubMed		Fisher et al., 2013, Br. J. Cancer		3	accepted	1594	624	3529	10	129894923	129924649			ENST00000368654.3					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1594	https://civic.genome.wustl.edu/links/variants/624	https://civic.genome.wustl.edu/links/genes/3529
RB1	5925	LOSS-OF-FUNCTION	Glioblastoma Multiforme	3068		Palbociclib		Predictive	Supports	D	Resistance	A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb. Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb. shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance.	20354191	PubMed		Michaud et al., 2010, Cancer Res.		3	accepted	1595	606	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1595	https://civic.genome.wustl.edu/links/variants/606	https://civic.genome.wustl.edu/links/genes/4795
KRAS	3845	MUTATION	Pseudomyxoma Peritonei	3559				Prognostic	Supports	B	Poor Outcome	40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.	27502722	PubMed		Pietrantonio et al., 2016, Ann. Oncol.		3	accepted	1596	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1596	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
RAD23B	5887	EXPRESSION	Sarcoma	1115		Vorinostat		Predictive	Supports	D	Sensitivity/Response	Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST.	27499916	PubMed		Angelika Ihle et al., 2016, J Pathol Clin Res		2	accepted	1597	625	4760	9	110045560	110094475			ENST00000358015.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1597	https://civic.genome.wustl.edu/links/variants/625	https://civic.genome.wustl.edu/links/genes/4760
BRAF	673	V600	Colorectal Cancer	9256		Cetuximab,Vemurafenib	Combination	Predictive	Does Not Support	B	Sensitivity/Response	Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six).	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	2	accepted	1598	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1598	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
CCND1	595	AMPLIFICATION	Ovarian Cancer	2394		Palbociclib		Predictive	Does Not Support	D	Sensitivity/Response	A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).	21278246	PubMed		Konecny et al., 2011, Clin. Cancer Res.		3	accepted	1599	18	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	Somatic	2021-03-31 18:22:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/1599	https://civic.genome.wustl.edu/links/variants/18	https://civic.genome.wustl.edu/links/genes/8
PIK3CA	5290	MUTATION	Breast Cancer	1612		Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone.	25002028	PubMed		Vora et al., 2014, Cancer Cell	NCT01219699	4	accepted	1600	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1600	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
RET	5979	CCDC6-RET	Lung Non-small Cell Carcinoma	3908		Nintedanib		Predictive	Supports	C	Sensitivity/Response	Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial. Docetaxel was discontinued after 22 cycles because of edema and fatigue. A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013. Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH).	26787234	PubMed		Takeda et al., 2016, Ann. Oncol.		2	accepted	1601	626	42														Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1601	https://civic.genome.wustl.edu/links/variants/626	https://civic.genome.wustl.edu/links/genes/42
MAP2K1	5604	C121S	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Resistance	A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.	21383288	PubMed		Wagle et al., 2011, J. Clin. Oncol.		4	accepted	1602	627	31	15	66729154	66729154	G	C	ENST00000307102.5					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1602	https://civic.genome.wustl.edu/links/variants/627	https://civic.genome.wustl.edu/links/genes/31
FGFR3	2261	S249C	Transitional Cell Carcinoma	2671		Pazopanib		Predictive	Supports	C	Sensitivity/Response	Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.	25766722	PubMed		Palma et al., 2015, Eur. Urol.		2	accepted	1603	628	23	4	1803568	1803568	C	G	ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1603	https://civic.genome.wustl.edu/links/variants/628	https://civic.genome.wustl.edu/links/genes/23
FGFR1	2260	AMPLIFICATION	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.	23658459	PubMed		Andr et al., 2013, Clin. Cancer Res.		2	accepted	1604	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	N/A	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1604	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR2	2263	AMPLIFICATION	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.	23658459	PubMed		Andr et al., 2013, Clin. Cancer Res.		2	accepted	1605	629	22	10	123239371	123357917			ENST00000457416.2					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1605	https://civic.genome.wustl.edu/links/variants/629	https://civic.genome.wustl.edu/links/genes/22
FGF3	2248	AMPLIFICATION	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative).	23658459	PubMed		Andr et al., 2013, Clin. Cancer Res.		2	accepted	1606	630	1873	11	69624992	69633792			ENST00000334134.2					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1606	https://civic.genome.wustl.edu/links/variants/630	https://civic.genome.wustl.edu/links/genes/1873
PIK3CA	5290	MUTATION	Breast Cancer	1612		Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines.	25002028	PubMed		Vora et al., 2014, Cancer Cell	NCT01219699	3	accepted	1607	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1607	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
VHL	7428	R200W (c.598C>T)	Chuvash Polycythemia	0060474	Polycythemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.	27518686	PubMed		Zhou et al., 2016, N. Engl. J. Med.		4	accepted	1608	631	58	3	10191605	10191605	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1608	https://civic.genome.wustl.edu/links/variants/631	https://civic.genome.wustl.edu/links/genes/58
RB1	5925	PHOSPHORYLATION	Breast Cancer	1612		Alpelisib		Predictive	Supports	B	Resistance	The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression.	25002028	PubMed		Vora et al., 2014, Cancer Cell	NCT01219699	3	accepted	1609	632	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1609	https://civic.genome.wustl.edu/links/variants/632	https://civic.genome.wustl.edu/links/genes/4795
PIK3CA	5290	MUTATION	Breast Cancer	1612		Everolimus,MTOR Kinase Inhibitor PP242	Substitutes	Predictive	Supports	D	Sensitivity/Response	A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.	21358673	PubMed		Weigelt et al., 2011, Oncogene		3	accepted	1610	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1610	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Breast Cancer	1612		MTOR Kinase Inhibitor PP242,Everolimus	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.	21358673	PubMed		Weigelt et al., 2011, Oncogene		3	accepted	1611	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1611	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PIK3R1	5295	MUTATION	Breast Cancer	1612		MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1. Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242. Approximately 70% of PIK3CA wild type lines were not sensitive to PP242. This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition.	21358673	PubMed		Weigelt et al., 2011, Oncogene		2	accepted	1612	633	4289	5	67511548	67597649			ENST00000521381.1					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1612	https://civic.genome.wustl.edu/links/variants/633	https://civic.genome.wustl.edu/links/genes/4289
ERBB2	2064	AMPLIFICATION	Breast Cancer	1612		MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.	21358673	PubMed		Weigelt et al., 2011, Oncogene		2	accepted	1613	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1613	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PTEN	5728	LOSS	Endometrial Cancer	1380		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. .	23674493	PubMed		Weigelt et al., 2013, Clin. Cancer Res.		3	accepted	1614	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1614	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
CD274	29126	EXPRESSION	Melanoma	1909		Ipilimumab,Nivolumab	Combination	Predictive	Does Not Support	B	Sensitivity/Response	A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).	23724867	PubMed		Wolchok et al., 2013, N. Engl. J. Med.	NCT01024231	3	accepted	1615	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1615	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
PIK3CA	5290	MUTATION	Endometrial Cancer	1380		Pictilisib		Predictive	Supports	D	Sensitivity/Response	A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fishers exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity.	23674493	PubMed		Weigelt et al., 2013, Clin. Cancer Res.		3	accepted	1616	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1616	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
STK11	6794	D194E	Pancreatic Cancer	1793		Everolimus		Predictive	Supports	C	Sensitivity/Response	Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.	21189378	PubMed		Klmpen et al., 2011, J. Clin. Oncol.		2	accepted	1617	634	5534	19	1220489	1220489	C	A	ENST00000326873.7					75	GRCh37		Rare Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1617	https://civic.genome.wustl.edu/links/variants/634	https://civic.genome.wustl.edu/links/genes/5534
STK11	6794	LOSS	Peutz-Jeghers Syndrome	3852		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamycin treatment significantly suppressed polyposis (p=0.017) and pS6 staining (IHC, p=0.011).	18281551	PubMed		Wei et al., 2008, Clin. Cancer Res.		1	accepted	1618	485	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Rare Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1618	https://civic.genome.wustl.edu/links/variants/485	https://civic.genome.wustl.edu/links/genes/5534
STK11	6794	LOSS	Peutz-Jeghers Syndrome	3852		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin treatment. Rapamycin treatment abolished FDG-PET signal on imaging.	19541609	PubMed		Shackelford et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	1619	485	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Rare Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1619	https://civic.genome.wustl.edu/links/variants/485	https://civic.genome.wustl.edu/links/genes/5534
STK11	6794	LOSS	Lung Non-small Cell Carcinoma	3908		Sirolimus,Everolimus	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.	26027660	PubMed		Xiao et al., 2015, Acta Pharmacol. Sin.		3	accepted	1620	485	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1620	https://civic.genome.wustl.edu/links/variants/485	https://civic.genome.wustl.edu/links/genes/5534
AKT2	208	AMPLIFICATION	Lung Adenocarcinoma	3910		Vandetanib,Everolimus	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.	25982012	PubMed		Subbiah et al., 2015, Lung Cancer	NCT01582191	1	accepted	1621	635	254	19	40736224	40791302			ENST00000392038.2					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1621	https://civic.genome.wustl.edu/links/variants/635	https://civic.genome.wustl.edu/links/genes/254
RET	5979	KIF5B-RET	Lung Adenocarcinoma	3910		Everolimus,Vandetanib	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.	25982012	PubMed		Subbiah et al., 2015, Lung Cancer	NCT01582191	2	accepted	1622	273	42	10	32306071	32345359			ENST00000302418.4	10	43609928	43625799	ENST00000355710.3	75	GRCh37	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)	Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1622	https://civic.genome.wustl.edu/links/variants/273	https://civic.genome.wustl.edu/links/genes/42
PIK3CA	5290	H1047R	Her2-receptor Positive Breast Cancer	0060079		Everolimus,Fulvestrant	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).	27445490	PubMed		Sun et al., 2016, Onco Targets Ther		2	accepted	1623	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1623	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	EXPRESSION	Her2-receptor Positive Breast Cancer	0060079		Fulvestrant,Everolimus	Combination	Predictive	Supports	C	Resistance	Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).	27445490	PubMed		Sun et al., 2016, Onco Targets Ther		1	accepted	1624	313	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1624	https://civic.genome.wustl.edu/links/variants/313	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	H1047R	Thyroid Cancer	1781		Temsirolimus,Perifosine	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation.	19706758	PubMed		Liu et al., 2009, Cancer Res.		3	accepted	1625	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1625	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E542K	Thyroid Cancer	1781		Temsirolimus,Perifosine	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector	19706758	PubMed		Liu et al., 2009, Cancer Res.		3	accepted	1626	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1626	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	R130*	Thyroid Cancer	1781		Perifosine,Temsirolimus	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model.	19706758	PubMed		Liu et al., 2009, Cancer Res.		2	accepted	1627	636	41	10	89692904	89692904	C	T	ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1627	https://civic.genome.wustl.edu/links/variants/636	https://civic.genome.wustl.edu/links/genes/41
FBXW7	55294	LOSS-OF-FUNCTION	Renal Cell Carcinoma	4450		Everolimus		Predictive	Supports	E	Sensitivity/Response	mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels. It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors.	24253377	PubMed		Okazaki et al., 2014, Cancer Res.		2	accepted	1628	637	12903	4	153242410	153457253			ENST00000281708.4					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1628	https://civic.genome.wustl.edu/links/variants/637	https://civic.genome.wustl.edu/links/genes/12903
CCNE1	898	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	0060075		Palbociclib		Predictive	Supports	D	Resistance	Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 mol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib.	27020857	PubMed		Herrera-Abreu et al., 2016, Cancer Res.		3	accepted	1629	187	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1629	https://civic.genome.wustl.edu/links/variants/187	https://civic.genome.wustl.edu/links/genes/11
RB1	5925	M695FS*26	Estrogen-receptor Positive Breast Cancer	0060075		Palbociclib		Predictive	Supports	D	Resistance	Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244. Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26).	27020857	PubMed		Herrera-Abreu et al., 2016, Cancer Res.		2	accepted	1630	638	4795	13	49033946	49033947		A	ENST00000267163.4					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1630	https://civic.genome.wustl.edu/links/variants/638	https://civic.genome.wustl.edu/links/genes/4795
FBXW7	55294	MUTATION	Cancer	162		MTOR Inhibitor		Predictive	Supports	B	Sensitivity/Response	418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks.	24586741	PubMed		Jardim et al., 2014, PLoS ONE		2	accepted	1631	281	12903	4	153245446	153332714			ENST00000281708.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1631	https://civic.genome.wustl.edu/links/variants/281	https://civic.genome.wustl.edu/links/genes/12903
FBXW7	55294	LOSS-OF-FUNCTION	Cancer	162		Sirolimus		Predictive	Supports	D	Sensitivity/Response	FBXW7 was shown to target mTOR for ubiquitination and degradation.  A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).  In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7). Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin. In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway.	18787170	PubMed		Mao et al., 2008, Science		4	accepted	1632	637	12903	4	153242410	153457253			ENST00000281708.4					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1632	https://civic.genome.wustl.edu/links/variants/637	https://civic.genome.wustl.edu/links/genes/12903
JUN	3725	OVEREXPRESSION	Colorectal Adenocarcinoma	0050861		Irbesartan		Predictive	Supports	C	Sensitivity/Response	A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.	27022066	PubMed		Jones et al., 2016, Ann. Oncol.		2	accepted	1633	639	3094	1	59246465	59249785			ENST00000371222.2					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1633	https://civic.genome.wustl.edu/links/variants/639	https://civic.genome.wustl.edu/links/genes/3094
FOS	2353	OVEREXPRESSION	Colon Adenocarcinoma	234		Irbesartan		Predictive	Supports	C	Sensitivity/Response	A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.	27022066	PubMed		Jones et al., 2016, Ann. Oncol.		2	accepted	1634	640	1955	14	75745477	75748933			ENST00000303562.4					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1634	https://civic.genome.wustl.edu/links/variants/640	https://civic.genome.wustl.edu/links/genes/1955
CDKN2A	1029	RS3814960	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.335.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.304.61, P = 0.005) compared to patients without this mutation.	27414035	PubMed		Li et al., 2016, PLoS ONE		3	accepted	1635	641	14	9	21975017	21975017	C	T	ENST00000498124.1					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1635	https://civic.genome.wustl.edu/links/variants/641	https://civic.genome.wustl.edu/links/genes/14
MDM2	4193	RS34886328	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Better Outcome	124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.130.56, P = 4.7104, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.110.43, P < .0001) when compared to patients without this mutation.	27414035	PubMed		Li et al., 2016, PLoS ONE		2	accepted	1636	642	3465	12	69234988	69234988	A		ENST00000462284.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1636	https://civic.genome.wustl.edu/links/variants/642	https://civic.genome.wustl.edu/links/genes/3465
CBLB	868	RS2305035	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466).  Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome compared to wildtype however, rs2305035 A genotype  (A/A or A/G) had better local recurrence-free survival, metastasis-free survival and overall survival when compared to GG genotype (n=186).	26732495	PubMed		Li et al., 2016, Clin Lung Cancer		2	accepted	1637	643	779	3	105439026	105439026	G	A	ENST00000264122.4					75	GRCh37		Common Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1637	https://civic.genome.wustl.edu/links/variants/643	https://civic.genome.wustl.edu/links/genes/779
PRDM1	639	MUTATION	Diffuse Large B-cell Lymphoma	0050745				Prognostic	Supports	B	Poor Outcome	Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression. Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1.	27568520	PubMed		Xia et al., 2016, Leukemia		2	accepted	1638	644	593	6	106534195	106557813			ENST00000369096.4					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1638	https://civic.genome.wustl.edu/links/variants/644	https://civic.genome.wustl.edu/links/genes/593
IDH1	3417	MUTATION	Brain Glioma	0060108				Prognostic	Supports	B	Better Outcome	Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	26061751	PubMed		2015, N. Engl. J. Med.		3	accepted	1639	645	26	2	209101803	209116275			ENST00000415913.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1639	https://civic.genome.wustl.edu/links/variants/645	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	MUTATION	Brain Glioma	0060108				Prognostic	Supports	B	Better Outcome	Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	26061751	PubMed		2015, N. Engl. J. Med.		3	accepted	1640	570	27	15	90626277	90645736			ENST00000330062.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1640	https://civic.genome.wustl.edu/links/variants/570	https://civic.genome.wustl.edu/links/genes/27
MYD88	4615	L265P	Waldenstrm's Macroglobulinemia	0060901		IRAK-1/4 Inhibitor,IMG-2005-5	Substitutes	Predictive	Supports	D	Sensitivity/Response	In a study of 30 patients with Waldenstrms macroglobulinemia, 87% had MYD88(L265P) mutations.  Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.  The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation.	22931316	PubMed		Treon et al., 2012, N. Engl. J. Med.		1	accepted	1641	424	3742	3	38182641	38182641	T	C	ENST00000396334.3					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/1641	https://civic.genome.wustl.edu/links/variants/424	https://civic.genome.wustl.edu/links/genes/3742
KRAS	3845	MUTATION	Hepatocellular Carcinoma	684		Sorafenib,Refametinib	Combination	Predictive	Supports	B	Sensitivity/Response	Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.	25294897	PubMed		Lim et al., 2014, Clin. Cancer Res.	NCT01204177	2	accepted	1642	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1642	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
PRKACA	5566	DNAJB1-PRKACA	Mixed Fibrolamellar Hepatocellular Carcinoma	0080182				Diagnostic	Supports	C	Positive	A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples.	27029710	PubMed		Griffith et al., 2016, Ann. Oncol.		4	accepted	1643	31	17	19	14628951	14629232			ENST00000254322.2	19	14202500	14218221	ENST00000308677.4	75	GRCh37	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/1643	https://civic.genome.wustl.edu/links/variants/31	https://civic.genome.wustl.edu/links/genes/17
SMAD4	4089	DELETION	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056).	12237773	PubMed		Boulay et al., 2002, Br. J. Cancer		3	accepted	1644	646	77	18	48556583	48611409			ENST00000342988.3					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1644	https://civic.genome.wustl.edu/links/variants/646	https://civic.genome.wustl.edu/links/genes/77
LRP1B	53353	DELETION	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Poor Outcome	A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001). Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio.	26428308	PubMed		Tabouret et al., 2015, J. Neurol. Sci.		4	accepted	1645	647	12146	2	140988992	142889270			ENST00000389484.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1645	https://civic.genome.wustl.edu/links/variants/647	https://civic.genome.wustl.edu/links/genes/12146
TERT	7015	C228T	Thyroid Cancer	1781				Diagnostic	Supports	B	Positive	In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations. The biomarker displayed 100% diagnostic specificity and 7% sensitivity.	25121551	PubMed		Liu et al., 2014, Endocr. Relat. Cancer		3	accepted	1646	248	79	5	1295228	1295228	G	A	ENST00000310581.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/1646	https://civic.genome.wustl.edu/links/variants/248	https://civic.genome.wustl.edu/links/genes/79
ATRX	546	UNDEREXPRESSION	Astrocytoma	3069		Vincristine,Temozolomide,Procarbazine,Lomustine	Substitutes	Predictive	Supports	B		A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038).	23904111	PubMed		Wiestler et al., 2013, Acta Neuropathol.		3	accepted	1647	648	525	X	76760356	77041702			ENST00000373344.5					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1647	https://civic.genome.wustl.edu/links/variants/648	https://civic.genome.wustl.edu/links/genes/525
ATRX	546	UNDEREXPRESSION	Glioblastoma Multiforme	3068				Prognostic	Supports	D	Poor Outcome	In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at earlier time points. ATRX loss was also associated with greater microsatellite instability.	26936505	PubMed		Koschmann et al., 2016, Sci Transl Med		4	accepted	1648	648	525	X	76760356	77041702			ENST00000373344.5					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1648	https://civic.genome.wustl.edu/links/variants/648	https://civic.genome.wustl.edu/links/genes/525
CALR	811	EXON 9 FRAMESHIFT	Myelofibrosis	4971				Prognostic	Supports	B	Better Outcome	In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.510.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.54.0, N=169). These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization. These results were also validated in an independent cohort of 293 patients.	24496303	PubMed		Tefferi et al., 2014, Leukemia		4	accepted	1649	559	732	19	13054527	13054727			ENST00000316448.5					75	GRCh37	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.	Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1649	https://civic.genome.wustl.edu/links/variants/559	https://civic.genome.wustl.edu/links/genes/732
AURKA	6790	OVEREXPRESSION	Ovarian Serous Carcinoma	0050933		Platinum Compound		Predictive	Supports	B	Resistance	A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P=0.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tumor samples.	27209210	PubMed		Mignogna et al., 2016, J Ovarian Res		3	accepted	1650	181	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1650	https://civic.genome.wustl.edu/links/variants/181	https://civic.genome.wustl.edu/links/genes/61
MET	4233	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.	26845194	PubMed		Shea et al., 2016, J Thorac Oncol		2	accepted	1651	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/1651	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
MET	4233	D1228N	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.	27343442	PubMed		Heist et al., 2016, J Thorac Oncol		2	accepted	1652	649	52	7	116423407	116423407	G	A	ENST00000397752.3					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1652	https://civic.genome.wustl.edu/links/variants/649	https://civic.genome.wustl.edu/links/genes/52
AURKA	6790	EXPRESSION	Esophagus Squamous Cell Carcinoma	3748		Cisplatin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003).	25924824	PubMed		Tamotsu et al., 2015, BMC Cancer		3	accepted	1653	158	61	20	54944446	54967393			ENST00000395913.3					75	GRCh37		N/A	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/1653	https://civic.genome.wustl.edu/links/variants/158	https://civic.genome.wustl.edu/links/genes/61
CASP8	841	D302H	Neuroblastoma	769				Prognostic	Supports	B	Poor Outcome	21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0.049) and worse event-free survival (P = 0.0002; Q = 0.042) in those samples that had MYCN amplification (N = 94).	25502557	PubMed		Rihani et al., 2014, PLoS ONE		3	accepted	1654	650	761	2	202149589	202149589	G	C	ENST00000264275.5					75	GRCh37		Common Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1654	https://civic.genome.wustl.edu/links/variants/650	https://civic.genome.wustl.edu/links/genes/761
AXL	558	EXPRESSION	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029).	27172793	PubMed		Hsieh et al., 2016, Oncotarget		4	accepted	1655	651	533	19	41725108	41767671			ENST00000301178.4					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1655	https://civic.genome.wustl.edu/links/variants/651	https://civic.genome.wustl.edu/links/genes/533
GAS6	2621	EXPRESSION	Prostate Cancer	10283		Docetaxel		Predictive	Supports	D	Resistance	Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel. Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6. PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel.	27153245	PubMed		Lee et al., 2016, J. Cell. Biochem.		3	accepted	1656	652	2186	13	114523524	114567046			ENST00000357389.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1656	https://civic.genome.wustl.edu/links/variants/652	https://civic.genome.wustl.edu/links/genes/2186
GAS6	2621	EXPRESSION	Oral Squamous Cell Carcinoma	0050866				Prognostic	Supports	B	Poor Outcome	128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ). Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 ).	26207647	PubMed		Jiang et al., 2015, PLoS ONE		4	accepted	1657	652	2186	13	114523524	114567046			ENST00000357389.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1657	https://civic.genome.wustl.edu/links/variants/652	https://civic.genome.wustl.edu/links/genes/2186
ETV4	2118	OVEREXPRESSION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040).	25544710	PubMed		Qi et al., 2015, Tumour Biol.		3	accepted	1658	653	1767	17	41605212	41623800			ENST00000319349.5					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1658	https://civic.genome.wustl.edu/links/variants/653	https://civic.genome.wustl.edu/links/genes/1767
STAG2	10735	UNDEREXPRESSION	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	27500726	PubMed		Shen et al., 2016, Nat. Med.		4	accepted	1659	422	8553	X	123095568	123236506			ENST00000371157.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1659	https://civic.genome.wustl.edu/links/variants/422	https://civic.genome.wustl.edu/links/genes/8553
STAG3	10734	UNDEREXPRESSION	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	27500726	PubMed		Shen et al., 2016, Nat. Med.		4	accepted	1660	654	8552	7	99775186	99812003			ENST00000426455.1					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1660	https://civic.genome.wustl.edu/links/variants/654	https://civic.genome.wustl.edu/links/genes/8552
MAP2K1	5604	Q56_V60del	Ovarian Serous Carcinoma	0050933		Selumetinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.	26324360	PubMed		Grisham et al., 2015, J. Clin. Oncol.		4	accepted	1661	655	31	15	66727449	66727463	CCAGAAGCAGAAGGT		ENST00000307102.5					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1661	https://civic.genome.wustl.edu/links/variants/655	https://civic.genome.wustl.edu/links/genes/31
BRAF	673	BRAF-CUL1	Ovarian Serous Carcinoma	0050933		Mitogen-Activated Protein Kinase Kinase Inhibitor		Predictive	Supports	C	Sensitivity/Response	One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months.	26324360	PubMed		Grisham et al., 2015, J. Clin. Oncol.		2	accepted	1662	656	5	7	140434279	140487384			ENST00000288602.6	7	148395737	148457588	ENST00000602748.1	75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1662	https://civic.genome.wustl.edu/links/variants/656	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	ZKSCAN1-BRAF	Melanoma	1909		Trametinib		Predictive	Supports	C	Sensitivity/Response	Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins.	26314551	PubMed		Ross et al., 2016, Int. J. Cancer		3	accepted	1663	657	5	7	99613222	99627575			ENST00000426572.1	7	140434279	140482957	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1663	https://civic.genome.wustl.edu/links/variants/657	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	KIAA1549-BRAF	Sarcoma	1115		Sorafenib,Bevacizumab,Temsirolimus	Combination	Predictive	Supports	C	Sensitivity/Response	A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well.	24422672	PubMed		Subbiah et al., 2014, J Hematol Oncol	NCT01187199	2	accepted	1664	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1664	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).	18509184	PubMed		Yang et al., 2008, J. Clin. Oncol.		3	accepted	1665	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/1665	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).	18509184	PubMed		Yang et al., 2008, J. Clin. Oncol.		3	accepted	1666	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1666	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib,Afatinib	Substitutes	Predictive	Supports	B	Resistance	48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.	27304188	PubMed		Belchis et al., 2016, Oncotarget		3	accepted	1667	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1667	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
BRAF	673	L505H	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.	24112705	PubMed		Wagenaar et al., 2014, Pigment Cell Melanoma Res		4	accepted	1668	658	5	7	140477794	140477794	A	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1668	https://civic.genome.wustl.edu/links/variants/658	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L505H	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Resistance	In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation.	25515853	PubMed		Hoogstraat et al., 2015, Pigment Cell Melanoma Res		3	accepted	1669	658	5	7	140477794	140477794	A	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1669	https://civic.genome.wustl.edu/links/variants/658	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	E545K	Lung Adenocarcinoma	3910		Afatinib,Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.	27304188	PubMed		Belchis et al., 2016, Oncotarget		2	accepted	1670	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1670	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
NF2	4771	MUTATION	Acoustic Neuroma	12689		Everolimus		Predictive	Supports	B	N/A	Ten patients with Neurofibromatosis 2 were enrolled for treatment with Everolimus.  At 12 months, no patients had reduction in tumor volume >20%, however, five patients had stable disease with a reduction in annual growth rate from 67% growth/year to 0.5% growth/year.  Growth of tumors ensued after discontinuation of Everolimus.	25567352	PubMed		Goutagny et al., 2015, J. Neurooncol.		3	accepted	1671	659	3870	22	29999547	30094587			ENST00000338641.4					75	GRCh37		Rare Germline	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1671	https://civic.genome.wustl.edu/links/variants/659	https://civic.genome.wustl.edu/links/genes/3870
VHL	7428	MUTATION	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	Sensitivity/Response	VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial. Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both. 8 patients exhibited neither mutation nor methylation of VHL. There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy.	23881929	PubMed		Choueiri et al., 2013, Clin. Cancer Res.		2	accepted	1672	160	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1672	https://civic.genome.wustl.edu/links/variants/160	https://civic.genome.wustl.edu/links/genes/58
EPAS1	2034	OVEREXPRESSION	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	N/A	HIF-2A (EPAS1) staining was conducted on 66 tumors.  Of the 66 patients, 25 were classified as responders and 41 were classified as non-responders.  There was no significant difference between responders and non-responders with regards to overall response rate to pazopanib (44% vs 33%; P=0.36).	23881929	PubMed		Choueiri et al., 2013, Clin. Cancer Res.		3	accepted	1673	435	1705	2	46524541	46613836			ENST00000263734.3					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1673	https://civic.genome.wustl.edu/links/variants/435	https://civic.genome.wustl.edu/links/genes/1705
HIF1A	3091	EXPRESSION	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	N/A	Immunohistochemical staining was performed on 65 patients for HIF1A such that 23 were considered responders and 42 were considered non-responders.  There was no difference between the two groups with regards to overall response rate to pazopanib.  There was no difference between the two groups with regards to progression free survival.	23881929	PubMed		Choueiri et al., 2013, Clin. Cancer Res.		2	accepted	1674	660	2596	14	62164340	62214489			ENST00000539097.1					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1674	https://civic.genome.wustl.edu/links/variants/660	https://civic.genome.wustl.edu/links/genes/2596
BRCA1	672	MUTATION	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.	26740259	PubMed		Harter et al., 2016, Gynecol. Oncol.		3	accepted	1675	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1675	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.	26740259	PubMed		Harter et al., 2016, Gynecol. Oncol.		3	accepted	1676	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1676	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	MUTATION	Ovarian Cancer	2394		Olaparib,Cediranib	Combination	Predictive	Supports	B	Sensitivity/Response	46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).	25218906	PubMed		Liu et al., 2014, Lancet Oncol.	NCT01116648	3	accepted	1677	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1677	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Ovarian Cancer	2394		Olaparib,Cediranib	Combination	Predictive	Supports	B	Sensitivity/Response	46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).	25218906	PubMed		Liu et al., 2014, Lancet Oncol.	NCT01116648	3	accepted	1678	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1678	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	D3095E	Breast Cancer	1612				Diagnostic	Supports	C	Positive	49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations.  Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign. The authors assessment of the factors predicts a pathogenicity probability of 0.73 and an Odds Ratio of 2.7.	18951446	PubMed		Plon et al., 2008, Hum. Mutat.		1	accepted	1679	661	7	13	32968854	32968854	C	A	ENST00000544455.1					75	GRCh37		Rare Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1679	https://civic.genome.wustl.edu/links/variants/661	https://civic.genome.wustl.edu/links/genes/7
MLH1	4292	EXPRESSION	Stomach Carcinoma	5517				Prognostic	Supports	B	Poor Outcome	46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020).	27313181	PubMed		Rokutan et al., 2016, J. Pathol.		3	accepted	1680	662	3532	3	37034823	37092409			ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1680	https://civic.genome.wustl.edu/links/variants/662	https://civic.genome.wustl.edu/links/genes/3532
BCOR	54880	MUTATION	Stomach Cancer	10534				Prognostic	Supports	B	Better Outcome	46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038).	27313181	PubMed		Rokutan et al., 2016, J. Pathol.		3	accepted	1681	663	12555	X	39910501	40036582			ENST00000342274.4					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1681	https://civic.genome.wustl.edu/links/variants/663	https://civic.genome.wustl.edu/links/genes/12555
CDH1	999	MUTATION	Stomach Carcinoma	5517				Prognostic	Supports	E	Poor Outcome	285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).	27313181	PubMed		Rokutan et al., 2016, J. Pathol.		2	accepted	1682	664	888	16	68771128	68869451			ENST00000261769.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1682	https://civic.genome.wustl.edu/links/variants/664	https://civic.genome.wustl.edu/links/genes/888
RHOA	387	MUTATION	Stomach Carcinoma	5517				Prognostic	Supports	E	Poor Outcome	285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).	27313181	PubMed		Rokutan et al., 2016, J. Pathol.		2	accepted	1683	665	399	3	49396578	49449635			ENST00000418115.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1683	https://civic.genome.wustl.edu/links/variants/665	https://civic.genome.wustl.edu/links/genes/399
BRCA1	672	MUTATION	Triple-receptor Negative Breast Cancer	0060081		Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.	25847936	PubMed		Isakoff et al., 2015, J. Clin. Oncol.	NCT00483223	3	accepted	1684	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1684	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Triple-receptor Negative Breast Cancer	0060081		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.	25847936	PubMed		Isakoff et al., 2015, J. Clin. Oncol.	NCT00483223	3	accepted	1685	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1685	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		4	accepted	1686	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1686	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		4	accepted	1687	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1687	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability).	23348520	PubMed		Martin et al., 2013, Br. J. Cancer		2	accepted	1688	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1688	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Lapatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.	27108243	PubMed		Sartore-Bianchi et al., 2016, Lancet Oncol.		4	accepted	1689	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1689	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ROS1	6098	REARRANGEMENT	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later. This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion.	25922291	PubMed		Le et al., 2015, Clin Lung Cancer		3	accepted	1690	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/1690	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
ALK	238	ALK FUSIONS	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later.	25922291	PubMed		Le et al., 2015, Clin Lung Cancer		3	accepted	1691	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1691	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
MET	4233	AMPLIFICATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.	25922291	PubMed		Le et al., 2015, Clin Lung Cancer		3	accepted	1692	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1692	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
ERBB2	2064	AMPLIFICATION	Scrotum Paget's Disease	3444		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	A 71-year old male with metastatic extramammary Pagets disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease.	25692060	PubMed		Barth et al., 2015, Case Rep Oncol Med		2	accepted	1693	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1693	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	MUTATION	Bladder Carcinoma	4007		Platinum Compound		Predictive	Supports	C	Sensitivity/Response	In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003).	25636205	PubMed		Groenendijk et al., 2016, Eur. Urol.		3	accepted	1694	666	20	17	37868196	37881332			ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1694	https://civic.genome.wustl.edu/links/variants/666	https://civic.genome.wustl.edu/links/genes/20
MEN1	4221	FRAMESHIFT TRUNCATION	Thyroid Hurthle Cell Carcinoma	8161				Diagnostic	Supports	C	Positive	Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.  One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.  These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors.	25625803	PubMed		Kasaian et al., 2015, J. Clin. Endocrinol. Metab.		2	accepted	1695	667	3485	11	64572092	64572092	C		ENST00000337652.1					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1695	https://civic.genome.wustl.edu/links/variants/667	https://civic.genome.wustl.edu/links/genes/3485
KMT2C	58508	MUTATION	Skin Squamous Cell Carcinoma	3151				Prognostic	Supports	B	Poor Outcome	Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).  Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).  This worse prognosis did not appear to be correlated with bone invasion (p=0.98).	25303977	PubMed		Pickering et al., 2014, Clin. Cancer Res.		3	accepted	1696	668	14089	7	151832010	152133090			ENST00000262189.6					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1696	https://civic.genome.wustl.edu/links/variants/668	https://civic.genome.wustl.edu/links/genes/14089
STAG2	10735	MUTATION	Ewing Sarcoma Of Bone	3368				Prognostic	Supports	B	Poor Outcome	In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002).	25186949	PubMed		Crompton et al., 2014, Cancer Discov		4	accepted	1697	669	8553	X	123176418	123217308			ENST00000218089.9					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1697	https://civic.genome.wustl.edu/links/variants/669	https://civic.genome.wustl.edu/links/genes/8553
BRAF	673	V600E	Multiple Myeloma	9538		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.	24997557	PubMed		Sharman et al., 2014, Clin Lymphoma Myeloma Leuk		3	accepted	1698	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1698	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Multiple Myeloma	9538		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.	24997557	PubMed		Sharman et al., 2014, Clin Lymphoma Myeloma Leuk		2	accepted	1699	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1699	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	MUTATION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).	22810899	PubMed		Johnson et al., 2013, Cancer		4	accepted	1700	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/1700	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
EGFR	1956	MUTATION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Better Outcome	In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).	22810899	PubMed		Johnson et al., 2013, Cancer		4	accepted	1701	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1701	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
KRAS	3845	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		3	accepted	1702	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/1702	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		2	accepted	1703	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1703	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		2	accepted	1704	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1704	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.	22586653	PubMed		Bertotti et al., 2011, Cancer Discov		1	accepted	1705	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/1705	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
MYCL	4610	EXPRESSION	Multiple Myeloma	9538		I-BET151,JQ1	Substitutes	Predictive	Supports	D	Sensitivity/Response	Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors. Microarray analysis showed a downregulation of MYC-dependent genes after treatment. qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1. In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC.	27276402	PubMed		Suzuki et al., 2016, Anticancer Drugs		1	accepted	1706	670	3738	1	40361098	40367685			ENST00000397332.2					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1706	https://civic.genome.wustl.edu/links/variants/670	https://civic.genome.wustl.edu/links/genes/3738
HGF	3082	EXPRESSION	Glioblastoma Multiforme	3068		MET Tyrosine Kinase Inhibitor SGX523		Predictive	Supports	D	Sensitivity/Response	Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523. Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05).	22203985	PubMed		Xie et al., 2012, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	1707	671	2591	7	81328322	81399514			ENST00000222390.5					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1707	https://civic.genome.wustl.edu/links/variants/671	https://civic.genome.wustl.edu/links/genes/2591
EGFR	1956	EXPRESSION	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study.	17470858	PubMed		Van Cutsem et al., 2007, J. Clin. Oncol.		2	accepted	1708	354	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1708	https://civic.genome.wustl.edu/links/variants/354	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXPRESSION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months.	14993230	PubMed		Saltz et al., 2004, J. Clin. Oncol.		1	accepted	1709	354	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1709	https://civic.genome.wustl.edu/links/variants/354	https://civic.genome.wustl.edu/links/genes/19
SOX10	6663	LOSS	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF- signalling and upregulation of EGFR and PDGFRB. EGFR expression or exposure to TGF- becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors. Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib. This study finds evidence for SOX10 loss (N=2) and/or activation of TGF- signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.	24670642	PubMed		Sun et al., 2014, Nature		4	accepted	1710	672	5418	22	38368307	38380544			ENST00000396884.2					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1710	https://civic.genome.wustl.edu/links/variants/672	https://civic.genome.wustl.edu/links/genes/5418
FGF2	2247	EXPRESSION	Acute Myeloid Leukemia	9119		Quizartinib		Predictive	Supports	D	Resistance	AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations	27671675	PubMed		Traer et al., 2016, Cancer Res.		4	accepted	1711	673	1872	4	123747863	123819391			ENST00000264498.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1711	https://civic.genome.wustl.edu/links/variants/673	https://civic.genome.wustl.edu/links/genes/1872
EIF1AX	1964	MUTATION	Uveal Melanoma	6039				Prognostic	Supports	C	Better Outcome	EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%20% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis. This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases.	23793026	PubMed		Martin et al., 2013, Nat. Genet.		4	accepted	1712	674	1646	X	20156713	20159754			ENST00000379607.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1712	https://civic.genome.wustl.edu/links/variants/674	https://civic.genome.wustl.edu/links/genes/1646
MET	4233	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of two patients with MET amplification (MET:CEP7 ratio 5) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.	27664533	PubMed		Caparica et al., 2017, J Thorac Oncol		2	accepted	1713	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1713	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
MET	4233	AMPLIFICATION	Cancer	162		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.	25232318	PubMed		Palma et al., 2014, Case Rep Oncol		3	accepted	1714	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1714	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
KRAS	3845	G12V	Cancer	162		Crizotinib		Predictive	Does Not Support	C	Resistance	Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.	25232318	PubMed		Palma et al., 2014, Case Rep Oncol		2	accepted	1715	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1715	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
PAX8	7849	EXPRESSION	Female Reproductive Organ Cancer	120				Diagnostic	Supports	A	Positive	The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC. Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression. The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively.	24800185	PubMed		Heidarpour et al., 2014, Adv Biomed Res		4	accepted	1716	683	75	2	113973574	114036527			ENST00000429538.3					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1716	https://civic.genome.wustl.edu/links/variants/683	https://civic.genome.wustl.edu/links/genes/75
PRDM1	639	MUTATION	Diffuse Large B-cell Lymphoma	0050745				Prognostic	Supports	B	Poor Outcome	In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients. This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients. Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor.	27568520	PubMed		Xia et al., 2016, Leukemia		2	accepted	1717	644	593	6	106534195	106557813			ENST00000369096.4					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1717	https://civic.genome.wustl.edu/links/variants/644	https://civic.genome.wustl.edu/links/genes/593
ERRFI1	54206	E384*	Cholangiocarcinoma	4947		Erlotinib		Predictive	Supports	C	Sensitivity/Response	An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.	24550739	PubMed		Borad et al., 2014, PLoS Genet.		2	accepted	1724	691	12271	1	8073509	8073509	C	A	ENST00000377482.5					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1724	https://civic.genome.wustl.edu/links/variants/691	https://civic.genome.wustl.edu/links/genes/12271
KIT	3815	D816V	Systemic Mastocytosis	349		Midostaurin		Predictive	Supports	B	Sensitivity/Response	In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.	27355533	PubMed		Gotlib et al., 2016, N. Engl. J. Med.	NCT00782067	4	accepted	1725	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1725	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816V	Systemic Mastocytosis	349				Prognostic	Supports	B	Poor Outcome	The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54).	26464169	PubMed		Jawhar et al., 2016, Leukemia		4	accepted	1726	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1726	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29
ESR1	2099	S463P	Estrogen-receptor Positive Breast Cancer	0060075		Aromatase Inhibitor		Predictive	Supports	D	Resistance	ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER and appeared to possess estrogen-independent activity.	24185512	PubMed		Toy et al., 2013, Nat. Genet.		2	accepted	1727	692	21	6	152415537	152415537	T	C	ENST00000440973.1					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1727	https://civic.genome.wustl.edu/links/variants/692	https://civic.genome.wustl.edu/links/genes/21
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	B	Sensitivity/Response	In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments. Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib. Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017.	27083334	PubMed		Park et al., 2016, Lancet Oncol.	NCT01466660	4	accepted	1728	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1728	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
SGK1	6446	OVEREXPRESSION	Breast Cancer	1612		Alpelisib		Predictive	Supports	D	Resistance	SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed clear elevation of protein levels in 3/5 resistant cell lines. Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment. Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment. Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines.	27451907	PubMed		Castel et al., 2016, Cancer Cell		5	accepted	1729	693	5225	6	134490384	134639196			ENST00000367858.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1729	https://civic.genome.wustl.edu/links/variants/693	https://civic.genome.wustl.edu/links/genes/5225
SGK1	6446	OVEREXPRESSION	Breast Cancer	1612		Alpelisib		Predictive	Supports	B	Resistance	A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response.	27451907	PubMed		Castel et al., 2016, Cancer Cell		3	accepted	1730	693	5225	6	134490384	134639196			ENST00000367858.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1730	https://civic.genome.wustl.edu/links/variants/693	https://civic.genome.wustl.edu/links/genes/5225
SGK1	6446	OVEREXPRESSION	Breast Cancer	1612		Alpelisib,SGK1-Inh	Combination	Predictive	Supports	D	Sensitivity/Response	The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC.	27451907	PubMed		Castel et al., 2016, Cancer Cell		4	accepted	1731	693	5225	6	134490384	134639196			ENST00000367858.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1731	https://civic.genome.wustl.edu/links/variants/693	https://civic.genome.wustl.edu/links/genes/5225
KRAS	3845	G12D	Pancreatic Ductal Carcinoma	3587				Prognostic	Supports	B	Poor Outcome	Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy. 72 patients had wild-type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically. There was no significant difference in overall survival between wild-type patients and patients with any type of exon-12 mutation. However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild-type patients in univariate and multivariate analyses. This difference in overall survival between wild-type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment.	27010960	PubMed		Bournet et al., 2016, Clin Transl Gastroenterol		3	accepted	1732	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1732	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.	27718847	PubMed		Reck et al., 2016, N. Engl. J. Med.	NCT02142738	3	accepted	1733	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1733	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CCNE1	898	OVEREXPRESSION	Ovarian Cancer	2394		CDK Inhibitor SNS-032		Predictive	Supports	D	Sensitivity/Response	Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.	26204491	PubMed		Yang et al., 2015, Oncotarget		2	accepted	1734	24	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.	N/A	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/1734	https://civic.genome.wustl.edu/links/variants/24	https://civic.genome.wustl.edu/links/genes/11
CCNE1	898	AMPLIFICATION	Ovarian Serous Cystadenocarcinoma	5746		Dinaciclib,Akt Inhibitor MK2206	Combination	Predictive	Supports	D	Sensitivity/Response	A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors	27663592	PubMed		Au-Yeung et al., 2016, Clin. Cancer Res.		4	accepted	1735	187	11	19	30302805	30315215			ENST00000262643.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1735	https://civic.genome.wustl.edu/links/variants/187	https://civic.genome.wustl.edu/links/genes/11
EGFR	1956	G719S	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719 mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C).	26124334	PubMed		Otsuka et al., 2015, Anticancer Res.		3	accepted	1736	134	19	7	55241707	55241707	G	A	ENST00000275493.2					75	GRCh37	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1736	https://civic.genome.wustl.edu/links/variants/134	https://civic.genome.wustl.edu/links/genes/19
STK11	6794	LOSS	Peutz-Jeghers Syndrome	3852				Predisposing	Supports	B	Positive	In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations occurred in 10/13 patients with familial PJS and 7/20 patients with sporadic PJS.	12865922	PubMed		Lim et al., 2003, Br. J. Cancer		3	accepted	1737	485	5534	19	1205740	1228428			ENST00000326873.7					75	GRCh37		Rare Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1737	https://civic.genome.wustl.edu/links/variants/485	https://civic.genome.wustl.edu/links/genes/5534
BRAF	673	G596C	Lung Non-small Cell Carcinoma	3908		Dabrafenib,Trametinib	Combination	Predictive	Supports	D	Sensitivity/Response	non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations	27577079	PubMed		Noeparast et al., 2016, Oncotarget			accepted	1738	694	5	7	140453149	140453149	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1738	https://civic.genome.wustl.edu/links/variants/694	https://civic.genome.wustl.edu/links/genes/5
SMARCB1	6598	UNDEREXPRESSION	Synovial Sarcoma	5485		Tazemetostat		Predictive	Supports	D	Sensitivity/Response	Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas.	27391784	PubMed		Kawano et al., 2016, PLoS ONE		2	accepted	1739	695	5356	22	24129150	24176703			ENST00000344921.6					75	GRCh37		N/A	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1739	https://civic.genome.wustl.edu/links/variants/695	https://civic.genome.wustl.edu/links/genes/5356
SMARCB1	6598	DELETION	Rhabdoid Cancer	3672		Tazemetostat		Predictive	Supports	D	Sensitivity/Response	EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells. This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild-type) cell lines. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.	23620515	PubMed		Knutson et al., 2013, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	1740	696	5356	22	24129150	24176703			ENST00000344921.6					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1740	https://civic.genome.wustl.edu/links/variants/696	https://civic.genome.wustl.edu/links/genes/5356
PTEN	5728	DELETION	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.1451.439), pathological stage (OR: 1.628, 95% CI = 1.2702.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.2642.390).	27470558	PubMed		Gao et al., 2016, Biomed. Pharmacother.		4	accepted	1741	213	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1741	https://civic.genome.wustl.edu/links/variants/213	https://civic.genome.wustl.edu/links/genes/41
NF2	4771	LOSS	Thyroid Gland Carcinoma	3963		Selumetinib		Predictive	Supports	D	Sensitivity/Response	NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model.	26359368	PubMed		Garcia-Rendueles et al., 2015, Cancer Discov		4	accepted	1742	697	3870	22	29999547	30094587			ENST00000338641.4					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1742	https://civic.genome.wustl.edu/links/variants/697	https://civic.genome.wustl.edu/links/genes/3870
NF1	4763	LOSS	Malignant Peripheral Nerve Sheath Tumor	5940		JQ1 Compound		Predictive	Supports	D	Sensitivity/Response	BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts	24373973	PubMed		Patel et al., 2014, Cell Rep		3	accepted	1743	698	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1743	https://civic.genome.wustl.edu/links/variants/698	https://civic.genome.wustl.edu/links/genes/3867
SH2B3	10019	RS3184504	Colorectal Cancer	9256				Predisposing	Supports	B	Positive	A genome wide association study (GWAS) meta-analysis of 13,265 cancer cases (colorectal cancer and endometrial cancer) and 40,245 controls found this variant to be associated with colorectal cancer (OR=1.10, P=7.23109). The authors speculated that since this polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, it might influence cancer risk through its role in the immune response.	26621817	PubMed		Cheng et al., 2015, Sci Rep		2	accepted	1744	699	7954	12	111884608	111884608	T	C	ENST00000341259.2					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1744	https://civic.genome.wustl.edu/links/variants/699	https://civic.genome.wustl.edu/links/genes/7954
KIF23	9493	EXPRESSION	Hepatocellular Carcinoma	684				Prognostic	Supports	B	Better Outcome	KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patients for this isoform. Using IHC and custom generated antibody, the overall survival with respect to KIF23 V1 expression was evaluated using the kaplan-meier method with a log rank test. It was found that positive KIF23 V1 staining was correlated with longer overall survival over a period of 5 years (p=.0052). This pattern was seen to a lesser degree over a period of 3 years (p=.1604). KIF23 V1 expression was independent of gender, age, tumor size, or TNM stage (multivariate cox regression).	26674738	PubMed		Sun et al., 2015, BMC Cancer		3	accepted	1745	700	7502	15	69706688	69740756			ENST00000260363.4					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1745	https://civic.genome.wustl.edu/links/variants/700	https://civic.genome.wustl.edu/links/genes/7502
ERBB3	2065	V104M	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.	27044931	PubMed		Choudhury et al., 2016, J. Clin. Oncol.		3	accepted	1746	701	1733	12	56478854	56478854	G	A	ENST00000267101.3					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1746	https://civic.genome.wustl.edu/links/variants/701	https://civic.genome.wustl.edu/links/genes/1733
ERBB3	2065	R103G	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.	27044931	PubMed		Choudhury et al., 2016, J. Clin. Oncol.		3	accepted	1747	702	1733	12	56478851	56478851	C	G	ENST00000267101.3					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1747	https://civic.genome.wustl.edu/links/variants/702	https://civic.genome.wustl.edu/links/genes/1733
ERBB3	2065	G284R	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.	27044931	PubMed		Choudhury et al., 2016, J. Clin. Oncol.		3	accepted	1748	703	1733	12	56481922	56481922	G	A	ENST00000267101.3					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1748	https://civic.genome.wustl.edu/links/variants/703	https://civic.genome.wustl.edu/links/genes/1733
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients (N=37/48). Patients without the V600E mutation had evidence of tumor regression.	20818844	PubMed		Flaherty et al., 2010, N. Engl. J. Med.		4	accepted	1749	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1749	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study. In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).  The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group.	22663011	PubMed		Flaherty et al., 2012, N. Engl. J. Med.	NCT01245062	3	accepted	1750	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/1750	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
GADD45A	1647	rs681673	Ovarian Cancer	2394				Predisposing	Supports	B	Positive	GADD45A (1506T>C) association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis. A significant difference in genotype distribution was observed between cases and controls  (TT vs. TC vs. CC, P = 0.0021). A statistically significant difference in the GADD454A (1506T>C) variant between the controls groups was found in correlation with an increased risk of ovarian cancer (P<0.001, OR = 1.71, 95% CI 1.282.29).  Presence of the GADD45A (1506T>C) variant was also found to have higher GADD45A mRNA expression, longer ovarian cancer relapse free survival and overall survival.	26422378	PubMed		Yuan et al., 2015, PLoS ONE		3	accepted	1751	705	1411	1	68152388	68152388	T	C	ENST00000370986.4					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1751	https://civic.genome.wustl.edu/links/variants/705	https://civic.genome.wustl.edu/links/genes/1411
EWSR1	2130	EWSR1-FLI1	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	3163261	PubMed		Turc-Carel et al., 1988, Cancer Genet. Cytogenet.		4	accepted	1752	706	54	22	29664307	29688158			ENST00000414183.2	11	128638013	128683162	ENST00000527786.2	75	GRCh37	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.	Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1752	https://civic.genome.wustl.edu/links/variants/706	https://civic.genome.wustl.edu/links/genes/54
EWSR1	2130	EWSR1-FLI1	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered.	9741544	PubMed		Park et al., 1998, J. Korean Med. Sci.		2	accepted	1753	706	54	22	29664307	29688158			ENST00000414183.2	11	128638013	128683162	ENST00000527786.2	75	GRCh37	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.	Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1753	https://civic.genome.wustl.edu/links/variants/706	https://civic.genome.wustl.edu/links/genes/54
EWSR1	2130	EWSR1-FLI1	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both.	16258512	PubMed		Bridge et al., 2006, Mod. Pathol.		3	accepted	1754	706	54	22	29664307	29688158			ENST00000414183.2	11	128638013	128683162	ENST00000527786.2	75	GRCh37	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.	Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1754	https://civic.genome.wustl.edu/links/variants/706	https://civic.genome.wustl.edu/links/genes/54
MTHFR	4524	A222V	Pancreatic Cancer	1793				Prognostic	Supports	B	Better Outcome	Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.	27819322	PubMed		Wu et al., 2016, Sci Rep		4	accepted	1756	258	3672	1	11856378	11856378	G	A	ENST00000376592.1					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1756	https://civic.genome.wustl.edu/links/variants/258	https://civic.genome.wustl.edu/links/genes/3672
MTHFR	4524	A222V	Rectum Cancer	1993		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T).	26693073	PubMed		Nikas et al., 2015, Am J Cancer Res		4	accepted	1757	258	3672	1	11856378	11856378	G	A	ENST00000376592.1					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1757	https://civic.genome.wustl.edu/links/variants/258	https://civic.genome.wustl.edu/links/genes/3672
BRCA2	675	TRUNCATING MUTATION	Breast Cancer	1612				Predisposing	Supports	C	Uncertain Significance	De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families. However, the segregation data and mRNA results in this study were conflicting or inconclusive.	16088935	PubMed		Teugels et al., 2005, Hum. Mutat.		1	accepted	1758	708	7														Rare Germline	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1758	https://civic.genome.wustl.edu/links/variants/708	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	Alu insertion	Breast Cancer	1612				Predisposing	Supports	C	Likely Pathogenic	In a Portuguese family with 6 cases of breast cancer and 1 of ovarian cancer, a 46 year old woman was diagnosed with breast cancer. She was negative for BRCA1/2 mutations using standard methods but a Southern blot identified a ~350bp Alu element (AluYa5 subtype) insertion in exon 3. RT-PCR revealed exon 3 was excluded from the spliced transcript in this patient. Blood samples from 24 family members were collected and the Alu element was identified in the 3 with ovarian or breast cancer that had evaluable samples.	16088935	PubMed		Teugels et al., 2005, Hum. Mutat.		3	accepted	1759	709	6														Rare Germline	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1759	https://civic.genome.wustl.edu/links/variants/709	https://civic.genome.wustl.edu/links/genes/6
HOXB13	10481	G84E	Prostate Cancer	10283				Predisposing	Supports	B	Uncertain Significance	G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnosed with cancer (n=2,595). Cancer diagnosis was more common in G84E carriers than in non-carriers (51.5% vs 30.6%, P = 0.004). G84E was highly prevalent in patients with prostate cancer than those without cancer (P < 0.0001). Evidence also supported a possible link between G84E with bladder cancer (P = 0.06) and leukemia (P = 0.01). Patient family history indicated a history of prostate cancer with a first degree relative was more common when compared to non-carriers (36.2% vs. 16.0%, P = 0.0003).	26108461	PubMed		Beebe-Dimmer et al., 2015, Cancer Epidemiol. Biomarkers Prev.		4	accepted	1760	772	8351	17	46805705	46805705	C	T	ENST00000290295.7					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1760	https://civic.genome.wustl.edu/links/variants/772	https://civic.genome.wustl.edu/links/genes/8351
KLLN	100144748	PROMOTER METHYLATION	Breast Cancer	1612				Predisposing	Supports	B	Positive	123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a 3-fold increased prevalence of breast cancer (35/42 vs 24/64; p<0.0001) over individuals with germline PTEN mutations.	21177507	PubMed		Bennett et al., 2010, JAMA		3	accepted	1761	711	32083														N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1761	https://civic.genome.wustl.edu/links/variants/711	https://civic.genome.wustl.edu/links/genes/32083
KLLN	100144748	PROMOTER METHYLATION	Renal Cell Carcinoma	4450				Predisposing	Supports	B	Positive	123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a greater than 2-fold increase of kidney cancer (4/45 vs 6/155; p=0.004) over individuals with germline PTEN mutations.	21177507	PubMed		Bennett et al., 2010, JAMA		3	accepted	1762	711	32083														N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1762	https://civic.genome.wustl.edu/links/variants/711	https://civic.genome.wustl.edu/links/genes/32083
EGFR	1956	D761Y	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	C	Resistance	D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment. Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells).	17085664	PubMed		Balak et al., 2006, Clin. Cancer Res.		3	accepted	1763	712	19	7	55242511	55242511	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1763	https://civic.genome.wustl.edu/links/variants/712	https://civic.genome.wustl.edu/links/genes/19
ERBB2	2064	AMPLIFICATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.	21172893	PubMed		Burris et al., 2011, J. Clin. Oncol.		4	accepted	1764	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1764	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
CDKN2A	1029	LOSS	Her2-receptor Negative Breast Cancer	0060080		Letrozole,Palbociclib	Combination	Predictive	Supports	C	Sensitivity/Response	A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.	26715889	PubMed		Gao et al., 2015, Curr Oncol		3	accepted	1765	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1765	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
CRBN	51185	MUTATION	Multiple Myeloma	9538		Lenalidomide,Pomalidomide	Substitutes	Predictive	Supports	C	Resistance	A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations. Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing.	23480694	PubMed		Egan et al., 2013, Br. J. Haematol.		3	accepted	1766	713	11761	3	3191695	3221394			ENST00000231948.4					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1766	https://civic.genome.wustl.edu/links/variants/713	https://civic.genome.wustl.edu/links/genes/11761
FGFR1	2260	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	0060075		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.	22238366	PubMed		Gozgit et al., 2012, Mol. Cancer Ther.		3	accepted	1767	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1767	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
TSC1	7248	R1062W	Tuberous Sclerosis	13515				Predisposing	Supports	C	Uncertain Significance	Deep sequencing of TSC1 and TSC2 was performed on blood from a group of 38 sporadic Tuberous Sclerosis patients who had been previously studied with no mutation identified in TSC1 or TSC2. Five patients had readily observable mutations in these genes, one of which was a previously unidentified TSC1 missense change R1062W. The authors indicate that the mutation may not be pathogenic.	20165957	PubMed		Qin et al., 2010, Hum. Genet.		2	accepted	1768	714	46	9	135771933	135771933	G	A	ENST00000298552.3					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1768	https://civic.genome.wustl.edu/links/variants/714	https://civic.genome.wustl.edu/links/genes/46
STK11	6794	MUTATION	Peutz-Jeghers Syndrome	3852				Predisposing	Supports	B	Pathogenic	Retrospective analysis of the Danish tumor bank. 43 patients with Peutz-Jeghers Syndrome were identified (clinical criteria + STK11 mutations). STK11 mutations were detected in 86% of those tested (18 of 21 probands) and included eight nonsense mutations, five frameshift mutations, two splice site mutations, two large genomic rearrangements, and one missense mutation.	26979979	PubMed		Jelsig et al., 2016, Int J Colorectal Dis		4	accepted	1769	715	5534	19	1205740	1223074			ENST00000326873.7					75	GRCh37		Rare Germline	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/1769	https://civic.genome.wustl.edu/links/variants/715	https://civic.genome.wustl.edu/links/genes/5534
BTK	695	C481S	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	B	Resistance	In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richters transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality.	26182309	PubMed		Maddocks et al., 2015, JAMA Oncol	NCT01105247,NCT01217749,NCT01578707,NCT01589302	4	accepted	1770	168	65	X	100611165	100611165	A	T	ENST00000308731.7					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/1770	https://civic.genome.wustl.edu/links/variants/168	https://civic.genome.wustl.edu/links/genes/65
PDGFRA	5156	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Sunitinib		Predictive	Supports	D	Sensitivity/Response	In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression was associated with focal PDGFRA gene amplification. This alteration was detected in a small fraction of primary squamous cell NSCLC tumor specimens. Focal amplification of PDGFC, the gene encoding the PDGFR ligand, was also detected.	19366796	PubMed		McDermott et al., 2009, Cancer Res.		3	accepted	1771	716	38	4	55095264	55164414			ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1771	https://civic.genome.wustl.edu/links/variants/716	https://civic.genome.wustl.edu/links/genes/38
BRCA1	672	MUTATION	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.	21862407	PubMed		Gelmon et al., 2011, Lancet Oncol.	NCT00679783	3	accepted	1772	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1772	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.	21862407	PubMed		Gelmon et al., 2011, Lancet Oncol.	NCT00679783	3	accepted	1773	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1773	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
PDGFRA	5156	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks.	24456122	PubMed		Srinivas et al., 2014, Br. J. Haematol.		3	accepted	1774	574	38	4	54243812	54294350			ENST00000337488.6	4	55141008	55164414	ENST00000257290.5	75	GRCh37	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).	Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/1774	https://civic.genome.wustl.edu/links/variants/574	https://civic.genome.wustl.edu/links/genes/38
BRCA1	672	MUTATION	Triple-receptor Negative Breast Cancer	0060081		Olaparib		Predictive	Supports	B	Resistance	In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.	21862407	PubMed		Gelmon et al., 2011, Lancet Oncol.	NCT00679783	3	accepted	1775	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1775	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Triple-receptor Negative Breast Cancer	0060081		Olaparib		Predictive	Does Not Support	B	Sensitivity/Response	In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.	21862407	PubMed		Gelmon et al., 2011, Lancet Oncol.	NCT00679783	3	accepted	1776	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1776	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
PDGFRA	5156	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound.	24407160	PubMed		Sadovnik et al., 2014, Exp. Hematol.		3	accepted	1777	574	38	4	54243812	54294350			ENST00000337488.6	4	55141008	55164414	ENST00000257290.5	75	GRCh37	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).		2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/1777	https://civic.genome.wustl.edu/links/variants/574	https://civic.genome.wustl.edu/links/genes/38
DDIT3	1649	EWSR1-DDIT3	Myxoid Liposarcoma	5363				Diagnostic	Supports	C	Positive	Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	8637704	PubMed		Panagopoulos et al., 1996, Oncogene		3	accepted	1778	717	1413	22	29664307	29687588			ENST00000414183.2	12	57910376	57911536	ENST00000346473.3	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1778	https://civic.genome.wustl.edu/links/variants/717	https://civic.genome.wustl.edu/links/genes/1413
PDGFRA	5156	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Ponatinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory effects on both mutants were seen only with ponatinib.	24407160	PubMed		Sadovnik et al., 2014, Exp. Hematol.		3	accepted	1779	577	38	4	55144547	55144547	C	T	ENST00000257290.5					75	GRCh37	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/1779	https://civic.genome.wustl.edu/links/variants/577	https://civic.genome.wustl.edu/links/genes/38
EGFR	1956	G719	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	B	Sensitivity/Response	In a meta-analysis of 7 clinical trials of erlotinib, 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved progression-free and overall survival. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.	26773740	PubMed		Klughammer et al., 2016, J Thorac Oncol		2	accepted	1780	718	19	7	55241707	55241708			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1780	https://civic.genome.wustl.edu/links/variants/718	https://civic.genome.wustl.edu/links/genes/19
BRD4	23476	BRD4-NUTM1	NUT Midline Carcinoma	0060463		JQ1		Predictive	Supports	D	Sensitivity/Response	Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM)  provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation.  Non-BRD4-dependent cell lines including a squamous carcinoma cell line (TE10) failed to exhibit differentiation effects when treated with JQ1.	20871596	PubMed		Filippakopoulos et al., 2010, Nature		3	accepted	1781	719	9588														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1781	https://civic.genome.wustl.edu/links/variants/719	https://civic.genome.wustl.edu/links/genes/9588
EGFR	1956	S720	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes.	26773740	PubMed		Klughammer et al., 2016, J Thorac Oncol		3	accepted	1782	720	19	7	55241710	55241711			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1782	https://civic.genome.wustl.edu/links/variants/720	https://civic.genome.wustl.edu/links/genes/19
ALK	238	ALK FUSIONS	Inflammatory Myofibroblastic Tumor	0050905				Diagnostic	Supports	C	Positive	Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.	10383129	PubMed		Griffin et al., 1999, Cancer Res.		4	accepted	1783	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1783	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
CYP2D6	1565	LOSS-OF-FUNCTION	Breast Cancer	1612				Prognostic	Does Not Support	B	Poor Outcome	Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer. The meta-analysis investigated the association between CYP2D6 genotypes and response to tamoxifen treatment (loss/reduced function vs. unchanged/increased function). The authors examine a prevailing hypothesis that individuals carrying a reduced function CYP2D6 allele have poorer outcomes due to less metabolism of tamoxifen to active metabolites. The study concludes that there is insufficient evidence to support use of CYP2D6 genotyping as a guide for tamoxifen use in breast cancer.	24098545	PubMed		Lum et al., 2013, PLoS ONE		4	accepted	1784	721	1342	22	42522501	42526908			ENST00000360608.5					75	GRCh37		Common Germline	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1784	https://civic.genome.wustl.edu/links/variants/721	https://civic.genome.wustl.edu/links/genes/1342
DDIT3	1649	FUS-DDIT3	Myxoid Liposarcoma	5363				Diagnostic	Supports	A	Positive	The FUS-DDIT3 fusion is pathognomonic of myxoid liposarcomas.  It encompasses parts  of the FUS gene on l6pll at its 5 end and the DDIT3 gene at 12q13 at its 3 ends	1568170	PubMed		Sreekantaiah et al., 1992, Cancer		5	accepted	1785	722	1413														Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1785	https://civic.genome.wustl.edu/links/variants/722	https://civic.genome.wustl.edu/links/genes/1413
EGFR	1956	K757R	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation.	26773740	PubMed		Klughammer et al., 2016, J Thorac Oncol		3	accepted	1786	723	19	7	55242500	55242500	A	G	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1786	https://civic.genome.wustl.edu/links/variants/723	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E746G	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.	26773740	PubMed		Klughammer et al., 2016, J Thorac Oncol		1	accepted	1787	724	19	7	55242467	55242467	A	G	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1787	https://civic.genome.wustl.edu/links/variants/724	https://civic.genome.wustl.edu/links/genes/19
MLH1	4292	E13FS*3	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a MLH1 p.G606fs*2 mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1788	725	3532	3	37035075	37035075	G		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1788	https://civic.genome.wustl.edu/links/variants/725	https://civic.genome.wustl.edu/links/genes/3532
MSH2	4436	R383*	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in two patients was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (one endometrial cancer, one ovarian cancer) with suspected Lynch Syndrome (LS). These patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. LOH of the WT allele was confirmed in the case of ovarian cancer.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1790	727	3628	2	47656951	47656951	C	T	ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1790	https://civic.genome.wustl.edu/links/variants/727	https://civic.genome.wustl.edu/links/genes/3628
MLH1	4292	V534R	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1791	728	3532	3	37081718	37081719	GT	AG	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1791	https://civic.genome.wustl.edu/links/variants/728	https://civic.genome.wustl.edu/links/genes/3532
UGT1A1	54658	UGT1A1*28	Cancer	162		Belinostat		Predictive	Supports	A	Adverse Response	The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.	26313268	PubMed		Goey et al., 2016, J Clin Pharmacol		5	accepted	1792	729	12422	2	234668881	234668882		TATATATATATATA	ENST00000305208.5					75	GRCh37		Common Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1792	https://civic.genome.wustl.edu/links/variants/729	https://civic.genome.wustl.edu/links/genes/12422
MLH1	4292	G606FS*2	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a MLH1 p.E13fs*3 mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1793	730	3532	3	37089094	37089095	GG		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1793	https://civic.genome.wustl.edu/links/variants/730	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	c.790+1G>A	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored a p.K618del mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1794	731	3532	3	37056036	37056036	G	A	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1794	https://civic.genome.wustl.edu/links/variants/731	https://civic.genome.wustl.edu/links/genes/3532
UGT1A1	54658	UGT1A1*60	Cancer	162		Belinostat		Predictive	Supports	B	Adverse Response	In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation. Belinostat AUC and half-life was significantly increased in UGT1A1*60 carriers, and they were at greater risk for thrombocytopenia.	26313268	PubMed		Goey et al., 2016, J Clin Pharmacol		4	accepted	1795	732	12422														Common Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1795	https://civic.genome.wustl.edu/links/variants/732	https://civic.genome.wustl.edu/links/genes/12422
MLH1	4292	K618DEL	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Both patients harbored a second MLH1 mutation (c.790+1G>A and p.M1L, respectively).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1796	733	3532	3	37089130	37089132	AAG		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1796	https://civic.genome.wustl.edu/links/variants/733	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	R687FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated. Patient also had a BRAF p.D594G mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1798	735	3532	3	37090464	37090464	C		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1798	https://civic.genome.wustl.edu/links/variants/735	https://civic.genome.wustl.edu/links/genes/3532
EGFR	1956	V769_770insASV	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	Although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy.	26773740	PubMed		Klughammer et al., 2016, J Thorac Oncol		3	accepted	1799	736	19	7	55249009	55249010		GCCAGCGTG	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1799	https://civic.genome.wustl.edu/links/variants/736	https://civic.genome.wustl.edu/links/genes/19
DPYD	1806	DPYD*2A HOMOZYGOSITY	Cancer	162		Capecitabine,Fluorouracil,Tegafur	Substitutes	Predictive	Supports	A	Adverse Response	The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.	23988873	PubMed		Caudle et al., 2013, Clin. Pharmacol. Ther.		5	accepted	1800	737	1526	1	97915614	97915614	C	T	ENST00000370192.3					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1800	https://civic.genome.wustl.edu/links/variants/737	https://civic.genome.wustl.edu/links/genes/1526
DPYD	1806	DPYD*13 HOMOZYGOSITY	Cancer	162		Fluorouracil,Capecitabine,Tegafur	Substitutes	Predictive	Supports	A	Adverse Response	The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.	23988873	PubMed		Caudle et al., 2013, Clin. Pharmacol. Ther.		5	accepted	1801	738	1526	1	97981343	97981343	A	C	ENST00000370192.3					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1801	https://civic.genome.wustl.edu/links/variants/738	https://civic.genome.wustl.edu/links/genes/1526
FOS	2353	TRUNCATING FUSION	Bone Epithelioid Hemangioma	6610				Diagnostic	Supports	C	Positive	FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma. The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA.  The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases.	26173738	PubMed		van IJzendoorn et al., 2015, Genes Chromosomes Cancer		3	accepted	1802	739	1955	14	75745477	75748127			ENST00000303562.4					75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1802	https://civic.genome.wustl.edu/links/variants/739	https://civic.genome.wustl.edu/links/genes/1955
DPYD	1806	RS67376798 HOMOZYGOSITY	Cancer	162		Capecitabine,Tegafur,Fluorouracil	Substitutes	Predictive	Supports	A	Adverse Response	The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.	23988873	PubMed		Caudle et al., 2013, Clin. Pharmacol. Ther.		5	accepted	1803	740	1526														Common Germline	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1803	https://civic.genome.wustl.edu/links/variants/740	https://civic.genome.wustl.edu/links/genes/1526
MLH1	4292	R100*	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was confirmed.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1804	741	3532	3	37042536	37042536	C	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1804	https://civic.genome.wustl.edu/links/variants/741	https://civic.genome.wustl.edu/links/genes/3532
WWTR1	25937	WWTR1-CAMTA1	Malignant Epithelioid Hemangioendothelioma	0080190				Diagnostic	Supports	B	Positive	Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined.	21584898	PubMed		Errani et al., 2011, Genes Chromosomes Cancer		4	accepted	1805	742	9952	3	149235022	149290787			ENST00000465804.1	1	7721786	7829766	ENST00000303635.7	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1805	https://civic.genome.wustl.edu/links/variants/742	https://civic.genome.wustl.edu/links/genes/9952
MLH1	4292	T117M	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in three cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Two patients had loss of heterozygosity effecting the wildtype allele while one patient harbored a second MLH1 mutation (p.I68S).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1806	743	3532	3	37045935	37045935	C	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1806	https://civic.genome.wustl.edu/links/variants/743	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	Q426FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (LS). The patient was therefore negative for LS. However, based on this study, we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1807	744	3532	3	37067365	37067365	C		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1807	https://civic.genome.wustl.edu/links/variants/744	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	V49A	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. The patient also harbored a second MLH1 mutation (p.D667fs) which demonstrated loss of heterozygosity.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1808	745	3532	3	37038139	37038139	T	C	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1808	https://civic.genome.wustl.edu/links/variants/745	https://civic.genome.wustl.edu/links/genes/3532
EGFR	1956	EXON 20 INSERTION	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Resistance	In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses.	26051236	PubMed		Yang et al., 2015, Lancet Oncol.	NCT00525148,NCT00949650,NCT01121393	3	accepted	1809	726	19	7	55248991	55249022			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/1809	https://civic.genome.wustl.edu/links/variants/726	https://civic.genome.wustl.edu/links/genes/19
MLH1	4292	D667FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity leading to primarily the D667fs allele detected (90% VAF). This patient also harbored a heterozygous p.V49A variant.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1810	746	3532	3	37090406	37090406	C		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1810	https://civic.genome.wustl.edu/links/variants/746	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	M1L	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity resulting in overrepresentation of the M1L allele was observed. Additionally, this patient harbored a heterozygous MLH1 p.K618del mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1811	747	3532	3	37035039	37035039	A	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1811	https://civic.genome.wustl.edu/links/variants/747	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	*757L	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable villous adenomas was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. The patient also harbored an MLH1 c.453+1G>A mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1812	748	3532	3	37092143	37092143	A	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1812	https://civic.genome.wustl.edu/links/variants/748	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	R265G	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1813	749	3532	3	37058999	37058999	C	G	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1813	https://civic.genome.wustl.edu/links/variants/749	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	V213FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in both patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1814	750	3532	3	37053551	37053551	T		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1814	https://civic.genome.wustl.edu/links/variants/750	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	N551T	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1815	751	3532	3	37081770	37081770	A	C	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1815	https://civic.genome.wustl.edu/links/variants/751	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	A424T	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Patient also harbored a BRAF V600E mutation.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1816	752	3532	3	37067359	37067359	G	A	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1816	https://civic.genome.wustl.edu/links/variants/752	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	Q149*	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored MLH1 p.R226* and MSH6 p.I972F mutations at similar variant allele frequencies.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1817	753	3532	3	37048546	37048546	C	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/1817	https://civic.genome.wustl.edu/links/variants/753	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	R226*	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also harbored MLH1 p.Q149* and MSH6 p.I972F mutations as similar variant allele frequencies.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1818	754	3532	3	37053589	37053589	C	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1818	https://civic.genome.wustl.edu/links/variants/754	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	P536FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated resulting in higher mutated allele representation (80% variant allele frequency).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1820	756	3532	3	37081726	37081726	T		ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1820	https://civic.genome.wustl.edu/links/variants/756	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	G67R	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity of the wildtype allele was demonstrated.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1821	757	3532	3	37038192	37038192	G	A	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1821	https://civic.genome.wustl.edu/links/variants/757	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	I68S	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity leading to  p.I68S at 77% variant allele frequency was demonstrated. The patient also harbored a heterozygous MLH1 p.T117M mutation (38% VAF).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1822	758	3532	3	37038196	37038196	T	G	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1822	https://civic.genome.wustl.edu/links/variants/758	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	G65D	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient also had loss of heterozygosity.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1823	759	3532	3	37038187	37038187	G	A	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1823	https://civic.genome.wustl.edu/links/variants/759	https://civic.genome.wustl.edu/links/genes/3532
MLH1	4292	A681V	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. Loss of heterozygosity (wildtype allele loss) was also demonstrated.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1824	760	3532	3	37090447	37090447	C	T	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1824	https://civic.genome.wustl.edu/links/variants/760	https://civic.genome.wustl.edu/links/genes/3532
MSH6	2956	P138T	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1825	761	2478	2	48018217	48018217	C	A	ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1825	https://civic.genome.wustl.edu/links/variants/761	https://civic.genome.wustl.edu/links/genes/2478
MSH2	4436	V273FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.  LOH of the WT allele was demonstrated.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1826	762	3628	2	47641433	47641433	T		ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1826	https://civic.genome.wustl.edu/links/variants/762	https://civic.genome.wustl.edu/links/genes/3628
MSH2	4436	E28FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (LS). This patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient had two pathogenic mutations in MSH2 (E28fs, K172*).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1827	763	3628	2	47630413	47630414		G	ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1827	https://civic.genome.wustl.edu/links/variants/763	https://civic.genome.wustl.edu/links/genes/3628
VHL	7428	E55FS (c.163_164delGA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	In a 54 year old male patient with sporadic renal cell carcinoma, a c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative. Since this is a somatic variant, albeit with likely functional effect, we can only infer that if observed in a germline context, it might predispose for VHL.	10408776	PubMed		Gallou et al., 1999, Hum. Mutat.		2	accepted	1828	764	58	3	10183694	10183695	GA		ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1828	https://civic.genome.wustl.edu/links/variants/764	https://civic.genome.wustl.edu/links/genes/58
MSH6	2956	I891FS	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1829	765	2478	2	48027794	48027795	TC		ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1829	https://civic.genome.wustl.edu/links/variants/765	https://civic.genome.wustl.edu/links/genes/2478
VHL	7428	E55RfsTer11 (c.163delG)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	This is a frameshift mutation that results in a stop at codon 66.   Family 3682 in this publication, variant segregates with disease.  VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma	8956040	PubMed		Zbar et al., 1996, Hum. Mutat.		3	accepted	1830	766	58	3	10183694	10183694	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1830	https://civic.genome.wustl.edu/links/variants/766	https://civic.genome.wustl.edu/links/genes/58
MSH6	2956	R1242H	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1831	767	2478	2	48033421	48033421	G	A	ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1831	https://civic.genome.wustl.edu/links/variants/767	https://civic.genome.wustl.edu/links/genes/2478
MLH1	4292	M490T	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant may predispose to LS in a germline setting. The patient also harbored PMS2 R315*, MSH2 p.E483G and MSH6 p.V352I mutations.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		1	accepted	1833	769	3532	3	37070334	37070334	T	C	ENST00000231790.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1833	https://civic.genome.wustl.edu/links/variants/769	https://civic.genome.wustl.edu/links/genes/3532
MSH2	4436	K172*	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting. This patient had two somatic pathogenic mutations in MSH2 (E28fs, K172*).	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1834	770	3628	2	47637380	47637380	A	T	ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/1834	https://civic.genome.wustl.edu/links/variants/770	https://civic.genome.wustl.edu/links/genes/3628
VHL	7428	A56FS (c.164_165insG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	B	Uncertain Significance	c.164insG causes a framehift and truncation allele. One family is described with this allele segregating with disease; 10 affected individuals: 2  patients with renal cell carcinoma, 3 with pheochromocytoma, 7 with retinal angioma, 3 with central nervous system hemangioma. ACMG evidence codes supported by this paper are possibly PVS1 and PP1.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	1835	771	58	3	10183695	10183696		G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1835	https://civic.genome.wustl.edu/links/variants/771	https://civic.genome.wustl.edu/links/genes/58
HOXB13	10481	G84E	Prostate Cancer	10283				Predisposing	Supports	B	Positive	Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls.  In a random effect model the pooled OR (3.38 (95% CI: 2.454.66)) of the studies supported the link between HOXB13 G84E variant and a susceptibility to prostate cancer.	27626483	PubMed		Zhang et al., 2016, Oncotarget		4	accepted	1836	772	8351	17	46805705	46805705	C	T	ENST00000290295.7					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1836	https://civic.genome.wustl.edu/links/variants/772	https://civic.genome.wustl.edu/links/genes/8351
MSH2	4436	E483G	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1837	773	3628	2	47690231	47690231	A	G	ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1837	https://civic.genome.wustl.edu/links/variants/773	https://civic.genome.wustl.edu/links/genes/3628
PDGFRA	5156	TNKS2-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient harbouring a novel TNKS2PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	25658984	PubMed		Chalmers et al., 2015, Blood Cancer J		3	accepted	1838	774	38	10	93558069	93619405			ENST00000371627.4	4	55141008	55164414	ENST00000257290.5	75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1838	https://civic.genome.wustl.edu/links/variants/774	https://civic.genome.wustl.edu/links/genes/38
MSH6	2956	V352I	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1839	775	2478	2	48026176	48026176	G	A	ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1839	https://civic.genome.wustl.edu/links/variants/775	https://civic.genome.wustl.edu/links/genes/2478
MSH6	2956	R1242C	Lynch Syndrome	3883				Predisposing	Supports	E	Uncertain Significance	This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. However, based on this study we can infer that the variant would predispose to LS in a germline setting.	25111426	PubMed		Geurts-Giele et al., 2014, J. Pathol.		2	accepted	1840	776	2478	2	48033420	48033420	C	T	ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1840	https://civic.genome.wustl.edu/links/variants/776	https://civic.genome.wustl.edu/links/genes/2478
SLCO1B1	10599	RS4149056	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	23652803	PubMed		Radtke et al., 2013, Blood		3	accepted	1841	777	8450	12	21331549	21331549	T	C	ENST00000256958.2					75	GRCh37		Common Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1841	https://civic.genome.wustl.edu/links/variants/777	https://civic.genome.wustl.edu/links/genes/8450
SLCO1B1	10599	N130D	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	23652803	PubMed		Radtke et al., 2013, Blood		3	accepted	1842	778	8450	12	21329738	21329738	A	G	ENST00000256958.2					75	GRCh37		Common Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1842	https://civic.genome.wustl.edu/links/variants/778	https://civic.genome.wustl.edu/links/genes/8450
TYMS	7298	RS34743033	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = 0.48; 95% CI, 0.84, 0.12; R2 = 0.018; P = .009)	23652803	PubMed		Radtke et al., 2013, Blood		3	accepted	1843	779	5971	18	657646	657646	C	T	ENST00000323274.10					75			Common Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1843	https://civic.genome.wustl.edu/links/variants/779	https://civic.genome.wustl.edu/links/genes/5971
GLI1	2735	ACTB-GLI1	Pericytoma					Diagnostic	Supports	B	Positive	Pericytoma with t(7;12) is a soft tissue tumor characterized by fusion of the ACTB and GLI genes through the translocation t(7;12)(p22;q13). In this study the genomic breakpoints of 5 cases were characterized.	15555571	PubMed		Dahln et al., 2004, Biochem. Biophys. Res. Commun.		3	accepted	1844	780	2279													Fusion of the hedgehog pathway component gene GLI1 to the -actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/1844	https://civic.genome.wustl.edu/links/variants/780	https://civic.genome.wustl.edu/links/genes/2279
ERBB3	2065	V855A	Lung Non-small Cell Carcinoma	3908		Afatinib,Pertuzumab	Substitutes	Predictive	Supports	D	Sensitivity/Response	Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V. Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab.	26689995	PubMed		Umelo et al., 2016, Oncotarget		2	accepted	1845	781	1733	12	56491672	56491672	T	C	ENST00000267101.3					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1845	https://civic.genome.wustl.edu/links/variants/781	https://civic.genome.wustl.edu/links/genes/1733
FGFR2	2263	FGFR2-BICC1	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%).	24122810	PubMed		Arai et al., 2014, Hepatology		4	accepted	1846	782	22	10	123239371	123357917			ENST00000457416.2	10	60461834	60591195	ENST00000373886.3	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1846	https://civic.genome.wustl.edu/links/variants/782	https://civic.genome.wustl.edu/links/genes/22
FGFR2	2263	FGFR2-AHCYL1	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%).	24122810	PubMed		Arai et al., 2014, Hepatology		4	accepted	1847	783	22	10	123239371	123357917			ENST00000457416.2	1	110554984	110566357	ENST00000369799.5	75	GRCh37			2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1847	https://civic.genome.wustl.edu/links/variants/783	https://civic.genome.wustl.edu/links/genes/22
CDKN2B	1030	METHYLATION	Acute Promyelocytic Leukemia	0060318				Prognostic	Supports	B	Poor Outcome	This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples. While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS.	16307009	PubMed		Chim et al., 2006, Leukemia		4	accepted	1848	784	916	9	22009121	22009172			ENST00000276925.6					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1848	https://civic.genome.wustl.edu/links/variants/784	https://civic.genome.wustl.edu/links/genes/916
CHEK2	11200	1100DELC	Prostate Cancer	10283				Predisposing	Supports	B	Positive	Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).	26629066	PubMed		Wang et al., 2015, Int J Clin Exp Med		3	accepted	1850	785	8950	22	29091857	29091857	G		ENST00000328354.6					75	GRCh37		Rare Germline	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/1850	https://civic.genome.wustl.edu/links/variants/785	https://civic.genome.wustl.edu/links/genes/8950
FGFR2	2263	FGFR2-BICC1	Cholangiocarcinoma	4947		PD173074,Infigratinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		Arai et al., 2014, Hepatology		3	accepted	1851	782	22	10	123239371	123357917			ENST00000457416.2	10	60461834	60591195	ENST00000373886.3	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1851	https://civic.genome.wustl.edu/links/variants/782	https://civic.genome.wustl.edu/links/genes/22
CHEK2	11200	I157T	Prostate Cancer	10283				Predisposing	Supports	B	Uncertain Significance	Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).	26629066	PubMed		Wang et al., 2015, Int J Clin Exp Med		3	accepted	1852	787	8950	22	29121087	29121087	A	G	ENST00000328354.6					75	GRCh37		Rare Germline	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/1852	https://civic.genome.wustl.edu/links/variants/787	https://civic.genome.wustl.edu/links/genes/8950
FGFR2	2263	FGFR2-AHCYL1	Cholangiocarcinoma	4947		Infigratinib,PD173074	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		Arai et al., 2014, Hepatology		3	accepted	1853	783	22	10	123239371	123357917			ENST00000457416.2	1	110554984	110566357	ENST00000369799.5	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1853	https://civic.genome.wustl.edu/links/variants/783	https://civic.genome.wustl.edu/links/genes/22
CHEK2	11200	IVS2+1G>A	Prostate Cancer	10283				Predisposing	Does Not Support	B	Uncertain Significance	Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.	26629066	PubMed		Wang et al., 2015, Int J Clin Exp Med		2	accepted	1854	788	8950														Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1854	https://civic.genome.wustl.edu/links/variants/788	https://civic.genome.wustl.edu/links/genes/8950
PTPRD	5789	V253I	Ewing Sarcoma Of Bone	3368		Teprotumumab,Cixutumumab	Substitutes	Predictive	Supports	C	Sensitivity/Response	Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had stable disease (T781A mutant). Four wildtype patients had stable or progressive disease.	23800680	PubMed		Jiang et al., 2013, Oncotarget		4	accepted	1856	792	4692	9	8521481	8521481	C	T	ENST00000381196.4					75	GRCh37		Rare Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/1856	https://civic.genome.wustl.edu/links/variants/792	https://civic.genome.wustl.edu/links/genes/4692
VHL	7428	A56fs (c.164_165insA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A variants resulting in A56G frameshift (with stop introduced at position 131) was observed in a single patient of a VHL family. (family #146 in the publication). Neither the VHL phenotype details or segregation data were provided by this publication. Since this is a frameshift occurring early in the protein sequence we can assign an ACMG evidence code of 'PVS1'.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		2	accepted	1857	793	58	3	10183695	10183696		A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/1857	https://civic.genome.wustl.edu/links/variants/793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E55= (c.165G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	c.165G>A results in synonymous change Glu55Glu. This is family V5 in the paper (VHL Type 1, no phechromocytoma).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	1858	794	58	3	10183696	10183696	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1858	https://civic.genome.wustl.edu/links/variants/794	https://civic.genome.wustl.edu/links/genes/58
RRM1	6240	OVEREXPRESSION	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	D	Resistance	The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM1 progressively increased during the development of gemcitabine resistance.	17224927	PubMed		Nakano et al., 2007, Br. J. Cancer		2	accepted	1859	795	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		N/A	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1859	https://civic.genome.wustl.edu/links/variants/795	https://civic.genome.wustl.edu/links/genes/5051
RRM2	6241	OVEREXPRESSION	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	D	Resistance	The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines  cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.	17224927	PubMed		Nakano et al., 2007, Br. J. Cancer		2	accepted	1860	796	5052	2	10262455	10271545			ENST00000360566.2					75	GRCh37		N/A	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1860	https://civic.genome.wustl.edu/links/variants/796	https://civic.genome.wustl.edu/links/genes/5052
POLE	5426	MUTATION	Glioblastoma Multiforme	3068		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis. An objective radiographic response was noted in the intracranial lesion. A high neoantigen load was identified.	27683556	PubMed		Johanns et al., 2016, Cancer Discov		3	accepted	1861	797	4386	12	133202900	133256623			ENST00000320574.5					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1861	https://civic.genome.wustl.edu/links/variants/797	https://civic.genome.wustl.edu/links/genes/4386
POLE	5426	MUTATION	Endometrial Cancer	1380		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression.	27159395	PubMed		Mehnert et al., 2016, J. Clin. Invest.		3	accepted	1862	797	4386	12	133202900	133256623			ENST00000320574.5					75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1862	https://civic.genome.wustl.edu/links/variants/797	https://civic.genome.wustl.edu/links/genes/4386
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	B	Resistance	Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).	24035188	PubMed		Sun et al., 2013, Lung Cancer		4	accepted	1863	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1863	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
MET	4233	D1228V	Lung Non-small Cell Carcinoma	3908		Cabozantinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).	27694386	PubMed		Bahcall et al., 2016, Cancer Discov		4	accepted	1864	798	52	7	116423408	116423408	A	T	ENST00000397752.3					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1864	https://civic.genome.wustl.edu/links/variants/798	https://civic.genome.wustl.edu/links/genes/52
MET	4233	D1228V	Lung Non-small Cell Carcinoma	3908		Savolitinib		Predictive	Supports	C	Resistance	Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).	27694386	PubMed		Bahcall et al., 2016, Cancer Discov		4	accepted	1865	798	52	7	116423408	116423408	A	T	ENST00000397752.3					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1865	https://civic.genome.wustl.edu/links/variants/798	https://civic.genome.wustl.edu/links/genes/52
RB1	5925	MUTATION	Lung Small Cell Carcinoma	5409		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2).	26802149	PubMed		Dowlati et al., 2016, Ann. Oncol.		2	accepted	1866	799	4795	13	48877911	49056122			ENST00000267163.4					75	GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/1866	https://civic.genome.wustl.edu/links/variants/799	https://civic.genome.wustl.edu/links/genes/4795
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	A	Sensitivity/Response	Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).	27959700	PubMed		Mok et al., 2016, N. Engl. J. Med.	NCT02151981	5	accepted	1867	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1867	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
NTRK1	4914	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	3908		Entrectinib		Predictive	Supports	C	Sensitivity/Response	In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR.	26565381	PubMed		Farago et al., 2015, J Thorac Oncol	NCT02097810	3	accepted	1868	800	3983														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1868	https://civic.genome.wustl.edu/links/variants/800	https://civic.genome.wustl.edu/links/genes/3983
NTRK3	4916	ETV6-NTRK3	Salivary Gland Carcinoma	0050904		Entrectinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	26884591	PubMed		Drilon et al., 2016, Ann. Oncol.	NCT02097810	3	accepted	1869	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1869	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK3	4916	ETV6-NTRK3	Salivary Gland Carcinoma	0050904		Crizotinib		Predictive	Does Not Support	C	Sensitivity/Response	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks. The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	26884591	PubMed		Drilon et al., 2016, Ann. Oncol.	NCT02097810	2	accepted	1870	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/1870	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
RUNX1	861	K83E	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Likely Pathogenic	A pedigree of 48 individuals with multiple instances of bleeding and platelet disorders and 8 cases of leukemia showed an A>G substitution in RUNX1 exon 3 which segregated with Familial Platelet Disorder and Acute Myeloid Leukemia. The mutation was not present in 188 unrelated control chromosomes. Functional assay suggested the mutant RUNX1 transcription factor had impaired DNA binding.	11830488	PubMed		Michaud et al., 2002, Blood		4	accepted	1871	802	43	21	36259163	36259163	T	C	ENST00000344691.4					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1871	https://civic.genome.wustl.edu/links/variants/802	https://civic.genome.wustl.edu/links/genes/43
RUNX1	861	Y260*	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Uncertain Significance	A pedigree (Pedigree number 3) with 24 members with multiple instances of bleeding disorder and three cases of familial leukemia showed a C>A substitution in exon 7B of the transcription factor RUNX1.  This mutation resulted in a nonsense mutation, and the mutation segregated with familial platelet disorder and acute myeloid leukemia in the pedigree.	11830488	PubMed		Michaud et al., 2002, Blood		3	accepted	1872	803	43	21	36171704	36171704	G	T	ENST00000344691.4					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1872	https://civic.genome.wustl.edu/links/variants/803	https://civic.genome.wustl.edu/links/genes/43
RUNX1	861	R135FSX177	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Likely Pathogenic	A pedigree (Pedigree number 2) with familial platelet disorder and acute myeloid leukemia (FPD/AML) was studied and a one-base deletion was found in RUNX1 splice donor site. This resulted in use of a cryptic donor splice site and a novel transcript with frameshift, 41 novel amino acids and termination at codon 177. This mutation segregated with FDP/AML and was not found in 184 unrelated control chromosomes.	11830488	PubMed		Michaud et al., 2002, Blood		4	accepted	1873	804	43														Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1873	https://civic.genome.wustl.edu/links/variants/804	https://civic.genome.wustl.edu/links/genes/43
NTRK3	4916	ETV6-NTRK3 G623R	Breast Cancer	1612		Entrectinib		Predictive	Supports	C	Resistance	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.  A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.	26884591	PubMed		Drilon et al., 2016, Ann. Oncol.	NCT02097810	4	accepted	1874	805	3985	15	88476265	88476265	C	T	ENST00000394480.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1874	https://civic.genome.wustl.edu/links/variants/805	https://civic.genome.wustl.edu/links/genes/3985
RUNX1	861	D198Y	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Uncertain Significance	In a pedigree with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) spanning three generations, five members of generation II were sequenced at exons 3, 4 and 5 of the RUNX1 (or CBFA2) gene and the D198Y mutation (in the DNA binding RUNT domain) was found in 3/5 of the individuals with FPD/AML but not in 2/5 without FPD/AML. The mutation was not found in 108 control subjects.	11675361	PubMed		Buijs et al., 2001, Blood		3	accepted	1875	806	43	21	36231792	36231792	C	A	ENST00000300305.3					75	GRCh37	D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease.	Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/1875	https://civic.genome.wustl.edu/links/variants/806	https://civic.genome.wustl.edu/links/genes/43
RUNX1	861	A107P	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Positive	A pedigree of 3 generations and 8 individuals with familial platelet disease with propensity to acute myeloid leukemia (FPD/AML) was assessed for mutation in RUNX1 exons 3, 4, 5 and 6. Mutation was found in DNA binding RUNT domain at amino acid 107 from alanine to proline. This mutation was found in 5/8 individuals with FPD/AML but not in 3/8 unaffected individuals as well as 10 unrelated control samples.	12060124	PubMed		Walker et al., 2002, Br. J. Haematol.		5	accepted	1876	807	43	21	36252962	36252962	C	G	ENST00000344691.4					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1876	https://civic.genome.wustl.edu/links/variants/807	https://civic.genome.wustl.edu/links/genes/43
MSH2	4436	LOSS	Transitional Cell Carcinoma	2671		Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.	26674132	PubMed		Castro et al., 2015, J Immunother Cancer	NCT00938834	3	accepted	1877	808	3628	2	47630108	47710367			ENST00000233146.2					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1877	https://civic.genome.wustl.edu/links/variants/808	https://civic.genome.wustl.edu/links/genes/3628
MSH6	2956	LOSS	Transitional Cell Carcinoma	2671		Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.	26674132	PubMed		Castro et al., 2015, J Immunother Cancer	NCT00938834	3	accepted	1878	809	2478	2	48010221	48037240			ENST00000234420.5					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1878	https://civic.genome.wustl.edu/links/variants/809	https://civic.genome.wustl.edu/links/genes/2478
CDKN2A	1029	LOSS	Ewing Sarcoma	3369		Palbociclib,Linsitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth.	27286459	PubMed		Murakami et al., 2016, Oncotarget		2	accepted	1879	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1879	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
CDKN2B	1030	LOSS	Ewing Sarcoma	3369		Palbociclib,Linsitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth.	27286459	PubMed		Murakami et al., 2016, Oncotarget		2	accepted	1880	555	916	9	22002902	22009362			ENST00000276925.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1880	https://civic.genome.wustl.edu/links/variants/555	https://civic.genome.wustl.edu/links/genes/916
CDKN2A	1029	LOSS	Dermatofibrosarcoma Protuberans	3507		Palbociclib		Predictive	Supports	D	Sensitivity/Response	An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated COL1A1-PDGFB fusion was consistent with the most common form, a supernumerary ring chromosome. Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo.	25852058	PubMed		Eilers et al., 2015, Mol. Cancer Ther.		2	accepted	1881	554	14	9	21967752	21994623			ENST00000579755.1					75	GRCh37		Unknown	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/1881	https://civic.genome.wustl.edu/links/variants/554	https://civic.genome.wustl.edu/links/genes/14
RUNX1	861	T148HFSX9	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Uncertain Significance	A 2 year old male presented with easy bruising and bleeding. At 6 years old he was diagnosed with AML. The patients mother showed mile thrombocytopenia. Sequencing of RUNX1 exons 3-6 revealed an 8 bp deletion which was hypothesized to result in a null allele. The mutation was found in the mother and son. The patient's maternal grandparents were haematologicaly  normal. Relevant ACMG codes from this paper are 'PVS1' (frameshift/null variant) and 'PP1' (limited segregation data).	18478040	PubMed		Bri-Dexheimer et al., 2008, Eur. J. Hum. Genet.		2	accepted	1882	810	43	21	36252913	36252920	GCTGCGGT		ENST00000300305.3					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1882	https://civic.genome.wustl.edu/links/variants/810	https://civic.genome.wustl.edu/links/genes/43
DDX41	51428	R164W	Hematologic Cancer	2531				Predisposing	Supports	C	Positive	Eight members of larger pedigree spanning four generations with inherited hematological cancers were sequenced with whole exome sequencing or sanger sequencing of DDX41 exons 5 and 6. A mutation c.490C>T or R164W was found in 5/5 members with Non Hodkin's lymphoma, Hodgkin lymphoma, or multiple myeloma but not in 3/3 unaffected individuals. The site of mutation is reported to potentially be important for DDX41 helicase activity.	26712909	PubMed		Lewinsohn et al., 2016, Blood		3	accepted	1887	814	11932	5	176942767	176942767	G	A	ENST00000507955.1					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1887	https://civic.genome.wustl.edu/links/variants/814	https://civic.genome.wustl.edu/links/genes/11932
ERBB2	2064	Y772_A775DUP	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with Y772_A775dup (Case 1 in the paper), maintained a metabolic complete response for 3 months, ultimately received a total of 9 months of Afatinib, and survived one year from study entry.	22325357	PubMed		De Grve et al., 2012, Lung Cancer	NCT00730925	3	accepted	1888	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1888	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	G776L	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation.	22325357	PubMed		De Grve et al., 2012, Lung Cancer	NCT00730925	3	accepted	1889	816	20	17	37880997	37880998	GG	CT	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1889	https://civic.genome.wustl.edu/links/variants/816	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	G778_P780DUP	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G778_P780dup (Case 3 in the paper), had a rapid clinical and symptomatic response to Afatinib and stable disease which lasted for 3 months. Progressive disease at 4 months led to the addition of paclitaxel, resulting in partial response. Total Afatinib treatment was 15 months (11 in combination) at which time the patient developed a brain metastasis but no other progressive disease.	22325357	PubMed		De Grve et al., 2012, Lung Cancer	NCT00730925	3	accepted	1890	817	20	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1890	https://civic.genome.wustl.edu/links/variants/817	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Does Not Support	B	Sensitivity/Response	Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.	25899785	PubMed		Kris et al., 2015, Ann. Oncol.	NCT00818441	3	accepted	1891	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1891	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	G778_P780DUP	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA) and no amplification. Both had a confirmed partial response lasting 11 and 14 months. Only 3/30 patients on this trial had a partial response (no complete responses).	25899785	PubMed		Kris et al., 2015, Ann. Oncol.	NCT00818441	3	accepted	1892	817	20	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1892	https://civic.genome.wustl.edu/links/variants/817	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	Y772_A775DUP	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Does Not Support	B	Sensitivity/Response	Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]. No partial responses were found in this subgroup even though some were on study treatment for >2 years and 3 patients with other HER2 mutations achieved PRs.	25899785	PubMed		Kris et al., 2015, Ann. Oncol.	NCT00818441	2	accepted	1893	414	20	17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5					75	GRCh37	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1893	https://civic.genome.wustl.edu/links/variants/414	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	M774DELINSWLV	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.	25899785	PubMed		Kris et al., 2015, Ann. Oncol.	NCT00818441	3	accepted	1894	818	20	17	37880991	37880991	A	TGGCTGG	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1894	https://civic.genome.wustl.edu/links/variants/818	https://civic.genome.wustl.edu/links/genes/20
PTPRB	5787	LOSS-OF-FUNCTION	Angiosarcoma	0001816		Sunitinib		Predictive	Supports	D	Sensitivity/Response	The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications. In HUVEC cell line model, silencing of PTPRB  induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR.	24633157	PubMed		Behjati et al., 2014, Nat. Genet.		3	accepted	1895	819	4690	12	70910630	71031220			ENST00000334414.6					75	GRCh37		Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1895	https://civic.genome.wustl.edu/links/variants/819	https://civic.genome.wustl.edu/links/genes/4690
VHL	7428	A149S (c.445G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Study of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma (spread over four generations). 25 proven cases of VHLD and 17 cases with pheochromocytoma were identified. Mutation analysis was performed in 14 family members (7 affected, 7 unaffected).  11 cases had the same mutation resulting in a predicted amino acid substitution of A149S.  The cases with mutation that appeared unaffected were all very young (before the likely age of onset). The three cases without the mutation that appeared unaffected were aged 18, 54, and 69.  ACMG evidence codes: 'PP1' based on segregation results, 'PM5' because the authors describe a prior report of a similar mutation at the same site (A149T), 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology.	9435426	PubMed		Atuk et al., 1998, J. Clin. Endocrinol. Metab.		4	accepted	1896	820	58	3	10188302	10188302	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1896	https://civic.genome.wustl.edu/links/variants/820	https://civic.genome.wustl.edu/links/genes/58
BRCA1	672	MUTATION	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344	3	accepted	1897	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1897	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
KRAS	3845	G12D	Colorectal Cancer	9256		Therapeutic Tumor Infiltrating Lymphocytes		Predictive	Supports	C	Sensitivity/Response	A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response.	27959684	PubMed		Tran et al., 2016, N. Engl. J. Med.		3	accepted	1898	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/1898	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
HLA-C	3107	COPY-NEUTRAL LOSS OF HETEROZYGOSITY	Colorectal Cancer	9256		Therapeutic Tumor Infiltrating Lymphocytes		Predictive	Supports	C	Resistance	A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D and HLA-C*08:02. A single lesion that progressed after 9 months still expressed the KRAS G12D mutation. Whole-exome analysis revealed copy-neutral loss of heterozygosity at chromosome 6, encoding the HLA locus and resulting in loss of the targeted HLA-C*08:02 allele.	27959684	PubMed		Tran et al., 2016, N. Engl. J. Med.		3	accepted	1899	821	2608														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1899	https://civic.genome.wustl.edu/links/variants/821	https://civic.genome.wustl.edu/links/genes/2608
JAK1	3716	S703I	Hepatocellular Carcinoma	684		Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.	26701727	PubMed		Yang et al., 2016, Oncotarget		4	accepted	1900	822	3090	1	65311203	65311203	C	A	ENST00000342505.4					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1900	https://civic.genome.wustl.edu/links/variants/822	https://civic.genome.wustl.edu/links/genes/3090
EPCAM	4072	3' EXON DELETION	Lynch Syndrome	3883				Predisposing	Supports	B	Uncertain Significance	Rare but recurring germline truncating mutations of the 3 end of EPCAM, were reported for 27 independent families, shown to lead to epigenetic silencing of a neighbouring gene, MSH2, and suggested to cause Lynch syndrome.	21309036	PubMed		Kuiper et al., 2011, Hum. Mutat.		4	accepted	1901	823	3364	2	47612305	47614173			ENST00000263735					75	GRCh37		Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/1901	https://civic.genome.wustl.edu/links/variants/823	https://civic.genome.wustl.edu/links/genes/3364
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib,Cetuximab,Irinotecan	Combination	Predictive	Supports	B	Sensitivity/Response	Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies.	27729313	PubMed		Hong et al., 2016, Cancer Discov	NCT01787500	4	accepted	1902	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1902	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
ARAF	369	S490T	Colorectal Cancer	9256		Vemurafenib,Cetuximab,Irinotecan	Combination	Predictive	Supports	C	Resistance	Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.	27729313	PubMed		Hong et al., 2016, Cancer Discov	NCT01787500	1	accepted	1905	825	3	X	47429340	47429340	T	A	ENST00000377045.4					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1905	https://civic.genome.wustl.edu/links/variants/825	https://civic.genome.wustl.edu/links/genes/3
GNAS	2778	R201C	Colorectal Cancer	9256		Irinotecan,Cetuximab,Vemurafenib	Combination	Predictive	Supports	C	Resistance	Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression.	27729313	PubMed		Hong et al., 2016, Cancer Discov	NCT01787500	2	accepted	1906	826	2319	20	57484420	57484420	C	T	ENST00000371085.3					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1906	https://civic.genome.wustl.edu/links/variants/826	https://civic.genome.wustl.edu/links/genes/2319
ATM	472	MUTATION	Mantle Cell Lymphoma	0050746		Olaparib		Predictive	Supports	D	Sensitivity/Response	Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increased sensitivity to olaparib. These results were confirmed in a xenograft model.	20124459	PubMed		Williamson et al., 2010, Mol. Cancer Ther.		3	accepted	1907	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1907	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
FGFR1	2260	AMPLIFICATION	Lung Squamous Cell Carcinoma	3907		Infigratinib		Predictive	Supports	B	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		3	accepted	1908	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	N/A	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1908	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR1	2260	AMPLIFICATION	Breast Cancer	1612		Infigratinib		Predictive	Does Not Support	B	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25,  n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden. In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		2	accepted	1909	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).		2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1909	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR3	2261	MUTATION	Bladder Carcinoma	4007		Infigratinib		Predictive	Supports	B	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses  100 mg, the disease control rate (SD + PR) was 75%. 3 patients achieved PRs and 3 patients had SD. Of the six patients with disease control, the time on treatment ranged from 15.1 to  101 weeks, with one ongoing at data cutoff.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		3	accepted	1910	827	23	4	1795039	1810599			ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/1910	https://civic.genome.wustl.edu/links/variants/827	https://civic.genome.wustl.edu/links/genes/23
FGFR1	2260	AMPLIFICATION	Bladder Carcinoma	4007		Infigratinib		Predictive	Does Not Support	C	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		2	accepted	1911	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	N/A	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1911	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
FGFR2	2263	MUTATION	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		2	accepted	1912	511	22	10	123239371	123357917			ENST00000457416.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1912	https://civic.genome.wustl.edu/links/variants/511	https://civic.genome.wustl.edu/links/genes/22
FGFR2	2263	FGFR2 fusions	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Two cholangiocarcinoma patients harbored FGFR2 fusions. Both were treated at BGJ398 doses >100mg and saw stable disease. One patient had an unknown FGFR2 fusion partner and saw 20.2% reduction in target lesion size. The other patient harbored FGFR2 BICC1 fusion, and saw a 9.8% reduction in target lesion size.	27870574	PubMed		Nogova et al., 2017, J. Clin. Oncol.		2	accepted	1913	2202	22														Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1913	https://civic.genome.wustl.edu/links/variants/2202	https://civic.genome.wustl.edu/links/genes/22
VHL	7428	M54IFS (c.162_166delGGAGG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	A study of sporadic renal cell carcinoma identified this frameshift confirmed somatic variant along with LOH of the VHL gene in a case with clear cell renal carcinoma (case #152 in the study). VHL mutated clear cell carcinoma is associated with Von Hippel-Lindau Disease. Confidence in this variant being pathogenic for VHL disease is not high enough to warrant classification of Likely Pathogenic, and is therefore classified as Uncertain Significance.	8187067	PubMed		Shuin et al., 1994, Cancer Res.		2	accepted	1914	829	58	3	10183693	10183697	GGAGG		ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1914	https://civic.genome.wustl.edu/links/variants/829	https://civic.genome.wustl.edu/links/genes/58
FGFR2	2263	FGFR2-BICC1	Transitional Cell Carcinoma	2671		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR.	26324363	PubMed		Tabernero et al., 2015, J. Clin. Oncol.	NCT01703481	3	accepted	1917	782	22	10	123239371	123357917			ENST00000457416.2	10	60461834	60591195	ENST00000373886.3	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1917	https://civic.genome.wustl.edu/links/variants/782	https://civic.genome.wustl.edu/links/genes/22
FGFR2	2263	FGFR2 fusions	Cancer	162		Erdafitinib		Predictive	Supports	B	Sensitivity/Response	Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2 fusions, 1 patient with urothelial cancer had a PR harbored FGFR2-BICC1/FGFR2-CASP7 fusions, a patient with endometrial cancer and synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR, and tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions.	26324363	PubMed		Tabernero et al., 2015, J. Clin. Oncol.	NCT01703481	3	accepted	1918	2202	22														Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1918	https://civic.genome.wustl.edu/links/variants/2202	https://civic.genome.wustl.edu/links/genes/22
FGFR3	2261	FGFR3-TACC3	Cancer	162		Erdafitinib		Predictive	Supports	B	Sensitivity/Response	Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion).	26324363	PubMed		Tabernero et al., 2015, J. Clin. Oncol.	NCT01703481	3	accepted	1919	830	23	4	1795039	1808661			ENST00000340107.4	4	1741429	1746898	ENST00000313288.4	75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/1919	https://civic.genome.wustl.edu/links/variants/830	https://civic.genome.wustl.edu/links/genes/23
FGFR2	2263	FGFR2-BICC1	Endometrial Cancer	1380		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR.	26324363	PubMed		Tabernero et al., 2015, J. Clin. Oncol.	NCT01703481	3	accepted	1920	782	22	10	123239371	123357917			ENST00000457416.2	10	60461834	60591195	ENST00000373886.3	75	GRCh37		Somatic	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1920	https://civic.genome.wustl.edu/links/variants/782	https://civic.genome.wustl.edu/links/genes/22
TSC1	7248	R1062W	Tuberous Sclerosis	13515				Predisposing	Supports	D	Uncertain Significance	The authors used a transfection based immunoblot assay to assess the impact of TSC1 (and TSC2) variants. Numerous variants were tested independently across 4 replicates and the mean and s.e.m. were plotted relative to wild type TSC1. The R1062W variant does not display a significant functional impact relative to the wildtype.  The authors state that SIFT (an in-silico missense functional prediction program) predicts the variant is tolerated.	21309039	PubMed		Hoogeveen-Westerveld et al., 2011, Hum. Mutat.		3	accepted	1921	714	46	9	135771933	135771933	G	A	ENST00000298552.3					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1921	https://civic.genome.wustl.edu/links/variants/714	https://civic.genome.wustl.edu/links/genes/46
AKT3	10000	OVEREXPRESSION	Breast Cancer	1612		Akt Inhibitor MK2206		Predictive	Supports	D	Resistance	Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.	27297869	PubMed		Stottrup et al., 2016, Mol. Cancer Ther.		4	accepted	1922	1301	7936														N/A	2021-03-31 18:22:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1922	https://civic.genome.wustl.edu/links/variants/1301	https://civic.genome.wustl.edu/links/genes/7936
AKT3	10000	OVEREXPRESSION	Triple-receptor Negative Breast Cancer	0060081		Pan-AKT Kinase Inhibitor GSK690693		Predictive	Supports	E	Sensitivity/Response	AKT3 was found to be preferentially required for the proliferation and tumor growth of TNBC. It was found to be upregulated in a set of TNBC cell lines compared to other breast cancer types. Depletion of AKT3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. It was found that depletion of Akt3 potentially inhibits the growth of TNBC cell lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, which imply that therapeutic targeting of AKT3 may provide a new treatment option for TNBCs.	24335962	PubMed		Chin et al., 2014, Cancer Res.		4	accepted	1923	1301	7936														N/A	2021-03-31 18:22:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1923	https://civic.genome.wustl.edu/links/variants/1301	https://civic.genome.wustl.edu/links/genes/7936
BRCA1	672	LOSS-OF-FUNCTION	Breast Cancer	1612		Pol I Inhibitor CX5461,Quarfloxin	Substitutes	Predictive	Supports	D	Sensitivity/Response	The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.	28211448	PubMed		Xu et al., 2017, Nat Commun	NCT02719977	4	accepted	1924	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Unknown	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/1924	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Breast Cancer	1612		Pol I Inhibitor CX5461,Quarfloxin	Substitutes	Predictive	Supports	D	Sensitivity/Response	The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.	28211448	PubMed		Xu et al., 2017, Nat Commun	NCT02719977	4	accepted	1925	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Unknown	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1925	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
PTEN	5728	R173C	Cancer	162				Predisposing	Supports	D	Uncertain Significance	Han et al functionally tested the R173C mutation in PTEN using an expression vector construct, assessing phosphatase activity of the mutant construct with two phosphoinositide substrates ("with[ PtdIns(3,4,5)P3] or without[ Ins(1,3,4,5)P4] a diacylglycerol chain"). R173C resides in the NH2-terminal phosphatase domain of PTEN. R173C was one of four mutations (out of 42 tested) that displayed no significant phosphatase activity against either substrate, indicating, by this assay, that the mutation negatively impacts the function of PTEN.   However this mutation did not affect the ability of PTEN to bind lipid membranes in-vivo.  This data justifies PS3 level evidence for pathogenicity according to ACMG guidelines.	10866302	PubMed		Han et al., 2000, Cancer Res.		3	accepted	1930	838	41	10	89711899	89711899	C	T	ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1930	https://civic.genome.wustl.edu/links/variants/838	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	MUTATION	Glioblastoma Multiforme	3068				Diagnostic	Supports	C	Positive	Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compared to low-grade and child gliomas (68 others, varied). Mutation analysis performed using SSCP. No further testing was done.	9331072	PubMed		Rasheed et al., 1997, Cancer Res.		2	accepted	1931	510	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1931	https://civic.genome.wustl.edu/links/variants/510	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	R173C	Endometrial Hyperplasia	0080365				Predisposing	Supports	E	Uncertain Significance	Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%). No additional functional testing or clinical description was given.	9635567	PubMed		Maxwell et al., 1998, Cancer Res.		1	accepted	1934	838	41	10	89711899	89711899	C	T	ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1934	https://civic.genome.wustl.edu/links/variants/838	https://civic.genome.wustl.edu/links/genes/41
PTEN	5728	R173C	PTEN Hamartoma Tumor Syndrome	0080191				Predisposing	Supports	C	Uncertain Significance	Hopman et al presents a case study with an affected proband carrying PTEN R173C, and meeting the pediatric criteria for PTEN testing of Tan et al (2011). The proband died at 2 years due to a fatal chylothorax, having been seen at 1 year with progressive dyspnoea and displaying extensive lymphatic and venus malformations that displaced the right lung, as well as osteolytic lesions of the bones.  Proband's mother and two siblings (one 7 years and one 7 months) also carried the PTEN R173C mutation and were thus far asymptomatic. The mother's parents did not carry the R173C mutation. PP4 ACMG evidence criteria are met as PTEN hamartoma tumor syndrome is a disease with a single genetic etiology.	22628360	PubMed		Hopman et al., 2012, Am. J. Med. Genet. A		3	accepted	1935	838	41	10	89711899	89711899	C	T	ENST00000371953.3					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1935	https://civic.genome.wustl.edu/links/variants/838	https://civic.genome.wustl.edu/links/genes/41
ALK	238	ALTERNATIVE TRANSCRIPT (ATI)	Skin Melanoma	8923		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Expression of an alternative ALK transcript (ATI), encompassing exons 2029 preceded by ~400 base pairs (bp) of intron 19, but not exons 119 was identified in three samples of thyroid cancer and melanoma. In TCGA samples, ALK ATI was expressed in approx. 11% of melanoma samples. Functional activity of ALK ATI was shown in-vitro. In vivo studies confirmed oncogenic activity of ALK ATI similar to other ALK mutations or fusions and sensitivity to crizotinib. A patient with metastatic melanoma and ALK ATI expression but no MET or ALK aberrations identified with FISH and a 341-gene panel sequencing  was treated with crizotinib and had symptomatic improvement and tumor shrinkage within 6 weeks of therapy	26444240	PubMed		Wiesner et al., 2015, Nature		4	accepted	1936	839	1													This novel ALK transcript (alternative isoform) initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19.	N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1936	https://civic.genome.wustl.edu/links/variants/839	https://civic.genome.wustl.edu/links/genes/1
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and L858R).  88 patients were treated with EGFR inhibitor gefitinib, while 89 were treated with cisplatin/docetaxel. Progression free survival was significantly longer with gefitinib treatment with a median of 9.2 months vs. 6.3 with cisplatin/docetaxel (HR 0.48; 95% CI 0.336-0.710; p<0.0001). Difference in response to gefitinib between the two EGFR mutation types was not observed.	20022809	PubMed		Mitsudomi et al., 2010, Lancet Oncol.		5	accepted	1937	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/1937	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903).	27302369	PubMed		Schell et al., 2016, Nat Commun		4	accepted	1940	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/1940	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
VHL	7428	EXON 1-3 DELETION	Von Hippel-Lindau Disease	14175	Renal cyst,Hemangioblastoma,Renal cell carcinoma,Pancreatic cysts,Hepatic cysts			Predisposing	Supports	C	Pathogenic	Mutation detected in 4 separate cases. Two cases show CNS hemangioblastoma, pancreatic/hepatic/renal cysts, and renal cell carcinoma. One case shows CNS hemangioblastoma, pancreatic cysts, and Grawitz. ACMG evidence codes: 'PVS1' based on deletion of all exons, 'PP1' based on segregation results, 'PP4' because the patients phenotypes are highly specific for a disease with single genetic etiology.	20151405	PubMed		Nordstrom-O'Brien et al., 2010, Hum. Mutat.		4	accepted	1942	843	58	3	10183532	10191649			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1942	https://civic.genome.wustl.edu/links/variants/843	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 1 DELETION	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Pathogenic	Mutation detected in one case. Case shows CNS hemangioblastoma. ACMG evidence codes: 'PVS1' for a single exon deletion, 'PP1' based on segregation results, 'PP4' because patients phenotypes are highly specific for a disease with single genetic etiology.	20151405	PubMed		Nordstrom-O'Brien et al., 2010, Hum. Mutat.		3	accepted	1943	844	58	3	10183532	10183871			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/1943	https://civic.genome.wustl.edu/links/variants/844	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 1-2 DELETION	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes:Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes: 'PVS1' based on deletion of exon 1+2, 'PP4' since the patients phenotypes are highly specific for a disease with single genetic etiology.	20151405	PubMed		Nordstrom-O'Brien et al., 2010, Hum. Mutat.		3	accepted	1944	845	58	3	10183532	10188320			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1944	https://civic.genome.wustl.edu/links/variants/845	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	M1FS (c.1_17del17)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	This somatic mutation was detected in two samples from a single case with chromophobe renal cell carcinoma (a 74 year old male). The tumor also harbored a silent THR157THR (471T>A) somatic variant. Since this is a somatic variant, albeit with likely functional effect, we can only infer that if observed in a germline context, it might predispose for VHL.	15932632	PubMed		van Houwelingen et al., 2005, BMC Cancer		2	accepted	1945	846	58	3	10183532	10183548	ATGCCCCGGAGGGCGGA		ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1945	https://civic.genome.wustl.edu/links/variants/846	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	M1? (c.1-1_20del21)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context.	15932632	PubMed		van Houwelingen et al., 2005, BMC Cancer		2	accepted	1946	847	58	3	10183531	10183551	AATGCCCCGGAGGGCGGAGAA		ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1946	https://civic.genome.wustl.edu/links/variants/847	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	M1? (c.3G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	Mutation detected in one case. Case shows clear-cell renal cell carcinoma. This case also harbored a second somatic variant in VHL: 209-210delAG (Stop130). Since this was a case of sporadic RCC, with a somatic variant observed in the tumor, we can only infer that the variant is functional and would be predisposing if it occurred in a germline context.	11505222	PubMed		Gallou et al., 2001, Pharmacogenetics		2	accepted	1947	848	58	3	10183534	10183534	G	A	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1947	https://civic.genome.wustl.edu/links/variants/848	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N7D (c.19A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	A somatic mutation detected in one case, a 79ya patient with renal cell carcinoma (case '1VT'). The patient had a second in-frame deletion of 5 amino acids (41-45), but the author speculate that it could be an inherited polymorphism. Since this variant is found in renal cell carcinoma, we can make an inference that it might be relevant to VHL disease in a germline context. Grade 2 clear cell renal cess carcinoma is highly associated with VHL mutation, so PP4 label may be warranted.	11536052	PubMed		Ma et al., 2001, Oncogene		1	accepted	1948	849	58	3	10183550	10183550	A	G	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1948	https://civic.genome.wustl.edu/links/variants/849	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P25L (c.74C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Mutation was detected in three unaffected members of Polish VHL families. Described as being in the non-conserved portion of the VHL coding region where mutations are not typically seen according to these authors. Possibly benign but appears to have fairly low global mutation allele frequency.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		3	accepted	1949	850	58	3	10183605	10183605	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1949	https://civic.genome.wustl.edu/links/variants/850	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P59fs (c.173_174insC)	Von Hippel-Lindau Disease	14175	Neoplasm of the central nervous system,Pancreatic cysts,Hemangioblastoma,Pancreatic endocrine tumor,Renal cyst			Predisposing	Supports	C	Uncertain Significance	Mutation was detected in one patient. Patient shows CNS hemangioblastoma and pancreatic neuroendocrine tumors, renal and pancreatic cysts, or central nervous system tumors. ACMG evidence codes: 'PVS1' because the variant is an early frameshift and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology.	19270817	PubMed		Cho et al., 2009, J. Korean Med. Sci.		3	accepted	1950	851	58	3	10183704	10183705		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/1950	https://civic.genome.wustl.edu/links/variants/851	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98FS (c.291_310del20)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	E	Uncertain Significance	This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context.	15932632	PubMed		van Houwelingen et al., 2005, BMC Cancer		2	accepted	1951	852	58	3	10183822	10183841	CTACCCAACGCTGCCGCCTG		ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/1951	https://civic.genome.wustl.edu/links/variants/852	https://civic.genome.wustl.edu/links/genes/58
GNA11	2767	MUTATION	Uveal Melanoma	6039		MEK Inhibitor PD0325901,Sotrastaurin Acetate	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	24141786	PubMed		Chen et al., 2014, Oncogene		3	accepted	1952	506	2308	19	3094408	3124002			ENST00000078429.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/1952	https://civic.genome.wustl.edu/links/variants/506	https://civic.genome.wustl.edu/links/genes/2308
GNAQ	2776	MUTATION	Uveal Melanoma	6039		MEK Inhibitor PD0325901,Sotrastaurin Acetate	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	24141786	PubMed		Chen et al., 2014, Oncogene		4	accepted	1953	505	2317	9	80331003	80646374			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/1953	https://civic.genome.wustl.edu/links/variants/505	https://civic.genome.wustl.edu/links/genes/2317
NF1	4763	MUTATION	Plexiform Neurofibroma	5151		Selumetinib		Predictive	Supports	B	Sensitivity/Response	Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%).	28029918	PubMed		Dombi et al., 2016, N. Engl. J. Med.	NCT01362803	3	accepted	1958	587	3867	17	29421945	29704695			ENST00000358273.4					75	GRCh37		Rare Germline	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/1958	https://civic.genome.wustl.edu/links/variants/587	https://civic.genome.wustl.edu/links/genes/3867
ATM	472	MUTATION	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline).	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	3	accepted	1960	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/1960	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
PALB2	79728	BIALLELIC INACTIVATION	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion).	26510020	PubMed		Mateo et al., 2015, N. Engl. J. Med.	NCT01682772	3	accepted	1963	532	15013	16	23614491	23652631			ENST00000261584.4					75	GRCh37		Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/1963	https://civic.genome.wustl.edu/links/variants/532	https://civic.genome.wustl.edu/links/genes/15013
MET	4233	AMPLIFICATION	Colorectal Cancer	9256		Anti-EGFR Monoclonal Antibody		Predictive	Supports	D	Resistance	Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.	23729478	PubMed		Bardelli et al., 2013, Cancer Discov		3	accepted	1971	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1971	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
NTRK1	4914	EXPRESSION	Neuroblastoma	769				Prognostic	Supports	B	Better Outcome	A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence.	8441429	PubMed		Nakagawara et al., 1993, N. Engl. J. Med.		4	accepted	1972	860	3983	1	156830686	156851434			ENST00000524377.1					75	GRCh37		N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1972	https://civic.genome.wustl.edu/links/variants/860	https://civic.genome.wustl.edu/links/genes/3983
PDGFRA	5156	P577S	Melanoma	1909		Crenolanib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.	24132921	PubMed		Dai et al., 2013, Clin. Cancer Res.		3	accepted	1974	862	38	4	55141083	55141083	C	T	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/1974	https://civic.genome.wustl.edu/links/variants/862	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	R841K	Melanoma	1909		Crenolanib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). PDGFRA R841K was detected in one sample of mucosal melanoma. In vitro, PDGFRA R841K expressed in IL-3 dependent Ba/F3 cells resulted in strong auto-phosphorylation and cell growth of PDGFRA independent of the presence of IL-3, suggesting oncogenicity. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA and cell proliferation. The authors concluded that PDGFRA R841K is sensitive to imatinib and crenolanib.	24132921	PubMed		Dai et al., 2013, Clin. Cancer Res.		3	accepted	1975	863	38	4	55152090	55152090	G	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1975	https://civic.genome.wustl.edu/links/variants/863	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	H845Y	Melanoma	1909		Imatinib,Crenolanib	Substitutes	Predictive	Supports	D	Sensitivity/Response	PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.	24132921	PubMed		Dai et al., 2013, Clin. Cancer Res.		3	accepted	1976	864	38	4	55152101	55152101	C	T	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1976	https://civic.genome.wustl.edu/links/variants/864	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	G853D	Melanoma	1909		Imatinib,Crenolanib	Substitutes	Predictive	Supports	D	Sensitivity/Response	PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.	24132921	PubMed		Dai et al., 2013, Clin. Cancer Res.		3	accepted	1977	865	38	4	55152126	55152126	G	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1977	https://civic.genome.wustl.edu/links/variants/865	https://civic.genome.wustl.edu/links/genes/38
MET	4233	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.	23729478	PubMed		Bardelli et al., 2013, Cancer Discov		3	accepted	1979	270	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/1979	https://civic.genome.wustl.edu/links/variants/270	https://civic.genome.wustl.edu/links/genes/52
MTAP	4507	Underexpression	Breast Cancer	1612		Pyrimidine Antagonist		Predictive	Supports	D	Sensitivity/Response	MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expresison as well as promoter methylation status  was analyzed in breast cancer patients and seven breast cancer cell lines. Knockdown of MTAP in one cell line increased sensitivity to inhibitors of de novo adenine synthesis (5-FU, AZA and MTX), mainly 5-FU.	26751376	PubMed		de Oliveira et al., 2016, PLoS ONE		1	accepted	1980	867	3659														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1980	https://civic.genome.wustl.edu/links/variants/867	https://civic.genome.wustl.edu/links/genes/3659
VPS37A	137492	UNDEREXPRESSION	Ovarian Cancer	2394		Cetuximab		Predictive	Supports	D	Resistance	Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro.	22016507	PubMed		Wittinger et al., 2011, Clin. Cancer Res.		3	accepted	1981	868	18353	8	17104080	17155533			ENST00000324849.4					75	GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/1981	https://civic.genome.wustl.edu/links/variants/868	https://civic.genome.wustl.edu/links/genes/18353
EGFR	1956	EXPRESSION	Chordoma	3302		Lapatinib		Predictive	Supports	B	Sensitivity/Response	18 advanced progressing chordoma patients that were positive for EGFR by at least one technique (immunohistochemistry and/or phospho-arrays, real-time polymerase chain reaction for EGFR ligands, FISH) entered this phase 2 study investigating the efficacy of lapatinib (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%). Of the 25 patients screened, three tested negative for EGFR. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases. Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months. Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR. This phase II study showed a modest antitumor activity of lapatinib in chordoma	23559153	PubMed		Stacchiotti et al., 2013, Ann. Oncol.		2	accepted	1984	354	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/1984	https://civic.genome.wustl.edu/links/variants/354	https://civic.genome.wustl.edu/links/genes/19
BTK	695	T316A	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	C	Resistance	Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling.	27626698	PubMed		Sharma et al., 2016, Oncotarget		4	accepted	1985	870	65	X	100613633	100613633	T	C	ENST00000308731.7					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1985	https://civic.genome.wustl.edu/links/variants/870	https://civic.genome.wustl.edu/links/genes/65
ERBB2	2064	T862A	Stomach Carcinoma	5517		Lapatinib		Predictive	Supports	D	Sensitivity/Response	Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.	22046346	PubMed		Kancha et al., 2011, PLoS ONE		3	accepted	1986	871	20	17	37881392	37881392	A	G	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1986	https://civic.genome.wustl.edu/links/variants/871	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	V773A	Head And Neck Squamous Cell Carcinoma	5520		Lapatinib		Predictive	Supports	D	Sensitivity/Response	Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.	22046346	PubMed		Kancha et al., 2011, PLoS ONE		3	accepted	1987	872	20	17	37880989	37880989	T	C	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1987	https://civic.genome.wustl.edu/links/variants/872	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	N857S	Ovarian Cancer	2394		Lapatinib		Predictive	Supports	D	Sensitivity/Response	Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.	22046346	PubMed		Kancha et al., 2011, PLoS ONE		3	accepted	1988	873	20	17	37881378	37881378	A	G	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/1988	https://civic.genome.wustl.edu/links/variants/873	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	H878Y	Hepatocellular Carcinoma	684		Lapatinib		Predictive	Supports	D	Sensitivity/Response	Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.	22046346	PubMed		Kancha et al., 2011, PLoS ONE		3	accepted	1989	874	20	17	37881440	37881440	C	T	ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/1989	https://civic.genome.wustl.edu/links/variants/874	https://civic.genome.wustl.edu/links/genes/20
FGFR2	2263	AMPLIFICATION	Stomach Carcinoma	5517		FGFR Inhibitor AZD4547		Predictive	Supports	B	Sensitivity/Response	Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547.  Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (range=6.2-10.5). Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria. High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC). In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition. Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway.	27179038	PubMed		Pearson et al., 2016, Cancer Discov		3	accepted	1990	629	22	10	123239371	123357917			ENST00000457416.2					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/1990	https://civic.genome.wustl.edu/links/variants/629	https://civic.genome.wustl.edu/links/genes/22
FGFR1	2260	AMPLIFICATION	Breast Cancer	1612		FGFR Inhibitor AZD4547		Predictive	Supports	C	Sensitivity/Response	Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer.	27179038	PubMed		Pearson et al., 2016, Cancer Discov		2	accepted	1991	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	N/A	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/1991	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
ERBB2	2064	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Lapatinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and overexpression of HER2 was identified (IHC, 95% of cells, with high intensity 3+ staining) which was confirmed on RNA-level. The patient was treated with single-agent lapatinib. A locally recurrent tumor was excised (and found HER2-negative) and the patient continued on lapatinib (for 2 years) as well as 5 cycles 5-FU and irinotecan. All lung metastases decreased in size within 3 months of lapatinib mono therapy initiation. The patient remains free of local or distant disease 5 years after starting lapatinib.	28061634	PubMed		Seim et al., 2017, Ann. Otol. Rhinol. Laryngol.		2	accepted	1992	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/1992	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).	28223103	PubMed		Jeong et al., 2017, Clin Colorectal Cancer		3	accepted	1993	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/1993	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
GNAS	2778	R201	Pseudomyxoma Peritonei	3559				Prognostic	Supports	B	Poor Outcome	Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.007). The results were externally validated on a previous series of 11 peritoneal pseudomyxoma patients (5.1 vs 13 months; HR for progression 11.26, 95 % CI 3.6235.06; log-rank test p < 0.0001). 14/15 patients evaluated also harbored KRAS exon 2 mutations but no NRAS or BRAF mutations.	27154293	PubMed		Pietrantonio et al., 2016, J Transl Med		3	accepted	1994	876	2319														Somatic	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/1994	https://civic.genome.wustl.edu/links/variants/876	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.	24758907	PubMed		Hong et al., 2014, Zhongguo Fei Ai Za Zhi		2	accepted	1995	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1995	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Intrahepatic Cholangiocarcinoma	4928				Prognostic	Supports	B	Poor Outcome	Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both disease-specific OS and recurrence-free survival with the homozygous TT genotype of the GNAS1 gene (hazard ratio = 2.47; 95% CI = 1.037.28). Patients with T393 homozygosity exhibit a decreased survival time regardless of their resection status and show earlier tumor recurrence.	17356712	PubMed		Schmitz et al., 2007, Neoplasia		3	accepted	1996	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1996	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Breast Carcinoma	3459				Prognostic	Supports	B	Poor Outcome	This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype. GNAS 393C homozygous patients of pT2-4 stages displayed a significantly lower risk for death than T393 homozygous patients, with heterozygous patients being at intermediate risk. Ten-year survival rates were 63% for CC, 40% for TC and 23% for TT genotypes, respectively.	17186357	PubMed		Otterbach et al., 2007, Breast Cancer Res. Treat.		4	accepted	1997	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/1997	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
PIK3CA	5290	C420R	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	1999	931	37	3	178927980	178927980	T	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/1999	https://civic.genome.wustl.edu/links/variants/931	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	G12V	Colorectal Cancer	9256		Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		3	accepted	2001	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2001	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	G12D	Colorectal Cancer	9256		Cetuximab,Irinotecan	Combination	Predictive	Supports	C	Resistance	One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and BRAF. This patient was a 64 year old male treated with cetuximab and irinotecan as 5th line therapy who experienced stable disease and had PFS of 64 weeks and OS of 84 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2002	878	36	1	115258747	115258747	C	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2002	https://civic.genome.wustl.edu/links/variants/878	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	G12/G13	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Resistance	In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of panitumumab on PFS in the KRAS wt group was significantly greater than in the KRAS mutant group (HR:0.45, 95% CI:0.34-0.59 vs HR:0.99, 95% CI:0.73-1.36; P<0.0001). None of the 84 panitumumab-treated patients with KRAS mutant tumors responded to treatment (100% positive predictive value for nonresponse in mutant group). In the KRAS wt group treated with panitumumab (n=124), 21 patients had partial response (17%), 42 experienced stable disease (34%). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and BSC alone (PFS: 7.4 wk vs 7.3 wk). The authors concluded that their findings support the hypothesis that KRAS mutations confer primary resistance to anti-EGFR antibodies and recommend that KRAS status be evaluated prior to panitumumab administration.	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776	3	accepted	2004	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2004	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2008	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2008	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).	19284554	PubMed		Greco et al., 2009, J. Exp. Clin. Cancer Res.		2	accepted	2009	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2009	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	11050000	PubMed		Rowley et al., 2000, Blood		2	accepted	2012	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2012	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	12483530	PubMed		Rowley et al., 2002, Oncogene		2	accepted	2013	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2013	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	16497971	PubMed		Hoang et al., 2006, Blood		2	accepted	2014	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2014	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
IDH1	3417	R132	Malignant Glioma	3070		Bevacizumab,Sunitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated with improved overall survival (OS 7.53 vs. 4.83 months; P=0.04), as compared to patients with wild-type IDH1.	22199315	PubMed		Lv et al., 2011, Anticancer Res.		2	accepted	2020	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2020	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
PIK3CA	5290	MUTATION	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients with tumors harboring PIK3CA mutations (n=192, 32.5%; 14.9% with H1047R; 4.2% with E542K; 4.9% with E545K; 8.5% across all other variants) experienced longer PFS, OS, and breast cancer specific survival than patients with PIK3CA wt tumors (p=0.06; p=0.03; p=0.004). PIK3CA mutations were positively associated with lymph node negativity, lower tumor stage, hormone receptor positivity, and HER2 negativity. Patients with PIK3CA mutated tumors experienced a 2 fold decrease in death due to breast cancer at 5 and 10 years. Tumors with hot spot mutations (E542K, E545K, H10447), were strongly correlated with lower grade (2), ER-positive, PR-positive, HR-positive, HER2-negative compared to PIK3CA wt tumors.	19671852	PubMed		Kalinsky et al., 2009, Clin. Cancer Res.		3	accepted	2025	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2025	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Breast Cancer	1612		Pictilisib Bismesylate		Predictive	Supports	D	Sensitivity/Response	Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor GDC-0941 compared to wildtype PIK3CA cell lines (n=54, P=0.005).	20453058	PubMed		O'Brien et al., 2010, Clin. Cancer Res.		2	accepted	2034	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2034	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Resistance	In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured from initiation of trastuzumab (HR = 1.92, P = 0.017) and diagnosis of first metastasis (HR = 1.69, P = 0.047).	21594665	PubMed		Razis et al., 2011, Breast Cancer Res. Treat.		2	accepted	2035	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/2035	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
PIK3CA	5290	E545K	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	2036	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2036	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Does Not Support	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the only variant noted in the primary tumor (found in the sigma-rectum junction) of one patient who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. See Patient 55 from Supplemental Table 1 for more information on this patient.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	2037	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2037	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	WILD TYPE	Colorectal Cancer	9256		Aspirin		Predictive	Does Not Support	B	Sensitivity/Response	This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803) and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). Among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with increased survival. The 5-year cumulative colorectal cancer specific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92).	23094721	PubMed		Liao et al., 2012, N. Engl. J. Med.		3	accepted	2038	2590	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/2038	https://civic.genome.wustl.edu/links/variants/2590	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Lung Non-small Cell Carcinoma	3908		PI103		Predictive	Supports	D	Sensitivity/Response	H460, a gefitinib-resistant NSCLC cell line harboring PIK3CA E545K (a PIK3CA activating mutation), was used to test the anti-tumor effects of PI103. Without treatment, H460 cells expressed high levels of phosphorylated AKT. Following treatment, p-AKT decreased which correlated with cell senescence. PI103 treatment resulted in greater cell senescence in the PIK3CA E545K cell line than in A549, a wildtype PIK3CA gefinitib-resistant NSCLC cell line.	19513541	PubMed		Zou et al., 2009, Int. J. Mol. Med.		2	accepted	2040	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2040	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	RARE MUTATION	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Tumors harboring rare PIK3CA mutations (N345K: 2.4%, C420R: 1.2%, E545A: 1.2%, E545Q: 0.3%, E545G: 0.3%, Q546R: 0.7%, Q546P: 0.2%, H1047L: 2.2%) were significantly associated with lower grade, HER2 negativity, and lymph-node negative status compared with WT.	19671852	PubMed		Kalinsky et al., 2009, Clin. Cancer Res.		2	accepted	2042	3222	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2042	https://civic.genome.wustl.edu/links/variants/3222	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death measured from initiation of trastuzumab (HR = 1.64, P = 0.029) and diagnosis of first metastasis (HR = 1.85, P = 0.003).	21594665	PubMed		Razis et al., 2011, Breast Cancer Res. Treat.		2	accepted	2043	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/2043	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. EGFR mutations (n=42) were associated with improved objective response to drug treatment (71.4% vs. 20.1%, p<0.0001), improved but not significant overall survival (36.9 vs. 24.8 months, p=0.09), and longer median time to progression (not reached vs. 3.7 months, p<0.0001) when compared to wild-type EGFR. Through multivariate analyses, it was shown that EGFR mutations are independent predictive favorable factors of response to drug treatment (p<0.0001) and are significant predictors of longer time to progression (HR: 0.27, 95% CI: 0.14-0.52, p=0.0001)	21258250	PubMed		Ludovini et al., 2011, J Thorac Oncol		4	accepted	2053	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2053	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
PIK3CA	5290	MUTATION	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	In retrospective study of 175 metastatic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 1.86, P = 0.014, multivariate analysis ) compared to wildtype PIK3CA.	21594665	PubMed		Razis et al., 2011, Breast Cancer Res. Treat.		3	accepted	2087	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2087	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients whose tumors harbored PIK3CA H1047R (n=88, 14.9%) experienced significantly higher 10-year overall survival rate (76% vs 62%) and lower 10-year probability of breast cancer specific death (11% vs 23%) compared to those with wildtype PIK3CA. They also experienced a 2.8 and 2 fold reduction in probability of death due to breast cancer at 5 and 10 years. Authors found that PIK3CA H1047R was specifically associated with lymph node-negative status: 64% of H1047R patients were lymph-node negative compared to 48% of patients with PIK3CA WT and helical domain mutated tumors (P=0.007). PIK3CA H1047R was positively associated with lymph node negative status, lower nodal stage, lower overall stage, and smaller tumor size compared to WT PIK3CA	19671852	PubMed		Kalinsky et al., 2009, Clin. Cancer Res.		2	accepted	2097	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/2097	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	B	Resistance	In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 2.50, P = 0.003, multivariate analysis) compared to wildtype PIK3CA.	21594665	PubMed		Razis et al., 2011, Breast Cancer Res. Treat.		3	accepted	2098	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2098	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival (p < .05).	17202311	PubMed		Maruyama et al., 2007, Clin. Cancer Res.		2	accepted	2100	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/2100	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Breast Cancer	1612		Trastuzumab		Predictive	Supports	D	Resistance	Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor, GDC-0941 (pictilisib), as compared to wildtype PIK3CA cell lines.	20453058	PubMed		O'Brien et al., 2010, Clin. Cancer Res.		3	accepted	2102	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/2102	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	2103	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/2103	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In colorectal cancer, PIK3CA mutations were associated with reduced relapse-free survival in stage II/III patients (HR:2.587, 95% CI:1.108-6.039, P=0.0280, univariate analysis; HR:2.478, 95% CI:1.028-5.973, P=0.0433, multivariate analysis) and reduced disease-specific survival in patients of any stage (n=18 vs. n=140, P=0.0357) compared to wildtype PIK3CA.	17590872	PubMed		Kato et al., 2007, Int. J. Cancer		3	accepted	2105	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/2105	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Rectum Cancer	1993				Prognostic	Supports	B	Poor Outcome	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mutations (listed as exon 9 and 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). Of the 19 patients whose tumors harbored PIK3CA mutations, nine harbored PIK3CA E545K. PIK3CA E545K was associated with poor outcome compared to other PIK3CA mutations for local and distant recurrences (HR: 11.6, P < 0.001; HR 3.7, P = 0.006). Additionally, 89% of patients whose tumors harbored PIK3CA E545K experienced a relapse.	19903786	PubMed		He et al., 2009, Clin. Cancer Res.		2	accepted	2106	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2106	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	V600E	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector.	19001320	PubMed		Di Nicolantonio et al., 2008, J. Clin. Oncol.		3	accepted	2115	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2115	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Oxaliplatin		Predictive	Supports	B	Resistance	Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	2117	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2117	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Resistance	The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	2118	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2118	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Bevacizumab,Capecitabine,Oxaliplatin	Combination	Predictive	Supports	B	Resistance	In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF.	19571295	PubMed		Tol et al., 2009, N. Engl. J. Med.		3	accepted	2121	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2121	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population.	22663011	PubMed		Flaherty et al., 2012, N. Engl. J. Med.	NCT01245062	4	accepted	2135	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2135	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis.	18682506	PubMed		Elisei et al., 2008, J. Clin. Endocrinol. Metab.		4	accepted	2137	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2137	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment. The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively.	19692680	PubMed		Mok et al., 2009, N. Engl. J. Med.	NCT00322452	5	accepted	2148	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2148	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	C	Sensitivity/Response	In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.	22452896	PubMed		Miller et al., 2012, Lancet Oncol.	NCT00656136		accepted	2153	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2153	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	Ex19 del L858R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when treated (n=13) with gefitinib and pemetrexed/platinum combination therapy (HR: 0.20, 95% CI: 0.05-0.75, P=0.017) as compared to treatment (n=18) with pemtrexed/platinum alone.  In the subgroup of patients without EGFR mutation (defined as all patients without the specific EGFR exon 19 deletion or L858R mutation) a difference in median PFS was not seen between the chemotherapy versus chemotherapy with gefitinib treatment groups.	24755888	PubMed		Yu et al., 2014, Cancer Biol. Ther.		4	accepted	2156	1854	19														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2156	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Sensitivity/Response	In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.	26269204	PubMed		Planchard et al., 2015, Ann. Oncol.		2	accepted	2157	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2157	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Resistance	In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.	15737014	PubMed		Pao et al., 2005, PLoS Med.			accepted	2158	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2158	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Resistance	In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.	17020982	PubMed		Kosaka et al., 2006, Clin. Cancer Res.			accepted	2159	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2159	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Lapatinib		Predictive	Supports	D	Resistance	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model	18408761	PubMed		Li et al., 2008, Oncogene		4	accepted	2160	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2160	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 mol/L for all three cell lines).	18089823	PubMed		Engelman et al., 2007, Cancer Res.		3	accepted	2161	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2161	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Neratinib		Predictive	Supports	D	Sensitivity/Response	The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 mol/L). In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.	16818618	PubMed		Shimamura et al., 2006, Cancer Res.		2	accepted	2162	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2162	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.	18408761	PubMed		Li et al., 2008, Oncogene		2	accepted	2163	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2163	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.	21732342	PubMed		Cha et al., 2012, Int. J. Cancer		2	accepted	2164	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2164	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Lung Non-small Cell Carcinoma	3908		Canertinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.	18408761	PubMed		Li et al., 2008, Oncogene		2	accepted	2165	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2165	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was moderately resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2167	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2167	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase (AP) patient improved to chronic phase. M351T, E255K, and F359V variants were each present in ~25% of transcripts beginning at 6, 11, and 14 months, respectively. At 20 months, the patient returned to accelerated phase with an increase in the proportion of E255K variants to ~75% of transcripts. Another AP patient had a complete hematologic response with the M351T variant present in ~25 to ~75% of transcripts and the F359V variant present in ~25% to ~50% of transcripts between 8 and 16 months after therapy initiation but prior to resistance. At 17 months, the patient progressed to myeloid blast crisis and there was cytogenetic evidence of a double Ph-chromosome. At that time, no secondary variants could be detected.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2168	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2168	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was  moderately resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2169	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2169	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3  cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2170	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2170	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
KRAS	3845	G13D	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2178	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/2178	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	Q61L	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PIK3CA. Both patients experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS Q61L included a 53 year old female treated with cetuximab and irinotecan as a 6th line treatment who had PFS of 12 weeks and OS of 25 weeks; and a 64 year old female treated with cetuximab and ironotecan as a 3rd line therapy who had PFS of 12 weeks and OS of 46 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2181	95	36	1	115256529	115256529	T	A	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2181	https://civic.genome.wustl.edu/links/variants/95	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	G13D	Colorectal Cancer	9256		Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		2	accepted	2183	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/2183	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
NRAS	4893	Q61R	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	2184	96	36	1	115256529	115256529	T	C	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/2184	https://civic.genome.wustl.edu/links/variants/96	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	MUTATION	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were KRAS wildtype and BRAF assessable. Patients harboring BRAF mutations (total n=24, V600E n=23, D594G n=1) had a lower response rate than did patients with wildtype BRAF (n=326; 2/24 [4.3%] vs 124/326 [38%], OR: 0.15, p=0.0012). BRAF mutant patients also experienced significantly lower disease control rate, PFS, and OS (median 26 vs 54 weeks, HR: 3.03 p<0.0001) in response to cetuximab treatment. In multivariate analysis, the significant associations between BRAF mutations and poor outcome were confirmed. The authors noted that two responders had the following genotypes: V600E mutation in low copy number, and BRAF D594G, and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2187	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2187	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	Q61K	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	C	Resistance	Four patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61K and were wildtype for KRAS, BRAF and PIK3CA. One patient experienced partial response and three patients experienced progressive disease. The four patients whose tumors harbored NRAS Q61K included an 80 year old male treated with cetuximab and irinotecan as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 43 weeks; a 51 year old male treated with cetuximab and ironotecan as a 3rd line therapy who experienced a partial response and had PFS of 24 weeks and OS of 54 weeks; a 64 year old male treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 8 weeks and OS of 33 weeks; and a 65 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who experienced progressive disease and had PFS of 31 weeks and OS of 50 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2189	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2189	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	Q61K	Colorectal Cancer	9256		Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D).	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		3	accepted	2192	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2192	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	G12D	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2193	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2193	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	Q546K	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Does Not Support	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 75 year old female treated with cetuximab and irinotecan as 2nd line therapy (discontinued for toxic/biochemical reasons) who experienced a partial response (PFS: 43 weeks, OS: 57 weeks). Using clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in the source) mutations predict weak or no resistance to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	2198	885	37	3	178936094	178936094	C	A	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/2198	https://civic.genome.wustl.edu/links/variants/885	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	D594G	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Does Not Support	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PIK3CA. This patient was a 63 year old female treated with cetuximab and irinotecan (3rd line) who was one of two patients harboring a BRAF mutant tumor to experience a partial response. Progression free survival was 36 weeks and overall survival was 42 weeks from time of cetuximab administration. Authors note that cetuximab response is in accordance with cell line data suggesting that D594G cannot directly activate MAPK signaling, and that D594G mutants have low levels of p-MEK and are resistant to MEK inhibition.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2201	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2201	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	G13R	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 68 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 18 weeks; OS: 34 weeks). Authors considered stable disease as both clinical benefit and non response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		1	accepted	2204	896	36	1	115258745	115258745	C	G	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2204	https://civic.genome.wustl.edu/links/variants/896	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	A146T	Colorectal Cancer	9256		Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		3	accepted	2206	906	30	12	25378562	25378562	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/2206	https://civic.genome.wustl.edu/links/variants/906	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	A146V	Colorectal Cancer	9256		Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		3	accepted	2209	322	30	12	25378561	25378561	G	A	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/2209	https://civic.genome.wustl.edu/links/variants/322	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Colorectal Cancer	9256		Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		2	accepted	2212	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2212	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	E545Q	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Does Not Support	C	Resistance	Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab and irinotecan and experienced partial responses. One patient was a 44 year old female, on 5th line therapy, with a PFS of 67 weeks and an OS of 209 weeks. The other patient was a 46 year old male, on 2nd line therapy, with a PFS of 22 weeks and an OS of 105 weeks. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2213	881	37	3	178936091	178936091	G	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/2213	https://civic.genome.wustl.edu/links/variants/881	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2217	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2217	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	G12D	Colorectal Cancer	9256		Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations.	22392911	PubMed		Migliardi et al., 2012, Clin. Cancer Res.		3	accepted	2218	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2218	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	2219	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2219	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
ATM	472	T2666A	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2221	901	69	11	108204681	108204681	A	G	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2221	https://civic.genome.wustl.edu/links/variants/901	https://civic.genome.wustl.edu/links/genes/69
ATM	472	MUTATION	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary cells from chronic lymphocytic leukemia patients were treated with doxorubicin to induce double-strand (DSB). In this setting, cells harboring rare ATM variants (n=8) had significantly higher viability, measured by mitochondrial dehydrogenase activity, compared to wildtype cells (n=8, p < 0.001) suggesting resistance. A qPCR functional assay showed that samples with rare ATM variants (n= 20) had significantly less p21 expression after treatment with doxorubicin compared to treated wildtype controls (n=31, p < 0.001). Furthermore, there was significantly decreased expression of BBC3, BAX, and GADD45 genes which are downstream of ATM in the DNA damage response. In the above studies, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for p21 induction to confirm wildtype p53.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		4	accepted	2222	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/2222	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
ATM	472	R3008C	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2223	903	69	11	108236086	108236086	C	T	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2223	https://civic.genome.wustl.edu/links/variants/903	https://civic.genome.wustl.edu/links/genes/69
ATM	472	c.902-1G>T	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the c.902-1G>T variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the c.902-1G>T variant of ATM, confirmed by sanger sequencing, western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors note that this patient had uniparental disomy of 11q.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2224	3049	69														Unknown	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/2224	https://civic.genome.wustl.edu/links/variants/3049	https://civic.genome.wustl.edu/links/genes/69
KRAS	3845	A146P	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free survival compared to wildtype KRAS (3.8mo vs. 5.1mo, HR:0.46, 95% CI:0.11-0.88, P=0.028). In BRAF wildtype patients, KRAS mutations in codon 61 or 146 were associated with reduced response rate (0% vs. 37%, P=0.047) and reduced progression-free survival compared to wildtype KRAS patients (3.8mo vs. 5.3mo, HR:0.45, 95% CI:0.10-0.85, P=0.023).	19603018	PubMed		Loupakis et al., 2009, Br. J. Cancer		3	accepted	2225	905	30	12	25378562	25378562	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2225	https://civic.genome.wustl.edu/links/variants/905	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of BSC on PFS was the same in the KRAS mutant group as in the KRAS wildtype group (7.3 vs 7.3 weeks), suggesting that the presence of KRAS mutations does not support worse outcome compared to wildtype KRAS.	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776	3	accepted	2231	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2231	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776		accepted	2232	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2232	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776		accepted	2236	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2236	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2240	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2240	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).	19284554	PubMed		Greco et al., 2009, J. Exp. Clin. Cancer Res.		2	accepted	2247	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2247	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	11050000	PubMed		Rowley et al., 2000, Blood		2	accepted	2250	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2250	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	12483530	PubMed		Rowley et al., 2002, Oncogene			accepted	2251	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2251	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	16497971	PubMed		Hoang et al., 2006, Blood		2	accepted	2252	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2252	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776		accepted	2253	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2253	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2257	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2257	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).	19284554	PubMed		Greco et al., 2009, J. Exp. Clin. Cancer Res.			accepted	2258	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2258	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	11050000	PubMed		Rowley et al., 2000, Blood		2	accepted	2261	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2261	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	12483530	PubMed		Rowley et al., 2002, Oncogene			accepted	2262	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2262	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	16497971	PubMed		Hoang et al., 2006, Blood		2	accepted	2263	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/2263	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12R	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776		accepted	2264	530	30	12	25398285	25398285	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/2264	https://civic.genome.wustl.edu/links/variants/530	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Lung Cancer	1324		Gefitinib		Predictive	Supports	C	Resistance	In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2268	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2268	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).	18316791	PubMed		Amado et al., 2008, J. Clin. Oncol.	NCT00113763,NCT00113776		accepted	2269	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2269	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2273	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2273	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).	19284554	PubMed		Greco et al., 2009, J. Exp. Clin. Cancer Res.			accepted	2274	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2274	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	11050000	PubMed		Rowley et al., 2000, Blood		2	accepted	2277	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2277	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	12483530	PubMed		Rowley et al., 2002, Oncogene		2	accepted	2278	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2278	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.	16497971	PubMed		Hoang et al., 2006, Blood		2	accepted	2279	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2279	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
TP53	7157	R273L	Ovarian Cancer	2394		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	C	Resistance	Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.			accepted	2286	918	45	17	7577120	7577120	C	A	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2286	https://civic.genome.wustl.edu/links/variants/918	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273C	Stomach Carcinoma	5517		Etoposide,Cisplatin,Mitomycin	Combination	Predictive	Does Not Support	C	Sensitivity/Response	A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 0. Resection was performed on patients with greater than 50% size reduction of the lesion. This patient did not undergo resection, and had on overall survival of 7.4 months.	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.		3	accepted	2292	121	45	17	7577121	7577121	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/2292	https://civic.genome.wustl.edu/links/variants/121	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	Y220C	Stomach Carcinoma	5517		Etoposide,Mitomycin,Cisplatin	Combination	Predictive	Supports	C	Sensitivity/Response	A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 2. Resection was performed on patients with >50% size reduction of the lesion. Consistent with response to preoperative chemotherapy, this patient did undergo resection, and had an overall survival of 12.6 months.	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.		3	accepted	2306	922	45	17	7578190	7578190	T	C	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2306	https://civic.genome.wustl.edu/links/variants/922	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R175H	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.			accepted	2310	116	45	17	7578406	7578406	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/2310	https://civic.genome.wustl.edu/links/variants/116	https://civic.genome.wustl.edu/links/genes/45
IDH1	3417	R132C	Brain Glioma	0060108		Temozolomide		Predictive	Supports	B	Sensitivity/Response	In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01).	20975057	PubMed		Houillier et al., 2010, Neurology		2	accepted	2327	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2327	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132C	Malignant Glioma	3070		AGI-5198		Predictive	Supports	D	Sensitivity/Response	In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth.	23558169	PubMed		Rohle et al., 2013, Science		2	accepted	2329	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2329	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132	Malignant Glioma	3070		Bevacizumab		Predictive	Supports	B	Sensitivity/Response	In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, P=0.05), as compared to patients with wild-type IDH1.	22199315	PubMed		Lv et al., 2011, Anticancer Res.		2	accepted	2330	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2330	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132C	Acute Myeloid Leukemia	9119		Ivosidenib		Predictive	Supports	B	Sensitivity/Response	In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission.	25583779	PubMed		2015, Cancer Discov		2	accepted	2331	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2331	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
IDH1	3417	R132C	Acute Myeloid Leukemia	9119		BPTES		Predictive	Supports	D	Sensitivity/Response	In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) as compared to AML cell lines expressing wild-type IDH1. Sensitivity was determined by assessing cell growth.	24333121	PubMed		Emadi et al., 2014, Exp. Hematol.		3	accepted	2332	59	26	2	209113113	209113113	G	A	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2332	https://civic.genome.wustl.edu/links/variants/59	https://civic.genome.wustl.edu/links/genes/26
PIK3CA	5290	C420R	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	2346	931	37	3	178927980	178927980	T	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2346	https://civic.genome.wustl.edu/links/variants/931	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. PIK3CA mutations (n=6) were associated with no difference in objective response to drug treatment (16.6% vs. 35.2%, p=0.61), shorter overall survival (9.9 vs. 30.2 months, p<0.001), and shorter median time to progression (2.3 vs. 6.0 months, p=0.01) when compared to wild-type PIK3CA. Through multivariate analyses, it was shown that PIK3CA mutations are significant predictors of worse overall survival (HR: 5.81, 95% CI: 2.43-13.91, p=0.0001) and shorter time to progression (HR: 2.71 95% CI: 1.23-4.79, p=0.03).	21258250	PubMed		Ludovini et al., 2011, J Thorac Oncol		3	accepted	2355	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2355	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Does Not Support	C	Poor Outcome	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for BRAF exon 15 mutations. BRAF V600E was identified in 5 cases. The authors reported that no differences were found in overall survival between patients with and without BRAF mutations (P > 0.1).	19903786	PubMed		He et al., 2009, Clin. Cancer Res.		2	accepted	2362	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2362	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. KRAS mutations (n=11) were associated with lack of objective response to drug treatment (0.0% vs. 35.7%, p=0.03), no significant difference in overall survival (19.3 vs. 28.6 months, p=0.47), and shorter median time to progression (2.7 vs. 5.6 months, p=0.003) when compared to wild-type KRAS. Through multivariate analyses, it was shown that KRAS mutations were significant predictors of shorter time to progression (HR: 2.43, 95% CI: 1.23-4.79, p=0.01).	21258250	PubMed		Ludovini et al., 2011, J Thorac Oncol		3	accepted	2385	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2385	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KIT	3815	T417_D419delinsY	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. This patient's GIST had a KIT exon 8 deletion/insertion TYD417-419Y. This patient represents the first reported sporadic GIST with a KIT exon 8 mutation as germline DNA from surrounding normal tissue was was KIT wildtype. The patient had an unconfirmed partial response to 400mg daily imatinib (TTP 8.1 months) and a censored OS of 59.3 months.	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	2417	2620	29														Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2417	https://civic.genome.wustl.edu/links/variants/2620	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	F506_F508DUP	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Does Not Support	C	Sensitivity/Response	This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in the study were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored a tandem reduplication of KIT codons 506 to 508 (FAF) after F508 (F506_F508dup). The patient's response to imatinib was not assessed but the TTP was 10.6 months.	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		1	accepted	2441	2621	29														Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2441	https://civic.genome.wustl.edu/links/variants/2621	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822H	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2445	987	29	4	55599338	55599338	A	C							GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2445	https://civic.genome.wustl.edu/links/variants/987	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822K	Cancer	162		Imatinib		Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822K were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2448	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/2448	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816V	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L.	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2451	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/2451	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	V561D	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2454	941	38	4	55141036	55141036	T	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2454	https://civic.genome.wustl.edu/links/variants/941	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842_H845DELDIMH	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, PDGFRA D842_H845del was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842_H845del were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2460	943	38												GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2460	https://civic.genome.wustl.edu/links/variants/943	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842V	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2463	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2463	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	K484_G487DEL	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	This patient was from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in the study were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored a homozygous deletion of KIT codons 484 to 487 (KHNG; K484_G487del).  The patient's response to imatinib was not assessed, and the TTP was 46.9 months.	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		1	accepted	2465	2622	29														Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2465	https://civic.genome.wustl.edu/links/variants/2622	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 23 patients harbored KIT exon 9 mutated GISTs: 22 harbored A502_503Ydup and 1 harbored F506_F508dup. Of patients harboring KIT exon 9 mutated GISTs, 11 (47.8%) had a partial response, 6 had stable disease, 4 had progressive disease and 2 were nonassessable. Patients with KIT exon 9 mutant GISTs were significantly more likely to have a partial response than those with WT KIT (P = .013), though significantly less likely than those with KIT exon 11 mutated GISTs (P = .0006). Patients harboring KIT exon 9 mutant GISTs experienced longer event free survival (median: 200 days) than those with WT KIT GISTs (82 days). Furthermore, there was a signficant difference in overall survival between patients with KIT exon 9 mutant and double WT kinase GISTs (P = .0067). There was no significant difference in the rate of treatment failure for patients with exon 9 mutation compared with those with no KIT or PDGFRA mutation (P = .14).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		3	accepted	2466	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/2466	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560G	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2469	972	29	4	55593613	55593613	T	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/2469	https://civic.genome.wustl.edu/links/variants/972	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. The study found that patients whose tumors harbored mutations in KIT exon 11 had signficantly superior responses to imatinib, regardless of dose,  than those whose tumors harbored wildtype KIT or KIT exon 9 mutations. This is evidenced by the findings that imatinib-treated patients whose tumors contained KIT exon 11 mutations had longer overall survival compared to those with exon 9 mutations (60.0mo vs.38.4mo, P=0.011) or wildtype KIT (60mo vs. 49.0mo, P=0.049). Patients with exon 11 mutations had improved progression-free survival in comparison to those with exon 9 mutations (24.7mo vs. 16.7mo, P=0.0013) or wildtype KIT (24.7mo vs. 12.8mo, P=0.005).	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		4	accepted	2471	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2471	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K642E	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2472	978	29	4	55594221	55594221	A	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2472	https://civic.genome.wustl.edu/links/variants/978	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	V561D	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	This case study examines one patient from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in this cohort were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored PDGFRA exon 12 V561D. The patient was treated with 800mg of imatinib per day, and had not progressed or died as of 31 months of follow up (vs median TTP of 12.8 months for WT).	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		1	accepted	2474	941	38	4	55141036	55141036	T	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2474	https://civic.genome.wustl.edu/links/variants/941	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	EXON 13 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Two patients' GISTs harbored KIT exon 13 mutations, and both experienced partial responses to imatinib. The authors conclude that this uncommon variant is sensitive to imatinib.	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2475	2643	29														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2475	https://civic.genome.wustl.edu/links/variants/2643	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Reduced Sensitivity	This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. Of 33 patients with KIT exon-9 mutant GISTs, 31 harbored KIT A502_Y503 internal tandom duplication, one harbored K484_G487del (KHNG).  Of the KIT exon 9 mutant patients, 14 were treated with 400mg daily and 19 were treated with 800mg daily. Patients with KIT exon-9 mutant GISTs had a significantly higher response rate when treated with 800mg compared with 400mg (CR/PR 17% vs 67% for 400mg and 800mg, respectively; OR, 9.05; p = .02). However, the authors report that there was not a significant difference in time to progression or overall survival between the two dose groups for patients harboring KIT exon-9 mutant GISTs.	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	2477	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/2477	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2478	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2478	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	EXPRESSION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	In a prospective phase III study (SWOG S0033/CALGB 150105) of 407 patients with gastrointestinal stromal tumors (GISTs), 397 patients were observed to be CD117-positive (i.e. KIT-positive) and 10 patients were CD117-negative. Patients were treated with either 400mg or 800mg of imatinib per day. When compared to CD117-positive, GISTs, CD117-negative GISTs did not show significant difference in median time to progression (18.3 months vs. 20.5 months; P = 0.46), however, CD-117-negative GISTs showed reduced overall survival relative to CD-117-positive GISTs (25.8 months vs. 57.1 months; P= 0.01).	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	2480	429	29	4	55524085	55606881			ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/2480	https://civic.genome.wustl.edu/links/variants/429	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	W557_K558DELWK	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2481	961	29	4	55593603	55593608	TGGAAG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/2481	https://civic.genome.wustl.edu/links/variants/961	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	Y503_F504insAY	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		2	accepted	2484	946	29	4	55592185	55592186		GCCTAT	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2484	https://civic.genome.wustl.edu/links/variants/946	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	EXON 18 MUTATION	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Does Not Support	C	Sensitivity/Response	These four patients were part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. All four patients' GISTs harbored PDGFRA exon 18 mutatations (one I843_S847delinsM, three D842_H845del). The overall survival was more than 12 months for all four of these patients (mean 40.8 months), which is comparable to patients with WT PDGFRA (49.0months).	18955451	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		1	accepted	2486	2623	38														Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2486	https://civic.genome.wustl.edu/links/variants/2623	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	D579DEL	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Six GISTs harbored PDGFRA mutations, three of which were deemed imatinib-sensitive by the authors: 1 DIMH842-845 deletion, one I843 deletion, and one V561D point mutation. Two of these patients' GISTs experienced partial responses to imatinib and one experienced progressive disease. Overall, the partial response rate of patients with an imatinib sensitive mutation of KIT or PDGFRA was 75.7% (87 of 115 patients), whereas the partial response rate in patients with no kinase mutation or a previously described imatinib resistant mutation was 0% (0 of 12 patients). The authors concluded that PDGFRA gain-of-function mutations may account for imatinib sensivity in some WT KIT GISTs.	14645423	PubMed		Heinrich et al., 2003, J. Clin. Oncol.		3	accepted	2487	977	29	4	55593669	55593671	GAT		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2487	https://civic.genome.wustl.edu/links/variants/977	https://civic.genome.wustl.edu/links/genes/29
BRAF	673	V600E	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001).	21882184	PubMed		Kim et al., 2012, Cancer		3	accepted	2503	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/2503	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Melanoma	1909		Dabrafenib		Predictive	Supports	B	Sensitivity/Response	Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors.	21343559	PubMed		Long et al., 2011, J. Clin. Oncol.			accepted	2505	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/2505	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo, <0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR:0.54, 95% CI:0.32-0.92, P=0.01).	22663011	PubMed		Flaherty et al., 2012, N. Engl. J. Med.	NCT01245062		accepted	2506	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/2506	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	G719A	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients.	20038723	PubMed		Douillard et al., 2010, J. Clin. Oncol.	NCT00076388		accepted	2508	999	19	7	55241708	55241708	G	C	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2508	https://civic.genome.wustl.edu/links/variants/999	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	WILDTYPE	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Resistance	In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response compared to carboplatin plus paclitaxel treatment, but in patients shown to be negative for EGFR mutation (n=176), patients given gefitinib fared worse than those given carboplatin and paclitaxel: Hazard ratio 2.85 (85% CI 2.05-3.98) p<0.001	19692680	PubMed		Mok et al., 2009, N. Engl. J. Med.	NCT00322452	4	accepted	2512	2174	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2512	https://civic.genome.wustl.edu/links/variants/2174	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E746_A750del	Bronchiolo-alveolar Adenocarcinoma	4926		Erlotinib		Predictive	Supports	C	Sensitivity/Response	EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E2) had the E746_A750del mutation. The patient was a male never smoker, and demonstrated response for 8.5 months. Overall survival was 21+ months as the patient was alive at study end.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	2513	1002	19	7	55242465	55242479	GGAATTAAGAGAAGC		ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/2513	https://civic.genome.wustl.edu/links/variants/1002	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.	22370314	PubMed		Han et al., 2012, J. Clin. Oncol.		3	accepted	2519	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2519	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 patients who had not shown gefitinib response. 7 of 10 sensitive patients had mutations in EGFR, while none of the 8 gefitinib refractory patients showed EGFR mutation in these exons (p=0.004)	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	2559	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2559	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.	20038723	PubMed		Douillard et al., 2010, J. Clin. Oncol.	NCT00076388	4	accepted	2621	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2621	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	2624	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2624	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).	24893891	PubMed		Cross et al., 2014, Cancer Discov		2	accepted	2625	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2625	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Lapatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.	18408761	PubMed		Li et al., 2008, Oncogene		3	accepted	2626	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2626	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).	18089823	PubMed		Engelman et al., 2007, Cancer Res.		3	accepted	2627	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2627	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Neratinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 mol/L) compared to EGFRwt A549 cells (IC50 > 1 mol/L).	16818618	PubMed		Shimamura et al., 2006, Cancer Res.		3	accepted	2628	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2628	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.	18408761	PubMed		Li et al., 2008, Oncogene		2	accepted	2629	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2629	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Canertinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.	18408761	PubMed		Li et al., 2008, Oncogene		3	accepted	2631	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2631	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Sensitivity/Response	In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	2632	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2632	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.	22370314	PubMed		Han et al., 2012, J. Clin. Oncol.		3	accepted	2634	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2634	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Does Not Support	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial hematologic response which improved to a major cytogenetic response after dose escalation 18 months after therapy initiation. At months 7 and 8, the M244V was present in 100% of transcripts. No further testing for secondary variants was performed. At 18 months, 25% of cells were Ph-positive, but this did not meet the authors' threshold for loss of MCR which is >65% Ph-positive cells or an increase of 30%.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	2636	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2636	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Cancer	162		Imatinib		Predictive	Supports	D	Sensitivity/Response	A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for antiproliferative activity and substrate or auto-phosphorylation assays. The authors considered the M244V mutation sensitive to imatinib (IC50: 2000 vs. 260 nmol/L, 8x fold change, in a proliferative assay compared to Ba/F3 cells with unmutated BCR-ABL fusions).	15930265	PubMed		O'Hare et al., 2005, Cancer Res.		3	accepted	2638	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2638	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The L248V mutation was moderately resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2641	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2641	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance after 7 months of therapy and discontinued imatinib 3 months later. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in myeloid blast crisis at month 14 after a bone marrow transplant.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2642	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2642	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 2 M imatinib (3 clones recovered, ~2% of viable clones in this treatment), 50nM nilotinib (1 clone, ~2%), and 5nM dasatinib (3 clones, ~9%). In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	2644	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2644	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2645	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/2645	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response (CHR) but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14. An accelerated-phase patient had a CHR but progressed to partial hematologic response concurrent with the appearance of the G250E variant in ~25% of transcripts and the M351T variant in ~50% of transcripts. The patient died at 12 months.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2646	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/2646	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was  resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2647	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/2647	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2648	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/2648	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Sensitivity/Response	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Q252H mutation was sensitive to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2650	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2650	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase (CP) patient achieved a complete hematologic response (CHR). The Q252H variant was detected but was absent when the patient progressed to myeloid blast crisis (MBC) with a double Philadelphia chromosome and died. A second CP patient had a partial hematologic response (PHR) with the Q252H and M351T variants. They progressed to MBC and the double Ph-chromosome was later detected without any secondary variants prior to death. The third CP patient had a PHR but became resistant. The Q252H variant was later detected and the patient died in MBC. An accelerated-phase (AP) patient had a CHR but progressed to MBC with the appearance of the Q252H variant. The patient died in MBC after a bone marrow transplant.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	2651	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2651	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (14 clones recovered, ~30% of viable clones in this treatment), 500nM nilotinib (50 clones, ~63%), and 16 nM imatinib (16 clones; ~48%). Resistant clones were also found at 2, 4, and 8 M imatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		3	accepted	2654	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2654	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Y253F	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was moderately resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2655	1026	4	9	133738358	133738358	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2655	https://civic.genome.wustl.edu/links/variants/1026	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	2656	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2656	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Y253F	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was  moderately resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2657	1026	4	9	133738358	133738358	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2657	https://civic.genome.wustl.edu/links/variants/1026	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The E255K mutation was resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2659	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2659	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had a complete hematologic response but progressed to partial hematologic response just before the detection of E255K variants. The patient died from disease progression. Three accelerated phase (AP) patients had complete hematologic responses but became resistant concurrently or just prior to detection of the E255K variant. They died from disease progression. A fourth AP patient had the M351T variant and required dose escalation. After the addition of chemotherapy, E255K and F359V variants arose. The patient returned to AP at which point E255K variants were the most prevalent.	12623848	PubMed		Branford et al., 2003, Blood		4	accepted	2660	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2660	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for anti-proliferative activity and substrate or auto-phosphorylation assays. The E255K mutation was resistant to imatinib (20-fold IC50 increase for the proliferation assay).	15930265	PubMed		O'Hare et al., 2005, Cancer Res.		3	accepted	2661	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2661	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, Ba/F3 cell line stably expressing the E255K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 6.69-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2662	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2662	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The D276G mutation was moderately resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2663	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2663	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Does Not Support	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A CP patient had complete cytogenetic response until progressing to accelerated phase with concurrent detection of the E355G variant. After dose escalation, this patient achieved a major cytogenetic response with continued presence of E355G. Another CP patient had a major cytogenetic response to imatinib which was maintained after the detection of the E355G variant.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	2664	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/2664	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3  cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2666	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2666	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The T315I mutation was resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		4	accepted	2667	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2667	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had major cytogenetic response until 11 months after therapy initiation when they acquired resistance. The T315I variant was present in ~25%, ~75%, and ~100% of transcripts at month 9, 11, and 16 months, respectively. An accelerated-phase patient had a complete cytogenetic response but progressed to leukemic blast crisis 9 months after therapy initiation when the T315I variant was present in 100% of transcripts. The patient died at 9.5 months.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	2668	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2668	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for anti-proliferative activity and substrate or auto-phosphorylation assays. The T315I mutation was resistant to imatinib (>25-fold IC50 increase for the proliferation assay).	15930265	PubMed		O'Hare et al., 2005, Cancer Res.		4	accepted	2669	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2669	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3  cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 39.41-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		4	accepted	2670	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2670	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was moderately resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2674	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/2674	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic phase (CP) patient had complete hematologic response. The F317L variant was present in ~100% of transcripts at 4 months and the patient progressed to myeloid blast crisis 3 months later. Imatinib was discontinued 9 months after initiation, and the patient went into remission after chemotherapy at month 19.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2675	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/2675	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was  moderately resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2676	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/2676	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Cancer	162		Bafetinib,Nilotinib	Substitutes	Predictive	Does Not Support	D	Resistance	In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib treatment (IC50: 929.8 nM and 239.5 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation.	18191450	PubMed		Deguchi et al., 2008, Leuk. Res.		3	accepted	2677	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/2677	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	S417Y	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2679	1613	4	9	133750419	133750419	C	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/2679	https://civic.genome.wustl.edu/links/variants/1613	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F317L mutation was  moderately resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2680	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/2680	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Sensitivity/Response	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was sensitive to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2682	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/2682	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Three CP patients, with the M351T variants detected prior to resistance, had hematologic responses prior to progression. One patient became resistant after the appearance of the M351T variant but responded to dose escalation. The last patient, who also had the Q252H variant, progressed to myeloid blast crisis (MBC) after which there was cytogenetic evidence of a double Ph-chromosome and no detectable secondary variants. Three accelerated-phase (AP) patients returned to CP and had M351T variants. One of these patients also had E255K and F359V variants and progressed to AP. The remaining two, one of whom also had H396R variant, progressed to MBC and died. Two additional AP patients also had M351T variants but initially had CHRs. One who also had the G250E variant died from disease progression. The other also had the F359V variant progressed to MBC with cytogenetic evidence of the double Ph-chromosome and no detectable secondary variants at progression.	12623848	PubMed		Branford et al., 2003, Blood		4	accepted	2683	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/2683	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Sensitivity/Response	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was  sensitive to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2684	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/2684	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2685	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/2685	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was resistant to imatinib.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	2687	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2687	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chronic phase but progressed to myeloid blast crisis after 5 months of therapy. At that time, the M351T and H396R variants were detected in ~50% and ~25% of transcripts, respectively. At 10 months, the patient died.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	2688	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2688	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was  resistant to imatinib .	15930265	PubMed		O'Hare et al., 2005, Cancer Res.			accepted	2689	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2689	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
TP53	7157	OVEREXPRESSION	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with poor differentiation (p<0.001) and high S-phase fraction (p<0.001).	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.		3	accepted	2697	1306	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/2697	https://civic.genome.wustl.edu/links/variants/1306	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	Y234C	Ovarian Cancer	2394		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	C	Resistance	Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.			accepted	2745	1068	45	17	7577580	7577580	T	C	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/2745	https://civic.genome.wustl.edu/links/variants/1068	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	ALTERATION	Ovarian Cancer	2394		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Resistance	In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive). Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20)	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.		4	accepted	2771	1307	45													P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.	Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/2771	https://civic.genome.wustl.edu/links/variants/1307	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DNA BINDING DOMAIN MUTATION	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen.	10786679	PubMed		Berns et al., 2000, Cancer Res.		3	accepted	2783	242	45	17	7577149	7578443			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2783	https://civic.genome.wustl.edu/links/variants/242	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Breast Cancer	1612		Tamoxifen		Predictive	Supports	C	Resistance	In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).	10786679	PubMed		Berns et al., 2000, Cancer Res.		1	accepted	2784	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2784	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	OVEREXPRESSION	Stomach Cancer	10534		Mitomycin,Cisplatin,Etoposide	Combination	Predictive	Supports	B	Sensitivity/Response	In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003).	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.		4	accepted	2799	1306	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/2799	https://civic.genome.wustl.edu/links/variants/1306	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R282L	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.			accepted	2818	1108	45	17	7577093	7577093	C	A	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2818	https://civic.genome.wustl.edu/links/variants/1108	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R213P	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.			accepted	2819	1109	45	17	7578211	7578211	C	G	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2819	https://civic.genome.wustl.edu/links/variants/1109	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	MUTATION	Stomach Carcinoma	5517		Doxorubicin,Etoposide,Cisplatin	Combination	Predictive	Supports	C	Sensitivity/Response	In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).	14514923	PubMed		Bataille et al., 2003, MP, Mol. Pathol.		1	accepted	2820	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2820	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein. Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2829	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/2829	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
ATM	472	c.7089+1del	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the c.7089+1del variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the c.7089+1del variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2830	3050	69														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/2830	https://civic.genome.wustl.edu/links/variants/3050	https://civic.genome.wustl.edu/links/genes/69
ATM	472	c.7515+1_2del	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the c.7515+1_2del variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the c.7515+1_2del variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 95% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2831	3051	69														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/2831	https://civic.genome.wustl.edu/links/variants/3051	https://civic.genome.wustl.edu/links/genes/69
ATM	472	K293*	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2832	1155	69	11	108115729	108115729	A	T	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2832	https://civic.genome.wustl.edu/links/variants/1155	https://civic.genome.wustl.edu/links/genes/69
ATM	472	F1025L	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2835	1158	69	11	108142131	108142131	T	G	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/2835	https://civic.genome.wustl.edu/links/variants/1158	https://civic.genome.wustl.edu/links/genes/69
ATM	472	D1930V	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		2	accepted	2837	1160	69	11	108180913	108180913	A	T	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2837	https://civic.genome.wustl.edu/links/variants/1160	https://civic.genome.wustl.edu/links/genes/69
ATM	472	E2187*	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2839	1162	69	11	108192134	108192134	G	T	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/2839	https://civic.genome.wustl.edu/links/variants/1162	https://civic.genome.wustl.edu/links/genes/69
ATM	472	L2427P	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2840	1163	69	11	108199938	108199938	T	C	ENST00000278616.4					75	GRCh37		Unknown	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2840	https://civic.genome.wustl.edu/links/variants/1163	https://civic.genome.wustl.edu/links/genes/69
ATM	472	F2732V	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2841	1164	69	11	108206614	108206614	T	G	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/2841	https://civic.genome.wustl.edu/links/variants/1164	https://civic.genome.wustl.edu/links/genes/69
ATM	472	K468FS	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Does Not Support	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K468FS variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K468FS variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		2	accepted	2843	1166	69	11	108121594	108121595	AA		ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2843	https://civic.genome.wustl.edu/links/variants/1166	https://civic.genome.wustl.edu/links/genes/69
ATM	472	D1682H	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2845	1168	69	11	108170479	108170479	G	C	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/2845	https://civic.genome.wustl.edu/links/variants/1168	https://civic.genome.wustl.edu/links/genes/69
ATM	472	A2062V	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2846	1169	69	11	108186827	108186827	C	T	ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/2846	https://civic.genome.wustl.edu/links/variants/1169	https://civic.genome.wustl.edu/links/genes/69
ATM	472	C2488Y	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the C2488Y variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 90% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.	23585524	PubMed		Navrkalova et al., 2013, Haematologica		3	accepted	2849	1172	69	11	108201096	108201096	G	A	ENST00000278616.4					75	GRCh37		Rare Germline	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2849	https://civic.genome.wustl.edu/links/variants/1172	https://civic.genome.wustl.edu/links/genes/69
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3  cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2850	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2850	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to imatinib (1 clone, 0.43% of viable clones in this treatment, recovered in 4 M but none at 2, 8, or 16 M) and nilotinib (1 clone, 1.25%, recovered at 500nM but none at 50, 2000 or 5000nM). In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	2851	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2851	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E292V	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM). In a review of 20 publications, this mutation was not previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	2853	1183	4	9	133747568	133747568	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2853	https://civic.genome.wustl.edu/links/variants/1183	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (6 clones recovered, ~13% of viable clones in this treatment) and 2 M imatinib (6 clones, ~4%). In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	2854	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2854	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L384M	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance in 50nM nilotinib (1 clone recovered, ~2% of viable clones in this treatment) and 2 M imatinib (1 clone, ~0.7%). L384M was one of 3 novel mutations that were not identified in imatinib resistant patients from a review of 20 publications.	16772610	PubMed		Bradeen et al., 2006, Blood		1	accepted	2861	1230	4	9	133750319	133750319	C	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2861	https://civic.genome.wustl.edu/links/variants/1230	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2862	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/2862	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L387F	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM).	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	2863	1232	4	9	133750330	133750330	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2863	https://civic.genome.wustl.edu/links/variants/1232	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G398R	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		3	accepted	2864	1233	4	9	133750361	133750361	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2864	https://civic.genome.wustl.edu/links/variants/1233	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	K111N	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	2866	1234	37	3	178916946	178916946	G	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2866	https://civic.genome.wustl.edu/links/variants/1234	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	I391M	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	2867	1235	37	3	178927410	178927410	A	G	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/2867	https://civic.genome.wustl.edu/links/variants/1235	https://civic.genome.wustl.edu/links/genes/37
BRCA2	675	MUTATION	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344	2	accepted	2868	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/2868	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	M1I	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2869	1237	6	17	41276111	41276111	C	A	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2869	https://civic.genome.wustl.edu/links/variants/1237	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	C61G	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2870	1238	6	17	41258504	41258504	A	C	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2870	https://civic.genome.wustl.edu/links/variants/1238	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	C64Y	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2871	1239	6	17	41258494	41258494	C	T	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2871	https://civic.genome.wustl.edu/links/variants/1239	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	R71G	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2872	1240	6	17	41258474	41258474	T	C	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/2872	https://civic.genome.wustl.edu/links/variants/1240	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	R71K	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2873	1241	6	17	41258473	41258473	C	T	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2873	https://civic.genome.wustl.edu/links/variants/1241	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	R1495M	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2874	1242	6	17	41228505	41228505	C	A	ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2874	https://civic.genome.wustl.edu/links/variants/1242	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	E1559K	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2875	1243	6	17	41226348	41226348	C	T	ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2875	https://civic.genome.wustl.edu/links/variants/1243	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	D1692N	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2876	1244	6	17	41219625	41219625	C	T	ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2876	https://civic.genome.wustl.edu/links/variants/1244	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	R1443*	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2877	1245	6	17	41234451	41234451	G	A	ENST00000471181.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/2877	https://civic.genome.wustl.edu/links/variants/1245	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	Q1467*	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2878	1246	6	17	41228590	41228590	G	A	ENST00000357654.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2878	https://civic.genome.wustl.edu/links/variants/1246	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	M1R	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2879	1247	7	13	32890599	32890599	T	G	ENST00000544455.1						GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2879	https://civic.genome.wustl.edu/links/variants/1247	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	M1I	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2880	1248	7	13	32890600	32890600	G	T	ENST00000544455.1					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2880	https://civic.genome.wustl.edu/links/variants/1248	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	V159M	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2881	1249	7	13	32900287	32900287	G	A	ENST00000544455.1					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2881	https://civic.genome.wustl.edu/links/variants/1249	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	V211L	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2882	1250	7	13	32900751	32900751	G	C							GRCh37		Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2882	https://civic.genome.wustl.edu/links/variants/1250	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	V211I	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2883	1251	7	13	32900751	32900751	G	A							GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2883	https://civic.genome.wustl.edu/links/variants/1251	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	R2336P	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2884	1252	7	13	32921033	32921033	G	C	ENST00000544455.1					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2884	https://civic.genome.wustl.edu/links/variants/1252	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	R2336H	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344		accepted	2885	1253	7	13	32921033	32921033	G	A	ENST00000544455.1					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2885	https://civic.genome.wustl.edu/links/variants/1253	https://civic.genome.wustl.edu/links/genes/7
KIT	3815	D820Y	Melanoma	1909		Imatinib		Predictive	Supports	C	Resistance	FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylateresistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors.	21642685	PubMed		Carvajal et al., 2011, JAMA	NCT00470470	3	accepted	2886	986	29	4	55599332	55599332	G	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2886	https://civic.genome.wustl.edu/links/variants/986	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D820Y	Melanoma	1909		Sunitinib		Predictive	Supports	D	Sensitivity/Response	28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutation. Western blotting showed KIT phosphorylation (Y219) in this case and the SM3 cell line harboring the D820Y mutation. The SM3 cell line showed significant growth inhibition with sunitinib exposures of 1uM and 10uM while imatinib showed no activity. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas.	19035443	PubMed		Ashida et al., 2009, Int. J. Cancer		2	accepted	2888	986	29	4	55599332	55599332	G	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2888	https://civic.genome.wustl.edu/links/variants/986	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K642E	Mucosal Melanoma	0050929		Imatinib		Predictive	Supports	C	Sensitivity/Response	A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome.	18510589	PubMed		Lutzky et al., 2008, Pigment Cell Melanoma Res		2	accepted	2889	978	29	4	55594221	55594221	A	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/2889	https://civic.genome.wustl.edu/links/variants/978	https://civic.genome.wustl.edu/links/genes/29
GNAS	2778	T393C	Bladder Urothelial Carcinoma	4006				Prognostic	Supports	B	Better Outcome	This study demostrated that the progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in patients with T393 homozygosity i.e. TT genotypes (56%, 84%, 82%) compared with CC genotypes (35%, 53%, 58%). In multivariate Cox proportional hazard analysis, the T393C polymorphism was an independent prognostic factor for clinical outcome. Homozygous CC patients were at highest risk for progression [odds ratio (OR), 1.94; P = 0.020], metastasis (OR, 3.49; P = 0.005), and tumor-related death (OR, 2.49; P = 0.031) compared with TT genotypes.	15824158	PubMed		Frey et al., 2005, Cancer Epidemiol. Biomarkers Prev.		4	accepted	2892	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2892	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	In a retrospective study of 151 patients with sporadic colorectal cancer, 5-year survival rate was significantly higher in patients with International Union Against Cancer (UICC) stages I to II (mean follow-up, 43 months) and the GNAS1 T393C polymorphism-associated TT genotypes (87.8%) compared with TC (71.0%) and CC genotypes (50.0%; P = 0.009). No genotype effect could be observed for UICC stages III to IV. In multivariate Cox proportional analysis the T393C polymorphism was an independent prognostic factor for survival. Compatible with a gene-dose effect, homozygous CC patients were at highest risk for death (hazard ratio, 12.1; P = 0.006) compared with TT genotypes and heterozygous patients had an intermediate risk.	16033819	PubMed		Frey et al., 2005, Clin. Cancer Res.		4	accepted	2893	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2893	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Esophageal Cancer	5041		Cisplatin,Fluorouracil	Combination	Predictive	Supports	B	Resistance	Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%.	19274060	PubMed		Alakus et al., 2009, Pharmacogenomics J.		4	accepted	2895	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2895	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Better Outcome	In this study, Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015). Multivariate Cox proportional analysis of a 10-year follow-up confirmed the T393C polymorphism as an independent prognostic factor in clear cell renal cell carcinoma. Homozygous CC patients were at highest risk for progression (hazard ratio, 2.48; P = 0.009) or tumor-related death (hazard ratio, 3.15; P = 0.018) compared with T-allele carriers.	16467086	PubMed		Frey et al., 2006, Clin. Cancer Res.		4	accepted	2896	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2896	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Better Outcome	In a retrospective study of 144 patients with B-cell chronic lymphocytic leukemia, the median progression-free survival was significantly different between GNAS T393C genotypes (TT 130 months; TC 100 months; CC 31 months; P = 0.0066) and an independent prognostic factor for progression-free survival by multivariable analysis [hazard ratio (HR) CC versus TT 2.7; P = 0.010]. CC genotypes were at highest risk for death compared with T-alleles (median overall survival 197 vs 310 months, respectively) in both univariate (HR, 4.8; P < 0.0001) and multivariable analysis (HR, 5.6; P = 0.002).	17020971	PubMed		Frey et al., 2006, Clin. Cancer Res.		4	accepted	2897	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2897	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
GNAS	2778	T393C	Melanoma	1909				Prognostic	Supports	B	Better Outcome	This study showed that GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression in patients with malignant melanoma. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).	21156401	PubMed		Frey et al., 2010, Eur. J. Med. Res.		4	accepted	2898	877	2319	20	57428713	57428713	T	C	ENST00000371100					75	GRCh37		Common Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2898	https://civic.genome.wustl.edu/links/variants/877	https://civic.genome.wustl.edu/links/genes/2319
MGMT	4255	UNDEREXPRESSION	Glioblastoma Multiforme	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy.	17442989	PubMed		Chinot et al., 2007, J. Clin. Oncol.		3	accepted	2899	1255	34	10	131265448	131566271			ENST00000306010.7					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2899	https://civic.genome.wustl.edu/links/variants/1255	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	UNDEREXPRESSION	Malignant Glioma	3070		Temozolomide		Predictive	Supports	B	Sensitivity/Response	This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients. Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts.	21365007	PubMed		Kreth et al., 2011, PLoS ONE		3	accepted	2901	1255	34	10	131265448	131566271			ENST00000306010.7					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2901	https://civic.genome.wustl.edu/links/variants/1255	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	UNDEREXPRESSION	Oligodendroglioma	3181		Temozolomide		Predictive	Supports	B	Sensitivity/Response	In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation of 1p/19q status, and MGMT protein expression was studied in only 33%. Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas.	16541434	PubMed		Levin et al., 2006, Cancer		2	accepted	2902	1255	34	10	131265448	131566271			ENST00000306010.7					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2902	https://civic.genome.wustl.edu/links/variants/1255	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	UNDEREXPRESSION	Glioblastoma Multiforme	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384).	21331613	PubMed		Watanabe et al., 2011, Brain Tumor Pathol		3	accepted	2903	1255	34	10	131265448	131566271			ENST00000306010.7					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2903	https://civic.genome.wustl.edu/links/variants/1255	https://civic.genome.wustl.edu/links/genes/34
MGMT	4255	UNDEREXPRESSION	Neuroendocrine Tumor	169		Temozolomide		Predictive	Supports	B	Sensitivity/Response	Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached.	19118063	PubMed		Kulke et al., 2009, Clin. Cancer Res.		2	accepted	2904	1255	34	10	131265448	131566271			ENST00000306010.7					75	GRCh37		N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/2904	https://civic.genome.wustl.edu/links/variants/1255	https://civic.genome.wustl.edu/links/genes/34
RRM1	6240	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Gemcitabine,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286).	24595080	PubMed		Nie et al., 2013, Cancer Biomark		4	accepted	2905	1257	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		N/A	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/2905	https://civic.genome.wustl.edu/links/variants/1257	https://civic.genome.wustl.edu/links/genes/5051
EGFR	1956	S768I	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Does Not Support	C	Sensitivity/Response	S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.	27211795	PubMed		Leventakos et al., 2016, J Thorac Oncol		2	accepted	2906	562	19	7	55249005	55249005	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/2906	https://civic.genome.wustl.edu/links/variants/562	https://civic.genome.wustl.edu/links/genes/19
NRAS	4893	Q61K	Lung Non-small Cell Carcinoma	3908		Trametinib,Selumetinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors.	23515407	PubMed		Ohashi et al., 2013, Clin. Cancer Res.		2	accepted	2907	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2907	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
RET	5979	C609Y	Thyroid Gland Medullary Carcinoma	3973				Predisposing	Supports	B	Pathogenic	Study of a family with three generations of history indicating co-segregation of RET C609Y and multiple endocrine neoplasia type 2A, many of whom exhibited medullary thyroid cancers specifically.  22 individuals in this family were carriers of C609Y. Of these, 9 exhibited medullary thyroid cancers. While the variant is strongly suspected of being pathogenic for these tumors, this variant appears to result in later onset of cancer than some other variants and the authors recommend delaying prophylactic thyroidectomy until 10-15 years of age. In addition to this large family, the authors also provide an extensive review of prior reports of C609 variants, identifying a total of 111 patients from 19 publications, representing 21 affected kindreds and 15 sporadic cases. 89 of these cases had C609Y specifically.  The authors also summarize prior functional work that suggests that C609Y has transforming activity that is significant but not as strong as some other variants. Based on all of this analysis, the authors conclude that C609Y causes medullary thyroid cancers but a milder form than some other variants. Based on this paper, the following ACMG evidence codes seem potentially valid: 'PS1', 'PS3',  'PM5', 'PP1', 'PP4', and 'PP5'.	19472011	PubMed		Calva et al., 2009, Ann. Surg. Oncol.		4	accepted	2913	1260	42	10	43609070	43609070	G	A	ENST00000355710.3					75	GRCh37	There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.	Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/2913	https://civic.genome.wustl.edu/links/variants/1260	https://civic.genome.wustl.edu/links/genes/42
FGFR1	2260	EXPRESSION	Sarcoma	1115		FGFR Inhibitor AZD4547,Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Substitutes	Predictive	Supports	D	Sensitivity/Response	Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK-ERK1/2 axis as critical FGFR1 effector pathway.	27535980	PubMed		Chudasama et al., 2017, Clin. Cancer Res.		3	accepted	2915	268	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).	Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2915	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885
KIT	3815	N822K	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2918	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/2918	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	Y823D	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed "extreme" imatinib resistance.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2919	989	29	4	55599341	55599341	T	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2919	https://civic.genome.wustl.edu/links/variants/989	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	C809G	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient).	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2920	1264	29	4	55599299	55599299	T	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2920	https://civic.genome.wustl.edu/links/variants/1264	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D820A	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2921	1265	29	4	55599333	55599333	A	C	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/2921	https://civic.genome.wustl.edu/links/variants/1265	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D820G	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed "extreme" imatinib resistance.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2922	1266	29	4	55599333	55599333	A	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/2922	https://civic.genome.wustl.edu/links/variants/1266	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816H	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed "extreme" imatinib resistance. It was also highly resistant in isolation.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2923	983	29	4	55599320	55599320	G	C	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2923	https://civic.genome.wustl.edu/links/variants/983	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	T670I	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed "extreme" imatinib resistance. It also showed resistance in isolation.	16954519	PubMed		Heinrich et al., 2006, J. Clin. Oncol.		3	accepted	2924	1267	29	4	55595519	55595519	C	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/2924	https://civic.genome.wustl.edu/links/variants/1267	https://civic.genome.wustl.edu/links/genes/29
DNMT3A	1788	MUTATION	Cancer	162		Atezolizumab,Pembrolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Resistance	A subset of patients receiving PD1/PD-L1 inhibition appear to be "hyper-progressors," with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with "hyper-progression". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration.	28351930	PubMed		Kato et al., 2017, Clin. Cancer Res.		2	accepted	2926	189	18	2	25455845	25565459			ENST00000264709.3					75	GRCh37	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/2926	https://civic.genome.wustl.edu/links/variants/189	https://civic.genome.wustl.edu/links/genes/18
ATM	472	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	ATM point mutations were found in 8/57 patients with CLL and were associated with a shorter treatment-free interval, suggesting a more aggressive course.	21993670	PubMed		Guarini et al., 2012, Haematologica		3	accepted	2927	178	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/2927	https://civic.genome.wustl.edu/links/variants/178	https://civic.genome.wustl.edu/links/genes/69
BRAF	673	AMPLIFICATION	Colorectal Cancer	9256		Panitumumab,Dabrafenib	Combination	Predictive	Supports	C	Resistance	Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation.	25673644	PubMed		Ahronian et al., 2015, Cancer Discov		3	accepted	2929	1269	5	7	140434279	140624564			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/2929	https://civic.genome.wustl.edu/links/variants/1269	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	MUTATION	Skin Melanoma	8923		Binimetinib,Ribociclib	Combination	Predictive	Supports	B	Sensitivity/Response	Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)	26987942	PubMed		Vu et al., 2016, Pharmacol. Res.		3	accepted	2931	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2931	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
IDH1	3417	MUTATION	Brain Glioma	0060108		Olaparib		Predictive	Supports	D	Sensitivity/Response	Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG). 2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and inhibitors of mutant isocitrate dehydrogenase are in development to target this process. The authors discovered that 2HG overproduction impairs homologous recombination used in DNA repair and sensitizes cancer cells to treatment with PARP inhibitors, another class of cancer drugs that are already in clinical use.	28148839	PubMed		Sulkowski et al., 2017, Sci Transl Med		3	accepted	2933	645	26	2	209101803	209116275			ENST00000415913.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/2933	https://civic.genome.wustl.edu/links/variants/645	https://civic.genome.wustl.edu/links/genes/26
ROS1	6098	G2032R	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Resistance	Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.	23724914	PubMed		Awad et al., 2013, N. Engl. J. Med.	NCT00585195	1	accepted	2934	1271	4941	6	117638347	117638347	C	T	ENST00000368508.3					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2934	https://civic.genome.wustl.edu/links/variants/1271	https://civic.genome.wustl.edu/links/genes/4941
MAP2K1	5604	K57N	Lung Adenocarcinoma	3910				Diagnostic	Supports	C	Positive	This report identified 36 MEK1-mutated cases among 6,024 Lung adecarcinomas. The majority of patients were smokers (97%). There was no association with age, sex, race, or stage. The most common mutations were K57N (64%, 23/36) followed by Q56P (19%, 7/36), all mutually exclusive with other driver mutations in the targeted panel.  MEK1 mutations define a distinct subset of lung cancers (1%) with potential sensitivity to MEK inhibitors. Mutations are predominantly transversions, in keeping with a strong association with smoking.	25351745	PubMed		Arcila et al., 2015, Clin. Cancer Res.		3	accepted	2935	1272	31	15	66727455	66727455	G	T	ENST00000307102.5					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2935	https://civic.genome.wustl.edu/links/variants/1272	https://civic.genome.wustl.edu/links/genes/31
MAP2K1	5604	K57N	Lung Adenocarcinoma	3910		Selumetinib		Predictive	Supports	D	Sensitivity/Response	Mutational profiling of a large cohort of lung adenocarcinomas  identified in 2 of 207 primary lung tumors a somatic activating mutation in exon 2 of MEK1 (i.e., mitogen-activated protein kinase kinase 1 or MAP2K1) that substitutes asparagine for lysine at amino acid 57 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells.	18632602	PubMed		Marks et al., 2008, Cancer Res.		2	accepted	2936	1272	31	15	66727455	66727455	G	T	ENST00000307102.5					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/2936	https://civic.genome.wustl.edu/links/variants/1272	https://civic.genome.wustl.edu/links/genes/31
NRAS	4893	MUTATION	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine.	28284557	PubMed		Dummer et al., 2017, Lancet Oncol.	NCT01763164	5	accepted	2937	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/2937	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
EGFR	1956	MUTATION	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I744KIPVAI), on mutation in exon 20 (S768I), and 16 point mutations in exon 21 (L858R and E709H). Patients were treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and tumors harboring an EGFR mutation had an increased frequency of partial response (PR) and a lower rate of progressive disease (PD) (PR:22, PD:2 vs. PR:2, PD:17; P<0.0001) compared to wildtype EGFR patients. Patients with KRAS mutations also had a longer overall survival compared to wildtype EGFR patients (HR:2.526, 95% CI:1.314-4.858, P=0.0055).	17409929	PubMed		Endoh et al., 2006, J Thorac Oncol		2	accepted	2939	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2939	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
CTAG1B	1485	OVEREXPRESSION	Multiple Myeloma	9538		Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794		Predictive	Supports	B	Sensitivity/Response	Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/ore LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	26193344	PubMed		Rapoport et al., 2015, Nat. Med.		3	accepted	2940	1273	1278														Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/2940	https://civic.genome.wustl.edu/links/variants/1273	https://civic.genome.wustl.edu/links/genes/1278
CTAG2	30848	OVEREXPRESSION	Multiple Myeloma	9538		Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794		Predictive	Supports	B	Sensitivity/Response	Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/ore LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	26193344	PubMed		Rapoport et al., 2015, Nat. Med.		3	accepted	2941	1274	11492	X	153880246	153881853			ENST00000247306.4					75	GRCh37		Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/2941	https://civic.genome.wustl.edu/links/variants/1274	https://civic.genome.wustl.edu/links/genes/11492
KRAS	3845	A146T	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab.	20570890	PubMed		Janakiraman et al., 2010, Cancer Res.		3	accepted	2943	906	30	12	25378562	25378562	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/2943	https://civic.genome.wustl.edu/links/variants/906	https://civic.genome.wustl.edu/links/genes/30
NTRK1	4914	NTRK1 FUSIONS	Lung Non-small Cell Carcinoma	3908		Entrectinib		Predictive	Supports	C	Sensitivity/Response	1378 cases of NSCLC were screened. One patient (frequency 0.1%) with a NTRK1 gene rearrangement (SQSTM1-NTRK1 Fusion) was treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR.	26565381	PubMed		Farago et al., 2015, J Thorac Oncol	NCT02097810	3	accepted	2947	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2947	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	NTRK1 FUSIONS	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2948	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2948	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
NTRK3	4916	NTRK3 FUSIONS	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2949	1277	3985														Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/2949	https://civic.genome.wustl.edu/links/variants/1277	https://civic.genome.wustl.edu/links/genes/3985
NTRK1	4914	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	3908		Entrectinib		Predictive	Supports	C	Sensitivity/Response	Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2950	800	3983														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/2950	https://civic.genome.wustl.edu/links/variants/800	https://civic.genome.wustl.edu/links/genes/3983
ROS1	6098	REARRANGEMENT	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2951	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/2951	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
ALK	238	ALK FUSIONS	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2952	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2952	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
NTRK1	4914	NTRK1 FUSIONS	Cancer	162		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. This publication reported results from an AACR meeting for an ongoing study that had enrolled six patients with NTRK fusions, three of whom could be evaluated at the time. Each had a different, heavily pretreated advanced disease: soft-tissue sarcoma; gastrointestinal stromal tumor (GIST); and MASC. All three patients experienced partial responses by 3-4 months with resolution of key tumour-related symptoms within two weeks. One of three patients experienced near-complete response by 8 months.	26603524	PubMed		2016, Cancer Discov		2	accepted	2953	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2953	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	LMNA-NTRK1 e2;e11	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an in-frame LMNA-NTRK1 (exon 2 & exon 11) gene fusion encoding a functional LMNA-TRKA fusion oncoprotein. This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers.	26216294	PubMed		Doebele et al., 2015, Cancer Discov	NCT02122913	2	accepted	2955	3224	3983														Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/2955	https://civic.genome.wustl.edu/links/variants/3224	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	NTRK1 FUSIONS	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein.  This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers.	26216294	PubMed		Doebele et al., 2015, Cancer Discov	NCT02122913	2	accepted	2956	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/2956	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	AMPLIFICATION	Cancer	162		Entrectinib		Predictive	Supports	B	Resistance	Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1; ref. 38) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		4	accepted	2958	1280	3983	1	156830686	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2958	https://civic.genome.wustl.edu/links/variants/1280	https://civic.genome.wustl.edu/links/genes/3983
NTRK3	4916	AMPLIFICATION	Cancer	162		Entrectinib		Predictive	Supports	B	Resistance	Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1; ref. 38) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		4	accepted	2959	1281	3985	15	88418230	88799978			ENST00000394480.2					75	GRCh37		Somatic	2021-03-31 18:22:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2959	https://civic.genome.wustl.edu/links/variants/1281	https://civic.genome.wustl.edu/links/genes/3985
NTRK1	4914	LMNA-NTRK1 e11;e10	Colorectal Adenocarcinoma	0050861		Entrectinib		Predictive	Supports	C	Sensitivity/Response	A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months.	26546295	PubMed		Russo et al., 2016, Cancer Discov		3	accepted	2960	3225	3983														Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2960	https://civic.genome.wustl.edu/links/variants/3225	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	LMNA-NTRK1 G595R and G667C	Colorectal Adenocarcinoma	0050861		Entrectinib		Predictive	Supports	C	Resistance	A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling.	26546295	PubMed		Russo et al., 2016, Cancer Discov		4	accepted	2961	1282	3983	1	156846342	156849107			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2961	https://civic.genome.wustl.edu/links/variants/1282	https://civic.genome.wustl.edu/links/genes/3983
TP53	7157	WILD TYPE	Cancer	162		Nutlin-3a		Predictive	Supports	D	Sensitivity/Response	MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional TP53 were completely insensitive to the drug.	17671205	PubMed		Efeyan et al., 2007, Cancer Res.		4	accepted	2963	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/2963	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	WILD TYPE	Cancer	162		AMGMDS3		Predictive	Supports	D	Sensitivity/Response	MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53  status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	2964	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/2964	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	WILD TYPE	Leukemia	1240		RG7112		Predictive	Supports	B	Sensitivity/Response	Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. 96 patients were tested for TP53 mutation and 19 cases of mutation were detected. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.	26459177	PubMed		Andreeff et al., 2016, Clin. Cancer Res.		3	accepted	2965	369	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/2965	https://civic.genome.wustl.edu/links/variants/369	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DELETERIOUS MUTATION	Leukemia	1240		RG7112		Predictive	Supports	B	Resistance	Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.	26459177	PubMed		Andreeff et al., 2016, Clin. Cancer Res.		3	accepted	2966	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/2966	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DELETERIOUS MUTATION	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	2967	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/2967	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	DELETERIOUS MUTATION	Cancer	162		Nutlin-3a		Predictive	Supports	D	Resistance	MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking functional TP53 were completely insensitive to the drug.	17671205	PubMed		Efeyan et al., 2007, Cancer Res.		4	accepted	2968	221	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.	Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/2968	https://civic.genome.wustl.edu/links/variants/221	https://civic.genome.wustl.edu/links/genes/45
DCC	1630	EXPRESSION	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	Expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03).	8929264	PubMed		Shibata et al., 1996, N. Engl. J. Med.		3	accepted	2972	1284	1396														Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/2972	https://civic.genome.wustl.edu/links/variants/1284	https://civic.genome.wustl.edu/links/genes/1396
CTNNB1	1499	T41A	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		4	accepted	2973	1285	1290	3	41266124	41266124	A	G	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2973	https://civic.genome.wustl.edu/links/variants/1285	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	S45F	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		4	accepted	2974	1286	1290	3	41266137	41266137	C	T	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2974	https://civic.genome.wustl.edu/links/variants/1286	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	S45P	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		3	accepted	2975	1287	1290	3	41266136	41266136	T	C	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/2975	https://civic.genome.wustl.edu/links/variants/1287	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	S45F	Desmoid Tumor	0080366				Prognostic	Supports	B	Poor Outcome	Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		3	accepted	2976	1286	1290	3	41266137	41266137	C	T	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/2976	https://civic.genome.wustl.edu/links/variants/1286	https://civic.genome.wustl.edu/links/genes/1290
ARID1A	8289	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	0050934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	High-throughput  drug screens in OCCC tumor cell model identified synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and ARID1A mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both in vitro and in vivo.	27364904	PubMed		Miller et al., 2016, Mol. Cancer Ther.		3	accepted	2982	1293	6559														Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2982	https://civic.genome.wustl.edu/links/variants/1293	https://civic.genome.wustl.edu/links/genes/6559
ARID1A	8289	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	0050934		GSK126		Predictive	Supports	D	Sensitivity/Response	Inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated ovarian cancer cells. ARID1A mutational status correlates with response to the EZH2 inhibitor. Significantly, EZH2 inhibition causes regression of ARID1A mutated ovarian tumors in vivo.	25686104	PubMed		Bitler et al., 2015, Nat. Med.		4	accepted	2983	1293	6559														Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2983	https://civic.genome.wustl.edu/links/variants/1293	https://civic.genome.wustl.edu/links/genes/6559
PIK3CA	5290	E545K	Cervix Carcinoma	2893		Pictilisib		Predictive	Supports	D	Sensitivity/Response	CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA-E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941/Pictilisib.	27489350	PubMed		Arjumand et al., 2016, Oncotarget		3	accepted	2984	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2984	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Cervix Carcinoma	2893		Cisplatin		Predictive	Supports	D	Resistance	CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA-E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941/Pictilisib.	27489350	PubMed		Arjumand et al., 2016, Oncotarget		3	accepted	2985	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/2985	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
ALK	238	F1245V	Neuroblastoma	769		Entrectinib		Predictive	Supports	C	Sensitivity/Response	Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. The patient remained on study treatment for more than 3.5 years because of clinical benefit.	28183697	PubMed		Drilon et al., 2017, Cancer Discov		3	accepted	2987	1295	1	2	29436860	29436860	A	C	ENST00000389048.3					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/2987	https://civic.genome.wustl.edu/links/variants/1295	https://civic.genome.wustl.edu/links/genes/1
CTNNB1	1499	ACTIVATING MUTATION	Melanoma	1909		Anti-PD-L1 Monoclonal Antibody,Anti-CTLA-4 Monoclonal Antibody	Substitutes	Predictive	Supports	D	Resistance	Activation of melanoma-cell-intrinsic WNT/-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/-catenin signalling pathway and absence of a T-cell gene expression signature. In autochthonous mouse melanoma models active -catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.	25970248	PubMed		Spranger et al., 2015, Nature		4	accepted	2988	1296	1290	3	41240930	41281936			ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:22:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/2988	https://civic.genome.wustl.edu/links/variants/1296	https://civic.genome.wustl.edu/links/genes/1290
MERTK	10461	OVEREXPRESSION	Melanoma	1909		UNC1062		Predictive	Supports	D	Sensitivity/Response	Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells.	23585477	PubMed		Schlegel et al., 2013, J. Clin. Invest.		3	accepted	2991	1299	8331	2	112656056	112787138			ENST00000295408.4					75	GRCh37		Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2991	https://civic.genome.wustl.edu/links/variants/1299	https://civic.genome.wustl.edu/links/genes/8331
TP53	7157	CONSERVED DOMAIN MUT	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had undergone surgery. Overall survival was decreased in the cohort with conserved domian mutation (p=0.005).  Conserved domain mutation was an independent factor in univariate (but not multivariate) analysis of overall survival with relative risk 1.70 (1.17-2.47, p<0.007).	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.		3	accepted	2993	1300	45	17	7577062	7579398			ENST00000269305.4					75		This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292.	Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/2993	https://civic.genome.wustl.edu/links/variants/1300	https://civic.genome.wustl.edu/links/genes/45
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Sensitivity/Response	On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	24868098	PubMed		Khozin et al., 2014, Oncologist		5	accepted	2994	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2994	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Sensitivity/Response	On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	24868098	PubMed		Khozin et al., 2014, Oncologist		5	accepted	2995	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2995	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	A	Sensitivity/Response	Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test	23982599	PubMed		Dungo et al., 2013, Drugs		5	accepted	2996	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/2996	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	A	Sensitivity/Response	Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test	23982599	PubMed		Dungo et al., 2013, Drugs		5	accepted	2997	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/2997	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Selumetinib,Docetaxel	Combination	Predictive	Supports	A	Resistance	A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib+docetaxel and 2.8 months with placebo+docetaxel. Median overall survival was 8.7 months with selumetinib+docetaxel and 7.9 months with placebo+docetaxel. Objective response rate was 20.1% with selumetinib+docetaxel and 13.7% with placebo+docetaxel.	28492898	PubMed		Jnne et al., 2017, JAMA	NCT01933932	5	accepted	2998	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/2998	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
TP53	7157	MUTATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	N/A	A pooled analysis to investigate the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations (cm) in randomized trials of adjuvant chemotherapy compared to observational therapy encompassing a total of 3,553 patients. TP53/KRAS cm showed no prognostic effects but a borderline predictive effect (p=0,04) for negative effect of chemotherapy as compared to tp53/KRAS wt/wt. TP53/EGFR cm in was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival.	28453411	PubMed		Shepherd et al., 2017, J. Clin. Oncol.		5	accepted	2999	222	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/2999	https://civic.genome.wustl.edu/links/variants/222	https://civic.genome.wustl.edu/links/genes/45
CD274	29126	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5520		Radiation Therapy		Predictive	Supports	B	Resistance	Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1low expression group (P = 0.01, 1.9  103, and 9  104, respectively).	28476872	PubMed		Skinner et al., 2017, Clin. Cancer Res.		4	accepted	3000	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/3000	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
MYC	4609	OVEREXPRESSION	Lung Small Cell Carcinoma	5409		Cisplatin,Prexasertib,Olaparib	Combination	Predictive	Supports	D	Sensitivity/Response	A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexasertib had strong single agent efficacy and augmented the effect of Olaparib or Cisplatin in either combination, including platinum-resistant models. CHEK1 and MYC overexpression were predictors of response.	28490518	PubMed		Sen et al., 2017, Cancer Res.		4	accepted	3003	1303	3737														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/3003	https://civic.genome.wustl.edu/links/variants/1303	https://civic.genome.wustl.edu/links/genes/3737
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Tandutinib		Predictive	Supports	D	Resistance	Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).	15256420	PubMed		Clark et al., 2004, Blood		3	accepted	3007	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3007	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Sunitinib		Predictive	Does Not Support	D	Sensitivity/Response	Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM.	15304385	PubMed		Yee et al., 2004, Blood		3	accepted	3008	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3008	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Sunitinib,Cytarabine	Combination	Predictive	Supports	D	Sensitivity/Response	SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)	15304385	PubMed		Yee et al., 2004, Blood		2	accepted	3009	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3009	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Sunitinib,Daunorubicin	Combination	Predictive	Supports	D	Sensitivity/Response	SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)	15304385	PubMed		Yee et al., 2004, Blood		2	accepted	3010	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3010	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Quizartinib		Predictive	Does Not Support	D	Sensitivity/Response	Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib(AC220), a second generation class II tyrosine kinase inhibitor. (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM)	23497317	PubMed		Kampa-Schittenhelm et al., 2013, Mol. Cancer		5	accepted	3012	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3012	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
TP53	7157	OVEREXPRESSION	Ovarian Cancer	2394		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Resistance	In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/refractory and tested for p53 overexpression (>10% postive stained nuclei). 78% of p53 negative patients were classified as sensitive, in compariston to 39% of p53 positive patients (p=0.001).	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.		3	accepted	3013	1306	45	17	7571720	7590856			ENST00000269305.4					75	GRCh37		N/A	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/3013	https://civic.genome.wustl.edu/links/variants/1306	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	ALTERATION	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with p53 alterations showed increase in poor tumor cell differentiation (p<0.001) and increase in tumor cellular S-phase fraction (p<0.001). Out of 178 patients, p53 alteration (n=132) was associated with decreased overall survival in comparison to normal p53 (n=46), p=0.007.	11595686	PubMed		Reles et al., 2001, Clin. Cancer Res.		4	accepted	3014	1307	45													P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.	Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/3014	https://civic.genome.wustl.edu/links/variants/1307	https://civic.genome.wustl.edu/links/genes/45
EGFR	1956	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Osimertinib,Rociletinib	Substitutes	Predictive	Supports	D	Resistance	Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.	28202511	PubMed		Nukaga et al., 2017, Cancer Res.		3	accepted	3015	190	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/3015	https://civic.genome.wustl.edu/links/variants/190	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.	20038723	PubMed		Douillard et al., 2010, J. Clin. Oncol.	NCT00076388	3	accepted	3016	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3016	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
BRAF	673	V600E	Lung Non-small Cell Carcinoma	3908		Trametinib,Dabrafenib	Combination	Predictive	Supports	A	Sensitivity/Response	Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died.	27283860	PubMed		Planchard et al., 2016, Lancet Oncol.	NCT01336634	4	accepted	3017	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3017	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
FGFR1	2260	AMPLIFICATION	Lung Non-small Cell Carcinoma	3908		Dovitinib		Predictive	Supports	B	Sensitivity/Response	Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.	27315356	PubMed		Lim et al., 2016, Cancer		2	accepted	3027	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/3027	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
KIT	3815	V559D	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He responded well to therapy (Karnofsky index 90%). KIT V559D (Exon 11) was identified in the diagnostic biopsy and indicated as a positive predictor of imatinib response with long term usage.	22114577	PubMed		Cameron et al., 2011, Case Rep Oncol		3	accepted	3028	968	29	4	55593610	55593610	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/3028	https://civic.genome.wustl.edu/links/variants/968	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V559D	Cancer	162		Sunitinib,PD-180970,Imatinib,Tandutinib,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	KIT(V559D) were expressed in HEK-293 cells (in vitro). Imatinib, BMS-354825, PD-180970, MLN-518, and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit KIT autophosphorylation. Despite similar binding affinities, the cellular activity of BMS-354825 was >10-fold greater than that of SU-11248 or PD-180970, and the authors hypothesize that additional pharmaceutical properties may contribute to the greater cellular potency.	16046538	PubMed		Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	3029	968	29	4	55593610	55593610	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/3029	https://civic.genome.wustl.edu/links/variants/968	https://civic.genome.wustl.edu/links/genes/29
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		AS602868,Tyrphostin AG 1296	Substitutes	Predictive	Supports	D	Sensitivity/Response	Murine Ba/F3 cells with FLT3 D835V mutation were assessed as sensitive to both AS602868 and AG1296.(IC50 = 1.85uM and IC50 = 4.55uM, respectively)	17330097	PubMed		Griessinger et al., 2007, Leukemia		3	accepted	3034	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/3034	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
MET	4233	OVEREXPRESSION	Uveal Melanoma	6039		Trametinib,Selumetinib	Substitutes	Predictive	Supports	D	Resistance	In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition. Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT. Targeting ERBB3 and cMET could overcome resistance to trametinib.	25952648	PubMed		Cheng et al., 2015, Cancer Res.		3	accepted	3038	621	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/3038	https://civic.genome.wustl.edu/links/variants/621	https://civic.genome.wustl.edu/links/genes/52
AKT1	207	E17K	Cancer	162		Capivasertib		Predictive	Supports	B	Sensitivity/Response	AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA.	28489509	PubMed		Hyman et al., 2017, J. Clin. Oncol.		4	accepted	3039	4	2	14	105246551	105246551	C	T	ENST00000407796.2					75	GRCh37	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/3039	https://civic.genome.wustl.edu/links/variants/4	https://civic.genome.wustl.edu/links/genes/2
PIK3CA	5290	MUTATION	Cancer	162		Capivasertib		Predictive	Supports	B	Sensitivity/Response	In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045).	28489509	PubMed		Hyman et al., 2017, J. Clin. Oncol.		4	accepted	3040	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/3040	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
TP53	7157	R248Q	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	3042	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/3042	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
CTNNB1	1499	S45P	Desmoid Tumor	0080366				Prognostic	Supports	B	Better Outcome	Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). Because of their low frequency, patients with S45P mutations were excluded from these analyses but showed a recurrence course similar to T41A or wild type patients.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		1	accepted	3043	1287	1290	3	41266136	41266136	T	C	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/3043	https://civic.genome.wustl.edu/links/variants/1287	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	T41A	Desmoid Tumor	0080366				Prognostic	Supports	B	Better Outcome	In an analysis of 138 desmoid fibromatosis tumors, which is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence, 117 tumors (85%) had CTNNB1 mutations. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors.	18832571	PubMed		Lazar et al., 2008, Am. J. Pathol.		3	accepted	3044	1285	1290	3	41266124	41266124	A	G	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/3044	https://civic.genome.wustl.edu/links/variants/1285	https://civic.genome.wustl.edu/links/genes/1290
GNAS	2778	R201H	Follicular Thyroid Carcinoma	3962		Radioactive Iodine		Predictive	Supports	C	Sensitivity/Response	A 79 year old patient with prior history of graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested as a 13.5 cm mass. There were minimal lung, humerus and T9 spine metastases, and exhibited a very good response to the radioactive iodine treatment after he had underwent total thyroidectomy and bilateral neck dissection. They also screened other 23 fatal cases and revealed that none of them had GNAS p.R201H mutation. But two of them had NRAS p.Q61K mutation.	26788326	PubMed		Lu et al., 2016, Endocrinol Diabetes Metab Case Rep		2	accepted	3045	1319	2319														Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3045	https://civic.genome.wustl.edu/links/variants/1319	https://civic.genome.wustl.edu/links/genes/2319
BRAF	673	Non-V600	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	This study of  9,643 patients characterized clinical implications of non-V600 BRAF mutations in metastatic CRC. Of the patients with metastatic CRC that underwent NGS testing, 208 patients had non-V600 BRAF mutations (22% of BRAF mutations identified and 2.2% of total patients tested ). When compared to V600 BRAF mutations, tumors without V600 BRAF mutations were more prevalent in younger patients (58 v 68 years, respectively) and male patients (65% vs 46%, respectively). Additionally, non-V600 BRAF mutations were less prevalent in high-grade tumors (13% v 64%, respectively) and right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months).	28486044	PubMed		Jones et al., 2017, J. Clin. Oncol.		5	accepted	3046	2408	5														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3046	https://civic.genome.wustl.edu/links/variants/2408	https://civic.genome.wustl.edu/links/genes/5
GNA11	2767	MUTATION	Uveal Melanoma	6039		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	A randomized phase II trial assessing the efficacy of Cabozantinib in metastatic melanoma. 77 patients (62% cutaneous, 30% uveal, 8% mucosal). Patients received cabozantinib 100mg/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomised to cabozantinib or placebo. During lead-in phase 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months.	28103611	PubMed		Daud et al., 2017, Br. J. Cancer		3	accepted	3049	506	2308	19	3094408	3124002			ENST00000078429.4					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/3049	https://civic.genome.wustl.edu/links/variants/506	https://civic.genome.wustl.edu/links/genes/2308
NRAS	4893	Q61H	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA. This patient was was a 73 year old male treated with cetuximab and irinotecan as 4th line therapy who experienced progressive disease and had PFS of 10 weeks and OS of 36 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	3690	893	36	1	115256528	115256528	T	G	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/3690	https://civic.genome.wustl.edu/links/variants/893	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	G12D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.	25666295	PubMed		Kaczirek et al., 2015, Clin Colorectal Cancer			accepted	3693	878	36	1	115258747	115258747	C	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/3693	https://civic.genome.wustl.edu/links/variants/878	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	MUTATION	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codon 12 [n=183], 13 [n=47], 59 [n=1], 61 [n=13], 146 [n=9]) had a significantly lower response rate (17/253; 6.7%) compared to patients with KRAS wt tumors (126/352; 35.8%; OR: .13; P < .0001). Patients with KRAS mutant tumors also experienced significant lower disease control rate, shorter median progression free survival and overall survival. Association between KRAS mutation status and outcome was confirmed in multivariate analysis. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		4	accepted	3704	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/3704	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		2	accepted	3710	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/3710	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy. The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival. (HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)	21969500	PubMed		Brugger et al., 2011, J. Clin. Oncol.		3	accepted	3715	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/3715	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	E545K	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	3722	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/3722	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545G	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	3724	883	37	3	178936092	178936092	A	G	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/3724	https://civic.genome.wustl.edu/links/variants/883	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	EXON 21 MUTATION	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutations, 39% (73/189) had mutations in exon 21 (listed as exon 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 21 mutation was not significantly associated with colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.11 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted.	22357840	PubMed		Liao et al., 2012, Clin. Cancer Res.		2	accepted	3729	105	37	3	178951882	178952495			ENST00000263967.3					75	GRCh37	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/3729	https://civic.genome.wustl.edu/links/variants/105	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	D	Resistance	In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation.	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	3733	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/3733	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	V600E	Colorectal Cancer	9256		FOLFOX-4 Regimen,Cetuximab	Combination	Predictive	Supports	B	Resistance	In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF, NRAS and KRAS.	25666295	PubMed		Kaczirek et al., 2015, Clin Colorectal Cancer		4	accepted	3739	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3739	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively.	23569304	PubMed		Trunzer et al., 2013, J. Clin. Oncol.		4	accepted	3750	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3750	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In a clinical study (NCT01307397) of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), median overall survival was 61.9% (95% CI: 50.1-73.6) and median progression free survival was 7.4 months (95% CI: 5.5-9.2). Median duration of response was 7.4 months (95% CI: 5.7-9.2), with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively.	26557775	PubMed		Rutkowski et al., 2015, Contemp Oncol (Pozn)		3	accepted	3755	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3755	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases, while 15% (25/167) of patients harboring BRAF V600E experienced progressive disease.	25524477	PubMed		Ugurel et al., 2015, Ann. Oncol.		3	accepted	3757	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3757	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Skin Melanoma	8923		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compared to a 64% response rate (p<0.001) in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).	25399551	PubMed		Robert et al., 2015, N. Engl. J. Med.	NCT01597908	4	accepted	3758	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3758	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Childhood Pilocytic Astrocytoma	6812		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years later. This mass progressed under treatment at which point PCR amplification of BRAF exon 15 and subsequent Sanger sequencing the initial biopsy revealed the tumor harbored a BRAF V600E mutation. Based on these results, vemurafenib monotherapy was started and radiological and clinical response was noted after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease.	25524464	PubMed		del Bufalo et al., 2014, J Transl Med		3	accepted	3777	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3777	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Ovarian Serous Carcinoma	0050933		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year.	26490654	PubMed		Combe et al., 2015, Invest New Drugs		3	accepted	3787	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3787	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	Ex19 del L858R	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	B	Sensitivity/Response	The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitted) and included 160 patients with lung adenocarcinoma subtype. The patients had EGFR mutations (exon 19 deletions or L858R), and improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).	22285168	PubMed		Rosell et al., 2012, Lancet Oncol.	NCT00446225	4	accepted	3791	1854	19														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/3791	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Better Outcome	Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy. It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival. (HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)	21969500	PubMed		Brugger et al., 2011, J. Clin. Oncol.		3	accepted	3792	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3792	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 patients who did not.  EGFR mutations were seen in 5/7 responders but not in any of the non-responders, which was a significant result (p=0.003).	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	3794	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3794	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L861Q	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	3802	1020	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/3802	https://civic.genome.wustl.edu/links/variants/1020	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T790M	Cancer	162		Gefitinib,Multikinase Inhibitor AEE788,Erlotinib	Substitutes	Predictive	Supports	D	Resistance	Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.		3	accepted	3810	34	19	7	55249071	55249071	C	T	ENST00000275493.2					75	GRCh37	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/3810	https://civic.genome.wustl.edu/links/variants/34	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Cancer	162		Gefitinib,Multikinase Inhibitor AEE788,Erlotinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.		3	accepted	3811	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/3811	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359V evaluated, 6/6 had complete hematologic responses and 4/7 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	3815	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3815	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359V, 0/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	3816	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3816	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359V, 5/7 had MaHRs which was comparable to response rates among wild type patients, and 1/7 had MCyRs which which was lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	3817	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3817	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of the 27 with F359V mutations, 14, 17, and 25 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	3819	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3819	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	Prior to dasatinib treatment, two imatinib-resistant patients with chronic myeloid leukemia (CML) in chronic phase had the BCR-ABL1 fusion, one with the T315I, F359V, M244V, and G250E variants in 2/10, 6/10, 1/10, and 1/10 clones, respectively, and the other with F359V, F359V/F486S, F359V/L273M, and L273M variants in 6/10, 1/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patients had no best cytogenetic responses and no or complete best hematologic responses to dasatinib. Two additional patients with CML, in myeloid blast crisis,  had F359V in 1/10 and 9/10 clones. They had no hematologic and no cytogenetic responses. Overall, responses were poor compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	2	accepted	3820	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3820	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 933nM vs. 823 nM), indicating that the variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	3822	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/3822	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
KRAS	3845	G12V	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3824	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/3824	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
BRAF	673	V600E	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3827	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/3827	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
PIK3CA	5290	R88Q	Colorectal Cancer	9256		Cetuximab,Irinotecan	Combination	Predictive	Does Not Support	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old female treated with cetuximab and irinotecan as 2nd line therapy who experienced a partial response (PFS: 32 weeks, OS: 32 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3832	929	37												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/3832	https://civic.genome.wustl.edu/links/variants/929	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Colorectal Cancer	9256		Cetuximab,Irinotecan	Combination	Predictive	Supports	C	Resistance	Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS, BRAF and NRAS, and had individual response data. All patients were treated with cetuximab and irinotecan, four as 3rd line therapy, one as 4th line. Patient characteristics are as follows: a 65 year old female who experienced stable disease (PFS: 33 weeks, OS: 37 weeks); a 56 year old female who experienced stable disease (PFS: 28 weeks, OS: 43 weeks); a 69 year old female who experienced progressive disease (PFS: 10 weeks, OS: 28 weeks); a 63 year old male who experienced progressive disease (PFS:11 weeks, OS: 18 weeks); a 60 year old female who experienced progressive disease (PFS: 12 weeks, OS: 34 weeks). Based off this information and clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3841	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/3841	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
NRAS	4893	G13R	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		1	accepted	3842	896	36	1	115258745	115258745	C	G	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/3842	https://civic.genome.wustl.edu/links/variants/896	https://civic.genome.wustl.edu/links/genes/36
NRAS	4893	G12C	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, and BRAF. Both experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS G12C included a 63 year old female treated with cetuximab and irinotecan as a 3rd line treatment who had PFS of 34 weeks and OS of 55 weeks; and a 38 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who had PFS of 12 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3845	897	36	1	115258748	115258748	C	A	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/3845	https://civic.genome.wustl.edu/links/variants/897	https://civic.genome.wustl.edu/links/genes/36
PIK3CA	5290	G1049R	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3847	940	37	3	178952090	178952090	G	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/3847	https://civic.genome.wustl.edu/links/variants/940	https://civic.genome.wustl.edu/links/genes/37
HRAS	3265	G13D	Skin Squamous Cell Carcinoma	3151		Vemurafenib		Predictive	Supports	C	Resistance	In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.	22256804	PubMed		Su et al., 2012, N. Engl. J. Med.	NCT00405587,NCT00949702,NCT01001299,NCT01006980		accepted	3851	274	2747	11	534285	534285	C	T	ENST00000451590.1					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/3851	https://civic.genome.wustl.edu/links/variants/274	https://civic.genome.wustl.edu/links/genes/2747
HRAS	3265	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS.	26561417	PubMed		Boidot et al., 2016, Int J Colorectal Dis			accepted	3852	274	2747	11	534285	534285	C	T	ENST00000451590.1					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/3852	https://civic.genome.wustl.edu/links/variants/274	https://civic.genome.wustl.edu/links/genes/2747
KRAS	3845	A146T	Colorectal Cancer	9256		FOLFOX-4 Regimen,Cetuximab	Combination	Predictive	Supports	B	Resistance	In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS, NRAS and BRAF.	25666295	PubMed		Kaczirek et al., 2015, Clin Colorectal Cancer		3	accepted	3858	906	30	12	25378562	25378562	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/3858	https://civic.genome.wustl.edu/links/variants/906	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61H	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	Seven patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61H (either c.183A > C or >T) and were wildtype for BRAF and PIK3CA mutations. A 73 year old man who was treated with cetixumab and irinotecan as a fourth line therapy experienced stable disease, with a PFS of 36 weeks and OS of 57 weeks. A 65 year old man who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease with a PFS of 32 weeks and an OS of 51 weeks. A 70 year old female who was treated with cetuximab, oxaliplatin and 5FU as a second line therapy experienced progressive disease after 4 weeks of treatment. A 66 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 6 week and had an OS of 21 weeks. A 71 year old female who was treated with cetuximab and folfiri as a 3rd line therapy experienced progression after 8 weeks and had an OS of 116 weeks. A 77 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 8 weeks and had an overall survival of 17 weeks. A 66 year old male who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease (11 weeks) and an OS of 14 weeks. In this study, authors considered stable disease to be non-response to treatment.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3861	907	30	12	25380275	25380275	T	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/3861	https://civic.genome.wustl.edu/links/variants/907	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61H	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation.	22722830	PubMed		Misale et al., 2012, Nature			accepted	3862	907	30	12	25380275	25380275	T	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/3862	https://civic.genome.wustl.edu/links/variants/907	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61L	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61L. One patient, a 67 year old male, whose tumor was wildtype for BRAF and PIK3CA, was treated with cetuximab and irinotecan as a fourth line therapy. Cetuximab was discontinued due to toxicity and the patient experienced stable disease for 17 weeks and an overall survival of 23 weeks following treatment. The other patient was a 44 year old female whose tumor was wildtype for PIK3CA, BRAF and NRAS. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 23 weeks following treatment; overall survival was 30 weeks. Both patients experienced progressive disease following treatment.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3867	908	30	12	25380276	25380276	T	A	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/3867	https://civic.genome.wustl.edu/links/variants/908	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61R	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61R and were wild type for PIK3CA, BRAF, and NRAS. Both were treated with cetuximab and irinotecan as 3rd line treatments. One patient was a 72 year old female who experienced progressive disease 12 weeks following treatment; OS was 20 weeks. The other patient was a 43 year old female who experienced stable disease for the duration of the study and did not progress.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3870	909	30	12	25380276	25380276	T	C	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/3870	https://civic.genome.wustl.edu/links/variants/909	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61K	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61K. One patient was a 61 year old female whose tumor was wildtype for BRAF and PIK3CA. This patient was treated with cetuximab, oxaliplatin, and 5FU, as a second line therapy, and experienced progressive disease 6 weeks following cetuximab administration; overall survival was 90 weeks. The other patient was a 65 year old female whose tumor was wildtype for PIK3CA. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 10 week following cetuximab. Both patients experienced progressive disease following treatment.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3872	910	30	12	25380277	25380277	G	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/3872	https://civic.genome.wustl.edu/links/variants/910	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.	22722830	PubMed		Misale et al., 2012, Nature			accepted	3878	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3878	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3881	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3881	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.	25666295	PubMed		Kaczirek et al., 2015, Clin Colorectal Cancer			accepted	3882	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3882	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		1	accepted	3889	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3889	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Resistance	In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001).	21969500	PubMed		Brugger et al., 2011, J. Clin. Oncol.		3	accepted	3895	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/3895	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Q61	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Supports	B	Resistance	This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a significantly lower response rate than did patients with KRAS wildtype tumors (0/13 vs 123/345; p= .0055). Authors consider KRAS codon 61 mutations as supporting resistance to cetuximab and suggest that it should be included in KRAS mutation screening. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab monotherapy were not included.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		4	accepted	3917	203	30	12	25380275	25380277			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/3917	https://civic.genome.wustl.edu/links/variants/203	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		2	accepted	3924	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/3924	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	A146	Colorectal Cancer	9256		Cetuximab,Chemotherapy	Combination	Predictive	Does Not Support	B	Resistance	This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 146 mutant tumors (n=11) did not have a significantly lower response rate than did patients with KRAS wildtype tumors (2/11 [18.2%] vs 101/274 [36.9%]; p =0.34). Authors suggest that KRAS codon 146 mutations may not support resistance to cextuximab. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab monotherapy were not included.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3939	2979	30														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/3939	https://civic.genome.wustl.edu/links/variants/2979	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		1	accepted	3946	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/3946	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	3957	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/3957	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12D	Ovarian Cancer	2394		Cetuximab		Predictive	Supports	D	Resistance	In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth.	22246397	PubMed		Sato et al., 2012, Oncol. Rep.		3	accepted	3958	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/3958	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12C, were BRAF, NRAS and PIK3CA wt, and had individual response data. One patient had a partial response, 6 had stable disease, and 9 progressed. Treatments included cetuximab + irinotecan (n=15) and cetuximab + FOLFIRI (n=1). Median PFS was 11 weeks (6-65 weeks), median OS was 24 weeks (14-91 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 62 years old (46-73), and there were 8 males and 8 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3967	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/3967	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12C	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants.	26161928	PubMed		Camaj et al., 2015, Future Oncol		2	accepted	3973	78	30	12	25398285	25398285	C	A	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/3973	https://civic.genome.wustl.edu/links/variants/78	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12R	Colorectal Cancer	9256		Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G12R, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. One patient experienced stable disease, and two patients experienced progressive disease. Patient characteristics were as follows: a 67 year old female treated with cetuximab + irinotecan as a 4th line treatment who experienced progressive disease and had PFS of 8 weeks and OS of 17 weeks; a 78 year old female treated with cetuximab + irinotecan as a 3rd line therapy who experienced progressive disease and had PFS of 3 weeks and OS of 10 weeks; and a 55 year old male treated with cetuximab + FOLFIRI as a 3rd line therapy who experienced stable disease and had PFS of 13 weeks and OS of 15 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	3987	530	30	12	25398285	25398285	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3987	https://civic.genome.wustl.edu/links/variants/530	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12R	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.	22722830	PubMed		Misale et al., 2012, Nature		4	accepted	3989	530	30	12	25398285	25398285	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/3989	https://civic.genome.wustl.edu/links/variants/530	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12R	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		1	accepted	3991	530	30	12	25398285	25398285	C	G	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/3991	https://civic.genome.wustl.edu/links/variants/530	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	4006	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4006	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		2	accepted	4012	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4012	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
FLT3	2322	D835V	Acute Myeloid Leukemia	9119		Sunitinib		Predictive	Supports	C	Sensitivity/Response	In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy.	15459012	PubMed		Fiedler et al., 2005, Blood			accepted	4022	1302	24	13	28592641	28592641	T	A	ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4022	https://civic.genome.wustl.edu/links/variants/1302	https://civic.genome.wustl.edu/links/genes/24
AKT1	207	E17K	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.	24265155	PubMed		Shi et al., 2014, Cancer Discov			accepted	4029	4	2	14	105246551	105246551	C	T	ENST00000407796.2					75	GRCh37	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/4029	https://civic.genome.wustl.edu/links/variants/4	https://civic.genome.wustl.edu/links/genes/2
PIK3CA	5290	N345K	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		1	accepted	4047	930	37	3	178921553	178921553	T	A	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/4047	https://civic.genome.wustl.edu/links/variants/930	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	EXON 2 MUTATION	Rectum Cancer	1993				Prognostic	Does Not Support	B	Poor Outcome	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (listed as exon 1 in the source, as it was common at the time of publication to exclude non-coding exon 1). KRAS exon 2 mutations were identified in 81 cases. The authors reported that no differences were found in overall survival between patients with and without KRAS exon 2 mutations (P > 0.1).	19903786	PubMed		He et al., 2009, Clin. Cancer Res.		2	accepted	4052	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4052	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
PDGFRA	5156	V561D	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4056	941	38	4	55141036	55141036	T	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/4056	https://civic.genome.wustl.edu/links/variants/941	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	D842V	Cancer	162		Sunitinib		Predictive	Supports	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4060	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4060	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	V560_L576DEL	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Sensitivity/Response	A GIST430 patient derived cell line expressing KIT V560_L576del primary activating mutation demonstrated insensitivity to regorafenib (IC50: 191nmol/L) treatment. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		2	accepted	4061	1550	29	4	55593612	55593662									GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4061	https://civic.genome.wustl.edu/links/variants/1550	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K550_K558del	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1).	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4062	949	29	4	55593582	55593608	AAACCCATGTATGAAGTACAGTGGAAG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4062	https://civic.genome.wustl.edu/links/variants/949	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Resistance	In a phase I/II trial of sunitinib efficacy on imatinib resistant or intolerant gastrointestinal stromal tumor (GIST) patients (n=77), patients harboring primary (pre-imatinib treatment) KIT exon 11 mutant GISTs (n=44) treated with sunitinib experienced shorter progression free survival (5.1 vs 19.0 months, P = .0356) and overall survival (12.3 vs 30.5 months, P=0.0132) as compared to patients with wild-type KIT (n=9).	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		3	accepted	4072	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4072	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560D	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4077	971	29	4	55593613	55593613	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4077	https://civic.genome.wustl.edu/links/variants/971	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	W557_K558DELWK	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1).	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		3	accepted	4082	961	29	4	55593603	55593608	TGGAAG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4082	https://civic.genome.wustl.edu/links/variants/961	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	W557_K558DELWK	Gastrointestinal Stromal Tumor	9253		Ponatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to imatinib (IC50: 27nmol/L) and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability. In mice treated in vivo with Ba/F3 cells expressing KIT W557_K558 mutation, tumor volume was significantly reduced in response to both ponatinib and imatinib treatments.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4084	961	29	4	55593603	55593608	TGGAAG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4084	https://civic.genome.wustl.edu/links/variants/961	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	W557_K558DELWK	Gastrointestinal Stromal Tumor	9253		Sunitinib,Regorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to sunitinib (IC50: 7 +/-  2nmol/L) and regorafenib (IC50: 30 +/- 14nmol/L) treatments. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		2	accepted	4087	961	29	4	55593603	55593608	TGGAAG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4087	https://civic.genome.wustl.edu/links/variants/961	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K558_V559del	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4095	964	29	4	55593606	55593611	AAGGTT		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4095	https://civic.genome.wustl.edu/links/variants/964	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	A502_Y503insAY	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4100	1558	29	4	55592182	55592183		GCCTAT							GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4100	https://civic.genome.wustl.edu/links/variants/1558	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Reduced Sensitivity	This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. In response to regorafenib monotherapy, patients whose GISTs harbored KIT exon 9 mutations experienced lower rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 11 mutations or KIT/PDGFR wildtype SDH-deficient patients. Of 3 patients with KIT exon 9 mutant GISTs, 2 experienced clinical benefit (including one PR), and the median progression free survival was 5.7 months.	27371698	PubMed		Ben-Ami et al., 2016, Ann. Oncol.	NCT01068769	3	accepted	4104	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4104	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
BRAF	673	EXON 15 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Does Not Support	C	Sensitivity/Response	This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. One patient's GIST harbored a BRAF exon 15 mutation.This patient experienced progressive disease and a progression free survival of 1.6 months.	27371698	PubMed		Ben-Ami et al., 2016, Ann. Oncol.	NCT01068769	2	accepted	4121	2650	5														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4121	https://civic.genome.wustl.edu/links/variants/2650	https://civic.genome.wustl.edu/links/genes/5
KIT	3815	V560D	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		3	accepted	4122	971	29	4	55593613	55593613	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4122	https://civic.genome.wustl.edu/links/variants/971	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	P551_E554delPMYE	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated sensitivity to ponatinib treatment (IC50: 15nM). IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4125	1497	29	4	55593585	55593596									GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4125	https://civic.genome.wustl.edu/links/variants/1497	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560D	Gastrointestinal Stromal Tumor	9253		Regorafenib,Ponatinib,Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to imatinib (IC50: 3nmol/L), sunitinib (IC50: 2nmol/L), regorafenib (IC50: 3nmol/L), and ponatinib (IC50: 2nmol/L) treatments. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4127	971	29	4	55593613	55593613	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4127	https://civic.genome.wustl.edu/links/variants/971	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	L576P	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4136	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4136	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Reduced Sensitivity	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with at least imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 9 mutant GISTs (n=3) experienced decreased progression free survival as compared to patients with KIT exon 11 mutated GISTs (n=19) or wildtype (lacking KIT or PDGFRA mutations) GISTs (n= 8). The difference in PFS was significant between Exon 9 and 11 mutant GISTs (P = .01). Median PFS for the whole cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease <16 weeks) in 2/3 patients with KIT exon 9 mutant GISTs.	22614970	PubMed		George et al., 2012, J. Clin. Oncol.		2	accepted	4139	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4139	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	L576P	Cancer	162		Dasatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors.	25317746	PubMed		Vita et al., 2014, JAMA Dermatol		2	accepted	4141	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4141	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D579DEL	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	4142	977	29	4	55593669	55593671	GAT		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4142	https://civic.genome.wustl.edu/links/variants/977	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	WILDTYPE	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs were wildtype for KIT and PDGFR and who were succinate dehydrogenase (SDH) deficient (n=6) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs were wildtype for KIT and PDGFR but were not SDH deficient (n=2). 6/6 patients with SDH deficient GISTs had clinical benefit (including 2 PRs), and their median PFS was 10 months vs 1.6 months for patients with non-SDH deficient GISTs.	27371698	PubMed		Ben-Ami et al., 2016, Ann. Oncol.	NCT01068769	2	accepted	4144	2651	29														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4144	https://civic.genome.wustl.edu/links/variants/2651	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K642E	Melanoma	1909		Dasatinib		Predictive	Supports	C	Sensitivity/Response	In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to dasatinib monotherapy of 24 weeks with a 56% tumor reduction.	21523734	PubMed		Kluger et al., 2011, Cancer			accepted	4147	978	29	4	55594221	55594221	A	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4147	https://civic.genome.wustl.edu/links/variants/978	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822K	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4167	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4167	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822K	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Resistance	A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4169	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4169	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
BRAF	673	V600K	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016).	25524477	PubMed		Ugurel et al., 2015, Ann. Oncol.		3	accepted	4180	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4180	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Skin Melanoma	8923		Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600K mutation and treated with vemurafenib (n=34) were associated with a 44% response rate, as compared to a 65% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=34).	25399551	PubMed		Robert et al., 2015, N. Engl. J. Med.	NCT01597908	3	accepted	4181	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4181	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	R108K	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4186	994	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4186	https://civic.genome.wustl.edu/links/variants/994	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T263P	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4187	995	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4187	https://civic.genome.wustl.edu/links/variants/995	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	A289V	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4188	996	19	7	55221822	55221822	C	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/4188	https://civic.genome.wustl.edu/links/variants/996	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G719	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	EGFR G719 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272).	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4189	718	19	7	55241707	55241708			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4189	https://civic.genome.wustl.edu/links/variants/718	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G719S	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4190	134	19	7	55241707	55241707	G	A	ENST00000275493.2					75	GRCh37	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.	Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/4190	https://civic.genome.wustl.edu/links/variants/134	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	V742A	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4197	1001	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4197	https://civic.genome.wustl.edu/links/variants/1001	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E746_A750del	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 4 were del E746-A750. 3 had adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, with response duration and overall survival of 8 and 15 months, 5+ and 5+ months (treatment ongoing at study end) and 28 and 30+ months (alive at study end), and one former smoker with adenocarcinoma with BAC features, who had response duration of 5+ months with treatment ongoing at study end.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	4198	1002	19	7	55242465	55242479	GGAATTAAGAGAAGC		ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/4198	https://civic.genome.wustl.edu/links/variants/1002	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Sensitivity/Response	In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, EGFR mutation was assessed. In patients with EGFR mutation, erlotinib maintenance reduced progression and death significantly with median progression free survival (PFS) of 44.6 vs. 13 weeks over placebo. Erlotinib also significantly improved PFS in EGFR wildtype patients, but EGFR mutant tumors treated with erlotinib had significant better PFS than EGFR wildtype. Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001).	21969500	PubMed		Brugger et al., 2011, J. Clin. Oncol.		4	accepted	4201	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4201	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E746_T751>I	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen lung cancer patients who had shown partial response or clinical imporvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was del E746-T751insI. The patient was a female never smoker who had adenocarcinoma with bronchioloalveolar carcinoma features, and demonstrated response for 9 months, with overall survival 14 months.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	4209	1003	19												GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4209	https://civic.genome.wustl.edu/links/variants/1003	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	G719D	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end. The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4210	1420	19												GRCh37		Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4210	https://civic.genome.wustl.edu/links/variants/1420	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L747P	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.  Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end. The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4220	1891	19														Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4220	https://civic.genome.wustl.edu/links/variants/1891	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	V774A	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4226	1892	19														Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4226	https://civic.genome.wustl.edu/links/variants/1892	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	V774M	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4231	1894	19														Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4231	https://civic.genome.wustl.edu/links/variants/1894	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	K806E	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4239	1895	19	7	55249118	55249118	A	G	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4239	https://civic.genome.wustl.edu/links/variants/1895	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	N826Y	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4244	1896	19	7	55259418	55259418	A	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4244	https://civic.genome.wustl.edu/links/variants/1896	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	V834I	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 79, nonsmoker) had a partial response, progression free survival (PFS) of 5.0 months, overall survival (OS) of 15.0 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4248	1897	19														Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4248	https://civic.genome.wustl.edu/links/variants/1897	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L838P	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4252	1457	19												GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4252	https://civic.genome.wustl.edu/links/variants/1457	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	N842S	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4256	1899	19														Somatic	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/4256	https://civic.genome.wustl.edu/links/variants/1899	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T847I	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4260	1463	19												GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4260	https://civic.genome.wustl.edu/links/variants/1463	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	V851I	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 69, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.7 months, overall survival (OS) of 1.6 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common mutations (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4264	1466	19												GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4264	https://civic.genome.wustl.edu/links/variants/1466	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.	17877814	PubMed		de Gunst et al., 2007, Mol. Cancer		3	accepted	4265	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4265	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L747_P753delinsS	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4266	1012	19	7	55242470	55242487	TAAGAGAAGCAACATCTC		ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4266	https://civic.genome.wustl.edu/links/variants/1012	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	S768I	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.	22895145	PubMed		Lund-Iversen et al., 2012, J Thorac Oncol			accepted	4273	562	19	7	55249005	55249005	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4273	https://civic.genome.wustl.edu/links/variants/562	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	S768I	Cancer	162		Gefitinib,Erlotinib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively. Gefitinib was similarly tested and IC50 of 315 nanomolar was obtained, indicating non-response and potential resistance	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.		3	accepted	4274	562	19	7	55249005	55249005	G	T	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4274	https://civic.genome.wustl.edu/links/variants/562	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	D770_N771insSVD	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4275	1445	19	7	55249013	55249014		GCGTGGACA							GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4275	https://civic.genome.wustl.edu/links/variants/1445	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	H773_V774insH	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4276	1446	19												GRCh37		Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4276	https://civic.genome.wustl.edu/links/variants/1446	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	R831H	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR R831H demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4279	1017	19	7	55259434	55259434	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/4279	https://civic.genome.wustl.edu/links/variants/1017	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L838V	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4280	1018	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4280	https://civic.genome.wustl.edu/links/variants/1018	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.	18408761	PubMed		Li et al., 2008, Oncogene		2	accepted	4284	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4284	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.	21132006	PubMed		Harada et al., 2011, Oncogene		2	accepted	4285	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4285	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4286	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4286	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.	27612423	PubMed		Ray et al., 2016, Oncotarget			accepted	4287	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4287	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.	22235099	PubMed		Doebele et al., 2012, Clin. Cancer Res.			accepted	4288	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4288	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	B	Sensitivity/Response	In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.	27032107	PubMed		De Grve et al., 2016, PLoS ONE	NCT00339586	2	accepted	4290	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4290	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9  12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.	27102076	PubMed		Konduri et al., 2016, Cancer Discov		2	accepted	4291	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4291	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Cetuximab		Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.	27102076	PubMed		Konduri et al., 2016, Cancer Discov		3	accepted	4292	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4292	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Small Cell Carcinoma	5409		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated an sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).	24893891	PubMed		Cross et al., 2014, Cancer Discov			accepted	4293	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4293	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Hematologic Cancer	2531		Cetuximab		Predictive	Supports	D	Sensitivity/Response	EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).	24893891	PubMed		Cross et al., 2014, Cancer Discov			accepted	4294	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4294	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4295	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4295	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L861	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	EGFR L861 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272).	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4298	1866	19														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4298	https://civic.genome.wustl.edu/links/variants/1866	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L861Q	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4299	1020	19												GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4299	https://civic.genome.wustl.edu/links/variants/1020	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E868G	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR E868G demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4301	1482	19												GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4301	https://civic.genome.wustl.edu/links/variants/1482	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 46 patients with M244V mutations,  20, 27, and 45 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4302	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4302	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M244V, 4/5 had MaHRs which was higher than response rates among wild type patients, and 2/5 had MCyRs which was comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4304	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4304	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M244V secondary variant in 12/12 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	2	accepted	4305	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4305	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with M244V evaluated, 2/2 had complete hematologic responses and 2/3 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4307	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4307	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M244V evaluated, 3/3 had CHR and 2/3 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	4308	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4308	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L248V evaluated, 3/3 had complete hematologic responses and 2/3 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4310	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4310	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the L248V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1393nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4311	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4311	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with G250E evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4313	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4313	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with G250E, 3/6 had a CHR and 0/5 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	4314	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4314	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 60 patients with G250E mutations, 20, 29, and 56 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4316	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4316	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with G250E, 6/9 had MaHRs which was comparable to response rates among wild type patients, and 1/9 had MCyRs which was lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4318	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4318	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the G250E variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1295nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4320	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4320	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Q252H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1155nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4323	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4323	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 6 patients with  Q252H mutations, 1, 1, and 3 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. The authors identify Q252H as one of 4 variants with a low CCyR but advise caution when interpreting these results due to low sample size.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4327	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4327	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the Y253H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 867nM vs. 823 nM), indicating that the variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4329	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4329	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253H evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4331	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4331	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Y253H evaluated, 5/6 had CHR and 4/6 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	4332	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4332	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with Y253H, 5/6 had MaHRs which was higher than response rates among wild type patients and 2/6 had MCyRs which was comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4334	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4334	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 23 patients with the Y253H mutation, 14, 15, and 20 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4335	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4335	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the Y253H secondary variant in 11/11 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and complete response as best cytogenetic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	4	accepted	4336	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4336	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Y253F	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253F evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4340	1026	4	9	133738358	133738358	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/4340	https://civic.genome.wustl.edu/links/variants/1026	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Y253F	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Y253F variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1275nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4345	1026	4	9	133738358	133738358	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/4345	https://civic.genome.wustl.edu/links/variants/1026	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E255K, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4347	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4347	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255K evaluated, 2/2 had complete hematologic responses and 1/2 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4348	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4348	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 16 patients with E255K mutations, 6, 9, and 14 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4350	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4350	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E255K, 4/6 had MaHRs which was comparable to response rates among wild type patients, and 0/6 had MCyRs which was lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4352	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4352	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the E255K secondary variant in 12/12 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and minimal best cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4353	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4353	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the E255K variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1282nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4355	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4355	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D276G evaluated, 1/1 had a complete hematologic responses and 0/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4357	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4357	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with D276G mutations, 3, 4, and 7 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4359	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4359	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with the D276G variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1105nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4360	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4360	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with T315I, 2/7 had a CHR and 0/6 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	4362	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4362	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with T315I evaluated, 1/2 had a complete hematologic response and 0/3 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4364	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4364	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 21 patients with T315I mutations, 0, 2, and 6 achieved CCyR, MCyR, and CHR to dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4365	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4365	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	C	Sensitivity/Response	In this study, enzymatic profiling, crystal structures, and proliferation assays using Ba/F3 with the BCR-ABL1 variant showed higher sensitivity to axitinib in fusions with the T315I variant of ABL1 compared to wildtype ABL1 (IC50 of 21nM vs. 217 nM in resazurin assay; IC50 of 98 nM vs. 823 nM in tritiated thymidine assay). Bone marrow mononuclear cells (BM MNCs) were isolated from a chronic myeloid leukemia patients with the BCR-ABL1 T315I variant who was pretreated with imatinib, dasatinib, and chemotherapy. This patient's cells were sensitive to Ponatinib and Axitinib and insensitive to Nilotinib, Imatinib, and Dasatinib according to drug sensitivity scoring in proliferation assays. The patient was given axitinib monotherapy resulting in a significant decrease in T315I transcript levels in bone marrow (P<0.05). The authors note this as an example of a drug specifically targeting the secondary mutant resistant form of a protein.	25686603	PubMed		Pemovska et al., 2015, Nature		4	accepted	4369	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4369	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	Prior to dasatinib treatment, two imatinib-resistant patients with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with the T315I secondary variant in 8/10 and 10/10 bacterial clones generated using peripheral blood RNA. They had none as best hematologic response and none as best cytogenetic response to dasatinib which were worse compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4373	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4373	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Supports	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with T315I, 0/5 had MaHRs and 0/5 had MCyRs which were lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		2	accepted	4376	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4376	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F317L evaluated, 3/3 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	3	accepted	4381	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/4381	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F317L, 4/8 had a CHR and 1/7 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4382	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/4382	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the F317L variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1220nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4390	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/4390	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M351T, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4394	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4394	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 54 patients with M351T mutations, 25, 28, and 51 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	4	accepted	4396	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4396	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M351T, 3/6 had MaHRs which was comparable to response rates among wild type patients, and 1/6 had MCyRs which was lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4397	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4397	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, four imatinib-resistant patients with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M351T and M351S; M351T; M351T; and M351T secondary variants in 8/9 and 1/9; 4/10; 10/10; and 11/11 bacterial clones, respectively. Clones were generated using peripheral blood RNA. They had complete response as best hematologic response and complete (n = 3) or partial (n = 1) responses as best cytogenetic response to dasatinib. An additional patient, in myeloid blast crisis, had the M351T variant in 10/10 clones with complete response as best hematologic response and complete response as best cytogenetic response to dasatinib. An additional patient in accelerated phase had the M351T and M351A variants in 6/10 and 1/10 clones, respectively, with complete response as best hematologic response and none as best cytogenetic response to dasatinib. Overall, responses among these patients were comparable to those among patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4398	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4398	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E355G evaluated, 2/2 had complete hematologic responses and 1/2 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4400	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4400	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E355G, 2/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4402	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4402	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 19 patients with E355G mutations, 4, 9, and 17 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	2	accepted	4403	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4403	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, three imatinib-resistant patients with chronic myeloid leukemia had the BCR-ABL1 fusion with the E355G secondary variant in one or more bacterial clones. Clones were generated using peripheral blood RNA. The first two, in chronic and accelerated phases, had minimal or no best cytogenetic responses but had complete or no evidence of leukemia best hematologic responses, respectively. Of these, the first had E355G and E355G/Q252R variants in 8/10 and 1/10 clones, respectively, and the second had E355G, E355G/L324Q, and L324Q variants in 6/10, 1/10, and 3/10 clones, respectively. The third patient, in lymphoid blast crisis with the E355G variant in 10/10 clones, had complete best hematologic and partial best cytogenetic responses to dasatinib. All responses were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4404	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4404	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L387M	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with L387M mutations, 4, 4, and 5 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4406	1488	4	9	133750328	133750328	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4406	https://civic.genome.wustl.edu/links/variants/1488	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L387M	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with L387M, L387M/F192L, and E450G variants in 7/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had minimal best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4407	1488	4	9	133750328	133750328	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4407	https://civic.genome.wustl.edu/links/variants/1488	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with H396R, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4410	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4410	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396R evaluated, 1/1 had a complete hematologic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4411	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4411	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 33 patients with H396R mutations, 13, 17, and 30 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4413	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4413	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the H396R variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1247nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4417	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4417	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	E542K	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	4424	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/4424	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	G12A	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	4429	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4429	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	H1047L	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were males treated with cetuximab + irinotecan as 3rd line therapy and experienced progressive disease. One patient was 73 years old with a PFS of 11 weeks and an OS of 31 weeks. The other patient was 61 years old with a PFS and OS of 4 weeks. Authors concluded from this information and data from larger cohort that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	4432	1151	37	3	178952085	178952085	A	T	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4432	https://civic.genome.wustl.edu/links/variants/1151	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL L364I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the L364I secondary variant in 9/12 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4434	2902	4														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4434	https://civic.genome.wustl.edu/links/variants/2902	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Supports	C	Sensitivity/Response	Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using peripheral blood RNA. They had NEL (no evidence of leukemia) best hematologic and minor best cytogenetic responses to dasatinib.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4436	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/4436	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F486S variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 897nM vs. 823 nM), indicating baseline sensitivity.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4438	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/4438	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F486S, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4440	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/4440	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the E255V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1350nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4441	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4441	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4443	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4443	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E255V, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4444	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4444	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 11 patients with E255V mutations, 4, 4, and 9 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4447	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4447	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Three chronic myeloid leukemia patients had the BCR-ABL1 fusion with the E255V secondary variant in one or more bacterial clones generated using peripheral blood RNA. They had no best cytogenetic responses but had complete (n = 2) or minor best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1. The first patient, in chronic phase, had E255V, E255V/Q447R, E255V/T345A, and E255V/T345A/H396R variants in 6/10, 2/10, 1/10, and 1/10 clones, respectively. The second patient, in chronic phase, had E255V and E255K variants in 10/11 and 1/11 clones, respectively. The third patient, in myeloid blast crisis, had E255V and E292V variants in 10/12 and 2/12 clones, respectively.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4448	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4448	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
KIT	3815	P551_E554delPMYE	Gastrointestinal Stromal Tumor	9253		Regorafenib,Sunitinib,Imatinib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated insensitivity to regorafenib (IC50: 141nmol/L), imatinib (IC50: 90nmol/L), and sunitinib (IC50: 42nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 5 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4455	1497	29	4	55593585	55593596									GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4455	https://civic.genome.wustl.edu/links/variants/1497	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V559D	Gastrointestinal Stromal Tumor	9253		Imatinib,Ponatinib,Regorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro kinase study, a KIT V559D primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 36nmol/L vs. 640nmol/L), regorafenib (IC50: 57nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.8nmol/L vs. 6nmol/L) treatments compared to the wild-type KIT. IC50 was determined by assessing kinase activity.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		2	accepted	4459	968	29	4	55593610	55593610	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4459	https://civic.genome.wustl.edu/links/variants/968	https://civic.genome.wustl.edu/links/genes/29
PIK3CA	5290	S158L	Colorectal Cancer	9256		Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 53 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 1 week; OS: 3 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		3	accepted	4463	1499	37	3	178917598	178917598	C	T	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4463	https://civic.genome.wustl.edu/links/variants/1499	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E81K	Colorectal Cancer	9256		Cetuximab,Fluorouracil,Oxaliplatin	Combination	Predictive	Does Not Support	C	Resistance	Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy and experienced stable disease, resulting in a response rate of 0/2 and a clinical benefit rate of 2/2 according to author criteria. One patient was a 57 year old female with a PFS of 24 weeks and an OS of 100 weeks. The other patient was a 60 year old male with a PFS of 23 weeks.	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	4464	1500	37	3	178916854	178916854	G	A	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4464	https://civic.genome.wustl.edu/links/variants/1500	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	R93W	Colorectal Cancer	9256		Oxaliplatin,Fluorouracil,Cetuximab	Combination	Predictive	Supports	C	Resistance	One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old male treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy who experienced progressive disease (PFS: 8 weeks).	20619739	PubMed		De Roock et al., 2010, Lancet Oncol.		2	accepted	4467	1178	37	3	178916890	178916890	C	T	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/4467	https://civic.genome.wustl.edu/links/variants/1178	https://civic.genome.wustl.edu/links/genes/37
EGFR	1956	R776C	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4468	1181	19												GRCh37		Somatic	2021-03-31 18:22:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4468	https://civic.genome.wustl.edu/links/variants/1181	https://civic.genome.wustl.edu/links/genes/19
BRAF	673	D594G	Colorectal Cancer	9256		Cetuximab,Irinotecan	Combination	Predictive	Supports	C	Resistance	In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF.	26989027	PubMed		Hsu et al., 2016, Oncotarget		3	accepted	4472	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4472	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	L298V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4475	1506	4	9	133747585	133747585	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4475	https://civic.genome.wustl.edu/links/variants/1506	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F311I	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4478	1507	4	9	133748270	133748270	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4478	https://civic.genome.wustl.edu/links/variants/1507	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359C, 2/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4480	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4480	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359C, 2/2 had MaHRs and 2/2 had MCyRs which were comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		2	accepted	4481	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4481	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with F359C mutations, 3, 3, and 4 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4482	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4482	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with G250E and F359C variants in 3/10 and 5/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and complete best hematologic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	4	accepted	4483	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4483	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E453Q	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453Q evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4486	1509	4	9	133753888	133753888	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4486	https://civic.genome.wustl.edu/links/variants/1509	https://civic.genome.wustl.edu/links/genes/4
ARID1A	8289	Q456*	Ovarian Clear Cell Carcinoma	0050934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival.	27364904	PubMed		Miller et al., 2016, Mol. Cancer Ther.			accepted	4487	1510	6559	1	27057658	27057658	C	T	ENST00000324856.7					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4487	https://civic.genome.wustl.edu/links/variants/1510	https://civic.genome.wustl.edu/links/genes/6559
BRAF	673	V600D	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM).	18287029	PubMed		Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	4488	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/4488	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600D	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay. In addition, vemurafenib treatment strongly inhibited MEK and ERK phosphorylation in WM2664 cells.	20551065	PubMed		Yang et al., 2010, Cancer Res.		4	accepted	4489	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/4489	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	H773_V774insNPH	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a lung adenocarcinoma patient harboring EGFR H773_V774insNPH mutation, EGFR H773_V774insNPH was associated with progressive disease in response to erlotinib monotherapy.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4493	1513	19	7	55249012	55249013		AACCCCCAC							GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4493	https://civic.genome.wustl.edu/links/variants/1513	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	D770_N771insGL	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770_N771insGL mutation (n=3) experienced progressive disease.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4494	1514	19	7	55249012	55249013		GGGTTA	ENST00000275493.2						GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4494	https://civic.genome.wustl.edu/links/variants/1514	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	A864T	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4495	1187	19	7	55259532	55259532	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4495	https://civic.genome.wustl.edu/links/variants/1187	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	N826S	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.	19147750	PubMed		Kancha et al., 2009, Clin. Cancer Res.			accepted	4496	1188	19												GRCh37		Somatic	2021-03-31 18:22:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4496	https://civic.genome.wustl.edu/links/variants/1188	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	A763_Y764insFQEA	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048M and 0.082M, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006M and 0.068M, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4497	1515	19	7	55248992	55248993		TCCAGGAAGCCT	ENST00000275493.2						GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4497	https://civic.genome.wustl.edu/links/variants/1515	https://civic.genome.wustl.edu/links/genes/19
AKT1	207	Q79K	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.	24265155	PubMed		Shi et al., 2014, Cancer Discov			accepted	4498	169	2	14	105243048	105243048	G	T	ENST00000407796.2					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/4498	https://civic.genome.wustl.edu/links/variants/169	https://civic.genome.wustl.edu/links/genes/2
EGFR	1956	VIII	Malignant Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (010 uM).	17177598	PubMed		Lee et al., 2006, PLoS Med.		3	accepted	4500	312	19	7	55087058	55223523			ENST00000275493.2					75	GRCh37	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/4500	https://civic.genome.wustl.edu/links/variants/312	https://civic.genome.wustl.edu/links/genes/19
KIT	3815	T670I	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Resistance	A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	4510	1267	29	4	55595519	55595519	C	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/4510	https://civic.genome.wustl.edu/links/variants/1267	https://civic.genome.wustl.edu/links/genes/29
AKT3	10000	E17K	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033).	24265155	PubMed		Shi et al., 2014, Cancer Discov		3	accepted	4521	1227	7936	1	243859016	243859016	C	T	ENST00000366539.1					75	GRCh37		Somatic	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/4521	https://civic.genome.wustl.edu/links/variants/1227	https://civic.genome.wustl.edu/links/genes/7936
ABL1	25	BCR-ABL L384M	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the L384M variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 916nM vs. 823 nM), indicating baseline sensitivity.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4525	1230	4	9	133750319	133750319	C	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/4525	https://civic.genome.wustl.edu/links/variants/1230	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L384M	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, a majority of patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. However, out of 2 patients with the L384M mutation, 0 achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	1	accepted	4527	1230	4	9	133750319	133750319	C	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/4527	https://civic.genome.wustl.edu/links/variants/1230	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359I variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 975nM vs. 823 nM), indicating that the variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4529	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4529	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4530	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4530	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359I evaluated, 2/2 had CHR and 2/2 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	4531	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4531	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with F359I mutations, 7, 10, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4532	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4532	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the F359I secondary variant in 9/9 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4533	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4533	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M343T	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the M343T variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1175nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4534	1524	4	9	133748367	133748367	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4534	https://civic.genome.wustl.edu/links/variants/1524	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the F317V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1320nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	4535	1525	4	9	133748288	133748288	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4535	https://civic.genome.wustl.edu/links/variants/1525	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with V299L, 1/2 had a CHR and 0/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4538	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4538	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. There was 1 patient with a V299L mutation who did not achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	1	accepted	4540	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4540	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E279K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with E279K mutations, 5, 5, and 8 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4543	1526	4	9	133747528	133747528	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4543	https://civic.genome.wustl.edu/links/variants/1526	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q300R	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Q300R, 1/1 had a CHR and 1/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4545	1527	4	9	133747592	133747592	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4545	https://civic.genome.wustl.edu/links/variants/1527	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F311L	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311L evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4546	1528	4	9	133748270	133748270	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4546	https://civic.genome.wustl.edu/links/variants/1528	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL N331S	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with N331S evaluated, 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4549	1529	4	9	133748331	133748331	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/4549	https://civic.genome.wustl.edu/links/variants/1529	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L364P	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L364P evaluated, 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4551	1530	4	9	133750260	133750260	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4551	https://civic.genome.wustl.edu/links/variants/1530	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L387F	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with L387F, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4552	1232	4	9	133750330	133750330	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/4552	https://civic.genome.wustl.edu/links/variants/1232	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396P	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396P evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4554	1531	4	9	133750356	133750356	A	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/4554	https://civic.genome.wustl.edu/links/variants/1531	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D421G	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D421G evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4559	1532	4	9	133750431	133750431	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4559	https://civic.genome.wustl.edu/links/variants/1532	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G398R	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a Ba/F3  cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs. IC50: 1.83nM), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation.	19075254	PubMed		Redaelli et al., 2009, J. Clin. Oncol.		2	accepted	4561	1233	4	9	133750361	133750361	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4561	https://civic.genome.wustl.edu/links/variants/1233	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E450V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E450V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	2	accepted	4563	1534	4	9	133753880	133753880	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4563	https://civic.genome.wustl.edu/links/variants/1534	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E453K	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453K evaluated, 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4565	1535	4	9	133753888	133753888	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4565	https://civic.genome.wustl.edu/links/variants/1535	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E453A	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E453A, 1/1 had a CHR and 0/0 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4567	1536	4	9	133753889	133753889	A	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4567	https://civic.genome.wustl.edu/links/variants/1536	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL P480A	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with P480A evaluated, 1/1 had a major cytogenetic response.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	1	accepted	4568	1537	4	9	133755469	133755469	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4568	https://civic.genome.wustl.edu/links/variants/1537	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 13 patients with F486S mutations, 5, 6, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	4571	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/4571	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
KIT	3815	K550_W557del	Gastrointestinal Stromal Tumor	9253		Ponatinib,Regorafenib,Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K550_W557del primary activating mutation demonstrated sensitivity to imatinib (IC50: 13nmol/L), sunitinib (IC50: 5nmol/L), regorafenib (IC50: 22nmol/L), and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	4583	948	29	4	55593582	55593605	AAACCCATGTATGAAGTACAGTGG		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4583	https://civic.genome.wustl.edu/links/variants/948	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D820Y	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Sensitivity/Response	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. Three patients whose GIST harbored KIT D820Y experienced clinical benefit (defined as complete response, partial response, stable disease >16 weeks) in response to regorafenib. One patient remained on study without disease progression for >11 months, one patient developed disease progression at 5.7 months, and the other patient underwent surgical removal of all residual disease after 7 months, but continued on regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from these patients demonstrated decreased levels of KIT phosphorylation in response to regorafenib.	22614970	PubMed		George et al., 2012, J. Clin. Oncol.		2	accepted	4589	986	29	4	55599332	55599332	G	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/4589	https://civic.genome.wustl.edu/links/variants/986	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K558NP	Gastrointestinal Stromal Tumor	9253		Imatinib,Regorafenib,Ponatinib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K558NP primary activating mutation demonstrated sensitivity to imatinib (IC50: 2nmol/L), sunitinib (IC50: 2nmol/L ), regorafenib (IC50: 4nmol/L), and ponatinib (IC50: 1nmol/L) treatments. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4594	1549	29	4	55593608	55593608	G	TCCT							GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4594	https://civic.genome.wustl.edu/links/variants/1549	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822K	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Sensitivity/Response	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored KIT N882K did not experienced disease progression for >7 months following treatment by regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from this patient demonstrated decreased levels of KIT phosphorylation in response to regorafenib.	22614970	PubMed		George et al., 2012, J. Clin. Oncol.		2	accepted	4595	1403	29	4	55599340	55599340	T	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4595	https://civic.genome.wustl.edu/links/variants/1403	https://civic.genome.wustl.edu/links/genes/29
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		3	accepted	4597	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4597	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66). Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 11 mutations (n=51) treated with regorafenib were associated with similarly favorable progression free survival (HR: 0.212), as compared to patients with treated with placebo.	23177515	PubMed		Demetri et al., 2013, Lancet	NCT01271712	2	accepted	4599	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4599	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V569_L576DEL	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	This study (NCT01459757) is a retrospective analysis of sunitinib efficacy on imatinib resistant or intolerant gastrointestinal stromal tumor (GIST) patients who were treated in an open-label clinical trial (NCT00094029). Tumor tissue for mutational status assessment was obtained from 230 patients on one or more occassions (pre-imatinib, post-imatinib/pre-sunitinib, post-sunitinib). Tissue was assessed for mutations in KIT exons 9, 11, 13, and 17 and in PDGFRA exons 12 and 18.  With sunitinib treatment, patients with a primary (pre-imatinib) KIT exon 9 mutation (n=42) displayed significantly better PFS compared with those with a primary KIT exon 11 mutation (n=143; p = .011),  significantly longer OS (p =.002), and significantly higher ORR (p=.012). The authors conclude that sunitinib displays higher activity in KIT exon 9 vs KIT 11 mutant GIST patients.	26772734	PubMed		Reichardt et al., 2016, BMC Cancer	NCT01459757	3	accepted	4603	1551	29	4	55593639	55593662									GRCh37		Somatic	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4603	https://civic.genome.wustl.edu/links/variants/1551	https://civic.genome.wustl.edu/links/genes/29
BRAF	673	EXON 15 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Resistance	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored a BRAF exon 15 mutation and wildtype KIT and PDGFRA experienced rapid disease progression despite regorafenib administration.	22614970	PubMed		George et al., 2012, J. Clin. Oncol.		1	accepted	4605	2650	5														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4605	https://civic.genome.wustl.edu/links/variants/2650	https://civic.genome.wustl.edu/links/genes/5
BRCA1	672	W1815X	Ovarian Cancer	2394		Olaparib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time.	23415752	PubMed		Stordal et al., 2013, Mol Oncol			accepted	4623	1555	6	17	41199682	41199682	C	T							GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4623	https://civic.genome.wustl.edu/links/variants/1555	https://civic.genome.wustl.edu/links/genes/6
KIT	3815	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66).  Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 9 mutations (n=15) treated with regorafenib were associated with a similarly favorable progression free survival (HR: 0.239), as compared to patients with treated with placebo.	23177515	PubMed		Demetri et al., 2013, Lancet	NCT01271712	2	accepted	4628	509	29	4	55592023	55592216			ENST00000288135.5					75	GRCh37	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4628	https://civic.genome.wustl.edu/links/variants/509	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 11 mutant GISTs (n=19) experienced significantly increased progression free survival (P=0.01), as compared to patients with KIT exon 9 mutant GISTs (n=3). Median PFS for the entire cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease > 16 weeks) in 16/19 patients with KIT exon 11 mutant GISTs.	22614970	PubMed		George et al., 2012, J. Clin. Oncol.		2	accepted	4629	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4629	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	A502_Y503insAY	Gastrointestinal Stromal Tumor	9253		Regorafenib,Imatinib,Ponatinib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT A502_Y503insAY primary activating mutation demonstrated insensitivity to regorafenib (IC50: 138nmol/L), imatinib (IC50: 143nmol/L), and ponatinib (IC50: 56nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 3 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	4630	1558	29	4	55592182	55592183		GCCTAT							GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4630	https://civic.genome.wustl.edu/links/variants/1558	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816E	Gastrointestinal Stromal Tumor	9253		Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Resistance	Several preclinical studies were done in order to test the effects of various tyrosine kinase inhibitors (TKIs) on KIT-mutant cell lines derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and secondary mutation D816E. The cells were tested for Imatinib and Sunitinib resistances. GIST-T1/816 cells with 560-578 deletion and D816E mutations were resistant towards Imatinib and Sunitinib (Imatinib IC50: 604 nM and Sunitinib IC50: 3111 nM) compared to GIST-T1 cells with the 560-578 deletion mutation alone (Imatinib IC50: 30 nM and Sunitinib IC50: 15 nM). Imatinib inhibited phosphorylation in KIT and ERK at high concentrations. Sunitinib did not inhibit phosphorylation in KIT, ERK, or AKT at all. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. In Imatinib incubated cells, D816E mutations were seen in less than 5% of resistant Ba/F3 cell clones only in the lowest concentration. In Imatinib incubated cells, D816E mutations were seen in approximately 10% of resistant Ba/F3 cell clones.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	4631	1559	29	4	55599322	55599322	C	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4631	https://civic.genome.wustl.edu/links/variants/1559	https://civic.genome.wustl.edu/links/genes/29
EGFR	1956	D770_N771insGT	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.	23371856	PubMed		Arcila et al., 2013, Mol. Cancer Ther.			accepted	4643	1566	19	7	55249012	55249013		GGCACA	ENST00000275493.2						GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/4643	https://civic.genome.wustl.edu/links/variants/1566	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 20 INSERTION	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy.	22895145	PubMed		Lund-Iversen et al., 2012, J Thorac Oncol			accepted	4650	726	19	7	55248991	55249022			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4650	https://civic.genome.wustl.edu/links/variants/726	https://civic.genome.wustl.edu/links/genes/19
SMO	6608	L412F	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	D	Resistance	In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels.	25759020	PubMed		Atwood et al., 2015, Cancer Cell			accepted	4653	1570	5365	7	128846398	128846398	C	T	ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/4653	https://civic.genome.wustl.edu/links/variants/1570	https://civic.genome.wustl.edu/links/genes/5365
SMO	6608	L412F	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	C	Resistance	An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response.	26822128	PubMed		Khamaysi et al., 2016, Br. J. Dermatol.			accepted	4654	1570	5365	7	128846398	128846398	C	T	ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/4654	https://civic.genome.wustl.edu/links/variants/1570	https://civic.genome.wustl.edu/links/genes/5365
EGFR	1956	W731L	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR W731L demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4655	1571	19												GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4655	https://civic.genome.wustl.edu/links/variants/1571	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	E734Q	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR E734Q demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4656	1572	19												GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4656	https://civic.genome.wustl.edu/links/variants/1572	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	T785A	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR T785A demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4657	1573	19												GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4657	https://civic.genome.wustl.edu/links/variants/1573	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	C797Y	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR C797Y demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4658	1574	19	7	55249092	55249092	G	A	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4658	https://civic.genome.wustl.edu/links/variants/1574	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	Y801H	Malignant Mesothelioma	1790		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a COS-7 cell line expressing EGFR Y801H demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol			accepted	4659	1575	19												GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/4659	https://civic.genome.wustl.edu/links/variants/1575	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	A767_V769dupASV	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced progressive disease.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4665	1579	19	7	55249000	55249001		GCCAGCGTG	ENST00000275493.2						GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4665	https://civic.genome.wustl.edu/links/variants/1579	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L747_S752delinsQ	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written.	15329413	PubMed		Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	4667	1580	19												GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4667	https://civic.genome.wustl.edu/links/variants/1580	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L861R	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		3	accepted	4669	1477	19												GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4669	https://civic.genome.wustl.edu/links/variants/1477	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	BCR-ABL D363G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the D363G secondary variant in 2/10 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and complete best cytogenetic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4692	2900	4														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4692	https://civic.genome.wustl.edu/links/variants/2900	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V379I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with E279K, V379I, and V379I/F317L/M351T variants in 3/11, 5/11, and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and no evidence of leukemia as best hematologic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1. An additional patient, in myeloid blast crisis, had V379I in 9/10 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and none as best cytogenetic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4702	1609	4	9	133750304	133750304	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4702	https://civic.genome.wustl.edu/links/variants/1609	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V379I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with V379I, 3/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4704	1609	4	9	133750304	133750304	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4704	https://civic.genome.wustl.edu/links/variants/1609	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Sensitivity/Response	Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	4	accepted	4706	1	4	22	23522397	23632600			ENST00000305877.8	9	133729451	133763063	ENST00000318560.5	75	GRCh37	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/4706	https://civic.genome.wustl.edu/links/variants/1	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL A397P	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with A397P,  2/2 had MaHRs and 1/2 had MCyRs which were comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	4710	1612	4	9	133750358	133750358	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4710	https://civic.genome.wustl.edu/links/variants/1612	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E98G	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the E98G secondary variant in 11/11 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and complete best cytogenetic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4711	2901	4														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/4711	https://civic.genome.wustl.edu/links/variants/2901	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Supports	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using peripheral blood RNA. They had no best hematologic and no best cytogenetic responses to dasatinib which were worse compared to responses in patient with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	4718	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4718	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
BRAF	673	G596R	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation; IC50 9.89 uM vs 0.025-0.35uM for BRAF V600E expressing cell lines). Note that NCI-H508 also expresses PIK3CA E545K.	22180495	PubMed		Yang et al., 2012, Cancer Res.		1	accepted	4729	1627	5	7	140453149	140453149	C	G	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/4729	https://civic.genome.wustl.edu/links/variants/1627	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	RARE Exon 18-21 Mutation	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded at a rate of 47.5% (primarily G719 and L861, N=30/61). This was significantly greater (p<0.001) than a response rate of 16.5% in EGFR wild type patients but significantly smaller (p<0.001) than a 74.1% response in EGFR mutant patients with canonical exon 19 deletion or L858R mutation. Uncommon mutations also had greater median PFS (5.0 vs. 2.0 months, P < 0.001) and median overall survival (15.0 vs. 10.4 months, P = 0.030) than in patients with the wild-type EGFR.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		4	accepted	4755	1863	19													Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.	Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/4755	https://civic.genome.wustl.edu/links/variants/1863	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	Ex19 del L858R	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib). From 61 patients with uncommon EGFR mutations of unknown clinical significance, 47.5% were responders in contrast to the 74.1% responders in the exon 19 deletion/L858R group.	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		4	accepted	4759	1854	19														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4759	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	RARE Exon 18-21 Mutation	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mutations. Among patients that had UMUCS but not G719 or L861, the response rate to tyrosine kinase inhibitors erlotinib or gefitinib, progression free survival, and overall survival were 20%, 1.6 month and 11.1 months, which was similar for wild type EGFR (16.5%, 2.0 months and 10.4 months), which contrasted to higher response for more commonly occurring G719 and L861 mutations (53.3% and 60.0%, respectively).	21531810	PubMed		Wu et al., 2011, Clin. Cancer Res.		2	accepted	4762	1863	19													Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.	Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/4762	https://civic.genome.wustl.edu/links/variants/1863	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.	27566387	PubMed		Kanemaru et al., 2016, Respir Investig			accepted	4766	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4766	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
ABL1	25	C475V	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with C475V, 1/1 had a CHR and 1/1 had a MCyR. 9 patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4768	1639	4	9	133753954	133755455	TG	GT	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/4768	https://civic.genome.wustl.edu/links/variants/1639	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL N336S	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with N336S, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	4769	1640	4	9	133748346	133748346	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/4769	https://civic.genome.wustl.edu/links/variants/1640	https://civic.genome.wustl.edu/links/genes/4
POLD1	5424	C284Y	Lung Adenocarcinoma	3910		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit.	25765070	PubMed		Rizvi et al., 2015, Science			accepted	4776	1647	4384												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4776	https://civic.genome.wustl.edu/links/variants/1647	https://civic.genome.wustl.edu/links/genes/4384
POLD1	5424	E374K	Lung Non-small Cell Carcinoma	3908		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit.	25765070	PubMed		Rizvi et al., 2015, Science			accepted	4777	1648	4384												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4777	https://civic.genome.wustl.edu/links/variants/1648	https://civic.genome.wustl.edu/links/genes/4384
PIK3R2	5296	N561D	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3R2 N561D were significantly more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with an empty vector (40% vs 0% survival at the highest concentration, p < .0001).	24265155	PubMed		Shi et al., 2014, Cancer Discov		3	accepted	4783	1652	4290												GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4783	https://civic.genome.wustl.edu/links/variants/1652	https://civic.genome.wustl.edu/links/genes/4290
PIK3CA	5290	D350G	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	4784	1653	37	3	178921567	178921567	A	G	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/4784	https://civic.genome.wustl.edu/links/variants/1653	https://civic.genome.wustl.edu/links/genes/37
NRAS	4893	Q179X	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.	25666295	PubMed		Kaczirek et al., 2015, Clin Colorectal Cancer			accepted	4785	1654	36												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4785	https://civic.genome.wustl.edu/links/variants/1654	https://civic.genome.wustl.edu/links/genes/36
MET	4233	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12)  treated with crizotinib monotherapy, was  associated with a response as evident by the reduced size of tumors. Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment.	25769807	PubMed		Jenkins et al., 2015, Clin Lung Cancer		1	accepted	4786	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4786	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
ABL1	25	R351W	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.	26758680	PubMed		Testoni et al., 2016, EMBO Mol Med		4	accepted	4787	1656	4	9	133748333	133748333	C	T	ENST00000372348.2					75	GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4787	https://civic.genome.wustl.edu/links/variants/1656	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	G340L	Lung Non-small Cell Carcinoma	3908		Imatinib Mesylate,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a significant reduction in colony formation (P = 0.0001) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. A significant reduction in colony formation (P < 0.001) with dasatinib treatment vs vehicle was also observed. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Moreover, a significant increase in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.001) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.	26758680	PubMed		Testoni et al., 2016, EMBO Mol Med		3	accepted	4788	1657	4	9	133748300	133748301	GG	CT	ENST00000372348.2					75	GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4788	https://civic.genome.wustl.edu/links/variants/1657	https://civic.genome.wustl.edu/links/genes/4
KIT	3815	S628N	Cancer	162		Imatinib,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-sensitive control. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors.	25317746	PubMed		Vita et al., 2014, JAMA Dermatol		2	accepted	4791	1659	29	4	55594180	55594180	G	A							GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/4791	https://civic.genome.wustl.edu/links/variants/1659	https://civic.genome.wustl.edu/links/genes/29
EGFR	1956	M766_A767insAI	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4799	1664	19												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4799	https://civic.genome.wustl.edu/links/variants/1664	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	Y764_V765insHH	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4800	1665	19												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4800	https://civic.genome.wustl.edu/links/variants/1665	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	D770_N771insGY	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progressive disease. Both patients had increases in target lesions (38.1% and 6.0%) and PFS of just 1 month.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med		4	accepted	4801	1666	19	7	55249010	55249012	GAC	GGGTAT	ENST00000275493.2						GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4801	https://civic.genome.wustl.edu/links/variants/1666	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	P772_H773insYNP	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Resistance	In a non-small cell lung cancer patient harboring EGFR P772_H773insYNP mutation, EGFR P772_H773insYNP was associated with progressive disease in response to erlotinib monotherapy.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4802	1667	19												GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4802	https://civic.genome.wustl.edu/links/variants/1667	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	P772_V774insPHV	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In a lung adenocarcinoma patient harboring EGFR P772_V774insPHV mutation, EGFR P772_V774insPHV was associated with progressive disease in response to erlotinib monotherapy.	24353160	PubMed		Yasuda et al., 2013, Sci Transl Med			accepted	4803	1668	19												GRCh37		Somatic	2021-03-31 18:22:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4803	https://civic.genome.wustl.edu/links/variants/1668	https://civic.genome.wustl.edu/links/genes/19
ESR1	2099	D538G	Breast Cancer	1612		Palbociclib,Letrozole	Combination	Predictive	Does Not Support	B	Sensitivity/Response	In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11). There was no significant difference in overall survival (median; 14.1 versus 12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24).	27556863	PubMed		Gyanchandani et al., 2016, Oncotarget		2	accepted	4814	47	21	6	152419926	152419926	A	G	ENST00000206249.3					75	GRCh37	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	Somatic	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/4814	https://civic.genome.wustl.edu/links/variants/47	https://civic.genome.wustl.edu/links/genes/21
JAK2	3717	F547 SPLICE SITE MUTATION	Melanoma	1909		Pembrolizumab		Predictive	Supports	C	Resistance	In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient.	27433843	PubMed		Zaretsky et al., 2016, N. Engl. J. Med.			accepted	4825	1681	28	9	5070054	5070054	T	G							GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4825	https://civic.genome.wustl.edu/links/variants/1681	https://civic.genome.wustl.edu/links/genes/28
ARID1A	8289	P1175FS*5	Ovarian Clear Cell Carcinoma	0050934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, a HCH1 cell line expressing ARID1A P1175fs*5 mutation demonstrated increased sensitivity to dasatinib treatment, compared to ES2, KK and RMG-1 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival.	27364904	PubMed		Miller et al., 2016, Mol. Cancer Ther.			accepted	4826	1682	6559												GRCh37		Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4826	https://civic.genome.wustl.edu/links/variants/1682	https://civic.genome.wustl.edu/links/genes/6559
VHL	7428	LOSS	Renal Cell Carcinoma	4450		Anti-VEGF Monoclonal Antibody		Predictive	Does Not Support	B	Sensitivity/Response	A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. Six studies (total of 633 patients) were included. 61,8% had a VHL mutation. The meta-analysis showed no association between the VHL gene alteration and overall response rate or progression free survival. There was also no correlation to overall survival. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab.	28103578	PubMed		Kim et al., 2017, Oncotarget		4	accepted	4830	436	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4830	https://civic.genome.wustl.edu/links/variants/436	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	MUTATION	Renal Cell Carcinoma	4450		Anti-VEGF Monoclonal Antibody		Predictive	Supports	B	Resistance	A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. There were six studies including a total of 633 patients: 244 patients who received anti-VEGF therapy in the predictive value analysis and 419 in the prognostic value analysis. 410 (61.8%) had VHL alteration. The meta-analysis showed no association between the VHL gene alteration and ORR or PFS, as well as no correlation to OS. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab.	28103578	PubMed		Kim et al., 2017, Oncotarget		4	accepted	4832	160	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/4832	https://civic.genome.wustl.edu/links/variants/160	https://civic.genome.wustl.edu/links/genes/58
IDH2	3418	MUTATION	Acute Myeloid Leukemia	9119		Enasidenib		Predictive	Supports	D	Sensitivity/Response	Mutations in IDH1 or IDH2 are identified in approximately 20% of patients with AML.This study report the discovery and characterization of AG-221, orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed oncometobolite 2HG production and induced cellular differentiation in primary human IDH2 mutated AML cells in vivo and in xenograft mouse models, providing a statistically significant benefit in an aggressive IDH2 R140Q-mutant AML xenograft mouse model. Clinical trials are ongoing.	28193778	PubMed		Yen et al., 2017, Cancer Discov		4	accepted	4833	570	27	15	90626277	90645736			ENST00000330062.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/4833	https://civic.genome.wustl.edu/links/variants/570	https://civic.genome.wustl.edu/links/genes/27
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Brigatinib		Predictive	Supports	B	Sensitivity/Response	In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.	28475456	PubMed		Kim et al., 2017, J. Clin. Oncol.		4	accepted	4835	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4835	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
BRCA1	672	LOSS-OF-FUNCTION	Breast Cancer	1612		Talazoparib		Predictive	Supports	B	Sensitivity/Response	In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.	28242752	PubMed		de Bono et al., 2017, Cancer Discov		4	accepted	4838	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4838	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Breast Cancer	1612		Talazoparib		Predictive	Supports	B	Sensitivity/Response	In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.	28242752	PubMed		de Bono et al., 2017, Cancer Discov		4	accepted	4839	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4839	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
ERBB2	2064	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	Trastuzumab emtansine has its indication for patients with HER2-positive metastatic breast cancer after therapy with Trastuzumab and Taxane, approval based on PFS and preliminary OS data. EMILIA was a randomised open-label, phase III study for patients with HER2-positive, unresectable, locally advanced, or metastatic breast cancer previously treated with Trastuzumab and a Taxane, randomized 1:1 to Trastuzumab-emtansine or Capecitabine plus Lapatinib. 991 patients were enrolled. Median OS was 29.9m vs. 25.9m. Fewer grade 3 or worse AE occurred with trastuzumab emtansine than with capecitabine plus lapatinib control treatment.	28526536	PubMed		Diras et al., 2017, Lancet Oncol.	NCT00829166	4	accepted	4840	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4840	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
CDK4	1019	AMPLIFICATION	Liposarcoma	3382		Palbociclib		Predictive	Supports	B	Sensitivity/Response	More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification.  A prior phase 2 study demonstrated that treatment with palbociclib (200 mg/d for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects. In this phase 2, nonrandomized, open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advanced WD/DDLS and measurable disease by RECIST 1.1 were enrolled from December 2011 to January 2014 and followed to March 2015. Patients received oral palbociclib at new dose scheme, 125 mg/d for 21 days in 28-day cycles. Progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks. There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n=20 [33%]; grade 4, n=2 [3%]) but no neutropenic fever.  Compared to other dose scheme in PMID 23569312 with 200mg/d: 12week PFS 66%, overall median PFS 18 weeks.	27124835	PubMed		Dickson et al., 2016, JAMA Oncol	NCT01209598	3	accepted	4841	553	13	12	58141510	58146304			ENST00000257904.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4841	https://civic.genome.wustl.edu/links/variants/553	https://civic.genome.wustl.edu/links/genes/13
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Abemaciclib		Predictive	Supports	B	Sensitivity/Response	In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort. Stable disease lasting 24 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respectively.	27217383	PubMed		Patnaik et al., 2016, Cancer Discov		3	accepted	4842	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4842	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
CD274	29126	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045).	28079291	PubMed		Wang et al., 2017, Breast J		2	accepted	4844	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4844	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
ACVR1	90	Gain-of-Function	Astrocytoma	3069				Diagnostic	Supports	B	Positive	The authors used whole exome sequencing on 39 midline pediatric high-grade astrocytomas (pHGAs) and identified 5 with mutations in ACVR1, with 2 occurring at G328 (G328V and G328E). The authors state that somatic mutations are specific to tumor location -- gain-of-function mutations in ACVR1 (such as G328V) occur in tumors of the pons in conjunction with H3.1 K27M (as compared to thalamic tumors with FGFR1 mutations).	24705250	PubMed		Fontebasso et al., 2014, Nat. Genet.		3	accepted	4845	2061	154														Somatic	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/4845	https://civic.genome.wustl.edu/links/variants/2061	https://civic.genome.wustl.edu/links/genes/154
ACVR1	90	G328V	Diffuse Intrinsic Pontine Glioma	0080684				Diagnostic	Supports	B	Positive	Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test).	24705250	PubMed		Fontebasso et al., 2014, Nat. Genet.		3	accepted	4846	1686	154	2	158622516	158622516	C	A	ENST00000434821.1					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4846	https://civic.genome.wustl.edu/links/variants/1686	https://civic.genome.wustl.edu/links/genes/154
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. An open-label, two-stage, single-centre, phase 2, single-arm trial in the USA in metastatic/unresectable lung cancer harbouring RET rearrangement. 26 Patients were given 60 mg of cabozantinib orally per day. The primary objective was overall response, 25 patients assessable. KIF5B-RET was the predominant fusion in 16 (62%) patients. With confirmed PR seen in 7/25 (28%) response-assessable patients. The reported activity of cabozantinib in patients with RET-rearranged lung cancers defines RET rearrangements as actionable drivers in patients with lung cancers	27825636	PubMed		Drilon et al., 2016, Lancet Oncol.	NCT01639508	3	accepted	4847	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/4847	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Vandetanib		Predictive	Supports	B	Sensitivity/Response	RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset.  This study was a multi-center, open-label, phase II clinical trial to examine the safety and efficacy of Vandetanib (300 mg/d) in RET positive NSCLC patients (confirmed by FISH), Primary endpoint was the objective response rate. 18 patients were enrolled, the majority were a heavily pretreated population. Among the 17 evaluable patients, three had a partial response (ORR=18%) and eight had a stable disease (DCR=65%). Among these patients, the PR or SD was durable for more than 6 months in 8 patients. Vandetanib also showed a PFS of 4.5 months, and an OS of 11.6 months during a median follow-up duration of 14 months.	27803005	PubMed		Lee et al., 2017, Ann. Oncol.	NCT01823068	3	accepted	4848	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/4848	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Vandetanib		Predictive	Supports	B	Sensitivity/Response	We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. 1536 patients with EGFR mutation-negative NSCLC were screened,, 34 were RET-positive (2%), 19 were enrolled and 17 patients were eligible for primary analysis.   9 patients (53%) achieved and objective response, in the intention to treat population of 19 patients, 9 patients (47% achieved an OR. At data cutoff, median PFS was 4,7 months. The results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy.	27825616	PubMed		Yoh et al., 2017, Lancet Respir Med		3	accepted	4849	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/4849	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had received prior RET TKIs, including cabozantinib and experimental RET inhibitors. We observed two (50%) objective radiographic responses after treatment with alectinib (one confirmed and one unconfirmed), with durations of therapy of 6 months and more than 5 months (treatment ongoing). Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. In addition, one patient (25%) experienced a best response of stable disease lasting approximately 6 weeks. A fourth patient who was RET TKI-naive had primary progression while receiving alectinib.	27544060	PubMed		Lin et al., 2016, J Thorac Oncol		3	accepted	4850	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/4850	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
CD274	29126	EXPRESSION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC).	28430626	PubMed		Zhang et al., 2017, Oncotarget		3	accepted	4855	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4855	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Cancer	162				Prognostic	Supports	B	Better Outcome	PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002).	28453554	PubMed		Zhao et al., 2017, PLoS ONE		2	accepted	4856	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4856	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pembrolizumab,Durvalumab,Avelumab,Atezolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).	28472902	PubMed		Aguiar et al., 2017, Immunotherapy		4	accepted	4857	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4857	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib,Crizotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib).	28586279	PubMed		Peters et al., 2017, N. Engl. J. Med.	NCT02075840	5	accepted	4858	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4858	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
EGFR	1956	EXON 19 DELETION	Lung Non-small Cell Carcinoma	3908		Dacomitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.3351.024], two-sided log-rank, P = 0.058) but did not reach significance.	26768165	PubMed		Ramalingam et al., 2016, Ann. Oncol.	NCT00769067,NCT01360554	3	accepted	4859	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4859	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Sensitivity/Response	The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.	26768165	PubMed		Ramalingam et al., 2016, Ann. Oncol.	NCT00769067,NCT01360554	5	accepted	4860	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4860	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
FGFR3	2261	FGFR3 FUSIONS	Adrenal Carcinoma	3950		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. Tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions.	26324363	PubMed		Tabernero et al., 2015, J. Clin. Oncol.	NCT01703481	3	accepted	4861	1691	23														Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/4861	https://civic.genome.wustl.edu/links/variants/1691	https://civic.genome.wustl.edu/links/genes/23
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Trametinib,Docetaxel,Pemetrexed	Combination	Predictive	Supports	B	Sensitivity/Response	This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC.	27876675	PubMed		Gandara et al., 2017, J Thorac Oncol	NCT01192165	3	accepted	4862	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4862	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Atezolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs.	28525386	PubMed		Kim et al., 2017, Oncotarget		3	accepted	4863	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4863	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Immune Checkpoint Inhibitor		Predictive	Supports	E	Sensitivity/Response	This meta-analysis of 5 studies with 752 non-small cell lung cancer patients examined the association between PD-L1 expression and KRAS mutation status. KRAS-mutant tumors were marginally more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; odds ratio: 1.69; 95% CI 1.01-2.84; p = 0.045). Authors concluded that this result contributes to a theoretical basis for including PD-L1 inhibitors in combination with other molecularly targeted drugs in the treatment of patients with KRAS mutations.	28259530	PubMed		Li et al., 2017, Eur J Surg Oncol		2	accepted	4864	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4864	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		Selumetinib,Cetuximab	Combination	Predictive	Does Not Support	B	Sensitivity/Response	A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response. Five patients experienced stable disease, nine had progressive disease.  Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC.	26666244	PubMed		Deming et al., 2016, Invest New Drugs	NCT01287130	3	accepted	4866	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4866	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197). Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). These data suggest that trametinib is associated with similar PFS and response rates as docetaxel.	25722381	PubMed		Blumenschein et al., 2015, Ann. Oncol.	NCT01362296	4	accepted	4867	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4867	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Selumetinib	Combination	Predictive	Does Not Support	B	Sensitivity/Response	38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib. 41 KRAS mutant patients were randomized to selumetinib or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Median PFS in the KRAS wild-type arm was 2.4 months for erlotinib alone and 2.1 months for the combination. The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination. These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC.	26802155	PubMed		Carter et al., 2016, Ann. Oncol.	NCT01229150	4	accepted	4868	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4868	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Colorectal Cancer	9256		Palbociclib,Binimetinib	Combination	Predictive	Supports	D	Sensitivity/Response	A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.   The combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner Combination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo.	27167191	PubMed		Lee et al., 2016, Oncotarget		4	accepted	4869	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4869	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
CDK4	1019	EXPRESSION	Sarcoma	1115		Palbociclib		Predictive	Supports	D	Sensitivity/Response	A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines correlated with their levels of CDK4 mRNA as well as in vivo PDX, but not against sarcomas displaying low levels of CDK4 and high levels of p16ink4a (CDKN2A).	26528855	PubMed		Perez et al., 2015, Oncotarget		4	accepted	4872	25	13	12	58141510	58146304			ENST00000257904.6					75	GRCh37	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4872	https://civic.genome.wustl.edu/links/variants/25	https://civic.genome.wustl.edu/links/genes/13
CHEK1	1111	OVEREXPRESSION	Lung Small Cell Carcinoma	5409		Cisplatin,Prexasertib,Olaparib	Combination	Predictive	Supports	D	Sensitivity/Response	A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexasertib had strong single agent efficacy and augmented the effect of Olaparib or Cisplatin in either combination, including platinum-resistant models. CHEK1 and MYC overexpression were predictors of response.	28490518	PubMed		Sen et al., 2017, Cancer Res.		4	accepted	4874	1693	981														N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4874	https://civic.genome.wustl.edu/links/variants/1693	https://civic.genome.wustl.edu/links/genes/981
BRCA2	675	LOSS-OF-FUNCTION	Ovarian Cancer	2394		Talazoparib		Predictive	Supports	B	Sensitivity/Response	In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.	28242752	PubMed		de Bono et al., 2017, Cancer Discov		3	accepted	4875	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4875	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	LOSS-OF-FUNCTION	Ovarian Cancer	2394		Talazoparib		Predictive	Supports	B	Sensitivity/Response	In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.	28242752	PubMed		de Bono et al., 2017, Cancer Discov		3	accepted	4876	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4876	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
EGFR	1956	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of 18.4%, a PFS of 2.7 months and a median overall survival of 7.6 months. For individuals taking 500mg/day objective response rate was 19%, PFS was 2.8 months, and median overall survival was 8.0 months. For those who responded, median duration of the response was 3 months (ranges=1-5.5 months). The disease control rate was found to be 54.4% and 51.4% for the two groups.	12748244	PubMed		Fukuoka et al., 2003, J. Clin. Oncol.		3	accepted	4877	354	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4877	https://civic.genome.wustl.edu/links/variants/354	https://civic.genome.wustl.edu/links/genes/19
TP53	7157	R248W	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4879	118	45	17	7577539	7577539	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/4879	https://civic.genome.wustl.edu/links/variants/118	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R175H	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4880	116	45	17	7578406	7578406	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/4880	https://civic.genome.wustl.edu/links/variants/116	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273C	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4881	121	45	17	7577121	7577121	G	A	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4881	https://civic.genome.wustl.edu/links/variants/121	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273H	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4882	122	45	17	7577120	7577120	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/4882	https://civic.genome.wustl.edu/links/variants/122	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	G245S	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4883	879	45	17	7577548	7577548	C	T	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4883	https://civic.genome.wustl.edu/links/variants/879	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	Y220C	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4884	922	45	17	7578190	7578190	T	C	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4884	https://civic.genome.wustl.edu/links/variants/922	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	M237I	Glioblastoma Multiforme	3068		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line (T98G, glioblastoma) and it is insensitive to MDM2 Inhibitor AMGMDS3 (IC50: 49.97uM).	25730903	PubMed		Saiki et al., 2015, Oncotarget		3	accepted	4885	1066	45	17	7577570	7577570	C	A	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4885	https://civic.genome.wustl.edu/links/variants/1066	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R158H	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4886	1695	45	17	7578457	7578457	C	T	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/4886	https://civic.genome.wustl.edu/links/variants/1695	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	V157F	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4887	1092	45	17	7578461	7578461	C	A	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4887	https://civic.genome.wustl.edu/links/variants/1092	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R249S	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R249S loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4888	1696	45														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4888	https://civic.genome.wustl.edu/links/variants/1696	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R280K	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280K loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4889	1697	45														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4889	https://civic.genome.wustl.edu/links/variants/1697	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R280T	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280T loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4890	1698	45														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4890	https://civic.genome.wustl.edu/links/variants/1698	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R158L	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		Saiki et al., 2015, Oncotarget		4	accepted	4891	1699	45	17	7578457	7578457	C	A	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/4891	https://civic.genome.wustl.edu/links/variants/1699	https://civic.genome.wustl.edu/links/genes/45
VHL	7428	E46* (c.136G>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Likely Pathogenic	Study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Frameshift truncation mutation found in a single patient with VHL retinal manifestation, which coincides with mutations confirmed to be associated with VHL type 1 in this study. Only moderate evidence of pathogenicity since the protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants (AMCG code: PM4).	12202531	PubMed		Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci.		4	accepted	4895	1733	58	3	10183667	10183667	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4895	https://civic.genome.wustl.edu/links/variants/1733	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E55* (c.163G>T)	Von Hippel-Lindau Disease	14175	Retinal detachment,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Likely Pathogenic	Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with type von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. The mutations could not be found within 100 healthy controls. One germline truncation mutation was found in a 15-year-old male patient with bilateral renal cell carcinoma and retinal hemangioblastoma with serious retinal detachment. Neither of his parents displayed any mutations in the VHL gene indicating a de novo mutation. ACMG evidence codes: 'PS2' because they observe a de novo mutation (maternity and paternity confirmed), 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Renal cell carcinoma, Retinal hemangioblastoma	23298237	PubMed		Losonczy et al., 2013, BMC Med. Genet.		3	accepted	4898	1736	58	3	10183694	10183694	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/4898	https://civic.genome.wustl.edu/links/variants/1736	https://civic.genome.wustl.edu/links/genes/58
BRAF	673	L597Q	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months.	24933606	PubMed		Bowyer et al., 2014, Melanoma Res.		3	accepted	4905	583	5	7	140453145	140453145	A	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/4905	https://civic.genome.wustl.edu/links/variants/583	https://civic.genome.wustl.edu/links/genes/5
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation found in two VHL type 2A families of 55 individuals altogether (family IDs 3476, 3127). 26 of 55 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 30 with pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		3	accepted	4906	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/4906	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115Q (c.345C>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 12 individuals (Family ID 4486 in publication). All 12 family members identified with cerebellar hemangioblastomas, 2 of 12 family members with retinal hemangioblastomas, one with renal cell carcinoma and one with pheochromocytoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Pheochromocytoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4907	1742	58	3	10188202	10188202	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/4907	https://civic.genome.wustl.edu/links/variants/1742	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F119L (c.357C>G)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Pheochromocytoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 7 individuals (Family ID 4414 in publication). Two of seven individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas, one with renal cell carcinoma, and one with pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4908	1743	58	3	10188214	10188214	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4908	https://civic.genome.wustl.edu/links/variants/1743	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A149T (c.445G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL (Family ID 3969 in publication). One carried pheochromocytoma, while both carried angiomas.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4909	1744	58	3	10188302	10188302	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4909	https://civic.genome.wustl.edu/links/variants/1744	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T157I (c.470C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This mutation was found in 2 family members with VHL disease (family ID 4402). One carried pheochromocytoma and both carried retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4910	1745	58	3	10191477	10191477	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4910	https://civic.genome.wustl.edu/links/variants/1745	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pheochromocytoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 2B patient with retinal hemangioblastoma, renal cell carcinoma, and pheochromocytoma (family ID 4422). Only supporting evidence for pathogenicity because patient's phenotyoe is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4911	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/4911	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Pheochromocytoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in four VHL type 2 families of 51 individuals altogether (family IDs 2338, 3490, 4477, 4405). 36 of 51 individuals had retinal hemangioblastomas, 17 had cerebellar hemangioblastomas, 16 with renal cell carcinoma, and 36 with pheochromocytomas. This mutation was also detected in a VHL type 1 patient with angiomas (family ID 3699). Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4912	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/4912	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in six VHL type 2 families (including one family with 9 affected individuals) and one VHL type 1 family totaling 23 individuals altogether (family IDs 4421, 3718, 3767, 3493, 3731, 3517, 3739). Twelve of 23 individuals had retinal hemangioblastomas, 12 carried cerebellar hemangioblastomas, 8 carried renal cell carcinoma and 12 carried pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		3	accepted	4913	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/4913	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL disease type 2A, who both had retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3786). One of 2 individuals carried pheochromocytomas as well. Mutation also found in 8 individuals with VHL type 1 phenotype (family IDs 3314, 4419, 4403, 3708). Three of 8 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4914	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4914	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V62fs (c.180del)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was found in a VHL type 1 family of 8 individuals (family ID 3563). Two of 8 individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas and 3 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4916	1750	58	3	10183711	10183711	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4916	https://civic.genome.wustl.edu/links/variants/1750	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of four individuals (family ID 4325). Three of 4 individuals were identified with retinal hemangioblastomas and one with cerebellar hemangioblastomas. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4917	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4917	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q73* (c.217C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 7 individuals (family ID 2753). Six of 7 individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas and one with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4918	1752	58	3	10183748	10183748	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4918	https://civic.genome.wustl.edu/links/variants/1752	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	This deletion mutation was found in two VHL type 1 families of 15 individuals altogether (Family IDs 2693 and 2956 in publication). Five of 7 individuals were identified with retinal hemangioblastomas, 8 with cerebellar hemangioblastomas, and 7 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4919	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/4919	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78H (c.232A>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient (family ID 4389) with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4920	1754	58	3	10183763	10183763	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/4920	https://civic.genome.wustl.edu/links/variants/1754	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 4327). All 3 individuals carried cerebellar hemangioblastomas and one also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4921	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4921	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78T (c.233A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 3101). One of 3 members carried retinal hemangioblastomas and 2 carried cerebellar hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4922	1756	58	3	10183764	10183764	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4922	https://civic.genome.wustl.edu/links/variants/1756	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80I (c.239G>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3630). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4923	1757	58	3	10183770	10183770	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4923	https://civic.genome.wustl.edu/links/variants/1757	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86fs (c.254_255insC)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was found in 3 family members with VHL type 1 phenotype (family ID 3312). All 3 individuals carried retinal hemangioblastomas, 2 of 3 carried cerebellar hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4924	1758	58	3	10183785	10183786		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/4924	https://civic.genome.wustl.edu/links/variants/1758	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86L (c.257C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in two VHL type 1 families of 12 individuals altogether (family IDs 2612 and 3568). Nine of 12 individuals were identified with cerebellar hemangioblastomas, 6 with retinal hemangioblastomas, and 6 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4926	1760	58	3	10183788	10183788	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/4926	https://civic.genome.wustl.edu/links/variants/1760	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88R (c.262T>A)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 1255). All 3 individuals carried cerebellar hemangioblastomas and retinal hemangioblastomas. Two of 3 also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4927	1761	58	3	10183793	10183793	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/4927	https://civic.genome.wustl.edu/links/variants/1761	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111FS (c.331delA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 3669). Only supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4928	1762	58	3	10183862	10183862	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/4928	https://civic.genome.wustl.edu/links/variants/1762	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111N (c.332G>A)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 4 individuals (family ID 3315). One of the 4 individuals was identified with retinal hemangioblastomas, 2 with cerebellar hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4929	1763	58	3	10183863	10183863	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4929	https://civic.genome.wustl.edu/links/variants/1763	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111R (c.333C>G)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 4401). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4930	1764	58	3	10183864	10183864	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4930	https://civic.genome.wustl.edu/links/variants/1764	https://civic.genome.wustl.edu/links/genes/58
EGFR	1956	Gain-of-function	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	Study found somatic EGFR mutations localized to exons 19,21 in 8/9 patients who exhibited a response to Gefitinib treatment. Of these mutations 7/8 were localized near the ATP cleft Gefitinib targets, suggesting a specific gain-of-function mechanism. No EGFR mutations were observed in 7 patients with no response to Gefitinib. An expansion cohort independent of the Gefitinib study showed 2/25 patients harbored EGFR mutations. A second expansion independent of Gefitinib consisting of 95 tumors and 108 cell lines showed no mutations in exons 19,21.	15118073	PubMed		Lynch et al., 2004, N. Engl. J. Med.		4	accepted	4931	1765	19														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4931	https://civic.genome.wustl.edu/links/variants/1765	https://civic.genome.wustl.edu/links/genes/19
VHL	7428	Y112* (c.336C>A)	Von Hippel-Lindau Disease	14175	Hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 patient and familiy of 4 individuals (family IDs 3759 and 3760). Four of 5 individuals were identified with angiomas, 2 with cerebellar hemangioblastomas, and one with renal cell carcinoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4932	1766	58	3	10183867	10183867	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4932	https://civic.genome.wustl.edu/links/variants/1766	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W117C (c.351G>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 10 individuals (family ID 1239). Seven of 10 individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One identified with retinal hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4933	1767	58	3	10188208	10188208	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4933	https://civic.genome.wustl.edu/links/variants/1767	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L129Q (c.386insAGA)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This insertion mutation was detected in a VHL type 1 patient (family ID 4410 in publication) with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4934	1768	58														Rare Germline	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/4934	https://civic.genome.wustl.edu/links/variants/1768	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L135* (c.404T>A)	Von Hippel-Lindau Disease	14175	Hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 6 individuals (family ID 3720). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with angiomas and 3 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4935	1769	58	3	10188261	10188261	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4935	https://civic.genome.wustl.edu/links/variants/1769	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N150fs (c.449del)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This mutation causes a stop codon at amino acid 158. Mutation also found in 3 family members with VHL type 1 phenotype (family ID 3575). Two of 3 members carried retinal hemangioblastomas, one carried cerebellar hemangioblastomas and one with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		3	accepted	4936	1770	58		10188305	10188305	A		ENST00000256474.2					75	GRCh37	There are no similar variants in ClinVar with this exact genomic location.	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/4936	https://civic.genome.wustl.edu/links/variants/1770	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154fs (c.462delA)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Mutation causes a stop codon at amino acid 158. This mutation was also found in 4 family members with VHL type 1 phenotype (family ID 3616). Two of 4 members carried retinal hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		3	accepted	4937	1771	58	3	10188319	10188319	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4937	https://civic.genome.wustl.edu/links/variants/1771	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162R (c.484T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation detected in a VHL type 1 patient (Family ID 3509 in publication) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4939	1772	58	3	10191491	10191491	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/4939	https://civic.genome.wustl.edu/links/variants/1772	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162F (c.485G>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 4 family members with VHL type 1 phenotype (Family ID 3820 in publication). All 4 family members carried cerebellar hemangioblastomas, 2 of 4 carried retinal hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4940	1773	58	3	10191492	10191492	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/4940	https://civic.genome.wustl.edu/links/variants/1773	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in VHL type 1 patient (Family ID 3618 in publication) with cerebellar hemangioblastomas. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4941	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/4941	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V166D (c.497T>A)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 4480). Both individuals were identified with cerebellar hemangioblastomas and one with retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	4942	1775	58	3	10191504	10191504	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4942	https://civic.genome.wustl.edu/links/variants/1775	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184P (c.551T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma			Predisposing	N/A	C	N/A	In a study of 114 unrelated VHL affected families, germline mutations in the VHL gene were identified in 85 of the families. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals, however it seems unaffected family members were not tested genetically for the mutations. Mutations in the VHL gene were detected by SSCP and DNA sequencing. Haplotypes were determined with four microsatellite polymorphic probes. The missense mutation L184P (c.551T>C) (In the paper noted as nucleotide position 764 and codon position 255 due to old reference transcript), was found in 2 individuals in family 3708. Both individuals were identified with renal cell carcinoma and one also presented with a CNS hemangioblastoma. Additional information regarding the family information, including a pedigree, were not provided. ACMG evidence codes: 'flag for PP4' since the patients phenotype and family history is consistent with VHL, 'flag for PP1' because there is co-segregation of variant with the phenotype in two members of the family.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4943	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4943	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E186* (c.556G>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals .This nonsense mutation was found in a VHL type 1 family of 6 individuals (Family ID 3770 in publication). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with retinal hemangioblastomas, and 5 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		3	accepted	4944	1777	58	3	10191563	10191563	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4944	https://civic.genome.wustl.edu/links/variants/1777	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E186K (c.556G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (Family ID 3736 in publication). One of 2 individuals were identified with retinal hemangioblastomas, one with cerebellar hemangioblastomas, and one with renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		2	accepted	4945	1778	58	3	10191563	10191563	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4945	https://civic.genome.wustl.edu/links/variants/1778	https://civic.genome.wustl.edu/links/genes/58
ERBB2	2064	L755S	Colorectal Adenocarcinoma	0050861		Trastuzumab,Leucovorin,Fluorouracil	Combination	Predictive	Does Not Support	C	Sensitivity/Response	Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRAF. He was then treated with trastuzumab combined with infusional 5-Fu and leucovorin but exhibited no response.	27626067	PubMed		Aung et al., 2016, Cold Spring Harb Mol Case Stud		3	accepted	4955	39	20	17	37880220	37880220	T	C	ENST00000269571.5					75	GRCh37	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.	Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/4955	https://civic.genome.wustl.edu/links/variants/39	https://civic.genome.wustl.edu/links/genes/20
VHL	7428	A56fs (c.166_167insA)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes a frameshift and premature stop codon at amino acid 131 and was found in a VHL type 1 patient (kindred no. 110). This variant is likely to cause a dramatic alteration in protein function in a gene where loss-of-function mutations are a known mechanism (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		2	accepted	4956	1785	58	3	10183697	10183698		A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/4956	https://civic.genome.wustl.edu/links/variants/1785	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 25). Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4958	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4958	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 52).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4959	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/4959	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C77fs (c.228dup)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation causes a stop codon at amino acid 131 and was found in a VHL type 2 and a VHL type 1 patient (kindred no. 71, 85). A frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4961	2132	58	3	10183758	10183759		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/4961	https://civic.genome.wustl.edu/links/variants/2132	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78H (c.232A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type1). This mutation was found in a VHL type 1 patient (kindred no. 34).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4962	1754	58	3	10183763	10183763	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/4962	https://civic.genome.wustl.edu/links/variants/1754	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R79P (c.236G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 150). The presence of pheochromocytoma was not indicated.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4963	1791	58	3	10183767	10183767	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/4963	https://civic.genome.wustl.edu/links/variants/1791	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80R (c.240T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 103).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4964	1792	58	3	10183771	10183771	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4964	https://civic.genome.wustl.edu/links/variants/1792	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L89P (c.266T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 59).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4965	1793	58	3	10183797	10183797	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4965	https://civic.genome.wustl.edu/links/variants/1793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL family (kindred no. 22). Incidence of pheochromocytoma was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4967	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/4967	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114C (c.340G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 unrelated VHL families (kindred no. 40, 133). One was identified with pheochromocytoma, the other was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2). Relevant HPO term: pheochromocytoma.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4970	1797	58	3	10183871	10183871	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/4970	https://civic.genome.wustl.edu/links/variants/1797	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118P (c.353T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 19).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4971	1798	58	3	10188210	10188210	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/4971	https://civic.genome.wustl.edu/links/variants/1798	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131fs (c.390_391del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 133 and was found in VHL type 1 patient (kindred no. 64). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4973	1800	58	3	10188247	10188248	TA		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/4973	https://civic.genome.wustl.edu/links/variants/1800	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 27).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4974	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4974	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L153fs (c.457delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 158 and was found in  2 unrelated VHL patients (kindred no. 41, 99). One patient did not have pheochromocytoma.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4975	1802	58	3	10188317	10188317	C		ENST00000256474.2					75	GRCh37	There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/4975	https://civic.genome.wustl.edu/links/variants/1802	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154L (c.461C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 2 patient (kindred no. 49).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4976	1782	58	3	10188318	10188318	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4976	https://civic.genome.wustl.edu/links/variants/1782	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158V (c.472C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 91).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4977	1803	58	3	10191479	10191479	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/4977	https://civic.genome.wustl.edu/links/variants/1803	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170F (c.508G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 2 patient (kindred no. 26). Supporting evidence of pathogenicity because of a missense mutation in a gene in which missense variants are a common mechanism of disease. Relevant HPO terms: Pheochomocytoma.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4982	1806	58	3	10191515	10191515	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/4982	https://civic.genome.wustl.edu/links/variants/1806	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 44).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4983	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/4983	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I180V (c.538A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 79).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4984	1807	58	3	10191545	10191545	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/4984	https://civic.genome.wustl.edu/links/variants/1807	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 21). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	4987	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/4987	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib,Docetaxel	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	222 EGFR-wt patients with advanced NSCLC were randomized to receive docetaxel or erlotinib In this study (4 patients not eligible). KRAS was mutated in 25 and 26 out of 109 patients in the erlotinib and docetaxel arm, respectively. KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib.	26209642	PubMed		Rulli et al., 2015, Ann. Oncol.	NCT00637910	4	accepted	4996	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4996	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	MUTATION	Lung Non-small Cell Carcinoma	3908		Docetaxel		Predictive	Does Not Support	B	Sensitivity/Response	Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel.	20038723	PubMed		Douillard et al., 2010, J. Clin. Oncol.	NCT00076388	4	accepted	4997	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/4997	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 138 unrelated VHL families, 109 germline mutations were found. Missense mutations were more frequently found in families with pheochromocytoma. Deletions. Nonsense, and frameshift mutations were more frequently found in families without pheochromocytoma. Large deletions and mutations predicted to cause truncated protein were associated with lower risk pheochromocytoma. This missense mutation was found in one of the VHL families (family ID 39).	8730290	PubMed		Maher et al., 1996, J. Med. Genet.		3	accepted	4998	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/4998	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170D (c.509T>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 138 unrelated VHL families, 109 germline mutations were found. Missense mutations were more frequently found in families with pheochromocytoma (PC). Deletions. Nonsense, and frameshift mutations were more frequently found in families without PC. Large deletions and mutations predicted to cause truncated protein were associated with lower risk of PC. This missense mutation was found in a VHL family (family ID 77). No phenotype described.	8730290	PubMed		Maher et al., 1996, J. Med. Genet.		3	accepted	5013	1826	58	3	10191516	10191516	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5013	https://civic.genome.wustl.edu/links/variants/1826	https://civic.genome.wustl.edu/links/genes/58
POLE	5426	P286R	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis.	28404093	PubMed		Domingo et al., 2016, Lancet Gastroenterol Hepatol		3	accepted	5017	1830	4386														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/5017	https://civic.genome.wustl.edu/links/variants/1830	https://civic.genome.wustl.edu/links/genes/4386
POLE	5426	V411L	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis.	28404093	PubMed		Domingo et al., 2016, Lancet Gastroenterol Hepatol		3	accepted	5018	1831	4386														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/5018	https://civic.genome.wustl.edu/links/variants/1831	https://civic.genome.wustl.edu/links/genes/4386
POLE	5426	S459F	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis.	28404093	PubMed		Domingo et al., 2016, Lancet Gastroenterol Hepatol		3	accepted	5019	1832	4386														Somatic	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/5019	https://civic.genome.wustl.edu/links/variants/1832	https://civic.genome.wustl.edu/links/genes/4386
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of VHL gene product (pVHL). Missense mutation, affecting an amino acid within pVHL protein core, was found in 6 VHL type 1 families with 12 affected individuals altogether. Nine of 12 patients had retinal angioma, 5 had cerebellar hemangioblastoma, and 2 had renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5020	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5020	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L116V (c.346C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue with pVHL protein core, was detected in a VHL type 1 family with 3 affected individuals. All 3 patients had retinal angioma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5022	1820	58	3	10188203	10188203	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5022	https://civic.genome.wustl.edu/links/variants/1820	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V166F (c.496G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting surface residue of pVHL protein core, was found in 2 VHL type 2A families with 5 affected individuals altogether. Two of 5 patients had retinal angioma, 2 had cerebellar hemangioblastoma, and 4 had pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5024	1825	58	3	10191503	10191503	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5024	https://civic.genome.wustl.edu/links/variants/1825	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Cerebellar hemangioblastoma,Renal cell carcinoma,Pancreatic cysts,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with retinal and cerebellar hemangioblastoma, renal cell carcinoma, and renal and pancreatic cysts (family no. 3).  ACMG codes: PP4.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5026	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5026	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Cerebellar hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastoma, renal cysts and pancreatic cysts (family no. 6).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5027	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5027	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170D (c.509T>A)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pancreatic cysts,Pheochromocytoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was identified in 14 VHL patients (family no. 18). Six had retinal hemangioblastoma, 9 had cerebellar hemangioblastoma, 7 had renal cell carcinoma, 8 had renal cysts, 4 had pheochromocytoma, and 5 had pancreatic cysts.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5029	1826	58	3	10191516	10191516	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5029	https://civic.genome.wustl.edu/links/variants/1826	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65* (c.194C>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation found in VHL type 1 family (lineage 80). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5033	1811	58	3	10183725	10183725	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5033	https://civic.genome.wustl.edu/links/variants/1811	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 53).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5034	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5034	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70* (c.208G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 179). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: hemangioblastoma,  Renal cell carcinoma, Pheochromocytoma.	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5035	1834	58	3	10183739	10183739	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5035	https://civic.genome.wustl.edu/links/variants/1834	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76S (c.227T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 132).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5037	1835	58	3	10183758	10183758	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5037	https://civic.genome.wustl.edu/links/variants/1835	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L101G (c.301_302delinsGG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 103).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		2	accepted	5040	1838	58	3	10183832	10183833	CT	GG	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.302T>C (p.Leu101Pro; L101P) (https://www.ncbi.nlm.nih.gov/clinvar/variation/480963/)	Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5040	https://civic.genome.wustl.edu/links/variants/1838	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T105P (c.313A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in VHL type 1 family (lineage 208).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		2	accepted	5041	1839	58	3	10183844	10183844	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/5041	https://civic.genome.wustl.edu/links/variants/1839	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R107P (c.320G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 76).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5042	1840	58	3	10183851	10183851	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5042	https://civic.genome.wustl.edu/links/variants/1840	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113* (c.337C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 81). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5043	1796	58	3	10183868	10183868	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5043	https://civic.genome.wustl.edu/links/variants/1796	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W117C (c.351G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in 2 VHL type 1 families (lineage 83 and 146).Discovered the presence of the same missense mutation in another VHL type 1 family, so I changed evidence statement to include findings from both VHL families.	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5044	1767	58	3	10188208	10188208	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5044	https://civic.genome.wustl.edu/links/variants/1767	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118fs (c.352_353insA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 131 and was found in a VHL type 1 family (lineage 13). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: hemangioblastoma, Renal cell carcinoma, Pheochromocytoma.	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5045	1841	58	3	10188209	10188210		A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5045	https://civic.genome.wustl.edu/links/variants/1841	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131T (c.392A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 86).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5046	2580	58	3	10188249	10188249	A	C	ENST00000256474.2					75	GRCh37	A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.	Rare Germline	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/5046	https://civic.genome.wustl.edu/links/variants/2580	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T133fs (c.397del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 64). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5047	1843	58	3	10188252	10188252	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5047	https://civic.genome.wustl.edu/links/variants/1843	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D143fs (c.430delG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 119). Only moderate evidence for pathogenicity because protein length changes as a result of deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4).  Relevant HPO terms: hemangioblastoma, Renal cell carcinoma, Pheochromocytoma.	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5048	1844	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5048	https://civic.genome.wustl.edu/links/variants/1844	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in 3 VHL type 1 families and one VHL type 2 family (lineages 184, 93, 22, 92). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5049	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5049	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162F (c.485G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 69).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		2	accepted	5050	1773	58	3	10191492	10191492	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5050	https://civic.genome.wustl.edu/links/variants/1773	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164* (c.490C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 141). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5051	1845	58	3	10191497	10191497	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5051	https://civic.genome.wustl.edu/links/variants/1845	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in two VHL type 1 families and six VHL type 2 families (lineages 202, 47, 102, 106, 153, 109).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5052	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5052	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175D (c.523T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 7).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5053	1846	58	3	10191530	10191530	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5053	https://civic.genome.wustl.edu/links/variants/1846	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V181fs (c.540_543delCGTC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at amino acid 200 and was found in a VHL type 1 family (lineage 25). Only moderate evidence for pathogenicity because protein length changes as a result of deletions in a nonrepeat region and stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5054	1847	58	3	10191547	10191550	CGTC		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5054	https://civic.genome.wustl.edu/links/variants/1847	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184P (c.551T>C)	Von Hippel-Lindau Disease	14175				Predisposing	N/A	C	N/A	93 families that fulfilled the clinical criteria of VHL disease were assessed for germline mutations in the VHL gene, and mutations were found in all affected family members. The c.551T>C (p.L184P) mutation was found in a family (Lineage 14) in which members were clinically diagnosed with VHL presenting without pheochromocytoma (VHL type 1), however, no further phenotypic information about specific patients was provided. This mutation was recorded as c.764T>C in the paper, due to the use of an older VHL reference transcript. Genomic DNA was extracted from whole blood for analysis. Polymorphisms in the VHL gene were detected by southern blotting, and were further investigated by PCR and Sanger sequencing. Partial and total deletions of the VHL gene were investigated by southern blot. Relevant ACMG codes include: PP4, because the patients phenotype is highly specific for a disease with a single genetic etiology.	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		2	accepted	5055	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5055	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y185* (c.555C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 50). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5056	1809	58	3	10191562	10191562	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5056	https://civic.genome.wustl.edu/links/variants/1809	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E186* (c.556G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 78). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5057	1777	58	3	10191563	10191563	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5057	https://civic.genome.wustl.edu/links/variants/1777	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q96* (c.286C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 48). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5058	1848	58	3	10183817	10183817	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5058	https://civic.genome.wustl.edu/links/variants/1848	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86R (c.257C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 128).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5059	1849	58	3	10183788	10183788	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5059	https://civic.genome.wustl.edu/links/variants/1849	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 3).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5061	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5061	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in six VHL type 2 families (lineages 100, 42, 44, 88, 105, 135). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		4	accepted	5062	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5062	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G144* (c.430G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 2 family (lineage 65). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5064	1850	58	3	10188287	10188287	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5064	https://civic.genome.wustl.edu/links/variants/1850	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188P (c.563T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 73).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5066	1852	58	3	10191570	10191570	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5066	https://civic.genome.wustl.edu/links/variants/1852	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111C (c.330_331delinsTT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 174).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5067	1853	58	3	10183861	10183862	CA	TT	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar. Clinvar ID: 565557	Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5067	https://civic.genome.wustl.edu/links/variants/1853	https://civic.genome.wustl.edu/links/genes/58
GNAQ	2776	MUTATION	Uveal Melanoma	6039		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284).	28103611	PubMed		Daud et al., 2017, Br. J. Cancer		2	accepted	5068	505	2317	9	80331003	80646374			ENST00000286548.4					75	GRCh37		Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5068	https://civic.genome.wustl.edu/links/variants/505	https://civic.genome.wustl.edu/links/genes/2317
IDH2	3418	MUTATION	Acute Myeloid Leukemia	9119		Enasidenib		Predictive	Supports	B	Sensitivity/Response	A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months.	28588020	PubMed		Stein et al., 2017, Blood	NCT01915498	4	accepted	5069	570	27	15	90626277	90645736			ENST00000330062.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/5069	https://civic.genome.wustl.edu/links/variants/570	https://civic.genome.wustl.edu/links/genes/27
CTNNB1	1499	T41A	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		Le Guellec et al., 2012, Mod. Pathol.		4	accepted	5070	1285	1290	3	41266124	41266124	A	G	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/5070	https://civic.genome.wustl.edu/links/variants/1285	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	S45F	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		Le Guellec et al., 2012, Mod. Pathol.		4	accepted	5071	1286	1290	3	41266137	41266137	C	T	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/5071	https://civic.genome.wustl.edu/links/variants/1286	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	S45P	Desmoid Tumor	0080366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		Le Guellec et al., 2012, Mod. Pathol.		3	accepted	5072	1287	1290	3	41266136	41266136	T	C	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/5072	https://civic.genome.wustl.edu/links/variants/1287	https://civic.genome.wustl.edu/links/genes/1290
VHL	7428	V170D (c.509T>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of 469 VHL families reveled 300 mutations. The most common germline mutations were identified between codons 75-82, between codons 157-189 (Elongin binding domain) and at the splice site between exons 2 and 3. The association between mutations in codon 167 and pheochromocytoma was detected in all nationalities tested. This missense mutation was found in a VHL type 2 family (family ID R-D).	8956040	PubMed		Zbar et al., 1996, Hum. Mutat.		3	accepted	5092	1826	58	3	10191516	10191516	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5092	https://civic.genome.wustl.edu/links/variants/1826	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R64P (c.191G>C)	Von Hippel-Lindau Disease	14175	Paraganglioma,Renal cell carcinoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was found in a VHL type 2B family of 6 patients with the mutation, but incomplete penetrance (family no. 1; pedigree in Figure 2). A 59 yo carrier had no VHL manifestations but 2 unaffected children without the mutation and 2 children with the mutation, 1 with pheochromocytoma aged 32 and a 40 yo with no clinical manifestations. The 59 year old also had an affected family with the mutation - a parent (renal cell carcinoma) and a affected sibling (pheochromocytoma) and their child (paraganglioma) - and 4 unaffected siblings without the mutation. Only supporting evidence for pathogenicity because of cosegregation of the disease with multiple affected family in a gene definitively known to cause the disease (ACMG code: PP1).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5094	1867	58	3	10183722	10183722	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5094	https://civic.genome.wustl.edu/links/variants/1867	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164* (c.490C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas and renal cell carcinoma (family no. 21).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5096	1845	58	3	10191497	10191497	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5096	https://civic.genome.wustl.edu/links/variants/1845	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2A family members (family no. 23). Both had retinal hemangioblastomas, one had cerebellar hemangioblastomas, and one had pheochromocytoma.  Only supportive evidence for pathogenicity because patients phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5097	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5097	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E189fs (c.565del)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation causes an early stop codon at amino acid 201 and was found in a VHL type 1 patient with cerebellar hemangioblastomas and renal cysts (family no. 27).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5098	1869	58	3	10191572	10191572	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5098	https://civic.genome.wustl.edu/links/variants/1869	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.340+1G>A)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with renal cell carcinoma (family no. 31).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5099	2114	58	3	10183872	10183872	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5099	https://civic.genome.wustl.edu/links/variants/2114	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93S (c.277G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2C family members (family no. 9), both with pheochromocytoma.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5100	1859	58	3	10183808	10183808	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5100	https://civic.genome.wustl.edu/links/variants/1859	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I151T (c.452T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with cerebellar hemangioblastomas and renal cell carcinoma (family no. 11). Only supporting evidence for pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5101	1871	58	3	10188309	10188309	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5101	https://civic.genome.wustl.edu/links/variants/1871	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158P (c.473T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL family members with retinal hemangioblastomas (family no.13).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5103	1738	58	3	10191480	10191480	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5103	https://civic.genome.wustl.edu/links/variants/1738	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Multiple renal cysts,Epididymal cyst,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended.  This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas, renal cell carcinoma, renal cysts, epididymal cyst, and pancreatic cysts (family no. 2).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5104	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5104	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S68P (c.202T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL family with 2 individuals with retinal hemangioblastomas (family no. 4).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5105	1873	58	3	10183733	10183733	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5105	https://civic.genome.wustl.edu/links/variants/1873	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL protein core, was found in 2 VHL type 2C families with 4 patients altogether. All 4 patients had pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5125	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5125	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131fs (c.390_391del)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 133 and was found in a VHL patient with cerebellar hemangioblastomas. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5128	1800	58	3	10188247	10188248	TA		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5128	https://civic.genome.wustl.edu/links/variants/1800	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78H (c.232A>C)	Renal Cell Carcinoma	4450	Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue within the pVHL protein core, was found in 2 VHL family members. Both had retinal angiomas and cerebellar hemangioblastomas. One had renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5130	1754	58	3	10183763	10183763	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/5130	https://civic.genome.wustl.edu/links/variants/1754	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q132P (c.395A>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL, was found in a VHL family with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5131	2125	58	3	10188252	10188252	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5131	https://civic.genome.wustl.edu/links/variants/2125	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164R (c.491A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma. Relevant HPO terms: Retinal hemangioblastoma, Pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5133	1856	58	3	10191498	10191498	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5133	https://civic.genome.wustl.edu/links/variants/1856	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 9 patients altogether. Eight had retinal hemangioblastoma, one had cerebellar hemangioblastomas, 3 had renal cell carcinoma, and 5 had pheochromcytoma. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5134	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5134	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q73* (c.217C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 3 VHL families with 9 patients altogether. Seven had retinal hemangioblastomas, 3 had cerebellar hemangioblastomas, and 5 had renal cell carcinoma. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variants (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5135	1752	58	3	10183748	10183748	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5135	https://civic.genome.wustl.edu/links/variants/1752	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 6 patients altogether. All six had retinal hemangioblastomas and 2 had cerebellar hemangioblastomas. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5137	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5137	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P103FS (c.309_310delTG)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 130 and was found in a VHL type 1 family of 16 patients. Six patients had retinal hemangioblastomas, 10 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5138	1795	58	3	10183840	10183841	TG		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5138	https://civic.genome.wustl.edu/links/variants/1795	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114C (c.340G>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). This missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		2	accepted	5139	1797	58	3	10183871	10183871	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/5139	https://civic.genome.wustl.edu/links/variants/1797	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115P (c.344A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5140	1885	58	3	10188201	10188201	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5140	https://civic.genome.wustl.edu/links/variants/1885	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I151T (c.452T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families with 4 patients. Two had retinal hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		2	accepted	5141	1871	58	3	10188309	10188309	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5141	https://civic.genome.wustl.edu/links/variants/1871	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118P (c.353T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 3 VHL families of 7 patients altogether. Six had retinal hemangioblastomas, one had renal cell carcinoma, 6 had cerebellar hemangioblastomas, and 4 pheochromocytoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Renal cell carcinoma. retinal hemangioblastoma cerebellar hemangioblastoma, pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5143	1798	58	3	10188210	10188210	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5143	https://civic.genome.wustl.edu/links/variants/1798	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L128R (c.383T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemanioblastoma and retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5144	1886	58	3	10188240	10188240	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5144	https://civic.genome.wustl.edu/links/variants/1886	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L153fs (c.457delC)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 158 and was found in 2 VHL families with 5 patients altogether. Three had retinal angiomas, 5 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5145	1802	58	3	10188317	10188317	C		ENST00000256474.2					75	GRCh37	There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/5145	https://civic.genome.wustl.edu/links/variants/1802	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158V (c.472C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5146	1803	58	3	10191479	10191479	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5146	https://civic.genome.wustl.edu/links/variants/1803	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L169P (c.506T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family with retinal hemangioblastomas and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5147	1887	58	3	10191513	10191513	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/5147	https://civic.genome.wustl.edu/links/variants/1887	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178R (c.533T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL protein core, was found in a VHL type 1 patient with retinal hemanioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5148	1888	58	3	10191540	10191540	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5148	https://civic.genome.wustl.edu/links/variants/1888	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family of 3. All family members had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5149	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/5149	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L89P (c.266T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 patient with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5150	1793	58	3	10183797	10183797	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5150	https://civic.genome.wustl.edu/links/variants/1793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	M54fs (c.161dup)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in 2 VHL type 1 family members with cerebellar hemangioblastomas. ACMG codes as follows: Protein length changes as a result of insertion in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5151	1889	58	3	10183691	10183692	T		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5151	https://civic.genome.wustl.edu/links/variants/1889	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families of 5 patients altogether. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, 3 had renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5152	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5152	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F91* (c.272_273delinsAA)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	N/A	C	N/A	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastoma and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. c.272T>A and 273C>A mutations (HGVS nomenclature as c.272_273delinsAA) leads to this this nonsense mutation which was found in a VHL with retinal hemangioblastomas and cerebellar hemangioblastomas. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5153	1893	58														Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5153	https://civic.genome.wustl.edu/links/variants/1893	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154L (c.461C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL type 2B family with 6 patients. One patient had retinal hemangioblastomas, 2 had cerebellar hemangioblastomas, 3 had renal cell carcinoma, 2 had pheochromocytoma. Only supporting evidence of pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma and pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5154	1782	58	3	10188318	10188318	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5154	https://civic.genome.wustl.edu/links/variants/1782	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P59fs (c.176delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family of 5 patients. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This mutation also causes an early stop codon at amino acid 66. ACMG codes as follows: Protein length changes as a result of in-frame deletions in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5155	1929	58	3	10183707	10183707	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5155	https://civic.genome.wustl.edu/links/variants/1929	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86R (c.257C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangiolastomas and renal cell carcinoma. Only supporting evidence of pathogenicity because of cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: retinal hemangioblastoma and renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5156	1849	58	3	10183788	10183788	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5156	https://civic.genome.wustl.edu/links/variants/1849	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86L (c.257C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5157	1760	58	3	10183788	10183788	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5157	https://civic.genome.wustl.edu/links/variants/1760	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86S (c.256C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5158	1902	58	3	10183787	10183787	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5158	https://civic.genome.wustl.edu/links/variants/1902	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This missense mutation was found in 4 VHL families of 11 patients altogether. Ten had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Two other amino acid changes at this site were also reported in this publication in association with disease (S65W and S65P). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		2	accepted	5159	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5159	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65P (c.193T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5160	1903	58	3	10183724	10183724	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5160	https://civic.genome.wustl.edu/links/variants/1903	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL family with 8 affected individuals including 6 with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 1 with renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5161	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5161	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S72P (c.214T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in two VHL families of 4 patients altogether. One patient had retinal hemagioblastomas and two had cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5162	1904	58	3	10183745	10183745	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5162	https://civic.genome.wustl.edu/links/variants/1904	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S72fs (c.214del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastoma and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, an early stop codon at amino acid 158, and was found in a VHL type 1 family with retinal hemangioblastoma, cerebellar hemangioblastomas, and renal cell carcinoma. There is very strong evidence for pathogenicity in the form of  a frameshift variant in a gene where loss-of-function is  known mechanism of disease (ACMG code: PSV1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5163	1816	58	3	10183745	10183745	T		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5163	https://civic.genome.wustl.edu/links/variants/1816	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T124fs (c.369del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation results in a frameshift, a premature stop codon at amino acid 158, and was found in a VHL patient with retinal hemangioblastomas, There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).  Relevant HPO terms: Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5164	1905	58	3	10188224	10188224	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5164	https://civic.genome.wustl.edu/links/variants/1905	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L135FS (c.404delT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation results in a frameshift, an early stop codon at amino acid 158, and was found in a VHL type 1 family with retinal hemangioblastomas and cerebellar hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5165	1906	58	3	10188261	10188261	T		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5165	https://civic.genome.wustl.edu/links/variants/1906	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R176fs (c.526del)	Renal Cell Carcinoma	4450				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, an early stop codon at amino acid 201, and was found in two VHL families of 3 patients. One patient had retinal hemangioblastomas, three had cerebellar hemangioblastomas, and one with renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).   Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5166	1780	58	3	10191533	10191533	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5166	https://civic.genome.wustl.edu/links/variants/1780	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R177fs (c.528del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, a stop codon at amino acid 217, and was found in a VHL type 1 family with cerebellar hemangioblastomas and renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5167	1907	58	3	10191535	10191535	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5167	https://civic.genome.wustl.edu/links/variants/1907	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88R (c.262T>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastoms, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5168	1761	58	3	10183793	10183793	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/5168	https://civic.genome.wustl.edu/links/variants/1761	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88* (c.264G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangoblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in a VHL family with retinal hemangioblastomas, cerebellar hemangioblastomas, renal cell carcinoma, and pheochromocytoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5169	1908	58	3	10183795	10183795	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5169	https://civic.genome.wustl.edu/links/variants/1908	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y185* (c.555C>G)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangiobastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 3 VHL families with 4 patients altogether. All four had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5170	1809	58	3	10191562	10191562	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5170	https://civic.genome.wustl.edu/links/variants/1809	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V155E (c.464T>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL type 2B family with retinal hemangioblastomas, cerebellar hemangioblastomas, and pheochromocytoma. ACMG codes as follows:   Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5171	1909	58	3	10191471	10191471	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5171	https://civic.genome.wustl.edu/links/variants/1909	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170G (c.509T>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Pheochromocytoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL family of 4, 3 with retinal hemangioblastomas, 1 with renal cell carcinoma, and 1 with pheochromocytoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		2	accepted	5172	1935	58	3	10191516	10191516	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5172	https://civic.genome.wustl.edu/links/variants/1935	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76fs (c.223_224insT)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This variant is predicted to cause a frameshift and premature stop codon. This variant was found in a 24 year old Korean female with hemangioblastomas of the central nervous system and retinal hemangioblastomas (patient no. 4). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	19270817	PubMed		Cho et al., 2009, J. Korean Med. Sci.		3	accepted	5174	1912	58	3	10183754	10183755		T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5174	https://civic.genome.wustl.edu/links/variants/1912	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162R (c.484T>C)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This missense mutation (p.C162R) was found in a 30 year old Korean female with hemangioblastomas of the central nervous system, retinal hemangioblastomas, and renal cell carcinoma (patient no. 7). This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4). Relevant HPO terms: hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma.	19270817	PubMed		Cho et al., 2009, J. Korean Med. Sci.		2	accepted	5175	1772	58	3	10191491	10191491	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/5175	https://civic.genome.wustl.edu/links/variants/1772	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	K196* (c.586A>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This nonsense mutation was found in a 22 year old Korean female with hemangioblastomas of the central nervous system (patient no. 3). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	19270817	PubMed		Cho et al., 2009, J. Korean Med. Sci.		2	accepted	5176	1913	58	3	10191593	10191593	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5176	https://civic.genome.wustl.edu/links/variants/1913	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113* (c.337C>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This nonsense mutation was found in a 23 year old VHL patient with no family history and hemangioblastomas of the central nervous system (index case 77). There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		3	accepted	5177	1796	58	3	10183868	10183868	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5177	https://civic.genome.wustl.edu/links/variants/1796	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R120G (c.358A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 24 year old VHL patient with hemangioblastomas of the central nervous system, retinal hemangioblastomas, pancreatic cysts, clear cell renal cell carcinoma, and multiple renal cysts (index case 100). ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4)Relevant HPO terms: Renal cell carcinoma, hemangioblastoma, retinal hemangioblastoma, pheochromocytoma, multiple pancreatic cysts and multiple renal cysts.	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		3	accepted	5178	1914	58	3	10188215	10188215	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5178	https://civic.genome.wustl.edu/links/variants/1914	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 8 year old VHL patient with pheochromocytoma (index case 244). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		3	accepted	5179	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5179	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167L (c.500G>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. A novel, missense mutation, was found in 57 year old and 31 year old patients with hemangioblastomas of the central nervous system, retinal hemangioblastomas and pheochromocytoma (index cases 24, 232). This mutation was predicted to alter the linker region between beta and alpha domains of VHL protein. ACMG codes as follows: Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before (PM5). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5183	1916	58	3	10191507	10191507	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5183	https://civic.genome.wustl.edu/links/variants/1916	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Renal cyst,Pheochromocytoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in five VHL patients. The 13 yr old patient had pheochromocytoma (PH) (index case 164). The 25 yr old patient had pheochromocytoma and multiple renal cysts (index case 260). The 27 yr old patient had pheochromocytoma, hemangioblastomas of the central nervous system (CNS) and retinal hemangioblastoma (index case 6). The 30 yr old patient had CNS hemangioblastomas and pheochromocytoma (index case 217). The 33 yr old patient had retinal hemangioblastomas and multiple renal cysts (index case 44). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5184	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5184	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D126FS (c.375_376insC)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Pathogenic	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This de novo frameshift mutation was found in a 24 yr old VHL patient with no family history and central nervous system and retinal hemangioblastomas (index case 107). This variant also potentially alters the beta domain of the VHL protein. ACMG codes as follows: Frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). De novo in a patient with the disease and no family history (PS2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5188	1918	58	3	10188232	10188233		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5188	https://civic.genome.wustl.edu/links/variants/1918	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162F (c.485G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Pancreatic cysts,Retinal capillary hemangioma,Multiple renal cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 34 yr old VHL patient with multiple pancreatic cysts, pheochromocytoma, multiple renal cysts, and central nervous system and retinal hemangioblastomas (index case 74). There is supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Hemangioblastoma, retinal hemangioblastoma, multiple renal cysts, multiple pancreatic cysts, pheochromocytoma.	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5189	1773	58	3	10191492	10191492	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5189	https://civic.genome.wustl.edu/links/variants/1773	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E160FS (c.479_480delAG)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This frameshift mutation introduces a premature stop codon at amino acid 172 and was found in a 35 yr old VHL patient with hemangioblastomas of the central nervous system and clear cell renal cell carcinoma (index case 182). There is very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code : PVS1). Relevant HPO terms: hemangioblastoma, clear cell renal cell carcinoma.	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5191	1919	58	3	10191486	10191487	AG		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/5191	https://civic.genome.wustl.edu/links/variants/1919	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115Y (c.343C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple pancreatic cysts as well as central nervous system and retinal hemangioblastomas (index case 118). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5193	1921	58	3	10188200	10188200	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5193	https://civic.genome.wustl.edu/links/variants/1921	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L153P (c.458T>C)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Renal cyst,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple renal cysts as well as central nervous system and retinal hemangioblastoma (index case 191). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: hemangioblastoma, retinal hemangioblastoma, multiple renal cysts	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5196	1923	58	3	10188315	10188315	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5196	https://civic.genome.wustl.edu/links/variants/1923	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L169P (c.506T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas (index case 344). ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5197	1887	58	3	10191513	10191513	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/5197	https://civic.genome.wustl.edu/links/variants/1887	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Retinal capillary hemangioma,Pheochromocytoma,Pancreatic cysts,Renal cyst			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 14 yr old VHL patient with retinal hemangioblastomas, multiple pancreatic cysts, pheochromocytoma, and multiple renal cysts (index case 160). This patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5198	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/5198	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184R (c.551T>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma,Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 44 yr old VHL patient with clear cell renal cell carcinoma as well as central nervous system and retinal hemangioblastomas (index case 363). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5199	1808	58	3	10191558	10191558	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5199	https://civic.genome.wustl.edu/links/variants/1808	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188R (c.563T>G)	Von Hippel-Lindau Disease	14175	Renal cyst,Hemangioblastoma,Multiple renal cysts			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 48 yr old VHL patient with multiple renal cysts and hemangioblastomas of the central nervous system (index case 109). This variant potentially alters the alpha domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5200	1924	58	3	10191570	10191570	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5200	https://civic.genome.wustl.edu/links/variants/1924	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 30 yr old VHL patient with hemangioblastomas of the central nervous system (index case 207). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5202	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5202	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This deletion mutation was found in a 25 yr old VHL patient with multiple pancreatic cysts and hemangioblastomas of the central nervous system (index case 280). This study contains moderate support for pathogenicity because the protein length changes as a result changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5203	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5203	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P138T (c.412C>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas and pheochromocytoma (index case 115). This variant potentially alters the beta domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5205	1928	58	3	10188269	10188269	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5205	https://civic.genome.wustl.edu/links/variants/1928	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Renal cyst			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, and none were present in 200 unaffected control individuals. This missense variant was found in a 33 yr old VHL patient with pancreatic cyst or tumour, renal cystic lesion and CNS hemangioblastoma (index case 214). ACMG codes as follows: supporting evidence of pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5212	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5212	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
ATM	472	UNDEREXPRESSION	Stomach Cancer	10534		Olaparib,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Combination treatment did not significantly improve ORR (26,4% vs 19,1%) or PFS (3,91m vs 3,55 m) but OS (13,8 m vs. 8,3 m) in the overall cohort.  A subcohort of ATM low expressing tumours (14%) experienced a greater improvement of OS (not reached vs. 8,2 m) and a trend towards improved PFS (5,29 m vs 3,68 m).	26282658	PubMed		Bang et al., 2015, J. Clin. Oncol.		1	accepted	5215	179	69	11	108093559	108239826			ENST00000278616.4					75	GRCh37		N/A	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/5215	https://civic.genome.wustl.edu/links/variants/179	https://civic.genome.wustl.edu/links/genes/69
VHL	7428	Y98C  (c.293A>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 30 yr old VHL patient with retinal hemangioblastomas and pheochromocytoma (index case 183). ACMG codes as follows:  Supporting evidence of pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4).	21463266	PubMed		Leonardi et al., 2011, Ann. Hum. Genet.		2	accepted	5217	1933	58	3	10183824	10183824	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5217	https://civic.genome.wustl.edu/links/variants/1933	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R69fs (c.204insG)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This mutation was found in a VHL type 1 male patient with hemangioblastomas of the central nervous system, retinal angiomas, and renal cell carcinomas (family G).	21972040	PubMed		Huang et al., 2012, Int. J. Mol. Med.		2	accepted	5245	1948	58														Rare Germline	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5245	https://civic.genome.wustl.edu/links/variants/1948	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.340+5G>C)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This splice-site alteration was found in two VHL type 2A female family members with hemangioblastomas of the central nervous system. Mutation was also found in a male VHL type 2A family member with hemangioblastomas of the central nervous system and pheochromocytomas (family C). This study contains very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		Huang et al., 2012, Int. J. Mol. Med.		2	accepted	5246	2104	58	3	10183876	10183876	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5246	https://civic.genome.wustl.edu/links/variants/2104	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G144fs (c.432insG)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This novel mutation was found in 2 male VHL type 1 family members with hemangioblastomas of the central nervous system (family B). Family also contained 5 asymptomatic individuals. This study contains very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		Huang et al., 2012, Int. J. Mol. Med.		2	accepted	5247	1949	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5247	https://civic.genome.wustl.edu/links/variants/1949	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q145* (c.433C>T)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This nonsense mutation was found in two separate families. One female VHL type 1 patient with hemangioblastomas of the central nervous system and an asymptomatic son (family D). Two male VHL type 1 family members with hemangioblastomas of the central nervous system and pancreatic cysts (family F). This study contains very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		Huang et al., 2012, Int. J. Mol. Med.		2	accepted	5248	1883	58	3	10188290	10188290	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5248	https://civic.genome.wustl.edu/links/variants/1883	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 1 DELETION	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This mutation was found two separate VHL families. One family contained a male VHL type 1 patient with hemangioblastomas of the central nervous system and a male asymptomatic patient (family A). The other family contained two male VHL type patients with hemangioblastomas of the central nervous system and 4 asymptomatic family members (family E). This study contains very strong evidence for pathogenicity in the form of a single exon deletion variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		Huang et al., 2012, Int. J. Mol. Med.		2	accepted	5249	844	58	3	10183532	10183871			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/5249	https://civic.genome.wustl.edu/links/variants/844	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas, pancreatic cysts, and retinal hemangioblastomas. ACMG evidence codes:  'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease.	19464396	PubMed		Ciotti et al., Eur J Med Genet		3	accepted	5250	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5250	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113* (c.337C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient V59). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5260	1796	58	3	10183868	10183868	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5260	https://civic.genome.wustl.edu/links/variants/1796	https://civic.genome.wustl.edu/links/genes/58
FLT3	2322	MUTATION	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	A	Sensitivity/Response	Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations.	28546144	PubMed		Levis, 2017, Blood		3	accepted	5261	519	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5261	https://civic.genome.wustl.edu/links/variants/519	https://civic.genome.wustl.edu/links/genes/24
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 unrelated VHL type 2A patients (patients V32, V60, V97). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). An additional 0, 4 or 1 unaffected family members, respectively, were negative for the R161Q mutation across the 3 families described.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5262	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5262	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Pathogenic	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in 2 unrelated VHL type 1 patients (patient V3, V46). ACMG codes as follows: A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5263	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5263	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient and two VHL type 2B patients (patient no. V322, V36, V262). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). No additional family members were screened in all 3 cases.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5264	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5264	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient, a VHL type 2B patient and a family with 5 VHL type 2B patients (patient no. V30, V23, V1). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). The first two individuals had no family screened but 14 unaffected family members showed no evidence of this mutation in the family with 5 mutation-positive affected members.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		4	accepted	5265	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5265	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131K (c.393C>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V233). A single unaffected family member available for screening did not have the N131K mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5266	1953	58	3	10188250	10188250	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/5266	https://civic.genome.wustl.edu/links/variants/1953	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no. V345). No additional family was screened for this mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5267	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5267	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T105fs (c.315insAC)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 2B patient (patient no. V89). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5268	1954	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5268	https://civic.genome.wustl.edu/links/variants/1954	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P71fs (c.211insT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V96). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5269	1955	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5269	https://civic.genome.wustl.edu/links/variants/1955	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q73* (c.217C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V64). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5270	1752	58	3	10183748	10183748	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5270	https://civic.genome.wustl.edu/links/variants/1752	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q96* (c.286C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V77). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5271	1848	58	3	10183817	10183817	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5271	https://civic.genome.wustl.edu/links/variants/1848	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E52K (c.154G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V285). No additional family members were screened.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5272	1734	58	3	10183685	10183685	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5272	https://civic.genome.wustl.edu/links/variants/1734	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V374). This patient was further described in Hes et al 2007 (family no. 5) to have bilateral, retinal hemangioblastoma.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5273	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/5273	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115Q (c.345C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V48). No unaffected family members were screened.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5274	1957	58	3	10188202	10188202	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5274	https://civic.genome.wustl.edu/links/variants/1957	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H191FS (c.571delC)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 201 and was found in a VHL type 2B patient (patient no. V51). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5275	1958	58	3	10191578	10191578	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5275	https://civic.genome.wustl.edu/links/variants/1958	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118P (c.353T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 1 family members (patient no. V27). Ten unaffected family members were screen with no evidence of the L188P variant. This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (ACMG code: PS4).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5276	1798	58	3	10188210	10188210	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5276	https://civic.genome.wustl.edu/links/variants/1798	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L140fs (c.417_418delTC)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Pathogenic	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. ACMG codes as follows. This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient and a VHL type 2B patient (patient no. V73, V80). A frameshift mutation in a gene where loss-of-function is a known mechanism of disease is strong evidence for pathogenicity (PVS1). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5279	1960	58														Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5279	https://civic.genome.wustl.edu/links/variants/1960	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	K159fs (c.473dup)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 173 and was found in a VHL type 1 patient (patient no. V235). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5280	1872	58	3	10191480	10191480		T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5280	https://civic.genome.wustl.edu/links/variants/1872	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158P (c.473T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V252). One unaffected individual family member did not have the L158P mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5281	1738	58	3	10191480	10191480	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5281	https://civic.genome.wustl.edu/links/variants/1738	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188P (c.563T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V269). Five unaffected family members were negative for the L188P variant.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5282	1852	58	3	10191570	10191570	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5282	https://civic.genome.wustl.edu/links/variants/1852	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	M54fs (c.161dup)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 131 and was found in a VHL type 2A patient (patient no. V69). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5283	1889	58	3	10183691	10183692	T		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5283	https://civic.genome.wustl.edu/links/variants/1889	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two unrelated VHL type 1 patients (patient no. V53, V94). No unaffected individuals from either family were tested for this mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5284	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5284	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154= (c.462A>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This silent mutation was found in two VHL type 2A family members (patient no. V78). Two unaffected family members did not harbor this synonymous mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5285	1962	58	3	10188319	10188319	A	C	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/)	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/5285	https://civic.genome.wustl.edu/links/variants/1962	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86S (c.256C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 2B family members (patient no. V11). One unaffected family member was negative for the P86S mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5286	1902	58	3	10183787	10183787	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5286	https://civic.genome.wustl.edu/links/variants/1902	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2 patient (patient no. V209).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5287	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5287	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80R (c.238A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V259). This S80R variant was not detected in 2 unaffected family members. An additional 2 unrelated, affected individuals had the similar S80N missense mutation in this study.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5288	1963	58	3	10183769	10183769	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5288	https://civic.genome.wustl.edu/links/variants/1963	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80N (c.239G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V19).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5289	1874	58	3	10183770	10183770	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5289	https://civic.genome.wustl.edu/links/variants/1874	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R60FS (c.179delG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation causes a premature stop codon at amino acid 66 and was found in a VHL type 1 patient (patient no. V9). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5290	1964	58	3	10183710	10183710	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5290	https://civic.genome.wustl.edu/links/variants/1964	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T105P (c.313A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 14 VHL type 1 family members (patient no. V8).  This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members (14 affected, 13 unaffected) in a gene definitively known to cause the disease (ACMG code: PP1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5293	1839	58	3	10183844	10183844	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/5293	https://civic.genome.wustl.edu/links/variants/1839	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T157I (c.470C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V240). No unaffected family members were tested.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5294	1745	58	3	10191477	10191477	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5294	https://civic.genome.wustl.edu/links/variants/1745	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W117C (c.351G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 4 VHL type 1 family members (patient no. V13). This study contains supporting evidence of pathogenicity for this variant due to cosegregation of disease with multiple family members (4 affected, 4 unaffected) in a gene definitively known to cause disease (ACMG code: PP1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5295	1767	58	3	10188208	10188208	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5295	https://civic.genome.wustl.edu/links/variants/1767	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88S (c.263G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V266). No unaffected family members were evaluated.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5296	1966	58	3	10183794	10183794	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5296	https://civic.genome.wustl.edu/links/variants/1966	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156D (c.466T>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no.V87). No unaffected family members were evaluated. An additional type 1 patient had a similar missense mutation (Y156C, patient no. V265).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5297	1967	58	3	10191473	10191473	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5297	https://civic.genome.wustl.edu/links/variants/1967	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156C (c.467A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V265). One unaffected family member was negative for this mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5298	1946	58	3	10191474	10191474	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5298	https://civic.genome.wustl.edu/links/variants/1946	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156* (c.468T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V41). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5299	1968	58	3	10191475	10191475	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/5299	https://civic.genome.wustl.edu/links/variants/1968	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175* (c.525C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V63). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5300	1969	58	3	10191532	10191532	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/5300	https://civic.genome.wustl.edu/links/variants/1969	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V130L (c.388G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V91). No unaffected family members were tested.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5301	1970	58	3	10188245	10188245	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5301	https://civic.genome.wustl.edu/links/variants/1970	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V166F (c.496G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V49). This variant was not found in 8 unaffected family members and previously reported in patients with VHL.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5302	1825	58	3	10191503	10191503	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5302	https://civic.genome.wustl.edu/links/variants/1825	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170G (c.509T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V81). No unaffected family members were tested but this mutation was reported in other unrelated patients previously.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5303	1935	58	3	10191516	10191516	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5303	https://civic.genome.wustl.edu/links/variants/1935	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114R (c.340G>C)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients (VHL-6 and -16) were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas and pancreatic cysts. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	19464396	PubMed		Ciotti et al., Eur J Med Genet		3	accepted	5305	1857	58	3	10183871	10183871	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5305	https://civic.genome.wustl.edu/links/variants/1857	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	MUTATION	Renal Cell Carcinoma	4450		Everolimus		Predictive	Supports	B	Sensitivity/Response	A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only.	26951309	PubMed		Powles et al., 2016, J. Clin. Oncol.	NCT01442090	4	accepted	5323	160	58	3	10182692	10193904			ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:22:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5323	https://civic.genome.wustl.edu/links/variants/160	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	14 Chinese patients from 10 families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Genetic testing demonstrated 2 members (Patient 1 and 2) of a single family (Family I) harbored the above mutation. Clinical manifestations in this family included: CNS hemangioblastoma and retinal hemangioblastoma. ACMG evidence codes: PP4 - because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology; PP1 - cosegregation with disease in multiple affected family members in a gene definitively known to cause disease.	20518900	PubMed		Zhou et al., 2010, Pathol. Int.		3	accepted	5328	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5328	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R177* (c.529A>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic endocrine tumor,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	14 Chinese patients from 10 VHL Type I families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Germline mutations were identified in 7/10 families. In all 14 patients, the first manifestation of VHL disease was a central nervous system hemangioblastoma. Their mean age of neurological symptom onset was 24.5 years (range: 1258 years). Genetic testing demonstrated that Patient 10 (from family VI) and Patient 11 (from family VII) carried this mutation. Patient 10 was reported to have a retinal hemangioblastoma, and patient 11 had a pancreatic tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.	20518900	PubMed		Zhou et al., 2010, Pathol. Int.		3	accepted	5331	1827	58	3	10191536	10191536	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5331	https://civic.genome.wustl.edu/links/variants/1827	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.340+1G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	14 Chinese patients from 10 families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Genetic testing demonstrated 1 member of a single family harbored the above mutation. Clinical manifestations in this family included: CNS hemangioblastoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Hemangioblastoma.	20518900	PubMed		Zhou et al., 2010, Pathol. Int.		3	accepted	5332	2114	58	3	10183872	10183872	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5332	https://civic.genome.wustl.edu/links/variants/2114	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	*214L (c.641G>T)	Von Hippel-Lindau Disease	14175	Neuroendocrine neoplasm,Retinal capillary hemangioma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214LextX15) in 3 individuals in 2 separate families. Clinical evidence suggested an additional 1 family member was affected with VHL, but genetic testing was not conducted on this individual. Clinical manifestations associated with this mutation include: pheochromocytoma, retinal hemangioblastoma, and pancreatic neuroendocrine tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results, and 'PS3' because in-vitro studies demonstrated this variant was unable to perform normal cellular functions (downregulate JunB).	20560986	PubMed		Sorrell et al., 2011, Clin. Genet.		4	accepted	5334	1986	58	3	10191648	10191648	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5334	https://civic.genome.wustl.edu/links/variants/1986	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	*214W (c.642A>G)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214WextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma and pancreatic cysts.	20560986	PubMed		Sorrell et al., 2011, Clin. Genet.		2	accepted	5335	1987	58	3	10191649	10191649	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5335	https://civic.genome.wustl.edu/links/variants/1987	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	*214C (c.642A>T)	Von Hippel-Lindau Disease	14175	Neuroendocrine neoplasm,Hemangioblastoma,Retinal capillary hemangioma,Clear cell renal cell carcinoma,Pheochromocytoma,Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214CextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma, CNS hemangioblastoma, retinal hemangioblastoma, clear cell renal cell carcinoma, and pancreatic neuroendocrine tumor. Relevant HPO terms: Pheochromocytoma, Hemangioblastoma, Retinal hemangioblastoma, Clear cell renal cell carcinoma, Neuroendocrine neoplasm.	20560986	PubMed		Sorrell et al., 2011, Clin. Genet.		2	accepted	5336	1988	58	3	10191649	10191649	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5336	https://civic.genome.wustl.edu/links/variants/1988	https://civic.genome.wustl.edu/links/genes/58
ERBB2	2064	MUTATION	Breast Cancer	1612		Neratinib		Predictive	Supports	B	Sensitivity/Response	16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Five of the 16 patients achieved clinical benefit including 1 complete response (6%), 1 partial response (6%) and 3 with stable disease >24 weeks (19%). Clinical benefit was observed across different HER2 mutations including L755S, V777_G778 insGSP, P780_Y781 insGSP, V842I, S310F, and L869R.	28679771	PubMed		Ma et al., 2017, Clin. Cancer Res.		4	accepted	5338	666	20	17	37868196	37881332			ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5338	https://civic.genome.wustl.edu/links/variants/666	https://civic.genome.wustl.edu/links/genes/20
BAP1	8314	MUTATION	Renal Cell Carcinoma	4450		Everolimus,Sunitinib	Sequential	Predictive	Supports	B	Resistance	This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 220 patients, 19% of had BAP1 mutations. Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02). For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06).	27751729	PubMed		Hsieh et al., 2017, Eur. Urol.		4	accepted	5339	183	70	3	52435029	52444366			ENST00000460680.1					75	GRCh37	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5339	https://civic.genome.wustl.edu/links/variants/183	https://civic.genome.wustl.edu/links/genes/70
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 3 individuals (Family B). Only one patient in this family developed symtoms, which included a brain stem hemangioblastoma and retinal angioma discovered at age 30. Parents of this individual showed no manifestations of VHL disease and were negative for bands via single-strand conformational polymorphism (SSCP) analysis where the proband showed extra bands. This study contains moderate evidence of pathogenicity because the protein length changes as a result of an in-frame deletion in a nonrepeat region (ACMG code: PM4).	8641976	PubMed		Kanno et al., 1996, Jpn. J. Cancer Res.		2	accepted	5340	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5340	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78H (c.232A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of five individuals. Only one VHL patient was identified with hemangioblastomas of the cerebellum and spinal cord, retinal angiomas, and renal cysts (family A).	8641976	PubMed		Kanno et al., 1996, Jpn. J. Cancer Res.		2	accepted	5341	1754	58	3	10183763	10183763	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:20 UTC	https://civic.genome.wustl.edu/links/evidence_items/5341	https://civic.genome.wustl.edu/links/variants/1754	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-1G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 10 individuals. Three VHL patients were identified with hemangioblastomas of the central nervous system and retinal angiomas (family C). The eldest patient also had renal cell carcinoma (listed as C-1 in publication). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8641976	PubMed		Kanno et al., 1996, Jpn. J. Cancer Res.		2	accepted	5343	1990	58	3	10191470	10191470	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5343	https://civic.genome.wustl.edu/links/variants/1990	https://civic.genome.wustl.edu/links/genes/58
NRAS	4893	MUTATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	A	Resistance	NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.	28275037	PubMed		Benson et al., 2017, J Natl Compr Canc Netw		4	accepted	5344	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5344	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	MUTATION	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	A	Resistance	NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.	28275037	PubMed		Benson et al., 2017, J Natl Compr Canc Netw		5	accepted	5345	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/5345	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
PDGFRA	5156	D842V	Cancer	162		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	5346	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/5346	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	V561D	Cancer	162		Imatinib Mesylate		Predictive	Does Not Support	D	Resistance	In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	5347	941	38	4	55141036	55141036	T	A	ENST00000257290.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/5347	https://civic.genome.wustl.edu/links/variants/941	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	V560D	Cancer	162		Imatinib Mesylate		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells expressing ligand-activated wild-type KIT. Sensitivity was determined by assessing KIT auto-phosphorylation.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	5348	971	29	4	55593613	55593613	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5348	https://civic.genome.wustl.edu/links/variants/971	https://civic.genome.wustl.edu/links/genes/29
VHL	7428	C162R (c.484T>C)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of 7 individuals. Two VHL patients were identified, 1 with brain stem hemangioblastomas and retinal angiomas, the other with renal cell carcinoma (family D). Single-strand conformational polymorphism (SSCP) analysis showed bands for the 2 affected individuals that were absent from 5 normal individuals. Direct sequencing was performed on SSCP positive patients. Supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members (ACMG code: PP1).	8641976	PubMed		Kanno et al., 1996, Jpn. J. Cancer Res.		2	accepted	5349	1772	58	3	10191491	10191491	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/5349	https://civic.genome.wustl.edu/links/variants/1772	https://civic.genome.wustl.edu/links/genes/58
PIK3CA	5290	EXON 10 and EXON 21 MUTATIONS	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	This was a prospective study involving 1,170 colorectal cancer patients confirmed by histology. PIK3CA mutations were found in 16% (189/1170) of cased via pyrosequencing of FFPE samples, of these 58% (109/189) had mutations in exon 10, 39% (73/189) had mutations in exon 21, and 3.7% (7/189) had mutations in both exons. Study found that exon 10 + exon 21 mutants were associated with shorter cancer specific survival and overall survival when compared to WT PIK3CA (P = 0.031, P = 0.0008). These mutants were also associated with higher colorectal cancer-specific mortality and overall mortality (multivariate hazard ratio (HR) = 3.51, multivariate HR 2.68). In contrast, mutations on either exon 10 or exon 21 alone were not statistically significant in terms of overall survival. Note that exons 10 and 21 are listed as exons 9 and 20 in the source, as it was common at the time of its publication to exclude non-coding exon 1. Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted.	22357840	PubMed		Liao et al., 2012, Clin. Cancer Res.		2	accepted	5350	1991	37													PIK3CA exon 10 and exon 21 mutations occasionally co-occur in the same tumor, same cell line, or same clone (if clonality information is available). Note that exons 10 and 21 are sometimes listed as exons 9 and 20 in publications, as it was once common to exclude non-coding exon 1.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5350	https://civic.genome.wustl.edu/links/variants/1991	https://civic.genome.wustl.edu/links/genes/37
VHL	7428	Splicing alteration (c.464-2A>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts. (family VHL 57). This study contains very strong evidence of pathogenicity in the form of a canonical -2 splice variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5351	1992	58	3	10191469	10191469	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5351	https://civic.genome.wustl.edu/links/variants/1992	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113* (c.337C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a German, VHL type 1 family (family VHL 55). Two patients were identified with retinal angiomas and hemangioblastomas of the central nervous system. This study contains very strong evidence of pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		3	accepted	5352	1796	58	3	10183868	10183868	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5352	https://civic.genome.wustl.edu/links/variants/1796	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161G (c.481C>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Pheochromocytoma,Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family. Only one patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytoma, and renal cell carcinoma. This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5353	1915	58	3	10191488	10191488	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5353	https://civic.genome.wustl.edu/links/variants/1915	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family with 5 affected individuals (family VHL 43). Each patient had retinal angiomas, 2 had hemangioblastomas of the central nervous system, and 2 had renal cell carcinoma. The patients phenotype and family history are highly specific for a disease with a single gene etiology (ACMG code: PP4).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5354	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5354	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 42). HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5355	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5355	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.463+2T>C)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a Croatian, VHL type 1 family of 3. Each individual had retinal angiomas, one had hemangioblastomas of the central nervous system, one had renal cell carcinoma, and one had pancreatic cysts (family VHL 7). This study contains very strong evidence of pathogenicity in the form of a canonical +2 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5356	2075	58	3	10188322	10188322	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5356	https://civic.genome.wustl.edu/links/variants/2075	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-1G>A)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 48). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5357	1974	58	3	10191470	10191470	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5357	https://civic.genome.wustl.edu/links/variants/1974	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q132* (c.394C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and pancreatic cysts (family VHL 30). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5358	1994	58	3	10188251	10188251	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5358	https://civic.genome.wustl.edu/links/variants/1994	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164* (c.490C>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in an Iranian, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and pancreatic islet cell tumors (family VHL 65). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5359	1845	58	3	10191497	10191497	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5359	https://civic.genome.wustl.edu/links/variants/1845	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 German, VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system (family VHL 56). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5360	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5360	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70* (c.208G>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a Filipino, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 50). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5361	1834	58	3	10183739	10183739	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5361	https://civic.genome.wustl.edu/links/variants/1834	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115Y (c.343C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas (family VHL 59).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5363	1921	58	3	10188200	10188200	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5363	https://civic.genome.wustl.edu/links/variants/1921	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C77_N78insL (c.230_231insTCT)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations.  This mutation was found in 2 Croatian, VHL type 1 family members (family VHL 26). Both have hemangioblastomas of the central nervous system, one has renal cell carcinoma, and one with pancreatic cysts.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5364	3096	58	3	10183761	10183762		TCT	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5364	https://civic.genome.wustl.edu/links/variants/3096	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L129fs (c.384delT)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This mutation was found in 2 German, VHL type 1 family members with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 44). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		3	accepted	5365	1996	58	3	10188241	10188241	T		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5365	https://civic.genome.wustl.edu/links/variants/1996	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178Q (c.533T>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 German, VHL type 2 family members with retinal angiomas, hemangioblastomas of the central nervous system, and pheochromocytomas (family VHL 29). Each patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5366	1997	58	3	10191540	10191540	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5366	https://civic.genome.wustl.edu/links/variants/1997	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L89P (c.266T>C)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 11. Three patients had retinal angiomas, 7 hand hemangioblastomas of the central nervous system, 7 had renal cell carcinoma, and 6 had pancreatic cysts (family VHL 3). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5368	1793	58	3	10183797	10183797	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5368	https://civic.genome.wustl.edu/links/variants/1793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P81S (c.241C>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 23).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5369	1837	58	3	10183772	10183772	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5369	https://civic.genome.wustl.edu/links/variants/1837	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S183* (c.548C>A)	Renal Cell Carcinoma	4450	Pancreatic cysts,Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 3 Italian, VHL type 1 family members. Two had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and all three had pancreatic cysts. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		3	accepted	5370	1784	58	3	10191555	10191555	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5370	https://civic.genome.wustl.edu/links/variants/1784	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80N (c.239G>A)	Renal Cell Carcinoma	4450	Retinal capillary hemangioma,Pancreatic endocrine tumor,Hemangioblastoma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a Slovakian, VHL type 1 family of 13 affected individuals. Seven had retinal angiomas, 7 had hemangioblastomas of the central nervous system, 5 had renal cell carcinoma, one had pancreatic cysts, and one had  pancreatic islet cell tumors (family VHL 39). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5371	1874	58	3	10183770	10183770	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5371	https://civic.genome.wustl.edu/links/variants/1874	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pheochromocytoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found 3 unrelated, German families, 2 of which had been previously described (Neumann et al. 1995). The newly-identified VHL type 2 patient had retinal angiomas and pheochromocytoma (family VHL 54). As previously described, one VHL type 2A family of 52 affected individuals had 26 patients with retinal angiomas, 6 with hemangioblastomas of the central nervous system, and 41 with pheochromocytoma (family VHL*). A VHL type 1 family of 3 had 2 patients with retinal angiomas and one with renal cell carcinoma (family VHL 47). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5372	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5372	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.463+1G>C)	Renal Cell Carcinoma	4450	Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 45). This study contains very strong evidence of pathogenicity in the form of a canonical +1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5373	1998	58	3	10188321	10188321	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5373	https://civic.genome.wustl.edu/links/variants/1998	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V74G (c.221T>G)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Pancreatic cysts,Pheochromocytoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 unrelated, German families. The VHL type 1 family of 4 affected individuals had 2 patients with retinal angiomas, 5 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family VHL 53). The VHL type 2B family of 3 affected individuals had one patient with retinal angioma, 3 with hemangioblastomas of the central nervous system, one with pheochromocytoma, one with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 9). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: papillary cystadenomas of the broad ligament	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5374	1999	58	3	10183752	10183752	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5374	https://civic.genome.wustl.edu/links/variants/1999	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Renal Cell Carcinoma	4450	Pancreatic cysts,Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 unrelated, German families. One VHL type 1 family of 2 affected individuals had one patient with retinal angiomas, 2 with hemangioblastomas of the central nervous system, one with renal cell carcinoma, one with pancreatic cysts, and  one with cystadenomas of the epididymis (family VHL 32). Another VHL type 1 family of 3 affected individuals had 3 patients with retinal angiomas, one with hemangioblastomas of the central nervous system, 2 with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 49). ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms:  papillary cystadenomas of the broad ligament.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		3	accepted	5375	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5375	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 6. Each patient had hemangioblastomas of the central nervous system and 4 had cystadenomas of the epididymis (family VHL 51). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: papillary cystadenomas of the broad ligament.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5376	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5376	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115R (c.344A>G)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 2. Both patients had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and cystadenomas of the epididymis (family VHL 60). One patient also had retinal angiomas. This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms:  papillary cystadenomas of the broad ligament.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5377	2000	58	3	10188201	10188201	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5377	https://civic.genome.wustl.edu/links/variants/2000	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families. Renal cell carcinoma occurred predominantly in non-missense mutations predicted to lead to gross alteration or complete loss of the VHL protein. This mutation was found in a VHL type 1 patient with hemangioblastomas of the central nervous system, pancreatic cyst or tumor, and renal cell carcinoma (family ID 80).	10761708	PubMed		Yoshida et al., 2000, Jpn. J. Cancer Res.		3	accepted	5386	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5386	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R107G  (c.319C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5399	2007	58	3	10183850	10183850	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5399	https://civic.genome.wustl.edu/links/variants/2007	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5400	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5400	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161P (c.482G>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5401	1855	58	3	10191489	10191489	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5401	https://civic.genome.wustl.edu/links/variants/1855	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5402	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5402	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164* (c.490C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5403	1845	58	3	10191497	10191497	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5403	https://civic.genome.wustl.edu/links/variants/1845	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5404	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5404	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5405	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5405	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93C (c.277G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5406	2008	58	3	10183808	10183808	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5406	https://civic.genome.wustl.edu/links/variants/2008	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93S (c.277G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5407	1859	58	3	10183808	10183808	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5407	https://civic.genome.wustl.edu/links/variants/1859	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93V (c.278G>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5408	2009	58	3	10183809	10183809	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5408	https://civic.genome.wustl.edu/links/variants/2009	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188V (c.562C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5409	1836	58	3	10191569	10191569	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5409	https://civic.genome.wustl.edu/links/variants/1836	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L198Q  (c.593T>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5410	2010	58	3	10191600	10191600	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5410	https://civic.genome.wustl.edu/links/variants/2010	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F119L (c.357C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5411	1743	58	3	10188214	10188214	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5411	https://civic.genome.wustl.edu/links/variants/1743	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136C (c.407T>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5412	1814	58	3	10188264	10188264	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5412	https://civic.genome.wustl.edu/links/variants/1814	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65A (c.193T>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5413	2011	58	3	10183724	10183724	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5413	https://civic.genome.wustl.edu/links/variants/2011	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S68W (c.203C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5414	2012	58	3	10183734	10183734	C	G	ENST00000256474.2						GRCh37	One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 625222 C>T).	Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5414	https://civic.genome.wustl.edu/links/variants/2012	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80N (c.239G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5415	1874	58	3	10183770	10183770	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5415	https://civic.genome.wustl.edu/links/variants/1874	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156N (c.466T>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5416	2013	58	3	10191473	10191473	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5416	https://civic.genome.wustl.edu/links/variants/2013	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156C (c.467A>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5417	1946	58	3	10191474	10191474	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5417	https://civic.genome.wustl.edu/links/variants/1946	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	5418	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5418	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P61fs (c.183insC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was detected in a previously diagnosed VHL patient by DHPLC (VHL 73). This frameshift mutation provides strong evidence of pathogenicity (PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		3	accepted	5420	2014	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5420	https://civic.genome.wustl.edu/links/variants/2014	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65* (c.194C>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 83). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		3	accepted	5422	1811	58	3	10183725	10183725	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5422	https://civic.genome.wustl.edu/links/variants/1811	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V74G (c.221T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 92). This was the same missense mutation as was described in the previously published Glava et al. (1996) study included in this study (VHL 9 and 53).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5424	1999	58	3	10183752	10183752	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5424	https://civic.genome.wustl.edu/links/variants/1999	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in 2  previously diagnosed VHL patients and a suspect VHL mutation carrier by DHPLC (family VHL 26, VHL 63, VHL 77). This variant results in an in frame deletion providing moderate evidence for pathogenicity (PM4).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5426	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5426	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80N (c.239G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 82).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5427	1874	58	3	10183770	10183770	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5427	https://civic.genome.wustl.edu/links/variants/1874	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80I (c.239G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 104).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5428	1757	58	3	10183770	10183770	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5428	https://civic.genome.wustl.edu/links/variants/1757	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V84L (c.250G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a suspect VHL mutation carrier by DHPLC (family VHL 110).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5430	1815	58	3	10183781	10183781	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5430	https://civic.genome.wustl.edu/links/variants/1815	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L85P (c.254T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 66).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5431	2020	58	3	10183785	10183785	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5431	https://civic.genome.wustl.edu/links/variants/2020	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93R (c.277G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a suspected VHL mutation carrier by DHPLC (family VHL 106).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5432	1920	58	3	10183808	10183808	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5432	https://civic.genome.wustl.edu/links/variants/1920	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 85). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5433	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5433	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R108dup (c.322_324dup)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 86). Protein length changes as a result of in-frame insertion in a nonrepeat region (ACMG code: PM4).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5434	2021	58	3	10183849	10183850		CGC	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5434	https://civic.genome.wustl.edu/links/variants/2021	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118P (c.353T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 94).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5435	1798	58	3	10188210	10188210	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5435	https://civic.genome.wustl.edu/links/variants/1798	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F119L (c.357C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 99).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5436	1743	58	3	10188214	10188214	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5436	https://civic.genome.wustl.edu/links/variants/1743	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D121G (c.362A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 105).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5437	1813	58	3	10188219	10188219	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5437	https://civic.genome.wustl.edu/links/variants/1813	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175* (c.525C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 103). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		3	accepted	5440	1969	58	3	10191532	10191532	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/5440	https://civic.genome.wustl.edu/links/variants/1969	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V194fs (c.581_582del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 79). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		3	accepted	5441	1977	58	3	10191587	10191588	TG		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5441	https://civic.genome.wustl.edu/links/variants/1977	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A149fs (c.449del14-nt)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 75). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5442	2023	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5442	https://civic.genome.wustl.edu/links/variants/2023	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	3'UTR alteration (c.639+10C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 80).	11409863	PubMed		Klein et al., 2001, Hum. Genet.		2	accepted	5443	2024	58	3	10191656	10191656	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5443	https://civic.genome.wustl.edu/links/variants/2024	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70* (c.208G>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes:  'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5445	1834	58	3	10183739	10183739	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5445	https://civic.genome.wustl.edu/links/variants/1834	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V74G (c.221T>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5446	1999	58	3	10183752	10183752	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5446	https://civic.genome.wustl.edu/links/variants/1999	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change: F76Cfs*83. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5447	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5447	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80R (c.240T>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5448	1792	58	3	10183771	10183771	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5448	https://civic.genome.wustl.edu/links/variants/1792	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L89P (c.266T>C)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5449	1793	58	3	10183797	10183797	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5449	https://civic.genome.wustl.edu/links/variants/1793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93R (c.277G>C)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5450	1920	58	3	10183808	10183808	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5450	https://civic.genome.wustl.edu/links/variants/1920	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5451	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5451	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114S (c.340G>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5452	2026	58	3	10183871	10183871	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5452	https://civic.genome.wustl.edu/links/variants/2026	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W117fs (c.349dup)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change W117LfsX1. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5453	2027	58	3	10188206	10188207		T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5453	https://civic.genome.wustl.edu/links/variants/2027	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F119L (c.357C>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5454	1743	58	3	10188214	10188214	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5454	https://civic.genome.wustl.edu/links/variants/1743	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D121G (c.362A>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5455	1813	58	3	10188219	10188219	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5455	https://civic.genome.wustl.edu/links/variants/1813	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A122I (c.364_365GC>AT)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the A122I mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5456	2028	58	3	10188221	10188222	GC	AT	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5456	https://civic.genome.wustl.edu/links/variants/2028	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131K (c.393C>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5457	1953	58	3	10188250	10188250	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/5457	https://civic.genome.wustl.edu/links/variants/1953	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q132* (c.394C>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5458	1994	58	3	10188251	10188251	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5458	https://civic.genome.wustl.edu/links/variants/1994	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N150fs (c.445_458del)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, this mutation causes the following protein change: N150SfsX19. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Neuroendocrine neoplasm.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5459	2029	58	3	10188302	10188315	GCCAATATCACACT		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5459	https://civic.genome.wustl.edu/links/variants/2029	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I151M (c.453C>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5460	2030	58	3	10188310	10188310	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5460	https://civic.genome.wustl.edu/links/variants/2030	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154L (c.461C>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5461	1782	58	3	10188318	10188318	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5461	https://civic.genome.wustl.edu/links/variants/1782	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-2A>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5462	2078	58	3	10191469	10191469	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5462	https://civic.genome.wustl.edu/links/variants/2078	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156C (c.467A>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5463	1946	58	3	10191474	10191474	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5463	https://civic.genome.wustl.edu/links/variants/1946	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158V (c.472C>G)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5464	1803	58	3	10191479	10191479	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5464	https://civic.genome.wustl.edu/links/variants/1803	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E160FS (c.478_479delGA)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. More specifically, this mutation causes the following protein change: E160AfsX12. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5465	2032	58	3	10191485	10191486	GA		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5465	https://civic.genome.wustl.edu/links/variants/2032	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 5 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5466	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5466	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L163H (c.488T>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5467	2033	58	3	10191495	10191495	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5467	https://civic.genome.wustl.edu/links/variants/2033	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 7 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5468	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5468	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 4 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5469	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5469	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5470	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/5470	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S183* (c.548C>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5471	1784	58	3	10191555	10191555	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5471	https://civic.genome.wustl.edu/links/variants/1784	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5472	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5472	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L198Q  (c.593T>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .	20660572	PubMed		Erlic et al., 2010, Endocr. Relat. Cancer		2	accepted	5473	2010	58	3	10191600	10191600	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5473	https://civic.genome.wustl.edu/links/variants/2010	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5474	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5474	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y112H (c.334T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5475	1865	58	3	10183865	10183865	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5475	https://civic.genome.wustl.edu/links/variants/1865	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114R (c.340G>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5476	1857	58	3	10183871	10183871	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5476	https://civic.genome.wustl.edu/links/variants/1857	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L118P (c.353T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5477	1798	58	3	10188210	10188210	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5477	https://civic.genome.wustl.edu/links/variants/1798	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L128F (c.382C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5478	3066	58	3	10188239	10188239	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/5478	https://civic.genome.wustl.edu/links/variants/3066	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L129P (c.386T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5479	2508	58	3	10188243	10188243	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5479	https://civic.genome.wustl.edu/links/variants/2508	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136C (c.407T>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5480	1814	58	3	10188264	10188264	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5480	https://civic.genome.wustl.edu/links/variants/1814	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5481	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5481	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162fs (c.483del)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. More specifically, this mutation causes the following protein change: C162AfsX8. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Pheochromocytoma.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5482	2035	58	3	10191490	10191490	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5482	https://civic.genome.wustl.edu/links/variants/2035	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This nonsense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina, and renal cell carcinoma (family no. 15). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		3	accepted	5483	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5483	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 2 patients from 2 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5484	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5484	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 12 patients from 4 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		2	accepted	5485	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5485	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Null (Partial deletion of Exons 2 & 3)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 3 patients from 3 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a multiexon deletion variant in a gene where loss of function is a known mechanism of disease.	20846682	PubMed		Benhammou et al., 2010, J. Urol.		3	accepted	5486	2036	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5486	https://civic.genome.wustl.edu/links/variants/2036	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). Arg167Trp and Arg167Gln mutations conferred a high (62%) risk for pheochromocytoma. Pheochromocytoma was diagnosed in all families with Arg167Gln mutation. This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma (family no. 17). This mutation was also found in a VHL family of 8 affected patients (family no. 18). Seven had retinal hemangioblastomas, six had hemangioblastomas of the central nervous system, and 2 had pheochromocytoma. Cosegregation of the disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5487	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5487	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78I (c.233A>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHLD family of 4 affected patients (family no. 10). All 4 patients had retinal hemangioblastomas, 3 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5489	2037	58	3	10183764	10183764	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5489	https://civic.genome.wustl.edu/links/variants/2037	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient and 2 VHL family members. The single patient had hemangioblastomas of the central nervous system and retina (family no. 8). One of the family members had retinal hemangioblastomas and the other had renal cell carcinoma (family no. 9).  HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5491	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5491	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162Y (c.485G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL family of 5 affected patients (family no. 16). Four had retinal hemangioblastomas and 4 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5493	1824	58	3	10191492	10191492	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5493	https://civic.genome.wustl.edu/links/variants/1824	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88FS (c.263_265delGGCinsTT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 11). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5495	2039	58	3	10183794	10183796	GGC	TT	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/5495	https://civic.genome.wustl.edu/links/variants/2039	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	K159fs (c.477_478insCA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system (family no. 14). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5496	2040	58	3	10191484	10191485		CA	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5496	https://civic.genome.wustl.edu/links/variants/2040	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111R (c.333C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 12). HPO terms: hemangioblastoma, retinal hemangioblastoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5498	1764	58	3	10183864	10183864	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/5498	https://civic.genome.wustl.edu/links/variants/1764	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a single VHL patient and 2 VHL families with multiple affected individuals. The patient had hemangioblastomas of the central nervous system (family no. 1). A VHL family of 4 affected individuals had one patient with retinal hemangioblastomas, 3 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family no. 2). A VHL family of 12 individuals had 10 with retinal hemangioblastomas, 3 with renal cell carcinoma, and 12 with hemangioblastomas of the central nervous system (family no. 3). Supporting evidence of pathogenicity since there is cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5499	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5499	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q73FS (c.217delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 4). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5500	2041	58	3	10183748	10183748	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5500	https://civic.genome.wustl.edu/links/variants/2041	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A149fs (c.445delG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL family of 3 individuals. All 3 had retinal hemangioblastomas, 2 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma (family no. 13). ACMG codes as follows: A frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12114495	PubMed		Cybulski et al., 2002, J. Med. Genet.		2	accepted	5501	2042	58	3	10188302	10188302	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5501	https://civic.genome.wustl.edu/links/variants/2042	https://civic.genome.wustl.edu/links/genes/58
MYC	4609	OVEREXPRESSION	Multiple Myeloma	9538		JQ-1		Predictive	Supports	D	Sensitivity/Response	BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic malignancy, JQ1 produces a potent antiproliferative effect associated with cell-cycle arrest and cellular senescence.	21889194	PubMed		Delmore et al., 2011, Cell		5	accepted	5505	1303	3737														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5505	https://civic.genome.wustl.edu/links/variants/1303	https://civic.genome.wustl.edu/links/genes/3737
RRM1	6240	UNDEREXPRESSION	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	B	Sensitivity/Response	There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.  Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).  The study also tested the role of ERCC1 expression and its correlation to RRM1 expression. It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127).	19543324	PubMed		Akita et al., 2009, Oncogene		3	accepted	5506	1257	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		N/A	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/5506	https://civic.genome.wustl.edu/links/variants/1257	https://civic.genome.wustl.edu/links/genes/5051
CD274	29126	EXPRESSION	Cancer	162				Prognostic	Supports	B	Poor Outcome	A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR=1.58, P<.001) and poor disease free/progression free survival (DFS/PFS) (HR=1.72, P=0.001). When split into sub groups by cancer type overall survival  was poor for breast (HR=1.98, P=0.014), urothelial (HR=2.24, P<0.001), renal (HR=3.30,  P<0.001), and gastric cancers (HR=1.56, P=0.040). DFS/PFS was poor in patients with hepatocellular carcinoma (HR=1.72,  P=0.003), melanoma (HR=3.39,  P<0.001), and renal carcinoma, (HR=5.04,  P<0.001).	28471952	PubMed		Wang et al., 2017, Medicine (Baltimore)		4	accepted	5507	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5507	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
RRM1	6240	UNDEREXPRESSION	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	B	Sensitivity/Response	In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-specic RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.  Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016).	17131328	PubMed		Nakahira et al., 2007, Int. J. Cancer		3	accepted	5508	1257	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		N/A	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/5508	https://civic.genome.wustl.edu/links/variants/1257	https://civic.genome.wustl.edu/links/genes/5051
RRM1	6240	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Gemcitabine,Docetaxel,Vinorelbine	Substitutes	Predictive	Supports	B	Sensitivity/Response	In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression.	24647522	PubMed		Dong et al., 2014, PLoS ONE		4	accepted	5530	1257	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		N/A	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/5530	https://civic.genome.wustl.edu/links/variants/1257	https://civic.genome.wustl.edu/links/genes/5051
DICER1	23405	E1705K	Malignant Sertoli-Leydig Cell Tumor	0050618				Diagnostic	Supports	B	Positive	Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian SertoliLeydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K. Additionally, DICER1 E1705K mutations were identified in 5/8 (63%) Sertoli cell tumors and 2/5 (40%) gynandroblastomas. However, no mutations were identified in 15 testicular sex cord-stromal tumors (8 classical Sertoli cell tumors, 3 Sertoli cell tumors-large cell calcifying variant, 4 sex cord-stromal tumors not otherwise specified).	26428316	PubMed		Conlon et al., 2015, Mod. Pathol.		4	accepted	5533	2050	9533	14	95560476	95560476	C	T	ENST00000526495.1					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5533	https://civic.genome.wustl.edu/links/variants/2050	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709N	Malignant Sertoli-Leydig Cell Tumor	0050618				Diagnostic	Does Not Support	B	Positive	In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed.	26428316	PubMed		Conlon et al., 2015, Mod. Pathol.		4	accepted	5534	2051	9533														Somatic	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5534	https://civic.genome.wustl.edu/links/variants/2051	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	E1813Q	Malignant Sertoli-Leydig Cell Tumor	0050618				Diagnostic	Does Not Support	B	Positive	In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed. 	26428316	PubMed		Conlon et al., 2015, Mod. Pathol.		4	accepted	5535	2052	9533	14	95557630	95557630	C	G	ENST00000526495.1					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5535	https://civic.genome.wustl.edu/links/variants/2052	https://civic.genome.wustl.edu/links/genes/9533
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 8 affected individuals (VHL family 12). Seven had hemangioblastomas of the central nervous system, one had retinal angiomas, and 2 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5543	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5543	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P146fs (c.437del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 158 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system, retinal angiomas, and renal carcinoma (VHL family 13). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5544	2055	58	3	10188293	10188293	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5544	https://civic.genome.wustl.edu/links/variants/2055	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 affected family members with pheochromocytoma (VHL family 15). One also had hemangioblastomas of the central nervous system.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5545	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5545	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 2 family of 4 affected individuals (VHL family 16). Two patients had hemangioblastomas of the central nervous system and three had pheochromocytoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5546	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/5546	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80R (c.238A>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5547	1963	58	3	10183769	10183769	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5547	https://civic.genome.wustl.edu/links/variants/1963	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S80R (c.238A>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5548	1963	58	3	10183769	10183769	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5548	https://civic.genome.wustl.edu/links/variants/1963	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88R (c.262T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 VHL family members (VHL family 3). One had hemangioblastomas of the central nervous system and the other had retinal angiomas. HPO terms: hemangioblastoma, retinal hemangioblastoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5549	2056	58	3	10183793	10183793	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5549	https://civic.genome.wustl.edu/links/variants/2056	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This nonsense mutation was found in a VHL type 1 family of 3 affected individuals. All three family members had retinal angiomas and 2 also had hemangioblastomas of the central nervous system (VHL family 4). A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5550	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5550	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115fs (c.344del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutstaion was found in a VHL type 1 family of 3 affected individuals (VHL family 9). One had hemangioblastomas of the central nervous system, one with retinal angiomas, and one with renal carcinoma. ACMG codes as follows: A frameshift mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5553	2057	58	3	10188201	10188201	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5553	https://civic.genome.wustl.edu/links/variants/2057	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P102fs (c.305delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system (VHL family 6). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma.	12624160	PubMed		Rocha et al., 2003, J. Med. Genet.		3	accepted	5554	2058	58	3	10183836	10183836	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5554	https://civic.genome.wustl.edu/links/variants/2058	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Case report of a female VHL patient presenting with spinal hemangioblastoma at the age of 32. Further workup showed the presence of pancreatic cysts and a history of spinal hemangioblastoma in the mother. Genetic testing confirmed the presence of the above mutation in the proband. ACMG evidence codes:  'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Spinal hemangioblastoma, Multiple pancreatic cysts.	22133049	PubMed		Sun et al., 2012, Br J Neurosurg		3	accepted	5561	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5561	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Thirty-five unrelated spanish patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This germline missense mutation was found in a patient with cerebellar hemangioblastomas, and clear cell renal carcinoma (patient no. F62). The patient's age and demographics were not listed. This evidence supports the following ACMG Codes: PM2 - Absent from controls (i.e. gnomAD), PP4- Patient's phenotype is specific for a disease with a single genetic etiology.	14722919	PubMed		Ruiz-Llorente et al., 2004, Hum. Mutat.		3	accepted	5582	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5582	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	The study looked to evaluate growth kinetic in VHL-associated renal cell carcinoma.  Of the 64 VHL patients with renal involvement, 61 were confirmed to have a germline variant. This variant was identified in one patient (Patient #3 - supplementary table). Clinical manifestations included renal cell carcinoma; other manifestations were not discussed.	22156657	PubMed		Jilg et al., 2012, Urol. Int.		2	accepted	5592	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5592	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
RRM1	6240	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	3908		Gemcitabine,Paclitaxel,Vinorelbine	Substitutes	Predictive	Supports	B	Sensitivity/Response	The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation.  In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366).	23038758	PubMed		Vilmar et al., 2013, Ann. Oncol.		3	accepted	5599	1257	5051	11	4116039	4160106			ENST00000300738.5					75	GRCh37		Unknown	2021-03-31 18:22:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/5599	https://civic.genome.wustl.edu/links/variants/1257	https://civic.genome.wustl.edu/links/genes/5051
VHL	7428	R82_V84del (c.243_251del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 35). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5637	2089	58	3	10183774	10183782	GCGCGTCGT		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/5637	https://civic.genome.wustl.edu/links/variants/2089	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P40fs (c.118ins)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 46).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5638	2090	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5638	https://civic.genome.wustl.edu/links/variants/2090	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T152fs (c.455insA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 151). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5639	2091	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5639	https://civic.genome.wustl.edu/links/variants/2091	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T157fs (c.472ins)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 76). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). However, the bases inserted were not described.	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5640	2092	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5640	https://civic.genome.wustl.edu/links/variants/2092	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 VHL type 1 patients (kindred no. 48, 75). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5641	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5641	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-1G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This splice mutation was found in a VHL type 1 patient (kindred no. 143). This study contains very strong evidence for pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5642	1990	58	3	10191470	10191470	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5642	https://civic.genome.wustl.edu/links/variants/1990	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R177fs (c.528del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 54). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		Crossey et al., 1994, Hum. Mol. Genet.		3	accepted	5643	1907	58	3	10191535	10191535	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5643	https://civic.genome.wustl.edu/links/variants/1907	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158fs (c.471dupT)	Von Hippel-Lindau Disease	14175				Predisposing	N/A	C	N/A	Germline mutation analysis of 469 VHL families reveled 300 mutations. The most common germline mutations were identified between codons 75-82, between codons 157-189 (Elongin binding domain) and at the splice site between exons 2 and 3. The association between mutations in codon 167 and pheochromocytoma was detected in all nationalities tested. This mutation was found in a VHL family (family ID 6BMS). No phenotype described. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8956040	PubMed		Zbar et al., 1996, Hum. Mutat.		2	accepted	5646	1783	58	3	10191478	10191479		T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/5646	https://civic.genome.wustl.edu/links/variants/1783	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D92_Y98del (c.275_292del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in VHL type 1 family (lineage 11). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame insertions in a nonrepeat region (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5649	2097	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5649	https://civic.genome.wustl.edu/links/variants/2097	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in 2 VHL type 1 families (lineages 136, 183). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5650	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5650	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E160fs (c.477del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes a premature stop codon at amino acid 170 and was found in a VHL type 1 family (lineage 16). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		Stolle et al., 1998, Hum. Mutat.		3	accepted	5651	2098	58	3	10191482	10191482	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5651	https://civic.genome.wustl.edu/links/variants/2098	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V66del (c.197_220del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V287). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4). One unaffected family member was tested and negative for this mutation.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5653	2099	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5653	https://civic.genome.wustl.edu/links/variants/2099	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V67). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5654	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5654	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
ARID1A	8289	UNDEREXPRESSION	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower in the cancerous tissue than in the normal tissue (P=0.0029). This was then again tested using Western Blotting. Consistent with the real-time PCR results, there was a lower expression of ARID1A in 13 of the tumor tissue samples compared to the normal tissue samples (P=0.0015). In an immunohistochemical analysis of 224 tissue blocks, 115 of those had a decreased ARID1A expression. The data conveyed that lower ARID1A expression was correlated with depth of tumor infiltration (P=0.001). Lastly, cell proliferation in regards to ARID1A expression was tested in cell lines. The cells with silenced expression of ARID1A had a much greater growth than those with greater expression of the protein.	22808142	PubMed		Wang et al., 2012, PLoS ONE		4	accepted	5675	2108	6559	1	27022524	27108595			ENST00000324856.7					75	GRCh37		N/A	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5675	https://civic.genome.wustl.edu/links/variants/2108	https://civic.genome.wustl.edu/links/genes/6559
ARID1A	8289	UNDEREXPRESSION	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohistochemical staining. Of the 290 patients, 213 had a low ARID1A expression and 77 patients had a high expression. Low ARID1A expression was associated with higher nuclear grade (P<0.001), advanced pTNM stage (P=0.013), shorter cancer-specific survival (p=0.001) and progression-free survival (P<0.001). After a multivariate analysis using Cox proportional hazards, it was found that ARID1A expression levels are an independent predictor of progression-free survival in patients with CCRCC, although no significant correlation was found between the expression levels and cancer-specific survival.	25628030	PubMed		Park et al., 2015, Hum. Pathol.		3	accepted	5676	2108	6559	1	27022524	27108595			ENST00000324856.7					75	GRCh37		N/A	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5676	https://civic.genome.wustl.edu/links/variants/2108	https://civic.genome.wustl.edu/links/genes/6559
VHL	7428	A149S (c.445G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	49 family members from three generations of a Turkish family were examined. A clinical presentation of VHL type 2B was noted. Genetic testing was performed on 17 family members. 11 members with the mutation had manifestations, while 6 members with the mutation were asymptomatic. 1 of the asymptomatic individuals belonged to generation 2, while the remaining 5 belonged to the fourth generation, suggesting they may be too young to present manifestations. From the members that had manifestations: 9 had pheochromocytoma (5 bilateral),  1 had lumbar spine hemangioblastoma, 1 had retinal hemangioblastoma, 4 had renal cell carcinoma (2 bilateral), and 3 had pancreatic neuroendocrine tumours (1 also had a serous cystadenoma in addition to the neuroendocrine tumour). ACMG evidence codes: 'PP1' because of segregation results, 'PP2' because there is a missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease, 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Spinal hemangioblastoma, Multiple pancreatic cysts, Pheochromocytoma, Neuroendocrine neoplasm, Retinal hemangioblastoma.	23673869	PubMed		Mete et al., 2014, Endocrine		3	accepted	5679	820	58	3	10188302	10188302	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/5679	https://civic.genome.wustl.edu/links/variants/820	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	This paper reports on 4 Chinese kindreds with VHL. The VHL gene was screened using direct DNA sequencing and MLPA in 44 volunteers among the 4 families. The above mutation was found in 1 kindred; 10 members were tested and 3 were found to harbour the mutation. The 7 members without a mutation were asymptomatic, while the 3 members with a mutation had manifestations. In addition to the 3 members who tested positive, there were 2 additional members who displayed manifestations, but died before testing could be performed. Clinical manifestations in this kindred included: renal cell carcinoma, CNS hemangioblastoma, pancreatic cysts, renal cysts, and retinal hemangioblastoma. ACMG evidence codes: 'PP1' because of segregation results, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology.	23143947	PubMed		Chen et al., 2013, Clin Transl Oncol		4	accepted	5682	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5682	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.340+1G>A)	Von Hippel-Lindau Disease	14175	Spinal hemangioblastoma,Clear cell renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. The mutations could not be found within 100 healthy controls. The above mutation was found in 2 members (father and daughter) of a single family. The mutation was absent in two healthy family members. The mutation destroys the conserved intronic donor splice site and likely leads to premature protein termination (G114Dfs*6). The 12-year-old daughter had retinal and spinal hemangioblastoma, while the 34-year-old father had retinal, spinal, and cerebellar hemangioblastoma, and bilateral clear cell renal cell carcinoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results.	23298237	PubMed		Losonczy et al., 2013, BMC Med. Genet.		4	accepted	5689	2114	58	3	10183872	10183872	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5689	https://civic.genome.wustl.edu/links/variants/2114	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. All 7 patients were found to have Type 1 VHL disease. The mutations could not be found within 100 healthy controls. The above mutation was found in 1 member of a single family. The patient developed retinal and cerebellar hemangioblastoma. ACMG evidence codes: 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease.	23298237	PubMed		Losonczy et al., 2013, BMC Med. Genet.		3	accepted	5691	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5691	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Renal cyst,Pancreatic cysts,Multiple renal cysts,Renal cell carcinoma,Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	A case report of a Chinese family with mosaic VHL is described. The proband first came to medical attention with bilateral renal cell carcinoma, renal cysts, and pancreatic cysts. However, she initially tested negative for VHL. Her daughter presented with spinal hemangioblastoma, and upon genetic testing was found to have the above mutation. The probands' DNA was reexamined and was determined to harbour the above mutation in approximately 18% of peripheral leukocytes. ACMG evidence codes:   'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	23384228	PubMed		Wu et al., 2013, Clin. Genet.		3	accepted	5693	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5693	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I151T (c.452T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A cohort of 141 patients with hemangioblastomas of the central nervous system was analyzed. 81 patients had germline mutations in the VHL gene. This missense mutation was found in one patient with hemangioblastomas of the central nervous system. No other phenotype described.  HPO terms: hemangioblastoma.	10567493	PubMed		Glsker et al., 1999, J. Neurol. Neurosurg. Psychiatry		2	accepted	5720	1871	58	3	10188309	10188309	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5720	https://civic.genome.wustl.edu/links/variants/1871	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94FS (c.279delC)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	This mutation was found in a 51 year old female with hemangioblastomas of the cerebellum, pancreatic cysts, and bilateral renal adenocarcinomas. Patient's mother died of a brain tumor. Mutation was not found in 55 normal individuals. This study contains very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	10862095	PubMed		Moore et al., 2000, Hum. Mutat.		2	accepted	5722	2127	58	3	10183810	10183810	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5722	https://civic.genome.wustl.edu/links/variants/2127	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-2A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This splice mutation was found in a VHL type 1 family of 3 individuals. One family member had retinal angiomas and 2 had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5724	2078	58	3	10191469	10191469	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5724	https://civic.genome.wustl.edu/links/variants/2078	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114dup (c.342dupGGT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in 2 VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system. HPO terms: retinal hemangioblastoma, hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5725	2129	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5725	https://civic.genome.wustl.edu/links/variants/2129	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R82_V84del (c.243_251del)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 family of 5 individuals. Four family members had retinal angiomas and 3 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: retinal hemangioblastoma, hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5726	2089	58	3	10183774	10183782	GCGCGTCGT		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/5726	https://civic.genome.wustl.edu/links/variants/2089	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65FS (c.194delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 2 family of 7 individuals. Three family members had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and one had pheochromocytoma. ACMG codes as follows: A frameshift variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5727	2130	58	3	10183725	10183725	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5727	https://civic.genome.wustl.edu/links/variants/2130	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q73fs (c.214insGCCC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 3. All three had retinal angiomas and hemangioblastomas of the central nervous system. One also had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5728	2131	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5728	https://civic.genome.wustl.edu/links/variants/2131	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C77fs (c.228dup)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed.  Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation was found in 3 VHL type 1 families of 7 individuals total. Five patients had retinal angiomas, 3 had hemangioblastomas of the central nervous system, 3 had renal cell carcinoma and 3 had pheochromocytoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, pheochromocytoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5729	2132	58	3	10183758	10183759		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5729	https://civic.genome.wustl.edu/links/variants/2132	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.341-2A>C)	Renal Cell Carcinoma	4450				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 2 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pheochromocytoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5730	2133	58	3	10188196	10188196	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/5730	https://civic.genome.wustl.edu/links/variants/2133	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114fs (c.341delCGTTTCCAACAATTTCTCGGTGT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This mutation was found in a VHL type 1 family of 3. All three family members had retinal angiomas. One also had renal cell carcinoma. HPO terms: retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		2	accepted	5731	2134	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5731	https://civic.genome.wustl.edu/links/variants/2134	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H125fs (c.374insA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 3. One family member had retinal angiomas, one had hemangioblastomas of the central nervous system, and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5733	2136	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5733	https://civic.genome.wustl.edu/links/variants/2136	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T152fs (c.455insA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 patient with retinal angiomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5734	2091	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5734	https://civic.genome.wustl.edu/links/variants/2091	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	K159fs (c.474_476delGAAinsC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family of 5 individuals. Three had hemangioblastomas of the central nervous system and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5735	2137	58	3	10191481	10191483	GAA	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5735	https://civic.genome.wustl.edu/links/variants/2137	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175* (c.525delC)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members. One family member had retinal angiomas and the other had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5736	2138	58	3	10191532	10191532	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5736	https://civic.genome.wustl.edu/links/variants/2138	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188fs (c.562delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members with renal cell carcinomas. One relative also had retinal angiomas, while the other had hemangioblastomas of the central nervous system. HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5737	2139	58	3	10191569	10191569	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5737	https://civic.genome.wustl.edu/links/variants/2139	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	K196fs (c.584_585delAG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and renal cell carcinoma. HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5738	2140	58	3	10191591	10191592	AG		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5738	https://civic.genome.wustl.edu/links/variants/2140	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D197FS (c.589delG)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family retinal angiomas and renal cell carcinoma. HPO terms: retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5739	2141	58	3	10191596	10191596	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5739	https://civic.genome.wustl.edu/links/variants/2141	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T202fs (c.606insA)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with hemangioblastomas of the central nervous system. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss-of-function is known mechanism of disease.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5740	2142	58														Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5740	https://civic.genome.wustl.edu/links/variants/2142	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113FS (c.337delC)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with retinal hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). Relevant HPO terms: Retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5741	2143	58	3	10183868	10183868	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5741	https://civic.genome.wustl.edu/links/variants/2143	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A56fs (c.166dup)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5742	2144	58	3	10183696	10183697		G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5742	https://civic.genome.wustl.edu/links/variants/2144	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P61FS (c.182_185delCCGT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5743	2145	58	3	10183713	10183716	CCGT		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5743	https://civic.genome.wustl.edu/links/variants/2145	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 4 unrelated families of 8 individuals total. 5 individuals had retinal hemangioblastomas, 4 had hemangioblastomas of the central nervous system, and 3 had renal cell carcinoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region or stop-loss variants, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		3	accepted	5744	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5744	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-1G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 unrelated VHL families with 4 individuals total. Three had hemangioblastomas of the central nervous system, 4 had retinal angiomas, and 2 had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.	17024664	PubMed		Ong et al., 2007, Hum. Mutat.		4	accepted	5745	2077	58	3	10191470	10191470	G	C	ENST00000256474.2					75	GRCh37	There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.	Rare Germline	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/5745	https://civic.genome.wustl.edu/links/variants/2077	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.341-2A>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This splice mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system, renal cell carcinoma, and pancreatic cysts (family no. 32). ACMG evidence codes: 'PSV1' because they observe a splice-site variant in a gene where loss-of-function is known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5748	2133	58	3	10188196	10188196	A	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/5748	https://civic.genome.wustl.edu/links/variants/2133	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 family members with retinal hemangioblastomas and renal cell carcinoma (family no. 25). One family member also had central nervous system hemangioblastoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region.	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	5749	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5749	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	This study reports 1,548 germline and somatic mutations from 945 VHL families. Mutation was detected in a VHL patient with hemangioblastomas of the central nervous system, retinal hemangioblastomas and Grawitz (case no. 2034). Protein length changes as a result of an in-frame deletion in a nonrepeat region (ACMG code: PM4). Patient's phenotypes or family history are highly specific for a disease with a single genetic etiology (ACMG code: PP4).	20151405	PubMed		Nordstrom-O'Brien et al., 2010, Hum. Mutat.		3	accepted	5750	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5750	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 40 year old type 1 VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 1) but no family history.	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		3	accepted	5765	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5765	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 42-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 12). ACMG evidence codes: 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology.	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		3	accepted	5766	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5766	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 3 DELETION	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in 3 family members and an unrelated patient. All three family members had hemangioblastomas of the central nervous system (proband no. 13). The 32-year-old sister and 27-year-old proband had renal cell carcinoma and pancreatic cysts. The proband also had retinal angiomas. The unrelated, 45-year-old VHL patient had hemangioblastomas of the central nervous system and retina, renal cell carcinoma, and pancreatic cysts (proband no. 14). ACMG codes as follows: A single exon deletion variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5767	1939	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/5767	https://civic.genome.wustl.edu/links/variants/1939	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161= (c.481C>A)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This silent mutation was found in a 34-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 15).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5768	2148	58	3	10191488	10191488	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5768	https://civic.genome.wustl.edu/links/variants/2148	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Epididymal cyst,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in 4 VHL family members (proband no. 6). The 65-year-old father had renal cell carcinoma; The 37-year old sister had pancreatic cysts and the 33-year old sister had retinal angiomas. The 38-year-old proband had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5769	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/5769	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E94* (c.280G>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma,Pancreatic cysts,Epididymal cyst			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated families. One family of 3 had a asymptomatic 27-year-old female, a 27-year-old male with epididymal cystadenoma, and a 55-year old with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 10). The other VHL family had 2 individuals with hemangioblastomas of the central nervous system (proband no. 11). ACMG codes as follows: A nonsense variant in a gene where loss-of-function is a known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5771	1794	58	3	10183811	10183811	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5771	https://civic.genome.wustl.edu/links/variants/1794	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115R (c.344A>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 45-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 4).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5772	2000	58	3	10188201	10188201	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5772	https://civic.genome.wustl.edu/links/variants/2000	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	I151F (c.451A>T)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Epididymal cyst,Renal cell carcinoma,Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 43-year-old VHL patient with renal cell carcinoma, pancreatic cysts, an endolymphatic sac tumor, and an epididymal /ovarian cystadenoma (proband no. 5).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5773	2150	58	3	10188308	10188308	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/5773	https://civic.genome.wustl.edu/links/variants/2150	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178R (c.533T>G)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a VHL family of 6 individuals (proband no. 7). A 62-year-old female carrying the mutation and a male with an unknown mutation had hemangioblastomas of the central nervous system (CNS). A 58-year-old male family member had retinal angiomas and renal cell carcinoma. The 60 year-old proband had CNS hemangioblastomas, retinal angiomas, renal cell carcinoma, and pancreatic cysts. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5774	1888	58	3	10191540	10191540	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/5774	https://civic.genome.wustl.edu/links/variants/1888	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86S (c.256C>T)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Pheochromocytoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 2 VHL family members (proband no. 2). The 33-year-old proband had retinal angiomas, renal cell carcinoma, pancreatic cysts, and pheochromocytoma. The proband's 8-year-old had no clinical manifestations of VHL disease.	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5775	1902	58	3	10183787	10183787	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/5775	https://civic.genome.wustl.edu/links/variants/1902	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88* (c.263G>A)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma,Epididymal cyst			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated families. One family had a 32-year-old with hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma, and their 8-year-old asymptomatic son (proband no. 8). The other family had a 39-year-old with renal cell carcinoma and pancreatic cysts and their 81-year-old mother with CNS hemangioblastomas (proband no. 9). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5776	2151	58	3	10183794	10183794	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5776	https://civic.genome.wustl.edu/links/variants/2151	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	3'UTR alteration (c.642+70C>A)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 30-year-old VHL patient with hemangioblastomas of the central nervous system, retinal angiomas, renal cell carcinoma, and pancreatic cysts (proband no. 16). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.	22357542	PubMed		Wu et al., 2012, J. Hum. Genet.		2	accepted	5777	2152	58	3	10191719	10191719	C	A							GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5777	https://civic.genome.wustl.edu/links/variants/2152	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	In the analysis of 63 clinically diagnosed VHL patients, 55 patients were found with pancreatic involvement. Genetic tests on 35 of 55 VHL patients revealed VHL variants in 28 patients. Of the 55 enrolled patients, hemangioblastomas of the central nervous system were previously documented in 47 patients, renal cell carcinoma in 25, and pheochromocytoma in 11 patients. This missense variant was found in 37-year-old female with reported VHL type 1 phenotype and pancreatic lesions (case no. 1).	25562111	PubMed		Park et al., 2015, Scand. J. Gastroenterol.		2	accepted	5780	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/5780	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
ARID1A	8289	UNDEREXPRESSION	Ovarian Clear Cell Carcinoma	0050934				Prognostic	Supports	B	Poor Outcome	In this study, tissue sampling began with 77 ovarian cancer patients. Following, 60 of those samples, the patients withe clear cell ovarian cancer, were analyzed for ARID1A expression using immunohistochemistry.  Of those 60, 9 patients had a loss of ARID1A expression. Also, 17 high-grade serous adenocarcinomas were also analyzed and none of them showed a loss of ARID1A expression. The loss was more frequent in clear cell ovarian carcinoma than in the high-grade serous adenocarcinoma. Results showed that a low ARID1A expression was significantly related to advanced FIGO stages and high CAI25 levels (P=0.02). Those patients with a low expression experienced shorter progression free survival than those with no loss of expression (P<0.01). In a multivariate analysis it was found that a loss of ARID1A expression was significant for shorter disease free survival (P=0.03) and shorter overall survival for patients whose ovarian clear cell carcinoma was treated with platinum-based chemotherapy (P=0.015). Lastly, tumors with low expression were significantly more likely to be resistant to primary adjuvant chemotherapy than tumors with a higher expression (P=0.04).	22101352	PubMed		Katagiri et al., 2012, Mod. Pathol.		3	accepted	5787	2108	6559	1	27022524	27108595			ENST00000324856.7					75	GRCh37			2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5787	https://civic.genome.wustl.edu/links/variants/2108	https://civic.genome.wustl.edu/links/genes/6559
VHL	7428	Y98FS (c.291delC)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Renal cyst,Clear cell renal cell carcinoma,Cerebellar hemangioblastoma,Spinal hemangioblastoma,Multiple renal cysts			Predisposing	Supports	C	Uncertain Significance	A case report of a female Korean patient with VHL. She presented initially with gestational diabetes mellitus, and on routine abdominal scan displayed renal and pancreatic cysts. Family history demonstrated 2 family members with features consistent with VHL (cerebellar hemangioblastoma), which prompted genetic testing. Molecular analysis revealed the presence of the above mutation. Subsequently, she developed spinal hemangioblastoma and clear cell renal cell carcinoma. ACMG evidence codes: 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology, 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease.	24396697	PubMed		Ku et al., 2013, Endocrinol Metab (Seoul)		4	accepted	5794	2160	58	3	10183822	10183822	C		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/5794	https://civic.genome.wustl.edu/links/variants/2160	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q145* (c.433C>T)	Von Hippel-Lindau Disease	14175	Polycythemia			Predisposing	Supports	C	Uncertain Significance	This is a case report on a 9-month-old female with polycythemia. The patient carries a paternally inherited missense mutation (EID5799) and this de novo, nonsense mutation. ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Assumed de novo, but without confirmation of paternity and maternity (PM6).	25586603	PubMed		Sidhu et al., 2015, Pediatr Blood Cancer		2	accepted	5798	1883	58	3	10188290	10188290	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5798	https://civic.genome.wustl.edu/links/variants/1883	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N150S (c.449A>G)	Von Hippel-Lindau Disease	14175	Polycythemia			Predisposing	Supports	C	Uncertain Significance	This is a case report on a 9-month-old female with polycythemia. The patient carries a de novo nonsense mutation [Q145* (c.433C>T)] and this paternally inherited, missense mutation. The authors of this paper believed this missense mutation was the cause of the aforementioned clinical manifestations. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	25586603	PubMed		Sidhu et al., 2015, Pediatr Blood Cancer		2	accepted	5799	2162	58	3	10188306	10188306	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5799	https://civic.genome.wustl.edu/links/variants/2162	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Spinal hemangioblastoma,Adenocarcinoma of the colon,Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	A case report of a 74-year-old male with colorectal adenocarcinoma, clear cell renal cell carcinoma, and hemangioblastomas of the central nervous system. The spinal hemangioblastoma was histopathologically confirmed. Bilateral multifocal cerebellar hemangioblastomas were inferred on brain MRI. Family history included a mother with a brain tumor of unconfirmed pathology, 2 brothers with the E70K variant and renal cell carcinoma, and an asymptomatic son in his 40s who was also found to have this variant. ACMG evidence codes: 'PP1' because of cosegregation with disease in multiple affected family members in a gene known to cause the disease, 'PP4' because the patient's phenotype and family history are highly specific for a disease with a single genetic etiology.	25715769	PubMed		Heo et al., 2016, Cancer Res Treat		3	accepted	5805	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/5805	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Genetic analysis of 21 patients with known germline mutations in an inherited pheochromocytoma/paraganglioma gene, ten of which were in the VHL gene. This missense mutation was found in 8 unrelated patients with pheochromocytoma (tumor IDs P5, P6, P7, P8, P9, P10, P11, P12). ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	25883647	PubMed		Luchetti et al., 2015, Int J Endocrinol		2	accepted	5807	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5807	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
CD274	29126	EXPRESSION	Lung Non-small Cell Carcinoma	3908		Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.	25891174	PubMed		Garon et al., 2015, N. Engl. J. Med.	NCT01295827	4	accepted	5811	276	11335	9	5450525	5470547			ENST00000381577.3					75	GRCh37		N/A	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5811	https://civic.genome.wustl.edu/links/variants/276	https://civic.genome.wustl.edu/links/genes/11335
NRG1	3084	SLC3A2-NRG1	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	13 patients with invasive mucinous adenocarcinoma of the lung from a cohort of 59 were found to be SLC3A2-NRG1 fusion positive. Survival was assessed according to the presence of the NRG1 fusion. NRG1 fusions positive patients demonstrated  inferior overall survival (OS) and disease-free survival (DFS) compared with those without NRG1 fusion. To exclude the impact of stage on survival OS and DFS was compared only in patients with stage I disease. Patients with NRG1 fusions showed significantly inferior OS and DFS compared to those without NRG1 fusions.	27626312	PubMed		Shin et al., 2016, Oncotarget		3	accepted	5814	2166	2593														Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5814	https://civic.genome.wustl.edu/links/variants/2166	https://civic.genome.wustl.edu/links/genes/2593
BRCA1	672	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	0060080		Olaparib		Predictive	Supports	B	Sensitivity/Response	302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).	28578601	PubMed		Robson et al., 2017, N. Engl. J. Med.	NCT02000622	5	accepted	5815	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/5815	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	0060080		Olaparib		Predictive	Supports	B	Sensitivity/Response	302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.	28578601	PubMed		Robson et al., 2017, N. Engl. J. Med.	NCT02000622	3	accepted	5816	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/5816	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
RAD50	10111	L1237F	Ureter Small Cell Carcinoma	6886		Checkpoint Kinase Inhibitor AZD7762,Irinotecan	Combination	Predictive	Supports	C	Sensitivity/Response	The publication describes a patient with a somatic RAD50 L1237F mutation in combination with LOH and a TP53 A161T mutation that showed a complete response to a combination treatment with Irinotecan and the CHK1 inhibitor AZD7762.	24934408	PubMed		Al-Ahmadie et al., 2014, Cancer Discov		4	accepted	5829	2168	8032														Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5829	https://civic.genome.wustl.edu/links/variants/2168	https://civic.genome.wustl.edu/links/genes/8032
BRCA1	672	MUTATION	Breast Cancer	1612		Olaparib		Predictive	Supports	B	Sensitivity/Response	Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.	28792849	PubMed		2017, N. Engl. J. Med.		4	accepted	5830	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5830	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Breast Cancer	1612		Olaparib		Predictive	Supports	B	Sensitivity/Response	Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.	28792849	PubMed		2017, N. Engl. J. Med.		4	accepted	5831	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5831	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BTK	695	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	A patient cohort of 308 individuals was created from trails of Ibrutinib in CLL (see Maddocks 2015 PMID 26182309).  A secondary cohort was created from a prospective collection of  112 patients.  83/308 patients discontinued because of disease progression (27 Richter's transformation; 1 prolymphocytic leukemia; 55 progressive CLL).  46/55 progressive patients had a relapse sample available for sequencing of BTK and PLCG2. 31 patients only had BTK C481(F/R/A/S)  mutations, 3 patients only had PLCG2 mutations, and 6 patients had both BTK C481 and PLCG2 mutations.  In the 112 patients sequencing of BTK and PLGC2 coding regions was performed every 3 months. At publication at 8 patients had experienced relapse. All 8 had BTK C481S  mutations with clonal expansion before relapse.  8 additional patients did not have clinical relapse but had  BTK  C481S  mutations with VAF >1% and increasing CLL cells in peripheral blood.	28418267	PubMed		Woyach et al., 2017, J. Clin. Oncol.		4	accepted	5833	2169	65														Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5833	https://civic.genome.wustl.edu/links/variants/2169	https://civic.genome.wustl.edu/links/genes/65
PLCG2	5336	MUTATION	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	Whole exome sequencing was performed on baseline and relapse samples from six patients with CLL.  One relapse sample had mutations in BTK and PLCG2, and a second relapse sample only had a mutation in PLCG2.  Both samples with PLCG2 mutations had a mutation at R665W.  Mutations in PLCG2 at L845F and S707Y were observed in the relapse samples with an additional BTK C481S mutation.	24869598	PubMed		Woyach et al., 2014, N. Engl. J. Med.		5	accepted	5834	2170	4327														Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5834	https://civic.genome.wustl.edu/links/variants/2170	https://civic.genome.wustl.edu/links/genes/4327
MET	4233	OVEREXPRESSION	Stomach Carcinoma	5517		Rilotumumab		Predictive	Does Not Support	B	Sensitivity/Response	In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab. Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm. Median overall survival was 88 months (95% CI 77-102) in the rilotumumab group compared with 107 months (96-124) in the placebo group (stratified hazard ratio 134, 95% CI 110-163; p=0003).	28958504	PubMed		Catenacci et al., 2017, Lancet Oncol.	NCT01697072	5	accepted	5835	621	52	7	116312459	116436396			ENST00000318493.6					75	GRCh37		N/A	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5835	https://civic.genome.wustl.edu/links/variants/621	https://civic.genome.wustl.edu/links/genes/52
KRAS	3845	AMPLIFICATION	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplification were highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (P<0.001). Amplification of KRAS maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.25.8, P=0.02). In contrast, presence of KRAS mutation did not influence prognosis (P=0.67)	23099803	PubMed		Birkeland et al., 2012, Br. J. Cancer		3	accepted	5836	592	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5836	https://civic.genome.wustl.edu/links/variants/592	https://civic.genome.wustl.edu/links/genes/30
PTEN	5728	LOSS	Cancer	162		Everolimus		Predictive	Does Not Support	B	Sensitivity/Response	In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint.	28330462	PubMed		Kim et al., 2017, BMC Cancer	NCT02449538	3	accepted	5840	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		N/A	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5840	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
VHL	7428	Splicing alteration (c.340+1G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A study describing phenotypic and genotypic characteristics of VHL in an Indian population of 31 subjects, from 15 families diagnosed with VHL. Multi-cystic pancreas and CNS hemangioblastomas were the most common manifestations in this population. This splice site mutation was found in a VHL family of 8 individuals(family ID AD). 3 family members had renal cell carcinoma, 4 had hemangioblastomas of the central nervous system, 7 had multi-cystic pancreatic lesions, and 1 had retinal hemangioblastomas. ACMG codes as follows: A splice-site variant in a gene where loss-of-function is a known mechanism of disease (PVS1), patient's phenotypes or family history are highly specific for a disease with single genetic etiology (PP4), cosegregation with the disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Multiple pancreatic cysts.	25952756	PubMed		Vikkath et al., 2015, Fam. Cancer		4	accepted	5845	2114	58	3	10183872	10183872	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5845	https://civic.genome.wustl.edu/links/variants/2114	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-2A>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts and cystadenomas of the epididymis. (family VHL 31).  HPO terms: hemangioblastomas, retinal hemangioblastomas, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament.	8707293	PubMed		Glavac et al., 1996, Hum. Genet.		2	accepted	5851	2078	58	3	10191469	10191469	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5851	https://civic.genome.wustl.edu/links/variants/2078	https://civic.genome.wustl.edu/links/genes/58
NRG1	3084	ATP1B1-NRG1	Cholangiocarcinoma	4947		Afatinib		Predictive	Supports	C	Sensitivity/Response	In a single patient with presumed cholangiocarcinoma a novel ATP1B1-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the gene fusion, prioritizing a therapeutic strategy targeting the HER-family of growth factor receptors with afatinib. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed significant and durable response to treatment.	28950338	PubMed		Jones et al., 2017, Ann. Oncol.	NCT02155621	3	accepted	5858	2178	2593														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/5858	https://civic.genome.wustl.edu/links/variants/2178	https://civic.genome.wustl.edu/links/genes/2593
NRG1	3084	SDC4-NRG1	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed a significant and durable response to treatment.	28950338	PubMed		Jones et al., 2017, Ann. Oncol.	NCT02155621	3	accepted	5859	2179	2593														Somatic	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5859	https://civic.genome.wustl.edu/links/variants/2179	https://civic.genome.wustl.edu/links/genes/2593
VHL	7428	V170D (c.509T>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	20 patients from 6 families in the Netherlands were analyzed for Von Hippel Lindau manifestations. 1 family consisting of 12 members had the above mutation. Manifestations in this family included: renal cell carcinoma, cerebellar hemangioblastoma, pancreatic cyst, retinal hemangioblastoma, and pheochromocytoma. ACMG evidence codes: 'PP1' based on segregation results, 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Cerebellar hemangioblastoma, Multiple pancreatic cysts, Retinal hemangioblastoma, Pheochromocytoma.	9681858	PubMed		Wittebol-Post et al., 1998, J. Intern. Med.		4	accepted	5863	1826	58	3	10191516	10191516	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/5863	https://civic.genome.wustl.edu/links/variants/1826	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R82P (c.245G>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 2B family members (kindred no. V12). Patients have pheochromocytoma, while other manifestations are unknown. ACMG evidence codes: 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	5864	1980	58	3	10183776	10183776	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5864	https://civic.genome.wustl.edu/links/variants/1980	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R177ins (c.531insCTGAGAGTAAAGCCTGAA)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This insertion mutation was found in 3 VHL type 1 family members (kindred no, V31). No specific VHL manifestations were discussed. Relevant HPO terms:.	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		2	accepted	5865	2181	58														Rare Germline	2021-03-31 18:22:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/5865	https://civic.genome.wustl.edu/links/variants/2181	https://civic.genome.wustl.edu/links/genes/58
DICER1	23405	D1709N	Malignant Sertoli-Leydig Cell Tumor	0050618				Predisposing	Supports	B	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		3	accepted	5886	2051	9533														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5886	https://civic.genome.wustl.edu/links/variants/2051	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709G	Malignant Sertoli-Leydig Cell Tumor	0050618				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		3	accepted	5887	2195	9533														Rare Germline	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/5887	https://civic.genome.wustl.edu/links/variants/2195	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709E	Malignant Sertoli-Leydig Cell Tumor	0050618				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		2	accepted	5888	2196	9533														Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5888	https://civic.genome.wustl.edu/links/variants/2196	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	E1813Q	Malignant Sertoli-Leydig Cell Tumor	0050618				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in E1813Q.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		2	accepted	5892	2052	9533	14	95557630	95557630	C	G	ENST00000526495.1					75	GRCh37		Rare Germline	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5892	https://civic.genome.wustl.edu/links/variants/2052	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709G	Ovarian Granulosa Cell Tumor	2999				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a germline mutation in D1709G.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		2	accepted	5897	2195	9533														Rare Germline	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/5897	https://civic.genome.wustl.edu/links/variants/2195	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709N	Glandular Pattern Ovarian Yolk Sac Tumor	6511				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a germline mutation in D1709N.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		2	accepted	5899	2051	9533														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/5899	https://civic.genome.wustl.edu/links/variants/2051	https://civic.genome.wustl.edu/links/genes/9533
DICER1	23405	D1709E	Glandular Pattern Ovarian Yolk Sac Tumor	6511				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a germline mutation in D1709E.	22187960	PubMed		Heravi-Moussavi et al., 2012, N. Engl. J. Med.		2	accepted	5900	2196	9533														Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5900	https://civic.genome.wustl.edu/links/variants/2196	https://civic.genome.wustl.edu/links/genes/9533
BRAF	673	V600E	Cholangiocarcinoma	4947		Trametinib Dimethyl Sulfoxide,Dabrafenib	Combination	Predictive	Supports	C	Sensitivity/Response	Chemotherapy-refractory, metastatic cholangiocarcinoma with BRAF V600E showed dramatically response for Dabrafenib and Trametinib combination.	28480077	PubMed		Kocsis et al., 2017, J Gastrointest Oncol		3	accepted	5902	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5902	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Cholangiocarcinoma	4947		Trametinib Dimethyl Sulfoxide,Dabrafenib	Combination	Predictive	Supports	C	Sensitivity/Response	Two cases of patients with BRAF V600E positive cholangiocarcinoma showed excellent response for Dabrafenib and Trametinib.	28078132	PubMed		Lavingia et al., 2016, J Gastrointest Oncol		3	accepted	5903	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5903	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Cholangiocarcinoma	4947		Trametinib Dimethyl Sulfoxide,Dabrafenib	Combination	Predictive	Supports	C	Sensitivity/Response	Dabrafenib and trametinib combination showed durable response for patients with standard chemotherapy refractory cholangiocarcinoma havoring BRAF V600E.	25435907	PubMed		Loaiza-Bonilla et al., 2014, Ecancermedicalscience		3	accepted	5904	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5904	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Cholangiocarcinoma	4947		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months.	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	4	accepted	5905	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/5905	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Cholangiocarcinoma	4947		Irinotecan,Panitumumab,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. Multiple lung metastasis was dramatically regressed and this treatment was continued.	26687137	PubMed		Silkin et al., 2016, J Gastrointest Cancer		3	accepted	5906	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5906	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
FGFR2	2263	FGFR2 fusions	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	B	Sensitivity/Response	This Phase II trial of BGJ398 for FGFR2 aberant cholangiocarcinoma included 48 patients with FGFR2 fusions. Among these patients with FGFR2 fusions, eight showed tumor response (18.8%) and thirty-six showed tumor shrinkage (75%).	29182496	PubMed		Javle et al., 2018, J. Clin. Oncol.	NCT02150967	4	accepted	5908	2202	22														Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/5908	https://civic.genome.wustl.edu/links/variants/2202	https://civic.genome.wustl.edu/links/genes/22
EGFR	1956	EGFR-RAD51	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	A 48-year-old Chinese man with right lung tumor and multiple brain metastases of a lung adenocarcinoma (T1N2M1, stage IV).  NGS analysis indicated an EGFR-RAD51 fusion rather than the most common kind of EGFR mutations. The patient underwent oral erlotinib treatment and was considered to have a partial response (PR) (according to RECIST). Thus far, after 5 months, the disease is stable and he is continuing treatment with erlotinib.	29290255	PubMed		Zhu et al., 2018, Lung Cancer		3	accepted	5909	2203	19														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/5909	https://civic.genome.wustl.edu/links/variants/2203	https://civic.genome.wustl.edu/links/genes/19
FGFR2	2263	FGFR2 mutations	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	B	Sensitivity/Response	Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in  size. Water fall plot of this article showed 5 patients with stable disease.	29182496	PubMed		Javle et al., 2018, J. Clin. Oncol.	NCT02150967	4	accepted	5912	2206	22														Somatic	2021-03-31 18:23:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/5912	https://civic.genome.wustl.edu/links/variants/2206	https://civic.genome.wustl.edu/links/genes/22
BRCA2	675	MUTATION	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.	25366685	PubMed		Kaufman et al., 2015, J. Clin. Oncol.		4	accepted	5913	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5913	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	MUTATION	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.	25366685	PubMed		Kaufman et al., 2015, J. Clin. Oncol.		4	accepted	5914	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5914	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA1	672	MUTATION	Pancreatic Cancer	1793		Cisplatin,Oxaliplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)	25072261	PubMed		Golan et al., 2014, Br. J. Cancer		4	accepted	5915	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5915	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Pancreatic Cancer	1793		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)	25072261	PubMed		Golan et al., 2014, Br. J. Cancer		4	accepted	5916	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5916	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
EGFR	1956	MUTATION	Peritoneal Mesothelioma	1788		Hyperthermic Intraperitoneal Chemotherapy,Cytoreductive Surgery	Combination	Predictive	Supports	B	Sensitivity/Response	25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR mutations in the tyrosine kinase domain. Each mutation was not found in 100 unrelated controls. At study end 10/18 wildtype patients had died with median survival of 14 months, while 2/7 EGFR mutant patients had died and median survival was not yet reached. Median time to progression (TTP) was 12 months in the wildtype group and in the mutant group median TTP was not yet reached. 3 year progression free survival was 71% in the mutant group and 28% in the wildtype group.	20942962	PubMed		Foster et al., 2010, World J Surg Oncol		4	accepted	5923	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/5923	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in patients with advanced NSCLC.	20826716	PubMed		Dahabreh et al., 2011, Ann. Oncol.		4	accepted	5924	191	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5924	https://civic.genome.wustl.edu/links/variants/191	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes.	27664271	PubMed		Zhang et al., 2017, J. Investig. Med.		4	accepted	5925	191	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5925	https://civic.genome.wustl.edu/links/variants/191	https://civic.genome.wustl.edu/links/genes/19
BAP1	8314	ALTERNATIVE TRANSCRIPT (ATI)	Malignant Mesothelioma	1790		Olaparib,Apitolisib	Combination	Predictive	Supports	D	Sensitivity/Response	Novel alternative splice isoform of BAP1 (BAP1) that misses part of the catalytic domain showed reduced deubiquitinating activity compared with full-length BAP1. MPM cell lines expressing more than 20% of BAP1 are more sensitive to olaparib (a PARP1 inhibitor), and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K-mTOR inhibitor).	28389374	PubMed		Parrotta et al., 2017, J Thorac Oncol		3	accepted	5929	2211	70														Somatic	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/5929	https://civic.genome.wustl.edu/links/variants/2211	https://civic.genome.wustl.edu/links/genes/70
BRCA1	672	MUTATION	Pancreatic Cancer	1793		Gemcitabine,Cisplatin,Veliparib	Combination	Predictive	Supports	B	Sensitivity/Response	In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.	29338080	PubMed		O'Reilly et al., 2018, Cancer		3	accepted	5932	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5932	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Pancreatic Cancer	1793		Gemcitabine,Veliparib,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.	29338080	PubMed		O'Reilly et al., 2018, Cancer		3	accepted	5933	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5933	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA1	672	MUTATION	Pancreatic Cancer	1793		Veliparib		Predictive	Does Not Support	B	Sensitivity/Response	Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum therapy. No confirmed partial response was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.	29223478	PubMed		Lowery et al., 2018, Eur. J. Cancer	NCT01585805,NCT02184195	3	accepted	5934	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/5934	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	MUTATION	Pancreatic Cancer	1793		Veliparib		Predictive	Does Not Support	B	Sensitivity/Response	Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.	29223478	PubMed		Lowery et al., 2018, Eur. J. Cancer	NCT01585805,NCT02184195	3	accepted	5935	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5935	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
BRCA2	675	MUTATION	Pancreatic Cancer	1793		Iniparib		Predictive	Supports	C	Sensitivity/Response	Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected	21508395	PubMed		Fogelman et al., 2011, Anticancer Res.		3	accepted	5936	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5936	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
ALK	238	STRN-ALK	Colon Adenocarcinoma	234		Ceritinib		Predictive	Supports	C	Sensitivity/Response	Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumbilica cutaneous metastasis disappeared. Although the size of pelvic tumor by CT scan did not changed, there has been resolution of all contrast enhancing tumor by CT scan.	26933125	PubMed		Yakirevich et al., 2016, Clin. Cancer Res.		3	accepted	5952	2218	1														Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5952	https://civic.genome.wustl.edu/links/variants/2218	https://civic.genome.wustl.edu/links/genes/1
BARD1	580	LOSS-OF-FUNCTION	Colorectal Cancer	9256		Olaparib		Predictive	Supports	D	Sensitivity/Response	Loss of BARD1 function through the expression of a BARD1 splice variant, BARD1, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, and decreased nuclear BRCA1 protein localization. BARD1 sensitizes colon cancer cells to poly ADP ribose polymerase 1 (PARP-1) inhibition even in a BRCA1 WT background.	27197561	PubMed		Ozden et al., 2016, Sci Rep		3	accepted	5953	2219	549														Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5953	https://civic.genome.wustl.edu/links/variants/2219	https://civic.genome.wustl.edu/links/genes/549
ALK	238	ALK FUSIONS	Anaplastic Thyroid Carcinoma			Crizotinib		Predictive	Supports	C	Sensitivity/Response	A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor volume, and her response has been stable on follow-up.	24687827	PubMed		Godbert et al., 2015, J. Clin. Oncol.		3	accepted	5954	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/5954	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ERBB2	2064	OVEREXPRESSION	Pancreatic Cancer	1793		Trastuzumab,Capecitabine	Combination	Predictive	Does Not Support	B	Sensitivity/Response	This is Phase II trial of Trastuzumab and capecitabine as first line treatment in patients with IHC 3+ HER2 expressing advanced pancreatic cancer or cancer with HER2 gene amplification of stage IVB. Total 207 patients could be assessed for HER2 expression. From the 23 patient with IHC 3+ HER2 expression or IHC 2+ and HER2 gene amplification, 17 patients were included in the study and could be assessed for response to the treatment. Contrary to breast and gastric cancer, only 7 out of 11 (64%) patients with IHC 3+ HER2 expression showed gene amplification. PFS rate at 12 weeks was estimated as 23.5%. Median PFS was 65 days. Median OS was 6.9 months. Authors concluded not to recommend further evaluation of anti-HER2 treatment in patients with metastatic pancreatic cancer.	22374460	PubMed		Harder et al., 2012, Br. J. Cancer		4	accepted	5955	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5955	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	OVEREXPRESSION	Pancreatic Cancer	1793		Trastuzumab,Gemcitabine	Combination	Predictive	Does Not Support	B	Sensitivity/Response	Patients with metastatic pancreatic cancer with IHC 2+/3+ HER2 received gemcitabine and Trastuzumab combination. Screening logs demonstrated the rate of HER2 overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Confirmed partial responses were observed in 2 of 32 patients (6%). The median survival for all 34 patients was 7 months.	15581051	PubMed		Safran et al., 2004, Cancer Invest.		4	accepted	5956	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/5956	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
PTEN	5728	LOSS	Solid Tumor			Paclitaxel,Buparlisib,Carboplatin	Combination	Predictive	Does Not Support	B	Sensitivity/Response	No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for 6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors.	28281183	PubMed		Smyth et al., 2017, Invest New Drugs	NCT01297452	4	accepted	5957	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5957	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
BRAF	673	V600E	Lung Non-small Cell Carcinoma	3908		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	4	accepted	5958	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5958	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Ovarian Cancer	2394		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	3	accepted	5959	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5959	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5960	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5960	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Anaplastic Thyroid Carcinoma			Pertuzumab,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	3	accepted	5961	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5961	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Laryngeal Squamous Cell Carcinoma	2876		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	3	accepted	5962	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/5962	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G464V	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5964	1106	5	7	140481417	140481417	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/5964	https://civic.genome.wustl.edu/links/variants/1106	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G469A	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5965	992	5	7	140481402	140481402	C	G	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/5965	https://civic.genome.wustl.edu/links/variants/992	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G496A	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5966	2221	5														Somatic	2021-03-31 18:22:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5966	https://civic.genome.wustl.edu/links/variants/2221	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	N581S	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5967	1186	5	7	140453193	140453193	T	C							GRCh37		Somatic	2021-03-31 18:22:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/5967	https://civic.genome.wustl.edu/links/variants/1186	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G466V	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5968	2222	5	7	140481411	140481411	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/5968	https://civic.genome.wustl.edu/links/variants/2222	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G596R	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5969	1627	5	7	140453149	140453149	C	G	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/5969	https://civic.genome.wustl.edu/links/variants/1627	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G606E	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5970	2223	5	7	140453118	140453118	C	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/5970	https://civic.genome.wustl.edu/links/variants/2223	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	L597Q	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5971	583	5	7	140453145	140453145	A	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/5971	https://civic.genome.wustl.edu/links/variants/583	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	P731T	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5972	2224	5	7	140434507	140434507	G	T	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/5972	https://civic.genome.wustl.edu/links/variants/2224	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	intron 9 rearrangement	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5973	2225	5														Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5973	https://civic.genome.wustl.edu/links/variants/2225	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	intron 10 rearrangement	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5974	2226	5														Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5974	https://civic.genome.wustl.edu/links/variants/2226	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MACF1-BRAF	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5975	2227	5														Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/5975	https://civic.genome.wustl.edu/links/variants/2227	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	WASFL-BRAF	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5976	2228	5														Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/5976	https://civic.genome.wustl.edu/links/variants/2228	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	CUX1-BRAF	Pancreatic Cancer	1793		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5977	2229	5														Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/5977	https://civic.genome.wustl.edu/links/variants/2229	https://civic.genome.wustl.edu/links/genes/5
PTCH1	5727	MUTATION	Cancer	162		Vismodegib		Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients with PTCH1 mutations had PRs to vismodegib (17%; unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	1	accepted	5978	301	4645	9	98205262	98270943			ENST00000331920.6					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5978	https://civic.genome.wustl.edu/links/variants/301	https://civic.genome.wustl.edu/links/genes/4645
SMO	6608	MUTATION	Cancer	162		Vismodegib		Predictive	Does Not Support	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). None of the patients with SMO mutations responded to SHH-inhibition with vismodegib.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5979	300	5365	7	128828713	128853386			ENST00000249373.3					75	GRCh37		Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/5979	https://civic.genome.wustl.edu/links/variants/300	https://civic.genome.wustl.edu/links/genes/5365
ERBB2	2064	MUTATION	Lung Non-small Cell Carcinoma	3908		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty-six patients that received treatment with trastuzumab plus pertuzumab because of a HER2 mutation (without amplification/overexpression) four patients (11%; 95% CI, 3% to 26%) had objective responses.  Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD > 120 days. Only one of the other 22 patients with HER2-mutated tumors responded to treatment with pertuzumab plus trastuzumab (biliary cancer).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5980	666	20	17	37868196	37881332			ENST00000269571.5					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/5980	https://civic.genome.wustl.edu/links/variants/666	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.  Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR).  Patients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	4	accepted	5981	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5981	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Bladder Carcinoma	4007		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	3	accepted	5982	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5982	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Biliary Tract Cancer	4607		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5983	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5983	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Salivary Gland Carcinoma	0050904		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR).	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5984	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5984	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Pancreatic Cancer	1793		Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5985	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5985	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	AMPLIFICATION	Uterine Cancer	363		Pertuzumab,Trastuzumab	Combination	Predictive	Does Not Support	B	Sensitivity/Response	The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab.	29320312	PubMed		Hainsworth et al., 2018, J. Clin. Oncol.	NCT02091141	2	accepted	5986	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	N/A	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/5986	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
IDH1	3417	R132H	Pancreatic Ductal Adenocarcinoma	3498		Ivosidenib		Predictive	Does Not Support	C	Sensitivity/Response	A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response.	27466707	PubMed		Brody et al., 2016, Cancer Biol. Ther.		2	accepted	5987	420	26	2	209113112	209113112	C	T	ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/5987	https://civic.genome.wustl.edu/links/variants/420	https://civic.genome.wustl.edu/links/genes/26
ASS1	445	LOSS	Sarcoma	1115		Pegargiminase,Chloroquine	Combination	Predictive	Supports	D	Sensitivity/Response	90% out of 700 sarcoma samples (comprising 45 histologies) demonstrated loss or reduction of argininosuccinate synthetase 1 expression. Arginine auxotrophy confers sensitivity to arginine deprivation. In sarcoma models, arginine deprivation therapy with pegylated arginine deiminase (ADI-PEG20) maintains a prolonged state of arginine starvation without causing cell death. Combination of ADI-PEG20 and chloroquine led to synergistic cell death via necroptosis and apoptosis.	27735949	PubMed		Bean et al., 2016, Cell Death Dis		3	accepted	5988	2230	450														Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5988	https://civic.genome.wustl.edu/links/variants/2230	https://civic.genome.wustl.edu/links/genes/450
ASS1	445	LOSS	Ovarian Cancer	2394		Platinum Compound		Predictive	Supports	D	Resistance	Preclinical evidence for epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy suggesting that silencing of ASS1 contributes to treatment failure and clinical relapse in ovarian cancer.	19533750	PubMed		Nicholson et al., 2009, Int. J. Cancer		3	accepted	5989	2230	450														Somatic	2021-03-31 18:22:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/5989	https://civic.genome.wustl.edu/links/variants/2230	https://civic.genome.wustl.edu/links/genes/450
BCL2	596	MUTATION	Follicular Lymphoma	0050873				Prognostic	Supports	B	Poor Outcome	In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited enhanced antiapoptotic capacity in vitro.	25452615	PubMed		Correia et al., 2015, Blood		3	accepted	5992	2233	59														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5992	https://civic.genome.wustl.edu/links/variants/2233	https://civic.genome.wustl.edu/links/genes/59
RASA1	5921	LOSS-OF-FUNCTION	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Supports	D	Sensitivity/Response	Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations. Unexpectedly, RASA1 truncating mutations had a strong tendency to co-occur with NF1 truncating mutations (p<0.001). While growth of cell lines with inactivation of only one of these two RasGAPs showed moderate and variable sensitivity to inhibitors of MEK or PI3K, cells with concurrent RASA1/NF1 mutations were profoundly more sensitive (IC50: 0.040M trametinib).	29127119	PubMed		Hayashi et al., 2018, Clin. Cancer Res.		3	accepted	5994	2235	4791														Somatic	2021-03-31 18:22:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5994	https://civic.genome.wustl.edu/links/variants/2235	https://civic.genome.wustl.edu/links/genes/4791
TLK2	11011	AMPLIFICATION	Breast Cancer	1612		Go6983,GF109203X	Substitutes	Predictive	Supports	D	Sensitivity/Response	TLK2 inhibition selectively inhibits the growth of TLK2-high breast cancer cells, downregulates ER, BCL2 and SKP2, impairs G1/S cell cycle progression, induces apoptosis and significantly improves progression-free survival in vivo.	27694828	PubMed		Kim et al., 2016, Nat Commun		3	accepted	6000	2240	8787														Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6000	https://civic.genome.wustl.edu/links/variants/2240	https://civic.genome.wustl.edu/links/genes/8787
BRAF	673	D594G	Skin Melanoma	8923		Sorafenib		Predictive	Supports	D	Sensitivity/Response	In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.	18794803	PubMed		Smalley et al., 2009, Oncogene		3	accepted	6001	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6001	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594G	Skin Melanoma	8923		U0126		Predictive	Supports	D	Resistance	In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.	18794803	PubMed		Smalley et al., 2009, Oncogene		3	accepted	6002	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6002	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G469E	Skin Melanoma	8923		Sorafenib		Predictive	Supports	D	Sensitivity/Response	In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.	18794803	PubMed		Smalley et al., 2009, Oncogene		3	accepted	6003	993	5	7	140481402	140481402	C	T							GRCh37	The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.	Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/6003	https://civic.genome.wustl.edu/links/variants/993	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G469E	Skin Melanoma	8923		U0126		Predictive	Supports	D	Resistance	In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib.	18794803	PubMed		Smalley et al., 2009, Oncogene		3	accepted	6004	993	5	7	140481402	140481402	C	T							GRCh37	The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.	Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/6004	https://civic.genome.wustl.edu/links/variants/993	https://civic.genome.wustl.edu/links/genes/5
VHL	7428	L184P (c.551T>C)	Renal Cell Carcinoma	4450	Renal cell carcinoma,Sporadic			Predisposing	N/A	C	N/A	In a study of 31 kidney tumors from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with non-tumor cells. Genomic DNA was extracted from tumors, lymphocytes and cell lines using standard phenol/chloroform extraction or salt extraction protocols. Three sets of primers were designed to amplify the entire exons 2 and 3 and the last one third 3'-region of exon 1, the genotyping method used was PCR-SSCP (polymerase chain reaction-single-strand conformation polymorphism). A metastatic clear cell renal cell carcinoma sample (sample 3087) was obtained from a 68 year old male who was known to smoke one pack of cigarettes per day and had intense alcohol drinking habits. In this patient's tumor (sample 3087), a c.551T>C variant (noted in the paper as nucleotide 764) was identified as a somatic mutation, found only in the tumor. The second mutation, a C>G transversion, c.183C>G (p.P61=) (noted in the paper at nucleotide 396) was present in the non-tumor DNA, a germline synonymous mutation. The patient had no metastasis after nephrectomy and patients survival was >4 months. ACMG codes: none.	7591282	PubMed		Bailly et al., 1995, Int. J. Cancer		2	accepted	6027	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6027	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
FOXL2	668	C134W	Ovarian Sex-cord Stromal Tumor	0080369				Diagnostic	Supports	A	Positive	FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs.	26033501	PubMed		Goulvent et al., 2016, Histopathology		5	accepted	6034	198	72	3	138665163	138665163	G	C	ENST00000330315.3					75	GRCh37	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.	Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6034	https://civic.genome.wustl.edu/links/variants/198	https://civic.genome.wustl.edu/links/genes/72
ALK	238	ALK FUSIONS	Vagina Sarcoma	1901		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed  anaplastic lymphoma kinase gene rearrangements. A 3-cm mass recurred 1 month later. Treatment with crizotinib resulted in complete regression of all visible or palpable tumor within 3 weeks.	26942346	PubMed		Forde et al., 2016, Obstet Gynecol		2	accepted	6042	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6042	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Epithelioid Inflammatory Myofibroblastic Sarcoma	0080372		Crizotinib		Predictive	Supports	C	Sensitivity/Response	This is a case report of a  22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion. Despite two surgical excision procedures, local recurrence rapidly occurred, and the tumor developed resistance to conventional chemotherapy with doxorubicin. Subsequent administration of crizotinib resulted in relief of severe pain and durable tumor shrinkage at least 10 months.	25028698	PubMed		Kimbara et al., 2014, Jpn. J. Clin. Oncol.		2	accepted	6043	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6043	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
BRAF	673	V600	Melanoma	1909		Vemurafenib,Cobimetinib	Combination	Predictive	Supports	A	Sensitivity/Response	In this double-blind, randomized, placebo-controlled, multicentre study, adult patients with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) to receive cobimetinib or placebo, in combination with oral vemurafenib. Progression-free survival was the primary endpoint. Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). Investigator-assessed median progression-free survival was 12.3 months for cobimetinib and vemurafenib versus 7.2 months for placebo and vemurafenib (HR 0.58 [95% CI 0.46-0.72], p<0.0001). Median overall survival was 22.3 months for cobimetinib and vemurafenib versus 17.4 months for placebo and vemurafenib (HR 0.70, 95% CI 0.55-0.90; p=0.005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up.	27480103	PubMed		Ascierto et al., 2016, Lancet Oncol.	NCT01689519	5	accepted	6044	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6044	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Anaplastic Thyroid Carcinoma			Vemurafenib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 basket study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%.	26287849	PubMed		Hyman et al., 2015, N. Engl. J. Med.	NCT01524978	3	accepted	6045	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6045	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Colorectal Cancer	9256		Encorafenib,Cetuximab	Combination	Predictive	Supports	B	Sensitivity/Response	In a Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab, Twenty-six patients with refractory BRAF V600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab).  Confirmed overall response rates of 19% were observed and median progression-free survival was 3.7 months.	28363909	PubMed		van Geel et al., 2017, Cancer Discov		4	accepted	6046	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6046	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Colorectal Cancer	9256		Encorafenib,Cetuximab,Alpelisib	Combination	Predictive	Supports	B	Sensitivity/Response	In a Phase Ib Dose-Escalation Study of Encorafenib, Cetuximab and Alpelisib, Twenty-eight patients with refractory BRAFV600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3K inhibitor (alpelisib).  Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months	28363909	PubMed		van Geel et al., 2017, Cancer Discov		3	accepted	6047	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6047	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
CTNNB1	1499	S45F	Desmoid Tumor	0080366		Meloxicam		Predictive	Does Not Support	C	Sensitivity/Response	Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of -catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)	24788118	PubMed		Hamada et al., 2014, PLoS ONE		2	accepted	6049	1286	1290	3	41266137	41266137	C	T	ENST00000349496.5					75	GRCh37		Somatic	2021-03-31 18:23:23 UTC	https://civic.genome.wustl.edu/links/evidence_items/6049	https://civic.genome.wustl.edu/links/variants/1286	https://civic.genome.wustl.edu/links/genes/1290
VHL	7428	E70* (c.208G>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Spinal hemangioblastoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense variant was found in a VHL type 1 patient  with CNS hemangioblastomas (family ID 4479).	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	6059	1834	58	3	10183739	10183739	G	T	ENST00000256474.2					75	GRCh37		N/A	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6059	https://civic.genome.wustl.edu/links/variants/1834	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R82_V84del (c.244_252del)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This in-frame deletion was  found in a VHL type 1 family of 6 individuals (family ID 3177). Four of 6 individuals were identified with angiomas and 3 had CNS hemangioblastomas.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	6060	2264	58	3	10183775	10183783	CGCGTCGTG		ENST00000256474.2					75	GRCh37		N/A	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6060	https://civic.genome.wustl.edu/links/variants/2264	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188Q (c.563T>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense variant was found in 2 family members with VHL type 1 phenotype (family ID 3513). Both individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One also had angiomas.	7728151	PubMed		Chen et al., 1995, Hum. Mutat.		4	accepted	6061	1861	58	3	10191570	10191570	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6061	https://civic.genome.wustl.edu/links/variants/1861	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A56_P59del (c.166_178del)	Renal Cell Carcinoma	4450	Renal cell carcinoma,Sporadic			Predisposing	Supports	C	Uncertain Significance	Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and variants in all cell lines. All mutations cluster to the 3 end of the VHL gene open reading frame, implicating this region as important for the tumor-suppressor function of the VHL protein. From findings VHL gene was concluded to have "an important and specific role in the etiology of sporadic RCCs." This in-frame deletion results in a premature stop codon at amino acid 62 and was found in one of the tumor samples (tumor no. 22). No phenotype described.	7977367	PubMed		Whaley et al., 1994, Am. J. Hum. Genet.		3	accepted	6062	2265	58														Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6062	https://civic.genome.wustl.edu/links/variants/2265	https://civic.genome.wustl.edu/links/genes/58
BRCA1	672	LOSS-OF-FUNCTION	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day.  Tumor response rate was 21.7% (five of 23 patients).Stable disease more than 8 weeks was observed in 35% of patients.	25366685	PubMed		Kaufman et al., 2015, J. Clin. Oncol.		3	accepted	6075	131	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6075	https://civic.genome.wustl.edu/links/variants/131	https://civic.genome.wustl.edu/links/genes/6
BRCA2	675	LOSS-OF-FUNCTION	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day.  Tumor response rate was 21.7% (five of 23 patients).Stable disease more than 8 weeks was observed in 35% of patients.	25366685	PubMed		Kaufman et al., 2015, J. Clin. Oncol.		3	accepted	6076	132	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.		2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6076	https://civic.genome.wustl.edu/links/variants/132	https://civic.genome.wustl.edu/links/genes/7
ACVR1	90	G328E	Diffuse Intrinsic Pontine Glioma	0080684				Diagnostic	Supports	C	Positive	Sequencing (whole genome or exome) was performed on a series of 26 pediatric patients (1.7 to 13.6 years old), 7 had missense mutations in ACVR1. Two patients with G328E mutation were identified. This mutation had not been previously reported in other cancer types, indicating it was supportive of a diagnosis of high grade pontine glioma. PEDIATRIC	24705252	PubMed		Taylor et al., 2014, Nat. Genet.		3	accepted	6091	2283	154													This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.	Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/6091	https://civic.genome.wustl.edu/links/variants/2283	https://civic.genome.wustl.edu/links/genes/154
NRG1	3084	NRG1 FUSIONS	Mucinous Adenocarcinoma	3030		Afatinib		Predictive	Does Not Support	C	Sensitivity/Response	One patient with an NRG1-rearranged invasive mucinous adenocarcinomas (IMAs) of the lung had a response with an anti-ERBB3 monoclonal antibody (GSK2849330). No response was achieved with afatinib in four NRG1-rearranged IMA patients (including the index patient post-GSK2849330).	29610121	PubMed		Drilon et al., 2018, Cancer Discov	NCT01966445	3	accepted	6096	2286	2593													NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6096	https://civic.genome.wustl.edu/links/variants/2286	https://civic.genome.wustl.edu/links/genes/2593
NTRK2	4915	STRN-NTRK2	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	One Patient with soft tissue sarcoma and a STRN-NTRK2 fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	3	accepted	6098	2287	3984														Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6098	https://civic.genome.wustl.edu/links/variants/2287	https://civic.genome.wustl.edu/links/genes/3984
NTRK3	4916	ETV6-NTRK3	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	4	accepted	6099	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6099	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK1	4914	LMNA-NTRK1	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	3	accepted	6100	1278	3983	1	156084498	156108548			ENST00000368300.4	1	156844363	156851434	ENST00000524377.1	75	GRCh37		Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/6100	https://civic.genome.wustl.edu/links/variants/1278	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	TPM3-NTRK1	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	Four patients with infantile fibrosarcoma and soft tissue sarcoma and a NTRK1-TPM3 fusion were treated with larotrectinib. Two had a partial, and two had a complete response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	4	accepted	6101	2992	3983														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/6101	https://civic.genome.wustl.edu/links/variants/2992	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	PDE4DIP-NTRK1	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	3	accepted	6102	2289	3983														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6102	https://civic.genome.wustl.edu/links/variants/2289	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	SQSTM1-NTRK1	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	3	accepted	6103	800	3983														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6103	https://civic.genome.wustl.edu/links/variants/800	https://civic.genome.wustl.edu/links/genes/3983
VHL	7428	G144E (c.431G>A)	Adrenal Gland Pheochromocytoma	0050892	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This missense mutation was found in a 51 year-old female with unilateral, benign, adrenal pheochromocytoma (patient no. 48).	9663592	PubMed		van der Harst et al., 1998, Int. J. Cancer		2	accepted	6106	2290	58	3	10188288	10188288	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6106	https://civic.genome.wustl.edu/links/variants/2290	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.463+8C>T)	Adrenal Gland Pheochromocytoma	0050892	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This splice variant causes a premature stop codon at amino acid 66 and was found in a 33 year-old male with unilateral, benign, adrenal pheochromocytoma (patient no. 54).	9663592	PubMed		van der Harst et al., 1998, Int. J. Cancer		2	accepted	6108	2292	58	3	10188328	10188328	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6108	https://civic.genome.wustl.edu/links/variants/2292	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G104A (c.311G>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. S6150).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	6109	2043	58	3	10183842	10183842	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6109	https://civic.genome.wustl.edu/links/variants/2043	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F91L (c.273C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL patient (patient no. S3940).	9829912	PubMed		Olschwang et al., 1998, Hum. Mutat.		3	accepted	6111	2294	58	3	10183804	10183804	C	G	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.273C>A (p.Phe91Leu; F91L) (https://www-ncbi-nlm-nih-gov/clinvar/variation/411978/)	Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6111	https://civic.genome.wustl.edu/links/variants/2294	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184P (c.551T>C)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cyst,Pancreatic cysts,Spinal hemangioblastoma			Predisposing	N/A	C	N/A	Thirty-five unrelated patients suspected of having von Hippel-Lindau disease had genomic DNA from peripheral blood leukocytes analyzed using sequence analysis of the coding region for VHL / Southern blot analyses. 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered, although this only reached significance when combining data from other studies (p=0.101 for present study; p=0.0086 for present study + other study data). This missense variant was found in a patient with spinal and cerebellar hemangioblastomas, retinal hemangioblastomas, pancreatic cysts, renal cysts, and cysts of the broad ligament (patient no. F43). The patient was 27 years old. ACMG PP4 as patient's phenotypes are highly specific for VHL disease.	14722919	PubMed		Ruiz-Llorente et al., 2004, Hum. Mutat.		3	accepted	6119	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6119	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Pheochromocytoma,Epididymal cyst,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This in-frame deletion variant was detected in a VHL type 2 patient with cerebellar hemangioblastoma, pheochromocytoma, renal cell carcinoma, and epididymal cysts (family no. 24).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	6121	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6121	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	W88fs (c.261dup)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This variant was detected in a VHL type 1 patient with cerebellar hemangioblastoma, retinal hemangioblastomas, and renal cell carcinoma (family no. 28).	17661816	PubMed		Hes et al., 2007, Clin. Genet.		3	accepted	6122	2299	58	3	10183791	10183792		A	ENST00000256474.3					75	GRCh37		Rare Germline	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6122	https://civic.genome.wustl.edu/links/variants/2299	https://civic.genome.wustl.edu/links/genes/58
BRAF	673	V600E	Colorectal Cancer	9256		Panitumumab,Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.	29431699	PubMed		Corcoran et al., 2018, Cancer Discov		4	accepted	6123	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6123	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Adenocarcinoma	0050861		Panitumumab,Trametinib	Combination	Predictive	Does Not Support	B	Sensitivity/Response	In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.	29431699	PubMed		Corcoran et al., 2018, Cancer Discov		3	accepted	6124	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6124	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
VHL	7428	S65L (c.194C>T)	Clear Cell Renal Cell Carcinoma	4467	Sporadic,Clear cell renal cell carcinoma			Predisposing	Supports	E	Uncertain Significance	This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'genotypes for genes encoding several carcinogen-metabolizing enzymes.' Higher frequency of VHL transversion variants was found in patients with presence of GETT1 and defective NAT1. This missense variant was found in a 68 year-old male (tumour 311).	11505222	PubMed		Gallou et al., 2001, Pharmacogenetics		2	accepted	6131	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6131	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184P (c.551T>C)	Clear Cell Renal Cell Carcinoma	4467	Sporadic,Clear cell renal cell carcinoma			Predisposing	N/A	C	N/A	195 patients with sporadic clear cell renal cell carcinoma (sporadic CCRCC) were investigated for variants in the VHL gene, in order to determine the possible relationship between VHL mutations in CCRCC patients and polymorphisms in genes encoding enzymes involved in carcinogen metabolism. For each patient, fragments of tumor and non-tumoral kidney tissue were sampled, and DNA was extracted for analysis. PCR, SSCP (single strand conformation polymorphism,) and direct sequencing were used to investigate VHL variants. Tumor number 347 (a cytological grade 1 stage I tumor) was taken from a 60 year old female, and found to have the c.551T>C (p.L184P) somatic mutation in exon 3 of the VHL gene. No other phenotypic information was available for any of the patients included in this study. Relevant ACMG evidence codes: none.	11505222	PubMed		Gallou et al., 2001, Pharmacogenetics		2	accepted	6167	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6167	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
ERBB2	2064	OVEREXPRESSION	Salivary Gland Cancer	8850		Paclitaxel,Trastuzumab	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a 61-year-old caucasian male with a renal mass and subsequent liver metastases. Histopathological examination of the liver led to the diagnosis of metastastic adenocarcinoma of the salivary Gland, which had been diagnosed and treated in the Patient 20 years earlier. IHC revealed Her2/neu, 3+. The patient was treated successfully with trastuzumab/paclitaxel with near-complete response as measured by PET-CT scans for more than a year.	23826550	PubMed		Firwana et al., 2012, Avicenna J Med		2	accepted	6170	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6170	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
ERBB2	2064	OVEREXPRESSION	Salivary Gland Cancer	8850		Trastuzumab,Capecitabine,Zoledronic Acid	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a a 58 year old man with multiple bone metastases after local therapy of a carcinoma ex pleomorphic adenoma one year earlier. The original tumor tested strongly positive for HER2/neu by immunohistochemistry. The patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment resulted in maintenance of disease control for over 2 years.	20504363	PubMed		Sharon et al., 2010, Head Neck Oncol		3	accepted	6171	875	20														N/A	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6171	https://civic.genome.wustl.edu/links/variants/875	https://civic.genome.wustl.edu/links/genes/20
BRAF	673	V600E	Melanoma	1909		Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58).	28891408	PubMed		Long et al., 2017, N. Engl. J. Med.	NCT01682083	5	accepted	6178	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6178	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600K	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 78 (9%) patients had V600K, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 16/41 patients (39%) in the treatment group and 19/37 patients (51%) in the placebo group for a 95% CI Hazard Ratio of 0.54 (0.27-1.06).	28891408	PubMed		Long et al., 2017, N. Engl. J. Med.	NCT01682083	4	accepted	6179	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/6179	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group  with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group.	28891408	PubMed		Long et al., 2017, N. Engl. J. Med.	NCT01682083	5	accepted	6180	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6180	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	G719A	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a G719A mutation, was administered a TKI, and an NSCLC progression was observed.	23749122	PubMed		Locatelli-Sanchez et al., 2013, Lung		2	accepted	6181	999	19	7	55241708	55241708	G	C	ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:23:22 UTC	https://civic.genome.wustl.edu/links/evidence_items/6181	https://civic.genome.wustl.edu/links/variants/999	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	R705K	Lung Non-small Cell Carcinoma	3908		Erlotinib,Gefitinib	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a R705K mutation, was administered a TKI, and an NSCLC progression was observed.	23749122	PubMed		Locatelli-Sanchez et al., 2013, Lung		2	accepted	6182	2333	19														Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6182	https://civic.genome.wustl.edu/links/variants/2333	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	L858R	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Does Not Support	B	Reduced Sensitivity	In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).	27022112	PubMed		Urata et al., 2016, J. Clin. Oncol.		2	accepted	6183	33	19	7	55259515	55259515	T	G	ENST00000275493.2					75	GRCh37	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/6183	https://civic.genome.wustl.edu/links/variants/33	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	EXON 19 DELETION	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Does Not Support	B	Reduced Sensitivity	A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were pretreated with at least one chemotherapy regimen, but no tyrosine kinase inhibitors. In the subgroup of 156 patients with exon 19 deletions as their sole EGFR mutation, 83 and 78 were treated with erlotinib and gefitinib, respectively. Objective response (defined as complete + partial response) was approximately 65 percent for both erlotinib gefitinib and non significantly different  (p= .965). Disease control rate (defined as complete response + partial response + stable disease) was 91.6 and 83.3 percent for erlotinib and gefitinib, respectively (p=.113). The study was unable to demonstrate statistical noninferiority via the planned end point; however, the lack of statistically significant differences between erlotinib and gefitinib responses, and the milder adverse effects experienced by gefitinib treated patients, led the authors to conclude that gefitinib is a feasible alternative to erlotinib in treating patients with ex19del EGFR positive, advanced lung adenocarcinoma.	27022112	PubMed		Urata et al., 2016, J. Clin. Oncol.		3	accepted	6184	133	19	7	55242415	55242513			ENST00000275493.2					75	GRCh37	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6184	https://civic.genome.wustl.edu/links/variants/133	https://civic.genome.wustl.edu/links/genes/19
EGFR	1956	RARE EGRF MUT	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Does Not Support	C	Reduced Sensitivity	A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had prior chemotherapy but no treatment with TKIs. 19 patients had unspecified uncommon EGFR mutations, including single mutations other than ex19del and L858R and double mutations. Of those 19 patients, 7 were treated with erlotinib and 12 were treated with gefitinib. Objective response and disease control rate between erlotinib and gefitinib were not significantly different. The study failed to satisfy the primary endpoint of demonstrating statistical noninferiority in PFS of gefitinib.	27022112	PubMed		Urata et al., 2016, J. Clin. Oncol.		2	accepted	6186	2334	19														Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6186	https://civic.genome.wustl.edu/links/variants/2334	https://civic.genome.wustl.edu/links/genes/19
PIK3CA	5290	MUTATION	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 66/270 (24%) tumors. Of these, 36 tumors (55%) harbored mutations in exon 20 33 H1047R, 1 Y1021C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9 11 E542K, 18 E545K, 1 Q546P. The study found that the risk of relapse with a local recurrence was significantly lower among patients with a PIK3CA mutation in comparison with those who carried wild-type PIK3CA (p= 0.023). When adjusting for other factors, including ER status, node status, tumor size, and treatment (tamoxifen vs no tamoxifen or radiotherapy vs chemotherapy), mutations in the PIK3CA gene were associated with approximately half the risk for local recurrence in comparison with wtPIK3CA (p = .07).	17575221	PubMed		Prez-Tenorio et al., 2007, Clin. Cancer Res.		3	accepted	6188	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6188	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Estrogen-receptor Positive Breast Cancer	0060075		Tamoxifen		Predictive	Does Not Support	B	Sensitivity/Response	This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 65/270 (24%) tumors. Of these, 36 (55%) were in exon 20 33 H1047R, 1 Y10121C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9 11 E542K, 18 E545K, 1 Q546P. Within the group of 188 patients with ER+ tumors, PIK3CA mutation status did not predict response to tamoxifen.	17575221	PubMed		Prez-Tenorio et al., 2007, Clin. Cancer Res.		3	accepted	6189	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6189	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL T315A	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 60 of these clones had T315A mutations. To validate resistance to dasatinib, Ba/F3 cell lines stably expressing a T315A mutation in the ABL1 region of the BCR-ABL fusion were generated. T315A was associated with higher dasatinib IC50 of 125 nM vs 1.34 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6190	2335	4	9	133748282	133748282	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6190	https://civic.genome.wustl.edu/links/variants/2335	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	MUTATION	Breast Cancer	1612		Paclitaxel,Epirubicin,Cyclophosphamide,Fluorouracil,Doxorubicin	Combination	Predictive	Does Not Support	B	Sensitivity/Response	This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. 23/170 patients had PIK3CA mutations. Of those patients, 12 received six courses of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide; this treatment group contained 7 patient with E545K mutations, 1 with E542K, and 4 with H1047R. The other 11 patients received 12 weekly courses of paclitaxel followed by four courses of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide; this treatment group contained 1 patient with an E545K mutation, 1 with Q546R, 1 with E542K, 1 with E542V, 5 with H1047R, 1 with G1049R, and 1 with H1047T. The study did not find evidence that PIK3CA mutations are associated with preoperative chemotherapy sensitivity in breast cancer treated with an anthracycline (doxorubicin or epirubicin), 5-fluorouracil and cyclophosphamide regardless of whether paclitaxel was also administered. The lack of association was true of estrogen receptor (ER)-positive and ER-negative tumors.	18371219	PubMed		Liedtke et al., 2008, Breast Cancer Res.		3	accepted	6191	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6191	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Dasatinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of the p210 BCR-ABL fusion were generated and stably expressed in Ba/F3 cell lines from mutagenized libraries. Combination therapy with 10 M imatinib and 50 nM dasatinib resulted in a single clone with the T315I variant. Combination therapy with 25 nM dasatinib resulted in 11 clones, 6 of which had the T315I variant.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	6192	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6192	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of the p210 BCR-ABL fusion were generated and stably expressed in Ba/F3 cell lines from mutagenized libraries. Combination therapy with 10 M imatinib and 50 nM Dasatinib resulted in 11 clones, 5 of which had the E255K variant.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		2	accepted	6193	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6193	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. The E255V mutation was associated with resistance in 4 M imatinib ( 1 clone, 0.43%) and 500 nM nilotinib (1 clone, 1.25%) tyrosine kinase inhibitors.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6194	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6194	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 400 nM imatinib + 50 nM nilotinib (3 clones, ~16%), 2 M imatinib + 1 M nilotinib (8 clones, 100%), and 4 M imatinib + 2 M nilotinib  (2 clones, 100%) combination treatments.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6196	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6196	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	EXON 21 MUTATION	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 20 mutations showed significantly better 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.011 and P = .01, respectively). Furthermore, patients with exon 20 mut showed especially better OS and DFS than patients with exon 9 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1.	17947469	PubMed		Barbareschi et al., 2007, Clin. Cancer Res.		4	accepted	6198	105	37	3	178951882	178952495			ENST00000263967.3					75	GRCh37	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/6198	https://civic.genome.wustl.edu/links/variants/105	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	EXON 10 MUTATION	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 9 mutations showed significantly worse 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.018 and P = .04, respectively). Furthermore, patients with exon 9 mut showed especially worse OS and DFS than patients with exon 20 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1.	17947469	PubMed		Barbareschi et al., 2007, Clin. Cancer Res.		4	accepted	6199	106	37	3	178935998	178936122			ENST00000263967.3					75	GRCh37	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/6199	https://civic.genome.wustl.edu/links/variants/106	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150 nM. In patients with Y253H mutations prior to nilotinib treatment, complete hematologic response was achieved in 0 of 6 patients, major cytogenetic response in 1 of 8 patients, complete cytogenetic response in 0 of 8 patients, and major molecular response in 0 of 7 patients. After median follow-up of 15.5 months, 3 of 8 patients with this mutation progressed or died. The Y253H mutation was present in two patients at baseline and newly emerged in two patients at progression.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6200	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6200	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 83 of these clones had F317V mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the F317V mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 53 nM vs 1.34 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6208	1525	4	9	133748288	133748288	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6208	https://civic.genome.wustl.edu/links/variants/1525	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248R	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an L248R mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the L248R mutation in the ABL1 region of the BCR-ABL fusion was generated. The L248R variants was associated with higher dasatinib IC50 of 16 nM vs 1.34 nM in wildtype and higher imatinib IC50 of >10,000 nM vs 323 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6210	2340	4	9	133738343	133738343	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6210	https://civic.genome.wustl.edu/links/variants/2340	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Dasatinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 4 of these clones had E255K mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the E255K mutation in the ABL1 region of the BCR-ABL fusion was generated. The E255K variants was associated with higher dasatinib IC50 of 13 nM vs 1.34 nM in wildtype and higher imatinib IC50 of 8,400 nM vs 323 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6214	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6214	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 10 of these clones had F317L mutations. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6215	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6215	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an V299L mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6216	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6216	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317I mutation.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	6217	1625	4	9	133748288	133748288	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6217	https://civic.genome.wustl.edu/links/variants/1625	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317S	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317S mutation.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	6218	2343	4	9	133748289	133748289	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6218	https://civic.genome.wustl.edu/links/variants/2343	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using 50 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an Q252H mutation.	15705718	PubMed		Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.		1	accepted	6219	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6219	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Clear cell renal cell carcinoma,Hemangioblastoma,Pancreatic endocrine tumor			Diagnostic	Supports	C	Positive	A case report of a 51Y male patient presenting with headaches and a family history of VHL disease revealed multiple CNS Hemangioblastomas, bilateral ccRCC, pheochromocytoma, and a pancreatic neuroendocrine tumour. A germline mutation of p.Arg167Trp was confirmed in the patient's VHL gene. ACMG: PM1, PP1, PP4	29396065	PubMed		Taylor et al., 2018, J Clin Neurosci		3	accepted	6222	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/6222	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	C	Resistance	In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 greater than 150 nM. In patients with E255K and/or E255V mutations prior to nilotinib treatment, complete hematological responses were achieved in 5 of 7 patients, major cytogenetic responses in 3 of 7 patients, complete cytogenetic responses in 0 of 7 patients, and a major molecular response in 1 of 7 patients. After a median follow-up of 15.5 months, 6 of 7 patients with this mutation progressed or died. The E255K mutation was present in 6 patients at baseline and newly emerged in 4 patients at progression. The E255V mutation was present in 0 patients at baseline and newly emerged in 3 patients at progression.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6232	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6232	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6233	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6233	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 400 nM imatinib + 10 nM dasatinib (10 clones, ~91%), 2 M imatinib + 50 nM dasatinib (8 clones, 100%), and 4 M imatinib + 100 nM dasatinib (8 clones, 100%) combination treatments.	16772610	PubMed		Bradeen et al., 2006, Blood		3	accepted	6234	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6234	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Nilotinib,Dasatinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 50 nM nilotinib + 10 nM dasatinib (7 clones, 100% of viable clones in this treatment), 1 M nilotinib + 50 nM dasatinib (9 clones, 100%), and 2 M nilotinib + 100 nM dasatinib (2 clones, 100%) combination treatments.	16772610	PubMed		Bradeen et al., 2006, Blood		3	accepted	6235	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6235	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 2 (~11%) were found to have L248V mutations.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6236	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6236	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 5 (~26%) were found to have Y253H mutations.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6237	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6237	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F311L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an F311L mutation.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6238	1528	4	9	133748270	133748270	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6238	https://civic.genome.wustl.edu/links/variants/1528	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 7 (~37%) were found to have F359C mutations.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6239	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6239	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396P	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an H396P mutation.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6240	1531	4	9	133750356	133750356	A	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/6240	https://civic.genome.wustl.edu/links/variants/1531	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. Of the 11 clones that grew in a combination of 400 nM imatinib and 10 nM dasatinib, 1 (9%) was found to have a V299L mutation.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6241	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6241	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M244V mutation was associated with resistance in 2 M imatinib (1 clone recovered, 0.71%). In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6242	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/6242	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248R	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The L248R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~1%) and 8 M imatinib (1 clone, ~2%). In a review of 20 publications, this mutation had not been described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6243	2340	4	9	133738343	133738343	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6243	https://civic.genome.wustl.edu/links/variants/2340	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6244	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6244	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6245	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6245	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL D276G	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The D276G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6246	1027	4	9	133747520	133747520	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6246	https://civic.genome.wustl.edu/links/variants/1027	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V299L mutation was associated with resistance in 10 nM dasatinib (3 clone recovered, ~5%). No clones were recovered in 5 nM dasatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6247	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6247	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317C	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317C mutation was associated with resistance in 5 nM dasatinib (1 clone recovered, ~ 3%) and 10 nM dasatinib (6 clones, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6250	2359	4	9	133748289	133748289	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6250	https://civic.genome.wustl.edu/links/variants/2359	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317I mutation was associated with resistance in 5 nM dasatinib (2 clone recovered, ~ 6%) and 10 nM dasatinib (10 clones, ~18%).	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6251	1625	4	9	133748288	133748288	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6251	https://civic.genome.wustl.edu/links/variants/1625	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317L mutation was associated with resistance in 2 M imatinib (2 clones recovered, ~1%), 5 nM dasatinib (6 clones, ~ 17%), and 10 nM dasatinib (4 clones, ~7%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6252	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6252	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317V mutation was associated with resistance in 5 nM dasatinib (1 clone recovered,  ~ 3%) and 25 nM dasatinib (1 clone, ~3%). No clones were recovered at 10 nM dasatinib.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6253	1525	4	9	133748288	133748288	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6253	https://civic.genome.wustl.edu/links/variants/1525	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M351T mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6254	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/6254	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E355G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6255	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/6255	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F359V mutation was associated with resistance in 2 M imatinib (3 clones recovered, ~2%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6256	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6256	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V379I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V379I mutation was associated with resistance in 2 M imatinib (2 clones recovered, ~1%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6257	1609	4	9	133750304	133750304	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6257	https://civic.genome.wustl.edu/links/variants/1609	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The H396R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%) and 4 M imatinib (1 clone, ~0.74%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6258	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6258	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
AKT1	207	OVEREXPRESSION	Melanoma	1909		Vemurafenib		Predictive	Does Not Support	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wild-type AKT1 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT1 (via viral transduction with additional copies of AKT1) were not significantly more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors, which served as the negative controls.	24265155	PubMed		Shi et al., 2014, Cancer Discov		3	accepted	6259	2360	2														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6259	https://civic.genome.wustl.edu/links/variants/2360	https://civic.genome.wustl.edu/links/genes/2
AKT1	207	Q79K	Melanoma	1909		Dabrafenib		Predictive	Supports	C	Resistance	In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600Kno other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy.	24265155	PubMed		Shi et al., 2014, Cancer Discov		4	accepted	6260	169	2	14	105243048	105243048	G	T	ENST00000407796.2					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/6260	https://civic.genome.wustl.edu/links/variants/169	https://civic.genome.wustl.edu/links/genes/2
AKT3	10000	OVEREXPRESSION	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT3 (via viral transduction of additional copies of wild type AKT3) were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with empty vectors (30% vs 20% survival, p = .0064).	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6261	1301	7936														Somatic	2021-03-31 18:22:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/6261	https://civic.genome.wustl.edu/links/variants/1301	https://civic.genome.wustl.edu/links/genes/7936
BRAF	673	V600E/K and AMPLIFICATION	Melanoma	1909		Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6262	2361	5														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6262	https://civic.genome.wustl.edu/links/variants/2361	https://civic.genome.wustl.edu/links/genes/5
NRAS	4893	MUTATION	Melanoma	1909		Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6263	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/6263	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36
KRAS	3845	MUTATION	Melanoma	1909		Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6264	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/6264	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
PIK3R2	5296	OVEREXPRESSION	Melanoma	1909		Vemurafenib		Predictive	Does Not Support	D	Resistance	An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3R2 (via viral transduction with additional copies of wildtype PIK3R2) were not significantly more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors, which served as the negative controls.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6266	2363	4290														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6266	https://civic.genome.wustl.edu/links/variants/2363	https://civic.genome.wustl.edu/links/genes/4290
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6267	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6267	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
PREX2	80243	R172I	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown.	24265155	PubMed		Shi et al., 2014, Cancer Discov		4	accepted	6268	2364	15344														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6268	https://civic.genome.wustl.edu/links/variants/2364	https://civic.genome.wustl.edu/links/genes/15344
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317L mutation was associated with resistance in 2 M imatinib (2 clones recovered, ~1%), 5 nM dasatinib (6 clones, ~ 17%), and 10 nM dasatinib (4 clones, ~7%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6270	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6270	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
PTEN	5728	LOSS	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via lentiviral transduction of shPTEN) were more resistant to vemurafenib (a BRAF inhibitor) than cells expressing wildtype PTEN. Lentiviral mediated reintroduction of PTEN restored vemurafenib sensitivity in WM2664, a vemurafenib resistant, PTEN non-expressing and BRAF V600D mutated human melanoma cell line.	24265155	PubMed		Shi et al., 2014, Cancer Discov		4	accepted	6271	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6271	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
NRG1	3084	NRG1 FUSIONS	Pancreatic Adenocarcinoma	4074		Afatinib		Predictive	Supports	C	Sensitivity/Response	In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in two patients with NRG1-rearranged tumors that had proved resistant to standard treatment. One patient (30) was treated with afatinib monotherapy and showed improvement at 7 weeks, followed by progression at 3 months after necessary dose reduction.	29802158	PubMed		Heining et al., 2018, Cancer Discov		4	accepted	6273	2286	2593													NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6273	https://civic.genome.wustl.edu/links/variants/2286	https://civic.genome.wustl.edu/links/genes/2593
ABL1	25	BCR-ABL Q252H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6274	1024	4	9	133738356	133738356	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6274	https://civic.genome.wustl.edu/links/variants/1024	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	AMPLIFICATION	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3CA (via viral transduction with additional copies of wild type PIK3CA) were significantly more resistant to vemurafenib (a BRAFi) than cells transduced with an empty vector (30% vs 20% survival, p < .0001). Though statistics were not provided, it appears that amplification of wildtype PIK3CA confers less resistance than the positive control variant, PIK3CA E545K.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6275	212	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6275	https://civic.genome.wustl.edu/links/variants/212	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E255K mutation was associated with resistance in 16 M imatinib ( 1 clone recovered, ~3%) and all lower concentrations as well as in 50 nM nilotinib (5 clones, ~11%) and 5 nM dasatinib (2 clones, ~6%), the lowest concentrations tested for these two drugs. In a review of 20 publications, this mutation was described in imatinib resistant patients.	16772610	PubMed		Bradeen et al., 2006, Blood		2	accepted	6282	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6282	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 16 M imatinib ( 15 clones, 45% of viable clones in this treatment), 5000 nM nilotinib (10 clones, 100%), and 25 nM dasatinib (32 clones, 100%) which were the highest concentrations used. T315I resistant clones were also found at all lower concentrations tested.	16772610	PubMed		Bradeen et al., 2006, Blood		3	accepted	6285	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6285	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
VHL	7428	3p26.3-25.3 11Mb del	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Diagnostic	Supports	C	Positive	A case report of a woman with de novo 3p deletion syndrome (encompassing the VHL gene) was associated with cerebellar hemangioblastoma at the age of 16 years old. This is the first report of a patient with 3p- with cerebral hemangioblastoma that may be associated with VHL disease. ACMG: PVS1, PS2, PP4	26365017	PubMed		Suzuki-Muromoto et al., 2016, Brain Dev.		3	accepted	6287	2367	58														Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6287	https://civic.genome.wustl.edu/links/variants/2367	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma			Diagnostic	Supports	C	Positive	74-year-old man admitted to the  Department of Neurosurgery at Yonsei University College of Medicine was found carry a p.Glu70Lys VHL gene mutation and presented with colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS. Patient's mother suffered from a brain tumor of unconfirmed pathology, and both brothers  (79Y and 70Y) presented with renal cell carcinoma and the same VHL gene mutation. One of the patient's son tested positive for the mutation without any clinical manifestations of disease. ACMG:PP2, PP1, PP4	25715769	PubMed		Heo et al., 2016, Cancer Res Treat		3	accepted	6288	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/6288	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Pancreatic cysts,Multiple renal cysts,Retinal capillary hemangioma,Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	A male patient with Type 1 VHL disease  presented with vision loss and retinal angiomatosis in the right eye at 19Y, left retinal angiomatosis at 23Y as well as CNS hemangioblastomas, neuroendocrine tumor of the pancreas which metastases to the liver, and renal tumors at 25Y. Patient was found to carry c.233A>G (p.Asn78Ser) mutation in the VHL gene. Patient had a positive family history of VHL clinical manifestations, although the genotype of affected family members was not confirmed. His mother presented with pancreatic and renal cysts at 37Y and retinal angiomatosis at 47Y. Patient's grandmother suffered from loss of vision  in her 30s, and renal cancer and brain tumour at 58Y. ACMG: PP2, PP4	26984080	PubMed		Kobayashi et al., 2016, Intern. Med.		2	accepted	6289	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/6289	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
KRAS	3845	G12/G13	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and post treatment progression free survival (PFS) and overall survival (OS). Of the 168 patients, 106 had wildtype KRAS and 62 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. Regardless of first line chemotherapy regimen or use of monoclonal antibody treatment, patients with KRAS-mutated tumors did not have a significantly worse outcome than patients with wtKRAS tumors,  as evidenced by non-significant differences in PFS (12.3 vs 11.8 months, respectively) and OS (35.8 and 40.5 months, respectively).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6292	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6292	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256		Oxaliplatin		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 61 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype KRAS, as evidenced by a nonsignificant difference in PFS (11.7 and 11.4 months, respectively).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6293	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6293	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256		Irinotecan		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between KRAS mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 26 had wildtype KRAS and 18 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype KRAS. The difference in PFS between patients with KRAS-mutated tumors and the patients with wtKRAS tumors was nonsignificant (PFS: 13.7 and 12.0 months; p= 0.074).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6294	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6294	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256		Bevacizumab		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between KRAS mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 58 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype KRAS, as evidenced by a non-significant difference in PFS between the two groups (12.1 and 11.7 months, respectively).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6295	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6295	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between KRAS mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 60 had wildtype KRAS and 32 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were trending toward resistance to cetuximab-containing salvage chemotherapy as compared to patients with wildtype KRAS (p=0.094). Note: while differences in PFS were nonsignificant between patients with wildtype or mutant KRAS, differences in objective response (defined as reduction by at least 30% in the sum of the longest diameters of target lesions compared to baseline) were significantly different. Of the 32 patients with mutant KRAS, none responded to cetuximab-containing salvage therapy, while 14/60 of the patients with wildtype KRAS (23%) responded (p=.002).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6296	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6296	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	MUTATION	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and post treatment PFS. Of 168 patients, 142 had wildtype PIK3CA and 26 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation did not have a significantly worse outcome than patients expressing wildtype PIK3CA, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment.	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6297	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6297	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Oxaliplatin		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 81 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups (10.7 and 11.7 months, respectively).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6298	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6298	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Irinotecan		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between PIK3CA mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 40 had wildtype PIK3CA and 4 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups.	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6299	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6299	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Bevacizumab		Predictive	Does Not Support	B	Resistance	This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between PIK3CA mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 83 had wildtype PIK3CA and 14 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups.	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6300	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6300	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between PIK3CA mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 79 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype PIK3CA (Median PFS: 2.5 and 3.9 months, respectively; p = .014).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6301	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6301	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment PFS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median PFS: 4.3 and 12.5 months, respectively; p <.0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6302	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6302	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256		Oxaliplatin		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 94 had wildtype BRAF and 6 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype BRAF (Median PFS: 5.0 and 11. 7 months, respectively; p < .0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6303	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6303	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6304	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6304	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256		Bevacizumab		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between BRAF mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients,89 had wildtype BRAF and 8 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype BRAF (Median PFS: 4.2 and 12.5 months, respectively; p < .0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6305	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6305	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between BRAF mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 83 had wildtype BRAF and 9 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype BRAF (Median PFS: 2.0 and 3.9, respectively; p = .0005).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6306	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6306	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment OS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median OS: 10.9 and 40.5 months, respectively; p <.0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6307	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6307	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 15 patients with L248V mutations, 6, 10, and 15 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	6308	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/6308	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 14 patients with F317L mutations, 1, 2, and 13 achieved CCyR, MCyR, and CHR to dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. Despite high CHR in patients with the F317L variant, of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance or lower levels of response to dasatinib due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these three variants.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	6309	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6309	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E459K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with the E459K mutations, 4, 6, and 11 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	6310	2370	4	9	133753906	133753906	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6310	https://civic.genome.wustl.edu/links/variants/2370	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	TKD MUTATION	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, imatinib-resistant patients with and without ABL1 mutation  had comparable complete hematologic response [CHR= 90% (345/384) vs. 93% (390/421)], major cytogenetic response [MCyR= 56% (211/384) vs. 58% (243/421)], complete cytogenetic response [CCyR= 43% (164/384) vs. 47% (196/421)], and major molecular response [MMR= 31% (115/367) vs. 36% (145/404)]. Of the 63 imatinib-resistant variants observed (see comment), the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. However, F317L does have a high CHR. They suggest considering alternative treatment options for patients with these three variants.	19779040	PubMed		Mller et al., 2009, Blood	NCT00101660,NCT00103844,NCT00123474	3	accepted	6311	2371	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6311	https://civic.genome.wustl.edu/links/variants/2371	https://civic.genome.wustl.edu/links/genes/4
KRAS	3845	G13V	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G13V was the only variant noted in the primary colon tumor of one patient who experienced disease progression (Patient 4; Supplemental Table 1) following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6312	1517	30	12	25398280	25398281	GC	AA	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6312	https://civic.genome.wustl.edu/links/variants/1517	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12S	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G12S was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment (colon tumor of patient 20; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6314	913	30	12	25398285	25398285	C	T	ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6314	https://civic.genome.wustl.edu/links/variants/913	https://civic.genome.wustl.edu/links/genes/30
PTEN	5728	LOSS	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a significant association between PTEN protein expression loss and lack of response to panitumumab or cetuximab (P = 0.0012). Patients with PTEN non-expressing tumors (32/80) had shorter overall survival, compared to those with PTEN expressing tumors (P = 0.0048), though they had a nonsignificant difference in progression free survival (p = .0681).  PIK3CA, PTEN, and KRAS were evaluated for mutations; PTEN loss was the only variant noted in 17 of the patients who experienced either stable disease or disease progression, while the other patients experienced PTEN loss in combination with a KRAS or PIK3CA mutation.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	6315	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6315	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
KRAS	3845	G12D	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12D was the only variant noted in the primary tumor of two patients who experienced stable disease  following treatment (Patients 22 and 36; colon and rectum tumors; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6316	79	30	12	25398284	25398284	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6316	https://civic.genome.wustl.edu/links/variants/79	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	AMPLIFICATION	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype KRAS4a or KRAS4b (via viral transduction with additional copies of KRAS4a or KRAS4b) were more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors. Resistance was determined by assessing cell survival.	24265155	PubMed		Shi et al., 2014, Cancer Discov		2	accepted	6317	592	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6317	https://civic.genome.wustl.edu/links/variants/592	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12A	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12A was the only variant noted in the both the primary and metastatic colon tumors of one patient (Patient 29; Supplemental table 1) , and the primary colon tumor of another patient (104; Table S1),  who both experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6319	148	30	12	25398284	25398284	C	G	ENST00000256078.4					75	GRCh37	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6319	https://civic.genome.wustl.edu/links/variants/148	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Does Not Support	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G13D was the only variant noted in the primary colon tumors of two patients who experienced partial response following treatment (Patients 37, 47; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6320	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/6320	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6322	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic	2021-03-31 18:23:17 UTC	https://civic.genome.wustl.edu/links/evidence_items/6322	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	G12V	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12V was the only variant noted in the primary rectal tumor of one patient who experienced disease progression (patient 56; Supplemental Table 1), and the primary colon tumors of two patients (9, 13; Supplemental Table 1) who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		2	accepted	6323	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6323	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30
VHL	7428	c.128-?_250+?	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Renal cyst,Hemangioblastoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Eleven RCCs and 16 renal cysts from eight patients with VHL were analyzed. All patients had known germline VHL mutations. One male patient had a germline deletion (c.128?_250+?) in the VHL gene and presented with bilateral RCC and cysts, CNS hemangioblastoma, and pancreatic cysts. Family history was not described for the patient.	15709172	PubMed		Lee et al., 2005, Clin. Cancer Res.		2	accepted	6329	2373	58														Rare Germline	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6329	https://civic.genome.wustl.edu/links/variants/2373	https://civic.genome.wustl.edu/links/genes/58
ABL1	25	TKD MUTATION	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with Abl1 mutation versus without [CHR = 33/34 vs. 27/27; MCyR = 41/59 (69%) vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	3	accepted	6335	2371	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6335	https://civic.genome.wustl.edu/links/variants/2371	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	P-Loop Mutation	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with P-loop mutations versus patients without Abl1 mutations [ CHR = 9/9 vs. 27/27; MCyR = 7/10 vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	3	accepted	6336	2375	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6336	https://civic.genome.wustl.edu/links/variants/2375	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Non-P-Loop Mutation	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with non-P-loop mutations versus patient without Abl1 mutations [ CHR = 22/23 (96%) vs. 27/27; MCyR = 26/39 (67%) vs. 19/35 (54%)]. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I.	21865346	PubMed		Cortes et al., 2011, Blood	NCT00261846	3	accepted	6337	2376	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6337	https://civic.genome.wustl.edu/links/variants/2376	https://civic.genome.wustl.edu/links/genes/4
BRCA1	672	MUTATION	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 14 had germline BRCA1 mutation, 13 of which were homozygous mutation and one with unknown zygosity. Confirmed objective response was seen in 86% (12/14) of the germline BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344	3	accepted	6341	185	6	17	41196312	41277387			ENST00000357654.3					75	GRCh37		Rare Germline	2021-03-31 18:22:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/6341	https://civic.genome.wustl.edu/links/variants/185	https://civic.genome.wustl.edu/links/genes/6
ABL1	25	TKD MUTATION	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Does Not Support	B	Resistance	In this open-label, phase II registration trial, patients that were imatinib resistant (n = 192) or intolerant (n = 89) underwent nilotinib monotherapy. Prior to nilotinib treatment, 105 and 9 patients with baseline BCR-ABL mutations were imatinib resistant and intolerant, respectively. Within 12 months of therapy, among patients with baseline mutations, complete hematologic response was achieved in 57 (71%) of 80 [vs. 35 (80%) of 80 Abl1 wildtype patients, P = .393], major cytogenetic response in 49 of 100 [vs. 52 (60%) of 87, P = .145], complete cytogenetic response in 32 of 100 [vs. 35 (40%) of 87, P = .285], and major molecular response in 19 (22%) of 87 [vs. 22 (29%) of 76, P = .366]. These data shows no significant difference in nilotinib efficacy between patients with baseline mutations in the Abl1 kinase domain versus without. The authors observe clinical efficacy of nilotinib for many of the 29 variants found and identify only Y253H, E255K/V, and F359C/V as resistance conferring variants with IC50 greater than 150 nM. Individuals with T315I variants (3% of total population) were excluded.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6342	2371	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6342	https://civic.genome.wustl.edu/links/variants/2371	https://civic.genome.wustl.edu/links/genes/4
BRCA2	675	MUTATION	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 6 had germline homozygous BRCA2 mutation. Confirmed objective response was seen in 83% (5/6) of the germline BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).	27908594	PubMed		Swisher et al., 2017, Lancet Oncol.	NCT01891344	3	accepted	6343	186	7	13	32889611	32973347			ENST00000380152.3					75	GRCh37		Rare Germline	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6343	https://civic.genome.wustl.edu/links/variants/186	https://civic.genome.wustl.edu/links/genes/7
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	37 Danish patients diagnosed with VHL before 18 years from a prospective cohort study from Denmark's National vHL Research Database (Binderup et al., 2013) were assessed. Two families  (Family ID 9 and 13) were found with a germline missense mutation in the VHL gene (S65W; c.194C>G). Family ID9 had 3 patients: Patient 1 and 2 were both diagnosed at 0Y and had no manifestations by the end of the study at 5Y and 10Y respectively. Patient 3 was diagnosed at 16Y and developed 2 CNS hemangioblastomas at 16Y and 2 pancreatic cysts at 16Y. Family ID13 had 1 patient who was diagnosed at age 13Y and had 8 retinal hemangioblastomas at 13Y, 16Y, 17Y, and 18Y, 1 pancreatic cyst at 17Y, and 1 CNS hemangioblastoma at 17Y.  ACMG codes: PM1, PM5, PS3; and PP5.	28650583	PubMed		Launbjerg et al., 2017, Am. J. Med. Genet. A		3	accepted	6352	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6352	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, PIK3CA mutations (H1047R or E545K) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 0/15 vs 22/95 for patients harboring PIK3CA mutated or wildtype tumors, respectively; P = 0.038). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of PIK3CA mutation on objective response (P = 0.0337; OR = 0.1153; CI for OR: 0.0000.865). Patients with tumors harboring either PIK3CA H1047R or E545K mutations (15/109) had decreased PFS, compared to those with wild-type tumors (P = 0.0035), though they had a nonsignificant difference in OS. Authors note a trend in decreasing OS in patients with PIK3CA mutated tumors.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	6362	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6362	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, KRAS mutations (G12V, G12S, G12D, G12A, G13V, G13D) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 2/32 vs 20/77 for patients harboring KRAS mutated or wildtype tumors, respectively; P = 0.019). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of KRAS mutations on objective response (p = 0.0029). Authors noted that patients with tumors harboring KRAS mutations (32/108) tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.	19223544	PubMed		Sartore-Bianchi et al., 2009, Cancer Res.		3	accepted	6363	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6363	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30
PIK3CA	5290	MUTATION	Colorectal Cancer	9256		Aspirin		Predictive	Supports	B	Sensitivity/Response	This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803)  and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). This study found thatamong patients with mutated PIK3CA cancer regular use of aspirin following diagnosis was correlated with superior colorectal cancer specific survival (multivariate hazard ratio, 0.18; 95% CI, 0.06-0.61; P<0.001) and overall survival (multivariate hazard ratio, 0.54; 95% CI, 0.31-0.94; P = 0.01). Conversely, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with colorectal cancerspecific survival or overall survival. Among patients with mutated-PIK3CA tumors, 23 of 90 patients who did not use aspirin after diagnosis (26%) died within 5 years after diagnosis, whereas only 2 of 62 regular users of aspirin after diagnosis (3%) died within 5 years after diagnosis (P<0.001). In contrast, among patients with wild-type PIK3CA tumors, the 5-year cumulative colorectal cancerspecific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92). The authors conclude that PIK3CA mutation may predict response to aspirin therapy in patients with newly diagnosed colorectal cancer.	23094721	PubMed		Liao et al., 2012, N. Engl. J. Med.		3	accepted	6375	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6375	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	R351W	Lung Non-small Cell Carcinoma	3908		Imatinib		Predictive	Supports	D	Sensitivity/Response	In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses.	26758680	PubMed		Testoni et al., 2016, EMBO Mol Med		5	accepted	6376	1656	4	9	133748333	133748333	C	T	ENST00000372348.2					75	GRCh37		Somatic	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/6376	https://civic.genome.wustl.edu/links/variants/1656	https://civic.genome.wustl.edu/links/genes/4
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs harbored KIT exon 11 mutations (n=19) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 9 mutations.  15/19 patients with exon 11 mutant GISTs experienced clinical benefit (including 2 PRs). KIT exon 11 mutant GISTs treated with regorafenib monotherapy were associated with improved median progression free survival (13.4 months vs. 5.7 and 1.6 months, P<0.0001), as compared to patients with KIT exon 9 mutation (n=2) and patients with KIT wildtype, non-succinate dehydrogenase-deficient tumors (n=2).	27371698	PubMed		Ben-Ami et al., 2016, Ann. Oncol.	NCT01068769	3	accepted	6377	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/6377	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29
CSF3R	1441	T618I	Chronic Neutrophilic Leukemia	0080187		Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition.	24081659	PubMed		Fleischman et al., 2013, Blood		4	accepted	6380	2387	1239														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6380	https://civic.genome.wustl.edu/links/variants/2387	https://civic.genome.wustl.edu/links/genes/1239
CSF3R	1441	T618I	Chronic Neutrophilic Leukemia	0080187		Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms.	25180155	PubMed		Dao et al., 2014, Leuk Res Rep	NCT02092324	4	accepted	6381	2387	1239														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6381	https://civic.genome.wustl.edu/links/variants/2387	https://civic.genome.wustl.edu/links/genes/1239
CALR	811	MUTATION	Essential Thrombocythemia	2224				Diagnostic	Supports	A	Positive	Diagnostic criterion for essential thrombocytemia according to the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues 2016.	27069254	PubMed		Arber et al., 2016, Blood		5	accepted	6382	2388	732														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6382	https://civic.genome.wustl.edu/links/variants/2388	https://civic.genome.wustl.edu/links/genes/732
NTRK1	4914	NTRK1-TRIM63	Melanoma	1909	Melanoma	Larotrectinib		Predictive	Supports	E	Sensitivity/Response	In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-TRIM63 fusion occurred in a 63 yo man with a nodular melanoma with the primary tumor on the shin and skin and lymph node metastases. No known melanoma drivers were identified as co-occurring in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma.	29683819	PubMed		Lezcano et al., 2018, Am. J. Surg. Pathol.		2	accepted	6392	2393	3983														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/6392	https://civic.genome.wustl.edu/links/variants/2393	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	NTRK1-DDR2	Melanoma	1909	Melanoma	Larotrectinib		Predictive	Supports	E	Sensitivity/Response	In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-DDR2 fusion occurred in a 55 yo woman with a nodular melanoma. Her primary tumor was umbilical with a metastasis to the colon. NF1 truncation and RAC1 p295 were identified as co-occurring melanoma drivers in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma.	29683819	PubMed		Lezcano et al., 2018, Am. J. Surg. Pathol.		2	accepted	6393	2394	3983														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/6393	https://civic.genome.wustl.edu/links/variants/2394	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	NTRK1-GON4L	Melanoma	1909		Larotrectinib		Predictive	Supports	E	Sensitivity/Response	In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1 (TRIM63, DDR2, and GON4L), 1 involving NTRK2 (TRAF2). All tumors were cytologically characterized by the presence of large epithelioid melanocytes and were immunoreactive with anti-Trk antibody. The NTRK1-GON4L fusion occurred in a 36 yo woman with a nodular melanoma. Her primary tumor was on her back with a metastasis to the duodenum. NRAS Q61L was identified as a co-occurring melanoma driver in this patient. Thus, the presence of an NTRK family fusion in nonspitzoid metastasizing melanomas of adults may provide a therapeutic opportunity for NTRK inhibitors such as larotrectinib in a small subset of patients with metastatic melanoma.	29683819	PubMed		Lezcano et al., 2018, Am. J. Surg. Pathol.		2	accepted	6394	2395	3983														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6394	https://civic.genome.wustl.edu/links/variants/2395	https://civic.genome.wustl.edu/links/genes/3983
NTRK2	4915	ETV6-NTRK2	Acute Myeloid Leukemia	9119	Hematological neoplasm	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. In this manuscript, TRK fusions were screened for in 7,311 patients with a variety of hematologic malignancies. Overall, 8 TRK-fusions were identified including 1 ETV6-NTRK2 fusion in a patient with acute myeloid leukemia (AML) Treatment with TRK-Inhibitor larotrectinib led to a partial Response in an AML patient with ETV6-NTRK2 fusion after sucessful xenograft studies.	29920189	PubMed		Taylor et al., 2018, J. Clin. Invest.		4	accepted	6396	2396	3984														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6396	https://civic.genome.wustl.edu/links/variants/2396	https://civic.genome.wustl.edu/links/genes/3984
BRAF	673	intron 10 rearrangement	Melanoma	1909		Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.	24265155	PubMed		Shi et al., 2014, Cancer Discov		3	accepted	6400	2226	5														Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6400	https://civic.genome.wustl.edu/links/variants/2226	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	intron 9 rearrangement	Melanoma	1909		Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.	24265155	PubMed		Shi et al., 2014, Cancer Discov		3	accepted	6401	2225	5														Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/6401	https://civic.genome.wustl.edu/links/variants/2225	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594K	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Resistance	The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6402	2398	5														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6402	https://civic.genome.wustl.edu/links/variants/2398	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594K	Colorectal Cancer	9256		Oxaliplatin		Predictive	Supports	B	Resistance	Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).	19603024	PubMed		Souglakos et al., 2009, Br. J. Cancer		3	accepted	6403	2398	5														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6403	https://civic.genome.wustl.edu/links/variants/2398	https://civic.genome.wustl.edu/links/genes/5
FGFR3	2261	FGFR3-TACC3	Transitional Cell Carcinoma	2671		Infigratinib		Predictive	Supports	B	Sensitivity/Response	In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response.	29848605	PubMed		Pal et al., 2018, Cancer Discov		3	accepted	6409	830	23	4	1795039	1808661			ENST00000340107.4	4	1741429	1746898	ENST00000313288.4	75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/6409	https://civic.genome.wustl.edu/links/variants/830	https://civic.genome.wustl.edu/links/genes/23
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and six patients with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		4	accepted	6416	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6416	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	A122I (c.364_365GC>AT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This mutation was found in the VHL gene and one patient with pheochromocytoma.	12000816	PubMed		Neumann et al., 2002, N. Engl. J. Med.		3	accepted	6417	2028	58	3	10188221	10188222	GC	AT	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/6417	https://civic.genome.wustl.edu/links/variants/2028	https://civic.genome.wustl.edu/links/genes/58
IDH1	3417	R132	Intrahepatic Cholangiocarcinoma	4928		Dasatinib		Predictive	Supports	D	Sensitivity/Response	Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib,  identifying SRC as a critical dasatinib target in IDHm ICC. Dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression.	27231123	PubMed		Saha et al., 2016, Cancer Discov		4	accepted	6439	58	26	2	209113111	209113113			ENST00000415913.1					75	GRCh37	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6439	https://civic.genome.wustl.edu/links/variants/58	https://civic.genome.wustl.edu/links/genes/26
STK11	6794	MUTATION	Lung Adenocarcinoma	3910		Nivolumab,Pembrolizumab,Atezolizumab	Substitutes	Predictive	Supports	B	Resistance	In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.	29773717	PubMed		Skoulidis et al., 2018, Cancer Discov		4	accepted	6441	715	5534	19	1205740	1223074			ENST00000326873.7					75	GRCh37		Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/6441	https://civic.genome.wustl.edu/links/variants/715	https://civic.genome.wustl.edu/links/genes/5534
SDHB	6390	p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC)	Paraganglioma	0050773				Predisposing	Supports	C	Uncertain Significance	An in-frame duplication of 12 nucleotides resulting in the insertion of 4 amino acids within exon 6 of the SDHB gene was found in a single female case (a 13-year-old) with confirmed paraganglioma. The patient also exhibited refractory hypertension, sweating and headaches, and elevated norepinephrine concentrations in plasma and urine. The same mutation was in four other family members with no evidence of disease.	20193854	PubMed		Musil et al., 2010, Cancer Genet. Cytogenet.		2	accepted	6442	2411	5177	1	17350521	17350522		GCAGCTGGTGCT	ENST00000375499.3					75	GRCh37	ClinGen Canonical Allele Identifier: CA658820851	Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/6442	https://civic.genome.wustl.edu/links/variants/2411	https://civic.genome.wustl.edu/links/genes/5177
H3-3A	3020	K27M	Diffuse Intrinsic Pontine Glioma	0080684				Diagnostic	Supports	B	Positive	Wu et al analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs) by whole genome, whole exome, and/or transcriptome sequencing. In addition to ACVR1, they identified 41 recurrent K27M mutations in H3F3A (H3.3, 41/112 = 36.6%), and in 14 HIST1H3B (H3.1, 14/112, 12.5%) in NBS-HGGs and DIPGs. The authors focus on ACVR1 mutations, as H3F3A and HIST1H3A mutations in pediatric gliomas have previously been reported. However, this evidence helps confirm potential diagnostic utility of H3F3A K27M mutations.	24705251	PubMed		Wu et al., 2014, Nat. Genet.		3	accepted	6450	2416	2537														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6450	https://civic.genome.wustl.edu/links/variants/2416	https://civic.genome.wustl.edu/links/genes/2537
H3-3A	3020	K27M	Diffuse Intrinsic Pontine Glioma	0080684				Diagnostic	Supports	B	Positive	Wu et al performed whole genome sequencing of 7 [diffuse intrinsic pontine gliomas] DIPGs and matched germline DNA, and targeted sequencing of an additional 43 DIPGs and 36 non-brainstem paediatric [pediatric] glioblastomas (non-BS-PGs).  They identified 30/50 (60%) K27M mutations in pediatric DPIGs and 7/36 (19%) pediatric non-brainstem glioblastomas. [See Table 1]. The authors comment that the K27M mutation appeared exclusive to pediatric high grade gliomas, stating "The identified alterations in histone H3 appear to be exclusive to paediatric high-grade gliomas. We also detected H3F3A p.K27M mutation in one of 9 paediatric anaplastic astrocytomas (Grade III), but no mutations in any of the 16 histone H3 genes were detected in other paediatric brain tumours including 7 low-grade brainstem gliomas evaluated by targeted Sanger sequencing, or in whole genome sequence data from 15 low-grade non-brainstem gliomas, 38 medulloblastomas, and 22 ependymomas, nor in an additional 170 non-central nervous system paediatric tumours."	22286216	PubMed		Wu et al., 2012, Nat. Genet.		3	accepted	6453	2416	2537														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6453	https://civic.genome.wustl.edu/links/variants/2416	https://civic.genome.wustl.edu/links/genes/2537
H3-3B	3021	K36M	Chondroblastoma	2649				Diagnostic	Supports	B	Positive	Behjati et al identified K36M mutations in a set of 77 chondroblastomas. Chondroblastoma is a typically a pediatric or early adult cancer. Of the 77, 5 had K36M mutations in H3F3A, 68 had K36M in H3F3B and 4 were WT. Of the 77, 65 of the cases were 25 years old or less. Of those, 3 had K36M in H3F3A and 59 had K36M in H3F3B with 3 being WT (See Supplementary Table 1).  Thus, 59/65 (90.7%) cases at age 25 or less had K36M mutations in H3F3B. Behjati et al screened over 268 other bone and cartilage tumor types, and identified only 1 K36M H3F3B mutation (a clear cell chondrosarcoma). The authors conclude discussing the remarkable specificity of these  mutations and implications for immediate diagnostic utility.	24162739	PubMed		Behjati et al., 2013, Nat. Genet.		4	accepted	6463	2420	2538														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6463	https://civic.genome.wustl.edu/links/variants/2420	https://civic.genome.wustl.edu/links/genes/2538
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Retinal capillary hemangioma,Epididymal cyst			Predisposing	Supports	C	Uncertain Significance	A 33 year old Asian male patient presented with advanced bilateral multicentric renal carcinoma. Genetic testing confirmed a de novo missense variant at c.194C>G of the VHL gene. The patient was diagnosed with an epididymal cyst at age 23, bilateral retinal angiomatosis at age 26, and bilateral clear cell renal cell carcinoma at age 33. ACMG codes:PM1; PM5; and PP4.	26622630	PubMed		Zhang et al., 2015, Oncol Lett		3	accepted	6468	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6468	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
H3-3A	3020	G34W	Bone Giant Cell Tumor	4305				Diagnostic	Supports	B	Positive	Behjati et al queried 53 samples of giant cell tumors of bone, which is a cancer typically identified in young adults, for histone gene variants. They identified 92% (49/53) with histone 3.3 variants exclusively in H3F3A (which were G34W or, in one case, G34L). Of the 53 samples, 12 were aged 25 or less. The authors queried these mutations in 268 other bone and cartilage cancers and did not identify G34W variant in any, although one G34R was identified in an osteosarcoma. The authors discuss these results as having diagnostic utility. Keyword: pediatric	24162739	PubMed		Behjati et al., 2013, Nat. Genet.		4	accepted	6469	2421	2537														Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6469	https://civic.genome.wustl.edu/links/variants/2421	https://civic.genome.wustl.edu/links/genes/2537
NTRK3	4916	ETV6-NTRK3	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosinrelated kinase (TRK) signaling pathway from an ETS variant gene 6neurotrophin 3 receptor gene (ETV6NTRK3) gene fusion. The patient was diagnosed with IFS at 6 months of age. At 16 months the patient enrolled in a pediatric Phase 1 trial of LOXO101 (Larotrectinib, ARRY-470), an experimental, highly selective inhibitor of TRK. The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO101 to provide benefit for IFS harboring NTRK gene fusions.	27093299	PubMed		Nagasubramanian et al., 2016, Pediatr Blood Cancer		2	accepted	6473	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6473	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK3	4916	ETV6-NTRK3	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) had NTRK3-ETV6 fusion oncogenes. The authors compare NTRK3-ETV6 (and include 2 other NTRK fusion samples) to PTCs with BRAF(V) (600E) and find they are associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05), solid and diffuse variants (11 of 13 vs 0 of 13 tumors, respectively; P < .001), and lymphovascular invasion (12 of 13 vs 6 of 13 tumors, respectively; P = .02); The authors conclude that NTRK fusion oncogene PTC presents with more extensive disease and aggressive pathology than BRAF(V) (600E) PTC in the pediatric population.	26784937	PubMed		Prasad et al., 2016, Cancer		3	accepted	6474	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6474	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK3	4916	ETV6-NTRK3	Breast Secretory Carcinoma	4922		Larotrectinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4  8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic driver in this patient.	29623306	PubMed		Shukla et al., 2017, JCO Precis Oncol		3	accepted	6475	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6475	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient age 20Y at the last follow-up had retinal hemangioblastoma and a germline c.208G>A (p.Glu70Lys) mutation in the VHL gene. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		2	accepted	6503	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/6503	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	c.213 ?_463 ?del	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor,Multiple renal cysts,Spinal hemangioblastoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma,Pancreatic cysts			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Four patients were found with this deletion in the VHL gene. Their age at last follow-up was presented as a range, 38Y-48Y and their phenotypes were grouped together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, renal cysts, pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6504	2431	58														Rare Germline	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6504	https://civic.genome.wustl.edu/links/variants/2431	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P81S (c.241C>T)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Pancreatic endocrine tumor,Retinal capillary hemangioma,Multiple renal cysts,Pheochromocytoma			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Two patients were found with this missense mutation in the VHL gene. One patient was 34Y and the other was 59Y at last follow-up. Their phenotypes were grouped together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, pheochromocytoma, and renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6505	1837	58	3	10183772	10183772	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/6505	https://civic.genome.wustl.edu/links/variants/1837	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V87fs (c.259_260insA)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Spinal hemangioblastoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pancreatic cysts,Multiple renal cysts			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this insertion in the VHL gene. The patient was 42Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6506	2432	58	3	10183790	10183791		A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6506	https://civic.genome.wustl.edu/links/variants/2432	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G93S (c.277G>A)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Pancreatic cysts,Pheochromocytoma,Retinal capillary hemangioma,Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Two patients were found with this missense mutation in the VHL gene. One patient was 35Y and the other was 60Y at last follow-up. Their phenotypes were grouped together: retinal hemangioblastoma, spinal cord hemangioblastoma, pheochromocytoma, renal cysts, and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6507	1859	58	3	10183808	10183808	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/6507	https://civic.genome.wustl.edu/links/variants/1859	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.340+1G>A)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma,Spinal hemangioblastoma,Multiple renal cysts,Pancreatic cysts,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this splice varaint in the VHL gene. The patient was 32Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6509	2114	58	3	10183872	10183872	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/6509	https://civic.genome.wustl.edu/links/variants/2114	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	c.341-59_341-14del	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Multiple renal cysts,Pancreatic cysts,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Two patients were found with this deletion in the VHL gene. One patient was 33Y and the other was 67Y at the last follow-up. The phenotypes of the patients were presented together: retinal hemangioblastoma, cerebellar hemangioblastoma, renal cell carcinoma, pheochromocytoma, renal cysts and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6510	2435	58														Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6510	https://civic.genome.wustl.edu/links/variants/2435	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R120G (c.358A>G)	Von Hippel-Lindau Disease	14175	Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 15Y at the last follow-up and presented with: spinal cord hemangioblastoma. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6511	1914	58	3	10188215	10188215	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6511	https://civic.genome.wustl.edu/links/variants/1914	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Multiple renal cysts,Cerebellar hemangioblastoma,Pancreatic cysts,Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 41Y at the last follow-up and presented with: cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6512	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6512	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154= (c.462A>C)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Multiple renal cysts,Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 71Y at the last follow-up and presented with:  cerebellar hemangioblastoma, pheochromocytoma, and renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6513	1962	58	3	10188319	10188319	A	C	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/)	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6513	https://civic.genome.wustl.edu/links/variants/1962	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.463+2T>C)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma,Multiple renal cysts,Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this splice varaint in the VHL gene. The patient was 31Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, and renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6514	2075	58	3	10188322	10188322	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/6514	https://civic.genome.wustl.edu/links/variants/2075	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y156C (c.467A>G)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Pheochromocytoma			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Seven patients were found with this missense varaint in the VHL gene. The ages of the patients was represented as a range 7-88 (mean 45). Phenotypes were grouped together: phenochromocytoma and renal cysts, although it is unclear if only one of the seven patients had renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6516	1946	58	3	10191474	10191474	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6516	https://civic.genome.wustl.edu/links/variants/1946	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V166A (c.497T>C)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor,Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 27Y at the last follow-up and presented with: pancreatic neuroendocrine tumour and pheochromocytoma. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6518	2437	58	3	10191504	10191504	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6518	https://civic.genome.wustl.edu/links/variants/2437	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Multiple renal cysts,Renal cell carcinoma,Retinal capillary hemangioma,Pheochromocytoma,Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 43Y at the last follow-up and presented with: retinal hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pheochromocytoma, and renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6519	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6519	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Pancreatic cysts,Multiple renal cysts,Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Spinal hemangioblastoma,Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Eleven patients were found with this missense varaint in the VHL gene. The ages of the patient was represented as a range, 21-65Y. The phenotypes were presented together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, phenchromocytoma, renal cysts, and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6520	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/6520	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170D (c.509T>A)	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor,Cerebellar hemangioblastoma,Renal cell carcinoma,Multiple renal cysts,Pheochromocytoma,Pancreatic cysts,Retinal capillary hemangioma,Spinal hemangioblastoma			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. 15 patients were found with this missense varaint in the VHL gene. The ages of the patients were represented as a range, 16-71Y (mean 45). The phenotypes were presented together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, phenchromocytoma, renal cysts, and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6522	1826	58	3	10191516	10191516	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/6522	https://civic.genome.wustl.edu/links/variants/1826	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E189fs (c.565del)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Multiple renal cysts			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this frameshift mutation in the VHL gene. The patient was 30Y at the last follow-up and presented with: cerebellar hemangioblastoma and renal cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6523	1869	58	3	10191572	10191572	G		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6523	https://civic.genome.wustl.edu/links/variants/1869	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	REARRANGEMENT	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Cerebellar hemangioblastoma,Spinal hemangioblastoma,Multiple renal cysts,Pancreatic cysts			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with a VHL rearrangment determined by a southern blot. The patient was 25Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cysts and pancreatic cysts. Family history was not described.	24132471	PubMed		Kruizinga et al., 2014, Endocr. Relat. Cancer		3	accepted	6525	2439	58														Rare Germline	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6525	https://civic.genome.wustl.edu/links/variants/2439	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V66Gfs*89 (c.197_209del)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6546	2447	58														Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6546	https://civic.genome.wustl.edu/links/variants/2447	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Phe76del), which was found in 4 individuals from Germany or France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6547	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6547	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Asn78Ser), which was found in 2 individuals, one from Germany and the other from Japan.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6548	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/6548	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R79_S80del (c.236_241delGCAGTC)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6549	2448	58														Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6549	https://civic.genome.wustl.edu/links/variants/2448	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86A (c.256C>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6550	1759	58	3	10183787	10183787	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6550	https://civic.genome.wustl.edu/links/variants/1759	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P86S (c.256C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6551	1902	58	3	10183787	10183787	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6551	https://civic.genome.wustl.edu/links/variants/1902	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L89P (c.266T>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6552	1793	58	3	10183797	10183797	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/6552	https://civic.genome.wustl.edu/links/variants/1793	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	D92G (c.275A>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6553	2449	58	3	10183806	10183806	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6553	https://civic.genome.wustl.edu/links/variants/2449	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6554	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6554	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. An in-frame deletion (TCT) at nucleotide 227 was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6557	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6557	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
NTRK1	4914	NTRK1 FUSIONS	Cancer	162		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 17/23 patients with NTRK1-fusion showed maximum percent change in tumor size between -30% and -100%.	29466156	PubMed		Drilon et al., 2018, N. Engl. J. Med.	NCT02576431,NCT02122913,NCT02637687	4	accepted	6567	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6567	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
NTRK3	4916	NTRK3 FUSIONS	Cancer	162		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 26/27 patients with NTRK3-fusion showed maximum percent change in tumor size between -30% and -100%.	29466156	PubMed		Drilon et al., 2018, N. Engl. J. Med.	NCT02576431,NCT02122913,NCT02637687	4	accepted	6568	1277	3985														Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/6568	https://civic.genome.wustl.edu/links/variants/1277	https://civic.genome.wustl.edu/links/genes/3985
NTRK1	4914	NTRK1 FUSIONS	Sarcoma	1115		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 patients showed objective response, with 2 complete and 5 partial responses. The patient without objective response had soft tissue sarcoma, and showed stable disease.	29606586	PubMed		Laetsch et al., 2018, Lancet Oncol.	NCT02637687	4	accepted	6569	419	3983	1	156844175	156851434			ENST00000524377.1					75	GRCh37		Somatic	2021-03-31 18:23:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6569	https://civic.genome.wustl.edu/links/variants/419	https://civic.genome.wustl.edu/links/genes/3983
VHL	7428	F136S (c.407T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6573	1801	58	3	10188264	10188264	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6573	https://civic.genome.wustl.edu/links/variants/1801	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P138T (c.412C>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 5 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		2	accepted	6574	1928	58	3	10188269	10188269	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6574	https://civic.genome.wustl.edu/links/variants/1928	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L153P (c.458T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6576	1923	58	3	10188315	10188315	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6576	https://civic.genome.wustl.edu/links/variants/1923	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154= (c.462A>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6577	1962	58	3	10188319	10188319	A	C	ENST00000256474.2					75	GRCh37	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/)	Rare Germline	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6577	https://civic.genome.wustl.edu/links/variants/1962	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V155G (c.464T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6579	1934	58	3	10191471	10191471	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6579	https://civic.genome.wustl.edu/links/variants/1934	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T157I (c.470C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6581	1745	58	3	10191477	10191477	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6581	https://civic.genome.wustl.edu/links/variants/1745	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161G (c.481C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6582	1915	58	3	10191488	10191488	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6582	https://civic.genome.wustl.edu/links/variants/1915	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6583	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6583	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162F (c.485G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6584	1773	58	3	10191492	10191492	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6584	https://civic.genome.wustl.edu/links/variants/1773	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6585	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/6585	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 9 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		2	accepted	6587	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/6587	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167L (c.500G>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.500 G>T mutation was present in 3 individuas of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6588	1916	58	3	10191507	10191507	G	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6588	https://civic.genome.wustl.edu/links/variants/1916	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L169P (c.506T>C)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.506 T>C mutation was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6589	1887	58	3	10191513	10191513	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6589	https://civic.genome.wustl.edu/links/variants/1887	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	V170G (c.509T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations presented. The c.509 T>G mutation was present in 3 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6590	1935	58	3	10191516	10191516	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6590	https://civic.genome.wustl.edu/links/variants/1935	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S183* (c.548C>A)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.548 C>A mutation was present in 3 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6592	1784	58	3	10191555	10191555	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6592	https://civic.genome.wustl.edu/links/variants/1784	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L184R (c.551T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.551 T>G mutation was present in 1 individual of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6593	1808	58	3	10191558	10191558	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/6593	https://civic.genome.wustl.edu/links/variants/1808	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L188R (c.563T>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.563 T>G mutation was present in 3 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6595	1924	58	3	10191570	10191570	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6595	https://civic.genome.wustl.edu/links/variants/1924	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.583 C>T mutation was present in 2 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6596	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6596	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Null (Complete deletion)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. A complete deletion was present in 13 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		2	accepted	6597	2016	58														Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/6597	https://civic.genome.wustl.edu/links/variants/2016	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	REARRANGEMENT	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. A rearrangement mutation was present in 4 individuals of the 122 total number of variants captured in this population.	26763786	PubMed		Feletti et al., 2016, Neuro-oncology		1	accepted	6599	2439	58														Rare Germline	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6599	https://civic.genome.wustl.edu/links/variants/2439	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111C (c.331A>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6600	2045	58	3	10183862	10183862	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/6600	https://civic.genome.wustl.edu/links/variants/2045	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S111N (c.332G>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from the UK.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6601	1763	58	3	10183863	10183863	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6601	https://civic.genome.wustl.edu/links/variants/1763	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R113* (c.337C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6602	1796	58	3	10183868	10183868	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/6602	https://civic.genome.wustl.edu/links/variants/1796	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	G114Vfs*45 (c.339delA)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6603	2455	58														Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6603	https://civic.genome.wustl.edu/links/variants/2455	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	H115Q (c.345C>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6604	1957	58	3	10188202	10188202	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6604	https://civic.genome.wustl.edu/links/variants/1957	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R120G (c.358A>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6605	1914	58	3	10188215	10188215	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6605	https://civic.genome.wustl.edu/links/variants/1914	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N131T (c.392A>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6606	2580	58	3	10188249	10188249	A	C	ENST00000256474.2					75	GRCh37	A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.	Rare Germline	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6606	https://civic.genome.wustl.edu/links/variants/2580	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T133fs (c.397del)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6607	1843	58	3	10188252	10188252	A		ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6607	https://civic.genome.wustl.edu/links/variants/1843	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L135* (c.404T>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Spain.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6608	1769	58	3	10188261	10188261	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/6608	https://civic.genome.wustl.edu/links/variants/1769	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	P154L (c.461C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6609	1782	58	3	10188318	10188318	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6609	https://civic.genome.wustl.edu/links/variants/1782	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.463+2T>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6610	2075	58	3	10188322	10188322	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/6610	https://civic.genome.wustl.edu/links/variants/2075	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Splicing alteration (c.464-2G>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Spain.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6611	2457	58														Rare Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6611	https://civic.genome.wustl.edu/links/variants/2457	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	T157I (c.470C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6612	1745	58	3	10191477	10191477	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6612	https://civic.genome.wustl.edu/links/variants/1745	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L158P (c.473T>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6613	1738	58	3	10191480	10191480	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/6613	https://civic.genome.wustl.edu/links/variants/1738	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161* (c.481C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 3 individuals from France or Argentina.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6614	1804	58	3	10191488	10191488	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/6614	https://civic.genome.wustl.edu/links/variants/1804	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162Y (c.485G>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6615	1824	58	3	10191492	10191492	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6615	https://civic.genome.wustl.edu/links/variants/1824	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Cys162Trp), which was found in 2 individuals from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6616	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6616	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q164L (c.491A>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6617	2079	58	3	10191498	10191498	A	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6617	https://civic.genome.wustl.edu/links/variants/2079	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167W (c.499C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 3 individuals each from France, UK, and Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6618	1747	58	3	10191506	10191506	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6618	https://civic.genome.wustl.edu/links/variants/1747	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167Q (c.500G>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 4 individuals from France or Italy.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6619	1739	58	3	10191507	10191507	G	A	ENST00000256474.2					75	GRCh37	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.	Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/6619	https://civic.genome.wustl.edu/links/variants/1739	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R167P (c.500G>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6620	2458	58	3	10191507	10191507	G	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6620	https://civic.genome.wustl.edu/links/variants/2458	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175* (c.525C>A)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	6621	1932	58	3	10191532	10191532	C	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/6621	https://civic.genome.wustl.edu/links/variants/1932	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178P (c.532C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6622	2459	58														Rare Germline	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6622	https://civic.genome.wustl.edu/links/variants/2459	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Q195* (c.583C>T)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6623	1810	58	3	10191590	10191590	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/6623	https://civic.genome.wustl.edu/links/variants/1810	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 1 DELETION	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from the Netherlands.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6624	844	58	3	10183532	10183871			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/6624	https://civic.genome.wustl.edu/links/variants/844	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 2 DELETION	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6625	1938	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/6625	https://civic.genome.wustl.edu/links/variants/1938	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 3 DELETION	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 4 individuals from France, Germany, or Italy.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6626	1939	58														Rare Germline	2021-03-31 18:22:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/6626	https://civic.genome.wustl.edu/links/variants/1939	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 2-3 DELETION	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6627	1940	58														Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/6627	https://civic.genome.wustl.edu/links/variants/1940	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	EXON 1-3 DELETION	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 6 individuals from France, Germany, the Netherlands, or Spain.	25867206	PubMed		Bausch et al., 2016, Head Neck		3	accepted	6628	843	58	3	10183532	10191649			ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:22:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/6628	https://civic.genome.wustl.edu/links/variants/843	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Thirty-two surgically resected HB specimens from 28 patients treated at the University of Tokyo Hospital between 1995 and 2012 were analyzed retrospectively.  Of the 32 specimens, 11 were VHL-related HBs from 7 patients, and 21 were sporadic HBs from 21 patients. One of the 7 VHL patients was a female patient with a c.194C>T (p.Ser65Leu) mutation in the VHL gene. She developed a CNS hemangioblastoma in the cerebellum at 19Y. It is unclear whether she had germline testing. However, the patient met clinical criteria for VHL (Losner et al., 2003). Interestingly, the HB from this patient was noted to have LOH of chromosome 3p. No other phenotypic information was available.	28379443	PubMed		Takayanagi et al., 2017, Neuro-oncology		2	accepted	6644	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Unknown	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6644	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
PRKCB	5579	D427N	Adult T-cell Leukemia	0050523				Diagnostic	Supports	D	Positive	PRKCB was mutated in 33% of ATLL cases. 93% of these mutations were within the catalytic domain at Asp427. This gene has not been reported to be significantly mutated in any other cancers.  Indeed this is the first known example in any cancer that appears to involve activation by the PKC gene family.  Nearly all occurrences of this mutation in COSMIC correspond to ATLL.	26437031	PubMed		Kataoka et al., 2015, Nat. Genet.		3	accepted	6654	2468	4517														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6654	https://civic.genome.wustl.edu/links/variants/2468	https://civic.genome.wustl.edu/links/genes/4517
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	The national cohort study describes how the rate of new tumor development varies through the lifetimes of VHL patients and how it is influenced by age and genotype.  This study included 52 VHL mutation carriers who were retrospectively followed for a total of 799 person-years. From birth to current age, 581 manifestations were diagnosed during 2,583 examinations in the study subjects.   Genetic testing confirmed a germline variant at c.194C>G of the VHL gene in two patients. Detailed phenotype, demographic, and family history information was not available for the 2 patients.	25834951	PubMed		Binderup et al., 2016, Genet. Med.		3	accepted	6661	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6661	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	This retrospective study of 52 Danish patients with genetically confirmed VHL mutations analyzed the results of each individual's VHL-related examinations and manifestations diagnosed up to the time of study inclusion. All patients were enrolled in the Danish vHL surveillance program. Data was collected through detailed interviews and subsequent evaluation of each subjects clinical, radiographic, and histological records. Genetic testing confirmed a germline VHL mutation at c.194C>T  in four patients. Associated phenotypes, demographic, and family history is unknown.	25834951	PubMed		Binderup et al., 2016, Genet. Med.		2	accepted	6662	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6662	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	A retrospective study reviewed cases of 23 patients with advanced and complicated VHL eye disease who underwent pars plana vitrectomy in the years 1999 to 2012. These inidiviuals were part of 223 VHL patients consulted at the International Hereditary Cancer Center and Polish VHL Registry. 22/23 patients received genetic molecular testing to identify germline mutations in the VHL gene. 24 eyes from 23 patients were studied. Patient #6 (35 years old) had the p.Ser65Leu (c.194C>T) mutation and a previous history of HbCNS and RCC.  Patient # 16 (44 year old) also had this mutation, and had a previous history of HbCNS and RCC. Patient # 17 (20 year old) had this mutation, and had a previous history of HbCNS. Since patients were listed 'by eye' it is impossible to determine whether the three patients listed above actually represent 2 or 3 unique patients.	26308528	PubMed		Krzystolik et al., 2016, Retina (Philadelphia, Pa.)		3	accepted	6710	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6710	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	*214G (c.640T>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	A 49 year old female (Patient 3) from Europe presented with a unilateral adrenal pheochromocytoma. Genetic testing confirmed germline missense mutation found at c.640T>G in the VHL gene (reported as T852G in the paper). Family history and patient demographic is unknown. This patient underwent surgical resection.	12673678	PubMed		Dannenberg et al., 2003, Int. J. Cancer		2	accepted	6723	2488	58	3	10191647	10191647	T	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6723	https://civic.genome.wustl.edu/links/variants/2488	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	*214C (c.641_642insC)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	A female of unknown age (Patient 8) from Europe presented with a unilateral adrenal pheochromocytoma. Genetic testing confirmed a germline frameshift mutation found at c.641insC in the VHL gene. Family history and patient demographic is unknown. This patient underwent surgical resection.	12673678	PubMed		Dannenberg et al., 2003, Int. J. Cancer		2	accepted	6724	2489	58	3	10191648	10191649		C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/6724	https://civic.genome.wustl.edu/links/variants/2489	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	240 ccRCC specimens were genetically analyzed. 3 specimens (ccRCC-58, ccRCC-154, ccRCC-238) from 3 different patients were confirmed to carry the p.Ser65Leu; c.194C>T mutation. The mutation was found to be germline in one male patient, age 27, who had contralateral kidney cancer. Family history and patient demographics are unknown. This patient was the source of ccRCC-238. This evidence supports AMCG code 'PM2' - Absent from controls (i.e. gnomAD).	23797736	PubMed		Sato et al., 2013, Nat. Genet.		2	accepted	6728	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6728	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Thirteen unrelated Korean subjects and their family members were tested for VHL mutations with direct sequencing and multiplex ligation dependent probe amplification. Clinical manifestations and family histories were recorded for each subject. Genetic testing confirmed a c.208G>A missense mutation in members of family #2,3,4. Family #2; A 25-year-old male Korean proband presented with a central nervous system hemangioblastoma. This patient had no family history of VHL. Family #3; A 46-year-old female Korean proband presented with bilateral retinal hemangioblastomas. The patient's 19-year-old son was found to share her mutation, but did not exhibit and VHL symptoms at the time of the study. The proband had a sister with retinal hemangioblastoma, but she did not receive genetic testing. Family #4; A 20-year-old female Korean proband presented with bilateral retinal hemangioblastomas. The patient has a mother who had received treatment for retinal hemangioblastoma, but refused to undergo genetic analysis. No other VHL symptoms were observed in the proband or her mother. Suggested ACMG Code: 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology.	27439424	PubMed		Lee et al., 2016, BMC Med. Genet.		3	accepted	6742	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/6742	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65W (c.194C>G)	Von Hippel-Lindau Disease	14175	Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. The c.194C>G (p.Ser65Trp) variant was found in a 48Y patient with RCC and multiple pancreatic cysts or tumours, and his son who had a CNS hemangioblastoma at 22Y. The patient's mother and brother had CNS hemangioblastomas at age 61 and 33 respectively, although genotypic confirmation was not available.  This variant was also found in an unrelated woman with CNS hemangioblastoma diagnosed at age 34Y, and renal cell carcinoma and multiple pancreatic cysts or tumours diagnosed at age 37Y.  ACMG codes: PM2 -absent from controls in GnomAD; PP4 - patient's phenotype or FHx is highly specific for a disease with a single genetic etiology.	28388566	PubMed		Peng et al., 2017, Oncotarget		3	accepted	6789	1787	58	3	10183725	10183725	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/6789	https://civic.genome.wustl.edu/links/variants/1787	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Von Hippel-Lindau Disease	14175	Pheochromocytoma,Retinal capillary hemangioma,Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. A mutation c.194C>T (p.Ser65Leu) was found in 3 families (#4, #5, #6) with 11 genetically confirmed patients and 13 affected members in total. From family #4: one male patient presented with renal cell carcinoma at 33Y and pancreatic cysts or tumors at 33Y (mutation confirmed). From family #5: male proband with CNS haemangioblastoma at 21Y and multpile pancreatic cysts or tumours at 30Y (mutation confirmed), grandfather with CNS haemangioblastoma at 30Y (mutation status unknown), father with CNS haemangioblastoma at 36Y (mutation status unknown), and uncle with CNS haemangioblastoma at 33Y (mutation status unknown). From family #6: female proband with RCC at 36Y who then developed PCT at 37Y (mutation confirmed); daughter confirmed with the mutation but no manifestations and age unknown; mother with CNS hemangioblastoma diagnosed at 59Y (mutation confirmed); uncle 1 with CNS hemangioblastoma at 45Y, renal cell carcinoma at 59Y, and multiple pancreatic cysts or tumours at 65Y (mutation confirmed); son of uncle 1 with CNS hemangioblastoma at 22Y (mutation status unknown); Uncle 2 with CNS hemangioblastoma at 51Y, renal cell carcinoma at 51Y, and pancreatic cysts or tumours at 51Y (mutation status unknown); 1st son of uncle 2 with CNS hemangioblastoma at 22Y, renal cell carcinoma at 30Y, and pancreatic cysts or tumours at 31Y (mutation confirmed); 2nd son of uncle 2 with mutation confirmed but no manifestations and age unknown; granddaughter of uncle 2 with mutation confirmed but no manifestations and age unknown; Uncle 3 with multiple pancreatic cysts or tumours at 49Y (mutation confirmed); Aunt with CNS hemangioblastoma at 53Y and retinal angioma at 53Y (mutation confirmed). This evidence supports the following ACMG Codes: PP4 - the patient's phenotype and family history are highly specific for a disease with single genetic etiology, PP1- Co-segregation with disease in multiple affected family members (.e. family #6), PM2 - Absent from controls (i.e. gnomAD)	28388566	PubMed		Peng et al., 2017, Oncotarget		3	accepted	6791	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6791	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	E70K (c.208G>A)	Von Hippel-Lindau Disease	14175	Hemangioblastoma,Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Medical records of 26 patients with germline mutations of the VHL gene who had been diagnosed with VHL disease in Severance Hospital (Seoul, Republic of Korea) and Samsung Medical Center (Seoul, Republic of Korea) between 2003 and 2012 were reviewed. 9 unrelated patients diagnosed with Type 1 VHL disease shared the same VHL germline missense mutation (c.208G>A; p.Glu70Lys). The patients' phenotypes were as follows: 55 year old male with multiple CNS hemangioblastomas (patient 3), 55Y male with multiple CNS hemangioblastomas (Patient 4), 43Y male with multiple CNS hemangioblastomas (other phenotypic data not available, Patient 5), 11Y male with bilateral retinal hemangioblastoma (patient 6), 48Y female with CNS hemangioblastoma (Patient 7) , 64Y female with CNS hemangioblastoma (patient 8), 16Y F with retinal hemangioblastoma (Patient 9), 41Y female with CNS hemangioblastoma (patient 10).  One patient has concurrent missense and splicing mutations (208G>A and IVS1+5G>C). 52 year old male with retinal hemangioblstoma. ACMG codes as follows: PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation.	25078357	PubMed		Hwang et al., 2014, J. Hum. Genet.		3	accepted	6860	1956	58	3	10183739	10183739	G	A	ENST00000256474.2					75	GRCh37	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.	Rare Germline	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/6860	https://civic.genome.wustl.edu/links/variants/1956	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	F76del (c.224_226delTCT)	Von Hippel-Lindau Disease	14175	Renal cell carcinoma,Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Medical records of 26 patients diagnosed with VHL disease in two Korean hospitals between 2003-2012 and harboring germline VHL mutations were retrospectively reviewed. One male patient diagnosed with Type 1 VHL disease at 23Y (Patient 14) presented with renal cell carcinoma, multiple CNS hemangioblastomas and other manifestations. He had a germline inframe deletion in the VHL gene (c.227delTCT) and a negative family history of VHL disease.	25078357	PubMed		Hwang et al., 2014, J. Hum. Genet.		3	accepted	6862	2088	58	3	10183755	10183757	TCT		ENST00000256474.2					75	GRCh37	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).	Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6862	https://civic.genome.wustl.edu/links/variants/2088	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	S65L (c.194C>T)	Renal Carcinoma	4451	Clear cell renal cell carcinoma,Sporadic			Predisposing	Supports	C	Uncertain Significance	Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identified with VHL somatic mutations; Loss of heterozygosity was observed in 97% of those samples. This missense mutation was found in one of the clear cell renal carcinoma cell lines (sample UOK164). No phenotype described.	7915601	PubMed		Gnarra et al., 1994, Nat. Genet.		3	accepted	6890	1788	58	3	10183725	10183725	C	T	ENST00000256474.2					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6890	https://civic.genome.wustl.edu/links/variants/1788	https://civic.genome.wustl.edu/links/genes/58
NTRK3	4916	ETV6-NTRK3	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Larotrectinib		Predictive	Supports	D	Sensitivity/Response	Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytometry indicated the absence of leukemic cells in the bone marrow (p<.0001), peripheral blood (p=.0018), and spleen (p=.0001) after 6 weeks of Larotrectinib (n=10) compared to vehicle treated mice (n=10). Treated mice also had lower splenic weight (p<.001) and the absence of leukemia burden in the bone marrow and central nervous system as determined by histopathology. In 2 mice, leukemic burden increased while Larotrectinib was paused from weeks 6-25. Upon the reintroduction of treatment for 4 weeks, leukemic burden was lowered. Conditional knock-in Etv6-NTRK CD19-Cre cells isolated from bone marrow and cultured ex vivo were highly sensitive to serial dilutions of Larotrectinib. After 48 hours of Larotrectinib exposure, Ba/F3 cells stably expressing ETV6-NTRK3 demonstrated a response with an IC50 of 17.0nM (viability measured by CellTiter blue). Finally, Larotrectinib was 1000x more potent against 3 human cancer cell lines with an NTRK fusion versus the 76 with other alterations. The most sensitive was an AML cell line (M0-91) with an ETV6-NTRK3 fusion.	29880614	PubMed		Roberts et al., 2018, Blood		4	accepted	6930	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/6930	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
TERT	7015	PROMOTER MUTATION	Glioblastoma Multiforme	3068				Prognostic	Supports	B	Poor Outcome	In 50 patients with primary glioblastomas, patients without TERT promoter mutations (N=13, median 27 mo) survived longer than those harboring mutations (N=37, 14 mo; P = 0.01 by the log rank test; HR 0.38, 95% CI [0.18, 0.81]).	23530248	PubMed		Killela et al., 2013, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	6933	220	79	5	1295161	1295373			ENST00000310581.5					75	GRCh37	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.	Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/6933	https://civic.genome.wustl.edu/links/variants/220	https://civic.genome.wustl.edu/links/genes/79
BRAF	673	V600	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unrescectable stage IIIC or IV BRAF V600E or V600K melanoma received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival with secondary endpoints including disease response.   Hazard ratio for progression or death in the dabrafenibtrametinib group, 0.75; (95% confidence interval, 0.57 to 0.99; P=0.03). Of 210 patients in the dabrafenib + trametinib group, 67% of patients had a response, which was 16 percentage points higher than in the dabrafenib group. (95% CI, 6 to 25; P=0.002)	25265492	PubMed		Long et al., 2014, N. Engl. J. Med.	NCT01584648	5	accepted	6937	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6937	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival and secondary endpoints including disease response. The hazard ratio for progression or death in the V600E group was 0.81 for dabrafenib-trametinib vs dabrafenib-alone. Of 179 V600E patients in the dabrafenib-trametinib group, 68% of patients had a response, which was 15 percentage points higher than in the dabrafenib-alone group (95% CI, 4 to 24; P=0.006).	25265492	PubMed		Long et al., 2014, N. Engl. J. Med.	NCT01584648	5	accepted	6938	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6938	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monotherapy and 92 received combination therapy. Hazard ratio for progression or death was 0.43 (95% CI, 0.27-0.71). Both patients with the BRAF V600E and V600K mutation showed significant improvement in progression-free survival.	23020132	PubMed		Flaherty et al., 2012, N. Engl. J. Med.	NCT01072175	4	accepted	6940	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6940	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
ACVR1	90	G328V	Diffuse Intrinsic Pontine Glioma	0080684				Diagnostic	Supports	B	Positive	In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC	24705254	PubMed		Buczkowicz et al., 2014, Nat. Genet.		3	accepted	6955	1686	154	2	158622516	158622516	C	A	ENST00000434821.1					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/6955	https://civic.genome.wustl.edu/links/variants/1686	https://civic.genome.wustl.edu/links/genes/154
NRAS	4893	Q61	Follicular Thyroid Carcinoma	3962				Prognostic	Does Not Support	B	Poor Outcome	Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) or HRAS (2 Q61R and 1 Q61K) and TERT promoter mutations had persistent or recurrent disease compared to 1/11 patients with only a RAS mutation (100% vs 8%, P=0.03).	25448848	PubMed		Muzza et al., 2015, Mol. Cell. Endocrinol.		2	accepted	6959	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/6959	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36
HRAS	3265	Q61	Follicular Thyroid Carcinoma	3962				Prognostic	Does Not Support	B	Poor Outcome	Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) or HRAS (2 Q61R and 1 Q61K) and TERT promoter mutations had persistent or recurrent disease compared to 1/11 patients with only a RAS mutation (100% vs 8%, P=0.03).	25448848	PubMed		Muzza et al., 2015, Mol. Cell. Endocrinol.		2	accepted	6960	2570	2747														Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/6960	https://civic.genome.wustl.edu/links/variants/2570	https://civic.genome.wustl.edu/links/genes/2747
BRAF	673	V600K	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 56 had V600K mutation. 32 patients were treated with vemurafenib and placebo, and 24 were treated with vemurafenib and cobimetinib and tested for progression free survival. 17 of 32 monotherapy group patients had an event with median progression free survival of 5.3 months. In the combination group 4 of 24 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.27 (0.09-0.81).	25265494	PubMed		Larkin et al., 2014, N. Engl. J. Med.	NCT01689519	4	accepted	6965	563	5	7	140453136	140453137	AC	TT	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/6965	https://civic.genome.wustl.edu/links/variants/563	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Melanoma	1909		Vemurafenib,Cobimetinib	Combination	Predictive	Supports	B	Sensitivity/Response	In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (66 patients) or never received BRAF inhibitor (63 patients). The combination of vemurafenib and cobimetinib was deemed safe and tolerable. Confirmed objective responses were seen in 15% of vemurafenib progressed patients and median progression-free survival was 2.8 months (95% CI 2634). Confirmed objective responses were seen in 87% of patients who had never received BRAF inhibitor, including 10% with complete response. Median progression-free survival was 13.7 months (95% CI 101175). The majority of patients had BRAF V600E mutation. Post-hoc sequencing of 94 tumor samples indicated seven tumors with a mutation other than BRAF V600E.	25037139	PubMed		Ribas et al., 2014, Lancet Oncol.	NCT01271803	3	accepted	6966	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/6966	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	ETV6-ABL1	B-lymphoblastic Leukemia/lymphoma	0080630		Dasatinib		Predictive	Supports	C	Sensitivity/Response	An adult patient (82 yo) who presented with B-ALL (initial WBC of 183,000) with ETV6-ABL1 fusion was treated with dasatinib as a single agent after his chemotherapy had to be stopped due to toxicity. This resulted in morphological and cytogenetic remission after 2 weeks of treatment. Patient continued dasatinib daily plus 2 cycles of prednisolone (50 mg orally daily) for 4 weeks each. He remained in cytogenetic remission after 8 months of maintenance dasatinib. (See Supplementary Appendix 2, Page 11).	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		2	accepted	6969	2575	4														Somatic	2021-03-31 18:23:11 UTC	https://civic.genome.wustl.edu/links/evidence_items/6969	https://civic.genome.wustl.edu/links/variants/2575	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	C	Resistance	In this open-label, phase II registration trial, patients that were imatinib-resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6970	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6970	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 greater than 150 nM. In patients with E255K and/or E255V mutations prior to nilotinib treatment, complete hematological responses were achieved in 5 of 7 patients, major cytogenetic responses in 3 of 7 patients, complete cytogenetic responses in 0 of 7 patients, and a major molecular response in 1 of 7 patients. After a median follow-up of 15.5 months, 6 of 7 patients with this mutation progressed or died. The E255K mutation was present in 6 patients at baseline and newly emerged in 4 patients at progression. The E255V mutation was present in 0 patients at baseline and newly emerged in 3 patients at progression.	19652056	PubMed		Hughes et al., 2009, J. Clin. Oncol.		3	accepted	6971	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6971	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
BRAF	673	V600E	Anaplastic Thyroid Carcinoma			Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached after 120 weeks.	29072975	PubMed		Subbiah et al., 2018, J. Clin. Oncol.	NCT02034110	4	accepted	6975	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/6975	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
PDGFRB	5159	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Imatinib		Predictive	Supports	C	Sensitivity/Response	A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant.  MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5.	24186319	PubMed		Lengline et al., 2013, Haematologica		3	accepted	6976	535	4176	5	158134987	158526769			ENST00000517373.1	5	149493400	149505140	ENST00000261799.4	75	GRCh37	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/6976	https://civic.genome.wustl.edu/links/variants/535	https://civic.genome.wustl.edu/links/genes/4176
ABL1	25	C475V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6977	1639	4	9	133753954	133755455	TG	GT	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6977	https://civic.genome.wustl.edu/links/variants/1639	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, F317L was seen in 8 imatinib resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6978	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/6978	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL N336S	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, N336S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6979	1640	4	9	133748346	133748346	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/6979	https://civic.genome.wustl.edu/links/variants/1640	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E453A	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, E453A was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6980	1536	4	9	133753889	133753889	A	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/6980	https://civic.genome.wustl.edu/links/variants/1536	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L387F	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, L387F was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6981	1232	4	9	133750330	133750330	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/6981	https://civic.genome.wustl.edu/links/variants/1232	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, V299L was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6982	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6982	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Q300R	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, Q300R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6983	1527	4	9	133747592	133747592	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/6983	https://civic.genome.wustl.edu/links/variants/1527	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, F359I was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6984	1523	4	9	133748414	133748414	T	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6984	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, F359C was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6985	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/6985	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, E255V was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6986	1173	4	9	133738364	133738364	A	T	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/6986	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, F486S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6987	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/6987	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, H396R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6988	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/6988	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, M351T was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6989	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/6989	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, T315I was seen in 7 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6990	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/6990	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, E255K was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6991	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/6991	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, Y253H was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6992	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/6992	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, G250E was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6993	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/6993	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, M244V was seen in 3 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	6994	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/6994	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in one imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	1	accepted	6995	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/6995	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	TKD MUTATION	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Among 39 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with Abl1 mutation versus without [CHR = 26/39 (67%) vs. 34/44 (77%); MCyR = 11/35 (31%) vs. 15/43 (35%)]. The authors observe responses with bosutanib monotherapy across many BCR-ABL mutations with the notable exception of T315I.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6996	2371	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6996	https://civic.genome.wustl.edu/links/variants/2371	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	P-Loop Mutation	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Among 39 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with P-loop mutations versus patients without Abl1 mutations [ CHR = 9/14 (64%) vs. 34/44 (77%); MCyR = 4/13 (31%) vs. 15/43 (35%)]. The authors observe responses with bosutanib monotherapy across many BCR-ABL mutations with the notable exception of T315I.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	2	accepted	6997	2375	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6997	https://civic.genome.wustl.edu/links/variants/2375	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Non-P-Loop Mutation	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	B	Resistance	This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Among 39 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with non-P-loop mutations versus patient without Abl1 mutations [ CHR = 18/29 (62%) vs. 34/44 (77%); MCyR = 9/26 (35%) vs. 15/43 (35%)]. The authors observe responses with bosutanib monotherapy across many BCR-ABL mutations with the notable exception of T315I.	22371878	PubMed		Khoury et al., 2012, Blood	NCT00261846	3	accepted	6998	2376	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/6998	https://civic.genome.wustl.edu/links/variants/2376	https://civic.genome.wustl.edu/links/genes/4
VHL	7428	L178P (c.533T>C)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	7004	1748	58	3	10191540	10191540	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/7004	https://civic.genome.wustl.edu/links/variants/1748	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	Y175* (c.525C>G)	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France.	25867206	PubMed		Bausch et al., 2016, Head Neck		2	accepted	7005	1969	58	3	10191532	10191532	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7005	https://civic.genome.wustl.edu/links/variants/1969	https://civic.genome.wustl.edu/links/genes/58
JAK2	3717	GOLGA5-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650	Ph-positive acute lymphoblastic leukemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	A 10-year-old Caucasian boy with high risk B-cell acute lymphoblastic leukemia failed induction therapy. The patient had a complex karyotype and microarray revealed a 9p duplication involving JAK2 and deletions of IKZF1, PAX5, and CDKN2A. RNA studies demonstrated a Ph-like ALL expression signature but did not identify the underlying kinase fusion. Research level RNA sequencing identified a GOLGA5-JAK2 fusion which was confirmed by other methods and patient cells were introduced to patient-derived xenograft models that demonstrated a response to ruxolitinib. Therefore, 40mg/m2 ruxolitinib was added to the patients multiagent chemotherapy regiment. The treatment was well tolerated and the patient demonstrated significant clinical response by the end of consolidation, though MRD  0.01% was detected by flow cytometry. The patient received CART therapy and achieved MRD negative remission, then underwent HSCT, and remained in remission with full donor chimerism at 2-months post-HSCT.	29773603	PubMed		Ding et al., 2018, Haematologica		3	accepted	7007	3214	28														Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/7007	https://civic.genome.wustl.edu/links/variants/3214	https://civic.genome.wustl.edu/links/genes/28
NCOA2	10499	HEY1-NCOA2	Mesenchymal Chondrosarcoma	4545				Diagnostic	Supports	B	Positive	A HEY1-NCOA2 fusion joining exon 4 of HEY1 to exon 13 of NCOA2 was identified in 10 mesenchymal chondrosarcomas but was absent from all other sarcoma types tested including other chondrosarcoma subtypes suggesting this fusion is diagnostic for mesenchymal chondrosarcomas.	22034177	PubMed		Wang et al., 2012, Genes Chromosomes Cancer		4	accepted	7008	2581	8368	8	80	80			ENST00000337919.9	8	71	71	ENST00000452400.6	94	GRCh37	HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).	Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7008	https://civic.genome.wustl.edu/links/variants/2581	https://civic.genome.wustl.edu/links/genes/8368
FOXO1	2308	PAX3-FOXO1	Alveolar Rhabdomyosarcoma	4051				Diagnostic	Supports	B	Positive	In a cohort of 171 uniformly treated pediatric rhabdomyosarcoma (RMS) patients, 78 patients had alveolar rhabdomyosarcoma (ARMS). Of ARMS patients, 55% harbored a PAX3-FOXO1 fusion, 22% harbored a PAX7-FOXO1 fusion, and 23% were fusion negative. In contrast, all of the embryonal RMS or undifferentiated sarcoma patients (n=93) were fusion-negative. The authors concluded that PAX7-FOXO1 and PAX2-FOXO1 fusions are ARMS tumor specific.	12039929	PubMed		Sorensen et al., 2002, J. Clin. Oncol.		4	accepted	7009	2582	1925														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/7009	https://civic.genome.wustl.edu/links/variants/2582	https://civic.genome.wustl.edu/links/genes/1925
FOXO1	2308	PAX7-FOXO1	Alveolar Rhabdomyosarcoma	4051				Diagnostic	Supports	B	Positive	In a cohort of 171 uniformly treated pediatric rhabdomyosarcoma (RMS) patients, 78 patients had alveolar rhabdomyosarcoma (ARMS). Of ARMS patients, 55% harbored a PAX3-FOXO1 fusion, 22% harbored a PAX7-FOXO1 fusion, and 23% were fusion negative. In contrast, all of the embryonal RMS or undifferentiated sarcoma patients (n=93) were fusion-negative. The authors concluded that PAX7-FOXO1 and PAX3-FOXO1 fusions are ARMS tumor specific.	12039929	PubMed		Sorensen et al., 2002, J. Clin. Oncol.		4	accepted	7010	2583	1925														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/7010	https://civic.genome.wustl.edu/links/variants/2583	https://civic.genome.wustl.edu/links/genes/1925
PARP1	142	OVEREXPRESSION	Malignant Peripheral Nerve Sheath Tumor	5940		Olaparib		Predictive	Supports	D	Sensitivity/Response	The majority of MPNST samples were positive for PARP staining. Overall, moderate to high expression of PARP1 and PARP2 was observed (Table 1)....Overall, treatment continued for 60 d at which point 5 out of 7 mice in the AZD2281 treatment group were alive versus 0 out of 7 mice in the control group (Fig. 4). These results indicated that treatment with AZD2281 significantly increased the survival of mice with metastatic disease.	26650448	PubMed		Kivlin et al., 2016, Cancer Biol. Ther.		3	accepted	7016	2586	199														N/A	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/7016	https://civic.genome.wustl.edu/links/variants/2586	https://civic.genome.wustl.edu/links/genes/199
NCOA2	10499	HEY1-NCOA2	Mesenchymal Chondrosarcoma	4545				Diagnostic	Supports	B	Positive	6 of 6 patients with mesenchymal chondrosarcoma and sufficient tissue tested positive for NCOA2 rearrangments by FISH supporting that NCOA2 rearrangements (presumably HEY1-NCOA2 translocations) are prevalent in this disease.	26146478	PubMed		Bishop et al., 2015, Sarcoma		2	accepted	7017	2581	8368	8	80	80			ENST00000337919.9	8	71	71	ENST00000452400.6	94	GRCh37	HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).	Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7017	https://civic.genome.wustl.edu/links/variants/2581	https://civic.genome.wustl.edu/links/genes/8368
BRD4	23476	BRD4-NUTM1	NUT Midline Carcinoma	0060463		Birabresib		Predictive	Supports	C	Sensitivity/Response	In the clinic, compassionate use of the BET inhibitor birabresib (also known as OTX015 or MK-8628) induced rapid tumor regression in 2 of 4 patients with confirmed BRD4-NUTM1 fusions and significant disease stabilization in a third patient.  This study provides the first clinical evidence that a BET inhibitor can induce impressive and rapid antitumor activity in this  rare and exceptionally aggressive disease.	26976114	PubMed		Stathis et al., 2016, Cancer Discov		3	accepted	7018	719	9588														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7018	https://civic.genome.wustl.edu/links/variants/719	https://civic.genome.wustl.edu/links/genes/9588
BRD4	23476	BRD4-NUTM1	NUT Midline Carcinoma	0060463				Diagnostic	Supports	B	Positive	5 of 28 cases of undifferentiated carcinomas of the upper aerodigestive tract (UCUAT)  not associated with EBV infection were found to have NUTM1 rearrangements suggesting NUT midline carcinoma may be underdiagnosed and more prevalent than previously thought.	18391746	PubMed		Stelow et al., 2008, Am. J. Surg. Pathol.		3	accepted	7019	719	9588														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7019	https://civic.genome.wustl.edu/links/variants/719	https://civic.genome.wustl.edu/links/genes/9588
PDGFRA	5156	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	0080164		Imatinib		Predictive	Supports	C	Resistance	One patient with FIP1L1/PDGFRA-positive CEL was identified as developing secondary resistance to imatinib. A PDGFRA T674I mutation was identified in the tyrosine kinase domain. Salvage therapy with nilotinib and sorafenib each failed in this patient, who was eventually transplanted with an HLA-matched sibling donor.	21818111	PubMed		Metzgeroth et al., 2012, Leukemia		3	accepted	7020	577	38	4	55144547	55144547	C	T	ENST00000257290.5					75	GRCh37	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.	Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/7020	https://civic.genome.wustl.edu/links/variants/577	https://civic.genome.wustl.edu/links/genes/38
JAK2	3717	JAK2 F694L	Childhood B-cell Acute Lymphoblastic Leukemia	0080146	Acute lymphoblastic leukemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	A 17-year-old Native American female with B-ALL had persistent MRD at the end of induction. In addition to a complex karyotype, sequencing revealed a novel F694L mutation in JAK2, a p.Cys119_Ile121delinsTrpGlyLeu in IKZF1, and a IGH-CRLF2 translocation, all consistent with BCR-ABL1 like B-ALL. In addition to conventional cytotoxic therapy, the patient was started on 40 mg/m2/day ruxolitinib TKI BID for 2 weeks on, 2 weeks off, and MRD diminished to <0.01% prior to allogeneic transplant. The patient was in remission with 100% engraftment from a full match sibling at day 100 post-transplant.	27860260	PubMed		Mayfield et al., 2017, Pediatr Blood Cancer		2	accepted	7021	2587	28														Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/7021	https://civic.genome.wustl.edu/links/variants/2587	https://civic.genome.wustl.edu/links/genes/28
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous systemic anticancer therapy, were administered tyrosine kinase inhibitor erlotinib (83 patients) or gemcitabine plus carboplatin (82 patients). Median progression-free survival was found to be significantly longer with erlotinib than in patients on chemotherapy (13.1 [95% CI 10.5816.53] vs 4.6 [4.215.42] months; hazard ratio 0.16, 95% CI 0.100.26; p<0.0001). Chemotherapy was also associated with more grade 3 or 4 toxic effects. Authors conclude that in patients with advanced EGFR mutant NSCLC, erlotinib offers an improved first line treatment option.	21783417	PubMed		Zhou et al., 2011, Lancet Oncol.	NCT00874419	4	accepted	7024	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/7024	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
PDGFRB	5159	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Imatinib		Predictive	Supports	C	Sensitivity/Response	Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.	26872634	PubMed		Schwab et al., 2016, Blood		2	accepted	7028	535	4176	5	158134987	158526769			ENST00000517373.1	5	149493400	149505140	ENST00000261799.4	75	GRCh37	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7028	https://civic.genome.wustl.edu/links/variants/535	https://civic.genome.wustl.edu/links/genes/4176
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with L248V, 3/3 had MaHRs and 1/3 had MCyRs which were comparable to response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7029	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7029	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F317L, 4/4 had MaHRs which was higher than response rates among wild type patients, and 0/4 had MCyRs which was lower than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7030	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/7030	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E459K	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E459K, 1/3 had MaHRs which was lower than response rates among wild type patients, and 3/3 had MCyRs which was higher than response rates among wild type patients.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7031	2370	4	9	133753906	133753906	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/7031	https://civic.genome.wustl.edu/links/variants/2370	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V379I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had V379I mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7033	1609	4	9	133750304	133750304	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/7033	https://civic.genome.wustl.edu/links/variants/1609	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL A397P	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytogenetic response.	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7034	1612	4	9	133750358	133750358	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/7034	https://civic.genome.wustl.edu/links/variants/1612	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359C	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had F359C mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7035	1184	4	9	133748415	133748415	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7035	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had E355G mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7036	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/7036	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had M351T mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7037	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7037	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had T315I mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7038	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/7038	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had E255K mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7039	3	4	9	133738363	133738363	G	A	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7039	https://civic.genome.wustl.edu/links/variants/3	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had Y253H mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7040	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/7040	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL G250E	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 9 had G250E mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7041	1023	4	9	133738349	133738349	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:37 UTC	https://civic.genome.wustl.edu/links/evidence_items/7041	https://civic.genome.wustl.edu/links/variants/1023	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7042	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/7042	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 7 had F359V mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7043	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/7043	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248V	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7044	1022	4	9	133738342	133738342	C	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7044	https://civic.genome.wustl.edu/links/variants/1022	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had F317L mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7045	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/7045	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E459K	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had E459K mutations	17264298	PubMed		Guilhot et al., 2007, Blood		1	accepted	7046	2370	4	9	133753906	133753906	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/7046	https://civic.genome.wustl.edu/links/variants/2370	https://civic.genome.wustl.edu/links/genes/4
RET	5979	EXPRESSION	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patients with ASCL1 expression in stage I (P=0.007, N=15 vs 38) and all adenocarcinoma (P=0.037, N=31 vs 58). However, expression of RET did not affect survival in the ASCL1- tumors.	24037524	PubMed		Kosari et al., 2014, Oncogene		3	accepted	7056	295	42	10	43572475	43625799			ENST00000355710.3					75	GRCh37		Somatic	2021-03-31 18:22:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/7056	https://civic.genome.wustl.edu/links/variants/295	https://civic.genome.wustl.edu/links/genes/42
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Selpercatinib		Predictive	Supports	B	Sensitivity/Response	In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17/26). Responses occurred independent of fusion partner (9/13 KIF5B vs 7/9 non-KIF5B) and included 3 pts w/ baseline brain metastases.	161573	ASCO	102	Alexander E. Drilon, 2018, ASCO Annual Meeting, Abstract 102	NCT03157128	4	accepted	7066	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7066	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
NCOA2	10499	HEY1-NCOA2	Mesenchymal Chondrosarcoma	4545				Diagnostic	Supports	B	Positive	FISH was used to detect HEY1-NCOA2 fusions in 10 paraffin embedded samples from patients diagnosed with mesenchymal chondrosarcoma. HEY1 and NCOA2 are located on the same chromosome but generate distinct FISH signals, whereas the HEY1-NCOA2 fusion appears as a single fused dot. Specimens were considered positive for fusion when FISH showed overlapping signals of HEY1 and NCOA2 in greater than 20% of the cells. Overlap signal of over 20% was seen in 8/10 patients. The two patients with no overlap signal were also negative for FISH staining, suggesting insufficient or damaged material for FISH.	23252872	PubMed		Nakayama et al., 2012, Pathol. Int.		4	accepted	7124	2581	8368	8	80	80			ENST00000337919.9	8	71	71	ENST00000452400.6	94	GRCh37	HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).	Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7124	https://civic.genome.wustl.edu/links/variants/2581	https://civic.genome.wustl.edu/links/genes/8368
NCOA2	10499	HEY1-NCOA2	Mesenchymal Chondrosarcoma	4545				Diagnostic	Supports	B	Positive	Meningeal hemangiopericytoma (HPC) and mesenchymal chondrosarcoma (MC) are aggressive neoplasms with overlapping clinical presentations and morphology. Thirteen FFPE samples of MC (9 females, 4 males) from ages 19 to 54 and Eighteen cases of meningeal HPC (8 females, 10 males) from ages from 24 to 73 years were tested using RT-PCR for the presence of HEY1-NCOA2 fusion. Of cases with evaluable RNA, 6/6 MC cases were positive for the fusion, but 0/11 meningeal HPC cases were fusion positive.	24124145	PubMed		Fritchie et al., 2013, Am. J. Clin. Pathol.		4	accepted	7125	2581	8368	8	80	80			ENST00000337919.9	8	71	71	ENST00000452400.6	94	GRCh37	HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).	Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7125	https://civic.genome.wustl.edu/links/variants/2581	https://civic.genome.wustl.edu/links/genes/8368
PDGFRB	5159	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Dasatinib,Imatinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		2	accepted	7128	535	4176	5	158134987	158526769			ENST00000517373.1	5	149493400	149505140	ENST00000261799.4	75	GRCh37	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7128	https://civic.genome.wustl.edu/links/variants/535	https://civic.genome.wustl.edu/links/genes/4176
BRAF	673	KIAA1549-BRAF	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68).  Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration.	23817572	PubMed		Jones et al., 2013, Nat. Genet.		5	accepted	7148	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7148	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
SMARCA4	6597	LOSS	Lung Non-small Cell Carcinoma	3908		Abemaciclib,Palbociclib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Preclinical evidence showing that SMARCA4 inactivation results in downregulation of Cyclin D1 in NSCLC cells and confers sensitivity of such to CDK4/6 inhibitors. SMARCA4 loss is synthetic letha with CDK4/6 inhibition.	30718506	PubMed		Xue et al., 2019, Nat Commun		4	accepted	7155	2644	78														N/A	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7155	https://civic.genome.wustl.edu/links/variants/2644	https://civic.genome.wustl.edu/links/genes/78
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	Patients with completely resected colorectal adenocarcinoma (Stage II-III) were treated with fluorouracil and leucovorin +/- ironotecan. Of the 1,307 FFPE samples tested, V600E was observed in 31 Stage II samples (7.6%) and 72 Stage III samples (7.9%). V600E was prognostic for overall survival, but not for relapse-free survival, in patients with stages II and III combined, and in stage III alone. For all MSI low and stable tumors, BRAF V600E positive samples had a hazard ratio (HR) of 2.19 (95% CI, 1.43 to 3.37, P=0.00034). For all samples in the cohort (MSI-H and MSI-L) BRAF V600E positive samples had a 1.66 HR (95% CI, 1.15 to 2.40, P=0.0069). The authors note prognostic value for BRAF V600E, especially in non-MSI high tumors.	20008640	PubMed		Roth et al., 2010, J. Clin. Oncol.		4	accepted	7156	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/7156	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	The CRYSTAL Phase III Trial evaluated efficacy of irinotecan, fluorouracil, and leucovorin (FOLFIRI) with or without Cetuximab for colorectal cancer patients who presented with unresectable metastatic disease. BRAF mutation status (V600E) was analyzed via LightMix BRAF V600E Kit. V600E mutations were detected in 60/999 tumor samples (6%), 59 of which were wild-type for KRAS. When comparing patients with wildtype KRAS (n=625), BRAF V600E tumors had worse outcomes relative to BRAF wildtype. For patients with BRAF V600E tumors (n=566), median overall survival (OS) was 25.1 months with cetuximab and 21.6 months without cetuximab. For patients with wildtype BRAF (n=59), median OS was 14.1 months with cetuximab and 10.3 months without cetuximab.	21502544	PubMed		Van Cutsem et al., 2011, J. Clin. Oncol.		4	accepted	7157	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/7157	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A), or chemotherapy plus cetuximab (arm B). Median overall survival was found to differ by mutation, regardless of treatment. Median overall survival was 8.8 months (IQR 4.5-27) for patients with BRAF variants, 14.4 months (IQR 8.5-24.0) for patients with KRAS variants, and 20.1 months (IQR 11.5-31.7) for wildtype patients. BRAF mutations were found in 102/1291 samples (7.90%), and of these, 12 were D594G and 90 V600E.	21641636	PubMed		Maughan et al., 2011, Lancet		4	accepted	7158	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7158	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	MUTATION	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients), the odds ratio (OR) of a proximal lesion, which is associated with greater mortality in colon cancer, was increased for patients with BRAF mutations (OR 5.222, 95% CI 3.8017.174, P < 0.001). When evaluating 4 studies (n = 1526 patients), the odds ratio of T4 tumors, which indicates tumor growth past bowel lining, was increased for patients with BRAF mutations (OR 1.761, 95% CI 1.1642.663, P = 0.007). When evaluating 8 studies (n = 2786 patients), the odds ratio of poor tumor differentiation was increased in patients with BRAF mutations (OR 3.816, 95% CI 2.7145.365, P < 0.001). These results support that BRAF mutations indicate poor prognosis for patients with colorectal cancer.	24112392	PubMed		Clancy et al., 2013, Colorectal Dis		4	accepted	7159	399	5	7	140453136	140481403			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7159	https://civic.genome.wustl.edu/links/variants/399	https://civic.genome.wustl.edu/links/genes/5
TP53	7157	R248Q	Lymphoma	0060058				Predisposing	Supports	D	Likely Pathogenic	In mouse models, the R248Q variant had accelerated onset of all tumor types and accelerated death rate. Endogenous R248Q proteins are devoid of several important wildtype tp53 tumor-suppressor functions including transcription of cell cycle arrest genes, replicative senescence and irradiation-induced apoptosis. Patients with germline R248Q/+ genotype showed a drastically younger median age until first tumor onset compared with patients with a null/+ genotype (19.5 vs 30 years, P=0.023).	23538418	PubMed		Hanel et al., 2013, Cell Death Differ.		4	accepted	7161	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7161	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	C238Y	Breast Cancer	1612				Prognostic	Supports	E	Poor Outcome	Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype.	11051239	PubMed		Alsner et al., 2000, Clin. Cancer Res.		3	accepted	7173	2648	45	17	7577568	7577568	C	T	ENST00000269305.4					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7173	https://civic.genome.wustl.edu/links/variants/2648	https://civic.genome.wustl.edu/links/genes/45
H3-3A	3020	MUTATION	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Poor Outcome	Using Sanger sequencing, H3F3A mutations in patients with pediatric low-grade gliomas (PLGGs) were identified (K27M: 13/280; G34R: 5/280). Kaplan-Meier survival analysis showed that H3F3A mutations were associated with shorter progression-free survival (PFS) and overall survival (OS) [15 cases with H3F3A mutation (n=15) vs wt (n=197); p<0.0001 for both OS and PFS]. A further multivariate analysis indicated H3F3A mutation as an independent, unfavorable prognosis marker for both PFS [HR 2.76 (95% CI 1.106.94); p=0.031] and OS [HR 3.96 (95% CI 1.3611.53); p=0.012].	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7189	2652	2537														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7189	https://civic.genome.wustl.edu/links/variants/2652	https://civic.genome.wustl.edu/links/genes/2537
ATRX	546	DELETION	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Poor Outcome	Loss of ATRX was identified in 12 of 247 patients with PLGGs using immunohistochemistry. Survival analysis showed that ATRX loss was associated with adverse overall survival (p<0.0001) and progression-free survival (p<0.002) [mt (n=10) vs wt (n=175)].	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7190	2653	525														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7190	https://civic.genome.wustl.edu/links/variants/2653	https://civic.genome.wustl.edu/links/genes/525
BRAF	673	V600E	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Poor Outcome	Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%). This mutation was enriched in hemispheric tumors (p<0.007) and was associated with shorter progression-free survival (p=0.011) and overall survival (p=0.032) [mt (n=18) vs wt (n=166)].	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7191	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/7191	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
CDKN2A	1029	DELETION	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Poor Outcome	CDKN2A deletion was identified in 24 of 273 patients with PLGGs using FISH analysis. An association between this alteration and BRAFV600E was detected (p=0.0001). Hemispheric tumors with CDKN2A deletion were associated with shorter progression-free survival (p=0.0073) but did not affect overall survival (p=0.5) [mt (n=10) vs wt (n=59)]. CDKN2A deletion remained an independent prognostic factor in multivariate analysis for PFS [HR 4.38 (95% CI 1.0518.23); p=0.043]. CDKN2A deletion was not a prognostic factor in midline or cerebellar tumors.	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7192	2654	14														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7192	https://civic.genome.wustl.edu/links/variants/2654	https://civic.genome.wustl.edu/links/genes/14
BRAF	673	KIAA1549-BRAF	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Better Outcome	KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7193	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7193	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
MYB	4602	AMPLIFICATION	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Better Outcome	MYB amplification was detected in 28 of 263 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. The amplification of MYB was strongly associated with greater progression-free survival (p=0.04) but did not affect overall survival (p=0.13) [amplified (n=19) vs not amplified (n=177)]. MYB amplification was not an independent prognostic factor in multivariate analysis.	29948154	PubMed		Yang et al., 2018, Acta Neuropathol.		4	accepted	7194	2655	3730														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7194	https://civic.genome.wustl.edu/links/variants/2655	https://civic.genome.wustl.edu/links/genes/3730
BRAF	673	KIAA1549-BRAF	Pediatric Low-grade Glioma (PLGG)			Trametinib,Everolimus	Combination	Predictive	Supports	D	Sensitivity/Response	This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment.	29156677	PubMed		Jain et al., 2017, Oncotarget		2	accepted	7199	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7199	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	KIAA1549-BRAF	Pediatric Low-grade Glioma (PLGG)					Prognostic	Supports	B	Better Outcome	Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest.	21610142	PubMed		Hawkins et al., 2011, Clin. Cancer Res.		4	accepted	7200	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7200	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
FGFR1	2260	INTERNAL DUPLICATION	Pediatric Low-grade Glioma (PLGG)					Diagnostic	Supports	B	Positive	This GWAS study identified a structural variant of FGFR1. Duplication of the tyrosine kinase domain (TKD) of FGFR1 was found in 11 of 149 patients (13/151 tumor samples, including 2 recurrent tumors) with pediatric low-grade gliomas (PLGGs) and related low-grade glioneuronal tumors (LGGNTs). This alteration resulted in autophosphorylation of FGFR1 and subsequent activation of downstream PI3K and MAPK/ERK pathways. Also, transfection of Tp53-null astrocytes with TDK duplicated FGFR1 and implantation into the brains of nude mice results in high-grade astrocytic tumours with short latency and complete penetrance. Of note, this variant was present in 24% (8 of 34) of grade II diffuse cerebral gliomas.	23583981	PubMed		Zhang et al., 2013, Nat. Genet.		4	accepted	7203	2659	1885														Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7203	https://civic.genome.wustl.edu/links/variants/2659	https://civic.genome.wustl.edu/links/genes/1885
CRLF2	64109	CRLF2-IGH	B-cell Adult Acute Lymphocytic Leukemia	0060592				Prognostic	Supports	B	Poor Outcome	CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was significantly shorter among patients with CRLF2 overexpression (median 17.8 mo vs. 37.8 mo; P<0.03).	20018760	PubMed		Yoda et al., 2010, Proc. Natl. Acad. Sci. U.S.A.		4	accepted	7212	2663	14303														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/7212	https://civic.genome.wustl.edu/links/variants/2663	https://civic.genome.wustl.edu/links/genes/14303
PIK3CA	5290	EXON 10 and EXON 21 MUTATIONS	Rectum Cancer	1993	Neoplasm of the rectum			Prognostic	Supports	B	Poor Outcome	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA mutations in exons 10 and 21 (listed as exons 9 and 20 in the source, as it was common to exclude non-coding exon 1). PIK3CA mutations were identified in 19 cases (12 in exon 10 and 7 in exon 21). PIK3CA mutations were associated with a 3-fold increase in risk of recurrence of rectal tumors (5-year risk: 27.8% vs 9.4%, p = 0.008). Furthermore, patients with PIK3CA mutations experienced a shorter time to recurrence compared to those with WT PIK3CA (median: 7.9 vs 19.6 months, p = 0.07). Patients with concomitant PIK3CA and KRAS mutations had a similar local reoccurrence rate to patients with PIK3CA mutations only. In multivariate analysis, PIK3A mutation was an independent predictor for the development of local recurrences (HR: 3.4, P =0.017).	19903786	PubMed		He et al., 2009, Clin. Cancer Res.		3	accepted	7220	1991	37													PIK3CA exon 10 and exon 21 mutations occasionally co-occur in the same tumor, same cell line, or same clone (if clonality information is available). Note that exons 10 and 21 are sometimes listed as exons 9 and 20 in publications, as it was once common to exclude non-coding exon 1.	Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7220	https://civic.genome.wustl.edu/links/variants/1991	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	SNX2-ABL1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Dasatinib		Predictive	Supports	C	Resistance	A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. After first relapse the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, the patient eventually died of disease.	24215620	PubMed		Masuzawa et al., 2014, Eur. J. Haematol.		2	accepted	7241	2678	4														Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/7241	https://civic.genome.wustl.edu/links/variants/2678	https://civic.genome.wustl.edu/links/genes/4
FGFR1	2260	AMPLIFICATION	Breast Cancer	1612		Pazopanib		Predictive	Supports	C	Sensitivity/Response	Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Duration of Treatment or median PFS was not reported at the time of publication.	29223982	PubMed		Cheng et al., 2017, J Natl Compr Canc Netw		2	accepted	7246	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/7246	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
ABL1	25	ABL1-RCSD	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Imatinib		Predictive	Supports	C	Sensitivity/Response	The ABL1-RCSD1 fusion was identified in a 6 yo boy with Ph-like B-ALL and hyperleukocytosis. Following standard induction therapy the patient had an MRD of 16.4% in bone marrow, indicating a poor response. Addition of imatinib decreased MRD to 2% at day 29. In addition, this study reports that expression of the ABL1-RCSD1 fusion protein in murine Ba/F3 cells promotes cytokine-independent proliferation and that viable cells were reduced following exposure to dasatinib.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7248	2680	4														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7248	https://civic.genome.wustl.edu/links/variants/2680	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	ABL1-RCSD1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Dasatinib		Predictive	Supports	D	Sensitivity/Response	The ABL1-RCSD1 fusion was identified in a 6 yo boy with Ph-like B-ALL and hyperleukocytosis. Following standard induction therapy the patient had an MRD of 16.4% in bone marrow, indicating a poor response. Addition of imatinib decreased MRD to 2% at day 29. In addition, this study reports that expression of the ABL1-RCSD1 fusion protein in murine Ba/F3 cells promotes cytokine-independent proliferation and that viable cells were reduced following exposure to dasatinib.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7249	2681	4														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7249	https://civic.genome.wustl.edu/links/variants/2681	https://civic.genome.wustl.edu/links/genes/4
ABL2	27	ABL2 fusions	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650		Dasatinib		Predictive	Supports	D	Sensitivity/Response	The ABL2-RCSD1 fusion was identified in a 5 yo boy with Ph-like B-ALL and Klinefelter syndrome. Following standard induction therapy the patient had an MRD of 1.2% in bone marrow, and continued to be MRD positive at 6 months off therapy (0.029%). He received imatinib and a bone marrow performed 2 months later showed no MRD. He maintained remission at one year post-diagnosis, on chemotherapy and imatinib. In addition, this study reports that expression of the ABL2-RCSD1 fusion protein in murine Ba/F3 cells promotes cytokine-independent proliferation and viable cells were reduced following exposure to dasatinib.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7251	2571	101														Somatic	2021-03-31 18:23:11 UTC	https://civic.genome.wustl.edu/links/evidence_items/7251	https://civic.genome.wustl.edu/links/variants/2571	https://civic.genome.wustl.edu/links/genes/101
JAK2	3717	SSBP2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650		Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	The SSBP2-JAK2 fusion was identified in a 14 yo male with Ph-like B-ALL, a t(5;9)(q12;p1?3), and a WBC of 160,000. Following 4-drug induction therapy the patient had an MRD of 5.5%, indicating a poor response. After two additional weeks of induction, intermittent ruxolitinib was added to his regimen and a bone marrow performed 3 weeks after the addition of ruxolitinib showed 1% MRD. Following consolidation, the bone marrow showed 0.3% MRD.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7257	2661	28														Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7257	https://civic.genome.wustl.edu/links/variants/2661	https://civic.genome.wustl.edu/links/genes/28
MET	4233	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	3908		Tepotinib		Predictive	Supports	B	Sensitivity/Response	In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.	160289	ASCO	9016	Enriqueta Felip, 2018, ASCO Annual Meeting, Abstract 9016	NCT02864992	3	accepted	7272	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7272	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
IDH1	3417	MUTATION	Acute Myeloid Leukemia	9119		Ivosidenib		Predictive	Supports	A	Sensitivity/Response	I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%.	29860938	PubMed		DiNardo et al., 2018, N. Engl. J. Med.	NCT02074839	3	accepted	7278	645	26	2	209101803	209116275			ENST00000415913.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7278	https://civic.genome.wustl.edu/links/variants/645	https://civic.genome.wustl.edu/links/genes/26
ROS1	6098	FUSION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	In the ongoing phase 1 study, patients with NSCLC with ROS1 rearrangement received crizotinib. ORR was 72%, median duration of response was 24.7 months, mPFS was 19.3 months and mOS was 51.4 months.	30980071	PubMed		Shaw et al., 2019, Ann. Oncol.	NCT00585195	5	accepted	7282	2693	4941														Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/7282	https://civic.genome.wustl.edu/links/variants/2693	https://civic.genome.wustl.edu/links/genes/4941
FLT3	2322	MUTATION	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	B	Sensitivity/Response	In a phase 1/2 trial, patients with refractory or relapsed AML with FLT3 mutation (n=191; ITD n=162, D835 n=13, ITD-D835 n=16) received gilteritinib. 49% (93/191) of patients achieved an overall response, 9% (n=18) complete remission, 5% (n=10) complete remission with incomplete platelet recovery, 22% (n=42) complete remission with incomplete hematological recovery, and 12% (n=23) reached partial remission. The refractory or relapsed AML FLT wildtype group treated with gilteritinib(n=58) had lower overall response rate (12%), complete remission (2%), complete remission with incomplete platelet recovery (0%), complete remission with incomplete hematological recovery (7%), and fewer reached partiral remission (3%). Also, bone marrow myeloblast reduction was greater in FLT3 mutant patients compared to FLT3 wildtype.	28645776	PubMed		Perl et al., 2017, Lancet Oncol.	NCT02014558	4	accepted	7283	519	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/7283	https://civic.genome.wustl.edu/links/variants/519	https://civic.genome.wustl.edu/links/genes/24
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	In a phase 3 trial, 303 patients with NSCLC with ALK fusion were randomly assigned to alectinib arm (N=152) or crizotinib arm (N=151). PFS was significantly longer with alectinib than with crizotinib (HR for disease progression or death 0.47, 95% CI: 0.34-0.65, p<0.001). Investigator-assessed RR was 82.9% in alectinib arm and 75.5% in crizotinib arm. CNS RR in patients with measurable CNS lesions was 81% and 50% for alectinib and crizotinib, respectively. Eight patients in the alectinib group, in comparison to one patient with crizotinib, had a complete CNS response. Despite longer treatment duration for alectinib, there were fewer grade 3-5 adverse events compared with crizotinib treatment.	28586279	PubMed		Peters et al., 2017, N. Engl. J. Med.	NCT02075840	5	accepted	7284	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/7284	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	A	Sensitivity/Response	In a phase 3 trial, patients with previously treatmented NSCLC with ALK fusion were randomly assigned to ceritinib or chemotherapy. Ceritinib showed a significant improvement in median  PFS compared with chemotherapy (54 months [95% CI 41-69] for ceritinib vs 16 months [14-28] for chemotherapy; hazard ratio 049 [036-067]; p<00001).	28602779	PubMed		Shaw et al., 2017, Lancet Oncol.	NCT01828112	5	accepted	7285	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/7285	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	B	Sensitivity/Response	In a phase 2 trial, patients with NSCLC with ALK fusion received lorlatinib. In treatment-naive patients, ORR was 90.0% In patients with at least one previous ALK tyrosine kinase inhibitor, ORR were achieved in 47.0%.In patients who had only received crizotinib ORR was achieved in 69.5%.	30413378	PubMed		Solomon et al., 2018, Lancet Oncol.	NCT01970865	4	accepted	7286	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/7286	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
BRAF	673	V600	Melanoma	1909		Encorafenib,Binimetinib	Combination	Predictive	Supports	A	Sensitivity/Response	In a phase 3 trial, patients with melanoma with BRAF V600E or V600K mutation were randomly assigned to encorafenib plus binimetinib or vemurafenib or encorafenib. mPFS was 149 months (95% CI 110-185) in the encorafenib plus binimetinib group and 73 months (56-82) in the vemurafenib group (hazard ratio [HR] 054, 95% CI 041-071; two-sided p<00001)	29573941	PubMed		Dummer et al., 2018, Lancet Oncol.	NCT01909453	5	accepted	7287	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7287	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
KIT	3815	V555_V559DEL	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	Patient 36 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V555_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off.  The patient experienced progressive disease. Time to progression and overall survival were 10 and 108 weeks.	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	7288	2695	29														Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/7288	https://civic.genome.wustl.edu/links/variants/2695	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K550_K559DEL	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Does Not Support	C	Resistance	Patient 78 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/one weeks off. This patient experienced partial response; time to progression and overall survival were censored at 54 weeks and 84 weeks (Table A1).	18955458	PubMed		Heinrich et al., 2008, J. Clin. Oncol.		2	accepted	7289	2696	29	4	55593582	55593611	AAACCCATGTATGAAGTACAGTGGAAGGTT		ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7289	https://civic.genome.wustl.edu/links/variants/2696	https://civic.genome.wustl.edu/links/genes/29
ABL1	25	FOXP1-ABL1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Dasatinib		Predictive	Supports	C	Sensitivity/Response	A 16-year-old Caucasian boy was diagnosed with B-ALL. Karyotype showed an abnormal clone characterized by the t(3;9)(p13;q34.1). This translocation results in an abnormal fusion between the FOXP1 gene in 3p13 and the ABL1 in 9q34.1. The FOXP1-ABL1 fusion is known to be associated with Ph-like B-ALL subtype of B-ALL.  The patient was treated with Berlin-Frankfurt-Mnster (BFM) high-risk 4-drug induction chemotherapy with prednisone, daunorubicin, vincristine, and pegasparaginase and had 0.013% MRD at the end of indusciton. Tyrosine kinase inhibitor dasatinib was added to the consolidationchemotherapy with cyclophosphamide, cytarabine, peg-asparaginase, mercaptopurine, and vincristine. End-of-consolidation bone marrow tested negative for MRD. The patient was continued on standard high-risk BFM therapy, plus dasatinib.	30938769	PubMed		Yenamandra et al., 2019, Lab Med		1	accepted	7292	2682	4														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7292	https://civic.genome.wustl.edu/links/variants/2682	https://civic.genome.wustl.edu/links/genes/4
CDKN2A	1029	MUTATION	Pancreatic Cancer	1793		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed.	158598	ASCO	2532	Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532	NCT02693535	4	accepted	7299	2704	14														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7299	https://civic.genome.wustl.edu/links/variants/2704	https://civic.genome.wustl.edu/links/genes/14
CDKN2A	1029	MUTATION	Cholangiocarcinoma	4947		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks were observed.	158598	ASCO	2532	Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532	NCT02693535	4	accepted	7300	2704	14														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7300	https://civic.genome.wustl.edu/links/variants/2704	https://civic.genome.wustl.edu/links/genes/14
ERBB2	2064	AMPLIFICATION	Colorectal Cancer	9256		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	In update report of a phase 2 trial, Patients with colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objective response rate was 32% (n=18/57).	30857956	PubMed		Meric-Bernstam et al., 2019, Lancet Oncol.	NCT02091141	3	accepted	7302	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7302	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
PIK3CA	5290	MUTATION	Breast Cancer	1612		Fulvestrant,Alpelisib	Combination	Predictive	Supports	A	Sensitivity/Response	In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85.	31091374	PubMed		Andr et al., 2019, N. Engl. J. Med.	NCT02437318	5	accepted	7313	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/7313	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
EGFR	1956	EGFR-RAD51	Lung Adenocarcinoma	3910		Icotinib		Predictive	Supports	C	Sensitivity/Response	A case of EGFR-RAD51 fusion in lung adenocarcinoma that showed a response to icotinib, .	31064887	PubMed		Guan et al., 2019, Oncologist		2	accepted	7314	2203	19														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/7314	https://civic.genome.wustl.edu/links/variants/2203	https://civic.genome.wustl.edu/links/genes/19
PIK3CA	5290	E542K	Breast Cancer	1612		Fulvestrant,Alpelisib	Combination	Predictive	Supports	A	Sensitivity/Response	In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisibfulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H1047X.	31091374	PubMed		Andr et al., 2019, N. Engl. J. Med.	NCT02437318	3	accepted	7315	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/7315	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37
BRAF	673	KIAA1549-BRAF	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF.	18974108	PubMed		Jones et al., 2008, Cancer Res.		4	accepted	7319	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7319	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	KIAA1549-BRAF	Pilocytic Astrocytoma	4851				Functional	Supports	D	Gain of Function	This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose.	18974108	PubMed		Jones et al., 2008, Cancer Res.		3	accepted	7337	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7337	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600	Colorectal Cancer	9256		Vemurafenib,Irinotecan,Cetuximab	Combination	Predictive	Supports	B	Sensitivity/Response	A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enrolled from December 2014 to April 2016. The patients were randomized into groups with irinotecan and cetuximab with vemurafenib (VIC group) or without (IC group). The VIC group showed an improvement of progression of free survival (HR 0.42, 95% CI: 0.26 to 0.66, p < 0.001) with a median value of 4.4 months compared to 2.0 months for the IC group. In addition, for the VIC group, there was a 16% drug response rate while the IC group had a 4% drug response rate (p-value = 0.08). Some grade 3/4 adverse events were higher in the experimental arm, and skin toxicity and fatigue showed no increase.	147167	ASCO	3505	Scott Kopetz, 2017, ASCO Annual Meeting, Abstract 3505	NCT02164916	3	accepted	7355	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7355	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5
EGFR	1956	MUTATION	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Sensitivity/Response	In the ARCHER 1050 Phase 3 Trial (NCT01774721), 452 patients with newly diagnosed stage IIIB/IV or recurrent NSCLC exon 19 deletion or the Leu858Arg mutation, (with or without the T790M) were treated with second generation tyrosine kinase inhibitor (TKI) dacomitinib (227 patients) or first generation TKI gefitinib (225 patients).  Primary endpoint was progression free survival (PFS), and median PFS according to masked independent review was 14.7 months (95% CI 11.116.6) with dacomitinib group 9.2 months (9.111.0) with gefitinib (HR 059, 95% CI 047074; p<00001).  Benefit of dacomitinib over gefitinib was lower in non-Asian patient subgroup (n=106) than in Asian group (n=346) although authors note smaller sample size may explain this. Authors state that PFS was significantly improved with first line dacomitinib treatment, and that dacomitinib should be considered for EGFR mutant NSCLC treatment.	28958502	PubMed		Wu et al., 2017, Lancet Oncol.	NCT01774721	4	accepted	7363	442	19	7	55086794	55279321			ENST00000275493.2					75	GRCh37		Somatic	2021-03-31 18:22:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/7363	https://civic.genome.wustl.edu/links/variants/442	https://civic.genome.wustl.edu/links/genes/19
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In a preclinical trial, multiple experiments testing the effectiveness of ponatinib on the mutation FLT3-ITD in acute myeloid leukemia (AML) were conducted. Ponatinib was very effective in targeting the FLT3-ITD mutation in MV4-11 cell lines (growth inhibition: IC50=2 nmol/L) compared to native FLT3 in RS4;11 cell lines (IC50>100 nmol/L). Additionally, MV4-11 cell lines incubated for 1 hour were shown to have reduced phosphorylation of tyrosine kinases beginning at a ponatinib concentration of 0.3 nmol/L. Ponatinib was shown to induce apoptotic mechanisms measured by caspase-3/7 activity in MV4-cell lines. In mice with the MV4-11 xenograft, ponatinib was very effective in targeting the FLT3-ITD mutation, as dosages of 1-5 mg/kg led to tumor growth inhibition and regression, while dosages of 10 and 25 mg/kg led to complete tumor regression. In primary blast cells from AML patients, Ponatinib was selectively effective in growth inhibition of the FLT3-ITD patient cells (n=1, IC50=4nmol/L) when compared to the native FLT3 patient cells (n=3, IC50>100nmol/L).	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		5	accepted	7369	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7369	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
KIT	3815	N822K	Acute Myeloid Leukemia	9119		Sunitinib,Sorafenib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In a preclinical trial, the AML cell line Kasumi-1 with the KIT mutation N822K was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the KIT mutation (IC50=8 nmol/L) compared to sorafenib (IC50=59 nmol/L) and sunitinib (IC50=56 nmol/L).	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		3	accepted	7370	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7370	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
FGFR1	2260	FGFR1 FUSIONS	Acute Myeloid Leukemia	9119		Sorafenib,Sunitinib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the fusion mutation (IC50=17 nmol/L) compared to sorafenib (IC50>100 nmol/L) and sunitinib (IC50>100 nmol/L).	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		3	accepted	7375	569	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37		Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7375	https://civic.genome.wustl.edu/links/variants/569	https://civic.genome.wustl.edu/links/genes/1885
PDGFRA	5156	FIP1L1-PDGFRA	Acute Myeloid Leukemia	9119		Sorafenib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L).	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		3	accepted	7378	574	38	4	54243812	54294350			ENST00000337488.6	4	55141008	55164414	ENST00000257290.5	75	GRCh37	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).	Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/7378	https://civic.genome.wustl.edu/links/variants/574	https://civic.genome.wustl.edu/links/genes/38
KIT	3815	N822K	Acute Myeloid Leukemia	9119		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at IC50 values 20 nmol/L and 8 nmol/L respectively.	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		2	accepted	7379	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7379	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
FGFR1	2260	FGFR1OP2-FGFR1	Acute Myeloid Leukemia	9119		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In this preclinial trial, the AML cell line KG1 with FGFR1OP2-FGFR1 mutation was treated with Ponatinib. This drug effectively inhibits both FGFR phosphorylation and viability for KG1 cells at IC50 values 3 nmol/L and 17 nmol/L respectively.	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		2	accepted	7380	2743	1885														Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/7380	https://civic.genome.wustl.edu/links/variants/2743	https://civic.genome.wustl.edu/links/genes/1885
FLT3	2322	ITD	Leukemia	1240		Sorafenib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the FLT3-ITD mutation (IC50=2 nmol/L) compared to sorafenib (IC50=4 nmol/L) and sunitinib (IC50=12 nmol/L). Conversely, all three TKIs each were not effective in the growth inhibition of cells with native FLT3 (IC50>100 nmol/L).	21482694	PubMed		Gozgit et al., 2011, Mol. Cancer Ther.		4	accepted	7382	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7382	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
IKZF1	10320	IKZF1 deletion and mutation	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	This study reports on two pediatric cohorts with B-ALL. In the first cohort of 221 high risk, BCR-ABL1-negative pediatric patients, 55.2% of IKZF1 positive patients had a hematologic relapse, 73.4% of IKZF1 positive patients had any relapse, and 74.6% of IKZF1 positive patients had an event (hematologic relapse, any relapse, a second malignant condition or death) as compared to 14%, 25.2%, and 27.1%, respectively, without an IKZF1 alteration. In a less selected cohort of 258 patients with both standard and high risk disease, with common aneuploidies including BCR-ABL1, 46.3% of IKZF1 positive patients had a hematologic relapse, 48.4% of IKZF1 positive patients had any relapse, and 60.5% of IKZF1 positive patients had an event as compared to 22.5%, 25.6%, and 27.6%, respectively, without an IKZF1 alteration. IKZF1 alteration is defined as a deletion or mutation in the gene. Gene expression profiles were found to be similar to BCR-ABL1 positive B-ALL, even when the BCR-ABL1 translocation was not present. The study concludes that IKZF1 alterations are associated with a very poor outcome in B-ALL.	19129520	PubMed		Mullighan et al., 2009, N. Engl. J. Med.		4	accepted	7383	2744	73														Somatic	2021-03-31 18:23:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/7383	https://civic.genome.wustl.edu/links/variants/2744	https://civic.genome.wustl.edu/links/genes/73
KIT	3815	A502_Y503insAY	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	D	Sensitivity/Response	In an in vitro study, an IL3 independant Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to sunitinib treatment (IC50: 5nmol/L). IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		2	accepted	7392	1558	29	4	55592182	55592183		GCCTAT							GRCh37		Somatic	2021-03-31 18:22:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7392	https://civic.genome.wustl.edu/links/variants/1558	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560_L576DEL	Gastrointestinal Stromal Tumor	9253		Ponatinib,Imatinib	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	In the patient-derived cell line GIST430 harboring KIT V560_L576del primary activating mutation implanted in mice, imatinib and ponatinib were shown to reduce KIT phosphorylation compared to the vehicle. In GIST430 cell lines, ponatinib and imatinib reduced phospho-AKT and phospho-ERK levels. A cell line derived from GIST430 patients expressing KIT V560_L576del primary mutation demonstrated sensitivity to imatinib (IC50: 61nmol/L) and ponatinib (IC50: 12nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >5000nmol/L and 2807nmol/L for these drugs respectively. IC50 was determined by assessing cell viability.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	7393	1550	29	4	55593612	55593662									GRCh37		Somatic	2021-03-31 18:22:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/7393	https://civic.genome.wustl.edu/links/variants/1550	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	V560G	Gastrointestinal Stromal Tumor	9253		Ponatinib,Imatinib,Regorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In an in vitro kinase study, a KIT V560G primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 38nmol/L vs. 640nmol/L), regorafenib (IC50: 27nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.3nmol/L vs. 6nmol/L) treatments compared to the wildtype KIT. IC50 was determined by assessing kinase activity.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	7395	972	29	4	55593613	55593613	T	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7395	https://civic.genome.wustl.edu/links/variants/972	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	K642E	Gastrointestinal Stromal Tumor	9253		Ponatinib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	The GIST882 patient derived cell line expressing KIT K642E mutation demonstrated sensitivity to ponatinib (IC50: 31nmol/L) and sunitinib (IC50: 54nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >2807nmol/L and >5000nmol/L for these drugs respectively. IC50 was determined by assessing cell viability. The GIST882 cell line only showed reduced levels of phospho-KIT and phospho-ERK at high concentrations for ponatinib and sunitinib, while phospho-AKT levels were reduced at all concentrations for ponatinib and sunitinib.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		3	accepted	7397	978	29	4	55594221	55594221	A	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/7397	https://civic.genome.wustl.edu/links/variants/978	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816E	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	7401	1559	29	4	55599322	55599322	C	G	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7401	https://civic.genome.wustl.edu/links/variants/1559	https://civic.genome.wustl.edu/links/genes/29
BRAF	673	KIAA1549-BRAF	Childhood Pilocytic Astrocytoma	6812		Vemurafenib,Sorafenib	Substitutes	Predictive	Supports	D	Resistance	A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.	28002790	PubMed		Selt et al., 2017, Oncotarget		2	accepted	7402	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7402	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
KIT	3815	A829P	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	7413	990	29	4	55602664	55602664	G	C							GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7413	https://civic.genome.wustl.edu/links/variants/990	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	N822K	Gastrointestinal Stromal Tumor	9253		Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Resistance	Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and N822K mutations (Sunitinib IC50 for growth inhibition: 225 +- 19 nM, Imatinib IC50: 483 +- 24 nM) did show resistance towards Sunitinib and Imatinib compared to Ba/F3 cells with the del 557-558 alone (Sunitinib IC50: 7 +- 2 nM, Imatinib IC50: 27 +- 8 nM).  Sunitinib and Imatinib did not completely inhibit KIT phosphorylation at 1000 nM, which was the highest concentration tested. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. From these results, N822K mutations were the most frequent KIT mutation observed in resistant Ba/F3 cell populations incubated in Sunitinib. In Imatinib incubated cells, N822K mutations were seen in approximately 10% of resistant Ba/F3 cell clones.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	7414	1263	29	4	55599340	55599340	T	A	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7414	https://civic.genome.wustl.edu/links/variants/1263	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	A829P	Gastrointestinal Stromal Tumor	9253		Sunitinib,Imatinib	Substitutes	Predictive	Supports	D	Resistance	Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary sunitinib and imatinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and A829P mutations did show resistance towards Sunitinib and Imatinib (Sunitinib IC50 for growth inhibition: 319 +- 88 nM and Imatinib IC50: 179 +- 27 nM) compared to Ba/F3 cells with the del 557-558 mutation (Sunitinib IC50: 7 +- 2 nM and Imatinib IC50:  27 +- 8 nM). Imatinib and Sunitinib were shown to not reduce p-KIT at all in Ba/F3 cells with del 557-558/ A829P mutations.  Patient-derived GIST-T1/829 cells with 560-578 deletion/A829P mutations (Sunitinib IC50: 1168 nM and Imatinib IC50:1201 nM) did show resistance towards Sunitinib and Imatinib compared to GIST-T1 cells with 560-578 deletion alone (Sunitinib IC50: 15 nM and Imatinib IC50: 30 nM). Sunitinib and Imatinib did not inhibit p-KIT, p-ERK, and p-AKT in GIST-T1/829 cells.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		4	accepted	7415	990	29	4	55602664	55602664	G	C							GRCh37		Somatic	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7415	https://civic.genome.wustl.edu/links/variants/990	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	T670I	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		5	accepted	7416	1267	29	4	55595519	55595519	C	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/7416	https://civic.genome.wustl.edu/links/variants/1267	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	T670I	Gastrointestinal Stromal Tumor	9253		Sunitinib,Ponatinib	Substitutes	Predictive	Does Not Support	D	Resistance	Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary ponatinib and sunitinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Ponatinib and Sunitinib resistances. Ba/F3 cells with del 557-558/T670I mutations (Ponatinib IC50 = 15 +/- 1 nM, Sunitinib IC50 = 12 +/- 2 nM) did not show resistance towards Ponatinib and Sunitinib compared to Ba/F3 cells with del 557-558 alone (Ponatinib IC50 = 3 +/- 0, Sunitinib IC50 = 7  +/- 2 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (Ponatinib IC50 = 8 nM, Sunitinib IC50 = 15 nM) showed no resistance towards Ponatinib and Sunitinib compared to GIST-T1 cells with 560-578 deletion (Ponatinib IC50 = 5 nM, Sunitinib IC50 = 48 nM). Additionally, del 557-558/T670I cells was implanted into mice and treated with Ponatinib or Sunitinib. Ponatinib or Sunitinib were shown to be effective in treating the Ba/F3 mutant cells as tumor volume progressively decreased to zero at around 14 days.	25239608	PubMed		Garner et al., 2014, Clin. Cancer Res.		5	accepted	7417	1267	29	4	55595519	55595519	C	T	ENST00000288135.5					75	GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/7417	https://civic.genome.wustl.edu/links/variants/1267	https://civic.genome.wustl.edu/links/genes/29
NTRK3	4916	ETV6-NTRK3	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor burden (4 cycles showed ~50% reduction). Treatment was followed up by surgical resection resulting in a disease-free status at the time of last follow-up (>1 year).	30204247	PubMed		DuBois et al., 2018, Cancer	NCT02637687	3	accepted	7418	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/7418	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK1	4914	TPM3-NTRK1	Spindle Cell Sarcoma	4235		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a significant tumor burden reduction of 31%, he underwent surgical resection, with R0 resection and no evidence for tumor recurrence at the time of last follow-up (>7 months).	30204247	PubMed		DuBois et al., 2018, Cancer	NCT02637687	3	accepted	7419	2992	3983														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/7419	https://civic.genome.wustl.edu/links/variants/2992	https://civic.genome.wustl.edu/links/genes/3983
NTRK1	4914	PDE4DIP-NTRK1	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemotherapy, Larotrectinib reduced tumor size by 37% after 2 cycles and 64% after 6 cycles. An R2 resection was performed and Larotrectinib again reduced tumor progression. A second R2 resection was followed by adjuvant radiotherapy and Larotrectinib cycles and the patient remained in complete response at the time of the last follow-up.	30204247	PubMed		DuBois et al., 2018, Cancer	NCT02637687	2	accepted	7420	2289	3983														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/7420	https://civic.genome.wustl.edu/links/variants/2289	https://civic.genome.wustl.edu/links/genes/3983
ALK	238	ALTERNATIVE TRANSCRIPT (ATI)	Mucosal Melanoma	0050929		Entrectinib		Predictive	Does Not Support	C	Sensitivity/Response	ALK expression was analyzed in 45 melanoma patient-derived xenografts (PDXs), with 11/45 showing ALK expression. Four PDX tumours had only wild-type ALK expression, four had only ALK alternative transcript (ATI) expression, two had wild-type and ATI expression, and one had ALK ATI and multiple EML4-ALK fusion variants. In vitro and in vivo experiments showed that an EML4-ALK fusion expressing sample responded to ALK inhibitors while wild-type ALK and ALK ATI expressing samples did not. Decreased activity in downstream signaling targets with ALK inhibitor treatment was noted for samples expressing fusion ALK but not those expressing only ALK ATI. Further, a patient with metastatic mucosal melanoma expressing ALK ATI was treated with the ALK/ROS1/TRK inhibitor entrectinib but experienced rapid clinical and radiologic progression resulting in treatment discontinuation after two weeks.	29054983	PubMed		Couts et al., 2018, Mol. Cancer Ther.		4	accepted	7421	839	1													This novel ALK transcript (alternative isoform) initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19.	N/A	2021-03-31 18:22:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/7421	https://civic.genome.wustl.edu/links/variants/839	https://civic.genome.wustl.edu/links/genes/1
FGFR3	2261	MUTATION	Transitional Cell Carcinoma	2671		Erdafitinib		Predictive	Supports	A	Sensitivity/Response	In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a history of disease progression during or after at least one course of chemotherapy. The response rate in all patients was 40% (40/99). The response rate in patients with FGFR3 mutation was 49% (36/74). FGFR3 mutations included G370C, R248C, S249C, Y373C, and R48C.	31340094	PubMed		Loriot et al., 2019, N. Engl. J. Med.	NCT02365597	4	accepted	7422	827	23	4	1795039	1810599			ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7422	https://civic.genome.wustl.edu/links/variants/827	https://civic.genome.wustl.edu/links/genes/23
TP53	7157	R273H	Osteosarcoma	3347		Doxorubicin,Methotrexate	Substitutes	Predictive	Supports	D	Resistance	Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a western blot, Saos-2/TP53-R273H cells were shown to have a 0.6-fold down-regulation (compared to the Control) for Procaspase-3 protein expression. In addition, Saos-2/TP53-R273H cells were shown to be more resistant to methotrexate and doxorubicin. Reduced levels of drug-induced apoptosis were seen in Saos-2/TP53-R273H cells treated with doxorubicin (0.05 uM and 0.10 uM) and methotrexate (25 nM and 50 nM) in DNA fragmentation assays. According to the results, TP53-R273H induces drug resistance when procaspase-3 is down-regulated.	17363498	PubMed		Wong et al., 2007, Mol. Cancer Ther.		3	accepted	7430	122	45	17	7577120	7577120	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7430	https://civic.genome.wustl.edu/links/variants/122	https://civic.genome.wustl.edu/links/genes/45
NFE2L2	4780	MUTATION	Lung Squamous Cell Carcinoma	3907		Sapanisertib		Predictive	Supports	B	Sensitivity/Response	In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7and disease control rate was 100%. NFE2L2 mutations included Exon 2 deletion, F37V, D29H, W24C, E79K, G31R, R34G, R34Q, W24R, D77H, and T80R.	174406	ASCO	9085	Paul K. Paik, 2019, ASCO Annual Meeting, Abstract 9085	NCT02417701	3	accepted	7446	2749	3878														Somatic	2021-03-31 18:22:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/7446	https://civic.genome.wustl.edu/links/variants/2749	https://civic.genome.wustl.edu/links/genes/3878
IDH1	3417	MUTATION	Cholangiocarcinoma	4947		Ivosidenib		Predictive	Supports	B	Sensitivity/Response	In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 months, and median overall survival was 13.8 months.	31300360	PubMed		Lowery et al., 2019, Lancet Gastroenterol Hepatol	NCT02073994	3	accepted	7447	645	26	2	209101803	209116275			ENST00000415913.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7447	https://civic.genome.wustl.edu/links/variants/645	https://civic.genome.wustl.edu/links/genes/26
STAG2	10735	MUTATION	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Poor Outcome	In a retrospective cohort study of 389 uniformly treated acute myeloid leukemia (AML) patients, 23 patients harbored mutations in genes of the cohesin complex including 5 who harbored mutations in STAG2. Mutation in the cohesin complex was not associated with worse overall survival (OS) or relapse free survival (RFS) compared to wildtype patients. The presence of STAG2 mutations had no influence on OS or RFS compared to wildtype (OS HR: 1.53, p = 0.4; RFS HR: 1.26, P = 0.7), though the authors note that the analysis was limited by the small number of patients. Authors speculate that co-occurring mutations in NPM1 may mask prognostic effects of STAG2 mutations.	24335498	PubMed		Thol et al., 2014, Blood	NCT00209833	2	accepted	7451	669	8553	X	123176418	123217308			ENST00000218089.9					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7451	https://civic.genome.wustl.edu/links/variants/669	https://civic.genome.wustl.edu/links/genes/8553
KIT	3815	S628N	Melanoma	1909		Imatinib		Predictive	Does Not Support	C	Sensitivity/Response	A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S628N mutation was not present in the blood, which confirmed that it was a somatic mutation. After 3 months of imatinib treatment (300 mg/d for first three weeks, then 400 mg/d), the patient exhibited disease progression and increased tumor size, and after an additional three months of imatinib treatment (400 mg/d), the patient developed multiple supratentorial brain metastases in addition to increased lung metastases and died 5 days later. The authors reported preclinical data which indicated variant sensitivity to imatinib. although this outcome did not coroberate the preclinical result, the authors still concluded the variant may be sensitive.	25317746	PubMed		Vita et al., 2014, JAMA Dermatol		3	accepted	7463	1659	29	4	55594180	55594180	G	A							GRCh37		Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/7463	https://civic.genome.wustl.edu/links/variants/1659	https://civic.genome.wustl.edu/links/genes/29
KIT	3815	D816V	Cancer	162		Dasatinib,Imatinib	Substitutes	Predictive	Supports	C	Resistance	In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment.	25317746	PubMed		Vita et al., 2014, JAMA Dermatol		2	accepted	7465	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7465	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29
RET	5979	CCDC6-RET	Colorectal Cancer	9256		Agerafenib		Predictive	Supports	C	Sensitivity/Response	A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 19 months on treatment.	29538669	PubMed		Pietrantonio et al., 2018, Ann. Oncol.	NCT01877811	3	accepted	7480	626	42														Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7480	https://civic.genome.wustl.edu/links/variants/626	https://civic.genome.wustl.edu/links/genes/42
ALK	238	CAD-ALK	Colorectal Cancer	9256		Entrectinib		Predictive	Supports	C	Sensitivity/Response	A patient with colorectal cancer harboring CAD-ALK fusion gene was treated with ALK inhibitor entrectinib resulted in durable objective tumor response.	26633560	PubMed		Amatu et al., 2015, Br. J. Cancer		3	accepted	7481	2769	1														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7481	https://civic.genome.wustl.edu/links/variants/2769	https://civic.genome.wustl.edu/links/genes/1
ROS1	6098	GOPC-ROS1	Glioblastoma Multiforme	3068		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	Ectopic expression of GOPCROS1 in Ba/F3 cells induced cytokine-independent growth whereas overexpression of ROS1 alone did not. Using a series of tyrosine kinase inhibitors, lorlatinib was the most effective inhibitor of cytokine-independent growth. The glioblastoma cell line U118MG was shown to have the GOPCROS1 fusion. Lorlatinib and other TKIs were unable to inhibit growth of U118MG in standard growth assays (2D). However, lorlatinib did induce cell death in both ultra-low attachment dishes and spheroid assays, and significantly increased overall survival in an orthotopic intracranial xenograft model using this cell line (N=4) compared to mice on vehicle alone (N=4, p<0.001, ANOVA). Authors postulated that cell adhesion permitted sufficient to bypass survival signaling.	30171048	PubMed		Davare et al., 2018, Clin. Cancer Res.		3	accepted	7483	2770	4941														Somatic	2021-03-31 18:22:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7483	https://civic.genome.wustl.edu/links/variants/2770	https://civic.genome.wustl.edu/links/genes/4941
NRG1	3084	ATP1B1-NRG1	Pancreatic Ductal Adenocarcinoma	3498		Afatinib		Predictive	Supports	C	Sensitivity/Response	Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old metastatic PDAC patient harbored an in-frame fusion of exon 3 of ATP1B1 with exon 2 of NRG1 and no other observed clinically relevant small mutations. Compared to this PDAC cohort, significant overexpression of NRG1 (exons 2-7) was observed in the tumor. Of note, the EGF-like domain of NRG1 (exons 6 & 7), which is required for HER-family kinase activation, is preserved in the fusion. Treatment with afatinib resulted in significant clinical response as measured by imaging, as well as a drastic reduction in CA19-9 levels. Disease progression was noted 5.5 months after treatment initiation.	31068372	PubMed		Jones et al., 2019, Clin. Cancer Res.		3	accepted	7492	2178	2593														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7492	https://civic.genome.wustl.edu/links/variants/2178	https://civic.genome.wustl.edu/links/genes/2593
NRG1	3084	APP-NRG1	Pancreatic Ductal Adenocarcinoma	3498		Afatinib		Predictive	Supports	C	Sensitivity/Response	Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old with metastatic PDAC, a complex rearrangement involving the insertion of exons 6 and 7 of NRG1 between exons 15 and 16 of APP was found. This in-frame fusion resulted in the preservation and increased expression of the EGF-like domain of NRG1, which is required for HER-family kinase activation. Treatment with afatinib resulted in the resolution of multiple metastases and imaging showed ongoing response 5 months after treatment initiation.	31068372	PubMed		Jones et al., 2019, Clin. Cancer Res.		3	accepted	7493	2772	2593														Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7493	https://civic.genome.wustl.edu/links/variants/2772	https://civic.genome.wustl.edu/links/genes/2593
NTRK3	4916	ETV6-NTRK3	Cancer	162		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatment with larotrectinib resulted in reduced tumour burden for all patients with NTRK fusions. The average time on treatment was 28.4 months for patients with NTRK fusion cancer, compared to 1.8 months for those without an NTRK fusion.	30624546	PubMed		Hong et al., 2019, Ann. Oncol.	NCT02122913	3	accepted	7496	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/7496	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
MET	4233	R1004G	Head And Neck Cancer	11934		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid response to the treatment of crizotinib.	31391294	PubMed		Chu et al., 2019, Oncologist		3	accepted	7498	2774	52														Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7498	https://civic.genome.wustl.edu/links/variants/2774	https://civic.genome.wustl.edu/links/genes/52
TP53	7157	R248Q	Acute Myeloid Leukemia	9119				Functional	Supports	D	Dominant Negative	CRISPR-Cas9 editing was used to create five isogenic MOLM13-TP53 AML cell lines with combinations of wild-type, mutant, and null TP53 alleles at the endogenous locus: p53+/+, p53+/-, p53-/-, R248Q/+, and R248Q/-. Cells were treated with and without DNA damaging agent and p53 inducing agent Daunorubicin and western blot used to assess p21 induction. p21 was induced in +/+ and +/-, but not -/-, R248Q/+, and R248Q/- cells. Daunorubicin treatment caused less cell death in +/- than in +/+ cells, but induced significantly less death in -/-, R248Q/+, and R248Q/-, where these three conditions were not statistically different. A similar result was seen with p53 activating agent Nutlin-3a, where p53-/-, R248Q/+, and R248Q/- cells grouped together with equivalent resistance to the agent in comparison to +/+ and +/- cells. The grouping in results of  -/-, R248Q/+, and R248Q/- suggest that R248Q inactivates the wt p53 copy, which does not occur in the +/- condition.	31395785	PubMed		Boettcher et al., 2019, Science		4	accepted	7525	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Unknown	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7525	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	Y220C	Acute Myeloid Leukemia	9119				Functional	Does Not Support	D	Neomorphic	The Y220C mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. Y220C/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including Y220C. RNAseq studies determined that a novel gene expression program was not induced in Y220C cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that Y220C mutation does not induce a neomophic p53 function.	31395785	PubMed		Boettcher et al., 2019, Science		4	accepted	7527	922	45	17	7578190	7578190	T	C	ENST00000269305.4					75	GRCh37		Unknown	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/7527	https://civic.genome.wustl.edu/links/variants/922	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	M237I	Acute Myeloid Leukemia	9119				Functional	Does Not Support	D	Neomorphic	The M237I mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. M237I/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including M237I. RNAseq studies determined that a novel gene expression program was not induced in M237I cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that M237I mutation does not induce a neomophic p53 function.	31395785	PubMed		Boettcher et al., 2019, Science		4	accepted	7528	1066	45	17	7577570	7577570	C	A	ENST00000269305.4					75	GRCh37		Unknown	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7528	https://civic.genome.wustl.edu/links/variants/1066	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R248Q	Acute Myeloid Leukemia	9119				Functional	Does Not Support	D	Neomorphic	The R248Q mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R248Q/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R248Q. RNAseq studies determined that a novel gene expression program was not induced in R248Q cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R248Q mutation does not induce a neomophic p53 function.	31395785	PubMed		Boettcher et al., 2019, Science		4	accepted	7529	117	45	17	7577538	7577538	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	Unknown	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7529	https://civic.genome.wustl.edu/links/variants/117	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R273H	Acute Myeloid Leukemia	9119				Functional	Does Not Support	D	Neomorphic	The R273H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R273H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R273H. RNAseq studies determined that a novel gene expression program was not induced in R273H cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R273H mutation does not induce a neomophic p53 function.	31395785	PubMed		Boettcher et al., 2019, Science		4	accepted	7530	122	45	17	7577120	7577120	C	T	ENST00000269305.4					75	GRCh37	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	Unknown	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7530	https://civic.genome.wustl.edu/links/variants/122	https://civic.genome.wustl.edu/links/genes/45
TP53	7157	R282W	Acute Myeloid Leukemia	9119				Functional	Does Not Support	D	Neomorphic	The R282W mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R282W/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, while R282W cells indicated mutant p53 neomorphic binding at sites not occupied by wt. RNAseq studies determined that a novel gene expression program was not induced in R282W cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R282W mutation does not induce a neomophic p53 function.	31395785	PubMed		Boettcher et al., 2019, Science		3	accepted	7531	916	45												GRCh37		Unknown	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7531	https://civic.genome.wustl.edu/links/variants/916	https://civic.genome.wustl.edu/links/genes/45
IKZF1	10320	DELETION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	A meta-analysis of 8 published studies including 1008 adult patients (all patients were >14 years old) with B-ALL showed that IKZF 1 deletion had a negative impact on overall survival (HR=1.4, 95% CI 1.131.73) and event-free survival (EFS) (HR=1.67, 95% CI 1.282.17). In addition, IKZF1 deletion could independently predict unfavorable OS (HR=1.6) and EFS (HR= 1.67) in BCR-ABL1-negative but not BCR-ABL1 positive patients.	27815723	PubMed		Zhang et al., 2017, Ann. Hematol.		4	accepted	7532	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7532	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
IKZF1	10320	DELETION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	This study reports on a cohort of NCI high-risk, Ph-negative pediatric patients with B-ALL. Twenty eight out of 94 patients (~30%) were found to harbor IKZF1 deletions, which were associated with male sex (P=0.45), Hispanic ethnicity (P=0.011) and an inferior outcome. IKZF1 deletion was associated with inferior event-free survival (EFS) in univariate (HR: 3.21, P=0.002) and multivariate analysis (HR: 2.64, P=0.016). IKZF1 deletion was associated with inferior disease-free survival (DFS) in univariate analysis (HR: 3.27, P=0.008) and showed a trend toward inferior DFS in multivariate analysis (HR: 2.7, P=0.087). The IKZF1 deletion was an independent predictor of adverse outcome, irrespective of the presence of a kinase-activating fusion.	29507076	PubMed		Tran et al., 2018, Blood Adv		3	accepted	7541	200	73	7	50344378	50472799			ENST00000331340.3					75	GRCh37	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal  hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease.  Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.	Somatic	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7541	https://civic.genome.wustl.edu/links/variants/200	https://civic.genome.wustl.edu/links/genes/73
BRAF	673	G466V	Colorectal Cancer	9256		Irinotecan,Panitumumab	Combination	Predictive	Supports	D	Sensitivity/Response	In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.	28783719	PubMed		Yao et al., 2017, Nature		3	accepted	7552	2222	5	7	140481411	140481411	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7552	https://civic.genome.wustl.edu/links/variants/2222	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G466V	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.	28783719	PubMed		Yao et al., 2017, Nature		3	accepted	7553	2222	5	7	140481411	140481411	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7553	https://civic.genome.wustl.edu/links/variants/2222	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G466V	Solid Tumor			Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R).	28783719	PubMed		Yao et al., 2017, Nature		3	accepted	7554	2222	5	7	140481411	140481411	C	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7554	https://civic.genome.wustl.edu/links/variants/2222	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	D594G	Solid Tumor			Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R).	28783719	PubMed		Yao et al., 2017, Nature		3	accepted	7556	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7556	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
FGFR3	2261	MUTATION	Urinary Bladder Cancer	11054		Gemcitabine,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathological response (partial & complete) and 13 patients were resistant to neoadjuvant chemotherapy.35.9% (14/39) patients that responded to neoadjuvant chemotherapy had the following FGFR3 somatic mutations - p.S249C,p.V372C, p.G299S, p.V411M. FGFR3 somatic mutations exclusively occurred in the responder group.The somatic FGFR3 mutation frequency in the responder group was also compared with three unselected bladder cancer populations from TCGA, Kim et al.study and Guo et al. studies.This analysis revealed that FGFR3 somatic mutations were significantly enriched in the responder cohort compared with the unselected bladder cancer cohorts.	29941343	PubMed		Yang et al., 2018, EBioMedicine		3	accepted	7566	827	23	4	1795039	1810599			ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7566	https://civic.genome.wustl.edu/links/variants/827	https://civic.genome.wustl.edu/links/genes/23
H3-3A	3020	K27M	Glioma			Akt/ERK Inhibitor ONC201		Predictive	Supports	B	Sensitivity/Response	In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 3 patients had experienced durable partial response by RANO. 10 patients had a best response of stable disease by RANO.	172409	ASCO	3005	Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005	NCT03295396; NCT02525692	4	accepted	7601	2416	2537														Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/7601	https://civic.genome.wustl.edu/links/variants/2416	https://civic.genome.wustl.edu/links/genes/2537
BRAF	673	A728V	Cancer	162				Functional	Supports	D	Gain of Function	The BRAF mutation A728V (also known as A727V) resulted in elevated kinase activity relative to wild-type BRAF in vitro, as well as increased phosphorylation of ERK1/2 in COS cells.	15035987	PubMed		Wan et al., 2004, Cell		3	accepted	7614	1198	5	7	140434515	140434515	G	A							GRCh37		Somatic	2021-03-31 18:22:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/7614	https://civic.genome.wustl.edu/links/variants/1198	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600D	Melanoma	1909		BRAF Inhibitor		Predictive	Supports	C	Sensitivity/Response	In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/9) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.	31580757	PubMed		Menzer et al., 2019, J. Clin. Oncol.		3	accepted	7616	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7616	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600D	Melanoma	1909		BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Combination	Predictive	Supports	C	Sensitivity/Response	In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.	31580757	PubMed		Menzer et al., 2019, J. Clin. Oncol.		3	accepted	7629	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7629	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600_K601>E	Melanoma	1909		BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Combination	Predictive	Supports	C	Sensitivity/Response	In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.	31580757	PubMed		Menzer et al., 2019, J. Clin. Oncol.		3	accepted	7630	2820	5														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7630	https://civic.genome.wustl.edu/links/variants/2820	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	G469	Melanoma	1909		BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Combination	Predictive	Supports	B	Sensitivity/Response	In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.	31580757	PubMed		Menzer et al., 2019, J. Clin. Oncol.		3	accepted	7634	2822	5														Somatic	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7634	https://civic.genome.wustl.edu/links/variants/2822	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	A598V	Melanoma	1909		BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Combination	Predictive	Does Not Support	C	Sensitivity/Response	In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.	31580757	PubMed		Menzer et al., 2019, J. Clin. Oncol.		3	accepted	7635	2826	5	7	140453142	140453142	G	A	ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7635	https://civic.genome.wustl.edu/links/variants/2826	https://civic.genome.wustl.edu/links/genes/5
FGF19	9965	EXPRESSION	Hepatocellular Carcinoma	684		Fisogatinib		Predictive	Supports	B	Sensitivity/Response	In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily. FGF19 expression was evaluated by immunohistochemistry. Across doses, the overall response rate was 17% (11/66) in FGF19 positive patients and 0% (0/32) in FGF19 negative patients.	31575541	PubMed		Kim et al., 2019, Cancer Discov		4	accepted	7636	2827	7909														N/A	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7636	https://civic.genome.wustl.edu/links/variants/2827	https://civic.genome.wustl.edu/links/genes/7909
ERBB2	2064	AMPLIFICATION	Cholangiocarcinoma	4947		Pertuzumab,Trastuzumab	Combination	Predictive	Supports	C	Sensitivity/Response	A patient with cholangiocarcinoma harboring with ERBB2 amplification detected by circulating tumor DNA testing was treated with trastuzumab and pertuzumab. This treatment showed a tumor response and continued over 12 months.	31453370	PubMed		Yarlagadda et al., 2019, NPJ Precis Oncol		3	accepted	7638	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7638	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
MET	4233	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with MET exon 14-altered NSCLC had enrolled and 17 received treatment (15 response-evaluable). Antitumor activity per RECIST was documented in 10/15 pts: 5 with confirmed PRs and 5 with unconfirmed PRs. Median PFS could not be calculated, with no deaths or PD by the data cut-off. Treatment-related AEs were generally tolerable, and were most commonly edema, nausea, vision disorder, bradycardia, and vomiting. AEs were mostly grade 1 or 2, with one grade 3 edema, and no grade 4/5 AEs.	123413	ASCO	108	Alexander E. Drilon, 2016, ASCO Annual Meeting, Abstract 108	NCT00585195	1	accepted	7642	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7642	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial response was observed.	26892698	PubMed		Mahjoubi et al., 2016, Invest New Drugs		2	accepted	7643	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7643	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
VHL	7428	Y98H (c.292T>C)	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma,Retinal capillary hemangioma,Pheochromocytoma			Predisposing	N/A	B	N/A	Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG evidence codes: 'PP1', with the allele significant cosegregation with the disease in family members for a gene known to cause the described syndrome, and 'PP4' because the patients' phenotypes or family histories are highly specific for a disease with a single genetic etiology.	7759077	PubMed		Brauch et al., 1995, Hum. Genet.		4	accepted	7645	1741	58	3	10183823	10183823	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7645	https://civic.genome.wustl.edu/links/variants/1741	https://civic.genome.wustl.edu/links/genes/58
ERBB2	2064	AMPLIFICATION	Stomach Cancer	10534		Trastuzumab Deruxtecan		Predictive	Supports	B	Sensitivity/Response	In a phase 1 trial, patients with HER2-positive gastric cancer were treated with Trastuzumab Deruxtecan (DS-8201a). The response rate was 43.2% (19/44).	31047804	PubMed		Shitara et al., 2019, Lancet Oncol.	NCT02564900	4	accepted	7647	306	20	17	37856333	37884915			ENST00000269571.5					75	GRCh37	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.	Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7647	https://civic.genome.wustl.edu/links/variants/306	https://civic.genome.wustl.edu/links/genes/20
ABL1	25	SNX2-ABL1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Imatinib,Dasatinib		Predictive	Supports	D	Resistance	SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was transfected in murine Ba/F3 cells and proliferation rates in the presence of IL-3, and tyrosine kinase inhibitors, imatinib and dasatinib was compared to BCR-ABL1 p190 and p210 transfected Ba/F3 cells. Cell proliferation assays showed that SNX2-ABL1 transfected cells had over 20% and 50% of cell survival after 24-hr incubation with imatinib (2M) and dasatinib (10nM). SNX2-ABL1 transfected cells continued to proliferate again 48 hr after treatment with dasatinib (10nM). This data was further supported by apoptosis (annexin V-propidium iodide) studies. In addition, newer tyrosine kinase inhibitors including nilotinib (500nM), bafetinib (500nM), rebastinib (500nM), and ponatinib (100nM), were examined and SNX2-ABL1 cells showed a better response, but still some resistance to these compounds. Further examination of downstream phosphorylation of SNX2-ABL1 cells showed only partial inhibition with imatinib and dasatinib.	24367893	PubMed		Tomita et al., 2014, Leuk. Res.		3	accepted	7655	2678	4														Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/7655	https://civic.genome.wustl.edu/links/variants/2678	https://civic.genome.wustl.edu/links/genes/4
JAK2	3717	ATF7IP-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one male patient, an in-frame ATF7IP-JAK2 fusion (exon 13 and exon 17) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR, Sanger and FISH. This patient also harbored an IKZF1 deletion, was designated NCI high risk and Ph-like non-CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7671	2846	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7671	https://civic.genome.wustl.edu/links/variants/2846	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	EBF1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent female, an in-frame EBF1-JAK2 fusion (exon 14 and exon 17) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient also harbored an IKZF1 deletion and was designated Ph-like non CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7672	2847	28														Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7672	https://civic.genome.wustl.edu/links/variants/2847	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PPFIBP1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one young adult male patient, an in-frame PPFIBP1-JAK2 fusion (exon 12 and exon 19) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR, Sanger, and FISH. This patient also harbored an IKZF1 deletion and was designated Ph-like non-CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7673	2848	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7673	https://civic.genome.wustl.edu/links/variants/2848	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	STRN3-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one childhood NCI high risk female, an in-frame STRN3-JAK2 fusion (exon 9 and exon 17) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient also harbored an IKZF1 frameshift and deletion and was designated Ph-like non CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7674	2849	28														Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7674	https://civic.genome.wustl.edu/links/variants/2849	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	TPR-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one young adult male, an in-frame TPR-JAK2 fusion (exon 39 and exon 17) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR, Sanger and FISH. This patient also harbored an IKZF1 deletion and was designated Ph-like non CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7675	2850	28														Somatic	2021-03-31 18:23:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/7675	https://civic.genome.wustl.edu/links/variants/2850	https://civic.genome.wustl.edu/links/genes/28
BRAF	673	AMPLIFICATION	Melanoma	1909		Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Resistance	In a retrospective study, authors analyzed BRAF V600 mutated melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. An acquired resistance mechanism activating the MAPK pathway was identified in 9 tumors; BRAF amplification (n=4), MEK1/2 mutation (n=3), NRAS mutations (n=3). Among them, mutual exclusive alterations were BRAF amplification (n=4), MEK2 C125S (n=1), and NRAS Q61K (n=2).	25452114	PubMed		Long et al., 2014, Nat Commun		4	accepted	7677	1269	5	7	140434279	140624564			ENST00000288602.6					75	GRCh37		Somatic	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/7677	https://civic.genome.wustl.edu/links/variants/1269	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	SNX2-ABL1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	C	Poor Outcome	A 16 yr-old male with precursor B-ALL was found to have the t(5;9)(q23;q34) in his peripheral blasts. Fluorescence in situ hybridization (FISH), RT-PCR, and sequencing of the product confirmed a SNX2-ABL1 fusion gene (SNX2 exon 3 fused in frame to ABL1 exon 4) was present. The patient also was found to carry an IKZF1 deletion (exons 2-8) and amplification of PAX5. The patient was treated with vindesine, idarubicin, and dexamethasone (VDP) and VDCP (plus cyclophosphamide) regimens. He received two bone marrow transplants, but eventually died of disease. The patient did not receive tyrosine-kinase inhibitors.	28278724	PubMed		Mu et al., 2017, Leuk. Lymphoma		1	accepted	7694	2678	4														Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/7694	https://civic.genome.wustl.edu/links/variants/2678	https://civic.genome.wustl.edu/links/genes/4
JAK2	3717	ETV6-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In two patients, an in-frame ETV6-JAK2 fusion (exon 4 and exon 17; exon 5 and exon 17) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR, FISH, and/or Sanger. One patients was shown to also harbored an IKZF1 deletion and was designated Ph-like non CRLF2. This information was not provided for the second fusion patient.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7696	2859	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7696	https://civic.genome.wustl.edu/links/variants/2859	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	BCR-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In two male patients, in-frame BCR-JAK2 fusions (exon 1 and exon 19 (FISH validated); exon 1 and exons 15&17) with the tyrosine kinase domain intact were identified and confirmed by RT-PCR, Sanger. Both patients harbored an IKZF1 deletion and were designated Ph-like non-CRLF2. One patient was NCI childhood high risk while the other was young adult.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7697	2860	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7697	https://civic.genome.wustl.edu/links/variants/2860	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	BCR-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the 129 CRLF2 negative patients revealed that 4.9% of them had JAK2 rearrangements including two patients with a BCR-JAK2 fusion. These fusions were confirmed by Sanger sequencing and identified alternate breakpoint in BCR. All fusion-positive patient cases in this study were confirmed to have in-frame fusion of the 5 partner to the 3 kinase gene and retention of the tyrosine kinase domain of the 3 fusion partner.	28408464	PubMed		Reshmi et al., 2017, Blood		4	accepted	7698	2860	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7698	https://civic.genome.wustl.edu/links/variants/2860	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PAX5-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	B	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In seven patients, an in-frame PAX5-JAK2 fusion (exon 5 and exon 19) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. FISH validated the presence of the fusion in 2 patients. All patients were designated Ph-like non-CRLF2 and 5/7 had IKZF1 deletion.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7699	2861	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7699	https://civic.genome.wustl.edu/links/variants/2861	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PAX5-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 negative patients revealed 4.9% had JAK2 rearrangements. Four individuals had a PAX5-JAK2 fusion that was identified and confirmed by Sanger sequencing. These patients were designated Ph-like non CRLF2. All fusion-positive patient cases in this study were confirmed to have in-frame fusion of the 5 partner to the 3 kinase gene and retention of the tyrosine kinase domain of the 3 fusion partner.	28408464	PubMed		Reshmi et al., 2017, Blood		3	accepted	7700	2861	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7700	https://civic.genome.wustl.edu/links/variants/2861	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	TERF2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent female, an in-frame TERF2-JAK2 fusion (exon 8 and exon 19) with the tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient also harbored an IKZF1 deletion and was designated Ph-like non CRLF2.	25207766	PubMed		Roberts et al., 2014, N. Engl. J. Med.		3	accepted	7702	2862	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7702	https://civic.genome.wustl.edu/links/variants/2862	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PCM1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	The PCM1-JAK2 fusion is typically associated with 'myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements', which is a specific disease entity according to WHO classification. However, in this study, which investigated 1389 high-risk pediatric B-ALL cases, 284 of whom had a Ph-like gene signature (identified by TaqMan Low Density Array) the PCM1-JAK2 fusion was detected in association with Ph-like B-ALL in one individual. This fusion was detected by RT-PCR and was confirmed by Sanger sequencing. This patient was designated PH-like non CRLF2. All fusion-positive patient cases in this study were confirmed to have in-frame fusion of the 5 partner to the 3 kinase gene and retention of the tyrosine kinase domain of the 3 fusion partner.	28408464	PubMed		Reshmi et al., 2017, Blood		3	accepted	7704	571	28												GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7704	https://civic.genome.wustl.edu/links/variants/571	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	ZNF274-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	This study included 1389 cases of high-risk pediatric B-ALL, out of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the 129 CRLF2 negative patients revealed that 4.9% of them had JAK2 rearrangements including one patient with a rare and novel ZNF274-JAK2 fusion. All fusion-positive patient cases in this study were confirmed to have in-frame fusion of the 5 partner to the 3 kinase gene and retention of the tyrosine kinase domain of the 3 fusion partner. In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease.	28408464	PubMed		Reshmi et al., 2017, Blood		3	accepted	7706	2864	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7706	https://civic.genome.wustl.edu/links/variants/2864	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	RFX3-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	This study included 1389 cases of high-risk pediatric B-ALL, out of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the 129 CRLF2 negative patients revealed that 4.9% of them had JAK2 rearrangements including one patient with a rare and novel RFX3-JAK2 fusion. All fusion-positive patient cases in this study were confirmed to have in-frame fusion of the 5 partner to the 3 kinase gene and retention of the tyrosine kinase domain of the 3 fusion partner. In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease.	28408464	PubMed		Reshmi et al., 2017, Blood		3	accepted	7707	2865	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7707	https://civic.genome.wustl.edu/links/variants/2865	https://civic.genome.wustl.edu/links/genes/28
RET	5979	M918T	Thyroid Gland Medullary Carcinoma	3973		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	Cabozantinib significantly prolonged progression-free survival (PFS) versus placebo in patients with progressive, metastatic medullary thyroid cancer (HR 0.28). Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (HR 0.23).  Patients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).	27525386	PubMed		Sherman et al., 2016, Cancer		4	accepted	7710	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic	2021-03-31 18:23:14 UTC	https://civic.genome.wustl.edu/links/evidence_items/7710	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42
BRCA2	675	K3226*	Glioblastoma Multiforme	3068		Temozolomide,Olaparib	Combination	Predictive	Supports	C	Sensitivity/Response	In a case report, a 3yearold girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3226*) nonsense variant.  After debulking surgery, the patient received standardofcare treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. This regimen was well tolerated by the patient and serial imaging showed a reduction in tumor size.	32043779	PubMed		Valiakhmetova et al., 2019, Oncologist		3	accepted	7724	2871	7														Unknown	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/7724	https://civic.genome.wustl.edu/links/variants/2871	https://civic.genome.wustl.edu/links/genes/7
IDH1	3417	MUTATION	Chondrosarcoma	3371				Prognostic	Supports	B	Better Outcome	In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas.	31615936	PubMed		Zhu et al., 2020, Clin. Cancer Res.		4	accepted	7725	645	26	2	209101803	209116275			ENST00000415913.1					75	GRCh37		Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7725	https://civic.genome.wustl.edu/links/variants/645	https://civic.genome.wustl.edu/links/genes/26
IDH2	3418	MUTATION	Chondrosarcoma	3371				Prognostic	Supports	B	Better Outcome	In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas.	31615936	PubMed		Zhu et al., 2020, Clin. Cancer Res.		4	accepted	7726	570	27	15	90626277	90645736			ENST00000330062.3					75	GRCh37		Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7726	https://civic.genome.wustl.edu/links/variants/570	https://civic.genome.wustl.edu/links/genes/27
FLT3	2322	MUTATION	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	B	Sensitivity/Response	In this phase 3 trial (ADMIRAL), 371 patients with relapsed or refractory FLT3-mutated AML (required to have FLT3 ITD or TKD D835 or I836 mutations) were randomly assigned in a 2:1 ratio to receive either gilteritinib (n=247, at a dose of 120 mg per day) or salvage chemotherapy (n=124). Median overall survival in the gilteritinib group was significantly longer than in the chemotherapy group (9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001). Median event-free survival was 2.8 months in the gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The complete remission rate with full or partial hematologic recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4). Notably, gilteritinib treatment resulted in similar median overall survival (9.3 months vs. 8.0 months) and percentage of complete remission (20.5% vs. 19.0%) in patients with ITD mutations and patients with TKD mutations. The authors concluded gilteritinib therapy in relapsed or refractory FLT3-mutated AML patients resulted longer survival and improved response versus salvage chemotherapy.	31665578	PubMed		Perl et al., 2019, N. Engl. J. Med.	NCT02421939	5	accepted	7728	519	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/7728	https://civic.genome.wustl.edu/links/variants/519	https://civic.genome.wustl.edu/links/genes/24
BRAF	673	N486_P490del	Pancreatic Cancer	1793		Trametinib		Predictive	Supports	C	Sensitivity/Response	In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL, and the radiographic partial response was revealed by CT at 8 weeks after initiation of trametinib. cfDNA measurements for BRAF and TP53 alleles revealed a dramatic decline in response to trametinib.  After 6 months of therapy, radiographic progression was identified.	29903880	PubMed		Aguirre et al., 2018, Cancer Discov		3	accepted	7730	2794	5														Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7730	https://civic.genome.wustl.edu/links/variants/2794	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	SNX2-ABL1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	C	Poor Outcome	This case report describes a 7-year old boy with B-ALL who presented with high white blood count (115.4x109 /L). Karyotype analysis showed a t(5;9)(q22;q34), resulting in a SNX2-ABL1 fusion. The patient was treated based on the ALL-BFM95 regimen; although he received remission, he relapsed during maintenance, 15 months after the initial diagnosis.  He could not achieve the second remission using chemotherapy, but was treated at this time with imatinib (dose of 240 mg/m2 /d once daily); this allowed to achieve disease control and proceed with an umbilical cord blood transplant. However, at 6 months from transplantation, the patient developed bone marrow relapse again. He never achieved a remission after the second relapse (despite salvage chemotherapies and therapy with both imatinib and dasatinib). The patient died of progressive disease.	24215620	PubMed		Masuzawa et al., 2014, Eur. J. Haematol.		1	accepted	7744	2678	4														Somatic	2021-03-31 18:23:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/7744	https://civic.genome.wustl.edu/links/variants/2678	https://civic.genome.wustl.edu/links/genes/4
BRAF	673	D594G	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib.	28783719	PubMed		Yao et al., 2017, Nature		2	accepted	7760	611	5	7	140453154	140453154	T	C	ENST00000288602.6					75	GRCh37	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.	Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7760	https://civic.genome.wustl.edu/links/variants/611	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	NRF1-BRAF	Transitional Cell Carcinoma	2671		Trametinib		Predictive	Supports	C	Sensitivity/Response	In a case report, a patient with urothelial carcinoma harboring with NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in size of liver metastasis.	31010895	PubMed		Isaacson et al., 2019, Cold Spring Harb Mol Case Stud		3	accepted	7763	2883	5														Somatic	2021-03-31 18:22:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7763	https://civic.genome.wustl.edu/links/variants/2883	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	BCR-ABL T315V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed reduced incorporation when treated with axitinib in fusions with the T315V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 45nM vs. 823 nM), indicating the T315V variant induces sensitivity compared to BCR-ABL1 without secondary variants.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7766	2885	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7766	https://civic.genome.wustl.edu/links/variants/2885	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V299L	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the V299L variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 188nM vs. 823 nM), indicating V299L induces sensitivity compared to BCR-ABL1 without secondary variants.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7767	1231	4	9	133747588	133747588	G	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7767	https://civic.genome.wustl.edu/links/variants/1231	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315A	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the T315A variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 389nM vs. 823 nM), indicating T315A induces sensitivity compared to BCR-ABL1 without secondary variants.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7768	2335	4	9	133748282	133748282	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7768	https://civic.genome.wustl.edu/links/variants/2335	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M351T	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the M351T variant of ABL1 compared to those with wildtype ABL1 (IC50 of 553nM vs. 823 nM), indicating the M351T variant induces sensitivity compared to BCR-ABL1 without secondary variants.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7769	1029	4	9	133748391	133748391	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7769	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396P	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H396P variant of ABL1 compared to those with wildtype ABL1 (IC50 of 683nM vs. 823 nM), indicating the H396P variant induces sensitivity compared to BCR-ABL1 without secondary variants.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7770	1531	4	9	133750356	133750356	A	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/7770	https://civic.genome.wustl.edu/links/variants/1531	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the M244V variant of ABL1 compared to those with wildtype ABL1 (IC50 of 690nM vs. 823 nM), indicating that the M244V variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7771	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/7771	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E279K	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the E279K variant of ABL1 compared to those with wildtype ABL1 (IC50 of 778nM vs. 823 nM), indicating that the E279K variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7772	2886	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7772	https://civic.genome.wustl.edu/links/variants/2886	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E292L	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the E292L variant of ABL1 compared to those with wildtype ABL1 (IC50 of 863nM vs. 823 nM), indicating that the E292L variant does not induce resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7773	2887	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7773	https://civic.genome.wustl.edu/links/variants/2887	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317R	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the F317R variant of ABL1 compared to those with wildtype ABL1 (IC50 of 1286nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7774	2888	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7774	https://civic.genome.wustl.edu/links/variants/2888	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248R F359I	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar sensitivity to axitinib in fusions with the L248R and F359I variants of ABL1 compared to those with wildtype ABL1 (IC50 of 1385nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7775	2889	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7775	https://civic.genome.wustl.edu/links/variants/2889	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L248R	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the L248R variant of ABL1 compared to those with wildtype ABL1 (IC50 of 1399nM vs. 823 nM), indicating resistance.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7776	2340	4	9	133738343	133738343	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7776	https://civic.genome.wustl.edu/links/variants/2340	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Acute Lymphoblastic Leukemia	9952		Ponatinib,Axitinib	Substitutes	Predictive	Does Not Support	D	Resistance	Bone marrow mononuclear cells (BM MNCs) were isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant who were pretreated with various chemotherapeutics and dasatinib. 2/3 patient's BM MNCs were considered sensitive to ponatinib and axitinib using drug sensitivity scoring of proliferation assays. Additionally, BCR-ABL T315I showed sensitivity to ponitinib and axitinib in Ba/F3 cells.	25686603	PubMed		Pemovska et al., 2015, Nature		3	accepted	7777	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/7777	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Acute Lymphoblastic Leukemia	9952		Dasatinib,Nilotinib,Imatinib	Substitutes	Predictive	Supports	D	Resistance	Bone marrow mononuclear cells (BM MNCs) isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant. Patients were pretreated with various chemotherapeutics and dasatinib. The patients' cells were sensitive to Ponatinib and Axitinib and insensitive to Nilotinib, Imatinib, and Dasatinib using drug sensitivity scoring detailed in a referenced paper. Additionally, in a proliferation assay, T315I variants were resistant to imatinib.	25686603	PubMed		Pemovska et al., 2015, Nature		3	accepted	7778	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/7778	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Ponatinib		Predictive	Does Not Support	D	Resistance	Bone marrow mononuclear cells (BM MNCs) were isolated from a chronic myeloid leukemia patient with the BCR-ABL1 T315I variant. The patient was pretreated with imatinib, dasatinib, and chemotherapy. The patients' cells were sensitive to Ponatinib and Axitinib and insensitive to Nilotinib, Imatinib, and Dasatinib compared to BM MNCs from healthy controls using drug sensitivity scoring of proliferation assays. In a rezasurin proliferation assay, Ba/F3 cells carrying the T315I variant in the ABL1 portion of the BCR-ABL fusion showed high sensitivity to ponatinib (IC50 of 11 nM vs. 3.1 nM in wildtype fusions).	25686603	PubMed		Pemovska et al., 2015, Nature		3	accepted	7779	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/7779	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL T315I	Chronic Myeloid Leukemia	8552		Imatinib,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	Bone marrow mononuclear cells (BM MNCs) were isolated from a chronic myeloid leukemia patients with the BCR-ABL1 T315I variant who was pretreated with imatinib, dasatinib, and chemotherapy. The patient's cells were sensitive to Ponatinib and Axitinib and insensitive to Nilotinib, Imatinib, and Dasatinib compared to BM MNCs from healthy controls using drug sensitivity scoring of proliferation assays. Additionally, in a rezasurin proliferation assay, Ba/F3 cells carrying the BCR-ABL1 variant were resistant to imatinib in fusions with the T315I variant of ABL1 compared to wildtype ABL1 (IC50 of >4,000 nM vs. 257 nM).	25686603	PubMed		Pemovska et al., 2015, Nature		3	accepted	7780	2	4	9	133748283	133748283	C	T	ENST00000318560.5					75	GRCh37	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Somatic	2021-03-31 18:24:04 UTC	https://civic.genome.wustl.edu/links/evidence_items/7780	https://civic.genome.wustl.edu/links/variants/2	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E255K V299L	Chronic Myeloid Leukemia	8552		Dasatinib,Ponatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	Bone marrow mononuclear cells isolated from a chronic myeloid leukemia patient with the BCR-ABL1 fusion and E255K and V299L secondary variants in ABL1 showed a high drug sensitivity score to ponatinib and dasatinib.	25686603	PubMed		Pemovska et al., 2015, Nature		2	accepted	7781	2890	4														Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7781	https://civic.genome.wustl.edu/links/variants/2890	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	ABL1-RCSD1	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Imatinib		Predictive	Supports	C	Sensitivity/Response	This case report describes a patient with relapsed B-ALL positive for the RCSD1-ABL1 fusion, who was successfully treated with chemotherapy with addition of imatinib; the patient remained disease free  for 36 months. This case supports sensitivity of B-ALL with RCSD1-ABL1 fusions to ABL-type tyrosine kinase inhibitors.	27125982	PubMed		Perwein et al., 2016, Haematologica		3	accepted	7783	2681	4														Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/7783	https://civic.genome.wustl.edu/links/variants/2681	https://civic.genome.wustl.edu/links/genes/4
CTNNB1	1499	exon 3 mutation	Desmoid Tumor	0080366				Prognostic	Does Not Support	B	N/A	This study illustrates the prevalence of CTNNB1 mutations in sporadic desmoid tumors, and examines whether the presence of CTNNB1 mutations correlates with the disease outcome. CTNNB1 mutations (including specific exon 3 mutations T41A, S45F, S45P, and S45C) were found in 106 out of 145 desmoid tumor specimens, and in 86 out of 115 specimens from patients who had undergone complete surgical resection. At a median follow-up of 31 months, the 5-year recurrence free survival rate of patients with the beta-catenin mutated tumors was worse than that of the patients with wild-type tumors (58% vs 74%), however, the difference was not statistically significant (p = 0.285). Thus, the study shows that there is no statistically significant correlation between the CTNNB1 mutation and the recurrence risk of sporadic desmoid tumors, even though specific exon 3 CTNNB1 mutations are commonly identified in these tumors.	23960186	PubMed		Mullen et al., 2013, Oncologist		4	accepted	7784	2892	1290														Somatic	2021-03-31 18:23:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/7784	https://civic.genome.wustl.edu/links/variants/2892	https://civic.genome.wustl.edu/links/genes/1290
DPYD	1806	EXON 11-19 DELETION	Head And Neck Squamous Cell Carcinoma	5520		Fluorouracil,Leucovorin	Combination	Predictive	Supports	C	Sensitivity/Response	A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome analysis and the patient was started on systemic therapy. After showing resistance to the systemic therapy treatment with 5-FU and leucovorin was initiated based on the discovery of a somatic exon 11-19 in frame deletion in DPYD, which was hypothesized to increase sensitivity to 5-FU in the tumour. A dramatic clinical and radiographic response was sustained for 17 weeks, but following a 3 week treatment break a new nodule appeared. This recurrence showed resistance to re-initiation of treatment with capecitabine (oral 5-FU), and analysis of an additional biopsy provided no evidence as to the mechanism of resistance.	31871216	PubMed		Majounie et al., 2019, Cold Spring Harb Mol Case Stud		4	accepted	7787	2893	1526	1	97700408	98039526			ENST00000370192.3					75	GRCh37		Somatic	2021-03-31 18:23:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/7787	https://civic.genome.wustl.edu/links/variants/2893	https://civic.genome.wustl.edu/links/genes/1526
MET	4233	MET-ATXN7L1	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case Report of a a 56-year-old female (never-smoker) patient with stage IV NSCLC. NGS revealed a METATXN7L1 fusion. No additional known driver gene alterations were identified. Following progression after three months of chemotherapy [paclitaxel (135mg/m2 days 1 and 8; carboplatin AUC=5day 1)], the patient received crizotinib treatment (250mg/b.i.d. orally) and exhibited a partial response that lasted for 4 months.	30339198	PubMed		Zhu et al., 2018, Ann. Oncol.		3	accepted	7793	2894	52														N/A	2021-03-31 18:23:18 UTC	https://civic.genome.wustl.edu/links/evidence_items/7793	https://civic.genome.wustl.edu/links/variants/2894	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Histiocytic And Dendritic Cell Cancer	5621		Crizotinib		Predictive	Supports	C	Sensitivity/Response	An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and ZMYM3 c.3008-1G>A. After four months of crizotinib treatment tumour volume had decreased by >60%, however the patient showed progression at 11 months.	25971938	PubMed		Frampton et al., 2015, Cancer Discov		3	accepted	7796	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7796	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
MET	4233	EXON 14 SKIPPING MUTATION	Cancer	162		Capmatinib		Predictive	Supports	D	Sensitivity/Response	MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing MET with exon 15 deletion showed dose dependent inhibition of cell proliferation upon treatment with capmatinib, with significantly lower cell survival compared to control cells. In addition, HEK293 cells expressing MET with exon 14 deletion had increased ERK phosphorylation, while NIH3T3 cells expressing mouse MET with exon 15 deletion had increased MET phosphorylation and increased anchorage-independent colony formation compared to wt MET.	25971938	PubMed		Frampton et al., 2015, Cancer Discov		3	accepted	7797	324	52	7	116411903	116412043			ENST00000318493.6					75	GRCh37	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).	Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7797	https://civic.genome.wustl.edu/links/variants/324	https://civic.genome.wustl.edu/links/genes/52
CDK4	1019	EXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Dexamethasone,Ribociclib	Combination	Predictive	Supports	D	Sensitivity/Response	CDK4 was found to be significantly overexpressed in the bone marrow of MLL-rearranged B-ALL patients (n=70) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) and Ribociclib (a highly selective CDK4 / CDK6 inhibitor) of both glucocorticoid sensitive (Rs4;11 & NALM6) and glucocorticoid resistant (RCH-ACV & SEM) B-ALL cell lines synergistically reduced cell viability of all four lines greater than individual drug exposures. Combination therapy also synergistically reduced the cell viability of 5 primary B-ALL lines derived from diagnosis bone marrow compared to individual treatment. (Note: Expression of CDK4 was not quantitatively measured in the derived and primary B-ALL lines used). Further investigation in RCH-ACV and SEM lines revealed dexamethasone and Ribociclib combined increased apoptosis (annexin-V) and increased G1 arrest along with increased p16 (a CDK4 & CDK6 inhibitor) and decreased phosphorylation of downstream G1 to S cell cycle progression markers compared to single treatments. Combination treatment also led to the increase of NR3C1 expression. Knockdown of CDK4 and CDK6 by siRNAs in RCH-ACV sensitized these cells to dexamethasone treatment and increased NR3C1 expression.	29408328	PubMed		Bortolozzi et al., 2018, Biochem. Pharmacol.		2	accepted	7798	25	13	12	58141510	58146304			ENST00000257904.6					75	GRCh37	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	N/A	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/7798	https://civic.genome.wustl.edu/links/variants/25	https://civic.genome.wustl.edu/links/genes/13
CDK6	1021	OVEREXPRESSION	Glioblastoma Proneural Subtype	0050804		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Study of vehicle versus oral palbociclib (150 mg/kg/day) in mice with intracranial implantation of proneural GBM stem cell-like G448 cells, which are shown to have higher than normal expression of CDK6.  Mice receiving palbociclib had significantly longer survival time (p=0.038).	28903422	PubMed		Li et al., 2017, Oncotarget		2	accepted	7800	602	12	7	92234235	92463231			ENST00000265734.4					75	GRCh37		N/A	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7800	https://civic.genome.wustl.edu/links/variants/602	https://civic.genome.wustl.edu/links/genes/12
CDK6	1021	EXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Ribociclib,Dexamethasone	Combination	Predictive	Supports	D	Sensitivity/Response	CDK6 was found to be significantly overexpressed in the bone marrow of B-ALL patients (n=299) compared to normal bone marrow (n=74, p<.001).Combination treatment with dexamethasone (glucocorticoid) and Ribociclib (a highly selective CDK4 / CDK6 inhibitor) of both glucocorticoid sensitive (Rs4;11 & NALM6) and glucocorticoid resistant (RCH-ACV & SEM) B-ALL cell lines synergistically reduced cell viability of all four lines greater than individual drug exposures. Combination therapy synergistically reduced the cell viability of 5 primary B-ALL lines derived from diagnosis bone marrow compared to individual treatment. (Note: Expression of CDK6 was not quantitatively measured in the derived and primary B-ALL lines used). Further investigation in RCH-ACV and SEM revealed dexamethasone and Ribociclib combined increased apoptosis (annexin-V) and increased G1 arrest along with increased p16 (a CDK4 & CDK6 inhibitor) expression and decreased phosphorylation of downstream G1 to S cell cycle progression markers compared to single treatments. Combination treatment also led to the increase of NR3C1 expression. Knockdown of CDK4 and CDK6 by siRNAs in RCH-ACV sensitized these cells to dexamethasone treatment and increased NR3C1 expression.	29408328	PubMed		Bortolozzi et al., 2018, Biochem. Pharmacol.		2	accepted	7801	3042	12														N/A	2021-03-31 18:23:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/7801	https://civic.genome.wustl.edu/links/variants/3042	https://civic.genome.wustl.edu/links/genes/12
FGFR1	2260	AMPLIFICATION	Adenosquamous Cell Lung Carcinoma	4829		Pazopanib		Predictive	Supports	C	Sensitivity/Response	Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC.  Patient was treated with 400 mg pazopanib twice a day.  CT taken four and eight weeks after start of pazopanib showed tumor regression and cavitation.   Due to side effects, patient stopped taking pazopanib after 6 months.  No clinical or radiologic signs of tumor progression were present at that time.	24302556	PubMed		Malchers et al., 2014, Cancer Discov		3	accepted	7811	267	1885	8	38268656	38325363			ENST00000425967.3					75	GRCh37	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).	Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/7811	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885
NT5C2	22978	R367Q	Childhood Acute Lymphocytic Leukemia	0080144		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	C	Resistance	71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enriched to a variant allele frequency (VAF) of 25% at relapse and only a VAF of .02% at diagnosis. R367Q could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		2	accepted	7812	238	9189	10	104852955	104852955	C	T	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7812	https://civic.genome.wustl.edu/links/variants/238	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	R238W	Childhood Acute Lymphocytic Leukemia	0080144		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R238W led to increased 5 nucleotidase activity.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7813	2896	9189	10	104857107	104857107	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/7813	https://civic.genome.wustl.edu/links/variants/2896	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	S445F	Childhood Acute Lymphocytic Leukemia	0080144		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis.  Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of S445F led to increased 5 nucleotidase activity.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7814	2897	9189	10	104850483	104850483	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/7814	https://civic.genome.wustl.edu/links/variants/2897	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	R367Q	Childhood Acute Lymphocytic Leukemia	0080144		Gemcitabine,Cytarabine,Prednisolone,Doxorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 overexpression and GFP control lines.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7815	238	9189	10	104852955	104852955	C	T	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7815	https://civic.genome.wustl.edu/links/variants/238	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	R238W	Childhood Acute Lymphocytic Leukemia	0080144		Prednisolone,Cytarabine,Gemcitabine,Doxorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7816	2896	9189	10	104857107	104857107	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/7816	https://civic.genome.wustl.edu/links/variants/2896	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	S445F	Childhood Acute Lymphocytic Leukemia	0080144		Prednisolone,Cytarabine,Gemcitabine,Doxorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7817	2897	9189	10	104850483	104850483	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/7817	https://civic.genome.wustl.edu/links/variants/2897	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	NT5C2 MUTATION	Childhood Acute Lymphocytic Leukemia	0080144				Prognostic	Supports	B	Poor Outcome	Within a cohort of 71 pediatric B-ALL relapse cases, all 7 patients with NT5C2 mutations detected at relapse demonstrated early relapse (<36 months from initial diagnosis) with a median time to relapse of 516 days versus a 930-day median time to relapse for the 64 patients wild type for NT5C2 (p=.03).    Patients were derived from the Children's Oncology Group (COG), but Individual patient treatment regimens were not given.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7818	2898	9189														Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7818	https://civic.genome.wustl.edu/links/variants/2898	https://civic.genome.wustl.edu/links/genes/9189
ABL1	25	BCR-ABL D363G	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	One chronic myeloid leukemia patient in chronic phase had a partial best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA revealed the BCR-ABL1 fusion with the D363G secondary variant in 2/10 clones.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	1	accepted	7820	2900	4														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7820	https://civic.genome.wustl.edu/links/variants/2900	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E98G	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	One chronic myeloid leukemia patient in chronic phase had a complete best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the E98G secondary variant in 11/11 clones.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	1	accepted	7822	2901	4														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/7822	https://civic.genome.wustl.edu/links/variants/2901	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL H396R	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with H396R and E355G variants in 9/11 and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7823	1030	4	9	133750356	133750356	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/7823	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the M244V secondary variant in 12/12 clones.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	1	accepted	7825	1021	4	9	133738330	133738330	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/7825	https://civic.genome.wustl.edu/links/variants/1021	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL L364I	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later showed the BCR-ABL1 fusion with the L364I secondary variant in 9/12 clones.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	1	accepted	7826	2902	4														Somatic	2021-03-31 18:23:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/7826	https://civic.genome.wustl.edu/links/variants/2902	https://civic.genome.wustl.edu/links/genes/4
BRAF	673	Non-V600	Solid Tumor			Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligible and received therapy with trametinib. Most common tumor histopathologic subtypes were GI cancers (n=8, of which 7 were colorectal adenocarcinoma), lung adenocarcinoma (n=9), prostate adenocarcinoma (n=4), gynecologic cancer (n=4),  BRAF alterations included BRAF fusion (n=1), G464 (n=2), G466 (n=4), G469 (n=7), N581 (n=3), D594 (n=11), L597 (n=2) and K601 (n=1). Of the 32 patients evaluable for efficacy endpoints, the response rate was 3% (3/32). The patient with a partial response had invasive breast cancer with a BRAF G469E mutation. The median PFS was 1.8 months and the median OS was 5.7 months.	31924734	PubMed		Johnson et al., 2020, Clin. Cancer Res.		4	accepted	7855	2408	5														Somatic	2021-03-31 18:23:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/7855	https://civic.genome.wustl.edu/links/variants/2408	https://civic.genome.wustl.edu/links/genes/5
NT5C2	22978	R367Q	Childhood Acute Lymphocytic Leukemia	0080144		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R367Q led to increased 5 nucleotidase activity.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		4	accepted	7862	238	9189	10	104852955	104852955	C	T	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7862	https://civic.genome.wustl.edu/links/variants/238	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	R238W	Childhood Acute Lymphocytic Leukemia	0080144				Prognostic	Supports	C	Poor Outcome	71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed 3 early relapse cases with NT5C2 R238W enriched at relapse at variant allele frequencies (VAF) of 27%, 18%, and 31% and only a VAF of .01%, 0%, and 0% at diagnosis. R238W could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		2	accepted	7863	2896	9189	10	104857107	104857107	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:31 UTC	https://civic.genome.wustl.edu/links/evidence_items/7863	https://civic.genome.wustl.edu/links/variants/2896	https://civic.genome.wustl.edu/links/genes/9189
NT5C2	22978	S445F	Childhood Acute Lymphocytic Leukemia	0080144				Prognostic	Supports	C	Poor Outcome	71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enriched to a variant allele frequency (VAF) of 25% at relapse and was undetected at diagnosis. S445F could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily.	23377183	PubMed		Meyer et al., 2013, Nat. Genet.		2	accepted	7864	2897	9189	10	104850483	104850483	G	A	ENST00000343289.5					75	GRCh37		Somatic	2021-03-31 18:23:32 UTC	https://civic.genome.wustl.edu/links/evidence_items/7864	https://civic.genome.wustl.edu/links/variants/2897	https://civic.genome.wustl.edu/links/genes/9189
PRPS1	5631	PRPS1 MUTATION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	Sequencing revealed relapse specific PRPS1 mutations in 24/358 (6.7%) relapsed childhood B-ALL cases derived from multiple cohorts. In the Chinese cohort, 18/138 (13%) cases harbored relapse specific PRPS1 mutations. In the German cohort, 6/220 (6.7%) cases harbored relapse specific PRPS1 mutations.   All patients with PRPS1 mutations relapsed early (< 36 months after initial diagnosis) (Chinese: 18/18 PRPS1 vs. 77/120 (64.2%) wildtype, p=.002; German: 6/6 PRPS1 vs. 79/214 (36.9%) wildtype, p<.001). All patients with PRPS1 mutations also relapsed while on therapy (Chinese: 18/18 PRPS1 vs. 77/120 (64.2%) wildtype, p<.001; German: 6/6 PRPS1 vs. 51/214 (23.8%) ( p<.001). Of the 24 cases, there were 17 unique PRPS1 mutations. Further experimental data demonstrated 12/17 mutations conferred resistance to thiopurines.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7871	2916	4566														Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7871	https://civic.genome.wustl.edu/links/variants/2916	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	PRPS1 exons were sequenced in the diagnosis and relapse samples of 358 B-Cell Childhood Acute Lymphoblastic Leukemia relapse patients (138 Chinese and 220 German). PRPS1 A190T was detected only at relapse in 10 (8 Chinese; 2 German) cases, which all relapsed early while on therapy (Chinese 8/8, 100% vs. WT PRPS1 77/120 (64%); German 2/2 (100%) vs. WT PRPS1 79/214 (37%)). Based on protocols cited and the time to relapse, all 10 relapses harboring PRPS1 A190T were exposed to maintenance therapy that consisted of daily doses of thiopurine (mercaptopurine or thioguanine) treatment. A190T could drive clonal outgrowth through the promotion of thiopurine resistance.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7888	2929	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7888	https://civic.genome.wustl.edu/links/variants/2929	https://civic.genome.wustl.edu/links/genes/4566
VHL	7428	L188V (c.562C>G)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL.  Patient XVI, XX and XXI in VHL-associated pheochromocytoma were found with germline missense mutation (c.562C>G) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7889	1836	58	3	10191569	10191569	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/7889	https://civic.genome.wustl.edu/links/variants/1836	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	L178Q (c.533T>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XVII and XVIII in VHL-associated pheochromocytoma were found with a germline missense mutation (c.533T>A) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7890	1997	58	3	10191540	10191540	T	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/7890	https://civic.genome.wustl.edu/links/variants/1997	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	R161Q (c.482G>A)	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XIX with VHL-associated pheochromocytoma was found with a germline missense mutation (c.482G>A) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7891	1746	58	3	10191489	10191489	G	A	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7891	https://civic.genome.wustl.edu/links/variants/1746	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	106insR (c.316insGCC)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient I with VHL-Associated hemangioblastoma was found with a germline insertion mutation (c.316insGCC) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7892	2930	58														Rare Germline	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7892	https://civic.genome.wustl.edu/links/variants/2930	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	N78S (c.233A>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient II in VHL-Associated hemangioblastoma was found with germline missense mutation (c.233A>G) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7893	1755	58	3	10183764	10183764	A	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7893	https://civic.genome.wustl.edu/links/variants/1755	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C77_N78insL (c.230_231insTCT)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient III in VHL-Associated hemangioblastoma was found with germline insertion mutation (c.230insTCT) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7894	3096	58	3	10183761	10183762		TCT	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/7894	https://civic.genome.wustl.edu/links/variants/3096	https://civic.genome.wustl.edu/links/genes/58
VHL	7428	C162W (c.486C>G)	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient IV with VHL-Associated hemangioblastoma was found with a germline missense mutation (c.486C>G) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		Lui et al., 2002, Oncogene		3	accepted	7895	1774	58	3	10191493	10191493	C	G	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7895	https://civic.genome.wustl.edu/links/variants/1774	https://civic.genome.wustl.edu/links/genes/58
PRPS1	5631	T303S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed T303S cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. T303S cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, T303S cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7898	2918	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7898	https://civic.genome.wustl.edu/links/variants/2918	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	L191F	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed L191F cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. L191F cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, L191F cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7899	2919	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7899	https://civic.genome.wustl.edu/links/variants/2919	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	D183E	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed D183E cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. D183E cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, D183E cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7900	2920	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7900	https://civic.genome.wustl.edu/links/variants/2920	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	K176N	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed K176N cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. K176N cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, K176N cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7901	2921	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7901	https://civic.genome.wustl.edu/links/variants/2921	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	N144S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed N144S cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. N144S cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, N144S cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7903	2923	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7903	https://civic.genome.wustl.edu/links/variants/2923	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	S103I	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 S103I in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). After 6-MP exposure, mass spectrometry revealed S103I cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103I cells produce increased intracellular concentrations of hypoxanthine and IMP. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7905	2925	4566														Somatic	2021-03-31 18:23:54 UTC	https://civic.genome.wustl.edu/links/evidence_items/7905	https://civic.genome.wustl.edu/links/variants/2925	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	S103N	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed S103N cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103N cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, S103N cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7906	2926	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7906	https://civic.genome.wustl.edu/links/variants/2926	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	S103T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed S103T cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103T cells produce increased intracellular concentrations of hypoxanthine and IMP.  Also, after 6-MP exposure, S103T cells display reduced levels of DNA damage response and apoptosis protein markers.   S103T results in the activation of the de novo purine synthesis pathway by reducing feedback inhibition, allowing the cell to continue to create nucleotides even when concentrations are elevated. This overactivation creates increased hypoxanthine levels, which likely competitively inhibit thiopurine conversion. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.	25962120	PubMed		Li et al., 2015, Nat. Med.		5	accepted	7907	2927	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7907	https://civic.genome.wustl.edu/links/variants/2927	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	Lentiviral-mediated overexpression of PRPS1 A190T in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed A190T cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. A190T cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, A190T cells display reduced levels of DNA damage response and apoptosis protein markers.   A190T results in the activation of the de novo purine synthesis pathway by reducing feedback inhibition, allowing the cell to continue to create nucleotides even when concentrations are elevated. This overactivation creates increased hypoxanthine levels, which likely competitively inhibits the conversion of the thiopurines to their active form.	25962120	PubMed		Li et al., 2015, Nat. Med.		5	accepted	7909	2929	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7909	https://civic.genome.wustl.edu/links/variants/2929	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	N144S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Cytarabine		Predictive	Supports	D	Sensitivity/Response	Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.	25962120	PubMed		Li et al., 2015, Nat. Med.		2	accepted	7910	2923	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7910	https://civic.genome.wustl.edu/links/variants/2923	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	L191F	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Cytarabine		Predictive	Supports	D	Sensitivity/Response	Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.	25962120	PubMed		Li et al., 2015, Nat. Med.		2	accepted	7911	2919	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7911	https://civic.genome.wustl.edu/links/variants/2919	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Lometrexol,Mercaptopurine	Combination	Predictive	Supports	D	Sensitivity/Response	Treatment with the GART inhibitor, Lometrexol (de novo purine synthesis inhibitor), sensitized Reh cells overexpressing PRPS1 A190T to mercaptopurine (6-MP) as evidenced by significant reduction of the cell line's 6-MP IC50 and the significant increase of intracellular levels of TIMP. TIMP is one of the first metabolites 6-MP is converted to during activation.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7913	2929	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7913	https://civic.genome.wustl.edu/links/variants/2929	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	D139G	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 D139G in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, D139G is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7915	2935	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7915	https://civic.genome.wustl.edu/links/variants/2935	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	C77S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 C77S in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, C77S is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7916	2936	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7916	https://civic.genome.wustl.edu/links/variants/2936	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	I72V	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 I72V in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, I72V is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7917	2937	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7917	https://civic.genome.wustl.edu/links/variants/2937	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	V53A	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Mercaptopurine,Thioguanine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 V53A in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, V53A is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7918	2938	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7918	https://civic.genome.wustl.edu/links/variants/2938	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	A87T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 A87T in Reh cells resulted in similar cytotoxic response (IC50 and apoptosis %) compared to controls (empty vector and wildtype PRPS1 overexpression) after treatment with mercaptopurine (6-MP) or thioguanine (6-TG).  After 6-MP exposure, mass spectrometry revealed A87T cells possessed similar concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. Intracellular concentrations of hypoxanthine and IMP were similar in A87T cells and controls. After 6-MP exposure, no difference in DNA damage response and apoptosis protein markers were observed between A87T cells and controls.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7919	2939	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7919	https://civic.genome.wustl.edu/links/variants/2939	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	M115T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Thioguanine,Mercaptopurine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 M115T in Reh cells resulted in similar cytotoxic response (IC50 and apoptosis %) compared to controls (empty vector and wildtype PRPS1 overexpression) after treatment with mercaptopurine (6-MP) or thioguanine (6-TG).  After 6-MP exposure, mass spectrometry revealed M115T cells possessed similar concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. Intracellular concentrations of hypoxanthine and IMP were similar in M115T cells and controls. After 6-MP exposure, no difference in DNA damage response and apoptosis protein markers were observed between M115T cells and controls.	25962120	PubMed		Li et al., 2015, Nat. Med.		4	accepted	7920	2940	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7920	https://civic.genome.wustl.edu/links/variants/2940	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	L191F	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Methotrexate,Daunorubicin,Asparaginase	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7923	2919	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7923	https://civic.genome.wustl.edu/links/variants/2919	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	S103T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Methotrexate,Asparaginase,Daunorubicin,Cytarabine	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7924	2927	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7924	https://civic.genome.wustl.edu/links/variants/2927	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	S103N	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Daunorubicin,Methotrexate,Cytarabine,Asparaginase	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7925	2926	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7925	https://civic.genome.wustl.edu/links/variants/2926	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	K176N	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Methotrexate,Asparaginase,Cytarabine,Daunorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7926	2921	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7926	https://civic.genome.wustl.edu/links/variants/2921	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	D183E	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Cytarabine,Asparaginase,Methotrexate,Daunorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7927	2920	4566														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7927	https://civic.genome.wustl.edu/links/variants/2920	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Cytarabine,Asparaginase,Daunorubicin,Methotrexate	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 A190T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7928	2929	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7928	https://civic.genome.wustl.edu/links/variants/2929	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	T303S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Cytarabine,Asparaginase,Daunorubicin,Methotrexate	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7929	2918	4566														Somatic	2021-03-31 18:23:53 UTC	https://civic.genome.wustl.edu/links/evidence_items/7929	https://civic.genome.wustl.edu/links/variants/2918	https://civic.genome.wustl.edu/links/genes/4566
PRPS1	5631	N144S	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Asparaginase,Methotrexate,Daunorubicin	Substitutes	Predictive	Does Not Support	D	Resistance	Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.	25962120	PubMed		Li et al., 2015, Nat. Med.		3	accepted	7930	2923	4566														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7930	https://civic.genome.wustl.edu/links/variants/2923	https://civic.genome.wustl.edu/links/genes/4566
ROS1	6098	REARRANGEMENT	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	A phase 2 clinical trial studied the efficacy of Crizotinib in East Asian NSCLC patients positive for ROS1 rearrangements (detected by RT-PCR AmoyDx assay) and negative for ALK1 rearrangements. Of the 127 patients enrolled, 17 achieved complete response and 74 achieved partial response. Overall response rate by independent radiology review was 71.7% (95% CI 63-79.3%) Time to response was rapid (median 1.9 months) and durable (Duration of response median 19.7 months). Median progression free survival was 15.9 months. Crizotinib was clinically beneficial regardless of demographics and prior therapy. Based on these results, Crizotinib was approved for the treatment of ROS1 positive NSCLC in 2017 in Japan, Taiwan, China, and Korea.	29596029	PubMed		Wu et al., 2018, J. Clin. Oncol.	NCT01945021	4	accepted	7933	269	4941	6	117609463	117747018			ENST00000368508.3					75	GRCh37	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).	Somatic	2021-03-31 18:22:28 UTC	https://civic.genome.wustl.edu/links/evidence_items/7933	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941
ABL1	25	BCR-ABL E450Q	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with E450Q/M351T and E450Q variants in 1/10 and 9/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and complete best hematologic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	4	accepted	7942	2948	4														Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7942	https://civic.genome.wustl.edu/links/variants/2948	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M244V and L364I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in myeloid blast crisis had the BCR-ABL1 fusion with M244V/L364I, M244V/L364I/N53S, M244V/L364I/M458T, L364I/M458T, and L364I variants in 5/11, 2/11, 1/11, 1/11, and 2/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no best cytogenetic response and no evidence of leukemia as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7943	2949	4														Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7943	https://civic.genome.wustl.edu/links/variants/2949	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL N146S	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with G250E/E138G/I242T/K271R/V338M, G250E/E138G/I242T/K271R, G250E/I242T/K271R/V338M/N146S, and N146S variants in 3/12, 1/12, 1/12, and 7/12 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7945	2951	4														Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7945	https://civic.genome.wustl.edu/links/variants/2951	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL V298I	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with V289I, V289I/M388L, and G250E variants in 8/11, 1/11, and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had minimal response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7946	2952	4														Somatic	2021-03-31 18:23:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7946	https://civic.genome.wustl.edu/links/variants/2952	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and complete response as best hematologic response to dasatinib which were improved compared to responses in a patient with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7947	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/7947	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL S438C	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the S438C, K466E, and K466R secondary variants in 6/10, 1/10. and 1/10 bacterial clones generated using peripheral blood RNA. They had no best hematologic and no best cytogenetic responses to dasatinib which were poor compared to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7948	2953	4														Somatic	2021-03-31 18:23:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/7948	https://civic.genome.wustl.edu/links/variants/2953	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL Y253H	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with Y253H, M388L, and M388L/M244V variants in 4/10, 5/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7949	1025	4	9	133738357	133738357	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/7949	https://civic.genome.wustl.edu/links/variants/1025	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL M388L	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with Y253H, M388L, and M388L/M244V variants in 4/10, 5/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	3	accepted	7950	2954	4														Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7950	https://civic.genome.wustl.edu/links/variants/2954	https://civic.genome.wustl.edu/links/genes/4
IL6	3569	OVEREXPRESSION	Rhabdomyosarcoma	3247		Bazedoxifene		Predictive	Supports	D	Resistance	Treatment with bazedoxifene inhibited cell colony formation in rhabdomyosarcoma cell lines RH30 and RD.  Addition of excess IL6 reduced the inhibitory effect of bazedoxifene on colony formation.	28672024	PubMed		Xiao et al., 2017, PLoS ONE		2	accepted	7956	2911	2970														N/A	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/7956	https://civic.genome.wustl.edu/links/variants/2911	https://civic.genome.wustl.edu/links/genes/2970
CHEK2	11200	R474C c.1420C>T	Cancer	162				Predisposing	N/A	C	N/A	Siblings (brother and sister) each were diagnosed with multiple primary lung cancer at the age of 60, along with various other cancers in their lifetimes. Homozygosity mapping revealed their parents (who also had cancer) had a consanguineous union. Each sibling was homozygous for CHEK2 R474C. The brother also had a son who died of neuroblastoma at 22 months of age. Amino acid R474 is highly conserved (98%) and forms a salt bridge in both the inactive and active CHEK2 homodimer. Modeling reveals R474C likely negatively affects the saltbridge and destabilizes the protein. Calcium phosphate DNA precipitation to overexpress CHEK2 WT or R474C in NIH3T3 cells revealed limited expression of R474C and limited activation through phosphorylation after UV exposure compared to the WT CHEK2 controls. ACMG codes as follows: Mutation in critical and well established functional domain (saltbridge) (PM1). Absent from control databases (ESP, dnSNP) except 1000 genomes with 1/2503 cases (.02%)(PM2). Predicted deleterious/damaging by multiple (4; SIFT, PolyPhen, MutationTaster2, Align GCGD) in silico algorithms (PP3).	27900359	PubMed		Kukita et al., 2016, Cold Spring Harb Mol Case Stud		3	accepted	7962	2959	8950														Rare Germline	2021-03-31 18:23:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/7962	https://civic.genome.wustl.edu/links/variants/2959	https://civic.genome.wustl.edu/links/genes/8950
CTNNB1	1499	exon 3 mutations	Medulloblastoma	0050902				Diagnostic	Supports	B	Positive	A series of 72 pediatric medulloblastomas were evaluated for CTNNB1 mutations, copy number alterations, and beta-catenin protein expression. CTNNB1 mutations were detected in all six cases with nuclear staining of beta-catenin. Remarkably, five out of these six tumors demonstrated a loss of chromosome 6.	19197950	PubMed		Fattet et al., 2009, J. Pathol.		4	accepted	7965	2942	1290														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/7965	https://civic.genome.wustl.edu/links/variants/2942	https://civic.genome.wustl.edu/links/genes/1290
CTNNB1	1499	exon 3 mutations	Medulloblastoma	0050902				Diagnostic	Supports	B	Positive	A total of 51medulloblastomas were assessed for evidence of Wnt/Wg pathway activation, alongside a genome-wide analysis of associated copy-number aberrations.  Cases displaying evidence of Wnt/Wg activation (CTNNB1 mutation and/or beta-catenin nuclear stabilisation) were exclusively associated with a distinct genomic signature involving loss of an entire copy of chromosome 6 but few other aberrations. Loss of chromosome 6 was exclusively observed in Wnt/Wg-activated medulloblastomas.	17172831	PubMed		Clifford et al., 2006, Cell Cycle		4	accepted	7967	2942	1290														Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/7967	https://civic.genome.wustl.edu/links/variants/2942	https://civic.genome.wustl.edu/links/genes/1290
DDIT3	1649	FUS-DDIT3	Liposarcoma	3382				Diagnostic	Supports	B	Positive	Both RT-PCR and PCR were used to detect and confirm the presence of fusion transcripts in RNA extracted from the surgical resections of 74 liposarcomas and 98 lipomas.  FUS-DDIT3 (TLS-CHOP) was found in 22/74 (30%) liposarcomas, but not detected in any of the 98 noncancerous lipomas. Within the liposarcomas FUS-DDIT3 was found in 1/12 (8%) well-differentiated, 1/4 (25%) de-differentiated, 1/17 (6%) unclassified, and 19/41 (46%) myxoid subtypes. The results demonstrate the specificity of FUS-DDIT3 fusions to liposarcomas.	20332486	PubMed		Kubo et al., 2010, Anticancer Res.		4	accepted	7981	722	1413														Somatic	2021-03-31 18:22:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/7981	https://civic.genome.wustl.edu/links/variants/722	https://civic.genome.wustl.edu/links/genes/1413
PDGFRA	5156	OVEREXPRESSION	Rhabdomyosarcoma	3247		Sunitinib		Predictive	Supports	D	Sensitivity/Response	A high-throughput screen of 637 cancer cell lines revealed 2 to be sensitive to the multiple tyrosine kinase inhibitor, sunitinib. The most highly sensitive line was A-204, a rhabdomyosarcoma cell line. A-204 was then compared to a panel of 6 other rhabdomyosarcoma cell lines and was the only one of the 7 with detectable PDGFRA protein (Western) and to demonstrate sensitivity to sunitinib. In A-204, no PDGFRA gene amplification was detected by FISH, but qPCR revealed a an increased PDGFRA mRNA expression. Reduction of PDFGRA expression by shRNA decreased cell number similarly to sunitinib treatment. Additionally, targeting the PDGFRA ligand, PDGFC, with shRNA or antibody decreased cell number similarly to sunitinib treatment.	19366796	PubMed		McDermott et al., 2009, Cancer Res.		3	accepted	7988	2944	38														N/A	2021-03-31 18:22:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/7988	https://civic.genome.wustl.edu/links/variants/2944	https://civic.genome.wustl.edu/links/genes/38
PDGFRA	5156	BCR-PDGFRA	B-cell Acute Lymphoblastic Leukemia	0080638		Imatinib		Predictive	Supports	C	Sensitivity/Response	A 47-year-old man was diagnosed with pre-B-cell acute lymphoblastic leukemia. FISH and nested PCR revealed the patient had a t(4;22)(q12;11) translocation that created an in-frame BCR-PDGFRA fusion. The constitutively activating coiled-coil domain and serine/threonine kinase encoded by BCR exon 1 fused with exon 13 of PDGFRA, which retained both tyrosine kinase domains. During initial therapy, intensification, and consolidation, hyperleukocytosis persisted. Based on the presence of the BCR-PDGFRA fusion, single agent imatinib (Glivec) was administered. A complete hematological response was observed within 6 weeks as the presence of t(4;22) in the bone marrow went from a 70% down to 15%. However, the patient had a relapse in the central nervous system. Continued treatment with imatinib along with intrathecal chemotherapy achieved a meningeal remission after 2 weeks. According to the authors, this patients response implicates PDGFRA as a clinically actionable imatinib target.	12944919	PubMed		Trempat et al., 2003, Oncogene		3	accepted	7990	2971	38														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7990	https://civic.genome.wustl.edu/links/variants/2971	https://civic.genome.wustl.edu/links/genes/38
PDGFB	5155	COL1A1-PDGFB	Dermatofibrosarcoma Protuberans	3507		Sunitinib		Predictive	Supports	C	Sensitivity/Response	A 37-year-old man presented with dermatofibrosarcoma protuberans (DFSP). Post resection, multiple nodular metastases were found in both lungs and the disease progressed following treatments with cytotoxic agents and microwave ablation. Overexpression of PDGFRB was detected by IHC and a COL1A1-PDGFB fusion was detected by RT-PCR. Increased PDGFRB is activated by the COL1A1-PDGFB fusion product, which promotes the overactivation of downstream PDGFRB signaling pathways. Imatinib treatment failed as stable disease was followed by disease spread and progression. The patient was then treated with a daily oral dose of sunitinib (a multi-tyrosine kinase inhibitor) for 4 consecutive weeks, followed by a 2-week rest period. After 2 months on sunitinib, the patient experienced overall shrinkage of the bodys tumor mass (reduction of tumor in arm and partial response in lung and pancreas metastases). Sunitinib resulted in 9 months of progression free survival and improved quality of life. Ultimately, the disease progressed and the patient died 46 months after diagnosis.	29760553	PubMed		Xiao et al., 2018, Onco Targets Ther		3	accepted	7991	2972	4173														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7991	https://civic.genome.wustl.edu/links/variants/2972	https://civic.genome.wustl.edu/links/genes/4173
PDGFRB	5159	OVEREXPRESSION	Dermatofibrosarcoma Protuberans	3507		Sunitinib		Predictive	Supports	C	Sensitivity/Response	A 37-year-old man presented with dermatofibrosarcoma protuberans (DFSP). Post resection, multiple nodular metastases were found in both lungs and the disease progressed following treatments with cytotoxic agents and microwave ablation. Overexpression of PDGFRB was detected by IHC and a COL1A1-PDGFB fusion was detected by RT-PCR. Increased PDGFRB is activated by the COL1A1-PDGFB fusion product, which promotes the overactivation of downstream PDGFRB signaling pathways. Imatinib treatment failed as stable disease was followed by disease spread and progression. The patient was then treated with a daily oral dose of sunitinib (a multi-tyrosine kinase inhibitor) for 4 consecutive weeks, followed by a 2-week rest period. After 2 months on sunitinib, the patient experienced overall shrinkage of the bodys tumor mass (reduction of tumor in arm and partial response in lung and pancreas metastases). Sunitinib resulted in 9 months of progression free survival and improved quality of life. Ultimately, the disease progressed and the patient died 46 months after diagnosis.	29760553	PubMed		Xiao et al., 2018, Onco Targets Ther		3	accepted	7992	2973	4176														N/A	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/7992	https://civic.genome.wustl.edu/links/variants/2973	https://civic.genome.wustl.edu/links/genes/4176
NTRK3	4916	ETV6-NTRK3	B-cell Adult Acute Lymphocytic Leukemia	0060592		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 61-year-old man with B-ALL.  An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks after initial complete response to these therapies found a large increase in fusion transcripts and NTRK3 rearrangements were detectable by FISH in 50/50 blast nuclei whereas NRAS mutations were no longer detectable.  The patient was treated with oral monotherapy larotrectinib (100mg twice per day).  After 4 days on treatment peripheral blood blasts became undetectable; after 6 days on treatment lymphadenopathy and leukemia cutis resolved and a biopsy revealed an ablated bone marrow with only a few scattered blasts.  The patient experienced clinical benefit with no apparent side effects during 42 days of larotrectinib treatment, however, patient eventually succumbed to multifocal angioinvasive aspergillosis because of insufficient recovery of normal hematopoiesis. Later sequencing of the NTRK3 kinase domain did not detect any larotrectinib resistance mutations (p.G623R, p.G696A).	31905241	PubMed		Nardi et al., 2020, Blood Adv		3	accepted	7993	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/7993	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
NTRK3	4916	ETV6-NTRK3	Acute Myeloid Leukemia	9119		Entrectinib		Predictive	Supports	D	Sensitivity/Response	Two AML cell lines, IMS-M2 and M0-91, with the ETV6-NTRK3 fusion were treated with entrectinib.  Sequencing of these cell lines found no other driver mutations in 265 other cancer genes suggesting the ETV6-NTRK3 fusion is the oncogenic driver.  The IC50 for the IMS-M2 and M0-91 cell lines was 0.47 and 0.65 nmol/L, respectively.  Mouse xenografts treated with entrectinib at 10 or 30 mg/kg had complete remission while treatment with 3 mg/kg caused significant reduction in tumor growth.  Testing of the bone marrow of IMS-M2 xenografts after 3 weeks of treatment found no human CD45-positive cells in the 3, 10, and 30 mg/kg treatment groups; all vehicle treated mice had some human CD45-positive cells in their bone marrow.  Zebrafish xenotransplantation of M0-91 cells were sensitive to entrectinib treatment.	29237803	PubMed		Smith et al., 2018, Mol. Cancer Ther.		3	accepted	7994	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/7994	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
JAK2	3717	SMU1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The SMU1-JAK2 fusion is rare; in this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, only one case with the SMU1-JAK2 fusion was observed. SMU1 was detected as a novel JAK2 partner in Ph-like B-ALL. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	7996	2975	28														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7996	https://civic.genome.wustl.edu/links/variants/2975	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	OFD1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	To identify potentially druggable kinase fusions, this study of 278 B-ALL patients (all BCR-ABL1 negative), 34 (12.2%) harbored an IKZF1 deletion as determined by MLPA. Sufficient RNA from 16/34 of these IKZF1 deleted patients underwent mRNA sequencing and detected fusions were validated with RT-PCR and Sanger. Seven patients with clinical characteristics of Ph-like ALL were confirmed to harbor kinase fusions. The novel in-frame OFD1-JAK2 fusion (Exon 22 to Exon 13) was detected in an 11-year-old boy with hyperleukocytosis (185.8e9/l), no response to prednisolone therapy, and classified as NCI high risk. The authors hypothesize this fusion could constitutively activate the JAK-STAT pathway.	26404892	PubMed		Yano et al., 2015, Br. J. Haematol.		2	accepted	7997	2974	28														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/7997	https://civic.genome.wustl.edu/links/variants/2974	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	SNX29-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The SNX29-JAK2 fusion is rare; in this study involving 383 B-ALL patients (179 adult and 204 pediatric) of which 13 (8 adult, 5 pediatric) had Ph-like expression signature, only one case (adult) with the SNX29-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27428428	PubMed		Liu et al., 2016, EBioMedicine		3	accepted	7998	2976	28														Somatic	2021-03-31 18:23:56 UTC	https://civic.genome.wustl.edu/links/evidence_items/7998	https://civic.genome.wustl.edu/links/variants/2976	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	ZNF340-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The ZNF340-JAK2 fusion is rare; in this study involving 798 adult B-ALL patients of which 194 had Ph-like expression signature, only one case with the ZNF340-JAK2 fusion was observed. ZNF340 was detected as a novel JAK2 partner in Ph-like B-ALL. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	7999	2977	28														Somatic	2021-03-31 18:23:00 UTC	https://civic.genome.wustl.edu/links/evidence_items/7999	https://civic.genome.wustl.edu/links/variants/2977	https://civic.genome.wustl.edu/links/genes/28
ABL1	25	BCR-ABL F359V	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	Prior to dasatinib treatment, one imatinib-resistant patients with chronic myeloid leukemia (CML) in myeloid blast crisis had the BCR-ABL1 fusion with F359V, F359V/Q252R, and L273M secondary variants in 9/12, 1/12, and 2/12 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and no evidence of leukemia best hematologic responses to dasatinib which were better outcomes in comparison to those seen in patients with unmutated BCR-ABL in this phase.	16775234	PubMed		Talpaz et al., 2006, N. Engl. J. Med.	NCT00064233	1	accepted	8002	892	4	9	133748414	133748414	T	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/8002	https://civic.genome.wustl.edu/links/variants/892	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	V955I	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	Patient with acquired resistance (PFS > 12 weeks) determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK. Increased phosphorylation noted, which was not affected by the addition of cetuximab.	28424201	PubMed		Xu et al., 2017, Clin. Cancer Res.		4	accepted	8063	3001	37	3	178948091	178948091	G	A	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/8063	https://civic.genome.wustl.edu/links/variants/3001	https://civic.genome.wustl.edu/links/genes/37
ABL1	25	BCR-ABL E355G	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An acute-phase patient achieved complete hematologic response but progressed to chronic phase with detection of the E355G mutation and then to accelerated phase. After allograft, this patient relapsed into chronic phase and the E355G mutation was again detected in 100% of transcripts.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	8090	1487	4	9	133748403	133748403	A	G	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/8090	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F486S	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerate-phase patient had a complete cytogenetic response until progressing to major cytogenetic response (MCyR) at month 17 and then losing MCyR at month 24 despite dose escalation. At month 9, the F486S variant was found in ~25% of transcripts increasing to ~50% at month 16 and then remaining at a stable proportion.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	8091	1152	4	9	133755488	133755488	T	C	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/8091	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL E459K	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after treatment initiation. At month 11, the L248V, G250E, S417Y, and E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	8092	2370	4	9	133753906	133753906	G	A	ENST00000318560.5					75	GRCh37		Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/8092	https://civic.genome.wustl.edu/links/variants/2370	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	Double Ph	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase patient had a partial hematologic response with the Q252H and M351T variants present. The patient progressed to myeloid blast crisis (MBC) and was then negative for secondary variants. However, they had cytogenetic evidence of double Ph-chromosomes and later died. Another CP patient achieved a complete hematologic response (CHR). The Q252H variant was later detected but was absent when the patient progressed to myeloid blast crisis (MBC) at which time cytogenetic evidence of double Ph-chromosomes were present. The patient later died. An accelerated-phase patient had a complete hematologic response with the F359V and M351T variants present. The patient progressed to myeloid blast crisis at which point there were no secondary variants but cytogenetic evidence of double Ph-chromosomes.	12623848	PubMed		Branford et al., 2003, Blood		4	accepted	8093	3009	4														Somatic	2021-03-31 18:23:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/8093	https://civic.genome.wustl.edu/links/variants/3009	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	P-Loop Mutation	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Of 14 patients who started the study in late chronic phase and had p-loop or non-p-loop mutations, 6/6 with p-loop mutations died compared to no deaths during the course of the study for those with non-p-loop mutations (P=0.0013). 14 patients who started the study in accelerated phase and had p-loop or non-p-loop mutations, 6/7 with p-loop mutations died and 3/6 with non-p-loop mutations died (P=0.14). Overall, this data suggests p-loop mutations that arise during late-chronic phase support resistance to imatinib.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	8094	2375	4														Somatic	2021-03-31 18:23:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/8094	https://civic.genome.wustl.edu/links/variants/2375	https://civic.genome.wustl.edu/links/genes/4
JAK2	3717	ATF7IP-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The ATF7IP-JAK2 fusion is rare; in this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, two cases with the ATF7IP-JAK2 fusion were observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	8095	2846	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8095	https://civic.genome.wustl.edu/links/variants/2846	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	BCR-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, only one case with the BCR-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	8096	2860	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8096	https://civic.genome.wustl.edu/links/variants/2860	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	ETV6-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, only one case with the ETV6-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	8097	2859	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8097	https://civic.genome.wustl.edu/links/variants/2859	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PPFIBP1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease.The PPFIBP1-JAK2 fusion is rare; In this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, only one case with the PPFIBP1-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	8099	2848	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8099	https://civic.genome.wustl.edu/links/variants/2848	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	SSBP2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease.The SSBP2-JAK2 fusion is rare; In this study involving 798 B-ALL patients of which 194 had clinical characteristics of Ph-like ALL, two cases with the SSBP2-JAK2 fusion were observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27870571	PubMed		Roberts et al., 2017, J. Clin. Oncol.		3	accepted	8100	2661	28														Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/8100	https://civic.genome.wustl.edu/links/variants/2661	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	BCR-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In this study involving 574 pediatric B-ALL patients (from a Dutch/German cohort), 77 were shown to be Ph-like cases identified by hierarchical clustering of gene expression data. In one male patient with Ph-like disease, an in-frame BCR-JAK2 fusion involving exon 1 of BCR and exon 17 of JAK2 was identified. This fusion was confirmed by RT-PCR and targeted ligation amplification (TLA). A concurrent IKZF1 exon 2-3 deletion was detected. The patient experienced complete remission after induction but relapsed shortly after. .	27894077	PubMed		Boer et al., 2017, Oncotarget		4	accepted	8101	2860	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8101	https://civic.genome.wustl.edu/links/variants/2860	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	ETV6-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 negative patients revealed 4.9% had JAK2 rearrangements including one individual who had an ETV6-JAK2 fusion that was confirmed by Sanger sequencing. This patient was designated PH-like non CRLF2.	28408464	PubMed		Reshmi et al., 2017, Blood		4	accepted	8102	2859	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8102	https://civic.genome.wustl.edu/links/variants/2859	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	SSBP2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 negative patients revealed 4.9% had JAK2 rearrangements including two individuals that had an SSBP2-JAK2 fusion that were confirmed by Sanger sequencing. These patients were designated PH-like non CRLF2.	28408464	PubMed		Reshmi et al., 2017, Blood		4	accepted	8103	2661	28														Somatic	2021-03-31 18:23:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/8103	https://civic.genome.wustl.edu/links/variants/2661	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	OFD1-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The OFD1-JAK2 fusion is rare; In this study involving 373 high risk pediatric B-ALL cases of which 29 were kinase-fusion positive patients, only one case with the OFD1-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27176795	PubMed		Imamura et al., 2016, Blood Cancer J		3	accepted	8104	2974	28														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/8104	https://civic.genome.wustl.edu/links/variants/2974	https://civic.genome.wustl.edu/links/genes/28
JAK2	3717	PAX5-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650				Diagnostic	Supports	C	Positive	In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 373 high risk pediatric B-ALL cases of which 29 were kinase-fusion positive patients, only one case with the PAX5-JAK2 fusion was observed. There is pre-clinical and case-study evidence that the presence of JAK2 fusions in B-ALL predicts sensitivity to JAK2 inhibitors; clinical trials are ongoing to evaluate efficacy of adding JAK2 inhibitors to treatment of Ph-like B-ALL cases with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	27176795	PubMed		Imamura et al., 2016, Blood Cancer J		3	accepted	8105	2861	28														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8105	https://civic.genome.wustl.edu/links/variants/2861	https://civic.genome.wustl.edu/links/genes/28
FLT3	2322	D835Y	Cancer	162		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	Gilteritinib inhibited the cell growth of Ba/F3 cells expressing D835Y (IC50 1.6 nM; 95% CI: 1.12.4 nM) compared to controls (IC50 420nM; 95% CI: 350500 nM). Additionally, immunoblots showed gliteritinib reduced phosphorylation of FLT3 and downstream targets in Ba/F3 D835Y cells in a dose dependent manner. Furthermore, in nude mice xenografted with Ba/F3 cells expressing D835Y, gilteritinib showed antitumor efficacy at 10 mg/kg and 30 mg/kg, and induced tumor regression at 30 mg/k. Computational modelling demonstrated that gilteritinib interacts with activated FLT3 at the ATP-binding site, which is distant from the D835 containing activation loop. This inhibitory mechanism allows for kinase inhibition to occur in the face of D835 mutation.	28516360	PubMed		Mori et al., 2017, Invest New Drugs		4	accepted	8106	3011	24														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/8106	https://civic.genome.wustl.edu/links/variants/3011	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835Y	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	Gilteritinib showed cytotoxic response in relapse and refractory patient samples (AML4 and AML5) with D835 mutations in an immunoblot assay. A patient (AML4) presented with a FLT3-ITD mutation at diagnosis and was refractory to induction and salvage chemotherapy. He then received quizartinib but relpased after 6 months. He then responded to sorafenib but had disease progression with a FLT3-D835Y mutation. Patient derived relapse sample was sensitive to gilteritinib, which generated a cytotoxic response. Gilteritinib reduced FLT3 phosphorylation Ba/F3 cells expressing D835Y with IC50 1.4 nM.	27908881	PubMed		Lee et al., 2017, Blood		2	accepted	8108	3011	24														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/8108	https://civic.genome.wustl.edu/links/variants/3011	https://civic.genome.wustl.edu/links/genes/24
CCND1	595	OVEREXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	0080146				Prognostic	Supports	B	Poor Outcome	Reverse phase protein array (RPPA) revealed upregulation of CCND1 at diagnosis in B-ALL relapse patients (n=27) versus patients that did not relapse (n=86, p>.01). 5-year cumulative incidence of relapse analysis showed B-ALL patients within this cohort with CCND1 expression at diagnosis above the 75th percentile had a higher incidence of relapse versus those below the 75th percentile. CCND1 upregulation appears to impact relapse 500 days post initial diagnosis.	29408328	PubMed		Bortolozzi et al., 2018, Biochem. Pharmacol.		2	accepted	8115	20	8	11	69455855	69469242			ENST00000227507.2					75	GRCh37	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	N/A	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/8115	https://civic.genome.wustl.edu/links/variants/20	https://civic.genome.wustl.edu/links/genes/8
PML	5371	PML-RARA A216V	Acute Promyelocytic Leukemia	0060318		Arsenic Trioxide		Predictive	Supports	B	Resistance	Five point mutations were identified in the PML B2 domain of PML-RARA transcripts in 9 patients diagnosed with APL and resistant to arsenic. Of these five, A216V, S214L, and A216T mutations conveyed resistance to arsenic treatment in experimental models. DNA from these 9 patients was amplified using polymerase chain reaction (PCR) and constructed into flag-tagged pCag expression vectors. Immunoblotting analyses demonstrated that after the addition of arsenic, the A216V, S214L, and A216T mutants experienced no change in expression or degradation when compared to wild type cells, indicating that these mutants were not inhibited by arsenic and demonstrate resistance. Immunofluorescence to examine cellular localization was also performed and conveyed similar results. Arsenic treatment did not alter the nuclear localization pattern of mutants with A216V, S214L, or A216T, but had an effect on the localization of other mutants as well as wild type cells.	26537301	PubMed		Liu et al., 2016, Blood		4	accepted	8177	462	39	15	74315213	74315213	C	T	ENST00000268058.3					75	GRCh37	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	Somatic	2021-03-31 18:23:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/8177	https://civic.genome.wustl.edu/links/variants/462	https://civic.genome.wustl.edu/links/genes/39
MYOD1	4654	L122R	Spindle Cell Rhabdomyosarcoma	3260				Diagnostic	Supports	B	Positive	This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) variants. All 10 cases that were positive for the MYOD1 (L122R) variant were either the spindle cell (3/12) or the sclerosing (7/9) subtypes of RMS, while all 10 cases of the embryonal subtype of RMS were negative for the MYOD1 (L122R) variant. The study suggests that the MYOD1 L122R variant is specific for spindle cell and sclerosing subtype of RMS (where it was detected in 10/21 cases or 48%). The study also confirmed the positive relationship between the spindle cell and the sclerosing subtypes of RMS, which both can have the same molecular abnormality (MYOD1 L122R variant) and are now considered to be the same subtype. Finally, the study confirmed the negative correlation between the aforementioned subtypes with the embryonal subtype of rhabdomyosarcoma.	27562493	PubMed		Rekhi et al., 2016, Mod. Pathol.		4	accepted	8193	3032	3777														Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/8193	https://civic.genome.wustl.edu/links/variants/3032	https://civic.genome.wustl.edu/links/genes/3777
MYOD1	4654	L122R	Spindle Cell Rhabdomyosarcoma	3260				Prognostic	Supports	B	Poor Outcome	This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) mutations. 10/49 cases were positive for the MYOD1 (L122R) variant, and all the positive cases belonged to either spindle cell or sclerosing RMS subtype. None of the embryonal RMS cases was positive for the MYOD1 L122R variant. All cases were treated with surgical resection and either adjuvant chemotherapy, adjuvant radiotherapy, or both. On patient follow-up, the alive-with-disease ratio was higher in the adult than in the pediatric population. Furthermore, the patients positive for MYOD1 mutation showed a higher number of disease-positive states on follow-up, while the patients negative for MYOD1 mutation showed a higher number of disease-free states on follow-up. This suggests that the MYOD1 L122R variant is associated with a more aggressive clinical course, although the difference did not reach statistical significance (P=0.34).	27562493	PubMed		Rekhi et al., 2016, Mod. Pathol.		2	accepted	8194	3032	3777														Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/8194	https://civic.genome.wustl.edu/links/variants/3032	https://civic.genome.wustl.edu/links/genes/3777
PDGFRB	5159	EBF1-PDGFRB	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like	0080650		Chemotherapy,Imatinib	Combination	Predictive	Supports	C	Sensitivity/Response	A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months.	32068648	PubMed		Sakurai et al., 2020, J. Pediatr. Hematol. Oncol.		3	accepted	8260	535	4176	5	158134987	158526769			ENST00000517373.1	5	149493400	149505140	ENST00000261799.4	75	GRCh37	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.	Somatic	2021-03-31 18:23:51 UTC	https://civic.genome.wustl.edu/links/evidence_items/8260	https://civic.genome.wustl.edu/links/variants/535	https://civic.genome.wustl.edu/links/genes/4176
MYOD1	4654	L122R	Spindle Cell Rhabdomyosarcoma	3260				Prognostic	Supports	B	Poor Outcome	This study examined 17 cases of spindle cell/sclerosing rhabdomyosarcoma (SC/SRMS) for the presence of MYOD1 variants. 12 cases harbored a MYOD-1 mutation, of which 8 cases were homozygous for p.L122R, 3 were heterozygous for p.L122R, and 1 was heterozygous for a novel p.E118K variant. There was one case of predominantly spindle cell rhabdomyosarcoma with the MYOD-1 mutation that also contained a PIK3CA mutation. The case with both MYOD-1 and PIK3CA mutations consisted histologically of lipoblasts within focally myxoid stroma, thus demonstrating that the PIK3CA mutation was a secondary aberration while MYOD-1 was the primary neomorphic mutation. On clinical follow-up, seven of the MYOD-1 variant cases experienced local recurrences and/or metastatic disease. In a median of a 13.5 month follow-up, there was 1 patient who passed away, 8 patients who were alive with the disease, and 3 patients who were alive without the disease; there was no correlation with the type of treatment that the patients had received. This supports aggressive clinical course for SC/SRMS positive for MYOD-1 variants, regardless of the presence of a concurrent PIK3CA mutation.	30604891	PubMed		Tsai et al., 2019, Histopathology		3	accepted	8313	3032	3777														Somatic	2021-03-31 18:23:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/8313	https://civic.genome.wustl.edu/links/variants/3032	https://civic.genome.wustl.edu/links/genes/3777
FLT3	2322	Y842C	Acute Myeloid Leukemia	9119		FLT3/ABL/Aurora Kinase Inhibitor KW-2449		Predictive	Supports	D	Resistance	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.	22858906	PubMed		Williams et al., 2013, Leukemia		3	accepted	8336	3070	24														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/8336	https://civic.genome.wustl.edu/links/variants/3070	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	Y842C	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	D	Resistance	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.	22858906	PubMed		Williams et al., 2013, Leukemia		4	accepted	8337	3070	24														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/8337	https://civic.genome.wustl.edu/links/variants/3070	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	Y842C	Acute Myeloid Leukemia	9119		Sunitinib		Predictive	Supports	D	Resistance	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.	22858906	PubMed		Williams et al., 2013, Leukemia		3	accepted	8338	3070	24														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/8338	https://civic.genome.wustl.edu/links/variants/3070	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	Y842C	Acute Myeloid Leukemia	9119		Lestaurtinib		Predictive	Supports	D	Sensitivity/Response	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.	22858906	PubMed		Williams et al., 2013, Leukemia		4	accepted	8339	3070	24														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/8339	https://civic.genome.wustl.edu/links/variants/3070	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	Y842C	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	D	Sensitivity/Response	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.	22858906	PubMed		Williams et al., 2013, Leukemia		3	accepted	8340	3070	24														Somatic	2021-03-31 18:23:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/8340	https://civic.genome.wustl.edu/links/variants/3070	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	F691L	Acute Myeloid Leukemia	9119		Lestaurtinib		Predictive	Supports	D	Resistance	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD F691L mutation produced partial resistance to lestaurtinib and midostaurin.	22858906	PubMed		Williams et al., 2013, Leukemia		3	accepted	8341	3071	24														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/8341	https://civic.genome.wustl.edu/links/variants/3071	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	F691L	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	D	Resistance	The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD F691L mutation produced partial resistance to lestaurtinib and midostaurin.	22858906	PubMed		Williams et al., 2013, Leukemia		3	accepted	8342	3071	24														Somatic	2021-03-31 18:23:13 UTC	https://civic.genome.wustl.edu/links/evidence_items/8342	https://civic.genome.wustl.edu/links/variants/3071	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	D835I	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritinib inhibited this patients relapse sample. Additionally, immunoblot demonstrated gilteritinib inhibited FLT3 phosphoryaltion at a concentration of 20 nM in the patient dereivd relapse cells.	27908881	PubMed		Lee et al., 2017, Blood		2	accepted	8351	3075	24														Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/8351	https://civic.genome.wustl.edu/links/variants/3075	https://civic.genome.wustl.edu/links/genes/24
PIK3CA	5290	H1047R	Colorectal Cancer	9256		Vemurafenib,Akt Inhibitor MK2206	Combination	Predictive	Supports	D	Sensitivity/Response	Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in vitro and in vivo. In vitro, vemurafenib and MK-2206 combination treatment of RKO cells resulted in substantially greater proliferation inhibition than either agent in isolation or untreated control cells (combination index score = 0.691 at EC50). Synergistic effects of vemurafenib and MK-2206 on RKO cells was confirmed in vivo via xenografts on an athymic mouse model, where mice treated with vemurafenib monotherapy experienced minimal tumor growth inhibition (25%), mice treated with MK-2206 monotherapy experienced modest tumor growth inhibition (37%), and mice treated with both achieved 87% tumor growth inhibition compared to vehicle treated control mice (P <0.001).	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	8364	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/8364	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in vivo via mouse xenograft experiments. Three cell lines harbored KRAS exon 2 mutations and wt BRAF: HCT 116 (KRAS G13D), SW620 (KRAS G12V), LOVO (KRAS G13D). Cell lines with KRAS exon 2 mutations were insensitive to vemurafenib compare those with wt KRAS and BRAF V600E (a known vemurafenib sensitizing mutation; HT29, Colo205, Colo471, LS411N; IC50s >10uM vs 0.025-0.35 uM). Nude, athymic mice with HCT116 or LoVo xenografts did not experience tumor inhibition when treated with vemurafenib.	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	8367	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic	2021-03-31 18:22:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/8367	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30
BCL2	596	F104I	Follicular Lymphoma	0050873		Venetoclax		Predictive	Supports	C	Resistance	This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.	31234236	PubMed		Blombery et al., 2019, Br. J. Haematol.		2	accepted	8375	3082	59														Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/8375	https://civic.genome.wustl.edu/links/variants/3082	https://civic.genome.wustl.edu/links/genes/59
BCL2	596	F104I	Follicular Lymphoma	0050873		Venetoclax		Predictive	Supports	D	Resistance	Cell line overexpressing BCL2 F104I mutant exhibited over 40-fold less sensitive to venetoclax than cell line with BCL2 WT. The study also demonstrated marked impairment of venetoclax binding to the F104I mutant to a similar magnitude as that observed with the G101V and F104L.	31234236	PubMed		Blombery et al., 2019, Br. J. Haematol.		3	accepted	8376	3082	59														Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/8376	https://civic.genome.wustl.edu/links/variants/3082	https://civic.genome.wustl.edu/links/genes/59
VHL	7428	L184P (c.551T>C)	Von Hippel-Lindau Disease	14175	Abnormal renal morphology,Abnormality of the pancreas,Morphological abnormality of the central nervous system,Retinal vascular proliferation,Retinal capillary hemangioma			Predisposing	N/A	C	N/A	Of 14 patients with retinal vascular proliferation and known family history of VHL disease, 12 patients were enrolled in an approved study protocol at the National Cancer Institute. 11 of these patients underwent genetic testing and were found to have mutations in the VHL gene. Patient 1 presented with retinal capillary hemangioblastoma (RCH) in her left eye at age the age of 13, which was treated with radiation. At age 62 years, this eye had good visual acuity (20/20) without any RCHs. As of her last visit, patient 1 also presented with abnormalities in the CNS, pancreas and kidney. She was found to have the L184P (c.551T>C) mutation. Her last known age was 69 years old. ACMG evidence codes: 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.	18474773	PubMed		Wong et al., 2008, Arch. Ophthalmol.		3	accepted	8491	1776	58	3	10191558	10191558	T	C	ENST00000256474.2					75	GRCh37		Rare Germline	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/8491	https://civic.genome.wustl.edu/links/variants/1776	https://civic.genome.wustl.edu/links/genes/58
BRAF	673	V600E	Colorectal Cancer	9256		Cetuximab,Vemurafenib,Irinotecan	Combination	Predictive	Supports	D	Sensitivity/Response	This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Irinotecan, cetuximab and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 250% increased lifespan (ILS) compared to vehicle treated controls. Of the ten treated mice, nine experienced partial response and one experienced a complete response. Compared to all doublet and single agent combinations of vemurafenib, irinotecan, and cetuximab, triplet therapy produced the best TGI and ILS (p<0.05, p <0.0001 for all comparisons).	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	8506	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/8506	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	V600E	Colorectal Cancer	9256		Erlotinib,Vemurafenib	Combination	Predictive	Supports	D	Sensitivity/Response	This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Erlotinib and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 142% increased lifespan (ILS) compared to vehicle treated controls. Of ten treated mice, 9 experienced partial response. Doublet therapy produced a greater increase in TGI and ILS than either agent in isolation.	22180495	PubMed		Yang et al., 2012, Cancer Res.		3	accepted	8507	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic	2021-03-31 18:24:08 UTC	https://civic.genome.wustl.edu/links/evidence_items/8507	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5
ABL1	25	BCR-ABL Y253F	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation.	12623848	PubMed		Branford et al., 2003, Blood		3	accepted	8508	2909	4														Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/8508	https://civic.genome.wustl.edu/links/variants/2909	https://civic.genome.wustl.edu/links/genes/4
ABL1	25	BCR-ABL F317L	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Does Not Support	C	Resistance	In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had a complete cytogenetic response which was maintained despite detection of the F317L variant in ~75% of transcripts at month 18.	12623848	PubMed		Branford et al., 2003, Blood		2	accepted	8509	241	4	9	133748288	133748288	T	C	ENST00000318560.5					75	GRCh37	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Somatic	2021-03-31 18:24:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/8509	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated with similar median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=93; PFS: 10.9 vs. 9.8 months, ORR: 50% vs 47.4%, OS not reached for either group). Of PIK3CA mutant HER2 patients, those treated with T-DM1 experienced a greater decrease in disease progression than those treated with standard of care capecitabine + lapatinib. In vitro, HER2 amplified cell lines with various PIK3CA mutations were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3. In mouse xenograft models of various PIK3CA mutations (H1047R, E545K, or K111N), tumor regression or complete tumor suppression >20 days was seen following a single dose >10mg/kg for all models.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	8536	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/8536	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	E545K	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	D	Resistance	As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8547	104	37	3	178936091	178936091	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic	2021-03-31 18:23:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/8547	https://civic.genome.wustl.edu/links/variants/104	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	H1047R	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	D	Resistance	As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8548	107	37	3	178952085	178952085	A	G	ENST00000263967.3					75	GRCh37	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic	2021-03-31 18:22:29 UTC	https://civic.genome.wustl.edu/links/evidence_items/8548	https://civic.genome.wustl.edu/links/variants/107	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	C420R	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Supports	D	Resistance	As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8549	931	37	3	178927980	178927980	T	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/8549	https://civic.genome.wustl.edu/links/variants/931	https://civic.genome.wustl.edu/links/genes/37
FGFR3	2261	S249C	Transitional Cell Carcinoma	2671		Cisplatin		Predictive	Supports	D	Resistance	Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively).	31316618	PubMed		Xie et al., 2019, Exp Ther Med		3	accepted	8642	628	23	4	1803568	1803568	C	G	ENST00000340107.4					75	GRCh37		Somatic	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/8642	https://civic.genome.wustl.edu/links/variants/628	https://civic.genome.wustl.edu/links/genes/23
NTRK2	4915	KANK1-NTRK2	Pilocytic Astrocytoma	4851				Diagnostic	Supports	C	Positive	A case report showing a two-year-old girl with an unusual pilocytic astrocytoma (PA) with both classic- and anaplastic- appearing tumors. A custom NGS panel identified a novel KANK1-NTRK2 fusion in both the classic and anaplastic regions. The KANK1-NTRK2 fusion was also detected in the resected recurrence, which was histologically similar to the initial anaplastic region. The KIAA1549-BRAF fusion, the most common genetic alteration in PA, was absent in this case. Different from previously known mechanisms underlying the progression to anaplastic PA, this case lacks NF1 alterations and is radiation-nave.	29804288	PubMed		Lpez et al., 2019, Neuropathol. Appl. Neurobiol.		2	accepted	8653	3158	3984														Somatic	2021-03-31 18:24:02 UTC	https://civic.genome.wustl.edu/links/evidence_items/8653	https://civic.genome.wustl.edu/links/variants/3158	https://civic.genome.wustl.edu/links/genes/3984
ALK	238	ALK FUSIONS	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	A randomized phase 3 trial (J-ALEX) of 207 Japanese ALK-positive NSCLC patients compared the efficacy and safety of alectinib (300mg twice daily) and crizotinib (250mg twice daily) in the first-line setting. When used as a first line treatment the median progression-free survival of the alectinib group was unreached (95% CI 17.5not estimated) versus 10.2 months (95% CI 8.313.9) in the crizotinib group (HR 0.31; 95% CI 0.17057). In the overall intent to treat population, Alectinib showed improved median PFS (HR 0.34; 99.7% CI 0.17-0.71; stratified log-rank p<00001) with an unreached PFS (95% CI 20.3-not estimated) compared to 10.2 months (95% CI 8.2-12.0) for crizotinib. The safety profile of alectinib was favorable relative to crizotinib with fewer dose interruptions (29% vs 74%) and fewer grade 3-4 adverse events (26% vs 52%).	28501140	PubMed		Hida et al., 2017, Lancet		5	accepted	8657	499	1	2	29415640	29446394			ENST00000389048.3					75	GRCh37	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	Somatic	2021-03-31 18:24:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/8657	https://civic.genome.wustl.edu/links/variants/499	https://civic.genome.wustl.edu/links/genes/1
PIK3CA	5290	K111N	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8662	1234	37	3	178916946	178916946	G	C	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/8662	https://civic.genome.wustl.edu/links/variants/1234	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	I391M	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab		Predictive	Does Not Support	D	Resistance	As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8663	1235	37	3	178927410	178927410	A	G	ENST00000263967.3					75	GRCh37		Somatic	2021-03-31 18:23:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/8663	https://civic.genome.wustl.edu/links/variants/1235	https://civic.genome.wustl.edu/links/genes/37
PIK3CA	5290	MUTATION	Her2-receptor Positive Breast Cancer	0060079		Capecitabine,Lapatinib	Combination	Predictive	Supports	B	Resistance	In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination chemotherapy (n=39) were associated with lower median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=87; PFS: 4.3 vs. 6.4 months, ORR: 17.1% vs 39.7%, OS 17.3 vs 27.8 mo).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	8705	311	37	3	178866311	178957881			ENST00000263967.3					75	GRCh37	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.	Somatic	2021-03-31 18:24:07 UTC	https://civic.genome.wustl.edu/links/evidence_items/8705	https://civic.genome.wustl.edu/links/variants/311	https://civic.genome.wustl.edu/links/genes/37
PTEN	5728	LOSS	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ado-trastuzumab emtansine (T-DM1; n= 113) were associated with similar median progression free survival (PFS) compared to patients whose tumors expressed PTEN normally or greater (n=21; 8.4 vs. 9.9 months). In HER2 patients with decreased or absent PTEN expression, T-DM1 was a more effective treatment than standard of care capecitabine + lapatinib as measured by PFS, although no difference in OS was seen.	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		3	accepted	8706	214	41	10	89622870	89731687			ENST00000371953.3					75	GRCh37		Somatic	2021-03-31 18:22:34 UTC	https://civic.genome.wustl.edu/links/evidence_items/8706	https://civic.genome.wustl.edu/links/variants/214	https://civic.genome.wustl.edu/links/genes/41
ERBB3	2065	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	0060079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1; n=210) were associated with similar median progression free survival (PFS) compared to patients whose tumors harbored the median or lower levels of ERBB3 mRNA (n=214; PFS: 9.8 vs. 9.3 months).	26920887	PubMed		Baselga et al., 2016, Clin. Cancer Res.		2	accepted	8707	289	1733	12	56473645	56497289			ENST00000267101.3					75	GRCh37		N/A	2021-03-31 18:22:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/8707	https://civic.genome.wustl.edu/links/variants/289	https://civic.genome.wustl.edu/links/genes/1733
KRAS	3845	MUTATION	Ovary Serous Adenocarcinoma	5744		Binimetinib		Predictive	Supports	B	Sensitivity/Response	Post hoc analysis of a randomized phase 3 trial (MILO/ENGOT-ov11) suggests a possible association between KRAS mutation and response to binimetinib in patients with recurrent or persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. KRAS mutation status was significantly associated with local best response (P=0.004); 44% of patients with KRAS mutation versus 19% of patients with KRAS WT had CR or PR in the binimetinib arm. KRAS mutation was also associated with prolonged PFS in patients treated with binimetinib (median PFS: KRAS mutant: 17.7 months; KRAS wild-type (WT): 10.8 months; P = .006), but not in patients receiving standard stherapy (physicians' choice, median PFS: KRAS mutant: 14.6 months; KRAS WT: 11.5 months; P=.502)	32822286	PubMed		Monk et al., 2020, J. Clin. Oncol.		3	accepted	8773	336	30	12	25362365	25403737			ENST00000256078.4					75	GRCh37		Somatic	2021-03-31 18:23:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/8773	https://civic.genome.wustl.edu/links/variants/336	https://civic.genome.wustl.edu/links/genes/30
KRAS	3845	Wildtype	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	D	Resistance	In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS wildtype did not demonstrate resistance to regorafenib treatment (IC50: 114.28 nM) compared to SW48 cells expressing various common KRAS G12/G13 mutations. Resistance was determined by assessing cell viability. In vivo, SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth, although KRAS wt mice trended toward better response than KRAS G12C expressing mice. IHC analysis of mouse tissue revealed more pronounced changes in markers of proliferation (Ki67), angiogenesis (CD31), and apoptosis (TUNEL) in KRAS wt mice treated with regorafenib compared to KRAS G12C mice whose tumors did not display changes in these markers. Authors concluded that KRAS wildtype was not resistant to regorafenib compared to other common KRAS G12/G13 mutations.	26161928	PubMed		Camaj et al., 2015, Future Oncol		2	accepted	8840	3200	30														Somatic	2021-03-31 18:24:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/8840	https://civic.genome.wustl.edu/links/variants/3200	https://civic.genome.wustl.edu/links/genes/30
BCL2	596	G101V	Chronic Lymphocytic Leukemia	1040		Venetoclax		Predictive	Supports	D	Resistance	This study described the crystal structure of venetoclax bound to both BCL-2 wild-type and the G101V mutant and illustrated that the resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation.	31160589	PubMed		Birkinshaw et al., 2019, Nat Commun		3	accepted	8841	2960	59														Somatic	2021-03-31 18:23:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/8841	https://civic.genome.wustl.edu/links/variants/2960	https://civic.genome.wustl.edu/links/genes/59
RET	5979	RET FUSIONS	Lung Non-small Cell Carcinoma	3908		Selpercatinib		Predictive	Supports	B	Sensitivity/Response	Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100).	32846060	PubMed		Drilon et al., 2020, N. Engl. J. Med.	NCT03157128	4	accepted	8850	1687	42														Somatic	2021-03-31 18:23:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/8850	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42
FGFR3	2261	S249C	Thanatophoric Dysplasia, The Most Common Form Of Sporadic, Lethal Dwarfism					Functional	Supports	D	Gain of Function	Study focuses on acquiring quantitative measurement of the effect of cysteine mutations on membrane protein interactions; specifically the effect of 3 TDI mutations (Arg248Cys, Ser249Cys, and Tyr373Cys) on unliganded FGFR3 RTK dimer stability, using Forster Resonance Energy Transfer-based technique. Measurements were performed in plasma membrane vesicles from CHO cells. They report that the S249C mutation had a modest effect on dimer stability and structure, which is in contrast to the strong bond that they expected due to their covalent nature. Therefore, they conclude that this study does not support the 'simple view' that the TDI cysteine mutations cause pathologies by inducing constitutive FGFR3 dimerization.	25606676	PubMed		Del Piccolo et al., 2015, Biophys. J.		3	accepted	8854	628	23	4	1803568	1803568	C	G	ENST00000340107.4					75	GRCh37		Rare Germline	2021-03-31 18:23:19 UTC	https://civic.genome.wustl.edu/links/evidence_items/8854	https://civic.genome.wustl.edu/links/variants/628	https://civic.genome.wustl.edu/links/genes/23
SMARCB1	6598	LOSS	Atypical Teratoid Rhabdoid Tumor	2129				Diagnostic	Supports	B	Positive	53 pediatric tumors consisting of 20 AT/RT, 10 PNET, and 23 other central nervous system tumors were classified using microscopic diagnosis, and then tested for expression of the SMARCB1 gene product INI1. In the 20 cases of AT/RT, expression of INI1 was not detected in tumor cells using the BAF47/SNF5 monoclonal INI1 antibody. Expression of INI1 was detected in 31 out of the 33 remaining tumors, with one Oligodendroglioma showing no expression, and one pituitary adenoma showing weak expression. The authors conclude that immunohistochemical staining with an INI1 antibody may be useful in confirming histologic diagnosis of AT/RT.	15105654	PubMed		Judkins et al., 2004, Am. J. Surg. Pathol.		4	accepted	8862	3202	5356														Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/8862	https://civic.genome.wustl.edu/links/variants/3202	https://civic.genome.wustl.edu/links/genes/5356
NTRK1	4914	SQSTM1-NTRK1	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	In a pediatric phase 1 trial (NCT02637687), a 2 year old with infantile fibrosarcoma of the shoulder harbored the SQSTM1-NTRK1 fusion. After two surgical resections and multiple rounds of chemotherapy, Larotrectinib treatment resulted in 93% tumour reduction. An R1 resection was performed followed by adjuvant Larotrectinib. The patient remained on Larotrectinib without evidence of disease progression at the time of last follow-up.	30204247	PubMed		DuBois et al., 2018, Cancer	NCT02637687	3	accepted	8865	800	3983														Somatic	2021-03-31 18:22:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/8865	https://civic.genome.wustl.edu/links/variants/800	https://civic.genome.wustl.edu/links/genes/3983
ATRX	546	Loss-of-function	Astrocytoma	3069	Brain neoplasm,Glioma			Diagnostic	Supports	B	Positive	Whole exome sequencing of 4 low grade gliomas (LGGs) and targeted sequencing of 28 LGGs revealed ATRX variants are found exclusively in a subset of IDH1-mutant, 1p/19q intact LGGs. Paired blood samples were sequenced in all cases and mutations were confirmed by Sanger. IDH1mutation was found in 28/32 LGGs and of these 12 possessed an ATRX mutation (~43%). In all 12 ATRX mutated cases 1p/19q was intact (correlation p=0.0003), and ATRX variants were not observed in the 12 1p/19q codeleted cases. Additionally, multiplex mRNA profiling of 28 astrocytic tumors with subclasses assigned based on 75 gene signatures demonstrated ATRX mutations were associated (p=.0044) with the early progenitor-like subclass (EPL) (11/13 EPL cases harbored ATRX mutants).	23104868	PubMed		Kannan et al., 2012, Oncotarget		3	accepted	8868	3203	525														Somatic	2021-03-31 18:24:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/8868	https://civic.genome.wustl.edu/links/variants/3203	https://civic.genome.wustl.edu/links/genes/525
FOXO1	2308	PAX3-FOXO1	Alveolar Rhabdomyosarcoma	4051				Prognostic	Supports	B	Poor Outcome	In a cohort of 171 uniformly treated pediatric rhabdomyosarcoma (RMS) patients, 78 patients had alveolar rhabdomyosarcoma (ARMS). Of ARMS patients, 55% harbored a PAX3-FOXO1 fusion, 22% harbored a PAX7-FOXO1 fusion, and 23% were fusion negative. Authors found a trend toward worse overall survival (OS) for PAX3-FOXO1 positive ARMS compared to PAX7-FOXO1 ARMS (4 year survival 52% vs 77%, p=0.08); fusion-negative ARMS had an intermediate OS. Among patients with metastatic disease, the PAX3-FOXO1 fusions were associated with significantly worse OS (4-year survival: 8% vs 75% for PAX7-FOXO1 ARMS, p = 0.002). In multivariate analysis, PAX3-FOXO1 fusion was independently associated with failure or death compared to loco-regional embryonal RMS (P=0.033), and among metastatic fusion positive ARMS (for failure: p=0.025, for death: p=0.019). The authors concluded that PAX3-FOXO1 fusion is an independent indicator of poor outcome.	12039929	PubMed		Sorensen et al., 2002, J. Clin. Oncol.		3	accepted	8885	2582	1925														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/8885	https://civic.genome.wustl.edu/links/variants/2582	https://civic.genome.wustl.edu/links/genes/1925
FOXO1	2308	PAX7-FOXO1	Alveolar Rhabdomyosarcoma	4051				Prognostic	Supports	B	Better Outcome	In a cohort of 171 uniformly treated pediatric rhabdomyosarcoma (RMS) patients, 78 patients had alveolar rhabdomyosarcoma (ARMS). Of ARMS patients, 55% harbored a PAX3-FOXO1 fusion, 22% harbored a PAX7-FOXO1 fusion, and 23% were fusion negative. Authors found a trend toward better overall survival (OS) for PAX7-FOXO1 positive ARMS compared to PAX3-FOXO1 ARMS (4 year survival 77% vs 52%, p=0.08); fusion-negative ARMS had an intermediate OS. Among patients with metastatic disease, the PAX7-FOXO1 fusions were associated with significantly better OS (4-year survival: 75% vs 8% for PAX3-FOXO1 ARMS, p = 0.002). In multivariate analysis, among metastatic fusion positive ARMS, PAX7-FOXO1 fusion was not significantly associated with increased risk of failure or death. Further, among PAX7-FOXO1 fusion patients, there was little difference in outcome whether patients presented with loco-regional or metastatic disease, in striking contrast with PAX3-FOXO1 fusion positive patients. The authors concluded that PAX7-FOXO1 fusion is an independent indicator of favorable outcome in metastatic ARMS.	12039929	PubMed		Sorensen et al., 2002, J. Clin. Oncol.		3	accepted	8886	2583	1925														Somatic	2021-03-31 18:22:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/8886	https://civic.genome.wustl.edu/links/variants/2583	https://civic.genome.wustl.edu/links/genes/1925
NTRK3	4916	ETV6-NTRK3	Childhood B-cell Acute Lymphoblastic Leukemia	0080146		Methotrexate,Larotrectinib,Etoposide	Combination	Predictive	Supports	C	Sensitivity/Response	A 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk) received all lines of conventional therapy (including allogeneic HSCT, antibody therapy with blinatumomab, and CAR T cells), and all were inefficient. The patient had an aberrant karyotype at diagnosis. At relapse, RNA-sequencing was performed on the initial patient sample, and a cytogenetically cryptic ETV6-NTRK3 fusion was detected. An unbalanced translocation of the ETV6 locus (47,XY,+15[19].nuc ish 12p13(5ETV6x4)(3ETV6x2)(5ETV6 con 3ETV6x2)[85/100]) was detected by an ETV6 break-apart probe obtained from Abbott. Treatment with larotrectinib was thereby initiated in combination with chemotherapy with etoposide and methotrexate. The patient achieved continued molecular remission demonstrated through MRD (minimal residual disease) negativity in the CNS and bone marrow after treatment with larotrectinib, even after 2 relapses. There were no obvious adverse events related to this drug, which shows that larotrectinib has the potential to be an effective treatment for patients with ETV6-NTRK3positive B-cell ALL, including patients with CNS infiltration.	31725893	PubMed		Schewe et al., 2019, Blood Adv		4	accepted	8917	801	3985	12	11802788	12022903			ENST00000396373.4	15	88483984	88418230	ENST00000394480.2	75	GRCh37		Somatic	2021-03-31 18:23:05 UTC	https://civic.genome.wustl.edu/links/evidence_items/8917	https://civic.genome.wustl.edu/links/variants/801	https://civic.genome.wustl.edu/links/genes/3985
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	This study was designed to test the efficacy of FLT3 inhibitors in vitro against FLT3-ITD and other TKD variants clinically observed. IC50s were determined from immunoblots quantifying FLT3 phosphorylation in endogenous (Molm14) or ectopic expression FLT3-ITD cell lines (TF-1, Ba/F3) and the endogenous wildtype FLT3 SEMK2 cell line after gilteritinib treatment. IC50 values ranged from 1.4 to 1.8 nM in the three FLT3-ITD lines compared to 5nM in wildtype cells, suggesting increased sensitivity to the inhibitor. As measured by MTT assay, primary cultures from two AML patients with high allelic FLT3-ITD showed cytotoxic response to gilteritinib. Additionally, plasma taken from 3 patients receiving 120mg of gilteritinib daily was able to inhibit FLT3 phosphorylation in Molm14 cells.	27908881	PubMed		Lee et al., 2017, Blood		3	accepted	8923	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/8923	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	In vitro gilteritinib treatment of MV4-11 and MOLM-13 cells, which endogenously express FLT3-ITD, showed growth suppression based on CellTiter GLO cytotoxicity assays with IC50 values of 0.92 nM (95% CI: 0.233.6 nM) and 2.9 nM (95% CI: 1.45.8 nM), respectively. Phosphorylation of FLT3 and its downstream targets were rapidly inhibited in MV4-11 cells relative to control treatment (DMSO). In a mouse xenograft model using MV4-11 cells, increasing doses of gilteritinib further reduced tumor size and growth and inhibited phosphorylation of both FLT3 and STAT5 (N=6, p<0.05 at lowest dose). Gilteritinib inhibited growth in vitro of Ba/F3 cells expressing FLT3-ITD (IC50 1.8nM; 95% CI: 1.0-3.0 nM) and in vivo as tumor maintenance or shrinkage was also significant in mice xenografted with Ba/F3 FLT3-ITD cells (N=5, p<0.001). Mice receiving an intra-bone marrow injection of MV4-11 cells labelled with luciferase began gilteritinib treatment on day 15. Gilteritinib treated mice showed significantly less widespread disease at day 42 than control counterparts (N=10, p<0.001) and significantly improved survival (log-rank, p<0.001).	28516360	PubMed		Mori et al., 2017, Invest New Drugs		4	accepted	8924	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic	2021-03-31 18:24:09 UTC	https://civic.genome.wustl.edu/links/evidence_items/8924	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24
NRAS	4893	Q61K	Ovary Serous Adenocarcinoma	5744		Trametinib		Predictive	Supports	C	Sensitivity/Response	One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up.	30809568	PubMed		Champer et al., 2019, Gynecol Oncol Rep		2	accepted	8933	427	36	1	115256530	115256530	G	T	ENST00000369535.4					75	GRCh37		Somatic	2021-03-31 18:22:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/8933	https://civic.genome.wustl.edu/links/variants/427	https://civic.genome.wustl.edu/links/genes/36
BRAF	673	KIAA1549-BRAF	Childhood Pilocytic Astrocytoma	6812		Selumetinib		Predictive	Supports	D	Sensitivity/Response	In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10M. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib.	28002790	PubMed		Selt et al., 2017, Oncotarget		3	accepted	8943	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/8943	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
BRAF	673	KIAA1549-BRAF	Childhood Pilocytic Astrocytoma	6812		Trametinib		Predictive	Supports	D	Sensitivity/Response	In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib.	28002790	PubMed		Selt et al., 2017, Oncotarget		3	accepted	8944	618	5	7	138545885	138666064			ENST00000440172.1	7	140434279	140487384	ENST00000288602.6	75	GRCh37		Somatic	2021-03-31 18:23:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/8944	https://civic.genome.wustl.edu/links/variants/618	https://civic.genome.wustl.edu/links/genes/5
